FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Reef, SE Strebel, P Dabbagh, A Gacic-Dobo, M Cochi, S AF Reef, Susan E. Strebel, P. Dabbagh, A. Gacic-Dobo, M. Cochi, S. TI Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome-Worldwide, 2009 SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB The purpose of this report was to summarize globally reported cases of the congenital rubella syndrome (CRS) and progress toward eradication since worldwide introduction and use of rubella-containing vaccine (RCV). Although rubella usually is a mild febrile rash illness in children and adults, pregnant women infected early in pregnancy are at high risk of CRS and its consequences (miscarriage, fetal death, or an infant born with birth defects). Rubella vaccination and maternal immunity can prevent congenital rubella infection, including CRS. An estimated 110,000 infants were born with CRS in developing countries in 1996. Safe and effective RCVs have been available since 1969 but until the 1990s, their use was limited primarily to developed countries. The World Health Organization (WHO) published its first rubella vaccine position paper in 2000 to guide global introduction of RCV in national childhood immunization schedules. The number of WHO member states who have introduced routine use of RCV in their vaccination programs increased from 83 countries in 1996 to 130 in 2009, an increase of 57%. Moreover, target dates to eliminate rubella and CRS or accelerate control of the infection have been established in 3 of 6 WHO regions: elimination by 2010 in the WHO Region of the Americas and by 2015 in the WHO European Region, and accelerated control by 2015 in the WHO Western Pacific Region. From 2000 to 2009, the number of reported rubella cases reported by WHO member states decreased by 82% (from 670,894 to 121,344). These data show that incorporation of RCV into national childhood immunization schedules can achieve global rubella control and prevention of CRS. C1 [Reef, Susan E.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. World Hlth Org, Dept Immunizat Vaccines & Biol, Geneva, Switzerland. RP Reef, SE (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD OCT PY 2011 VL 66 IS 10 BP 614 EP 615 DI 10.1097/OGX.0b013e31823d8ac2 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 863EQ UT WOS:000298146000009 ER PT J AU Kulkarni, R Soucie, JM AF Kulkarni, Roshni Soucie, J. Michael TI Pediatric Hemophilia: A Review SO SEMINARS IN THROMBOSIS AND HEMOSTASIS LA English DT Review DE Hemophilia; inhibitor; prophylaxis; intracranial hemorrhage; central venous access devices; newborns; pediatrics ID FACTOR-VIII INHIBITOR; INTRACRANIAL HEMORRHAGE; RISK-FACTORS; BLEEDING DISORDERS; ACADEMIC-ACHIEVEMENT; AFFECTED INFANT; IX DEFICIENCY; JOINT DISEASE; OPTIMAL-MODE; MANAGEMENT AB The hemophilias are the most common X-linked inherited bleeding disorders, which if not properly managed can lead to chronic disease and lifelong disabilities. The challenges and issues in newborns are different from that in older children and adults. Bleeding events still predominate as the diagnostic trigger in children, however, the sites of bleeding vary with age. While delivery-associated intracranial hemorrhage (ICH), circumcision, and venipuncture bleeding are common in the newborn period, joint disease and head trauma occur in the older child and adolescent. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitors and ICH are the most challenging complications and prophylaxis is emerging as the optimal preventive care strategy. C1 [Kulkarni, Roshni] Michigan State Univ, MSU Ctr Bleeding Disorders, Dept Pediat & Human Dev, E Lansing, MI 48824 USA. [Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Kulkarni, R (reprint author), Michigan State Univ, MSU Ctr Bleeding Disorders, Dept Pediat & Human Dev, E Lansing, MI 48824 USA. EM Roshni.Kulkarni@hc.msu.edu NR 51 TC 19 Z9 19 U1 1 U2 7 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0094-6176 J9 SEMIN THROMB HEMOST JI Semin. Thromb. Hemost. PD OCT PY 2011 VL 37 IS 7 BP 737 EP 744 DI 10.1055/s-0031-1297164 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 866TO UT WOS:000298407000004 PM 22187396 ER PT J AU Fowler, DN Faulkner, M Learman, J Runnels, R AF Fowler, Dawnovise N. Faulkner, Monica Learman, Joy Runnels, Ratonia TI The Influence of Spirituality on Service Utilization and Satisfaction for Women Residing in a Domestic Violence Shelter SO VIOLENCE AGAINST WOMEN LA English DT Article DE domestic violence; services; spirituality ID ABUSIVE RELATIONSHIPS; PARTNER VIOLENCE; BATTERED WOMEN; ABUSED WOMEN; HEALTH; COMMUNITY; SURVIVORS; RELIGION; FAITH; INITIATIVES AB Little is known about the influence of spirituality on service utilization and satisfaction among women survivors of intimate partner abuse (IPA). The purpose of this study was to examine differences between shelter and faith-based service utilization and satisfaction in a shelter sample (N = 73). Multiple regression techniques were used. The findings suggest that survivors with higher spirituality were more likely to utilize faith-based resources than shelters. Those who experienced greater IPA reported dissatisfaction with faith-based resources. These results suggest that spirituality should be incorporated into shelter services to meet survivors' spiritual needs, and faith-based services should adequately address IPA. C1 [Fowler, Dawnovise N.] Ctr Dis Control, Atlanta, GA 30341 USA. [Faulkner, Monica; Learman, Joy; Runnels, Ratonia] Univ Texas Austin, Sch Social Work, Austin, TX USA. RP Fowler, DN (reprint author), Ctr Dis Control, 4770 Buford Hwy NE,MS F-63, Atlanta, GA 30341 USA. EM dnfowler71@yahoo.com NR 57 TC 4 Z9 4 U1 2 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-8012 J9 VIOLENCE AGAINST WOM JI Violence Against Women PD OCT PY 2011 VL 17 IS 10 BP 1244 EP 1259 DI 10.1177/1077801211424480 PG 16 WC Women's Studies SC Women's Studies GA 864SG UT WOS:000298259700003 PM 22016470 ER PT J AU Connor, TH AF Connor, T. H. TI Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings. SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Meeting Abstract CT 42nd Annual Meeting of the Environmental-Mutagen-Society on Environmental Impacts on the Genome and Epigenome - Mechanisms and Risks CY OCT 15-19, 2011 CL Montreal, CANADA SP Environm Mutagen Soc C1 [Connor, T. H.] NIOSH, Cincinnati, OH 45226 USA. NR 0 TC 0 Z9 0 U1 3 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD OCT PY 2011 VL 52 SU 1 BP S28 EP S28 PG 1 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA 860DU UT WOS:000297929800063 ER PT J AU Kemper, AR Wallace, DK Patel, N Crews, JE AF Kemper, Alex R. Wallace, David K. Patel, Nita Crews, John E. TI Preschool vision testing by health providers in the United States: Findings from the 2006-2007 Medical Expenditure Panel Survey SO JOURNAL OF AAPOS LA English DT Article ID CARE NEEDS; CHILDREN; PEDIATRICIANS; ACCURACY AB BACKGROUND Few data are available regarding the rate of preschool vision screening. The purpose of this study is to estimate the current rate of vision testing among children ages 3 through 6 years by any health care provider and to the characterize the children reported to have been tested. METHODS We conducted a cross-sectional analysis of the 4,237 children aged 3 through 6 years included in either the 2006 or 2007 Medical Expenditure Panel Survey. Household respondents were asked whether selected children ever had vision testing by a doctor or other health provider. Data were weighted to make estimates representative of the civilian non-institutionalized population. RESULTS Overall, 64.9% (95% CI, 62.9%-66.9%) of children 3 through 6 years of age were reported to have ever had vision testing. The likelihood of previous reported testing increased with age, from 42.9% among 3-year-olds to 79.4% among 6-year-olds (P < 0.001). After adjusting for age, family income, insurance status, whether the child had a regular health care provider, and whether the child had special health care needs, we found that lower odds of testing were reported among non-Hispanic white children (odds ratio [On 0.73; 95% CI, 0.55-0.97) and among Hispanic children (OR, 0.62; 95% CI, 0.47-0.82) compared with non-Hispanic black children (OR, 1). CONCLUSIONS These findings highlight the gaps in the delivery of preschool vision screening. Improved population-level surveillance of children's vision and methods to track use of vision-related health services are needed to inform policy makers to develop new strategies to improve care. (J AAPOS 2011;15:480-483) C1 [Kemper, Alex R.] Duke Univ, Duke Clin Res Inst, Durham, NC 27705 USA. [Kemper, Alex R.] Duke Univ, Dept Pediat, Durham, NC 27705 USA. [Wallace, David K.] Duke Univ, Dept Ophthalmol, Durham, NC 27705 USA. [Patel, Nita] Ctr Dis Control & Prevent, Vis Hlth Initiat, Atlanta, GA USA. [Crews, John E.] Prevent Blindness Amer, Chicago, IL USA. RP Kemper, AR (reprint author), Duke Univ, Duke Clin Res Inst, 2400 Pratt St,Room 0311 Terrace Level, Durham, NC 27705 USA. EM alex.kemper@duke.edu FU Centers for Disease Control and Prevention to Prevent Blindness America [U58DP001311] FX Supported by Cooperative Agreement Number U58DP001311 from the Centers for Disease Control and Prevention to Prevent Blindness America. NR 15 TC 10 Z9 10 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-8531 J9 J AAPOS JI J. AAPOS PD OCT PY 2011 VL 15 IS 5 BP 480 EP 483 DI 10.1016/j.jaapos.2011.07.007 PG 4 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA 856PZ UT WOS:000297657200018 PM 22108361 ER PT J AU Barbour, KE Hootman, JM Helmick, CG Murphy, L Cheng, YL Theis, KA Do, B Jordan, JM AF Barbour, Kamil E. Hootman, Jennifer M. Helmick, Charles G. Murphy, Louise Cheng, Yiling Theis, Kristina A. Do, Barbara Jordan, Joanne M. TI Physical Activity Levels and the Risk of Incident Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Barbour, Kamil E.; Hootman, Jennifer M.; Murphy, Louise; Theis, Kristina A.] CDC, Atlanta, GA 30333 USA. [Helmick, Charles G.; Cheng, Yiling; Do, Barbara] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jordan, Joanne M.] UNC Thurston ARC, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 1978 BP S769 EP S769 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621502364 ER PT J AU Barnhart, SM McCune, WJ Marder, W Cagnoli, PC Lewis, EE DeGuire, P Gordon, C Helmick, CG Dhar, JP Leisen, JC Somers, EC AF Barnhart, Sarah M. McCune, W. Joseph Marder, Wendy Cagnoli, Patricia C. Lewis, Emily E. DeGuire, Peter Gordon, C. Helmick, Charles G. Dhar, J. Patricia Leisen, James C. Somers, Emily C. CA MILES Grp TI Socioeconomic Status and Survival in Systemic Lupus Erythematosus: Results From the Michigan Lupus Epidemiology and Surveillance (MILES) Program. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Barnhart, Sarah M.; McCune, W. Joseph; Marder, Wendy; Cagnoli, Patricia C.; Lewis, Emily E.; Somers, Emily C.] Univ Michigan, Ann Arbor, MI 48109 USA. [DeGuire, Peter] MI Dept Community Hlth, Lansing, MI USA. [Gordon, C.] Univ Birmingham, Birmingham, W Midlands, England. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dhar, J. Patricia] Wayne State Univ, Detroit, MI USA. [Leisen, James C.] Henry Ford Hosp, Detroit, MI 48202 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 2442 BP S951 EP S951 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621503013 ER PT J AU Do, BT Murphy, L Helmick, CG Cheng, YLJ Barbour, KE Jordan, JM AF Do, Barbara T. Murphy, Louise Helmick, Charles G. Cheng, Yiling J. Barbour, Kamil E. Jordan, Joanne M. TI Incidence of Knee Symptoms and Radiographic and Symptomatic Knee Osteoarthritis in African Americans and Caucasians: The Johnston County Osteoarthritis Project. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Do, Barbara T.; Murphy, Louise; Helmick, Charles G.; Cheng, Yiling J.; Barbour, Kamil E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jordan, Joanne M.] UNC Thurston Arthritis Ctr, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 2508 BP S981 EP S981 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621503085 ER PT J AU Do, BT Murphy, L Helmick, CG Barbour, KE Cheng, YJ Jordan, JM AF Do, Barbara T. Murphy, Louise Helmick, Charles G. Barbour, Kamil E. Cheng, Yiling J. Jordan, Joanne M. TI Incidence of Hip Symptoms and Radiographic and Symptomatic Hip Osteoarthritis in African Americans and Caucasians: The Johnston County Osteoarthritis Project SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Do, Barbara T.; Murphy, Louise; Helmick, Charles G.; Barbour, Kamil E.; Cheng, Yiling J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jordan, Joanne M.] UNC Thurston Arthrit Ctr, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 879 BP S345 EP S345 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621501075 ER PT J AU Drenkard, CM Bao, GB Helmick, CG Gordon, C Bayakly, R Lim, SS AF Drenkard, Cristina M. Bao, Gaobin Helmick, Charles G. Gordon, C. Bayakly, Rana Lim, S. Sam TI The Georgia Lupus Registry: Differences in Age-Specific Incidence Rates Between Black and White Females with SLE SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Drenkard, Cristina M.; Bao, Gaobin; Lim, S. Sam] Emory Univ, Atlanta, GA 30322 USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gordon, C.] Univ Birmingham, Birmingham, W Midlands, England. [Bayakly, Rana] Georgia Dept Publ Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 1847 BP S719 EP S720 PG 2 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621502233 ER PT J AU Driban, JB Hootman, JM Sitler, MR Harris, KP Cattano, NM AF Driban, Jeffrey B. Hootman, Jennifer M. Sitler, Michael R. Harris, Kyle P. Cattano, Nicole M. TI Association Between Sports Participation and the Risk of Knee Osteoarthritis: A Systematic Review. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Driban, Jeffrey B.] Tufts Med Ctr, Boston, MA USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Kennesaw, GA USA. [Sitler, Michael R.] Temple Univ, Philadelphia, PA 19122 USA. [Harris, Kyle P.] Bucks Cty Community Coll, Newtown, PA USA. [Cattano, Nicole M.] W Chester Univ, W Chester, PA 19380 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 1977 BP S768 EP S769 PG 2 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621502363 ER PT J AU Hootman, JM Carroll, D McKnight-Eily, L Allen, KD AF Hootman, Jennifer M. Carroll, Dianna McKnight-Eily, Lela Allen, Kelli D. TI Physical Activity and Frequent Sleep Insufficiency Among US Adults with Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Kennesaw, GA USA. [Carroll, Dianna; McKnight-Eily, Lela] Ctr Dis Control & Prevent, Atlanta, GA USA. [Allen, Kelli D.] Duke & Durham VA Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 2542 BP S995 EP S995 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621503119 ER PT J AU Hootman, JM Helmick, CG Hannan, C AF Hootman, Jennifer M. Helmick, Charles G. Hannan, Casey TI Prevalence and Impact of Extreme Obesity (Class III) Among US Adults with Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Kennesaw, GA USA. [Helmick, Charles G.; Hannan, Casey] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 909 BP S357 EP S357 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621501105 ER PT J AU Lim, SS Bayakly, R Gordon, C Helmick, CG Easley, K Bao, GB Shenvi, N Drenkard, CM AF Lim, S. Sam Bayakly, Rana Gordon, C. Helmick, Charles G. Easley, Kirk Bao, Gaobin Shenvi, Neeta Drenkard, Cristina M. TI The Georgia Lupus Registry: The Incidence and Prevalence of Systemic Lupus Erythematosus. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Easley, Kirk; Shenvi, Neeta] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Bayakly, Rana] Georgia Dept Publ Hlth, Atlanta, GA USA. [Gordon, C.] Univ Birmingham, Birmingham, W Midlands, England. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 2444 BP S952 EP S952 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621503015 ER PT J AU Murphy, L Hawker, GA Odom, E Helmick, CG AF Murphy, Louise Hawker, Gillian A. Odom, Erica Helmick, Charles G. TI To What Degree Is the Rise in US Total Knee Replacement Rates Attributable to Aging of the Population? SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Murphy, Louise; Odom, Erica; Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hawker, Gillian A.] Womens Coll Hosp, Toronto, ON M5S 1B2, Canada. NR 0 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 882 BP S346 EP S346 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621501078 ER PT J AU Somers, EC Marder, W Cagnoli, PC Lewis, EE DeGuire, P Gordon, C Helmick, CG Wang, L Wing, JJ Dhar, JP Leisen, JC McCune, WJ AF Somers, Emily C. Marder, Wendy Cagnoli, Patricia C. Lewis, Emily E. DeGuire, Peter Gordon, Caroline Helmick, Charles G. Wang, Lu Wing, Jeffrey J. Dhar, J. Patricia Leisen, James C. McCune, W. Joseph CA MILES Grp TI Population-Based Incidence Estimates for Systemic Lupus Erythematosus in the USA, 2002-2005: Results From the Michigan Lupus Epidemiology and Surveillance (MILES) Program SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Somers, Emily C.; Marder, Wendy; Cagnoli, Patricia C.; Lewis, Emily E.; Wang, Lu; Wing, Jeffrey J.; McCune, W. Joseph] Univ Michigan, Ann Arbor, MI 48109 USA. [DeGuire, Peter] MI Dept Community Hlth, Lansing, MI USA. [Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dhar, J. Patricia] Wayne State Univ, Detroit, MI USA. [Leisen, James C.] Henry Ford Hosp, Detroit, MI 48202 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 1849 BP S720 EP S721 PG 2 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621502235 ER PT J AU Theis, KA Furner, S AF Theis, Kristina A. Furner, Sylvia TI Not So Golden Years: Older (>= 65 years) Women with Arthritis Are Employed Least and Disabled Most SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Theis, Kristina A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Furner, Sylvia] Univ Illinois, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 1539 BP S601 EP S601 PG 1 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621501733 ER PT J AU Theis, KA Helmick, CG Hootman, JM AF Theis, Kristina A. Helmick, Charles G. Hootman, Jennifer M. TI Musculoskeletal Conditions Are the Most Common Causes of Work Limitation in US Adults. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY NOV 04-09, 2011 CL Chicago, IL SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Professionals C1 [Theis, Kristina A.; Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Kennesaw, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2011 VL 63 IS 10 SU S MA 795 BP S313 EP S314 PG 2 WC Rheumatology SC Rheumatology GA 856EV UT WOS:000297621500791 ER PT J AU Krause, JC Tsibane, T Tumpey, TM Huffman, CJ Briney, BS Smith, SA Basler, CF Crowe, JE AF Krause, Jens C. Tsibane, Tshidi Tumpey, Terrence M. Huffman, Chelsey J. Briney, Bryan S. Smith, Scott A. Basler, Christopher F. Crowe, James E., Jr. TI Epitope-Specific Human Influenza Antibody Repertoires Diversify by B Cell Intraclonal Sequence Divergence and Interclonal Convergence SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HUMAN MONOCLONAL-ANTIBODIES; A H1N1; SOMATIC HYPERMUTATION; MOLECULAR ANALYSIS; VIRUS; IMMUNOGLOBULIN; HEMAGGLUTININ; GENERATION; SPLEEN; IG AB We generated from a single blood sample five independent human mAbs that recognized the Sa antigenic site on the head of influenza hemagglutinin and exhibited inhibitory activity against a broad panel of H1N1 strains. All five Abs used the V(H)3-7 and J(H)6 gene segments, but at least four independent clones were identified by junctional analysis. High-throughput sequence analysis of circulating B cells revealed that each of the independent clones were members of complex phylogenetic lineages that had diversified widely using a pattern of progressive diversification through somatic mutation. Unexpectedly, B cells encoding multiple diverging lineages of these clones, including many containing very few mutations in the Ab genes, persisted in the circulation. Conversely, we noted frequent instances of amino acid sequence convergence in the Ag combining sites exhibited by members of independent clones, suggesting a strong selection for optimal binding sites. We suggest that maintenance in circulation of a wide diversity of somatic variants of dominant clones may facilitate recognition of drift variant virus epitopes that occur in rapidly mutating virus Ags, such as influenza hemagglutinin. In fact, these Ab clones recognize an epitope that acquired three glycosylation sites mediating escape from previously isolated human Abs. The Journal of Immunology, 2011, 187: 3704-3711. C1 [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Dept Pediat,Med Ctr N T 2220, Nashville, TN 37232 USA. [Tsibane, Tshidi; Basler, Christopher F.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA. [Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Smith, Scott A.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA. [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA. RP Crowe, JE (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Dept Pediat,Med Ctr N T 2220, 1161 21st Ave S, Nashville, TN 37232 USA. EM james.crowe@vanderbilt.edu RI Crowe, James/B-5549-2009 OI Crowe, James/0000-0002-0049-1079 FU National Institutes of Health [P01 AI058113, R21AI085306, UL1RR029887]; Department of Defense [HDTRA1-08-10-BRCWMD-BAA]; National Institute of Allergy and Infectious Diseases [HHSN272200900047C]; Cancer Center [CA068485]; Vanderbilt Digestive Disease Research Center [DK058404]; Vanderbilt Vision Research Center [EY008126] FX This work was supported by National Institutes of Health Grants P01 AI058113, R21AI085306, and a pilot project from UL1RR029887 (to C. F. B.) and by Department of Defense Grant HDTRA1-08-10-BRCWMD-BAA and National Institute of Allergy and Infectious Diseases Contract HHSN272200900047C. The Genome Sciences Resource was supported by Cancer Center Support Grant CA068485, the Vanderbilt Digestive Disease Research Center (DK058404), and the Vanderbilt Vision Research Center (EY008126). J.E.C. is a Burroughs Wellcome Fund Clinical Scientist in Translational Research. NR 44 TC 44 Z9 44 U1 1 U2 7 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD OCT 1 PY 2011 VL 187 IS 7 BP 3704 EP 3711 DI 10.4049/jimmunol.1101823 PG 8 WC Immunology SC Immunology GA 822IB UT WOS:000295036400029 PM 21880983 ER PT J AU McCarver, G Bhatia, J Chambers, C Clarke, R Etzel, R Foster, W Hoyer, P Leeder, JS Peters, JM Rissman, E Rybak, M Sherman, C Toppari, J Turner, K AF McCarver, Gail Bhatia, Jatinder Chambers, Christina Clarke, Robert Etzel, Ruth Foster, Warren Hoyer, Patricia Leeder, J. Steven Peters, Jeffrey M. Rissman, Emilie Rybak, Michael Sherman, Claire Toppari, Jorma Turner, Katie TI NTP-CERHR Expert Panel Report on the Developmental Toxicity of Soy Infant Formula SO BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY LA English DT Article DE endocrine disrupters; nutrition; safety assessment ID SPRAGUE-DAWLEY RATS; HIGH-RISK INFANTS; MILK-BASED FORMULA; CHROMATOGRAPHY-MASS-SPECTROMETRY; SEXUALLY DIMORPHIC NUCLEUS; MAMMARY-GLAND DEVELOPMENT; MATERNAL DIETARY EXPOSURE; MOUSE REPRODUCTIVE-TRACT; PARTIAL WHEY HYDROLYSATE; GENE-EXPRESSION PROFILE AB Soy infant formula contains soy protein isolates and is fed to infants as a supplement to or replacement for human milk or cow milk. Soy protein isolates contains estrogenic isoflavones (phytoestrogens) that occur naturally in some legumes, especially soybeans. Phytoestrogens are nonsteroidal, estrogenic compounds. In plants, nearly all phytoestrogens are bound to sugar molecules and these phytoestrogen-sugar complexes are not generally considered hormonally active. Phytoestrogens are found in many food products in addition to soy infant formula, especially soy-based foods such as tofu, soy milk, and in some over-the-counter dietary supplements. Soy infant formula was selected for National Toxicology Program (NTP) evaluation because of (1) the availability of large number of developmental toxicity studies in laboratory animals exposed to the isoflavones found in soy infant formula (namely, genistein) or other soy products, as well as few studies on human infants fed soy infant formula, (2) the availability of information on exposures in infants fed soy infant formula, and (3) public concern for effects on infant or child development. On October 2, 2008 (73 FR 57360), the NTP Center for the Evaluation of Risks to Human Reproduction (CERHR) announced its intention to conduct an updated review of soy infant formula to complete a previous evaluation that was initiated in 2005. Both the current and previous evaluations relied on expert panels to assist the NTP in developing its conclusions on the potential developmental effects associated with the use of soy infant formula, presented in the NTP Brief on Soy Infant Formula. The initial expert panel met on March 15 to 17, 2006, to reach conclusions on the potential developmental and reproductive toxicities of soy infant formula and its predominant isoflavone constituent genistein. The expert panel reports were released for public comment on May 5, 2006 (71 FR 28368). On November 8, 2006 (71 FR 65537), CERHR staff released draft NTP Briefs on Genistein and Soy Formula that provided the NTP's interpretation of the potential for genistein and soy infant formula to cause adverse reproductive and/or developmental effects in exposed humans. However, CERHR did not complete these evaluations, finalize the briefs, or issue NTP Monographs on these substances based on this initial evaluation. Between 2006 and 2009, a substantial number of new publications related to human exposure or reproductive and/or developmental toxicity were published for these substances. Thus, CERHR determined that updated evaluations of genistein and soy infant formula were needed. However, the current evaluation focuses only on soy infant formula and the potential developmental toxicity of its major isoflavone components, e. g. genistein, daidzein (and estrogenic metabolite, equol), and glycitein. This updated evaluation does not include an assessment on the potential reproductive toxicity of genistein following exposures during adulthood as was carried out in the 2006 evaluation. CERHR narrowed the scope of the evaluation because the assessment of reproductive effects of genistein following exposure to adults was not considered relevant to the consideration of soy infant formula use in infants during the 2006 evaluation. To obtain updated information about soy infant formula for the CERHR evaluation, the PubMed (Medline) database was searched from February 2006 to August 2009 with genistein/genistin, daidzein/daidzin, glycitein/glycitin, equol, soy, and other relevant keywords. References were also identified from the biblioraphies of published literature. The updated expert panel report represents the efforts of a 14-member panel of government and nongovernment scientists, and was prepared with assistance from NTP staff. The finalized report, released on January 15, 2010 (75 FR 2545), reflects consideration of public comments received on a draft report that was released on October 19, 2009, for public comment and discussions that occurred at a public meeting of the expert panel held December 16 to 18, 2009 (74 FR 53509). The finalized report presents conclusions on (1) the strength of scientific evidence that soy infant formula or its isoflavone constituents are developmental toxicants based on data from in vitro, animal, or human studies; (2) the extent of exposures in infants fed soy infant formula; (3) the assessment of the scientific evidence that adverse developmental health effects may be associated with such exposures; and (4) knowledge gaps that will help establish research and testing priorities to reduce uncertainties and increase confidence in future evaluations. The Expert Panel expressed minimal concern for adverse developmental effects in infants fed soy infant formula. This level of concern represents a "2" on the five-level scale of concern used by the NTP that ranges from negligible concern ("1") to serious concern ("5"). The Expert Panel Report on Soy Infant Formula was considered extensively by NTP staff in preparing the 2010 NTP Brief on Soy Infant Formula, which represents the NTP's opinion on the potential for exposure to soy infant formula to cause adverse developmental effects in humans. The NTP concurred with the expert panel that there is minimal concern for adverse effects on development in infants who consume soy infant formula. This conclusion was based on information about soy infant formula provided in the expert panel report, public comments received during the course of the expert panel evaluation, additional scientific information made available since the expert panel meeting, and peer reviewer critiques of the draft NTP Brief by the NTP Board of Scientific Counselors (BSC) on May 10, 2010 (Meeting materials are available at http://ntp.niehs.nih.gov/go/9741.). The BSC voted in favor of the minimal concern conclusion with 7 yes votes, 3 no votes, and 0 abstentions. One member thought that the conclusion should be negligible concern and two members thought that the level of concern should be higher than minimal concern. The NTP's response to the May 10, 2010 review ("peer-review report") is available on the NTP website at http://ntp.niehs.nih.gov/go/9741. The monograph includes the NTP Brief on Soy Infant Formula as well as the entire final Expert Panel Report on Soy Infant Formula. Public comments received as part of the NTP's evaluation of soy infant formula and other background materials are available at http://cerhr.niehs.nih.gov/evals/index.html. Reports can be obtained from the web site (http://cerhr.niehs.nih.gov/) or from: Kristina A. Thayer, PhD, NIEHS/NTP K2-04, PO Box 12233, Research Triangle Park, NC 27709. E-mail: thayer@niehs.nih.gov. Birth Defects Res (Part B) 92:421-468, 2011. (C) 2011 Wiley Periodicals, Inc. C1 [McCarver, Gail] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Bhatia, Jatinder] Med Coll Georgia, Augusta, GA 30912 USA. [Chambers, Christina] Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA. [Clarke, Robert] Georgetown Univ, Sch Med, Washington, DC USA. [Etzel, Ruth] George Washington Univ, Washington, DC 20052 USA. [Foster, Warren] McMaster Univ, Hamilton, ON L8S 4L8, Canada. [Hoyer, Patricia] Univ Arizona, Tucson, AZ USA. [Leeder, J. Steven] Childrens Mercy Hosp & Clin, Kansas City, MO USA. [Peters, Jeffrey M.] Penn State Univ, University Pk, PA 16802 USA. [Rissman, Emilie] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Rybak, Michael] US Ctr Dis Control & Prevent, Atlanta, GA USA. Cerus Corp, P Val Gal Consulting, Davis, CA USA. [Sherman, Claire; Toppari, Jorma] Turku Univ, Univ Turku, Turku, Finland. [Turner, Katie] RTI Int, Res Triangle Pk, NC USA. RP McCarver, G (reprint author), Med Coll Wisconsin, Milwaukee, WI 53226 USA. EM gmccarv@mail.mcw.edu RI Clarke, Robert/A-6485-2008; Rybak, Michael/T-1026-2016 OI Clarke, Robert/0000-0002-9278-0854; Rybak, Michael/0000-0003-1650-8581 FU NIMH NIH HHS [R01 MH068729] NR 180 TC 31 Z9 35 U1 1 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-9733 J9 BIRTH DEFECTS RES B JI Birth Defects Res. Part B-Dev. Reprod. Toxicol. PD OCT PY 2011 VL 92 IS 5 SI SI BP 421 EP 468 DI 10.1002/bdrb.20314 PG 48 WC Oncology; Genetics & Heredity; Toxicology SC Oncology; Genetics & Heredity; Toxicology GA 842PT UT WOS:000296612100006 PM 21948615 ER PT J AU Yeung, CCS Powers, MLE Nguyen, TD Kreisel, F Frater, JL Zehnbauer, BA Burack, R Hassan, A AF Yeung, Cecilia C. S. Powers, Michelle L. E. Nguyen, Tu Dung Kreisel, Friederike Frater, John L. Zehnbauer, Barbara A. Burack, Richard Hassan, Anjum TI Relevance of IgVH Gene Somatic Hypermutation and Interphase Cytogenetics in Lymphomatous Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma (SLL); IgVH gene mutation; fluorescence in situ hybridization (FISH); cytogenetics ID V-H GENES; CHROMOSOMAL-ABNORMALITIES; GENOMIC ABERRATIONS; MUTATION STATUS; IMMUNOGLOBULIN; EXPRESSION; ZONE; CD38; CLL AB Background. Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are regarded as the same entity, with SLL restricted to tissue cases featuring no leukemic phase. In this study, the authors evaluate a group of SLL cases for cytogenetic abnormalities and IgVH gene mutational status to illicit differences between CLL and SLL. Design. IgVH gene polymerase chain reaction amplification and subsequent sequencing were preformed on formalin-fixed, paraffin-embedded archival tissue of 44 patients (SLL n = 34 or CLL n = 10). Cytogenetic data, CD38, and ZAP-70 expression were also evaluated for these cases. Results. The data indicate that 9/34 (26%) SLL cases have somatic hypermutation >2%, which is less than the CLL group where 40% were mutated (4/10). Cytogenetic abnormalities were seen in 58% of the SLL cases with many showing abnormalities associated with favorable to intermediate prognosis. Conclusion. The authors' attempt to compare CLL with SLL with regards to cytogenetic and IgVH mutational status shows no statistically significant difference. C1 [Yeung, Cecilia C. S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Zehnbauer, Barbara A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Burack, Richard] Univ Rochester, Rochester, NY USA. RP Yeung, CCS (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA. EM cyeung@path.wustl.edu NR 27 TC 2 Z9 2 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1066-8969 J9 INT J SURG PATHOL JI Int. J. Surg. Pathol. PD OCT PY 2011 VL 19 IS 5 BP 563 EP 569 DI 10.1177/1066896911406918 PG 7 WC Pathology; Surgery SC Pathology; Surgery GA 848TL UT WOS:000297077900002 PM 21536543 ER PT J AU Ceballos, LA Piccinali, RV Marcet, PL Vazquez-Prokopec, GM Cardinal, MV Schachter-Broide, J Dujardin, JP Dotson, EM Kitron, U Gurtler, RE AF Ceballos, Leonardo A. Piccinali, Romina V. Marcet, Paula L. Vazquez-Prokopec, Gonzalo M. Victoria Cardinal, M. Schachter-Broide, Judith Dujardin, Jean-Pierre Dotson, Ellen M. Kitron, Uriel Guertler, Ricardo E. TI Hidden Sylvatic Foci of the Main Vector of Chagas Disease Triatoma infestans: Threats to the Vector Elimination Campaign? SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID RURAL NORTHWESTERN ARGENTINA; TRYPANOSOMA-CRUZI INFECTION; SANTIAGO-DEL-ESTERO; RHODNIUS-PROLIXUS; BOLIVIAN CHACO; ENTOMOLOGICAL SURVEILLANCE; PERIDOMESTIC POPULATIONS; AMERICAN TRYPANOSOMIASIS; PYRETHROID INSECTICIDES; REDUVIIDAE POPULATIONS AB Background: Establishing the sources of reinfestation after residual insecticide spraying is crucial for vector elimination programs. Triatoma infestans, traditionally considered to be limited to domestic or peridomestic (abbreviated as D/PD) habitats throughout most of its range, is the target of an elimination program that has achieved limited success in the Gran Chaco region in South America. Methodology/Principal Findings: During a two-year period we conducted semi-annual searches for triatomine bugs in every D/PD site and surrounding sylvatic habitats after full-coverage spraying of pyrethroid insecticides of all houses in a well-defined rural area in northwestern Argentina. We found six low-density sylvatic foci with 24 T. infestans in fallen or standing trees located 110-2,300 m from the nearest house or infested D/PD site detected after insecticide spraying, when house infestations were rare. Analysis of two mitochondrial gene fragments of 20 sylvatic specimens confirmed their species identity as T. infestans and showed that their composite haplotypes were the same as or closely related to D/PD haplotypes. Population studies with 10 polymorphic microsatellite loci and wing geometric morphometry consistently indicated the occurrence of unrestricted gene flow between local D/PD and sylvatic populations. Mitochondrial DNA and microsatellite sibship analyses in the most abundant sylvatic colony revealed descendents from five different females. Spatial analysis showed a significant association between two sylvatic foci and the nearest D/PD bug population found before insecticide spraying. Conclusions: Our study shows that, despite of its high degree of domesticity, T. infestans has sylvatic colonies with normal chromatic characters (not melanic morphs) highly connected to D/PD conspecifics in the Argentinean Chaco. Sylvatic habitats may provide a transient or permanent refuge after control interventions, and function as sources for D/PD reinfestation. The occurrence of sylvatic foci of T. infestans in the Gran Chaco may pose additional threats to ongoing vector elimination efforts. C1 [Ceballos, Leonardo A.; Piccinali, Romina V.; Victoria Cardinal, M.; Schachter-Broide, Judith; Guertler, Ricardo E.] Univ Buenos Aires, Dept Ecol Genet & Evolut, Lab Ecoepidemiol, Buenos Aires, DF, Argentina. [Marcet, Paula L.; Dotson, Ellen M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Vazquez-Prokopec, Gonzalo M.; Kitron, Uriel] Emory Univ, Dept Environm Studies, Atlanta, GA 30322 USA. [Vazquez-Prokopec, Gonzalo M.; Kitron, Uriel] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Dujardin, Jean-Pierre] Ctr Natl Rech Sci, Inst Rech Dev, Unite Mixte Rech, Montpellier, France. RP Ceballos, LA (reprint author), Univ Buenos Aires, Dept Ecol Genet & Evolut, Lab Ecoepidemiol, Buenos Aires, DF, Argentina. EM gurtler@ege.fcen.uba.ar OI Marcet, Paula/0000-0002-0676-3020 FU National Institutes of Health/National Science Foundation [R01 TW05836]; Fogarty International Center; National Institute of Environmental Health Sciences; Agencia Nacional de Promocion Cientifica y Tecnica (Argentina); University of Buenos Aires; UNDP/World Bank/WHO/TDR [A70596]; International Development Research Centre [103696-009] FX This work was supported by the National Institutes of Health/National Science Foundation Ecology of Disease program through NIH Research Grant R01 TW05836 funded by the Fogarty International Center and the National Institute of Environmental Health Sciences (to U.K., R.E.G. and Joel E. Cohen), Agencia Nacional de Promocion Cientifica y Tecnica (Argentina) and by the University of Buenos Aires (R.E.G.). The participation of R.E.G. was also supported by UNDP/World Bank/WHO/TDR (Grant No. A70596) and International Development Research Centre (Grant No. 103696-009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 82 TC 37 Z9 37 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2011 VL 5 IS 10 AR e1365 DI 10.1371/journal.pntd.0001365 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 842FR UT WOS:000296579700035 PM 22039559 ER PT J AU Dodd, KA Bird, BH Khristova, ML Albarino, CG Carroll, SA Comer, JA Erickson, BR Rollin, PE Nichol, ST AF Dodd, Kimberly A. Bird, Brian H. Khristova, Marina L. Albarino, Cesar G. Carroll, Serena A. Comer, James A. Erickson, Bobbie R. Rollin, Pierre E. Nichol, Stuart T. TI Ancient Ancestry of KFDV and AHFV Revealed by Complete Genome Analyses of Viruses Isolated from Ticks and Mammalian Hosts SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID KYASANUR-FOREST-DISEASE; HEMORRHAGIC-FEVER VIRUS; SAUDI-ARABIA; POPULATION-DYNAMICS; ENCEPHALITIS-VIRUS; DENGUE VIRUS; FLAVIVIRUS; PHYLOGENIES; DATAMONKEY; DIVERSITY AB Background: Alkhurma hemorrhagic fever virus (AHFV) and Kyasanur forest disease virus (KFDV) cause significant human disease and mortality in Saudi Arabia and India, respectively. Despite their distinct geographic ranges, AHFV and KFDV share a remarkably high sequence identity. Given its emergence decades after KFDV, AHFV has since been considered a variant of KFDV and thought to have arisen from an introduction of KFDV to Saudi Arabia from India. To gain a better understanding of the evolutionary history of AHFV and KFDV, we analyzed the full length genomes of 16 AHFV and 3 KFDV isolates. Methodology/Principal Findings: Viral genomes were sequenced and compared to two AHFV sequences available in GenBank. Sequence analyses revealed higher genetic diversity within AHFVs isolated from ticks than human AHFV isolates. A Bayesian coalescent phylogenetic analysis demonstrated an ancient divergence of AHFV and KFDV of approximately 700 years ago. Conclusions/Significance: The high sequence diversity within tick populations and the presence of competent tick vectors in the surrounding regions, coupled with the recent identification of AHFV in Egypt, indicate possible viral range expansion or a larger geographic range than previously thought. The divergence of AHFV from KFDV nearly 700 years ago suggests other AHFV/KFDV-like viruses might exist in the regions between Saudi Arabia and India. Given the human morbidity and mortality associated with these viruses, these results emphasize the importance of more focused study of these significant public health threats. C1 [Dodd, Kimberly A.; Bird, Brian H.; Albarino, Cesar G.; Carroll, Serena A.; Comer, James A.; Erickson, Bobbie R.; Rollin, Pierre E.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Dodd, Kimberly A.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA. [Khristova, Marina L.] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Div Sci Resources, Atlanta, GA USA. RP Dodd, KA (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. EM stn1@cdc.gov FU Department of Health and Human Services, United States Government FX The study was funded by the Department of Health and Human Services, United States Government. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 21 Z9 21 U1 2 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2011 VL 5 IS 10 AR e1352 DI 10.1371/journal.pntd.0001352 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 842FR UT WOS:000296579700025 PM 21991403 ER PT J AU Engelthaler, DM Bowers, J Schupp, JA Pearson, T Ginther, J Hornstra, HM Dale, J Stewart, T Sunenshine, R Waddell, V Levy, C Gillece, J Price, LB Contente, T Beckstrom-Sternberg, SM Blaney, DD Wagner, DM Mayo, M Currie, BJ Keim, P Tuanyok, A AF Engelthaler, David M. Bowers, Jolene Schupp, James A. Pearson, Talima Ginther, Jennifer Hornstra, Heidie M. Dale, Julia Stewart, Tasha Sunenshine, Rebecca Waddell, Victor Levy, Craig Gillece, John Price, Lance B. Contente, Tania Beckstrom-Sternberg, Stephen M. Blaney, David D. Wagner, David M. Mayo, Mark Currie, Bart J. Keim, Paul Tuanyok, Apichai TI Molecular Investigations of a Locally Acquired Case of Melioidosis in Southern AZ, USA SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID REAL-TIME PCR; BURKHOLDERIA-PSEUDOMALLEI; TRANSMISSION; AUSTRALIA; DISTINCT; MALLEI; GENOME; AGENTS; MODEL AB Melioidosis is caused by Burkholderia pseudomallei, a Gram-negative bacillus, primarily found in soils in Southeast Asia and northern Australia. A recent case of melioidosis in non-endemic Arizona was determined to be the result of locally acquired infection, as the patient had no travel history to endemic regions and no previous history of disease. Diagnosis of the case was confirmed through multiple microbiologic and molecular techniques. To enhance the epidemiological analysis, we conducted several molecular genotyping procedures, including multi-locus sequence typing, SNP-profiling, and whole genome sequence typing. Each technique has different molecular epidemiologic advantages, all of which provided evidence that the infecting strain was most similar to those found in Southeast Asia, possibly originating in, or around, Malaysia. Advancements in new typing technologies provide genotyping resolution not previously available to public health investigators, allowing for more accurate source identification. C1 [Engelthaler, David M.; Bowers, Jolene; Schupp, James A.; Gillece, John; Price, Lance B.; Contente, Tania; Beckstrom-Sternberg, Stephen M.; Keim, Paul] Translat Genom Res Inst, Flagstaff, AZ USA. [Pearson, Talima; Ginther, Jennifer; Hornstra, Heidie M.; Dale, Julia; Beckstrom-Sternberg, Stephen M.; Wagner, David M.; Keim, Paul; Tuanyok, Apichai] No Arizona Univ, Flagstaff, AZ 86011 USA. [Stewart, Tasha; Sunenshine, Rebecca; Waddell, Victor; Levy, Craig] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Sunenshine, Rebecca; Blaney, David D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mayo, Mark; Currie, Bart J.] Menzies Sch Hlth Res, Darwin, NT, Australia. RP Engelthaler, DM (reprint author), Translat Genom Res Inst, Flagstaff, AZ USA. EM dengelthaler@tgen.org RI Keim, Paul/A-2269-2010 FU NIH [U01-AI075568, U54-A165359]; U.S. Department of Homeland Security S&T CB Division Bioforensics FX This research was supported, in part, by NIH grants U01-AI075568 (PI: Keim) and U54-A165359 (PI: Tuanyok) and from the U.S. Department of Homeland Security S&T CB Division Bioforensics R&D Program (PI: Pearson). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 10 Z9 10 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2011 VL 5 IS 10 AR e1347 DI 10.1371/journal.pntd.0001347 PG 6 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 842FR UT WOS:000296579700020 PM 22028940 ER PT J AU Richards, FO Eigege, A Miri, ES Kal, A Umaru, J Pam, D Rakers, LJ Sambo, Y Danboyi, J Ibrahim, B Adelamo, SE Ogah, G Goshit, D Oyenekan, OK Mathieu, E Withers, PC Saka, YA Jiya, J Hopkins, DR AF Richards, Frank O. Eigege, Abel Miri, Emmanuel S. Kal, Alphonsus Umaru, John Pam, Davou Rakers, Lindsay J. Sambo, Yohanna Danboyi, Jacob Ibrahim, Bako Adelamo, Solomon E. Ogah, Gladys Goshit, Danjuma Oyenekan, O. Kehinde Mathieu, Els Withers, P. Craig Saka, Yisa A. Jiya, Jonathan Hopkins, Donald R. TI Epidemiological and Entomological Evaluations after Six Years or More of Mass Drug Administration for Lymphatic Filariasis Elimination in Nigeria SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID WUCHERERIA-BANCROFTI INFECTION; ONCHOCERCIASIS CONTROL; GLOBAL PROGRAM; VECTOR CONTROL; PLATEAU STATE; IVERMECTIN; ALBENDAZOLE; DIETHYLCARBAMAZINE; SCHISTOSOMIASIS; TRANSMISSION AB The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at good coverage, for 6 or more years. We describe our programmatic experience delivering the MDA combination of ivermectin and albendazole in Plateau and Nasarawa states in central Nigeria, where LF is caused by anopheline transmitted Wuchereria bancrofti. Baseline LF mapping using rapid blood antigen detection tests showed mean local government area (LGA) prevalence of 23% (range 4-62%). MDA was launched in 2000 and by 2003 had been scaled up to full geographic coverage in all 30 LGAs in the two states; over 26 million cumulative directly observed treatments were provided by community drug distributors over the intervention period. Reported treatment coverage for each round was >= 85% of the treatment eligible population of 3.7 million, although a population-based coverage survey in 2003 showed lower coverage (72.2%; 95% CI 65.5-79.0%). To determine impact on transmission, we monitored three LF infection parameters (microfilaremia, antigenemia, and mosquito infection) in 10 sentinel villages (SVs) serially. The last monitoring was done in 2009, when SVs had been treated for 7-10 years. Microfilaremia in 2009 decreased by 83% from baseline (from 4.9% to 0.8%); antigenemia by 67% (from 21.6% to 7.2%); mosquito infection rate (all larval stages) by 86% (from 3.1% to 0.4%); and mosquito infectivity rate (L3 stages) by 76% (from 1.3% to 0.3%). All changes were statistically significant. Results suggest that LF transmission has been interrupted in 5 of the 10 SVs, based on 2009 finding of microfilaremia >= 1% and/or L3 stages in mosquitoes. Four of the five SVs where transmission persists had baseline antigenemia prevalence of >25%. Longer or additional interventions (e.g., more frequent MDA treatments, insecticidal bed nets) should be considered for ` hot spots' where transmission is ongoing. C1 [Richards, Frank O.; Rakers, Lindsay J.; Withers, P. Craig; Hopkins, Donald R.] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Eigege, Abel; Miri, Emmanuel S.; Kal, Alphonsus; Umaru, John; Sambo, Yohanna; Adelamo, Solomon E.; Oyenekan, O. Kehinde] Carter Ctr, Jos, Nigeria. [Pam, Davou; Ibrahim, Bako] Univ Jos, Jos, Nigeria. [Goshit, Danjuma] Plateau State Minist Hlth, Jos, Nigeria. [Danboyi, Jacob; Ogah, Gladys] Nasarawa State Minist Hlth, Lafia, Nigeria. [Saka, Yisa A.; Jiya, Jonathan] Nigeria Fed Minist Hlth, Abuja, Nigeria. [Mathieu, Els] Ctr Dis Control, Atlanta, GA 30333 USA. RP Richards, FO (reprint author), Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. EM lrakers@emory.edu FU GlaxoSmithKline; Bill & Melinda Gates Foundation; World Bank FX Funding for this work came from GlaxoSmithKline, Bill & Melinda Gates Foundation, World Bank, and numerous individual donors to The Carter Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 21 Z9 21 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2011 VL 5 IS 10 AR e1346 DI 10.1371/journal.pntd.0001346 PG 18 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 842FR UT WOS:000296579700019 PM 22022627 ER PT J AU Roess, AA Monroe, BP Kinzoni, EA Gallagher, S Ibata, SR Badinga, N Molouania, TM Mabola, FS Mombouli, JV Carroll, DS MacNeil, A Benzekri, NA Moses, C Damon, IK Reynolds, MG AF Roess, Amira A. Monroe, Benjamin P. Kinzoni, Eric A. Gallagher, Seamus Ibata, Saturnin R. Badinga, Nkenda Molouania, Trolienne M. Mabola, Fredy S. Mombouli, Jean V. Carroll, Darin S. MacNeil, Adam Benzekri, Noelle A. Moses, Cynthia Damon, Inger K. Reynolds, Mary G. TI Assessing the Effectiveness of a Community Intervention for Monkeypox Prevention in the Congo Basin SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID REPUBLIC-OF-CONGO; HUMAN INFECTION; VIRUS; EDUCATION; DISEASE; AFRICA AB Background: In areas where health resources are limited, community participation in the recognition and reporting of disease hazards is critical for the identification of outbreaks. This is particularly true for zoonotic diseases such as monkeypox that principally affect people living in remote areas with few health services. Here we report the findings of an evaluation measuring the effectiveness of a film-based community outreach program designed to improve the understanding of monkeypox symptoms, transmission and prevention, by residents of the Republic of the Congo (ROC) who are at risk for disease acquisition. Methodology/Principal Findings: During 90 days, monkeypox outreach was conducted for similar to 23,860 people in northern ROC. Two hundred seventy-one attendees (selected via a structured sample) were interviewed before and after participating in a small-group outreach session. The proportion of interviewees demonstrating monkeypox-specific knowledge before and after was compared. Significant gains were measured in areas of disease recognition, transmission, and mitigation of risk. The ability to recognize at least one disease symptom and a willingness to take a family member with monkeypox to the hospital increased from 49 and 45% to 95 and 87%, respectively (p<0.001, both). Willingness to deter behaviors associated with zoonotic risk, such as eating the carcass of a primate found dead in the forest, remained fundamentally unchanged however, suggesting additional messaging may be needed. Conclusions/Significance: These results suggest that our current program of film-based educational activities is effective in improving disease-specific knowledge and may encourage individuals to seek out the advice of health workers when monkeypox is suspected. C1 [Roess, Amira A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Monroe, Benjamin P.; Carroll, Darin S.; MacNeil, Adam; Benzekri, Noelle A.; Damon, Inger K.; Reynolds, Mary G.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. [Kinzoni, Eric A.; Gallagher, Seamus; Ibata, Saturnin R.; Molouania, Trolienne M.; Mabola, Fredy S.; Moses, Cynthia] Int Conservat & Educ Fund, Washington, DC USA. [Badinga, Nkenda] Med DAfrique, Brazzaville, Congo. [Mombouli, Jean V.] Lab Natl Sante Publ, Brazzaville, Congo. RP Roess, AA (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM nzr6@cdc.gov FU Department of Health and Human Services FX This evaluation was funded by the Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agency. The funders had no role in study design, data collection nad analysis, decision to publish, or preparation of the manuscript. NR 19 TC 3 Z9 3 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2011 VL 5 IS 10 AR e1356 DI 10.1371/journal.pntd.0001356 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 842FR UT WOS:000296579700028 PM 22028942 ER PT J AU Feeley, EM Sims, JS John, SP Chin, CR Pertel, T Chen, LM Gaiha, GD Ryan, BJ Donis, RO Elledge, SJ Brass, AL AF Feeley, Eric M. Sims, Jennifer S. John, Sinu P. Chin, Christopher R. Pertel, Thomas Chen, Li-Mei Gaiha, Gaurav D. Ryan, Bethany J. Donis, Ruben O. Elledge, Stephen J. Brass, Abraham L. TI IFITM3 Inhibits Influenza A Virus Infection by Preventing Cytosolic Entry SO PLOS PATHOGENS LA English DT Article ID WEST NILE VIRUS; GENE-EXPRESSION; EARLY ENDOSOMES; DENGUE VIRUS; CELLS; PROTEIN; ENDOCYTOSIS; AUTOPHAGY; RIBONUCLEOPROTEINS; HEMAGGLUTININ AB To replicate, viruses must gain access to the host cell's resources. Interferon (IFN) regulates the actions of a large complement of interferon effector genes (IEGs) that prevent viral replication. The interferon inducible transmembrane protein family members, IFITM1, 2 and 3, are IEGs required for inhibition of influenza A virus, dengue virus, and West Nile virus replication in vitro. Here we report that IFN prevents emergence of viral genomes from the endosomal pathway, and that IFITM3 is both necessary and sufficient for this function. Notably, viral pseudoparticles were inhibited from transferring their contents into the host cell cytosol by IFN, and IFITM3 was required and sufficient for this action. We further demonstrate that IFN expands Rab7 and LAMP1-containing structures, and that IFITM3 overexpression is sufficient for this phenotype. Moreover, IFITM3 partially resides in late endosomal and lysosomal structures, placing it in the path of invading viruses. Collectively our data are consistent with the prediction that viruses that fuse in the late endosomes or lysosomes are vulnerable to IFITM3's actions, while viruses that enter at the cell surface or in the early endosomes may avoid inhibition. Multiple viruses enter host cells through the late endocytic pathway, and many of these invaders are attenuated by IFN. Therefore these findings are likely to have significance for the intrinsic immune system's neutralization of a diverse array of threats. C1 [Feeley, Eric M.; Sims, Jennifer S.; John, Sinu P.; Chin, Christopher R.; Pertel, Thomas; Gaiha, Gaurav D.; Ryan, Bethany J.; Brass, Abraham L.] MIT, Ragon Inst, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Feeley, Eric M.; Sims, Jennifer S.; John, Sinu P.; Chin, Christopher R.; Pertel, Thomas; Gaiha, Gaurav D.; Ryan, Bethany J.; Brass, Abraham L.] Harvard Univ, Charlestown, MA USA. [Chen, Li-Mei; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Elledge, Stephen J.] Harvard Univ, Brigham & Womens Hosp, Dept Genet, Sch Med, Boston, MA 02115 USA. [Elledge, Stephen J.] Howard Hughes Med Inst, Chevy Chase, MD USA. [Brass, Abraham L.] Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Boston, MA 02114 USA. RP Feeley, EM (reprint author), MIT, Ragon Inst, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. EM abrass@partners.org OI Pertel, Thomas/0000-0002-2286-6011 FU Charles H. Hood Foundation; Phillip T. and Susan M. Ragon Institute Foundation FX The source of funding for this work was from the Charles H. Hood Foundation and the Phillip T. and Susan M. Ragon Institute Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 122 Z9 132 U1 2 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD OCT PY 2011 VL 7 IS 10 AR e1002337 DI 10.1371/journal.ppat.1002337 PG 17 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 844FY UT WOS:000296734300058 PM 22046135 ER PT J AU McKnight-Eily, LR Eaton, DK Lowry, R Croft, JB Presley-Cantrell, L Perry, GS AF McKnight-Eily, Lela R. Eaton, Danice K. Lowry, Richard Croft, Janet B. Presley-Cantrell, Letitia Perry, Geraldine S. TI Relationships between hours of sleep and health-risk behaviors in US adolescent students SO PREVENTIVE MEDICINE LA English DT Article DE Adolescent; Sleep; Risk-taking; Cannabis; Alcohol drinking; Suicide; Television; Computers; Motor activity AB Objective. To examine associations between insufficient sleep (<8 h on average school nights) and health-risk behaviors. Methods. 2007 national Youth Risk Behavior Survey data of U.S. high school students (n = 12,154) were analyzed. Associations were examined on weighted data using multivariate logistic regression. Results. Insufficient sleep on an average school night was reported by 68.9% of students. Insufficient sleep was associated with higher odds of current use of cigarettes (age-adjusted odds ratio [AOR], 1.67; 95% confidence interval [CI], 1.45-1.93), marijuana (AOR, 1.52; 95% CI, 1.31-1.76), and alcohol (AOR, 1.64: 95% CI. 1.46-1.84); current sexual activity (AOR, 1.41; 95% CI, 1.25-1.59); seriously considered attempting suicide (AOR, 1.86; 95% CI, 1.60-2.16); feeling sad or hopeless (AOR, 1.62; 95% CI, 1.43-1.84); physical fighting (AOR, 1.40; 95% CI, 1.24-1.60), not being physically active at least 60 min >= 5 days in the past 7 days (AOR. 1.16; 95% CI, 1.04-1.29), using the computer >= 3 h/day (AOR, 1.58; 95% CI, 1.38-1.80), and drinking soda/pop >1 time/day (AOR, 1.14; 95% CI, 1.03-1.28). Conclusion. Two-thirds of adolescent students reported insufficient sleep, which was associated with many health-risk behaviors. Greater awareness of the impact of sleep insufficiency is vital. Published by Elsevier Inc. C1 [McKnight-Eily, Lela R.; Croft, Janet B.; Presley-Cantrell, Letitia; Perry, Geraldine S.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Eaton, Danice K.; Lowry, Richard] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP McKnight-Eily, LR (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,NE MS K-67, Atlanta, GA 30341 USA. EM dvn1@cdc.gov RI Loureiro, Nuno/I-6400-2012 OI Loureiro, Nuno/0000-0002-1166-3219 NR 13 TC 80 Z9 85 U1 2 U2 23 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD OCT-NOV PY 2011 VL 53 IS 4-5 BP 271 EP 273 DI 10.1016/j.ypmed.2011.06.020 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 846WZ UT WOS:000296935200017 PM 21843548 ER PT J AU Tsai, J Ford, ES Zhao, GX Croft, JB AF Tsai, James Ford, Earl S. Zhao, Guixiang Croft, Janet B. TI Multiple health behaviors and serum hepatic enzymes among US adults with obesity SO PREVENTIVE MEDICINE LA English DT Article DE Obesity; Multiple health behaviors; Cigarette smoking; Excessive drinking; Physical activity; Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Gamma-glutamyl transferase (GGT) ID GAMMA-GLUTAMYL-TRANSFERASE; BODY-MASS INDEX; UNITED-STATES POPULATION; ALANINE AMINOTRANSFERASE; LIVER-ENZYMES; ALCOHOL-CONSUMPTION; METABOLICALLY HEALTHY; PROSPECTIVE COHORT; RISK; MORTALITY AB Introduction. This study was to examine the cumulative number and clustering patterns of low-risk health behaviors (i.e., not currently smoking, not excessive drinking, and physically active) associated with elevation of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) among adults with obesity in the United States. Methods. We estimated the age-adjusted prevalence of elevated ALT. AST, and GGT from 4547 adults with obesity aged >= 20 years who participated in the 2005-2008 National Health and Nutrition Examination Survey. The associations between the cumulative number or clustering patterns of low-risk health behaviors and measures of serum ALT. AST, and GGT were assessed using multivariate regression models. Results. Adult men who reported having three low-risk health behaviors were 62%, 39%, and 48% less likely to have elevated serum ALT, AST, and GGT, respectively; adult women were 56% and 73% less likely to have elevated serum AST and GGT, respectively, when compared to their respective counterparts who reported having none of the low-risk health behaviors. Conclusions. The findings of this study indicate that, among adults with obesity, having multiple low-risk health behaviors is associated with decreased likelihoods of elevated hepatic enzymes, including ALT in men, AST and GGT in both men and women. Published by Elsevier Inc. C1 [Tsai, James; Ford, Earl S.; Zhao, Guixiang; Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Tsai, J (reprint author), Ctr Dis Control & Prevent CDC, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mail Stop K67, Atlanta, GA 30341 USA. EM jxt9@cdc.gov NR 57 TC 3 Z9 3 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD OCT-NOV PY 2011 VL 53 IS 4-5 BP 278 EP 283 DI 10.1016/j.ypmed.2011.08.028 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 846WZ UT WOS:000296935200019 PM 21893086 ER PT J AU Franka, R Rupprech, CE AF Franka, Richard Rupprech, Charles E. TI Treatment of rabies in the 21st century: curing the incurable? SO FUTURE MICROBIOLOGY LA English DT Article DE antivirals; cultural and socioeconomic factors; human rabies; neglected zoonoses; pathogenicity; prophylaxis; survivors; treatment ID VIRUS; PATHOGENESIS; CLEARANCE; VACCINES AB Despite the extreme case fatality attributable to rabies, reports of survivors provide a faint glimpse of a possibility of overcoming this deadly disease, even after clinical symptoms manifest. At present, no existing approach fulfills modern medical criteria for the optimal therapy of rabies. Until new efficacious antiviral compounds and optimized treatment protocols are developed, animal population management and vaccination of major reservoirs and vectors, minimization of the risk of viral exposures, and appropriate and early postexposure prophylaxis, remain the hallmarks of modern public health intervention. C1 [Franka, Richard; Rupprech, Charles E.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Rupprech, CE (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd,MS G33, Atlanta, GA 30333 USA. EM cyr5@cdc.gov NR 21 TC 5 Z9 5 U1 3 U2 16 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0913 J9 FUTURE MICROBIOL JI Future Microbiol. PD OCT PY 2011 VL 6 IS 10 BP 1135 EP 1140 DI 10.2217/FMB.11.92 PG 6 WC Microbiology SC Microbiology GA 841FO UT WOS:000296498100011 PM 22004032 ER PT J AU Rasslan, O Ellingson, K Stricof, RL Grant, PS AF Rasslan, Ossama Ellingson, Katherine Stricof, Rachel L. Grant, Patricia S. TI Infection control: Accomplishments and priorities from an individual, state, national, and international perspective SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material ID EPIDEMIOLOGY C1 [Rasslan, Ossama] Ain Shams Fac Med, Cairo, Egypt. [Ellingson, Katherine] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Stricof, Rachel L.] Council State & Territorial Epidemiologists, Ft Pierce, FL USA. [Grant, Patricia S.] Med City Childrens Hosp, Med City Dallas Hosp, Dallas, TX USA. RP Rasslan, O (reprint author), Care of Bunner C, Columbia Univ, Sch Nursing, 617 168th St,Room 334, New York, NY 10032 USA. EM cmb2216@columbia.edu NR 15 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT PY 2011 VL 39 IS 8 BP 624 EP 627 DI 10.1016/j.ajic.2011.08.003 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 841TH UT WOS:000296535700004 PM 21962839 ER PT J AU Greeley, RD Semple, S Thompson, ND High, P Rudowski, E Handschur, E Xia, GL Ganova-Raeva, L Crawford, J Robertson, C Tan, C Montana, B AF Greeley, Rebecca D. Semple, Shereen Thompson, Nicola D. High, Patricia Rudowski, Ellen Handschur, Elizabeth Xia, Guo-liang Ganova-Raeva, Lilia Crawford, Jennifer Robertson, Corwin Tan, Christina Montana, Barbara TI Hepatitis B outbreak associated with a hematology-oncology office practice in New Jersey, 2009 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Cancer; bloodborne pathogen; health care-associated infection; infection control breaches; injection safety ID C VIRUS-INFECTIONS; HEALTH-CARE; UNITED-STATES; VIRAL-HEPATITIS; TRANSMISSION; VACCINATION AB Background: Transmission of bloodborne pathogens due to breaches in infection control is becoming increasingly recognized as greater emphasis is placed on reducing health care-associated infections. Two women, aged 60 and 77 years, were diagnosed with acute hepatitis B virus (HBV) infection; both received chemotherapy at the same physician's office. Due to suspicion of health care-associated HBV transmission, a multidisciplinary team initiated an investigation of the hematology-oncology office practice. Methods: We performed an onsite inspection and environmental assessment, staff interviews, records review, and observation of staff practices. Patients who visited the office practice between January 1, 2006 and March 3, 2009 were advised to seek testing for bloodborne pathogens. Patients and medical providers were interviewed. Specimens from HBV-infected patients were sent to the Centers for Disease Control and Prevention for HBV DNA testing and phylogenic analysis. Results: Multiple breaches in infection control were identified, including deficient policies and procedures, improper hand hygiene, medication preparation in a blood processing area, common-use saline bags, and reuse of single-dose vials. The office practice was closed, and the physician's license was suspended. Out of 2,700 patients notified, test results were available for 1,394 (51.6%). Twenty-nine outbreak-associated HBV cases were identified. Specimens from 11 case-patients demonstrated 99.9%-100% nucleotide identity on phylogenetic analysis. Conclusion: Systematic breaches in infection control led to ongoing transmission of HBV infection among patients undergoing invasive procedures at the office practice. This investigation underscores the need for improved regulatory oversight of outpatient health care settings, improved infection control and injection safety education for health care providers, and the development of mechanisms for ongoing communication and cooperation among public health agencies. C1 [Greeley, Rebecca D.; Semple, Shereen; Rudowski, Ellen; Handschur, Elizabeth; Robertson, Corwin; Tan, Christina; Montana, Barbara] New Jersey Dept Hlth & Senior Serv, Trenton, NJ 08625 USA. [Thompson, Nicola D.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Atlanta, GA USA. [High, Patricia; Crawford, Jennifer] Ocean Cty Hlth Dept, Toms River, NJ USA. [Xia, Guo-liang; Ganova-Raeva, Lilia] Ctr Dis Control & Prevent, Branch Lab, Div Viral Hepatitis, Atlanta, GA USA. RP Greeley, RD (reprint author), New Jersey Dept Hlth & Senior Serv, 135 E State St,POB 369, Trenton, NJ 08625 USA. EM Rebecca.greeley@doh.state.nj.us FU Applied Epidemiology Fellowship Program; Centers for Disease Control and Prevention [1U38HM000414] FX This report was supported in part by an appointment of the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by Centers for Disease Control and Prevention Cooperative Agreement 1U38HM000414. The findings and conclusions of this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the Council of State and Territorial Epidemiologists, the New Jersey Department of Health and Senior Services, or the Ocean County Health Department. NR 29 TC 15 Z9 15 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT PY 2011 VL 39 IS 8 BP 663 EP 670 DI 10.1016/j.ajic.2010.11.011 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 841TH UT WOS:000296535700010 PM 21658812 ER PT J AU Chang, MH Ned, RM Hong, YL Yesupriya, A Yang, QH Liu, TB Janssens, ACJW Dowling, NF AF Chang, Man-huei Ned, Renee M. Hong, Yuling Yesupriya, Ajay Yang, Quanhe Liu, Tiebin Janssens, A. Cecile J. W. Dowling, Nicole F. TI Racial/Ethnic Variation in the Association of Lipid-Related Genetic Variants With Blood Lipids in the US Adult Population SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE nutrition surveys; lipids; continental population groups; ethnology; cholesterol; genetics; risk ID NUTRITION EXAMINATION SURVEY; GENOME-WIDE ASSOCIATION; CORONARY-HEART-DISEASE; 3RD NATIONAL-HEALTH; AFRICAN-AMERICANS; COMPLEX DISEASES; UNITED-STATES; LOCI; CHOLESTEROL; PATTERNS AB Background-Genome-wide association studies (GWAS) have identified a number of single-nucleotide polymorphisms (SNPs) associated with serum lipid level in populations of European descent. The individual and the cumulative effect of these SNPs on blood lipids are largely unclear for the US population. Methods and Results-Using data from the second phase (1991-1994) of the Third National Health and Nutrition Examination Survey (NHANES III), a nationally representative survey of the US population, we examined associations of 57 GWAS-identified or well-established lipid-related genetic loci with plasma concentrations of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, total cholesterol, triglycerides, total cholesterol/HDL-C ratio, and non-HDL-C. We used multivariable linear regression to examine single SNP associations and the cumulative effect of multiple SNPs (using a genetic risk score [GRS]) on blood lipid levels. Analyses were conducted in adults from each of the 3 major racial/ethnic groups in the United States: non-Hispanic whites (n = 2296), non-Hispanic blacks (n = 1699), and Mexican Americans (n = 1713). Allele frequencies for all SNPs varied significantly by race/ethnicity, except rs3764261 in CETP. Individual SNPs had very small effects on lipid levels, effects that were generally consistent in direction across racial/ethnic groups. More GWAS-validated SNPs were replicated in non-Hispanic whites (<67%) than in non-Hispanic blacks (<44%) or Mexican Americans (<44%). GRSs were strongly associated with increased lipid levels in each racial/ethnic group. The combination of all SNPs into a weighted GRS explained no more than 11% of the total variance in blood lipid levels. Conclusions-Our findings show that the combined association of SNPs, based on a GRS, was strongly associated with increased blood lipid measures in all major race/ethnic groups in the United States, which may help in identifying subgroups with a high risk for an unfavorable lipid profile. (Circ Cardiovasc Genet. 2011; 4:523-533.) C1 [Chang, Man-huei; Ned, Renee M.; Yesupriya, Ajay; Yang, Quanhe; Liu, Tiebin; Dowling, Nicole F.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Hong, Yuling] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Janssens, A. Cecile J. W.] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. RP Chang, MH (reprint author), Ctr Dis Control & Prevent, Epidemiol & Anal Program Off, Mail Stop E-33,1600 Clifton Rd, Atlanta, GA 30333 USA. EM mchang@cdc.gov OI Janssens, A Cecile/0000-0002-6153-4976 FU Office of Public Health Genomics, Centers for Disease Control and Prevention FX Financial support was provided by the Office of Public Health Genomics, Centers for Disease Control and Prevention. NR 49 TC 16 Z9 19 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD OCT PY 2011 VL 4 IS 5 BP 523 EP 533 DI 10.1161/CIRCGENETICS.111.959577 PG 11 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 841RB UT WOS:000296529200013 PM 21831959 ER PT J AU Kusano, CT Bouldin, ED Anderson, LA McGuire, LC Salvail, FR Simmons, KW Andresen, EM AF Kusano, Claudia T. Bouldin, Erin D. Anderson, Lynda A. McGuire, Lisa C. Salvail, Florentina R. Simmons, Katrina Wynkoop Andresen, Elena M. TI Adult informal caregivers reporting financial burden in Hawaii, Kansas, and Washington: Results from the 2007 Behavioral Risk Factor Surveillance System SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Risk factors; Health behaviors; Care recipients; Disability; Stressors ID HEALTH; PEOPLE; CARE AB Background: Given the unpaid nature of the work, informal caregiving can create a financial burden for caregivers. Little has been done to identify specific predictors of experiencing financial burden. This study investigated demographic and health factors comparing caregivers who reported having or not having financial burden. Methods: Data are derived from adult caregivers (N = 3,317) as part of the 2007 Behavioral Risk Factor Surveillance System in Hawaii, Kansas, and Washington. The adjusted odds ratios for reporting a financial burden were estimated for demographic and other risk factors. Results: Caregivers who reported a financial burden were younger, had lower incomes, were more likely to be current smokers, have had a stroke, and rate their health as fair or poor compared to caregivers who did not report a financial burden. Caregivers who were younger (ages 18-34), resided with care recipients, spent 20-39 hours per week providing care, and reported having a disability were at a statistically significantly higher odds of reporting a financial burden. Conclusions/Implications: Given the current economic difficulties faced by many Americans, further insights into the perceived financial burdens experienced by informal caregivers as well as linkages to policy and programs designed to support caregivers are critical for public health professionals to address the expanding needs in states and communities. Published by Elsevier Inc. C1 [Kusano, Claudia T.; Bouldin, Erin D.] Univ Florida, Dept Epidemiol, Coll Med, Gainesville, FL 32610 USA. [Kusano, Claudia T.; Bouldin, Erin D.] Univ Florida, Dept Epidemiol, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32610 USA. [Anderson, Lynda A.] Emory Univ, Div Adult & Community Hlth, Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Anderson, Lynda A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30341 USA. [McGuire, Lisa C.] Ctr Dis Control & Prevent, Div Injury Response, Atlanta, GA 30341 USA. [Salvail, Florentina R.] Hawaii State Dept Hlth, Off Hlth Planning, Honolulu, HI 96813 USA. [Simmons, Katrina Wynkoop] Washington State Dept Hlth, Ctr Hlth Stat, Olympia, WA 98501 USA. [Andresen, Elena M.] Oregon Hlth & Sci Univ, Disabil & Hlth Res Grp, CDRC, Portland, OR 97239 USA. EM claudiak@phhp.ufl.edu FU Centers for Disease Control and Prevention (CDC) National Center for Chronic Disease Prevention and Health Promotion; National Center on Birth Defects and Developmental Disabilities [U59 DD000273] FX This research was supported, in part, by funding to Dr Andresen, Ms Kusano, and Ms Bouldin from the Centers for Disease Control and Prevention (CDC) National Center for Chronic Disease Prevention and Health Promotion and from the National Center on Birth Defects and Developmental Disabilities (U59 DD000273). All authors have no other financial disclosures to report. The authors contributed equally to the development of the research question, analysis of results, writing, and editing of this research article. All authors certify, and the first author has documentation, of their approval and participation. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 36 TC 6 Z9 6 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD OCT PY 2011 VL 4 IS 4 BP 229 EP 237 DI 10.1016/j.dhjo.2011.08.001 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 841XX UT WOS:000296549600004 PM 22014670 ER PT J AU Kahende, JW Malarcher, AM Teplinskaya, A Asman, KJ AF Kahende, Jennifer W. Malarcher, Ann M. Teplinskaya, Anna Asman, Kat J. TI Quit Attempt Correlates among Smokers by Race/Ethnicity SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE smoking; tobacco use; smoking cessation; smoking quit attempts ID HEALTH INTERVIEW SURVEY; NON-MENTHOL SMOKERS; SMOKING-CESSATION; UNITED-STATES; TOBACCO-CESSATION; NATIONAL-HEALTH; RACIAL/ETHNIC DISPARITIES; ETHNIC-DIFFERENCES; CIGARETTE-SMOKING; AMERICAN SMOKERS AB Introduction: Cigarette smoking is the leading preventable cause of premature deaths in the U. S., accounting for approximately 443,000 deaths annually. Although smoking prevalence in recent decades has declined substantially among all racial/ethnic groups, disparities in smoking-related behaviors among racial/ethnic groups continue to exist. Two of the goals of Healthy People 2020 are to reduce smoking prevalence among adults to 12% or less and to increase smoking cessation attempts by adult smokers from 41% to 80%. Our study assesses whether correlates of quit attempts vary by race/ethnicity among adult (>= 18 years) smokers in the U. S. Understanding racial/ethnic differences in how both internal and external factors affect quit attempts is important for targeting smoking-cessation interventions to decrease tobacco-use disparities. Methods: We used 2003 Tobacco Use Supplement to the Current Population Survey (CPS) data from 16,213 adults to examine whether the relationship between demographic characteristics, smoking behaviors, smoking policies and having made a quit attempt in the past year varied by race/ethnicity. Results: Hispanics and persons of multiple races were more likely to have made a quit attempt than whites. Overall, younger individuals and those with > high school education, who smoked fewer cigarettes per day and had smoked for fewer years were more likely to have made a quit attempt. Having a smoke-free home, receiving a doctor's advice to quit, smoking menthol cigarettes and having a greater time to when you smoked your first cigarette of the day were also associated with having made a quit attempt. The relationship between these four variables and quit attempts varied by race/ethnicity; most notably receiving a doctor's advice was not related to quit attempts among Asian American/Pacific Islanders and menthol use among whites was associated with a lower prevalence of quit attempts while black menthol users were more likely to have made a quit attempt than white non-menthol users. Conclusions: Most correlates of quit attempts were similar across all racial/ethnic groups. Therefore population-based comprehensive tobacco control programs that increase quit attempts and successful cessation among all racial/ethnic groups should be continued and expanded. Additional strategies may be needed to encourage quit attempts among less educated, older, and more addicted smokers. C1 [Kahende, Jennifer W.; Malarcher, Ann M.; Teplinskaya, Anna] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Asman, Kat J.] Res Triangle Int, Stat & Epidemiol Div, Atlanta, GA 30341 USA. RP Kahende, JW (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA. EM jkahende@cdc.gov; amalarcher@cdc.gov; ateplinskaya@cdc.gov; kasman@cdc.gov NR 58 TC 22 Z9 23 U1 1 U2 7 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD OCT PY 2011 VL 8 IS 10 BP 3871 EP 3888 DI 10.3390/ijerph8103871 PG 18 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 842GG UT WOS:000296582200004 PM 22073018 ER PT J AU Bowler, RM Gocheva, V Harris, M Ngo, L Abdelouahab, N Wilkinson, J Doty, RL Park, R Roels, HA AF Bowler, Rosemarie M. Gocheva, Vihra Harris, Matthew Ngo, Long Abdelouahab, Nadia Wilkinson, Jayne Doty, Richard L. Park, Robert Roels, Harry A. TI Prospective study on neurotoxic effects in manganese-exposed bridge construction welders SO NEUROTOXICOLOGY LA English DT Article DE Follow-up study; Welders; Manganese; Neurological; Neuropsychological ID CENTRAL-NERVOUS-SYSTEM; DANISH STEEL WORKERS; LONG-TERM EXPOSURE; NEUROMOTOR FUNCTION; RISK-ASSESSMENT; DIOXIDE; COHORT; SPACE AB Background: In a group of 43 confined space welders dose-effect relationships had been identified for adverse neurological/neuropsychological functional effects in relation to manganese (Mn) in blood or air (cumulative exposure index). The welders' exposure to Mn was unprotected and with poor ventilation, lasting on average 16.5 months. A follow-up examination 3.5 years later, after cessation of confined space welding, was carried out to re-assess the status of mood, movement/neuromotor and cognitive functions, and olfaction. Methods: In 2008, 26 welders (70% response rate) were retested using a similar methodology as at baseline (Bowler et al., 2007). A general linear model was used to estimate individual-specific endpoint differences over time. Mean age was 47 years, mean years of education 12.4, and mean total years of welding 16.9 years. Thirteen participants no longer welded. Results: At follow-up, mean blood Mn concentration had decreased from 10.0 to 8.4 mu g/L (p = 0.002). Those still welding had higher blood Mn than those no longer welding (9.9 mu g/L vs. 6.8 mu g/L, p = 0.002). Several domains of cognitive functioning improved substantially as shown by large effect sizes. Emotional disturbance improved only slightly clinically, but complaints of depression and anxiety persisted. Motor dexterity/tactile function and graphomotor tremor improved significantly, while psychomotor speed remained unchanged. The findings of the neurological examination (UPDRS) did not change compared to baseline, whereas rigidity, dominant postural hand tremor and body sway worsened. Olfactory test scores remained depressed. Conclusion: After 3.5 years of cessation of confined space welding, only cognitive function improved significantly, while olfactory, extrapyramidal, and mood disturbances remained constant or were exacerbated. This suggests differential intrinsic vulnerabilities of the brain loci involved with Mn exposure. As the Mn exposure of the Bay Bridge welders frequently exceeded the Cal-OSHA TLV of 0.2 mg Mn/m(3) at baseline, a more stringent preventive measure is recommended for confined space welding. (C) 2011 Elsevier Inc. All rights reserved. C1 [Bowler, Rosemarie M.; Gocheva, Vihra] San Francisco State Univ, Dept Psychol, San Francisco, CA 94132 USA. [Harris, Matthew] Alliant Int Univ, San Francisco, CA 94133 USA. [Ngo, Long] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Ngo, Long] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Abdelouahab, Nadia] Univ Quebec Montreal UQAM, CINBIOSE, Montreal, PQ H3C 3P8, Canada. [Wilkinson, Jayne] Univ Penn, PADRECC, Sch Med, VAMC, Philadelphia, PA 19104 USA. [Doty, Richard L.] Univ Penn, Sch Med, Ctr Smell & Taste, Philadelphia, PA 19104 USA. [Park, Robert] NIOSH, Cincinnati, OH 45226 USA. [Roels, Harry A.] Univ Catholique Louvain Brussels, Louvain Ctr Toxicol & Appl Pharmacol, B-3271 Averbode, Belgium. RP Bowler, RM (reprint author), 8371 Kent Dr, El Cerrito, CA 94530 USA. EM rbowl@sfsu.edu RI Doty, Richard/B-7623-2012; Doty, Richard/G-1602-2013 FU US Department of Defense; Manganese Health Research Program [W81XWH-05-1-0239]; USAMRAA [W81XWH-09-1-0467] FX We thank the US Department of Defense and Manganese Health Research Program for funding (Grant #: W81XWH-05-1-0239). Additionally thanked are: Dr. Donald Smith, Dr. Sabine Gysens, Dr. Patricia Perez-Arce, Dr. Stephen Rauch, Dr. Dawn Strongin, Dr. Nancy Wecker, Ms. Linda Mora, and Ms. Tara Dennehy, for assistance in this study. Dr. Russell Bowler is thanked for his extensive work on the results of spirometry findings. Dr. Doty's work was also funded by USAMRAA W81XWH-09-1-0467. NR 52 TC 25 Z9 25 U1 0 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X J9 NEUROTOXICOLOGY JI Neurotoxicology PD OCT PY 2011 VL 32 IS 5 SI SI BP 596 EP 605 DI 10.1016/j.neuro.2011.06.004 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA 843KX UT WOS:000296671800012 PM 21762725 ER PT J AU O'Connor, J Matthews, G AF O'Connor, Jean Matthews, Gene TI Informational Privacy, Public Health, and State Laws SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID CONFIDENTIALITY; ACT C1 [O'Connor, Jean] Ctr Dis Control & Prevent, Atlanta, GA USA. [Matthews, Gene] N Carolina Inst Publ Hlth, Chapel Hill, NC USA. RP O'Connor, J (reprint author), Oregon Publ Hlth Div, 800 NE Oregon St,Ste 930, Portland, OR 97212 USA. EM Jean.C.OConnor@state.or.us NR 17 TC 9 Z9 9 U1 0 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2011 VL 101 IS 10 BP 1845 EP 1850 DI 10.2105/AJPH.2011.300206 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 830LB UT WOS:000295657400017 PM 21852633 ER PT J AU Ford, ES Zhao, GX Tsai, J Li, CY AF Ford, Earl S. Zhao, Guixiang Tsai, James Li, Chaoyang TI Low-Risk Lifestyle Behaviors and All-Cause Mortality: Findings From the National Health and Nutrition Examination Survey III Mortality Study SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID CORONARY-HEART-DISEASE; RATE ADVANCEMENT PERIODS; MODERATE ALCOHOL INTAKE; PRIMARY PREVENTION; UNITED-STATES; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; COMBINED IMPACT; BREAST-CANCER; WOMEN AB Objectives. We examined the relationship between 4 low-risk behaviors never smoked, healthy diet, adequate physical activity, and moderate alcohol consumption and mortality in a representative sample of people in the United States. Methods. We used data from 16958 participants aged 17 years and older in the National Health and Nutrition Examination Survey III Mortality Study from 1988 to 2006. Results. The number of low-risk behaviors was inversely related to the risk for mortality. Compared with participants who had no low-risk behaviors, those who had all 4 experienced reduced all-cause mortality (adjusted hazard ratio [AHR]=0.37; 95% confidence interval [CI]=0.28, 0.49), mortality from malignant neoplasms (AHR =0.34; 95% CI=0.20, 0.56), major cardiovascular disease (AHR =0.35; 95% CI=0.24, 0.50), and other causes (AHR =0.43; 95% CI=0.25, 0.74). The rate advancement periods, representing the equivalent risk from a certain number of years of chronological age, for participants who had all 4 high-risk behaviors compared with those who had none were 11.1 years for all-cause mortality, 14.4 years for malignant neoplasms, 9.9 years for major cardiovascular disease, and 10.6 years for other causes. Conclusions. Low-risk lifestyle factors exert a powerful and beneficial effect on mortality. (Am J Public Health. 2011;101:1922-1929. doi:10.2105/AJPH.2011.300167) C1 [Ford, Earl S.; Zhao, Guixiang; Tsai, James; Li, Chaoyang] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ford, ES (reprint author), 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov NR 58 TC 72 Z9 80 U1 2 U2 20 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2011 VL 101 IS 10 BP 1922 EP 1929 DI 10.2105/AJPH.2011.300167 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 830LB UT WOS:000295657400031 PM 21852630 ER PT J AU Bean, LJH Allen, EG Tinker, SW Hollis, ND Locke, AE Druschel, C Hobbs, CA O'Leary, L Romitti, PA Royle, MH Torfs, CP Dooley, KJ Freeman, SB Sherman, SL AF Bean, Lora J. H. Allen, Emily G. Tinker, Stuart W. Hollis, NaTasha D. Locke, Adam E. Druschel, Charlotte Hobbs, Charlotte A. O'Leary, Leslie Romitti, Paul A. Royle, Marjorie H. Torfs, Claudine P. Dooley, Kenneth J. Freeman, Sallie B. Sherman, Stephanie L. TI Lack of Maternal Folic Acid Supplementation Is Associated with Heart Defects in Down Syndrome: A Report from the National Down Syndrome Project SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE atrial septal defect; atrioventricular septal defect; congenital heart defect; Down syndrome; folic acid ID NEURAL-TUBE DEFECTS; FOLATE METABOLISM GENES; METHYLENETETRAHYDROFOLATE REDUCTASE; SPINA-BIFIDA; HOMOCYSTEINE CONCENTRATIONS; METHIONINE SYNTHASE; VASCULAR-DISEASE; CARDIAC DEFECTS; UNITED-STATES; CARRIER A80G AB BACKGROUND: Maternal folic acid supplementation has been associated with a reduced risk for neural tube defects and may be associated with a reduced risk for congenital heart defects and other birth defects. Individuals with Down syndrome are at high risk for congenital heart defects and have been shown to have abnormal folate metabolism. METHODS: As part of the population-based case-control National Down Syndrome Project, 1011 mothers of infants with Down syndrome reported their use of supplements containing folic acid. These data were used to determine whether a lack of periconceptional maternal folic acid supplementation is associated with congenital heart defects in Down syndrome. We used logistic regression to test the relationship between maternal folic acid supplementation and the frequency of specific heart defects correcting for maternal race or ethnicity, proband sex, maternal use of alcohol and cigarettes, and maternal age at conception. RESULTS: Lack of maternal folic acid supplementation was more frequent among infants with Down syndrome and atrioventricular septal defects (odds ratio [OR], 1.69; 95% confidence interval [CI], 1.08-2.63; p = 0.011) or atrial septal defects (OR, 1.69; 95% CI, 1.11-2.58; p = 0.007) than among infants with Down syndrome and no heart defect. Preliminary evidence suggests that the patterns of association differ by race or ethnicity and sex of the proband. There was no statistically significant association with ventricular septal defects (OR, 1.26; 95% CI, 0.85-1.87; p = 0.124). CONCLUSIONS: Our results suggest that lack of maternal folic acid supplementation is associated with septal defects in infants with Down syndrome. Birth Defects Research (Part A) 91: 885-893, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Bean, Lora J. H.; Allen, Emily G.; Tinker, Stuart W.; Hollis, NaTasha D.; Locke, Adam E.; Freeman, Sallie B.; Sherman, Stephanie L.] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA. [Druschel, Charlotte] New York State Dept Hlth, Troy, NY USA. [Hobbs, Charlotte A.] Univ Arkansas Med Sci, Dept Pediat, Coll Med, Little Rock, AR 72205 USA. [O'Leary, Leslie] Ctr Dis Control & Prevent, Atlanta, GA USA. [Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Royle, Marjorie H.] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [Torfs, Claudine P.] Birth Defects Studies, Inst Publ Hlth, Emeryville, CA USA. [Dooley, Kenneth J.] Childrens Healthcare Atlanta, Sibley Heart Ctr Cardiol, Atlanta, GA USA. RP Bean, LJH (reprint author), Emory Univ, Dept Human Genet, 615 Michael St,Suite 301, Atlanta, GA 30322 USA. EM ljbean@emory.edu OI Locke, Adam/0000-0001-6227-198X FU National Institutes of Health [R01 HD38979, P01HD24605, F32 HD046337, RO1 HL083300] FX Supported by National Institutes of Health grants R01 HD38979, P01HD24605, F32 HD046337, and RO1 HL083300 and by the technical assistance of the General Clinical Research Center at Emory University (NIH/NCRR M01 RR00039). NR 50 TC 16 Z9 16 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2011 VL 91 IS 10 BP 885 EP 893 DI 10.1002/bdra.22848 PG 9 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 840DR UT WOS:000296419000004 PM 21987466 ER PT J AU Pollack, LA Hawkins, NA Peaker, BL Buchanan, N Risendal, BC AF Pollack, Lori A. Hawkins, Nikki A. Peaker, Brandy L. Buchanan, Natasha Risendal, Betsy C. TI Dissemination and Translation: A Frontier for Cancer Survivorship Research SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID PUBLIC-HEALTH IMPACT; RE-AIM FRAMEWORK; PSYCHOSOCIAL INTERVENTIONS; BREAST-CANCER; CARE PLANS; IMPLEMENTATION; DIFFUSION; INTEGRATION; PREVENTION; COMMUNITY AB As the field of survivorship research grows, the need for translation is imperative to expand new knowledge into arenas that directly impact survivors. This commentary seeks to encourage research focused on dissemination and translation of survivorship interventions and programs, including practice-based research. Weoverview diffusion, dissemination and translation in the context of cancer survivorship and present the RE-AIM and Knowledge to Action frameworks as approaches that can be used to expand research into communities. Many academic, governmental, and community-based organizations focus on cancer survivor. Future survivorship research should contribute to harmonizing these assets to identify effective interventions, maximize their reach and adoption, and integrate promising practices into routine care. Cancer Epidemiol Biomarkers Prev; 20(10); 2093-8. (C)2011 AACR. C1 [Pollack, Lori A.; Hawkins, Nikki A.; Buchanan, Natasha] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Atlanta, GA USA. [Peaker, Brandy L.] Ctr Dis Control & Prevent, Comprehens Canc Control Branch, Div Canc Prevent & Control, Atlanta, GA USA. [Risendal, Betsy C.] Univ Colorado, Colorado Sch Publ Hlth, Ctr Canc, Aurora, CO USA. RP Pollack, LA (reprint author), 1600 Clifton Rd,MS E-92, Atlanta, GA 30333 USA. EM lop5@cdc.gov FU Intramural CDC HHS [CC999999] NR 47 TC 13 Z9 13 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2011 VL 20 IS 10 BP 2093 EP 2098 DI 10.1158/1055-9965.EPI-11-0652 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 831GR UT WOS:000295717900012 PM 21980017 ER PT J AU Khoury, MJ Clauser, SB Freedman, AN Gillanders, EM Glasgow, RE Klein, WMP Schully, SD AF Khoury, Muin J. Clauser, Steven B. Freedman, Andrew N. Gillanders, Elizabeth M. Glasgow, Russ E. Klein, William M. P. Schully, Sheri D. TI Population Sciences, Translational Research, and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Review ID EGAPP WORKING GROUP; GENETIC TESTING STRATEGIES; WIDE ASSOCIATION; COLORECTAL-CANCER; BREAST-CANCER; LYNCH SYNDROME; MOLECULAR EPIDEMIOLOGY; PERSONALIZED MEDICINE; MUTATION CARRIERS; RESEARCH AGENDA AB Advances in genomics and related fields are promising tools for risk assessment, early detection, and targeted therapies across the entire cancer care continuum. In this commentary, we submit that this promise cannot be fulfilled without an enhanced translational genomics research agenda firmly rooted in the population sciences. Population sciences include multiple disciplines that are needed throughout the translational research continuum. For example, epidemiologic studies are needed not only to accelerate genomic discoveries and new biological insights into cancer etiology and pathogenesis, but to characterize and critically evaluate these discoveries in well-defined populations for their potential for cancer prediction, prevention and response to treatment. Behavioral, social, and communication sciences are needed to explore genomic-modulated responses to old and new behavioral interventions, adherence to therapies, decision making across the continuum, and effective use in health care. Implementation science, health services, outcomes research, comparative effectiveness research, and regulatory science are needed for moving validated genomic applications into practice and for measuring their effectiveness, cost-effectiveness, and unintended consequences. Knowledge synthesis, evidence reviews, and economic modeling of the effects of promising genomic applications will facilitate policy decisions and evidence-based recommendations. Several independent and multidisciplinary panels have recently made specific recommendations for enhanced research and policy infrastructure to inform clinical and population research for moving genomic innovations into the cancer care continuum. An enhanced translational genomics and population sciences agenda is urgently needed to fulfill the promise of genomics in reducing the burden of cancer. Cancer Epidemiol Biomarkers Prev; 20(10); 2105-14. (C)2011 AACR. C1 [Khoury, Muin J.] Ctr Dis Control & Prevent, Office Publ Hlth Genom, Atlanta, GA USA. [Khoury, Muin J.; Clauser, Steven B.; Freedman, Andrew N.; Gillanders, Elizabeth M.; Glasgow, Russ E.; Klein, William M. P.; Schully, Sheri D.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Khoury, MJ (reprint author), CDC, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM muk1@CDC.GOV FU Intramural NIH HHS [Z99 CA999999] NR 74 TC 23 Z9 23 U1 3 U2 21 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2011 VL 20 IS 10 BP 2105 EP 2114 DI 10.1158/1055-9965.EPI-11-0481 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 831GR UT WOS:000295717900014 PM 21795499 ER PT J AU Wisnewski, AV Hettick, JM Siegel, PD AF Wisnewski, Adam V. Hettick, Justin M. Siegel, Paul D. TI Toluene Diisocyanate Reactivity with Glutathione Across a Vapor/Liquid Interface and Subsequent Transcarbamoylation of Human Albumin SO CHEMICAL RESEARCH IN TOXICOLOGY LA English DT Article ID METHYL ISOCYANATE; EPITHELIAL-CELLS; PROTECTIVE ROLE; INDUCED ASTHMA; PROTEINS; ADDUCTS; EXPOSURE; LUNG; MICE; RAT AB Glutathione has previously been identified as a reaction target for toluene diisocyanate (TDI) in vitro and in vivo, and has been suggested to contribute to toxic and allergic reactions to exposure. In this study, the reactivity of reduced glutathione (GSH) with TDI in vitro was further investigated using a mixed phase (vapor/liquid) exposure system to model the in vivo biophysics of exposure in the lower respiratory tract. HPLC/MS/MS was used to characterize the observed reaction products. Under the conditions tested, the major reaction products between TDI vapor and GSH were S-linked bis-(GSH)-TDI and to a lesser extent mono (GSH)-TDI conjugates (with one N=C=O hydrolyzed). The vapor-phase-generated GSH-TDI conjugates were capable of transcarbamoylating human albumin in a pH-dependent manner, resulting in changes in the self-protein's conformation/charge, on the basis of electrophoretic mobility under native conditions. Specific sites of human albumin-TDI conjugation, mediated by GSH-TDI, were identified (Lys(73), Lys(159), Lys(190), Lys(199), Lys(212), Lys(351), Lys(136/137), Lys(413/414), and Lys(524/525)) along with overlap with those susceptible to direct conjugation by TDI. Together, the data extend the proof-of-principle for GSH to act as a "shuttle" for a reactive form of TDI, which could contribute to clinical responses to exposure. C1 [Wisnewski, Adam V.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. [Hettick, Justin M.; Siegel, Paul D.] NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Morgantown, WV USA. RP Wisnewski, AV (reprint author), Yale Univ, Sch Med, Dept Internal Med, 300 Cedar St,TAC S4157,POB 208057, New Haven, CT 06520 USA. EM adam.wisnewski@yale.edu RI Hettick, Justin/E-9955-2010 FU National Institute of Environmental Health Safety [R42-ES016728, R41-ES018021] FX The studies were supported by grants R42-ES016728 and R41-ES018021 from the National Institute of Environmental Health Safety. NR 40 TC 16 Z9 17 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0893-228X J9 CHEM RES TOXICOL JI Chem. Res. Toxicol. PD OCT PY 2011 VL 24 IS 10 BP 1686 EP 1693 DI 10.1021/tx2002433 PG 8 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology SC Pharmacology & Pharmacy; Chemistry; Toxicology GA 832PP UT WOS:000295817800011 PM 21806041 ER PT J AU Dainiak, N Gent, RN Carr, Z Schneider, R Bader, J Buglova, E Chao, N Coleman, CN Ganser, A Gorin, C Hauer-Jensen, M Huff, LA Lillis-Hearne, P Maekawa, K Nemhauser, J Powles, R Schunemann, H Shapiro, A Stenke, L Valverde, N Weinstock, D White, D Albanese, J Meineke, V AF Dainiak, Nicholas Gent, Robert Nicolas Carr, Zhanat Schneider, Rita Bader, Judith Buglova, Elena Chao, Nelson Coleman, C. Norman Ganser, Arnold Gorin, Claude Hauer-Jensen, Martin Huff, L. Andrew Lillis-Hearne, Patricia Maekawa, Kazuhiko Nemhauser, Jeffrey Powles, Ray Schuenemann, Holger Shapiro, Alla Stenke, Leif Valverde, Nelson Weinstock, David White, Douglas Albanese, Joseph Meineke, Viktor TI Literature Review and Global Consensus on Management of Acute Radiation Syndrome Affecting Nonhematopoietic Organ Systems SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Review DE countermeasures for ARS; acute radiation syndrome management; treatment of ARS; narrative review of countermeasures for ARS ID MESENCHYMAL STEM-CELLS; RESPIRATORY-DISTRESS-SYNDROME; MEDICAL-MANAGEMENT; CRITICALLY-ILL; GLUCOSE CONTROL; PUBLIC-HEALTH; CRITICAL-CARE; SEPTIC SHOCK; DOUBLE-BLIND; LUNG INJURY AB Objectives: The World Health Organization convened a panel of experts to rank the evidence for medical countermeasures for management of acute radiation syndrome (ARS) in a hypothetical scenario involving the hospitalization of 100 to 200 victims. The goal of this panel was to achieve consensus on optimal management of ARS affecting nonhematopoietic organ systems based upon evidence in the published literature. Methods: English-language articles were identified in MEDLINE and PubMed. Reference lists of retrieved articles were distributed to conferees in advance of and updated during the meeting. Published case series and case reports of ARS, publications of randomized controlled trials of relevant interventions used to treat nonirradiated individuals, reports of studies in irradiated animals, and prior recommendations of subject matter experts were selected. Studies were extracted using the Grading of Recommendations Assessment Development and Evaluation system. In cases in which data were limited or incomplete, a narrative review of the observations was made. Results: No randomized controlled trials of medical countermeasures have been completed for individuals with ARS. Reports of countermeasures were often incompletely described, making it necessary to rely on data generated in nonirradiated humans and in experimental animals. A strong recommendation is made for the administration of a serotonin-receptor antagonist prophylactically when the suspected exposure is >2 Gy and topical steroids, antibiotics, and antihistamines for radiation burns, ulcers, or blisters; excision and grafting of radiation ulcers or necrosis with intractable pain; provision of supportive care to individuals with neurovascular syndrome; and administration of electrolyte replacement therapy and sedatives to individuals with significant burns, hypovolemia, and/orshock. A strong recommendation is made against the use of systemic steroids in the absence of a specific indication. A weak recommendation is made for the use of fluoroquinolones, bowel decontamination, loperamide, and enteral nutrition, and for selective oropharyngeal/digestive decontamination, blood glucose maintenance, and stress ulcer prophylaxis in critically ill patients. Conclusions: High-quality studies of therapeutic interventions in humans exposed to nontherapeutic radiation are not available, and because of ethical concerns regarding the conduct of controlled studies in humans, such studies are unlikely to emerge in the near future. C1 [Meineke, Viktor] Bundeswehr Inst Radiobiol, D-80937 Munich, Germany. [Dainiak, Nicholas] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Dainiak, Nicholas] Yale New Haven Hlth Bridgeport Hosp, New Haven, CT USA. [Carr, Zhanat] World Hlth Org, Geneva, Switzerland. [Schneider, Rita] Univ Wurzburg, Dept Nucl Med, D-97070 Wurzburg, Germany. [Bader, Judith; Coleman, C. Norman] Natl Canc Inst, Bethesda, MD 20892 USA. [Chao, Nelson] Duke Univ, Durham, NC 27706 USA. [Ganser, Arnold] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany. [Gorin, Claude] Hosp St Antoine, St Antoine, France. [Hauer-Jensen, Martin] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Huff, L. Andrew; Lillis-Hearne, Patricia] Armed Forces Radiobiol Res Inst, Bethesda, MD 20814 USA. [Maekawa, Kazuhiko] Kanto Cent Hosp, Tokyo, Japan. [Nemhauser, Jeffrey] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Schuenemann, Holger] McMaster Univ, Hamilton, ON L8S 4L8, Canada. [Shapiro, Alla] US FDA, Rockville, MD 20857 USA. [Stenke, Leif] Karolinska Inst, S-10401 Stockholm, Sweden. [Weinstock, David] Dana Farber Canc Inst, Boston, MA 02115 USA. [White, Douglas] Univ Pittsburgh, Program Eth & Crit Care Med, Pittsburgh, PA 15260 USA. [Albanese, Joseph] Yale New Haven Hlth Ctr Emergency Preparedness &, New Haven, CT USA. RP Meineke, V (reprint author), Bundeswehr Inst Radiobiol, Neuherbergstr 11, D-80937 Munich, Germany. EM ViktorMeineke@bundeswehr.org FU National Institute of Allergy and Infectious Diseases FX Owing to their seminal contributions in the field of radiation biology and their pioneering approaches to treatment of victims of radiation injury, this consultancy report is dedicated to Theodor M. Fliedner and Angelina Guskova. The authors thank Makoto Akashi, Axel Bottger, Thierry de Revel, Patrick Gourmelon, Richard Hatchett, Mikhail Konchalovski, Ying Liu, Maria Julia Marinissen, Hilary Walker, Helmut Walerius, and Wei Zhang for participating in the consultancy and contributing to consensus building. The authors are grateful to Richard Hatchett and the National Institute of Allergy and Infectious Diseases for providing financial support for this consultancy. NR 181 TC 28 Z9 28 U1 1 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2011 VL 5 IS 3 BP 183 EP 201 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 839JU UT WOS:000296362300007 PM 21986999 ER PT J AU Dainiak, N Gent, RN Carr, Z Schneider, R Bader, J Buglova, E Chao, N Coleman, CN Ganser, A Gorin, C Hauer-Jensen, M Huff, LA Lillis-Hearne, P Maekawa, K Nemhauser, J Powles, R Schunemann, H Shapiro, A Stenke, L Valverde, N Weinstock, D White, D Albanese, J Meineke, V AF Dainiak, Nicholas Gent, Robert Nicolas Carr, Zhanat Schneider, Rita Bader, Judith Buglova, Elena Chao, Nelson Coleman, C. Norman Ganser, Arnold Gorin, Claude Hauer-Jensen, Martin Huff, L. Andrew Lillis-Hearne, Patricia Maekawa, Kazuhiko Nemhauser, Jeffrey Powles, Ray Schuenemann, Holger Shapiro, Alla Stenke, Leif Valverde, Nelson Weinstock, David White, Douglas Albanese, Joseph Meineke, Viktor TI First Global Consensus for Evidence-Based Management of the Hematopoietic Syndrome Resulting From Exposure to Ionizing Radiation SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Review DE countermeasures for ARS; cytokines and radiation injury; transplantation for ARS; acute radiation syndrome management; hematopoietic syndrome management ID COLONY-STIMULATING FACTOR; MEDICAL-MANAGEMENT; PROGENITOR CELLS; RHESUS-MONKEYS; RECOMMENDATIONS; ACCIDENT; MYELOSUPPRESSION; RADIOSENSITIVITY; TRANSPLANTATION; GROWTH AB Objective: Hematopoietic syndrome (HS) is a clinical diagnosis assigned to people who present with >1 new-onset cytopenias in the setting of acute radiation exposure. The World Health Organization convened a panel of experts to evaluate the evidence and develop recommendations for medical countermeasures for the management of HS in a hypothetical scenario involving the hospitalization of 100 to 200 individuals exposed to radiation. The objective of this consultancy was to develop recommendations for treatment of the HS based upon the quality of evidence. Methods: English-language articles were identified in MEDLINE and PubMed. Reference lists of retrieved articles were distributed to panel members before the meeting and updated during the meeting. Published case series and case reports of individuals with HS, published randomized controlled trials of relevant interventions used to treat nonirradiated individuals, reports of studies in irradiated animals, and prior recommendations of subject matter experts were selected. Studies were extracted using the Grading of Recommendations Assessment Development and Evaluation (GRADE) system. In cases in which data were limited or incomplete, a narrative review of the observations was made. No randomized controlled trials of medical countermeasures have been completed for individuals with radiation-associated HS. The use of GRADE analysis of countermeasures for injury to hematopoietic tissue was restricted by the lack of comparator groups in humans. Reliance on data generated in nonirradiated humans and experimental animals was necessary. Results: Based upon GRADE analysis and narrative review, a strong recommendation was made for the administration of granulocyte colony-stimulating factor or granulocyte macrophage colony-stimulating factor and a weak recommendation was made for the use of erythropoiesis-stimulating agents or hematopoietic stem cell transplantation. Conclusions: Assessment of therapeutic interventions for HS in humans exposed to nontherapeutic radiation is difficult because of the limits of the evidence. (Disaster Med Public Health Preparedness. 2011;5:202-212) C1 [Meineke, Viktor] Bundeswehr Inst Radiobiol, D-80937 Munich, Germany. [Dainiak, Nicholas] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Dainiak, Nicholas] Yale New Haven Hlth Bridgeport Hosp, New Haven, CT USA. [Carr, Zhanat] World Hlth Org, Geneva, Switzerland. [Schneider, Rita] Univ Wurzburg, Dept Nucl Med, D-97070 Wurzburg, Germany. [Bader, Judith; Coleman, C. Norman] Natl Canc Inst, Bethesda, MD 20892 USA. [Chao, Nelson] Duke Univ, Durham, NC 27706 USA. [Ganser, Arnold] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany. [Gorin, Claude] Hosp St Antoine, St Antoine, France. [Hauer-Jensen, Martin] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Huff, L. Andrew; Lillis-Hearne, Patricia] Armed Forces Radiobiol Res Inst, Bethesda, MD 20814 USA. [Maekawa, Kazuhiko] Kanto Cent Hosp, Tokyo, Japan. [Nemhauser, Jeffrey] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Schuenemann, Holger] McMaster Univ, Hamilton, ON L8S 4L8, Canada. [Shapiro, Alla] US FDA, Rockville, MD 20857 USA. [Stenke, Leif] Karolinska Inst, S-10401 Stockholm, Sweden. [Weinstock, David] Dana Farber Canc Inst, Boston, MA 02115 USA. [White, Douglas] Univ Pittsburgh, Program Eth & Crit Care Med, Pittsburgh, PA 15260 USA. [Albanese, Joseph] Yale New Haven Hlth Ctr Emergency Preparedness &, New Haven, CT USA. RP Meineke, V (reprint author), Bundeswehr Inst Radiobiol, Neuherbergstr 11, D-80937 Munich, Germany. EM ViktorMeineke@bundeswehr.org FU National Institute of Allergy and Infectious Diseases FX Owing to their seminal contributions in the field of radiation biology and their pioneering approaches to treatment of victims of radiation injury, this consultancy report is dedicated to Theodor M. Fliedner and Angelina Guskova. The authors thank Makoto Akashi, Axel Bottger, Thierry de Revel, Patrick Gourmelon, Richard Hatchett, Mikhail Konchalovski, Ying Liu, Maria Julia Marinissen, Hilary Walker, Helmut Walerius, and Wei Zhang for participating in the consultancy and contributing to consensus building. The authors are grateful to the National Institute of Allergy and Infectious Diseases for providing financial support for this consultancy. NR 44 TC 32 Z9 34 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2011 VL 5 IS 3 BP 202 EP 212 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 839JU UT WOS:000296362300008 PM 21987000 ER PT J AU Fischer, KE Grosse, SD Rogowski, WH AF Fischer, Katharina E. Grosse, Scott D. Rogowski, Wolf H. TI The role of health technology assessment in coverage decisions on newborn screening SO INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE LA English DT Article DE Neonatal screening; Decision-making processes; Reimbursement; Health technology assessment; Fourth hurdle ID ECONOMIC-EVALUATION; 4TH HURDLE; POLICY; SWEDEN; FRAMEWORK; SYSTEMS AB Objectives: The role and impact of health technology assessment (HTA) in health policy has been widely discussed. Researchers have started to analyze how decisions on coverage of new technologies are made. Although the involvement of HTA may be an indicator of a well established decision process, this hypothesis requires validation. Also, it is not known whether HTA involvement is associated with other characteristics of decision making like participation or transparency. The primary objective of this study was to develop and test statements on the association between the publication of an HTA and coverage decision making for newborn screening tests in European Union countries. Methods: Five statements were defined on the relative role of HTA during the steps of decision processes: trigger, participation, publication, assessment, and appraisal. For this purpose, data on twenty-two decision processes in the area of newborn screening across Europe were analyzed, defined as a coverage decision for a given disorder in a specific country. Decision processes were compared by whether the decision was accompanied by the publication of an HTA report. To test differences, nonparametric statistical tests were used. Results: The decision steps of trigger, participation and publication differed between the HTA and the non-HTA groups. No clear association between HTA and assessment methods in coverage decision making was identified. Conclusions: It appeared that there is an association between HTA and coverage decision processes that are more explicit, inclusive, and transparent. It is unclear whether HTA is associated with formal evidence reviews and economic evaluations. C1 [Fischer, Katharina E.; Rogowski, Wolf H.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management, D-85764 Neuherberg, Germany. [Grosse, Scott D.] US Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA 30333 USA. [Rogowski, Wolf H.] Univ Munich, Inst Occupat Social & Environm Med, Ctr Clin, D-80336 Munich, Germany. [Rogowski, Wolf H.] Univ Munich, Outpatient Clin Occupat Social & Environm Med, Ctr Clin, D-80336 Munich, Germany. RP Fischer, KE (reprint author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management, Ingolstadter Land Str 1, D-85764 Neuherberg, Germany. EM Katharina.Fischer@helmholtz-muenchen.de; sgg4@cdc.gov; Rogowski@helmholtz-muenchen.de RI Rogowski, Wolf/D-9334-2013 FU European Union [223533] FX The authors thank Jurgen John for valuable comments on earlier versions of this article, Matthias Hunger and Petra Menn for comments on statistical analysis, and Werner Maier for support with contacting respondents in French. Furthermore, the authors thank Gerard Loeber from the International Society for Neonatal Screening who provided contact to the respondents. All respondents contributed valuable expertise in the survey on decision processes in the area of newborn screening. The authors thank those respondents who preferred to stay anonymous as well as the following who agreed to disclose their names: Tadej Battelino (Slovenia), Matthias Baumgartner (Switzerland), Martina Cornel (The Netherlands), Francois Eyskens (Belgium), Jean Pierre Farriaux (France), David Hougaard (Denmark), Daniela Iorgulescu (Romania), Alastair Kent (England), Milan Macek (Czech Republic), Uta Nennstiel-Ratzel (Germany), Florence Orsini (France), Peter Saugmann-Jensen (Denmark), Toni Torresani (Switzerland), Felix Votava (Czech Republic), Mojca Zerjav-Tansek (Slovenia). Finally, the authors express their gratitude to the very helpful and supportive comments of two anonymous referees. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 223533. The funding source had no role in the study design, data collection, or interpretation of results. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 30 TC 3 Z9 3 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0266-4623 J9 INT J TECHNOL ASSESS JI Int. J. Technol. Assess. Health Care PD OCT PY 2011 VL 27 IS 4 BP 313 EP 321 DI 10.1017/S0266462311000468 PG 9 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics GA 840EH UT WOS:000296420600007 PM 22004771 ER PT J AU Hamel, MJ Adazu, K Obor, D Sewe, M Vulule, J Williamson, JM Slutsker, L Feikin, DR Laserson, KF AF Hamel, Mary J. Adazu, Kubaje Obor, David Sewe, Maquins Vulule, John Williamson, John M. Slutsker, Laurence Feikin, Daniel R. Laserson, Kayla F. TI A Reversal in Reductions of Child Mortality in Western Kenya, 2003-2009 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID DEMOGRAPHIC SURVEILLANCE; AFRICAN CHILDREN; VERBAL AUTOPSIES; CONTROLLED-TRIAL; DOUBLE-BLIND; MALARIA; HIV; HEALTH; TRANSMISSION; ZIDOVUDINE AB We report and explore changes in child mortality in a rural area of Kenya during 2003-2009, when major public health interventions were scaled-up. Mortality ratios and rates were calculated by using the Kenya Medical Research Institute/Centers for Disease Control and Prevention Demographic Surveillance System. Inpatient and outpatient morbidity and mortality, and verbal autopsy data were analyzed. Mortality ratios for children less than five years of age decreased from 241 to 137 deaths/1,000 live-births in 2003 and 2007 respectively. In 2008, they increased to 212 deaths/1,000 live-births. Mortality remained elevated during the first 8 months of 2009 compared with 2006 and 2007. Malaria and/or anemia accounted for the greatest increases in child mortality. Stock-outs of essential antimalarial drugs during a time of increased malaria transmission and disruption of services during civil unrest may have contributed to increased mortality in 2008-2009. To maintain gains in child survival, implementation of good policies and effective interventions must be complemented by reliable supply and access to clinical services and essential drugs. C1 [Hamel, Mary J.; Slutsker, Laurence; Feikin, Daniel R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Williamson, John M.; Laserson, Kayla F.] KEMRI CDC Res Stn, Unit 64112, Kisumu, Kenya. [Vulule, John] Kenya Medial Res Inst, Kisumu, Kenya. RP Hamel, MJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop F-22, Atlanta, GA 30333 USA. EM mhamel@cdc.gov; dobor@ke.cdc.gov; msewe@ke.cdc.gov; jvulule@ke.cdc.gov; jwilliamson@ke.cdc.gov; lIslutsker@cdc.gov; dfeikin@jhsph.edu; klaserson@ke.cdc.gov NR 33 TC 60 Z9 60 U1 1 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2011 VL 85 IS 4 BP 597 EP 605 DI 10.4269/ajtmh.2011.10-0678 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 833QB UT WOS:000295898900005 PM 21976557 ER PT J AU Phares, CR Kapella, BK Doney, AC Arguin, PM Green, M Mekonnen, L Galev, A Weinberg, M Stauffer, WM AF Phares, Christina R. Kapella, Bryan K. Doney, Annelise C. Arguin, Paul M. Green, Michael Mekonnen, Leul Galev, Aleksander Weinberg, Michelle Stauffer, William M. TI Presumptive Treatment to Reduce Imported Malaria among Refugees from East Africa Resettling in the United States SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; ARTEMETHER-LUMEFANTRINE; SULFADOXINE-PYRIMETHAMINE; TRANSMISSION; TANZANIA; EFFICACY; DRUG AB During May 4, 2007-February 29, 2008, the United States resettled 6,159 refugees from Tanzania. Refugees received pre-departure antimalarial treatment with sulfadoxine-pyrimethamine (SP), partially supervised (three/six doses) artemether-lumefantrine (AL), or fully supervised AL. Thirty-nine malaria cases were detected. Disease incidence was 15.5/1,000 in the SP group and 3.2/1,000 in the partially supervised AL group (relative change = -79%, 95% confidence interval = -56% to -90%). Incidence was 1.3/1,000 refugees in the fully supervised AL group (relative change = -92% compared with SP group; 95% confidence interval = -66% to -98%). Among 39 cases, 28 (72%) were in refugees <15 years of age. Time between arrival and symptom onset (median = 14 days, range = 3-46 days) did not differ by group. Thirty-two (82%) persons were hospitalized, 4 (10%) had severe manifestations, and 9 (27%) had parasitemias > 5% (range = < 0.1-18%). Pre-departure presumptive treatment with an effective drug is associated with decreased disease among refugees. C1 [Stauffer, William M.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA. [Phares, Christina R.; Doney, Annelise C.; Arguin, Paul M.; Green, Michael; Weinberg, Michelle] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kapella, Bryan K.] US Embassy Annex, Ctr Dis Control & Prevent, Hanoi, Vietnam. [Mekonnen, Leul] Int Org Migrat, Addis Ababa, Ethiopia. [Galev, Aleksander] Int Org Migrat, Nairobi, Kenya. RP Stauffer, WM (reprint author), Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Mayo D407,MMC 250,420 Delaware St SE, Minneapolis, MN 55455 USA. EM cphares@cdc.gov; kapellabk@vmcdc.gov; adoney@cdc.gov; parguin@cdc.gov; mdg4@cdc.gov; lmekonnen@iom.int; agalev@iom.int; mweinberg@cdc.gov; stauf005@umn.edu FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 23 TC 3 Z9 3 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2011 VL 85 IS 4 BP 612 EP 615 DI 10.4269/ajtmh.2011.11-0132 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 833QB UT WOS:000295898900007 PM 21976559 ER PT J AU Starr, MC Montgomery, SP AF Starr, Michelle C. Montgomery, Susan P. TI Soil-Transmitted Helminthiasis in the United States: A Systematic Review-1940-2010 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Review ID STRONGYLOIDES-STERCORALIS INFECTION; INTESTINAL HELMINTHS; EASTERN KENTUCKY; SCHOOL-CHILDREN; ENDEMIC AREA; HOOKWORM; ASCARIASIS; FEATURES; REVIEWS; GEORGIA AB The epidemiology of soil-transmitted helminth infections (hookworm, Trichuris trichiura, Ascaris lumbricoides, and Strongyloides stercoralis) in the United States is poorly understood. To gain understanding of the status of disease, a systematic review was performed to assess the prevalence of soil-transmitted helminth infections in the United States. Of all studies reviewed, 14 were designated as high-quality. High-quality studies were published from 1942 to 1982 and showed that infection was prevalent throughout the southern United States and Appalachia as recently as 1982, finding that hookworm (19.6%), T. trichiura (55.2%), A. lumbricoides (49.4%), and S. stercoralis (3.8%) affected significant percentages of the population. However, because the most recent high-quality studies were published over 25 years ago, the literature does not provide sufficient data to assess current endemic transmission. Because the status of disease remains unclear, there is a need for additional studies to determine if soil-transmitted helminths remain endemic in the United States. C1 [Starr, Michelle C.; Montgomery, Susan P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. RP Starr, MC (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Mailstop F22,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM kbz4@cdc.gov; zqu6@cdc.gov OI Starr, Michelle/0000-0001-9412-8950 FU Centers for Disease Control and Prevention (CDC); External Medical Affairs, Pfizer, Inc. FX This work was made possible through the Centers for Disease Control and Prevention (CDC) Experience Applied Epidemiology Fellowship, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer, Inc. NR 30 TC 19 Z9 19 U1 3 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2011 VL 85 IS 4 BP 680 EP 684 DI 10.4269/ajtmh.2011.11-0214 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 833QB UT WOS:000295898900020 PM 21976572 ER PT J AU Hochberg, NS Blackburn, BG Park, SY Sejvar, JJ Effler, PV Herwaldt, BL AF Hochberg, Natasha S. Blackburn, Brian G. Park, Sarah Y. Sejvar, James J. Effler, Paul V. Herwaldt, Barbara L. TI Eosinophilic Meningitis Attributable to Angiostrongylus cantonensis Infection in Hawaii: Clinical Characteristics and Potential Exposures SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ACHATINA-FULICA SNAILS; ETIOLOGIC ROLE; MENINGOENCEPHALITIS; OUTBREAK; TRANSMISSION; THAILAND; TAIWAN; VECTOR; LARVAE; RATS AB The most common infectious cause of eosinophilic meningitis is Angiostrongylus cantonensis, which is transmitted largely by consumption of snails/slugs. We previously identified cases of angiostrongyliasis that occurred in Hawaii from 2001 to 2005; the highest incidence was on the island of Hawaii. We now report symptoms, laboratory parameters, and exposures. Eighteen patients were evaluated; 94% had headache, and 65% had sensory symptoms (paresthesia, hyperesthesia, and/or numbness). These symptoms lasted a median of 17 and 55 days, respectively. Three persons recalled finding a slug in their food/drink. Case-patients on the island of Hawaii were more likely than case-patients on other islands to consume raw homegrown produce in a typical week (89% versus 0%, P <0.001) and to see snails/slugs on produce (56% versus 0%, P = 0.03). Residents and travelers should be aware of the potential risks of eating uncooked produce in Hawaii, especially if it is from the island of Hawaii and locally grown. C1 [Hochberg, Natasha S.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA. [Blackburn, Brian G.] Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. [Park, Sarah Y.] Hawaii State Dept Hlth, Dis Outbreak Control Div, Honolulu, HI USA. [Sejvar, James J.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Zoonot & Emerging Infect Dis, Atlanta, GA USA. [Effler, Paul V.] Dept Hlth, Prevent & Control Program, Communicable Dis Control Directorate, Perth, WA, Australia. [Herwaldt, Barbara L.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Hochberg, NS (reprint author), Boston Univ, Sch Publ Hlth, Dept Epidemiol, 715 Albany St,Talbot 420E, Boston, MA 02118 USA. EM nhoch@bu.edu; blackburn@stanford.edu; sarah.park@doh.hawaii.gov; zea3@cdc.gov; Paul.Effler@health.wa.gov.au; bxh4@cdc.gov RI Mo, Agnes/G-6497-2011; OI Hochberg, Natasha/0000-0002-5449-9973 FU Centers for Disease Control and Prevention FX Financial support came from the Centers for Disease Control and Prevention. NR 44 TC 11 Z9 14 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2011 VL 85 IS 4 BP 685 EP 690 DI 10.4269/ajtmh.2011.11-0322 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 833QB UT WOS:000295898900021 PM 21976573 ER PT J AU Brault, AC Langevin, SA Ramey, WN Fang, Y Beasley, DWC Barker, CM Sanders, TA Reisen, WK Barrett, ADT Bowen, RA AF Brault, Aaron C. Langevin, Stanley A. Ramey, Wanichaya N. Fang, Ying Beasley, David W. C. Barker, Christopher M. Sanders, Todd A. Reisen, William K. Barrett, Alan D. T. Bowen, Richard A. TI Reduced Avian Virulence and Viremia of West Nile Virus Isolates from Mexico and Texas SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ENVELOPE PROTEIN GLYCOSYLATION; LOUIS ENCEPHALITIS-VIRUS; SEROLOGIC EVIDENCE; NEW-YORK; AMERICAN CROWS; KUNJIN VIRUS; BIRDS; STRAINS; INFECTION; TRANSMISSION AB A West Nile virus (WNV) isolate from Mexico (TM171-03) and BIRD1153, a unique genotype from Texas, have exhibited reduced murine neuroinvasive phenotypes. To determine if murine neuroinvasive capacity equates to avian virulence potential, American crow (Corvus brachyrhynchos) and house sparrows (Passer domesticus) were experimentally inoculated with representative murine neuroinvasive/non-neuroinvasive strains. In both avian species, a plaque variant from Mexico that was E-glycosylation competent produced higher viremias than an E-glycosylation incompetent variant, indicating the potential importance of E-glycosylation for avian replication. The murine non-neuroinvasive BIRD1153 strain was significantly attenuated in American crows but not house sparrows when compared with the murine neuroinvasive Texas strain. Despite the loss of murine neuroinvasive properties of nonglycosylated variants from Mexico, our data indicate avian replication potential of these strains and that unique WNV virulence characteristics exist between murine and avian models. The implications of reduced avian replication of variants from Mexico for restricted WNV transmission in Latin America is discussed. C1 [Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. [Langevin, Stanley A.; Ramey, Wanichaya N.; Fang, Ying; Barker, Christopher M.; Reisen, William K.] Univ Calif Davis, Ctr Vector Borne Dis, Davis, CA 95616 USA. [Langevin, Stanley A.; Ramey, Wanichaya N.; Fang, Ying; Barker, Christopher M.; Reisen, William K.] Univ Calif Davis, Dept Pathol Microbiol & Immunol, Sch Vet Med, Davis, CA 95616 USA. [Beasley, David W. C.; Barrett, Alan D. T.] Univ Texas Med Branch, Dept Pathol, Ctr Emerging Infect Dis & Biodef, Inst Human Infect & Immun, Galveston, TX USA. [Beasley, David W. C.; Barrett, Alan D. T.] Univ Texas Med Branch, Dept Microbiol & Immunol, Ctr Emerging Infect Dis & Biodef, Inst Human Infect & Immun, Galveston, TX USA. [Sanders, Todd A.] US Fish & Wildlife Serv, Div Migratory Bird Management, Portland, OR USA. [Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM abrault@cdc.gov; salangevin1@gmail.com; wramey@berkeley.edu; ylfang@ucdavis.edu; dwbeasle@utmb.edu; cmbarker@ucdavis.edu; todd_sanders@fws.gov; arbo123@pacbell.net; abarrett@utmb.edu; rbowen@colostate.edu FU National Institutes of Health [AI061822, AI055607, AI67847]; Pacific Southwest Regional Center for Excellence (PSWRCE) [U54 AI065359]; Centers for Disease Control and Prevention [CI000235] FX This study was supported by National Institutes of Health grants AI061822, AI055607, and AI67847; Pacific Southwest Regional Center for Excellence (PSWRCE) U54 AI065359; and Centers for Disease Control and Prevention grant CI000235. NR 46 TC 15 Z9 16 U1 0 U2 12 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2011 VL 85 IS 4 BP 758 EP 767 DI 10.4269/ajtmh.2011.10-0439 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 833QB UT WOS:000295898900032 PM 21976584 ER PT J AU He, GX Wang, HY Borgdorff, MW van Soolingen, D van der Werf, MJ Liu, ZM Li, XZ Guo, H Zhao, YL Varma, JK Tostado, CP van den Hof, S AF He, Guang Xue Wang, Hai Ying Borgdorff, Martien W. van Soolingen, Dick van der Werf, Marieke J. Liu, Zhi Min Li, Xue Zheng Guo, Hui Zhao, Yan Lin Varma, Jay K. Tostado, Christopher P. van den Hof, Susan TI Multidrug-Resistant Tuberculosis, People's Republic of China, 2007-2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANT; NOSOCOMIAL OUTBREAK; BEIJING/W STRAINS; COMPLEX; EPIDEMIOLOGY; SURVEILLANCE; TRANSMISSION; EMERGENCE; GENOTYPE AB We conducted a case-control study to investigate risk factors for multidrug-resistant tuberculosis (MDR TB) in the People's Republic of China. Genotyping analysis was used to estimate the percentage of cases from recent transmission among 100 MDR TB case-patients hospitalized during April 2007-July 2009. Molecular subtyping of isolates showed that 41% of MDR TB strains clustered. Beijing genotype was found in 94% of the MDR TB isolates and 79% of the pan-susceptible isolates. In multivariate analysis, MDR TB was independently associated with Beijing genotype, retreatment for TB, symptoms lasting >= 3 months before first evaluation at the hospital, lack of health insurance, and being a farmer (vs. being a student). MDR TB was associated with Beijing genotype and lower socioeconomic status. A large percentage of MDR TB cases seemed to result from recent transmission. Early detection, effective treatment, and infection control measures for MDR TB are needed to reduce transmission. C1 [He, Guang Xue] Chinese Ctr Dis Control & Prevent, Natl Ctr TB Control & Prevent, Beijing 102206, Peoples R China. [He, Guang Xue; Borgdorff, Martien W.; van der Werf, Marieke J.; van den Hof, Susan] Univ Amsterdam, Amsterdam, Netherlands. [Wang, Hai Ying; Liu, Zhi Min; Li, Xue Zheng] Shandong Prov TB Control Ctr, Jinan, Peoples R China. [van Soolingen, Dick] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [van der Werf, Marieke J.; van den Hof, Susan] KNCV TB Fdn, The Hague, Netherlands. [Varma, Jay K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tostado, Christopher P.] Tsinghua Univ, Beijing 100084, Peoples R China. RP He, GX (reprint author), Chinese Ctr Dis Control & Prevent, Natl Ctr TB Control & Prevent, Beijing 102206, Peoples R China. EM heguangxue@chinatb.org OI van der Werf, Marieke J./0000-0001-8021-1358 FU China National Key Project (Beijing, China) [2008ZX10003-009, 2009ZX10004-714] FX This study was supported by the China National Key Project (2008ZX10003-009, 2009ZX10004-714; Beijing, China) NR 37 TC 17 Z9 20 U1 2 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2011 VL 17 IS 10 BP 1831 EP 1838 DI 10.3201/eid1710.110546 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 833PL UT WOS:000295897300006 PM 22000352 ER PT J AU Park, BJ Pappas, PG Wannemuehler, KA Alexander, BD Anaissie, EJ Andes, DR Baddley, JW Brown, JM Brumble, LM Freifeld, AG Hadley, S Herwaldt, L Ito, JI Kauffman, CA Lyon, GM Marr, KA Morrison, VA Papanicolaou, G Patterson, TF Perl, TM Schuster, MG Walker, R Wingard, JR Walsh, TJ Kontoyiannis, DP AF Park, Benjamin J. Pappas, Peter G. Wannemuehler, Kathleen A. Alexander, Barbara D. Anaissie, Elias J. Andes, David R. Baddley, John W. Brown, Janice M. Brumble, Lisa M. Freifeld, Alison G. Hadley, Susan Herwaldt, Loreen Ito, James I. Kauffman, Carol A. Lyon, G. Marshall Marr, Kieren A. Morrison, Vicki A. Papanicolaou, Genovefa Patterson, Thomas F. Perl, Trish M. Schuster, Mindy G. Walker, Randall Wingard, John R. Walsh, Thomas J. Kontoyiannis, Dimitrios P. TI Invasive Non-Aspergillus Mold Infections in Transplant Recipients, United States, 2001-2006 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HEMATOPOIETIC STEM-CELL; CARE CANCER CENTER; SURVEILLANCE NETWORK TRANSNET; FUNGAL-INFECTIONS; HEMATOLOGIC MALIGNANCIES; BREAKTHROUGH ZYGOMYCOSIS; SCEDOSPORIUM-PROLIFICANS; RECEIVING VORICONAZOLE; ANTIFUNGAL THERAPY; EPIDEMIOLOGY AB Recent reports describe increasing incidence of non-Aspergillus mold infections in hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients. To investigate the epidemiology of infections with Mucorales, Fusarium spp., and Scedosporium spp. molds, we analyzed data from the Transplant-Associated Infection Surveillance Network, 23 transplant centers that conducted prospective surveillance for invasive fungal infections during 2001-2006. We identified 169 infections (105 Mucorales, 37 Fusarium spp., and 27 Scedosporium spp.) in 169 patients; 124 (73.4%) were in HCT recipients, and 45 (26.6%) were in SOT recipients. The crude 90-day mortality rate was 56.6%. The 12-month mucormycosis cumulative incidence was 0.29% for HCT and 0.07% for SOT. Mucormycosis incidence among HCT recipients varied widely, from 0.08% to 0.69%, with higher incidence in cohorts receiving transplants during 2003 and 2004. Non-Aspergillus mold infections continue to be associated with high mortality rates. The incidence of mucormycosis in HOT recipients increased substantially during the surveillance period. C1 [Park, Benjamin J.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Pappas, Peter G.; Baddley, John W.] Univ Alabama, Med Ctr, Birmingham, AL 35294 USA. [Alexander, Barbara D.] Duke Univ, Med Ctr, Durham, NC USA. [Anaissie, Elias J.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Andes, David R.] Univ Wisconsin, Madison, WI USA. [Brown, Janice M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Brumble, Lisa M.] Mayo Clin, Jacksonville, FL 32224 USA. [Freifeld, Alison G.] Univ Nebraska Med Ctr, Omaha, NE USA. [Hadley, Susan] Tufts Med Ctr, Boston, MA USA. [Herwaldt, Loreen] Univ Iowa Hosp, Iowa City, IA USA. [Ito, James I.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Kauffman, Carol A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Kauffman, Carol A.] Vet Affairs Ann Arbor Healthcare Syst Med, Ann Arbor, MI USA. [Lyon, G. Marshall] Emory Univ, Sch Med, Atlanta, GA USA. [Marr, Kieren A.; Perl, Trish M.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Marr, Kieren A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Morrison, Vicki A.] Univ Minnesota, Minneapolis, MN USA. [Morrison, Vicki A.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Papanicolaou, Genovefa] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Schuster, Mindy G.] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Walker, Randall] Mayo Clin, Rochester, MN USA. [Wingard, John R.] Univ Florida, Gainesville, FL USA. [Walsh, Thomas J.] NIH, Bethesda, MD 20892 USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Park, BJ (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30333 USA. EM bpark1@cdc.gov OI Papanicolaou, Genovefa/0000-0002-2891-079X; Patterson, Thomas /0000-0002-9513-7127 FU Centers for Disease Control and Prevention [5U01CI000286-05]; Merck Co., Inc.; Astellas U.S., Inc.; Pfizer, Inc.; Schering-Plough Research Institute; Enzon Pharmaceuticals, Inc. FX This study was supported through Centers for Disease Control and Prevention Grant 5U01CI000286-05 and grants from Merck & Co., Inc.; Astellas U.S., Inc.; Pfizer, Inc.; Schering-Plough Research Institute; and Enzon Pharmaceuticals, Inc. NR 35 TC 74 Z9 74 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2011 VL 17 IS 10 BP 1855 EP 1864 DI 10.3201/eid1710.110087 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 833PL UT WOS:000295897300009 PM 22000355 ER PT J AU Zhou, Y Lv, BA Wang, Q Wang, RJ Jian, FC Zhang, LX Ning, CS Fu, KD Wang, YQ Qi, M Yao, HX Zhao, JF Zhang, XS Sun, YR Shi, K Arrowood, MJ Xiao, LH AF Zhou, Yang Lv, Biao Wang, Qiang Wang, Rongjun Jian, Fuchun Zhang, Longxian Ning, Changshen Fu, Kanda Wang, Yaqiang Qi, Meng Yao, Huixia Zhao, Jinfeng Zhang, Xiaoshan Sun, Yanru Shi, Ke Arrowood, Michael J. Xiao, Lihua TI Prevalence and Molecular Characterization of Cyclospora cayetanensis, Henan, China SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTION; CRYPTOSPORIDIUM; DIARRHEA AB To determine prevalence of Cyclospora cayetanensis infection in Henan, China, we conducted a study of 11,554 hospital patients. Prevalence was 0.70% (95% confidence interval 0.70% +/- 0.15%), with all age groups infected. Most cases were found in the summer. Minor sequence polymorphisms were observed in the 18S rRNA gene of 35 isolates characterized. C1 [Zhou, Yang; Lv, Biao; Wang, Qiang; Wang, Rongjun; Jian, Fuchun; Zhang, Longxian; Ning, Changshen; Qi, Meng; Yao, Huixia; Zhao, Jinfeng; Zhang, Xiaoshan; Sun, Yanru; Shi, Ke] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. [Fu, Kanda; Wang, Yaqiang] Henan Univ, Huaihe Hosp, Kaifeng, Peoples R China. [Arrowood, Michael J.; Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. EM zhanglx8999@yahoo.com.cn RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU Henan Province Major Research Fund of Public Welfare [81100912300]; National Natural Science Foundation of China [30871863, 30928019]; Key National Science and Technology Special Projects [2008ZX10004-011] FX This study was supported in part by Henan Province Major Research Fund of Public Welfare (no. 81100912300), the National Natural Science Foundation of China (nos. 30871863 and 30928019), and the Key National Science and Technology Special Projects (no. 2008ZX10004-011). NR 12 TC 13 Z9 16 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2011 VL 17 IS 10 BP 1887 EP 1890 DI 10.3201/eid1710.101296 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 833PL UT WOS:000295897300016 PM 22000362 ER PT J AU Filliol-Toutain, I Chiou, CS Mammina, C Gerner-Smidt, P Thong, KL Phung, DC Pichel, M Ranjbar, R Sow, AG Cooper, K Ribot, E Binsztein, N Liang, SY AF Filliol-Toutain, Ingrid Chiou, Chien-Shun Mammina, Caterina Gerner-Smidt, Peter Thong, Kwai-Lin Dac Cam Phung Pichel, Mariana Ranjbar, Reza Sow, Amy Gassama Cooper, Kara Ribot, Efrain Binsztein, Norma Liang, Shiu-Yun TI Global Distribution of Shigella sonnei Clones SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TANDEM-REPEAT ANALYSIS AB To investigate global epidemiology of Shigella sonnei, we performed multilocus variable number tandem repeat analysis of 1,672 isolates obtained since 1943 from 50 countries on 5 continents and the Pacific region. Three major clonal groups were identified; 2 were globally spread. Type 18 and its derivatives have circulated worldwide in recent decades. C1 [Chiou, Chien-Shun] Chung Shan Med Univ, Taichung, Taiwan. [Filliol-Toutain, Ingrid] Inst Pasteur, Natl Reference Ctr Escherichia Coli & Shigella, Paris, France. [Chiou, Chien-Shun; Liang, Shiu-Yun] Ctr Dis Control, Taipei, Taiwan. [Mammina, Caterina] Univ Palermo, Palermo, Italy. [Gerner-Smidt, Peter; Cooper, Kara; Ribot, Efrain] Ctr Dis Control & Prevent, Atlanta, GA USA. [Thong, Kwai-Lin] Univ Malaya, Kuala Lumpur, Malaysia. [Dac Cam Phung] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. [Pichel, Mariana; Binsztein, Norma] Inst Nacl Enfermedades Infecciosas, Buenos Aires, DF, Argentina. [Ranjbar, Reza] Baqiyatallah Univ Med Sci, Tehran, Iran. [Sow, Amy Gassama] Inst Pasteur, Dakar, Senegal. RP Chiou, CS (reprint author), Ctr Dis Control, 5F,20 Wen Sin S 3rd Rd, Taichung 40855, Taiwan. EM nipmesc@cdc.gov.tw RI Mammina, Caterina/M-9339-2013; Thong, Kwai Lin/B-3946-2009; OI Thong, Kwai Lin/0000-0001-8557-5185; Mammina, Caterina/0000-0003-2881-8018 FU Department of Health, Taiwan [DOH97-DC-2012] FX This study was supported by the Department of Health, Taiwan (grant no. DOH97-DC-2012). NR 7 TC 10 Z9 10 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2011 VL 17 IS 10 BP 1910 EP 1912 DI 10.3201/eid1710.101486 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 833PL UT WOS:000295897300023 PM 22000369 ER PT J AU Hirshon, JM Thompson, AD Limbago, B McDonald, LC Bonkosky, M Heimer, R Meek, J Mai, V Braden, C AF Hirshon, Jon Mark Thompson, Angela D. Limbago, Brandi McDonald, L. Clifford Bonkosky, Michelle Heimer, Robert Meek, James Mai, Volker Braden, Christopher TI Clostridium difficile Infection in Outpatients, Maryland and Connecticut, USA, 2002-2007 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SURVEILLANCE; COMMUNITY; STRAINS; DISEASE AB Clostridium difficile, the most commonly recognized diarrheagenic pathogen among hospitalized persons, can cause outpatient diarrhea. Of 1,091 outpatients with diarrhea, we found 43 (3.9%) who were positive for C. difficile toxin. Only 7 had no recognized risk factors, and 3 had neither risk factors nor co-infection with another enteric pathogen. C1 [Hirshon, Jon Mark] Univ Maryland, Sch Med, Dept Emergency Med, Baltimore, MD 21201 USA. [Thompson, Angela D.; Limbago, Brandi; McDonald, L. Clifford; Bonkosky, Michelle; Braden, Christopher] Ctr Dis Control & Prevent, Atlanta, GA USA. [Heimer, Robert; Meek, James] Yale Univ, Sch Med, New Haven, CT USA. [Mai, Volker] Univ Florida, Gainesville, FL USA. RP Hirshon, JM (reprint author), Univ Maryland, Sch Med, Dept Emergency Med, 110 South Paca St,4th Floor, Baltimore, MD 21201 USA. EM jhirs001@umaryland.edu OI Hirshon, Jon Mark/0000-0002-5247-529X FU National Center for Infectious Diseases of the Centers for Disease Control and Prevention [U01C1000296]; American Association of Medical Colleges [MM0205-02/02] FX Funding for this study was provided by the National Center for Infectious Diseases of the Centers for Disease Control and Prevention (grant no. U01C1000296), the American Association of Medical Colleges (grant no. MM0205-02/02). NR 15 TC 14 Z9 15 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2011 VL 17 IS 10 BP 1946 EP 1949 DI 10.3201/eid1710.110069 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 833PL UT WOS:000295897300033 PM 22000379 ER PT J AU Folk, S Steinbecker, S Windmeyer, J MacNeil, A Campbell, S Rollin, PE AF Folk, Scott Steinbecker, Shari Windmeyer, Joyce MacNeil, Adam Campbell, Shelley Rollin, Pierre E. TI Lymphocytic Choriomeningitis with Severe Manifestations, Missouri, USA SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID VIRUS; INFECTION C1 [MacNeil, Adam; Campbell, Shelley; Rollin, Pierre E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Folk, Scott; Steinbecker, Shari; Windmeyer, Joyce] Heartland Reg Med Ctr, St Joseph, MO USA. RP Rollin, PE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30333 USA. EM pyr3@cdc.gov NR 9 TC 3 Z9 3 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2011 VL 17 IS 10 BP 1973 EP 1974 DI 10.3201/eid1710.110911 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 833PL UT WOS:000295897300046 PM 22000392 ER PT J AU Potter, P AF Potter, Polyxeni TI Much have I travel'd in the realms of gold SO EMERGING INFECTIOUS DISEASES LA English DT Article C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmpl@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2011 VL 17 IS 10 BP 1985 EP 1986 DI 10.3201/eid1710.AC1710 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 833PL UT WOS:000295897300054 ER PT J AU de Perio, MA Niemeier, RT Groenewold, MR AF de Perio, Marie A. Niemeier, R. Todd Groenewold, Matthew R. TI The Effectiveness of Using Interferon-gamma Release Assays in Screening Immigration Employees for Latent Tuberculosis Infection SO INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE tuberculosis; tuberculin skin test; interferon-gamma release assay; screening ID HEALTH-CARE WORKERS; SKIN-TEST CONVERSION; QUANTIFERON-TB GOLD; MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; COST-EFFECTIVENESS; MEDICAL-CENTER; BORN PERSONS; FOREIGN-BORN; CELL ASSAYS AB We assessed the prevalence of latent tuberculosis infection in immigration employees and compared two of the screening methods. Using a cross-sectional study design, we administered questionnaires regarding demographics, work, medical history, and tuberculosis risk factors to employees at two immigration facilities. Participants underwent tuberculin skin test (TST) placement and blood collection for the QuantiFERON-TB Gold in-Tube (QFT-GIT) assay. Fifty-four employees underwent QFT-GIT and TST placement. All QFT-GIT results were negative, and three employees tested TST positive. Twenty-three (49%) of 47 employees requiring two-step TST testing underwent second TST placement. Return rates for first and second TST reading were 76% and 74%, respectively. The QFT-GIT completion rate was higher than that for TST (100% vs. 39%, P < 0.001). Agreement between TST and QFT-GIT was 94%. Immigration employees had low return rates for their TST reading and second TST placement. Performing the one-visit QFT-GIT has administrative and logistical advantages in this occupational group. C1 [de Perio, Marie A.; Niemeier, R. Todd; Groenewold, Matthew R.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP de Perio, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-10, Cincinnati, OH 45226 USA. EM Mdeperio@cdc.gov NR 41 TC 0 Z9 0 U1 0 U2 2 PU HAMILTON HARDY PUBL INC PI ATTLEBORO PA 8 N MAIN ST, STE 404A, ATTLEBORO, MA 02703 USA SN 1077-3525 J9 INT J OCCUP ENV HEAL JI Int. J. Occup. Environ. Health PD OCT-DEC PY 2011 VL 17 IS 4 BP 322 EP 327 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 833SG UT WOS:000295904600006 PM 22069930 ER PT J AU Kubota, K Kasuga, F Iwasaki, E Inagaki, S Sakurai, Y Komatsu, M Toyofuku, H Angulo, FJ Scallan, E Morikawa, K AF Kubota, Kunihiro Kasuga, Fumiko Iwasaki, Emiko Inagaki, Shunichi Sakurai, Yoshiharu Komatsu, Mayumi Toyofuku, Hajime Angulo, Frederick J. Scallan, Elaine Morikawa, Kaoru TI Estimating the Burden of Acute Gastroenteritis and Foodborne Illness Caused by Campylobacter, Salmonella, and Vibrio parahaemolyticus by Using Population-Based Telephone Survey Data, Miyagi Prefecture, Japan, 2005 to 2006 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; ACTIVE SURVEILLANCE NETWORK; UNITED-STATES; ENGLAND; FOOD; COMMUNITY; AUSTRALIA; DIARRHEA; CANADA; WALES AB Most cases of acute gastroenteritis and foodborne disease are not ascertained by public health surveillance because the ill person does not always seek medical care and submit a stool sample for testing, and the laboratory does not always test for or identify the causative organism. We estimated the total burden of acute gastroenteritis in Miyagi Prefecture, Japan, using data from two 2-week cross-sectional, population-based telephone surveys conducted in 2006 and 2007. To estimate the number of acute gastroenteritis illnesses caused by Campylobacter, Salmonella, and Vibrio parahaemolyticus in Miyagi Prefecture, we determined the number of cases for each pathogen from active laboratory-based surveillance during 2005 to 2006 and adjusted for seeking of medical care and submission of stool specimens by using data from the population-based telephone surveys. Monte Carlo simulation was used to incorporate uncertainty. The prevalence of acute gastroenteritis in the preceding 4 weeks was 3.3% (70 of 2,126) and 3.5% (74 of 2,121) in the winter and summer months, yielding an estimated 44,200 episodes of acute gastroenteritis each year in this region. Among people with acute gastroenteritis, the physician consultation rate was 32.0%, and 10.9% of persons who sought care submitted a stool sample. The estimated numbers of Campylobacter-, Salmonella-, and V. parahaemolyticus associated episodes of acute gastroenteritis were 1,512, 209, and 100 per 100,000 population per year, respectively, in this region. These estimates are significantly higher than the number of reported cases in surveillance in this region. Cases ascertained from active surveillance were also underrepresented in the present passive surveillance, suggesting that complementary surveillance systems, such as laboratory-based active surveillance in sentinel sites, are needed to monitor food safety in Japan. C1 [Kubota, Kunihiro; Kasuga, Fumiko; Morikawa, Kaoru] Natl Inst Hlth Sci, Tokyo, Japan. [Iwasaki, Emiko] Hlth & Prevent Policy Inst, Sendai, Miyagi, Japan. [Inagaki, Shunichi] Tohoku Reg Bur Hlth & Welf, Sendai, Miyagi, Japan. [Sakurai, Yoshiharu; Komatsu, Mayumi] Miyagi Med Assoc, Sendai, Miyagi, Japan. [Toyofuku, Hajime] Natl Inst Publ Hlth, Wako, Saitama 3510197, Japan. [Angulo, Frederick J.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Scallan, Elaine] Colorado Sch Publ Hlth, Aurora, CO 80045 USA. RP Kubota, K (reprint author), Natl Inst Hlth Sci, Tokyo, Japan. EM kubotak@nihs.go.jp FU Research on food safety, of the Ministry of Health, Labour and Welfare, Japan FX We thank the collaborators at the Shiogama City Medical Association Laboratory in Miyagi Prefecture for providing the stool testing results. This study was conducted with the support of Health and Labour Sciences Research Grants (HLSRG), Research on food safety, of the Ministry of Health, Labour and Welfare, Japan. NR 22 TC 25 Z9 25 U1 3 U2 9 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X J9 J FOOD PROTECT JI J. Food Prot. PD OCT PY 2011 VL 74 IS 10 BP 1592 EP 1598 DI 10.4315/0362-028X.JFP-10-387 PG 7 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 836AC UT WOS:000296077400002 PM 22004803 ER PT J AU Marinheiro, JC dos Santos, TG Siqueira-Silva, J Lu, XY Carvalho, D da Camara, AA Arruda, E Arruda, K Erdman, DD Harsi, CM AF Marinheiro, Juliana C. dos Santos, Tatiana G. Siqueira-Silva, Joselma Lu, Xiaoyan Carvalho, Daniela da Camara, Ataide A. Arruda, Eurico Arruda, Karla Erdman, Dean D. Harsi, Charlotte M. TI A naturally occurring human adenovirus type 7 variant with a 1743 bp deletion in the E3 cassette SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID ACUTE RESPIRATORY-INFECTION; MOLECULAR EPIDEMIOLOGY; GENOME TYPES; SAO-PAULO; MEMBRANE-PROTEIN; UNITED-STATES; RISK-FACTORS; CHILDREN; BRAZIL; IDENTIFICATION AB Human adenovirus type 7 (HAdV-7) is an important cause of acute respiratory disease (ARD). Different genomic variants of HAdV-7 have been described, designated 7a-7I. In a previous study to investigate risk factors for ARD and wheezing, nasopharyngeal samples were collected from 90 ill children seeking medical attention in Ribeirao Preto, Sao Paulo, Brazil. HAdVs were identified in 31 samples and were characterized by serum neutralization and genome restriction analysis. Eleven HAdVs were identified as being HAdV-7, five of which were classified as being of genome type 7p (Gomen). Six other HAdV-7 isolates gave new restriction profiles with all enzymes used and were classified as being a new genomic variant, 7m. These isolates were further characterized by sequencing. The hexon and fiber genes of the 7m variant were nearly identical to the prototype, 7p. However, nucleotide sequences from the E3 cassette revealed a 1743 bp deletion affecting the 16.1K, 19K, 20.1K and 20.5K ORFs. C1 [Marinheiro, Juliana C.; dos Santos, Tatiana G.; Siqueira-Silva, Joselma; Carvalho, Daniela; Harsi, Charlotte M.] Univ Sao Paulo, Dept Microbiol, Virol Labs, Inst Biomed Sci, Sao Paulo, Brazil. [Lu, Xiaoyan; Erdman, Dean D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA USA. [da Camara, Ataide A.; Arruda, Eurico; Arruda, Karla] Univ Sao Paulo, Dept Cell & Mol Biol, Sch Med, BR-14049 Ribeirao Preto, Brazil. RP Harsi, CM (reprint author), Univ Sao Paulo, Dept Microbiol, Virol Labs, Inst Biomed Sci, Sao Paulo, Brazil. EM chmharsi@icb.usp.br RI Arruda, Eurico/E-4101-2012; Arruda, L. Karla /D-5845-2013 OI Arruda, L. Karla /0000-0002-7505-210X FU FAPESP (Fundacao de Amparo ai Pesquisa do Estado de Sao Paulo) [06/56482-0, 03/02055-5]; Respiratory and Enteric Virus Branch, CDC, Atlanta, USA FX We thank Dr Teresa C. T. Peret for helpful discussions. This study was supported by FAPESP (Fundacao de Amparo ai Pesquisa do Estado de Sao Paulo, process 06/56482-0) and the Respiratory and Enteric Virus Branch, CDC, Atlanta, USA. Juliana Cristina Marinheiro received a FAPESP fellowship (03/02055-5). NR 43 TC 4 Z9 5 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 J9 J GEN VIROL JI J. Gen. Virol. PD OCT PY 2011 VL 92 BP 2399 EP 2404 DI 10.1099/vir.0.029181-0 PN 10 PG 6 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 833BE UT WOS:000295856000020 PM 21677090 ER PT J AU Matjasko, JL AF Matjasko, Jennifer L. TI How effective are severe disciplinary policies? School policies and offending from adolescence into young adulthood SO JOURNAL OF SCHOOL PSYCHOLOGY LA English DT Article DE School policies; Offending; Adolescence; Inattention; Impulsivity; Young adulthood ID LIFE-COURSE-PERSISTENT; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; LIMITED ANTISOCIAL PATHWAYS; CONDUCT PROBLEMS; BEHAVIOR; PREDICTION; CHILDHOOD; PATTERNS; MALES; AGE AB Based on the stage environment and the person environment fit perspectives, the current study examined the relation between school disciplinary policies and offending from adolescence into young adulthood. Using Waves I and III of the National Longitudinal Study of Adolescent Health (a.k.a., Add Health), hierarchical multinomial logistic regression models were utilized to test whether school disciplinary policies were related to offending patterns during adolescence and young adulthood. Descriptive results suggest that, overall, severe school policies were not associated with the course of offending. However, relations between individual characteristics (i.e., inattention and impulsivity) and offending patterns did appear to differ depending on the severity of disciplinary policies. Within schools with more severe policies, adolescents scoring higher on inattention were more likely to be in the adolescent-limited offender group over the persistent offender group. On the other hand, adolescents with high levels of impulsivity were more likely to be in the persistent group over the non-offender group within schools with more severe policies. The results suggest that severe policies may not be effective for all students and the policies, alone, may not be promising avenues for the prevention of offending during adolescence and young adulthood. Published by Elsevier Ltd. on behalf of Society for the Study of School Psychology. C1 Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Matjasko, JL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F64, Atlanta, GA 30341 USA. EM jmatjasko@cdc.gov FU NICHD NIH HHS [P01-HD31921] NR 53 TC 4 Z9 4 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4405 J9 J SCHOOL PSYCHOL JI J. Sch. Psychol. PD OCT PY 2011 VL 49 IS 5 BP 555 EP 572 DI 10.1016/j.jsp.2011.05.002 PG 18 WC Psychology, Educational SC Psychology GA 835LR UT WOS:000296038400004 PM 21930009 ER PT J AU Pivonka, E Seymour, J McKenna, J Baxter, SD Williams, S AF Pivonka, Elizabeth Seymour, Jennifer McKenna, Jeff Baxter, Suzanne Domel Williams, Simon TI Development of the Behaviorally Focused Fruits & Veggies-More Matters Public Health Initiative SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID VEGETABLE INTAKE; US ADULTS; CONSUMPTION; RISK AB Due to changing recommendations for fruit and vegetable (FAT) intake, public health and private organizations recognized the need to revise communications and programs that promote F/V consumption. This article describes formative research conducted in 2005 to develop a new identity for the 5 A Day Program, updated to the Fruits & Veggies-More Matters program. The objective was to re-brand the 5 A Day Program's campaign message to be adaptable, sustainable, and compelling, while leveraging the program's existing message dissemination infrastructure. Formative research included interviews with representatives from government, nonprofit organizations, and industry, and consumer perspectives from interviews, focus groups, and an online survey. Public health and private organizations agreed that a compelling emotional benefit was needed to motivate consumers to eat more F/V and that messaging needed to be used consistently among national, state, and local programs. Interviews and focus groups targeted mothers who believed they and their families were getting enough FAT, knew they could eat more, but needed to be convinced why they should do so. The most effective messages appealed to mothers' emotional needs to be responsible, leveraged functional intrinsic values of FAT, did not try to quantify "enough," and focused on small steps. When the Fruits & Veggies-More Matters slogan and graphic were viewed together, the majority (62%) said it increased their interest in eating more F/V. The Fruits & Veggies More Matters brand offers numerous opportunities for promoting F/V consumption through this public health initiative. J Am Diet Assoc. 2011;111:1570-1577. C1 [Pivonka, Elizabeth] Produce Better Hlth Fdn, Hockessin, DE 19707 USA. [Seymour, Jennifer] Ctr Dis Control & Prevent, Nutr Guidelines Dev & Recommendat Team, Div Nutr Phys Act & Obes, Atlanta, GA USA. [McKenna, Jeff] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Baxter, Suzanne Domel] Univ S Carolina, Inst Families Soc, Columbia, SC 29208 USA. [Williams, Simon] Sterling Brands, New York, NY USA. RP Pivonka, E (reprint author), Produce Better Hlth Fdn, 7465 Lancaster Pike,Suite J,2nd Floor, Hockessin, DE 19707 USA. EM epivonka@pbhfoundation.org OI Baxter, Suzanne D/0000-0002-9031-9087 FU National Institutes of Health; United States Department of Agriculture FX Dr Baxter's current and previous research has been funded externally by competitive grants from the National Institutes of Health as well as the United States Department of Agriculture. Dr Baxter has served as a grant reviewer for the National Institutes of Health and the Centers for Disease Control and Prevention. Dr Baxter is on the Board of Editors for the Journal, of the American Dietetic Association. Dr Pivonka, Dr Seymour, Mr McKenna, and Mr Williams have no conflicts of interest to disclose. NR 22 TC 10 Z9 10 U1 0 U2 13 PU AMER DIETETIC ASSOC PI CHICAGO PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD OCT PY 2011 VL 111 IS 10 BP 1570 EP 1577 DI 10.1016/j.jada.2011.07.001 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 833TF UT WOS:000295907100021 PM 21963025 ER PT J AU Belser, JA Zeng, H Katz, JM Tumpey, TM AF Belser, Jessica A. Zeng, Hui Katz, Jacqueline M. Tumpey, Terrence M. TI Ocular Tropism of Influenza A Viruses: Identification of H7 Subtype-Specific Host Responses in Human Respiratory and Ocular Cells SO JOURNAL OF VIROLOGY LA English DT Article ID BRONCHIAL EPITHELIAL-CELLS; NF-KAPPA-B; AVIAN-INFLUENZA; H5N1 VIRUSES; PROINFLAMMATORY CYTOKINES; BRITISH-COLUMBIA; SODIUM-SALICYLATE; DISTRESS-SYNDROME; SYNCYTIAL VIRUS; HONG-KONG AB Highly pathogenic avian influenza (HPAI) H7 virus infection in humans frequently results in conjunctivitis as a major symptom. However, our understanding of what properties govern virus subtype-specific tropism, and of the host responses responsible for eliciting ocular inflammation and pathogenicity following influenza virus infection, are not well understood. To study virus-host interactions in ocular tissue, we infected primary human corneal and conjunctival epithelial cells with H7, H5, and H1 subtype viruses. We found that numerous virus subtypes were capable of infecting and replicating in multiple human ocular cell types, with the highest titers observed with highly pathogenic H7N7 and H5N1 viruses. Similar patterns of proinflammatory cytokine and chemokine production following influenza virus infection were observed in ocular and respiratory cells. However, primary ocular cells infected with HPAI H7N7 viruses were found to have elevated levels of interleukin-1 beta (IL-1 beta), a cytokine previously implicated in ocular disease pathology. Furthermore, H7N7 virus infection of corneal epithelial cells resulted in enhanced and significant increases in the expression of genes related to NF-kappa B signal transduction compared with that after H5N1 or H1N1 virus infection. The differential induction of cytokines and signaling pathways in human ocular cells following H7 virus infection marks the first association of H7 subtype-specific host responses with ocular tropism and pathogenicity. In particular, heightened expression of genes related to NF-kappa B-mediated signaling transduction following HPAI H7N7 virus infection in primary corneal epithelial cells, but not respiratory cells, identifies activation of a signaling pathway that correlates with the ocular tropism of influenza viruses within this subtype. C1 [Belser, Jessica A.; Zeng, Hui; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, MS G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tft9@cdc.gov NR 52 TC 15 Z9 17 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2011 VL 85 IS 19 BP 10117 EP 10125 DI 10.1128/JVI.05101-11 PG 9 WC Virology SC Virology GA 837ZH UT WOS:000296253900044 PM 21775456 ER PT J AU Albarino, CG Bird, BH Chakrabarti, AK Dodd, KA Flint, M Bergeron, EE White, DM Nichol, ST AF Albarino, Cesar G. Bird, Brian H. Chakrabarti, Ayan K. Dodd, Kimberly A. Flint, Mike Bergeron, Eric White, David M. Nichol, Stuart T. TI The Major Determinant of Attenuation in Mice of the Candid1 Vaccine for Argentine Hemorrhagic Fever Is Located in the G2 Glycoprotein Transmembrane Domain SO JOURNAL OF VIROLOGY LA English DT Article ID REVERSE GENETICS GENERATION; STABLE SIGNAL PEPTIDE; PH-INDUCED ACTIVATION; JUNIN VIRUS; MEMBRANE-FUSION; ARENAVIRUSES; RECEPTOR; VIRULENCE; STRAIN AB Candid1, a live-attenuated Junin virus vaccine strain, was developed during the early 1980s to control Argentine hemorrhagic fever, a severe and frequently fatal human disease. Six amino acid substitutions were found to be unique to this vaccine strain, and their role in virulence attenuation in mice was analyzed using a series of recombinant viruses. Our results indicate that Candid1 is attenuated in mice through a single amino acid substitution in the transmembrane domain of the G2 glycoprotein. This work provides insight into the molecular mechanisms of attenuation of the only arenavirus vaccine currently available. C1 [Albarino, Cesar G.; Bird, Brian H.; Chakrabarti, Ayan K.; Dodd, Kimberly A.; Flint, Mike; Bergeron, Eric; White, David M.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. RP Albarino, CG (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd,MS G14, Atlanta, GA 30329 USA. EM bwu4@cdc.gov OI Flint, Michael/0000-0002-5373-787X NR 29 TC 33 Z9 33 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2011 VL 85 IS 19 BP 10404 EP 10408 DI 10.1128/JVI.00856-11 PG 5 WC Virology SC Virology GA 837ZH UT WOS:000296253900072 PM 21795336 ER PT J AU Krause, JC Tsibane, T Tumpey, TM Huffman, CJ Basler, CF Crowe, JE AF Krause, Jens C. Tsibane, Tshidi Tumpey, Terrence M. Huffman, Chelsey J. Basler, Christopher F. Crowe, James E., Jr. TI A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin SO JOURNAL OF VIROLOGY LA English DT Article ID B-CELLS; ORIGIN AB The conserved influenza virus hemagglutinin (HA) stem domain elicits cross-reactive antibodies, but epitopes in the globular head typically elicit strain-specific responses because of the hypervariability of this region. We isolated human monoclonal antibody 5J8, which neutralized a broad spectrum of 20th century H1N1 viruses and the 2009 pandemic H1N1 virus. Fine mapping of the interaction unexpectedly revealed a novel epitope between the receptor-binding pocket and the Ca(2) antigenic site on HA. This antibody exposes a new mechanism underlying broad immunity against H1N1 influenza viruses and identifies a conserved epitope that might be incorporated into engineered H1 virus vaccines. C1 [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Dept Pediat, Nashville, TN 37232 USA. [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA. [Tsibane, Tshidi; Basler, Christopher F.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA. [Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Crowe, JE (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Dept Pediat, T-2220 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA. EM james.crowe@vanderbilt.edu RI Crowe, James/B-5549-2009 OI Crowe, James/0000-0002-0049-1079 FU NIH [P01 AI058113, R21 AI085306, HHSN272200900047C]; DOD [HDTRA1-08-10-BRCWMD-BAA] FX J.E.C. is a Burroughs Wellcome Fund Clinical Scientist in Translational Research. This work was supported by NIH grants P01 AI058113 and R21 AI085306, by NIH contract HHSN272200900047C, and by DOD grant HDTRA1-08-10-BRCWMD-BAA. NR 25 TC 79 Z9 82 U1 2 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2011 VL 85 IS 20 BP 10905 EP 10908 DI 10.1128/JVI.00700-11 PG 4 WC Virology SC Virology GA 837ZJ UT WOS:000296254100046 PM 21849447 ER PT J AU Massetti, GM Vivolo, AM Brookmeyer, K DeGue, S Holland, KM Holt, MK Matjasko, JL AF Massetti, Greta M. Vivolo, Alana M. Brookmeyer, Kathryn DeGue, Sarah Holland, Kristin M. Holt, Melissa K. Matjasko, Jennifer L. TI Preventing Youth Violence Perpetration Among Girls SO JOURNAL OF WOMENS HEALTH LA English DT Article ID SERIOUS JUVENILE-OFFENDERS; RANDOMIZED CLINICAL-TRIAL; SUBSTANCE USE OUTCOMES; SOCIAL-PSYCHOLOGICAL ADJUSTMENT; POSITIVE PARENTING PROGRAM; FUNCTIONAL FAMILY-THERAPY; RAISING HEALTHY-CHILDREN; ADOLESCENT DRUG-USE; 2-YEAR FOLLOW-UP; PAST BASE-LINE AB In the last 10 years, several reviews of research on violence among girls have been conducted. This research helps to determine the extent of girls' use of violence however, it has not been translated into effective prevention programs for girls. This article reviews the research on risk and protective factors associated with violence, with particular attention on factors unique to girls or shared between boys and girls. Individual risk factors for youth violence include hyperactivity/inattention/impulsivity, risk taking/sensation seeking, low academic achievement, exposure to stress and victimization, and early puberty. Parent-child relationships/parental monitoring and supervision, parent criminal and antisocial behavior, and family conflicts and instability have been found to be relationship-level risk factors. Peer risk factors include deviant peer affiliation and gang membership. Risk factors at the community level include economic deprivation; community disorganization; the availability of drugs, alcohol, and firearms; and neighborhood crime. This review also includes a description of program effects for girls within the Model and Promising Blueprints for Violence Prevention Initiative programs. Very few evaluations have examined program effectiveness in preventing violence among girls. More evaluation research is needed to determine if evidence-based programs have positive impact on reducing violence and related risk factors among girls. C1 [Massetti, Greta M.; Vivolo, Alana M.; Brookmeyer, Kathryn; DeGue, Sarah; Holland, Kristin M.; Holt, Melissa K.; Matjasko, Jennifer L.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Massetti, GM (reprint author), 4770 Buford Highway,NE MS F 64, Atlanta, GA 30341 USA. EM gmassetti@cdc.gov RI Price, Katie/H-1931-2012; OI Massetti, Greta/0000-0002-3813-9839 NR 152 TC 8 Z9 8 U1 2 U2 29 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2011 VL 20 IS 10 BP 1415 EP 1428 DI 10.1089/jwh.2011.3057 PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 833IQ UT WOS:000295877900085 PM 21875306 ER PT J AU Benard, VB Saraiya, MS Soman, A Roland, KB Yabroff, KR Miller, J AF Benard, Vicki B. Saraiya, Mona S. Soman, Ashwini Roland, Katherine B. Yabroff, K. Robin Miller, Jackie TI Cancer Screening Practices Among Physicians in the National Breast and Cervical Cancer Early Detection Program SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HUMAN-PAPILLOMAVIRUS; SOCIETY GUIDELINES; UNITED-STATES; MANAGEMENT; WOMEN; AREAS; PAP AB Background: The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides low-income, uninsured women with screening and diagnostic services for breast and cervical cancer. Our study was conducted to describe the demographic and practice characteristics of participating and nonparticipating physicians, as well as their beliefs, adoption of new screening technologies, and recommendations for breast and cervical cancer screening. Methods: From a 2006-2007 nationally representative survey, we identified 1,111 practicing primary care physicians who provide breast and cervical cancer screenings and assessed their recommendations using clinical vignettes related to screening initiation, frequency, and cessation. Responses of physicians participating in the NBCCEDP were compared with those from nonparticipating physicians. Results: Of the physicians surveyed, 15% reported participation in the NBCCEDP, 65% were not participants, and 20% were not sure or did not respond to this question. Program physicians were significantly more likely to practice in multispecialty settings, in a rural location, and in a hospital or clinic setting and had more patients who were female and insured by Medicaid or uninsured compared with nonprogram physicians. Beliefs about the effectiveness of screening tools or procedures in reducing breast or cervical cancer mortality were similar by program participation. Adoption of new technologies, including digital mammography and human papillomavirus (HPV) testing, and making guideline-consistent recommendations for screening initiation, frequency, and cessation did not differ significantly by program participation. Conclusions: Although there may be differences in physician characteristics and practice settings, the beliefs and screening practices for both breast and cervical cancer are similar between program and nonprogram providers. C1 [Benard, Vicki B.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Yabroff, K. Robin] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Benard, VB (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, 4770 Buford Highway,Mailstop K-55, Atlanta, GA 30341 USA. EM vbenard@cdc.gov OI Yabroff, K. Robin/0000-0003-0644-5572 FU NCI [N02-PC-51308]; CDC [Y3-PC-6017-01]; AHRQ [Y3-PC-5019-01, Y3-PC-5019-02] FX Funding for this study was provided by NCI (contract N02-PC-51308), CDC (interagency agreement Y3-PC-6017-01) and AHRQ (interagency agreements Y3-PC-5019-01 and Y3-PC-5019-02). NR 21 TC 12 Z9 12 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2011 VL 20 IS 10 BP 1479 EP 1484 DI 10.1089/jwh.2010.2530 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 833IQ UT WOS:000295877900092 PM 21774673 ER PT J AU Valderrama, AL Fang, J Merritt, RK Hong, YL AF Valderrama, Amy L. Fang, Jing Merritt, Robert K. Hong, Yuling TI Cardiac arrest patients in the emergency department-National Hospital Ambulatory Medical Care Survey, 2001-2007 SO RESUSCITATION LA English DT Article DE Heart arrest; Cardiac arrest; Emergency treatment; Cardiopulmonary resuscitation (CPR) ID AMERICAN-HEART-ASSOCIATION; NUTRITION EXAMINATION SURVEY; CARDIOPULMONARY-RESUSCITATION; INSURANCE STATUS; US ADULTS; SURVIVAL; HEALTH; DISEASE; DEATH; COMMUNITY AB Aim of the study: Few studies have focused on the full complement of cardiac arrest cases seen in hospital emergency departments (ED). The aims of our study were to describe cardiac arrest visits in the ED by using a nationally representative sample of U.S. adults. Methods: ED data from the 2001-2007 National Hospital Ambulatory Medical Care Survey (NHAMCS) were analyzed. Cardiac arrest visits were considered to be those with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 427.5 as the primary diagnosis. Results and conclusions: From 2001 to 2007, adults in the U.S. made an estimated 600,729,000 ED visits. Of those, 1,001,000(0.17%) had a primary diagnosis of cardiac arrest. The majority of patients with such visits were dead on arrival or died in the ED (74.0%). The mean age for cardiac arrest visits was 66.7 years (95% confidence interval [CI], 64.6-68.8 years). Women had a lower rate of cardiac arrest visits than men (age-adjusted odds ratio [AOR], 0.6; 95% CI, 0.5-0.8), and the privately insured (AOR, 0.4; 95% CI, 0.2-0.7) and those with government insurance (AOR, 0.5; 95% CI, 0.3-0.9) had a lower proportion of cardiac arrest ED visits than uninsured persons. In addition, increasing age was a significant predictor of cardiac arrest visits. Cardiac arrest visits did not vary significantly by race, geographic region, or metropolitan statistical area. ED visits classified as cardiac arrest represent 1 in 600 visits and these visits differ by age, sex, payment source, and arrival time at the ED. Published by Elsevier Ireland Ltd. C1 [Valderrama, Amy L.; Fang, Jing; Merritt, Robert K.; Hong, Yuling] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Valderrama, AL (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4776 Buford Hwy NE,MS K-47, Atlanta, GA 30341 USA. EM AValderrama@cdc.gov NR 29 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD OCT PY 2011 VL 82 IS 10 BP 1298 EP 1301 DI 10.1016/j.resuscitation.2011.05.021 PG 4 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA 837CM UT WOS:000296168700011 PM 21703749 ER PT J AU Hirose, A Borchert, M Niksear, H Alkozai, AS Cox, J Gardiner, J Osmani, KR Filippi, V AF Hirose, Atsumi Borchert, Matthias Niksear, Homa Alkozai, Ahmad Shah Cox, Jonathan Gardiner, Julian Osmani, Khadija Ruina Filippi, Veronique TI Difficulties leaving home: A cross-sectional study of delays in seeking emergency obstetric care in Herat, Afghanistan SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Afghanistan; Near-miss; Maternal mortality; Delays; Antenatal care; Birth plan; Social resources; Obstretrics; Care-seeking ID INSTITUTIONAL MATERNAL MORTALITY; REPRODUCTIVE HEALTH; SEASONAL-VARIATION; SAFE MOTHERHOOD; BIRTH; BANGLADESH; MORBIDITY; AUTONOMY; MALARIA; KINSHIP AB This study used an analytical cross-sectional design to identify risk factors associated with delays in care-seeking among women admitted in life-threatening conditions to a maternity hospital in Herat. Afghanistan, from February 2007 to January 2008. Disease-specific criteria of 'near-miss' were used to identify women in life-threatening conditions. Among 472 eligible women and their husbands, 411 paired interviews were conducted, and information on socio-demographic factors; the woman's status and social resources; the husband's social networks; health care accessibility and utilisation; care-seeking costs; and community characteristics were obtained. Decision and departure delays were assessed quantitatively from reported timings of symptom recognition, care-seeking decision, and departure for health facilities. Censored normal regression analyses suggest that although determinants of decision delay were influenced by the nature and symptoms of complications, uptake of antenatal care (ANC) and the birth plan reduced decision delay at the time of the obstetric emergency. Access to care and social networks reduced departure delay. Programmatic efforts may be directed towards exploiting the roles of ANC and social resources in facilitating access to emergency obstetric care. Published by Elsevier Ltd. C1 [Hirose, Atsumi] US Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Hirose, Atsumi; Borchert, Matthias; Cox, Jonathan; Gardiner, Julian; Filippi, Veronique] London Sch Hyg & Trop Med, London, England. [Borchert, Matthias] Charite, Inst Trop Med & Int Hlth, D-13353 Berlin, Germany. [Gardiner, Julian] Birkbeck Coll, London, England. RP Hirose, A (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,NE MS-A06, Atlanta, GA 30329 USA. EM AHirose@cdc.gov OI Gardiner, Julian/0000-0001-8988-3812 FU World Vision Japan; Joint Japan/World Bank FX This project was funded by World Vision Japan. We would like to thank Dr. Saida Said and the doctors and midwives of the maternity ward of Herat Regional Hospital, who collaborated with us during fieldwork. AH was supported by the Joint Japan/World Bank Graduate Scholarship Program. NR 43 TC 15 Z9 15 U1 4 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD OCT PY 2011 VL 73 IS 7 BP 1003 EP 1013 DI 10.1016/j.socscimed.2011.07.011 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 831QD UT WOS:000295745300008 PM 21862194 ER PT J AU Charania, MR Crepaz, N Guenther-Gray, C Henny, K Liau, A Willis, LA Lyles, CM AF Charania, Mahnaz R. Crepaz, Nicole Guenther-Gray, Carolyn Henny, Kirk Liau, Adrian Willis, Leigh A. Lyles, Cynthia M. TI Efficacy of Structural-Level Condom Distribution Interventions: A Meta-Analysis of US and International Studies, 1998-2007 SO AIDS AND BEHAVIOR LA English DT Article DE HIV/AIDS prevention; Behavioral interventions; Condom distribution; Structural interventions; Meta-analysis ID FEMALE SEX WORKERS; SEXUALLY-TRANSMITTED-DISEASES; HIV PREVENTION INTERVENTIONS; UNITED-STATES; BEHAVIORAL INTERVENTIONS; RISK BEHAVIORS; MALE CLIENTS; USE PROGRAM; PROMOTION; AVAILABILITY AB This systematic review examines the overall efficacy of U. S. and international-based structural-level condom distribution interventions (SLCDIs) on HIV risk behaviors and STIs and identifies factors associated with intervention efficacy. A comprehensive literature search of studies published from January 1988 through September 2007 yielded 21 relevant studies. Significant intervention effects were found for the following outcomes: condom use, condom acquisition/condom carrying, delayed sexual initiation among youth, and reduced incident STIs. The stratified analyses for condom use indicated that interventions were efficacious for various groups (e. g., youth, adults, males, commercial sex workers, clinic populations, and populations in areas with high STI incidence). Interventions increasing the availability of or accessibility to condoms or including additional individual, small-group or community-level components along with condom distribution were shown to be efficacious in increasing condom use behaviors. This review suggests that SLCDIs provide an efficacious means of HIV/STI prevention. C1 [Charania, Mahnaz R.; Crepaz, Nicole; Guenther-Gray, Carolyn; Henny, Kirk; Liau, Adrian; Willis, Leigh A.; Lyles, Cynthia M.] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Charania, MR (reprint author), Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA. EM MCharania@cdc.gov OI Henny, Kirk/0000-0002-0886-8651 NR 59 TC 39 Z9 40 U1 2 U2 17 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2011 VL 15 IS 7 BP 1283 EP 1297 DI 10.1007/s10461-010-9812-y PG 15 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 825KA UT WOS:000295271200001 PM 20886277 ER PT J AU Kapadia, F Latka, MH Wu, Y Strathdee, SA Mackesy-Amiti, ME Hudson, SM Thiede, H Garfein, RS AF Kapadia, F. Latka, M. H. Wu, Y. Strathdee, S. A. Mackesy-Amiti, M. E. Hudson, S. M. Thiede, H. Garfein, R. S. TI Longitudinal Determinants of Consistent Condom Use by Partner Type Among Young Injection Drug Users: The Role of Personal and Partner Characteristics SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Injection drug use; Condom use; Sexual risk behavior ID SYRINGE EXCHANGE PROGRAMS; RISK BEHAVIORS; SELF-EFFICACY; SEXUAL RISK; PREDICT INTENTION; PLANNED BEHAVIOR; HIV PREVENTION; INTERVENTION; WOMEN; TRIAL AB We investigated the longitudinal influence of individual-, relationship-and social-level factors on condom use by partner type among young injections drug users (IDUs) enrolled in the Collaborative Injection Drug Users Study-III/Drug Users Intervention Trial (CIDUS-III/DUIT) from 2002 to 2004. Based on longitudinal analysis using generalized estimating equations (GEE), consistent condom use with main partners was more commonly reported among males and those with greater self-efficacy for condom use; main partner's desire for pregnancy and needle sharing were negatively associated with consistent condom use. Among those with casual partners, having fewer sex partners was associated with consistent condom use. Positive attitudes toward condom use and partner norms supporting condom use were associated with greater consistent condom use with both partner types. These findings suggest that intervention strategies targeting individual-and partner-level factors may provide avenues for intervening upon sexual risks among young IDUs. C1 [Kapadia, F.] New York Univ, Dept Nutr Food Studies & Publ Hlth, New York, NY 10012 USA. [Latka, M. H.] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA. [Wu, Y.] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, Mailman Sch Publ Hlth, New York, NY USA. [Strathdee, S. A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Mackesy-Amiti, M. E.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Hudson, S. M.] Hlth Res Assoc, Los Angeles, CA USA. [Thiede, H.] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Garfein, R. S.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kapadia, F (reprint author), New York Univ, Dept Nutr Food Studies & Publ Hlth, 35 W 4th St,12th Floor, New York, NY 10012 USA. EM farzana.kapadia@nyu.edu RI Mackesy-Amiti, Mary/B-7208-2008; OI Mackesy-Amiti, Mary/0000-0002-7238-5240 NR 41 TC 11 Z9 11 U1 1 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2011 VL 15 IS 7 BP 1309 EP 1318 DI 10.1007/s10461-009-9569-3 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 825KA UT WOS:000295271200003 PM 19449099 ER PT J AU Vogenthaler, NS Hadley, C Rodriguez, AE Valverde, EE del Rio, C Metsch, LR AF Vogenthaler, Nicholas S. Hadley, Craig Rodriguez, Allan E. Valverde, Eduardo E. del Rio, Carlos Metsch, Lisa R. TI Depressive Symptoms and Food Insufficiency Among HIV-Infected Crack Users in Atlanta and Miami SO AIDS AND BEHAVIOR LA English DT Article DE Depression; HIV/AIDS; Food insecurity; Crack cocaine ID ACTIVE ANTIRETROVIRAL THERAPY; LOW FAMILY INCOME; POSITIVE WOMEN; SAN-FRANCISCO; UNITED-STATES; DISEASE PROGRESSION; COCAINE SMOKERS; INJECTION-DRUG; MENTAL-HEALTH; LIFE EVENTS AB Depression contributes to worse general and HIV-related clinical outcomes. We examined the prevalence of and factors associated with depressive symptomatology among HIV-infected crack cocaine users recruited for Project HOPE (Hospital Visit is an Opportunity for Prevention and Engagement with HIV-positive Crack Users). We used multiple logistic regression to determine sociodemographic correlates associated with screening in for depression. Among 291 participants, three-quarters (73.5%) were identified as depressed. Higher odds of screening in for depression was associated with food insufficiency and monthly income below $600. Alcohol and crack use were not associated with screening in for depression. Depressive symptomatology is extremely prevalent among HIV-infected crack cocaine users and is associated with food insufficiency and lower income. Screening for depression and food insecurity should be included in HIV prevention and treatment programs. Improved recognition and mitigation of these conditions will help alleviate their contribution to HIV-related adverse health outcomes. C1 [Vogenthaler, Nicholas S.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30303 USA. [Hadley, Craig] Emory Univ, Dept Anthropol, Atlanta, GA 30303 USA. [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA. [Valverde, Eduardo E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [del Rio, Carlos] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30303 USA. [Metsch, Lisa R.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. RP Vogenthaler, NS (reprint author), Emory Univ, Sch Med, Div Infect Dis, 69 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA. EM nvogent@emory.edu RI del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 FU NCATS NIH HHS [UL1 TR000454]; NIAID NIH HHS [P30 AI073961, P30AI073961, 2P30AI050409, P30 AI050409]; NIDA NIH HHS [R01 DA017612, R01 DA017612-01A2] NR 55 TC 22 Z9 23 U1 5 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2011 VL 15 IS 7 BP 1520 EP 1526 DI 10.1007/s10461-010-9668-1 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 825KA UT WOS:000295271200025 PM 20099017 ER PT J AU Taylor, RD Bimbi, DS Joseph, HA Margolis, AD Parsons, JT AF Taylor, Raekiela D. Bimbi, David S. Joseph, Heather A. Margolis, Andrew D. Parsons, Jeffrey T. TI GIRLFRIENDS: EVALUATION OF AN HIV-RISK REDUCTION INTERVENTION FOR ADULT TRANSGENDER WOMEN SO AIDS EDUCATION AND PREVENTION LA English DT Article ID SAN-FRANCISCO; BEHAVIORS; PREVENTION; PREVALENCE; HEALTH; COMMUNITY AB This study evaluated Girlfriends, a behavioral HIV intervention, developed for male-to-female transgender persons, for whom there are few scientifically evaluated prevention programs. The Girlfriends intervention included four group-level sessions. We used a single group, pre-post test design to assess changes in sexual risk behaviors at 3-month follow-up. We enrolled 63 transgender women into the study. Forty-six percent were Hispanic and 35% were African American. Three months after the intervention, participants had fewer sexual partners (p = .043) and were less likely to have any unprotected anal intercourse (UAI) with male exchange partners (p = .013) and unprotected sex at last vaginal or anal sex episode with female and male partners (p = .039). The findings of this study are promising. We observed behavioral effects among a largely ethnic minority sample of transgender women. Replication with a larger sample and a control group is needed. C1 [Taylor, Raekiela D.; Joseph, Heather A.; Margolis, Andrew D.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA 30333 USA. [Bimbi, David S.] CUNY, LaGuardia Community Coll, Ctr HIV AIDS Educ Studies & Training, New York, NY 10021 USA. [Parsons, Jeffrey T.] CUNY Hunter Coll, Grad Ctr, Ctr HIV AIDS Educ Studies & Training, New York, NY 10021 USA. RP Taylor, RD (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,Mail Stop E-37, Atlanta, GA 30333 USA. EM RTaylor5@cdc.gov OI Parsons, Jeffrey/0000-0002-6875-7566 FU NCHHSTP CDC HHS [UR6/PS000422] NR 19 TC 12 Z9 12 U1 0 U2 5 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD OCT PY 2011 VL 23 IS 5 BP 469 EP 478 PG 10 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 831AW UT WOS:000295702100008 PM 22010810 ER PT J AU Chen, RT Hankins, C Osmanov, S Esparza, J Michael, NL McCluskey, M Warren, M AF Chen, R. T. Hankins, C. Osmanov, S. Esparza, J. Michael, N. L. McCluskey, M. Warren, M. TI Preparing for the Availability of a Partially Effective HIV Vaccine SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on AIDS Vaccine CY SEP 12-15, 2011 CL Bangkok, THAILAND C1 [Chen, R. T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hankins, C.] UNAIDS, Geneva, Switzerland. [Osmanov, S.] WHO, CH-1211 Geneva, Switzerland. [Esparza, J.] Bill & Melinda Gates Fdn, Seattle, WA USA. [McCluskey, M.] US Mil HIV Res Program, Washington, DC USA. [Warren, M.] AVAC, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2011 VL 27 IS 10 BP A82 EP A83 PG 2 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 832GD UT WOS:000295790500209 ER PT J AU Holtz, TH Raengsakulrach, B Chonwattana, W Thienkrua, W McNicholl, J Wimonsate, W Chaikummao, S Varangrat, A Sirivongrangson, P Mock, PA van Griensven, F AF Holtz, T. H. Raengsakulrach, B. Chonwattana, W. Thienkrua, W. McNicholl, J. Wimonsate, W. Chaikummao, S. Varangrat, A. Sirivongrangson, P. Mock, P. A. van Griensven, F. TI Hepatitis B Virus (HBV) Immunity After Vaccination in a Preparatory Cohort Study Among Men Who Have Sex with Men, Bangkok, Thailand, 2006-2009 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on AIDS Vaccine CY SEP 12-15, 2011 CL Bangkok, THAILAND C1 [Holtz, T. H.; Raengsakulrach, B.; Chonwattana, W.; Thienkrua, W.; Wimonsate, W.; Chaikummao, S.; Varangrat, A.; Mock, P. A.; van Griensven, F.] Thailand MOPH US CDC Collaborat, Nonthaburi, Thailand. [McNicholl, J.] US CDC, Div HIV AIDS Prevent, Atlanta, GA USA. [Sirivongrangson, P.] Thailand MOPH, Bur AIDS TB & STI, Nonthaburi, Thailand. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2011 VL 27 IS 10 BP A58 EP A58 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 832GD UT WOS:000295790500145 ER PT J AU Leelawiwat, W Rutvisuttinunt, W McNicholl, J Arroyo, M Raengsakulrach, B Mueanpai, F Kongpechsatit, O Assawadarachai, V de Souza, M Chaikummao, S Chonwattana, W Tongtoyai, J Sangiamkittikul, A Curlin, M van Griensven, F AF Leelawiwat, W. Rutvisuttinunt, W. McNicholl, J. Arroyo, M. Raengsakulrach, B. Mueanpai, F. Kongpechsatit, O. Assawadarachai, V. de Souza, M. Chaikummao, S. Chonwattana, W. Tongtoyai, J. Sangiamkittikul, A. Curlin, M. van Griensven, F. TI Characterization of HIV-1 Subtype Distribution Among Thai MSM Using MHAbce, a High Throughput Approach for Molecular Epidemiology Studies SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on AIDS Vaccine CY SEP 12-15, 2011 CL Bangkok, THAILAND C1 [Leelawiwat, W.; Raengsakulrach, B.; Mueanpai, F.; Kongpechsatit, O.; Chaikummao, S.; Chonwattana, W.; Tongtoyai, J.; Sangiamkittikul, A.] US CDC Collaborat, Thailand Minist Publ Health, Nonthaburi, Thailand. [Rutvisuttinunt, W.; Arroyo, M.; Assawadarachai, V.; de Souza, M.] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand. [McNicholl, J.; Curlin, M.; van Griensven, F.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2011 VL 27 IS 10 BP A114 EP A114 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 832GD UT WOS:000295790500295 ER PT J AU Vishwanathan, A Guenthner, PC Hendry, R McNicholl, JM Kersh, EN AF Vishwanathan, A. Guenthner, P. C. Hendry, R. McNicholl, J. M. Kersh, E. N. TI Influence of the Menstrual Cycle on Levels of Innate Immune Proteins in the Genital Tract of Female Pigtail Macaques SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on AIDS Vaccine CY SEP 12-15, 2011 CL Bangkok, THAILAND C1 [Vishwanathan, A.; Guenthner, P. C.; Hendry, R.; McNicholl, J. M.; Kersh, E. N.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2011 VL 27 IS 10 BP A117 EP A117 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 832GD UT WOS:000295790500303 ER PT J AU Bern, C Kjos, S Yabsley, MJ Montgomery, SP AF Bern, Caryn Kjos, Sonia Yabsley, Michael J. Montgomery, Susan P. TI Trypanosoma cruzi and Chagas' Disease in the United States SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review ID POLYMERASE-CHAIN-REACTION; RACCOONS PROCYON-LOTOR; TRIATOMA-SANGUISUGA LECONTE; NORTH-AMERICAN TRIATOMINAE; ST-CATHERINES ISLAND; US BLOOD-DONORS; HEART-TRANSPLANTATION; RURAL-COMMUNITY; EARLY-DIAGNOSIS; LATIN-AMERICA AB Chagas' disease is caused by the protozoan parasite Trypanosoma cruzi and causes potentially life-threatening disease of the heart and gastrointestinal tract. The southern half of the United States contains enzootic cycles of T. cruzi, involving 11 recognized triatomine vector species. The greatest vector diversity and density occur in the western United States, where woodrats are the most common reservoir; other rodents, raccoons, skunks, and coyotes are also infected with T. cruzi. In the eastern United States, the prevalence of T. cruzi is highest in raccoons, opossums, armadillos, and skunks. A total of 7 autochthonous vector-borne human infections have been reported in Texas, California, Tennessee, and Louisiana; many others are thought to go unrecognized. Nevertheless, most T. cruzi-infected individuals in the United States are immigrants from areas of endemicity in Latin America. Seven transfusion-associated and 6 organ donor-derived T. cruzi infections have been documented in the United States and Canada. As improved control of vector- and blood-borne T. cruzi transmission decreases the burden in countries where the disease is historically endemic and imported Chagas' disease is increasingly recognized outside Latin America, the United States can play an important role in addressing the altered epidemiology of Chagas' disease in the 21st century. C1 [Bern, Caryn; Montgomery, Susan P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kjos, Sonia] Marshfield Clin Res Fdn, Marshfield, WI USA. [Yabsley, Michael J.] Univ Georgia, Coll Vet Med, Athens, GA USA. RP Bern, C (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM cxb9@cdc.gov NR 352 TC 169 Z9 173 U1 6 U2 48 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0893-8512 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD OCT PY 2011 VL 24 IS 4 BP 655 EP 681 DI 10.1128/CMR.00005-11 PG 27 WC Microbiology SC Microbiology GA 832VL UT WOS:000295837000002 PM 21976603 ER PT J AU Hinton, CF Feuchtbaum, L Kus, CA Kemper, AR Berry, SA Levy-Fisch, J Luedtke, J Kaye, C Boyle, CA AF Hinton, Cynthia F. Feuchtbaum, Lisa Kus, Christopher A. Kemper, Alex R. Berry, Susan A. Levy-Fisch, Jill Luedtke, Julie Kaye, Celia Boyle, Coleen A. TI What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children SO GENETICS IN MEDICINE LA English DT Article DE newborn screening; long-term-follow-up; quality assurance; health outcomes; data collection ID CLINICAL-PRACTICE PROTOCOL; CYSTIC-FIBROSIS; PARTICIPATORY RESEARCH; NATIONAL-SURVEY; MEDICAL HOME; MANAGEMENT; CARE; DIAGNOSIS; CONSENSUS; INFANTS AB The US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children provides guidance on reducing the morbidity and mortality associated with heritable disorders detectable through newborn screening. Efforts to systematically evaluate health outcomes, beyond long-term survival, with a few exceptions, are just beginning. To facilitate these nascent efforts, the US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children initiated a project to define the major overarching questions to be answered to assure that newborn screening is meeting its goal of achieving the best quality outcome for the affected children and their families. The questions identified follow the central components of long-term follow-up-care coordination, evidence-based treatment, continuous quality improvement, and new knowledge discovery-and are framed from the perspectives of the state and nation, primary and specialty healthcare providers, and the impacted families. These overarching questions should be used to guide the development of long-term follow-up data systems, quality health indicators, and specific data elements for evaluating the newborn screening system. Genet Med 2011:13(10):861-865. C1 [Hinton, Cynthia F.; Boyle, Coleen A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Feuchtbaum, Lisa] Calif Dept Hlth Serv, Richmond, CA USA. [Kus, Christopher A.] New York State Dept Hlth, New York, NY USA. [Kemper, Alex R.] Duke Univ, Dept Pediat, Duke Clin Res Inst, Durham, NC 27706 USA. [Berry, Susan A.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. [Levy-Fisch, Jill] Save Babies Screening Fdn, Scarsdale, NY USA. [Luedtke, Julie] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA. [Kaye, Celia] Univ Colorado, Dept Pediat, Denver Sch Med, Aurora, CO USA. RP Hinton, CF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA. EM chinton@cdc.gov OI Berry, Susan/0000-0001-7970-688X FU Health Resources and Services Administration, Maternal and Child Health Bureau FX The authors extend their appreciation for the thoughtful comments offered by the members of the SACHDNC Follow-Up and Treatment Subcommittee, Round Table participants at the Association of Public Health Laboratories' 2010 Newborn Screening & Genetic Testing Symposium, members of the National Coordinating Center/Regional Collaborative Long-term-Follow-Up Workgroup, and Newborn Screening and Translational Research Network Clinical Centers Workgroup. The workshop was supported in part by the Health Resources and Services Administration, Maternal and Child Health Bureau. NR 19 TC 14 Z9 14 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD OCT PY 2011 VL 13 IS 10 BP 861 EP 865 DI 10.1097/GIM.0b013e3182209f09 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 833KN UT WOS:000295884200002 PM 21716119 ER PT J AU Khoury, MJ Gwinn, M Dotson, D Bowen, MS AF Khoury, Muin J. Gwinn, Marta Dotson, David Bowen, M. Scott TI Is there a need for PGxceptionalism? SO GENETICS IN MEDICINE LA English DT Editorial Material C1 [Khoury, Muin J.; Gwinn, Marta; Dotson, David; Bowen, M. Scott] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Khoury, Muin J.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Khoury, MJ (reprint author), CDC, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM muk1@cdc.gov OI Dotson, William David/0000-0002-9606-6594 NR 12 TC 5 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD OCT PY 2011 VL 13 IS 10 BP 866 EP 867 DI 10.1097/GIM.0b013e3182265bed PG 2 WC Genetics & Heredity SC Genetics & Heredity GA 833KN UT WOS:000295884200003 PM 21799428 ER PT J AU Smith, BD Patel, N Beckett, G Ward, JW AF Smith, Bryce D. Patel, Nita Beckett, Geoff Ward, John W. TI COMPARISON OF HEPATITIS C VIRUS INFECTION SCREENING STRATEGIES: ELEVATED ALANINE AMINOTRANSFERASE LEVELS VERSUS BIRTH COHORT SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Smith, Bryce D.; Beckett, Geoff; Ward, John W.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Patel, Nita] CDC Fdn, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 482A EP 482A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002241 ER PT J AU Holmberg, SD Ly, KN Xing, J Klevens, M Jiles, R Ward, JW AF Holmberg, Scott D. Ly, Kathleen N. Xing, Jian Klevens, Monina Jiles, Ruth Ward, John W. TI THE GROWING BURDEN OF MORTALITY ASSOCIATED WITH VIRAL HEPATITIS IN THE UNITED STATES, 1999-2007 SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Holmberg, Scott D.; Ly, Kathleen N.; Xing, Jian; Klevens, Monina; Jiles, Ruth; Ward, John W.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 483A EP 483A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002243 ER PT J AU Smith, BD Patel, N Beckett, G Ward, JW AF Smith, Bryce D. Patel, Nita Beckett, Geoff Ward, John W. TI HEPATITIS C VIRUS ANTIBODY PREVALENCE, CORRELATES AND PREDICTORS AMONG PERSONS BORN FROM 1945 THROUGH 1965, UNITED STATES, 1999-2008 SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Smith, Bryce D.; Beckett, Geoff; Ward, John W.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Patel, Nita] CDC Fdn, Atlanta, GA USA. NR 0 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 554A EP 555A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002394 ER PT J AU Southern, W Drainoni, ML Smith, BD Koppelman, E Mckee, MD Christiansen, CL Gifford, AL Weinbaum, CM Litwin, AH AF Southern, William Drainoni, Mari-Lynn Smith, Bryce D. Koppelman, Elisa McKee, M. D. Christiansen, Cindy L. Gifford, Allen L. Weinbaum, Cindy M. Litwin, Alain H. TI PHYSICIAN NON-ADHERENCE WITH A HEPATITIS C SCREENING PROGRAM SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Southern, William] Montefiore Med Ctr, Albert Einstein Coll Med, Div Hosp Med, Bronx, NY 10467 USA. [Litwin, Alain H.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. [Southern, William; Litwin, Alain H.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [McKee, M. D.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Family Med, Bronx, NY 10467 USA. [Drainoni, Mari-Lynn; Koppelman, Elisa; Christiansen, Cindy L.; Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Hlth & Policy Management Dept, Boston, MA USA. [Drainoni, Mari-Lynn; Koppelman, Elisa] ENRM Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Boston, MA USA. [Gifford, Allen L.] ENRM Vet Adm Hosp, VA QUERI HIV Hepatitis Program, Boston, MA USA. [Smith, Bryce D.; Weinbaum, Cindy M.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 577A EP 577A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002438 ER PT J AU Drainoni, ML Litwin, AH Smith, BD Koppelman, E McKee, MD Christiansen, CL Gifford, AL Weinbaum, CM Southern, W AF Drainoni, Mari-Lynn Litwin, Alain H. Smith, Bryce D. Koppelman, Elisa McKee, M. D. Christiansen, Cindy L. Gifford, Allen L. Weinbaum, Cindy M. Southern, William TI EFFECTIVENESS OF A RISK SCREENER IN IDENTIFYING HEPATITIS C VIRUS IN PRIMARY CARE SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Drainoni, Mari-Lynn; Koppelman, Elisa; Christiansen, Cindy L.; Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Med, Dept Med, Infect Dis Sect, Boston, MA 02118 USA. [Koppelman, Elisa; Christiansen, Cindy L.; Gifford, Allen L.] ENRM Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Smith, Bryce D.; Weinbaum, Cindy M.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Litwin, Alain H.] Albert Einstein Coll Med, Montefiore Med Ctr, Div Gen Internal Med, New York, NY USA. [McKee, M. D.] Albert Einstein Coll Med, Dept Family & Social Med, New York, NY USA. [Southern, William] Albert Einstein Coll Med, Montefiore Med Ctr, Sect Hosp Med, New York, NY USA. [Litwin, Alain H.; Southern, William] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 591A EP 591A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002466 ER PT J AU Rein, DB Smith, BD Wittenborn, JS Lesesne, SB Wagner, LD Roblin, DW Patel, N Weinbaum, CM AF Rein, David B. Smith, Bryce D. Wittenborn, John S. Lesesne, Sarah B. Wagner, Laura D. Roblin, Douglas W. Patel, Nita Weinbaum, Cindy M. TI THE COST-EFFECTIVENESS OF BIRTH COHORT HEPATITIS C ANTIBODY SCREENING IN US PRIMARY CARE SETTINGS SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Rein, David B.; Wittenborn, John S.; Wagner, Laura D.] RTI Int, Atlanta, GA USA. [Smith, Bryce D.; Weinbaum, Cindy M.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Lesesne, Sarah B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Roblin, Douglas W.] Kaiser Permanente Georgia, Ctr Hlth Res SE, Atlanta, GA USA. [Patel, Nita] CDC Fdn, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 596A EP 597A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002478 ER PT J AU Simons, B Zhang, YH Bulkow, L Choromanski, T Livingston, S Homan, CE Negus, S Lau, D McMahon, BJ AF Simons, Brenna Zhang, Yuhong Bulkow, Lisa Choromanski, Tammy Livingston, Stephen Homan, Chriss E. Negus, Susan Lau, Daryl McMahon, Brian J. TI LONGITUDINAL ANALYSIS OF INACTIVE HEPATITIS B CARRIERS: A POTENTIAL ROLE FOR HBSAG TITER AND VIRAL LOAD TO DETERMINE EFFECTIVE CONTROL OF CHRONIC HEPATITIS B AND HBSAG LOSS SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Simons, Brenna; Choromanski, Tammy; Livingston, Stephen; Homan, Chriss E.; Negus, Susan; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Bulkow, Lisa; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Zhang, Yuhong; Lau, Daryl] Beth Israel Deaconess Med Ctr, Ctr Liver, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 605A EP 606A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002497 ER PT J AU McMahon, BJ Bulkow, L Zhang, YH Simons, B Negus, S Homan, CE Livingston, S Lau, D AF McMahon, Brian J. Bulkow, Lisa Zhang, Yuhong Simons, Brenna Negus, Susan Homan, Chriss E. Livingston, Stephen Lau, Daryl TI MOST PATIENTS WITH HBV DNA BETWEEN 2,000 AND 20,000 IU/ML OVER TIME HAVE MILD INFLAMMATION AND FIBROSIS ON LIVER BIOPSY SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [McMahon, Brian J.; Simons, Brenna; Negus, Susan; Homan, Chriss E.; Livingston, Stephen] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Bulkow, Lisa] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Zhang, Yuhong; Lau, Daryl] Beth Israel Deaconess Med Ctr, Ctr Liver, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 611A EP 611A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578002508 ER PT J AU Iqbal, K Klevens, M Bornschlegel, K Gerard, K Rizzo, E Speers, S Sweet, K Thomas, A Vonderwahl, CW Khudyakov, Y Xia, GL AF Iqbal, Kashif Klevens, Monina Bornschlegel, Katherine Gerard, Kristin Rizzo, Elena Speers, Suzanne Sweet, Kristin Thomas, Ann Vonderwahl, Candace W. Khudyakov, Yury Xia, Guo-liang TI GENOTYPIC CHARACTERIZATION OF ACUTE HEPATITIS B VIRUS CASES FROM SELECTED SURVEILLANCE SITES, UNITED STATES, 2007-2010 SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Iqbal, Kashif; Klevens, Monina; Khudyakov, Yury; Xia, Guo-liang] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Bornschlegel, Katherine] NYCDOH, New York, NY USA. [Rizzo, Elena] New York State Dept Hlth, Albany, NY USA. [Sweet, Kristin] Minnesota Dept Hlth, St Paul, MN USA. [Gerard, Kristin; Speers, Suzanne] CT Dept Publ Hlth Hlth, Hartford, CT USA. [Thomas, Ann] Oregon Hlth Author, Portland, OR USA. [Vonderwahl, Candace W.] Colorado Dept Hlth, Denver, CO 80220 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 891A EP 891A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578003342 ER PT J AU Byrd, KK Holman, R Mehal, J Murphy, TV AF Byrd, Kathy K. Holman, Robert Mehal, Jason Murphy, Trudy V. TI CHRONIC LIVER DISEASE-ASSOCIATED HOSPITALIZATIONS AMONG ADULTS WITH DIABETES-UNITED STATES, 2001-2008 SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Byrd, Kathy K.; Holman, Robert; Mehal, Jason; Murphy, Trudy V.] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 1177A EP 1177A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578004192 ER PT J AU Tohme, RA Xing, J Liao, YL Holmberg, SD AF Tohme, Rania A. Xing, Jian Liao, Youlian Holmberg, Scott D. TI HEPATITIS C TESTING, PREVALENCE, AND LINKAGE TO CARE IN THE RACIAL AND ETHNIC APPROACHES TO COMMUNITY HEALTH ACROSS THE US (REACH US) SURVEY - UNITED STATES, 2009-2010 SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Tohme, Rania A.; Xing, Jian; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Tohme, Rania A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Liao, Youlian] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 1180A EP 1181A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578004201 ER PT J AU Spradling, PR Rupp, LB Moorman, AC Lu, M Teshale, EH Gordon, SC Nakasato, C Boscarino, JA Henkle, E Nerenz, DR Holmberg, SD AF Spradling, Philip R. Rupp, Lora B. Moorman, Anne C. Lu, Mei Teshale, Eyasu H. Gordon, Stuart C. Nakasato, Cynthia Boscarino, Joseph A. Henkle, Emily Nerenz, David R. Holmberg, Scott D. TI PREDICTORS OF TESTING FOR AND INFECTION WITH HEPATITIS B VIRUS (HBV) AND HEPATITIS C VIRUS (HCV) IN FOUR UNITED STATES HEALTH CARE ORGANIZATIONS (HCOS), 2006-2008 SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Spradling, Philip R.; Moorman, Anne C.; Teshale, Eyasu H.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, NCHHSTP, Atlanta, GA 30333 USA. [Rupp, Lora B.; Lu, Mei; Gordon, Stuart C.; Nerenz, David R.] Henry Ford Hlth Syst, Detroit, MI USA. [Nakasato, Cynthia] Kaiser Permanente, Ctr Hlth Res, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Ctr Hlth Res, Danville, PA USA. [Henkle, Emily] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 1185A EP 1185A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578004211 ER PT J AU Drobeniuc, J Greene-Montfort, T Le, NT Ganova-Raeva, L Teo, CG Kamili, S AF Drobeniuc, Jan Greene-Montfort, Tracy Ngoc-Thao Le Ganova-Raeva, Lilia Teo, Chong-Gee Kamili, Saleem TI HEPATITIS E IN THE UNITED STATES SO HEPATOLOGY LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 04-08, 2011 CL San Francisco, CA SP Amer Assoc Study Liver Dis C1 [Drobeniuc, Jan; Greene-Montfort, Tracy; Ngoc-Thao Le; Ganova-Raeva, Lilia; Teo, Chong-Gee; Kamili, Saleem] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 SU 1 BP 1438A EP 1438A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KG UT WOS:000295578004750 ER PT J AU Abrams, JY Schonberger, LB Belay, ED Maddox, RA Leschek, EW Mills, JL Wysowski, DK Fradkin, JE AF Abrams, Joseph Y. Schonberger, Lawrence B. Belay, Ermias D. Maddox, Ryan A. Leschek, Ellen W. Mills, James L. Wysowski, Diane K. Fradkin, Judith E. TI Lower Risk of Creutzfeldt-Jakob Disease in Pituitary Growth Hormone Recipients Initiating Treatment after 1977 SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID UNITED-STATES; CONTAMINATION; THERAPY; TIME AB Context: Creutzfeldt-Jakob disease (CJD) caused by contaminated cadaveric pituitary-derived human GH (hGH) has been responsible for hundreds of deaths worldwide. Studies of U. S. National Hormone and Pituitary Program (NHPP) hGH recipients have found CJD only in patients treated before 1977, when a new purification procedure with column chromatography was implemented for hGH extraction. Objective: Our objective was to provide updated information on transmission of CJD to NHPP hGH recipients and determine whether recipients of hGH produced after 1977 had a significantly lower CJD risk than pre-1977 recipients. Patients: A total of 5570 NHPP hGH recipients were included in the study: 2099 in the pre-1977 cohort and 3471 in the post-1977 cohort. Main Outcome Measure: We used probability distribution functions to determine whether the observed number of CJD cases in the post-1977 cohort was significantly fewer than expected if the CJD risk was equal to that of the pre-1977 cohort, controlling for treatment duration and follow-up time. Results: All 22 CJD cases (diagnosed from 1984-2009) occurred in the pre-1977 hGH recipients. Almost half (47.9%) of pre-1977 recipients had a treatment duration of at least 5 yr compared with only 13.8% for post-1977 recipients. Based on the rates present in the pre-1977 cohort, the probability of observing no cases in the post-1977 cohort by chance alone was low (P = 0.0019). Conclusions: Risk of acquiring CJD was significantly lower for post-1977 NHPP hGH recipients than for pre-1977 recipients, suggesting that the new purification procedure in 1977 may have greatly reduced or eliminated CJD agent in hGH. (J Clin Endocrinol Metab 96: E1666-E1669, 2011) C1 [Abrams, Joseph Y.; Schonberger, Lawrence B.; Belay, Ermias D.; Maddox, Ryan A.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Leschek, Ellen W.; Fradkin, Judith E.] NIDDK, Bethesda, MD 20817 USA. [Mills, James L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA. [Wysowski, Diane K.] US FDA, Silver Spring, MD 20993 USA. RP Abrams, JY (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,CDC Mailstop A30, Atlanta, GA 30333 USA. EM JAbrams@cdc.gov RI Belay, Ermias/A-8829-2013 NR 12 TC 5 Z9 5 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2011 VL 96 IS 10 BP E1666 EP E1669 DI 10.1210/jc.2011-1357 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 833JC UT WOS:000295879600016 PM 21816775 ER PT J AU Torres-Altoro, MI Mathur, BN Drerup, JM Thomas, R Lovinger, DM O'Callaghan, JP Bibb, JA AF Torres-Altoro, Melissa I. Mathur, Brian N. Drerup, Justin M. Thomas, Rachel Lovinger, David M. O'Callaghan, James P. Bibb, James A. TI Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatum SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE chlorpyrifos; dopamine; Gulf War illness; insecticide; neurotoxicity; organophosphate ID CYCLIN-DEPENDENT KINASE-5; NEONATAL CHLORPYRIFOS EXPOSURE; ALPHA-7 NICOTINIC RECEPTORS; CENTRAL-NERVOUS-SYSTEM; GULF-WAR SYNDROME; SYNAPTIC PLASTICITY; NEOSTRIATAL NEURONS; ALZHEIMERS-DISEASE; PESTICIDE EXPOSURE; PRENATAL EXPOSURE AB The neurological effects of organophosphate (OP) pesticides, commonly used on foods and in households, are an important public health concern. Furthermore, subclinical exposure to combinations of organophosphates is implicated in Gulf War illness. Here, we characterized the effects of the broadly used insecticide chlorpyrifos (CPF) on dopamine and glutamatergic neurotransmission effectors in corticostriatal motor/reward circuitry. CPF potentiated protein kinase A (PKA)-dependent phosphorylation of the striatal protein dopamine-and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) and the glutamate receptor 1 (GluR1) subunit of alpha-amino-3-hydroxy-5methyl- 4-isoxazolepropionic acid (AMPA) receptors in mouse brain slices. It also increased GluR1 phosphorylation by PKA when administered systemically. This correlated with enhanced glutamate release from cortical projections in rat striatum. Similar effects were induced by the sarin congener, diisopropyl fluorophosphate, alone or in combination with the putative neuroprotectant, pyridostigmine bromide and the pesticide N,N-diethyl-meta-toluamide (DEET). This combination, meant to mimic the neurotoxicant exposure encountered by veterans of the 1991 Persian Gulf War, also induced hyperphosphorylation of the neurofibrillary tangle-associated protein tau. Diisopropyl fluorophosphate and pyrodostigmine bromide, alone or in combination, also increased the aberrant activity of the protein kinase, Cdk5, as indicated by conversion of its activating cofactor p35 to p25. Thus, consistent with recent findings in humans and animals, organophosphate exposure causes dysregulation in the motor/reward circuitry and invokes mechanisms associated with neurological disorders and neurodegeneration. C1 [Torres-Altoro, Melissa I.; Drerup, Justin M.; Thomas, Rachel; Bibb, James A.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Mathur, Brian N.; Lovinger, David M.] NIAAA, Lab Integrat Neurosci, NIH, Rockville, MD 20852 USA. [O'Callaghan, James P.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. [Bibb, James A.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA. RP Bibb, JA (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd,NC5-410, Dallas, TX 75390 USA. EM james.bibb@utsouthwestern.edu RI O'Callaghan, James/O-2958-2013 FU US National Institutes of Health [MH79710, MH083711, DA016672]; Centers for Disease Control and Prevention-NIOSH; Division of Intramural Clinical and Biological Research of NIAAA; IDIQ [VA549-P-0027]; Department of Veterans Affairs Medical Center, Dallas, TX FX We thank Suzanne Saldanha, Brenda Billig, and Christopher Felton for technical assistance. This work was supported by US National Institutes of Health Grants to J.A.B (MH79710, MH083711, and DA016672), Intramural funds from Centers for Disease Control and Prevention-NIOSH, and the Division of Intramural Clinical and Biological Research of NIAAA. Portions of this research were supported by IDIQ contract VA549-P-0027 (Robert W. Haley, M.D., PI), awarded and administered by the Department of Veterans Affairs Medical Center, Dallas, TX. The content does not necessarily reflect the position or the policy of the Federal government or the sponsoring agency, and no official endorsement should be inferred. NR 54 TC 29 Z9 30 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD OCT PY 2011 VL 119 IS 2 BP 303 EP 313 DI 10.1111/j.1471-4159.2011.07428.x PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 834PE UT WOS:000295973900006 PM 21848865 ER PT J AU Hnizdo, E Hakobyan, A Fleming, JL Beeckman-Wagner, LA AF Hnizdo, Eva Hakobyan, Artak Fleming, James L. Beeckman-Wagner, Lu-Ann TI Periodic Spirometry in Occupational Setting Improving Quality, Accuracy, and Precision SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID FEV1; INDIVIDUALS; PREVENTION; PROGRAM; WORKERS; DISEASE; HEALTH AB Objective: Effectiveness of periodic spirometry in medical monitoring depends on spirometry quality. We describe an intervention on spirometry quality and its impact on accuracy and precision of longitudinal measurements. Methods: The intervention was conducted from 2005 to 2010 in a monitoring program involving approximately 2500 firefighters. Intervention supported adherence to 2005 American Thoracic Society/European Respiratory Society recommendations through monitoring of spirometry quality and longitudinal data precision, technician training, change of spirometer, and quality control. Results: The percentage of forced vital capacity tests meeting the American Thoracic Society/European Respiratory Society criteria increased from 60% to 95% and the mean longitudinal forced expiratory volume in 1 second within-person variation decreased from 6% to 4%. The increased accuracy and precision of measurements and estimated rates of forced expiratory volume in 1 second decline were statistically significant. Conclusion: Monitoring of quality and data precision helped to recognize the need for intervention. The intervention improved accuracy and precision of spirometry measurements and their usefulness. C1 [Hnizdo, Eva; Beeckman-Wagner, Lu-Ann] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Hakobyan, Artak] Syst Res & Applicat Int Inc, Morgantown, WV USA. [Fleming, James L.] Phoenix Fire Dept, Phoenix, AZ USA. RP Hnizdo, E (reprint author), NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ehnizdo@cdc.gov FU National Institute for Occupational Safety and Health FX This work was supported by funding through the National Institute for Occupational Safety and Health intramural program. Periodic spirometry in occupational setting: improving quality, accuracy, and precision. NR 24 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD OCT PY 2011 VL 53 IS 10 BP 1205 EP 1209 DI 10.1097/JOM.0b013e31823078b8 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 831NE UT WOS:000295737400017 PM 21915065 ER PT J AU Grijalva, CG Moore, MR Griffin, MR AF Grijalva, Carlos G. Moore, Matthew R. Griffin, Marie R. TI Assessing the effect of pneumococcal conjugate vaccines: what is the value of routinely collected surveillance data? SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material ID CHILDHOOD IMMUNIZATION; DISEASE C1 [Grijalva, Carlos G.; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Moore, Matthew R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Grijalva, CG (reprint author), Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. EM carlos.grijalva@vanderbilt.edu NR 13 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD OCT PY 2011 VL 11 IS 10 BP 724 EP 726 DI 10.1016/S1473-3099(11)70143-8 PG 3 WC Infectious Diseases SC Infectious Diseases GA 831ZD UT WOS:000295768700004 PM 21621465 ER PT J AU Strine, TW Zack, M Dhingra, S Druss, B Simoes, E AF Strine, Tara W. Zack, Matthew Dhingra, Satvinder Druss, Benjamin Simoes, Eduardo TI Uninsurance Among Nonelderly Adults With and Without Frequent Mental and Physical Distress in the United States SO PSYCHIATRIC SERVICES LA English DT Article ID NATIONAL-COMORBIDITY-SURVEY; QUALITY-OF-LIFE; SURVEY REPLICATION; HEALTH TREATMENT; MEDICAL-CARE; DISORDERS; MASSACHUSETTS; COVERAGE; REFORM; DEPRESSION AB Objectives: This research describes uninsurance rates over time among nonelderly adults in the United States with or without frequent physical and mental distress and provides estimates of uninsurance by frequent mental distress status and sociodemographic characteristics nationally and by state. Methods: Data from the 1993 through 2009 Behavioral Risk Factor Surveillance System, a telephone survey that uses random-digit dialing, were used to examine the prevalence of uninsurance among nearly 3 million respondents by self-report of frequent physical and frequent mental distress and sociodemographic characteristics, response year, and state of residence. Results: After adjustment for sociodemographic characteristics, uninsurance among adults aged 18 to 64 years was markedly higher among those with frequent mental distress only (22.6%) and those with both frequent mental and frequent physical distress (21.8%) than among those with frequent physical distress only (17.7%). The prevalence of uninsurance did not differ markedly between those with only frequent mental distress and those with both frequent mental distress and frequent physical distress. The prevalence of uninsurance among those with frequent mental distress only and those with neither frequent mental distress nor frequent physical distress increased significantly over time. Conclusions: Uninsurance rates among nonelderly adults with frequent mental distress were disproportionately high. The results of this analysis can be used as baseline data to assess whether implementation of the Affordable Care Act is accompanied by changes in health care access, utilization, and self-reported measures of health, particularly among those with mental illness. (Psychiatric Services 62:1131-1137, 2011) C1 [Strine, Tara W.; Zack, Matthew; Dhingra, Satvinder; Simoes, Eduardo] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Behav Surveillance Branch, Atlanta, GA 30341 USA. [Druss, Benjamin] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Strine, TW (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Behav Surveillance Branch, 4770 Buford Highway NE,Mailstop K-66, Atlanta, GA 30341 USA. EM tws2@cdc.gov OI Simoes, Eduardo/0000-0003-4371-4305 NR 28 TC 5 Z9 5 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD OCT PY 2011 VL 62 IS 10 BP 1131 EP 1137 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 827WT UT WOS:000295461000005 PM 21969638 ER PT J AU Pattanayak, CW Rubin, DB Zell, ER AF Pattanayak, Cassandra W. Rubin, Donald B. Zell, Elizabeth R. TI Propensity Score Methods for Creating Covariate Balance in Observational Studies SO REVISTA ESPANOLA DE CARDIOLOGIA LA Spanish DT Article DE Propensity scores; Observational studies; Covariate balance ID CAUSAL INFERENCE; CARDIAC-SURGERY; BIAS; APROTININ; RISK; SUBCLASSIFICATION; ADJUSTMENT; MORTALITY; DESIGN AB Randomization of treatment assignment in experiments generates treatment groups with approximately balanced baseline covariates. However, in observational studies, where treatment assignment is not random, patients in the active treatment and control groups often differ on crucial covariates that are related to outcomes. These covariate imbalances can lead to biased treatment effect estimates. The propensity score is the probability that a patient with particular baseline characteristics is assigned to active treatment rather than control. Though propensity scores are unknown in observational studies, by matching or subclassifying patients on estimated propensity scores, we can design observational studies that parallel randomized experiments, with approximate balance on observed covariates. Observational study designs based on estimated propensity scores can generate approximately unbiased treatment effect estimates. Critically, propensity score designs should be created without access to outcomes, mirroring the separation of study design and outcome analysis in randomized experiments. This paper describes the potential outcomes framework for causal inference and best practices for designing observational studies with propensity scores. We discuss the use of propensity scores in two studies assessing the effectiveness and risks of antifibrinolytic drugs during cardiac surgery. Full English text available from: www.revespcardiol.org Published by Elsevier Espana, S.L. on behalf of the Sociedad Espanola de Cardiologia. C1 [Pattanayak, Cassandra W.; Rubin, Donald B.] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA. [Zell, Elizabeth R.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Rubin, DB (reprint author), Harvard Univ, Dept Stat, 1 Oxford St,7th Floor, Cambridge, MA 02138 USA. EM rubin@stat.harvard.edu NR 20 TC 17 Z9 20 U1 1 U2 8 PU EDICIONES DOYMA S A PI BARCELONA PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN SN 0300-8932 J9 REV ESP CARDIOL JI Rev. Esp. Cardiol. PD OCT PY 2011 VL 64 IS 10 BP 897 EP 903 DI 10.1016/j.recesp.2011.06.008 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 832MM UT WOS:000295809100010 PM 21872981 ER PT J AU Rodriguez-Romo, R Morales-Buenrostro, LE Lecuona, L Escalante-Santillan, N Velasco-Villa, A Kuzmin, I Rupprecht, CE De-Leo, C Ramirez, J Alberu, J AF Rodriguez-Romo, R. Morales-Buenrostro, L. E. Lecuona, L. Escalante-Santillan, N. Velasco-Villa, A. Kuzmin, I. Rupprecht, C. E. De-Leo, C. Ramirez, J. Alberu, J. TI Immune response after rabies vaccine in a kidney transplant recipient SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE rabies virus; kidney transplant recipient; adequate immune response ID VIRUS AB A 48-year-old male kidney-transplant recipient was bitten by a rabid dog. His immunosuppressive treatment consisted of cyclosporine 60 mg b.i.d., mycophenolate mofetil (MMF) 250 mg t.i.d., and prednisone 5 mg. After wound care, he received 5 doses of purified vero cell rabies vaccine on days 0, 3, 7, 14, and 28, and human rabies immunoglobulin, according to international guidelines. Adequate levels of rabies virus neutralizing antibodies were observed after the administration of the third vaccine dose. However, a decrease of antibody titer was detected by day 28. Immunosuppressive medication was minimized, withdrawing MMF and reducing the dose of cyclosporine. Booster doses of the same vaccine were administered on days 38, 41, 45, 52, and 66. Adequate neutralizing antibody response was recovered during the ensuing 12 months, under reduced immunosuppression. Nineteen months after the incident, the patient remains with good graft function and is asymptomatic for rabies. It remains to be determined whether the attained immune response was either the result of the booster vaccinations or the reduction of immunosuppression alone. Nevertheless, such an outcome would have been possible only with the combined management strategy implemented. C1 [Rodriguez-Romo, R.; Morales-Buenrostro, L. E.; De-Leo, C.; Ramirez, J.; Alberu, J.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Transplantat, Mexico City, DF, Mexico. [Morales-Buenrostro, L. E.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Nephrol & Mineral Metab Dept, Mexico City, DF, Mexico. [Lecuona, L.] USDA APHIS IS WS Mexico, Wildlife Program, Mexico City, DF, Mexico. [Escalante-Santillan, N.] Jurisdicc Sanitaria Tizayuca City, Hidalgo, Mexico. [Velasco-Villa, A.; Kuzmin, I.; Rupprecht, C. E.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot Infect Dis, Div Viral & Rickettsial Dis, Atlanta, GA USA. RP Alberu, J (reprint author), Vasco Quiroga 15, Mexico City 14000, DF, Mexico. EM josefinaalberu@hotmail.com NR 15 TC 7 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD OCT PY 2011 VL 13 IS 5 BP 492 EP 495 DI 10.1111/j.1399-3062.2011.00665.x PG 4 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 832VR UT WOS:000295837900009 PM 21883758 ER PT J AU Krolewiecki, A Socias, E Echazu, A Cajal, S Juarez, M Villalpando, C Arias, L Davila, M Abril, M Olmedo, E Tapia, L Cimino, R Gil, J Lammie, P Gold, S AF Krolewiecki, A. Socias, E. Echazu, A. Cajal, S. Juarez, M. Villalpando, C. Arias, L. Davila, M. Abril, M. Olmedo, E. Tapia, L. Cimino, R. Gil, J. Lammie, P. Gold, S. TI Obstacles in the management of soil transmitted helminths: development of a comprehensive platform for the evaluation of new strategies SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Krolewiecki, A.; Juarez, M.; Davila, M.; Cimino, R.; Gil, J.] Univ Nacl Salta, Inst Invest Enfermedades Trop, Oran, Argentina. [Echazu, A.; Villalpando, C.; Olmedo, E.; Tapia, L.] Hosp San Vicente de Paul, Oran, Salta, Argentina. [Cajal, S.; Lammie, P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 22 EP 23 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100052 ER PT J AU Arevalo, M Bardaji, A Chitnis, C Desai, M Kochar, S Martinez-Espinosa, FE Mayor, A Menegon, M Mueller, I Padilla, N del Portillo, H Rogerson, S Severini, C Wahlgren, M Menendez, C AF Arevalo, M. Bardaji, A. Chitnis, C. Desai, M. Kochar, S. Martinez-Espinosa, F. E. Mayor, A. Menegon, M. Mueeller, I. Padilla, N. del Portillo, H. Rogerson, S. Severini, C. Wahlgren, M. Menendez, C. CA PregVax Study Grp TI Prevalence of submicroscopic P. vivax infections during pregnancy: a multicentre collaborative study SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Bardaji, A.; Mayor, A.; del Portillo, H.; Menendez, C.] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, E-08007 Barcelona, Spain. [Arevalo, M.] Inst Inmunol, Cali, Colombia. [Kochar, S.; Padilla, N.] Coll Med, Bikaner, Rajasthan, India. [Chitnis, C.] Int Ctr Genet Engn & Biotechnol, Delhi, India. [Wahlgren, M.] Karolinska Inst, Stockholm, Sweden. [Menegon, M.; Severini, C.] Ist Super Sanita, I-00161 Rome, Italy. [Desai, M.] CDC, Div Parasit Dis, Malaria Branch, Atlanta, GA 30333 USA. [Desai, M.] CDC, Malaria Ctr Global Hlth, Atlanta, GA 30333 USA. [Rogerson, S.] Univ Melbourne, Melbourne, Vic 3010, Australia. RI Mueller, Ivo/C-7251-2013 OI Mueller, Ivo/0000-0001-6554-6889 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 33 EP 33 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100087 ER PT J AU Sterling, T Cayla, J Miro, J Villarino, E AF Sterling, T. Cayla, J. Miro, J. Villarino, E. CA Prevent TB TB Study TB Trials Consortium TI The prevent TB study (TB trials consortium study 26): 3 months of once-weekly rifapentine plus isoniazid vs. 9 months of daily isoniazid for treatment of latent M. tuberculosis infection SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Sterling, T.] Vanderbilt Univ, Tennessee EEUU, Nashville, TN 37203 USA. [Cayla, J.; Miro, J.] Agencia Salut Publ Barcelona, Barcelona, Spain. [Villarino, E.; Prevent TB TB Study; TB Trials Consortium] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 63 EP 63 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100174 ER PT J AU Pell, C Menaca, A Were, F Afrah, NA Chatio, S Manda-Taylor, L Andrew, ECW Mathanga, D Kalilani, L Hodgson, A Tagbor, H Ouma, P Pool, R AF Pell, C. Menaca, A. Were, F. Afrah, N. A. Chatio, S. Manda-Taylor, L. Andrew, E. C. W. Mathanga, D. Kalilani, L. Hodgson, A. Tagbor, H. Ouma, P. Pool, R. TI Factors affecting timing of formal antenatal care attendance: results from qualitative studies carried out in Ghana, Kenya and Malawi SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Pell, C.; Menaca, A.; Andrew, E. C. W.; Pool, R.] Univ Barcelona, Hosp Clin, Ctr Recerca Salut Int Barcelona CRESIB, Barcelona, Spain. [Were, F.; Ouma, P.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Afrah, N. A.; Tagbor, H.] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Community Hlth, Kumasi, Ghana. [Chatio, S.; Hodgson, A.] Navrongo Hlth Res Ctr, Navrongo, Upper E Region, Ghana. [Mathanga, D.] Univ Malawi, Coll Med, Malaria Alert Ctr, Zomba, Malawi. [Tagbor, H.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England. [Ouma, P.] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA. [Pool, R.] Univ Amsterdam, Ctr Global Hlth & Inequal, Amsterdam, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 81 EP 81 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100227 ER PT J AU Kabanywanyi, A Alexander, M Alba, S Khatib, R Malila, A Schlienger, R Nathan, R Kachur, P Lengeler, C Abdulla, S Genton, B AF Kabanywanyi, A. Alexander, M. Alba, S. Khatib, R. Malila, A. Schlienger, R. Nathan, R. Kachur, P. Lengeler, C. Abdulla, S. Genton, B. TI Impact of artemether-lumefantrine as first line treatment policy on malaria transmission and under five mortality in a rural area with high insecticide-treated net coverage in Tanzania SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Kabanywanyi, A.; Alexander, M.; Khatib, R.; Malila, A.; Nathan, R.; Lengeler, C.; Abdulla, S.] Ifakara Hlth Inst, Basel, Switzerland. [Schlienger, R.] Novartis Pharmaceut, Basel, Switzerland. [Kachur, P.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 113 EP 113 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100320 ER PT J AU Thomson, R Festo, C Bruxvoort, K Thwing, J Kalolella, A Nchimbi, H Taylor, M Kachur, SP Goodman, C AF Thomson, R. Festo, C. Bruxvoort, K. Thwing, J. Kalolella, A. Nchimbi, H. Taylor, M. Kachur, S. Patrick Goodman, C. TI Determinants of access to acts and malaria diagnosis: results from a household survey in three regions of Tanzania SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Thomson, R.; Bruxvoort, K.; Taylor, M.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [Thwing, J.; Kachur, S. Patrick] Ctr Dis Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 124 EP 124 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100353 ER PT J AU Bruxwoort, K Festo, C Thwing, J Thomson, R Kalolella, A Nchimbi, H Taylor, M Goodman, C Kachur, SP AF Bruxwoort, K. Festo, C. Thwing, J. Thomson, R. Kalolella, A. Nchimbi, H. Taylor, M. Goodman, C. Kachur, S. Patrick TI Over and under-use of acts at public health facilities in three regions of Tanzania SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 London Sch Hyg & Trop Med, London WC1, England. Ifakara Hlth Inst, Dar Es Salaam, Tanzania. Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 132 EP 132 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100378 ER PT J AU Yangzom, T Cruz, I Bern, C den Boer, M Argaw, D Alvar, J Velez, I Bhattacharya, S AF Yangzom, T. Cruz, I. Bern, C. den Boer, M. Argaw, D. Alvar, J. Velez, I. Bhattacharya, S. TI Visceral leishmaniasis rapid assessment in Bhutan SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Cruz, I.] Inst Salud Carlos III, WHO Collaborating Ctr Leishmaniasis, Madrid, Spain. [Bern, C.] CDC, Atlanta, GA 30333 USA. [den Boer, M.; Argaw, D.; Alvar, J.] WHO NTD IDM Leishmaniasis Programme, Geneva, Switzerland. [Velez, I.] Univ Antioquia, PECET, Medellin, Colombia. [Bhattacharya, S.] WHO SEARO, New Delhi, India. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 231 EP 232 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100692 ER PT J AU Carod, JF Rakotondrazaka, M Ramahefarisoa, RM Menard, D Soares, JL Dorny, P Wilkins, P AF Carod, J-F. Rakotondrazaka, M. Ramahefarisoa, R. M. Menard, D. Soares, J-L. Dorny, P. Wilkins, P. TI Updated epidemiology of cysticercosis in Madagascar SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Dorny, P.] Inst Trop, Antwerp, Belgium. [Wilkins, P.] CDC, Atlanta, GA 30333 USA. RI Menard, Didier/O-3294-2013 OI Menard, Didier/0000-0003-1357-4495 NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 SU 1 SI SI BP 270 EP 270 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 828RC UT WOS:000295519100815 ER PT J AU Purdy, MA Khudyakov, YE AF Purdy, Michael A. Khudyakov, Yury E. TI The molecular epidemiology of hepatitis E virus infection SO VIRUS RESEARCH LA English DT Review DE Hepatitis E virus; Molecular epidemiology; Genotypes subtypes; Transmission; Population dynamics ID NON-B HEPATITIS; GENOTYPE 3; TRANSPLANT RECIPIENTS; PHYLOGENETIC ANALYSIS; SPORADIC ACUTE; UNITED-STATES; RT-PCR; NON-A; GENETIC IDENTIFICATION; BLOOD-TRANSFUSION AB Molecular characterization of various hepatitis E virus (HEV) strains circulating among humans and animals (particularly swine, deer and boars) in different countries has revealed substantial genetic heterogeneity. The distinctive four-genotype distribution worldwide of mammalian HEV and varying degrees of genetic relatedness among local strains suggest a long and complex evolution of HEV in different geographic regions. The population expansion likely experienced by mammalian HEV in the second half of the 20th century is consistent with an extensive genetic divergence of HEV strains and high prevalence of HEV infections in many parts of the world, including developed countries. The rate and mechanisms of human-to-human transmission and zoonotic transmission to humans vary geographically, thus contributing to the complexity of HEV molecular evolution. Published by Elsevier B.V. C1 [Purdy, Michael A.; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Purdy, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, MS-A33,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM mup3@cdc.gov NR 127 TC 50 Z9 52 U1 3 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD OCT PY 2011 VL 161 IS 1 SI SI BP 31 EP 39 DI 10.1016/j.virusres.2011.04.030 PG 9 WC Virology SC Virology GA 833VV UT WOS:000295914000005 PM 21600939 ER PT J AU Krawczynski, K Meng, XJ Rybczynska, J AF Krawczynski, Krzysztof Meng, Xiang-Jin Rybczynska, Jolanta TI Pathogenetic elements of hepatitis E and animal models of HEV infection SO VIRUS RESEARCH LA English DT Review DE Pathogenesis; Animal models; Chimpanzees; Rhesus and cynomolgus macaques; HEV in pigs ID E VIRUS-INFECTION; NON-B HEPATITIS; TRANSMITTED NON-A; CROSS-SPECIES INFECTION; CIS-REACTIVE ELEMENT; CYNOMOLGUS MACAQUES; IMMUNE-RESPONSE; RHESUS-MONKEYS; MACACA-FASCICULARIS; PROTECTIVE EFFICACY AB The pathogenesis of HEV infection responsible for liver pathology and clinical disease is not well understood. The main target for the virus is the hepatocyte, where it replicates and is released to bile and gastrointestinal tract. Viremia is regularly seen during the virus replication. The exact mechanism of hepatocytic death is uncertain. In experimentally infected non-human primates, the peak of liver lesions, measured by alanine aminotransferase activity elevation, is concordant with the virus disappearance from stool at the time of dynamic humoral immune response; the role of cellular immunity has not been researched adequately, especially HEV-specific immune response in the liver. Non-human primates (chimpanzees, rhesus and cynomolgus macaques) are most widely used animal models for the study of HEV infection, its pathogenesis and vaccine trials. Several other animal models including pigs, rabbits and chickens have recently been established for the study of various aspects of HEV infection. Infectivity studies in susceptible primates were of significance in molecular studies of the virus itself. Preclinical vaccine trials with the use of various recombinant HEV capsid proteins and viral DNA established basic platform for formulation of HEV vaccine applied in HEV-endemic regions (China, Nepal). (C) 2011 Published by Elsevier B.V. C1 [Krawczynski, Krzysztof] Ctr Dis Control & Prevent, Expt Pathol & Immunol Lab, Div Viral Hepatitis, NCHHSTP, Atlanta, GA 30333 USA. [Meng, Xiang-Jin] Virginia Polytech Inst & State Univ, Coll Vet Med, Dept Biomed Sci & Pathobiol, Ctr Mol Med & Infect Dis, Blacksburg, VA 24061 USA. RP Krawczynski, K (reprint author), Ctr Dis Control & Prevent, Expt Pathol & Immunol Lab, Div Viral Hepatitis, NCHHSTP, 1600 Clifton Rd,Bldg 18,3-134, Atlanta, GA 30333 USA. EM kzk1@cdc.gov RI Meng, X.J./B-8769-2009 OI Meng, X.J./0000-0002-2739-1334 NR 66 TC 23 Z9 24 U1 1 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD OCT PY 2011 VL 161 IS 1 SI SI BP 78 EP 83 DI 10.1016/j.virusres.2011.03.007 PG 6 WC Virology SC Virology GA 833VV UT WOS:000295914000010 PM 21414365 ER PT J AU Khudyakov, Y Kamili, S AF Khudyakov, Yury Kamili, Saleem TI Serological diagnostics of hepatitis E virus infection SO VIRUS RESEARCH LA English DT Review DE Hepatitis E; Hepatitis E virus; IgM anti-HEV; IgG anti-HEV; Serology ID LINKED-IMMUNOSORBENT-ASSAY; IMMUNOGLOBULIN-M ANTIBODIES; OPEN-READING FRAME-2; NON-B HEPATITIS; TRANSMITTED NON-A; CAPSID PROTEIN; CYNOMOLGUS MACAQUES; SYNTHETIC PEPTIDES; ENZYME-IMMUNOASSAY; HEV INFECTION AB Development of accurate diagnostic assays for the detection of serological markers of hepatitis E virus (HEV) infection remains challenging. In the course of nearly 20 years after the discovery of HEV, significant progress has been made in characterizing the antigenic structure of HEV proteins, engineering highly immunoreactive diagnostic antigens, and devising efficient serological assays. However, many outstanding issues related to sensitivity and specificity of these assays in clinical and epidemiological settings remain to be resolved. Complexity of antigenic composition, viral genetic heterogeneity and varying epidemiological patterns of hepatitis E in different parts of the world present challenges to the refinement of HEV serological diagnostic assays. Development of antigens specially designed for the identification of serological markers specific to acute infection and of IgG anti-HEV specific to the convalescent phase of infection would greatly facilitate accurate identification of active. recent and past HEV infections. Published by Elsevier BM. C1 [Khudyakov, Yury; Kamili, Saleem] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Kamili, S (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, MS-A33-1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM skamili@cdc.gov NR 124 TC 66 Z9 70 U1 2 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD OCT PY 2011 VL 161 IS 1 SI SI BP 84 EP 92 DI 10.1016/j.virusres.2011.06.006 PG 9 WC Virology SC Virology GA 833VV UT WOS:000295914000011 PM 21704091 ER PT J AU Kamili, S AF Kamili, Saleem TI Toward the development of a hepatitis E vaccine SO VIRUS RESEARCH LA English DT Review DE Hepatitis E; HEV; Vaccine; DNA vaccine; Macaques ID VIRUS-LIKE PARTICLES; CAPSID PROTEIN; RECOMBINANT VACCINE; PROTECTIVE EFFICACY; CYNOMOLGUS MONKEYS; STRUCTURAL PROTEIN; IMMUNE-RESPONSES; VIRAL-HEPATITIS; CROSS-CHALLENGE; FUSION PROTEIN AB Hepatitis E virus (HEV) causes large epidemics of enterically transmitted acute hepatitis and accounts for a majority of sporadic acute hepatitis in endemic countries. Due to a very high mortality rate among infected pregnant women and substantial morbidity, disability and costs associated with hepatitis E, concerted efforts are being made to develop an efficacious vaccine. Experimental vaccines, based on recombinant proteins derived from the capsid gene of HEV, have been shown efficacious in pre-clinical trials in macaques conferring cross-protection against various genotypes. Two vaccine candidates, the rHEV vaccine expressed in baculovirus and the HEV 239 vaccine, expressed in Escherichia coli, were successfully evaluated in Phase II/III trials. However, at this time no approved vaccine against hepatitis E is commercially available. Published by Elsevier B.V. C1 Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Kamili, S (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, MS-A33,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM skamili@cdc.gov NR 59 TC 25 Z9 30 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD OCT PY 2011 VL 161 IS 1 SI SI BP 93 EP 100 DI 10.1016/j.virusres.2011.05.008 PG 8 WC Virology SC Virology GA 833VV UT WOS:000295914000012 PM 21620908 ER PT J AU Gehle, KS Crawford, JL Hatcher, MT AF Gehle, Kimberly S. Crawford, Jewel L. Hatcher, Michael T. TI Integrating Environmental Health Into Medical Education SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PEDIATRICIANS ATTITUDES; CANCER; MORTALITY; EXPOSURE; CHILDREN; BELIEFS; IMPACT; COSTS; LEAD AB Although environmental factors contribute to more than 25% of all global disease, and toxic agents ranked fifth in underlying causes of U. S. deaths in 2000, environmental medicine education is largely omitted in the continuum of U. S. medical education. The paucity of specialists trained in environmental medicine (i.e., occupational medicine and other preventive medicine specialties and subspecialties), coupled with the lack of adequate general medical education on how to prevent, diagnose, refer, or treat patients exposed to hazardous substances in the environment, contributes to lost opportunities for primary prevention or early intervention to mitigate or minimize environmentally related disease burden. Survey findings of graduating medical students over the past few years have identified environmental health as a medical school topic area that can be improved. This article reflects a panel presentation on the challenge of including environmental health in general medical education. It was given at the 2010 "Patients and Populations: Public Health in Medical Education" conference cosponsored by the CDC and the American Association of Medical Colleges. A variety of educational strategies, models, and educational resources are presented that illustrate how recommended competency-based environmental health content can be integrated into medical education to better prepare medical students and physicians without specialized expertise in environmental medicine to provide or facilitate environmental preventive or curative patient care. (Am J Prev Med 2011;41(4S3):S296-S301) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Gehle, Kimberly S.; Crawford, Jewel L.; Hatcher, Michael T.] Agcy Toxic Subst & Dis Registry, Environm Med & Educ Serv Branch, Div Toxicol & Environm Med, Atlanta, GA USA. RP Gehle, KS (reprint author), 4770 Buford Highway NE,Mail Stop F62, Atlanta, GA 30341 USA. EM ebk2@cdc.gov FU CDC-AAMC (Association of American Medical Colleges) [5U36CD319276] FX Publication of this article was supported by the CDC-AAMC (Association of American Medical Colleges) Cooperative Agreement number 5U36CD319276. NR 39 TC 13 Z9 13 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2011 VL 41 IS 4 SU 3 BP S296 EP S301 DI 10.1016/j.amepre.2011.06.007 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 832SK UT WOS:000295827300026 PM 21961679 ER PT J AU Maeshiro, R Koo, D Keck, W AF Maeshiro, Rika Koo, Denise Keck, William TI Integration of Public Health Into Medical Education An Introduction to the Supplement SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 [Maeshiro, Rika] Assoc Amer Med Coll, Publ Hlth Project, Washington, DC 20037 USA. [Koo, Denise] CDC, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Keck, William] NE Ohio Med Univ, Dept Family & Community Med, Rootstown, OH USA. RP Maeshiro, R (reprint author), Assoc Amer Med Coll, Publ Hlth Project, 2450 N St NW, Washington, DC 20037 USA. EM rmaeshiro@aamc.org NR 49 TC 12 Z9 12 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2011 VL 41 IS 4 SU 3 BP S145 EP S148 DI 10.1016/j.amepre.2011.07.010 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 832SK UT WOS:000295827300001 PM 21961654 ER PT J AU Monroe, JA AF Monroe, Judith A. TI Exploring the Context Contemporary Public Health SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30329 USA. RP Monroe, JA (reprint author), CDC, Off State Tribal Local & Terr Support, 1600 Clifton Rd,MS E70, Atlanta, GA 30329 USA. EM fsu6@cdc.gov FU ODCDC CDC HHS [5U36CD319276] NR 10 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2011 VL 41 IS 4 SU 3 BP S155 EP S159 DI 10.1016/j.amepre.2011.06.015 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 832SK UT WOS:000295827300004 PM 21961657 ER PT J AU Campbell, GL Hills, SL Fischer, M Jacobson, JA Hoke, CH Hombach, JM Marfin, AA Solomon, T Tsai, TF Tsu, VD Ginsburg, AS AF Campbell, Grant L. Hills, Susan L. Fischer, Marc Jacobson, Julie A. Hoke, Charles H. Hombach, Joachim M. Marfin, Anthony A. Solomon, Tom Tsai, Theodore F. Tsu, Vivien D. Ginsburg, Amy S. TI Estimated global incidence of Japanese encephalitis: a systematic review SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Review ID CLINICAL-FEATURES; CHILDREN YOUNGER; SURVEILLANCE; DISEASE; BURDEN; CHINA; IMMUNIZATION; AUSTRALIA; INDONESIA; SHANGHAI AB Objective To update the estimated global incidence of Japanese encephalitis (JE) using recent data for the purpose of guiding prevention and control efforts. Methods Thirty-two areas endemic for JE in 24 Asian and Western Pacific countries were sorted into 10 incidence groups on the basis of published data and expert opinion. Population-based surveillance studies using laboratory-confirmed cases were sought for each incidence group by a computerized search of the scientific literature. When no eligible studies existed for a particular incidence group, incidence data were extrapolated from related groups. Findings A total of 12 eligible studies representing 7 of 10 incidence groups in 24 JE-endemic countries were identified. Approximately 67 900 JE cases typically occur annually (overall incidence: 1.8 per 100 000), of which only about 10% are reported to the World Health Organization. Approximately 33 900 (50%) of these cases occur in China (excluding Taiwan) and approximately 51 000 (75%) occur in children aged 0-14 years (incidence: 5.4 per 100 000). Approximately 55 000 (81%) cases occur in areas with well established or developing JE vaccination programmes, while approximately 12 900 (19%) occur in areas with minimal or no JE vaccination programmes. Conclusion Recent data allowed us to refine the estimate of the global incidence of JE, which remains substantial despite improvements in vaccination coverage. More and better incidence studies in selected countries, particularly China and India, are needed to further refine these estimates. C1 [Tsu, Vivien D.; Ginsburg, Amy S.] PATH, Seattle, WA USA. [Campbell, Grant L.] Ross River Consulting, La Porte, IN USA. [Hills, Susan L.; Fischer, Marc] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Jacobson, Julie A.] Bill & Melinda Gates Fdn, Seattle, WA USA. [Hoke, Charles H.] US Army Med Mat Dev Act, Pharmaceut Syst Project Management Off, Ft Detrick, MD USA. [Hombach, Joachim M.] World Hlth Org, Initiat Vaccine Res, Geneva, Switzerland. [Marfin, Anthony A.] Washington State Dept Hlth, Shoreline, WA USA. [Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Tsai, Theodore F.] Novartis Vaccines, Sci Affairs, Cambridge, MA USA. RP Ginsburg, AS (reprint author), PATH, POB 900922, Seattle, WA USA. EM AGinsburg@path.org OI Solomon, Tom/0000-0001-7266-6547 FU Program for Appropriate Technology in Health (PATH) FX This study was funded by the Program for Appropriate Technology in Health (PATH). NR 45 TC 189 Z9 210 U1 0 U2 11 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD OCT PY 2011 VL 89 IS 10 BP 766 EP 774 DI 10.2471/BLT.10.085233 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 831DA UT WOS:000295707700015 PM 22084515 ER PT J AU Eskenazi, B Fenster, L Castorina, R Marks, AR Sjodin, A Rosas, LG Holland, N Guerra, AG Lopez-Carillo, L Bradman, A AF Eskenazi, Brenda Fenster, Laura Castorina, Rosemary Marks, Amy R. Sjoedin, Andreas Rosas, Lisa Goldman Holland, Nina Guerra, Armando Garcia Lopez-Carillo, Lizbeth Bradman, Asa TI A Comparison of PBDE Serum Concentrations in Mexican and Mexican-American Children Living in California SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE biomarkers; children; DDE; DDT; flame retardants; human blood serum; human exposure; Mexican; PBDEs; prenatal ID POLYBROMINATED DIPHENYL ETHERS; IN-HOUSE DUST; POLYCHLORINATED-BIPHENYLS; THYROID-HORMONE; UNITED-STATES; INDOOR DUST; US CHILDREN; EXPOSURE; ASSOCIATIONS; POPULATION AB BACKGROUND: Polybrominated diphenyl ethers (PBDE), which are used as flame retardants, have been found to be higher in residents of California than of other parts of the United States. OBJECTIVES: We aimed to investigate the role of immigration to California on PBDE levels in Latino children. METHODS: We compared serum PBDE concentrations in a population of first-generation Mexican-American 7-year-old children (n = 264), who were born and raised in California [Center for Health Analysis of Mothers and Children of Salinas (CHAMACOS) study], with 5-year-old Mexican children (n = 283), who were raised in the states in Mexico where most CHAMACOS mothers had originated (Proyecto Mariposa). RESULTS: On average, PBDE serum concentrations in the California Mexican-American children were three times higher than their mothers' levels during pregnancy and seven times higher than concentrations in the children living in Mexico. The PBDE serum concentrations were higher in the Mexican-American children regardless of length of time their mother had resided in California or the duration of the child's breast-feeding. These data suggest that PBDE serum concentrations in these children resulted primarily from postnatal exposure. CONCLUSIONS: Latino children living in California have much higher PBDE serum levels than their Mexican counterparts. Given the growing evidence documenting potential health effects of PBDE exposure, the levels in young children noted in this study potentially present a major public health challenge, especially in California. In addition, as PBDEs are being phased out and replaced by other flame retardants, the health consequences of these chemical replacements should be investigated and weighed against their purported fire safety benefits. C1 [Eskenazi, Brenda; Fenster, Laura; Castorina, Rosemary; Marks, Amy R.; Rosas, Lisa Goldman; Holland, Nina; Bradman, Asa] Univ Calif Berkeley, CERCH, Sch Publ Hlth, Berkeley, CA 94602 USA. [Sjoedin, Andreas] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA. [Guerra, Armando Garcia; Lopez-Carillo, Lizbeth] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. RP Eskenazi, B (reprint author), Univ Calif Berkeley, CERCH, Sch Publ Hlth, 1995 Univ Ave,Suite 265, Berkeley, CA 94602 USA. EM eskenazi@berkeley.edu RI Sjodin, Andreas/F-2464-2010; OI Marks, Amy/0000-0002-3047-5379 FU U.S. Environmental Protection Agency (EPA) [RD 83171001, RD 826709, STAR RD-83273401]; National Institute of Environmental Health Sciences (NIEHS) [PO1 ES009605, RO1 ES012503-03]; UC-MEXUS; University of California Berkeley Health Initiative of the Americas; University of California Berkeley Center for Latino Policy Studies; University of California Institute for the Study of Social Change; W.K. Kellogg Foundation FX This publication was made possible by research supported by grants RD 83171001 and RD 826709 from the U.S. Environmental Protection Agency (EPA), PO1 ES009605and RO1 ES012503-03 from the National Institute of Environmental Health Sciences (NIEHS), U.S. EPA STAR RD-83273401, UC-MEXUS, University of California Berkeley Health Initiative of the Americas, University of California Berkeley Center for Latino Policy Studies, University of California Institute for the Study of Social Change, and the W.K. Kellogg Foundation Postdoctoral Fellowship. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, National Institutes of Health, or U.S. EPA. NR 52 TC 24 Z9 26 U1 2 U2 33 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2011 VL 119 IS 10 BP 1442 EP 1448 DI 10.1289/ehp.1002874 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 827CA UT WOS:000295402400030 PM 21498147 ER PT J AU Stapleton, HM Eagle, S Anthopolos, R Wolkin, A Miranda, ML AF Stapleton, Heather M. Eagle, Sarah Anthopolos, Rebecca Wolkin, Amy Miranda, Marie Lynn TI Associations between Polybrominated Diphenyl Ether (PBDE) Flame Retardants, Phenolic Metabolites, and Thyroid Hormones during Pregnancy SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE flame retardants; OH-BDEs; PBDEs; pregnancy; thyroid hormones ID CARP CYPRINUS-CARPIO; IN-VITRO; UNITED-STATES; COMMON CARP; BREAST-MILK; EXPOSURE; SERUM; BIOTRANSFORMATION; DISPOSITION; ENVIRONMENT AB BACKGROUND: Polybrominated diphenyl ethers (PBDEs) are chemical additives used as flame retardants in commercial products. PBDEs are bioaccumulative and persistent and have been linked to several adverse health outcomes. OBJECTIVES: This study leverages an ongoing pregnancy cohort to measure PBDEs and PBDE metabolites in serum collected from an understudied population of pregnant women late in their third trimester. A secondary objective was to determine whether the PBDEs or their metabolites were associated with maternal thyroid hormones. METHODS: One hundred forty pregnant women > 34 weeks into their pregnancy were recruited into this study between 2008 and 2010. Blood samples were collected during a routine prenatal clinic visit. Serum was analyzed for a suite of PBDEs, three phenolic metabolites (i.e., containing an -OH moiety), and five thyroid hormones. RESULTS: PBDEs were detected in all samples and ranged from 3.6 to 694 ng/g lipid. Two hydroxylated BDE congeners (4'-OH-BDE 49 and 6-OH-BDE 47) were detected in > 67% of the samples. BDEs 47, 99, and 100 were significantly and positively associated with free and total thyroxine (T(4)) levels and with total triiodothyronine levels above the normal range. Associations between T(4) and PBDEs remained after controlling for smoking status, maternal age, race, gestational age, and parity. CONCLUSIONS: PBDEs and OH-BDEs are prevalent in this cohort, and levels are similar to those in the general population. Given their long half-lives, PBDEs may be affecting thyroid regulation throughout pregnancy. Further research is warranted to determine mechanisms through which PBDEs affect thyroid hormone levels in developing fetuses and newborn babies. C1 [Stapleton, Heather M.] Duke Univ, Nicholas Sch Environm, LSRC, Durham, NC 27708 USA. [Wolkin, Amy] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Miranda, Marie Lynn] Duke Univ, Dept Pediat, Durham, NC 27708 USA. RP Stapleton, HM (reprint author), Duke Univ, Nicholas Sch Environm, LSRC, Box 90328, Durham, NC 27708 USA. EM heather.stapleton@duke.edu FU U.S. Environmental Protection Agency [RD-83329301]; National Institute of Environmental Health Sciences [R01 ES016099]; Centers for Disease Control and Prevention (CDC) FX This work was supported by a grant from the U.S. Environmental Protection Agency (RD-83329301). H.M.S. was also partially supported by grant R01 ES016099 from the National Institute of Environmental Health Sciences and by funds from the Centers for Disease Control and Prevention (CDC). NR 45 TC 82 Z9 82 U1 4 U2 60 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2011 VL 119 IS 10 BP 1454 EP 1459 DI 10.1289/ehp.1003235 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 827CA UT WOS:000295402400032 PM 21715241 ER PT J AU Barth, H Rybczynska, J Patient, R Choi, Y Sapp, RK Baumert, TF Krawczynski, K Liang, TJ AF Barth, Heidi Rybczynska, Jolanta Patient, Romuald Choi, Youkyung Sapp, Ronda K. Baumert, Thomas F. Krawczynski, Kris Liang, T. Jake TI Both Innate and Adaptive Immunity Mediate Protective Immunity Against Hepatitis C Virus Infection in Chimpanzees SO HEPATOLOGY LA English DT Article ID RECOVERED CHIMPANZEES; DENDRITIC CELLS; RESPONSES; REINFECTION; RECHALLENGE; INTERFERON; GENOTYPE; PERSISTENCE; CLEARANCE; KINETICS AB Understanding the immunological correlates associated with protective immunity following hepatitis C virus (HCV) reexposure is a prerequisite for the design of effective HCV vaccines and immunotherapeutics. In this study we performed a comprehensive analysis of innate and adaptive immunity following HCV reexposure of two chimpanzees that had previously recovered from HCV-JFH1 infection. One of the chimpanzees, CH10274, became protected from active viremia by repeated challenges with homologous HCV-JFH1 and developed neutralizing antibodies, but was later infected with high-level viremia by a heterologous challenge with the HCV H77 virus that persisted for more than 1 year. The other chimpanzee, CH10273, was protected from a similar, heterologous H77 challenge without any evidence of neutralizing antibodies. Peripheral HCV-specific T-cell responses were present in both chimpanzees after challenges and, interestingly, the overall magnitude of response was lower in uninfected CH10273, which, however, exhibited a more robust CD8+ T-cell response. CH10273 showed higher hepatic expression of CD8 and CD56 (natural killer) markers than CH10274 did shortly after inoculation with H77. The heightened T-cell response was associated with an enhanced hepatic production of interferons (both type I and II) and interferon-stimulated genes (ISGs) in CH10273. Therefore, protection or clearance of HCV reinfection upon heterologous rechallenge depends on the activation of both intrahepatic innate and cellular immune responses. Furthermore, our results suggest that serum neutralizing antibodies may contribute to early control of viral replication and spread after homologous HCV rechallenges but may not be sufficient for a long-term protective immunity. Conclusion: Our study shows that protective immunity against HCV reinfection is orchestrated by a complex network of innate and adaptive immune responses. (HEPATOLOGY 2011;54:1135-1148) C1 [Barth, Heidi; Patient, Romuald; Sapp, Ronda K.; Liang, T. Jake] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Barth, Heidi; Baumert, Thomas F.] INSERM, U748, Strasbourg, France. [Barth, Heidi; Baumert, Thomas F.] Univ Strasbourg, Strasbourg, France. [Rybczynska, Jolanta; Choi, Youkyung; Krawczynski, Kris] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Patient, Romuald] INSERM, Dept Biol Cellulaire, U966, Tours, France. [Baumert, Thomas F.] Hop Univ Strasbourg, Strasbourg, France. RP Liang, TJ (reprint author), NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. EM kzk1@cdc.gov; JakeL@bdg10.niddk.nih.gov FU Deutsche Forschungsgemeinschaft, Bonn, Germany [BA 3643/1-1]; National Institute of Diabetes and Digestive and Kidney Diseases; NIH; Division of Viral Hepatitis; NCHHSTP; CDC; Agence Nationale de Recherche sur le SIDA et les Hepatites Virales [2010-106, 2010-242]; Inserm, France FX Supported by the Deutsche Forschungsgemeinschaft, Bonn, Germany (BA 3643/1-1 to H.B.), the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, NIH, and programmatic support of Division of Viral Hepatitis, NCHHSTP, CDC, and the Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (2010-106; 2010-242 to H.B.), and Inserm, France. NR 30 TC 29 Z9 31 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2011 VL 54 IS 4 BP 1135 EP 1148 DI 10.1002/hep.24489 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 829KA UT WOS:000295577200006 PM 21674561 ER PT J AU Trehy, ML Brown, DJ Woodruff, JT Westenberger, BJ Nychis, WG Reuter, N Schier, JG Vagi, SJ Hwang, RJ AF Trehy, Michael L. Brown, Daniel J. Woodruff, Jeffrey T. Westenberger, Benjamin J. Nychis, William G. Reuter, Nicholas Schier, Joshua G. Vagi, Sara J. Hwang, Rong-Jen TI Determination of Levamisole in Urine by Gas Chromatography-Mass Spectrometry SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID CHIRAL STATIONARY PHASES; COCAINE; AGRANULOCYTOSIS; PLASMA C1 [Trehy, Michael L.; Woodruff, Jeffrey T.; Westenberger, Benjamin J.] US FDA, CDER, DPA, St Louis, MO 63101 USA. [Brown, Daniel J.] US FDA, ORA, Reg Field Off, Detroit, MI 48207 USA. [Nychis, William G.] US FDA, CDER, Off Compliance, Silver Spring, MD 20993 USA. [Reuter, Nicholas] US PHS, SAMHSA, Rockville, MD 20857 USA. [Schier, Joshua G.; Vagi, Sara J.] CDC, NCEH, EHHE, HSB MS F57, Atlanta, GA 30341 USA. [Hwang, Rong-Jen] New Mexico DH, Albuquerque, NM 87196 USA. RP Trehy, ML (reprint author), US FDA, CDER, DPA, 1114 Market St, St Louis, MO 63101 USA. RI Schier, Joshua/F-9861-2013 NR 14 TC 6 Z9 6 U1 0 U2 7 PU PRESTON PUBL INC PI NILES PA 6600 W TOUHY AVE, NILES, IL 60714-4588 USA SN 0146-4760 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD OCT PY 2011 VL 35 IS 8 BP 545 EP 550 PG 6 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA 829HL UT WOS:000295569100003 PM 22004673 ER PT J AU Bansil, P Kuklina, EV Merritt, RK Yoon, PW AF Bansil, Pooja Kuklina, Elena V. Merritt, Robert K. Yoon, Paula W. TI Associations Between Sleep Disorders, Sleep Duration, Quality of Sleep, and Hypertension: Results From the National Health and Nutrition Examination Survey, 2005 to 2008 SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; HEART HEALTH; WHITEHALL-II; APNEA; RISK AB Sleep is a contributing factor to optimal health and vitality. However, to date, no national study has evaluated the simultaneous relationship between sleep disorders, quality, and duration with hypertension. Using data from National Health and Nutrition Examination Survey (NHANES) (2005 to 2008), hypertension was defined by current use of antihypertensive medication or systolic blood pressure >= 140 mm Hg or diastolic blood pressure >= 90 mm Hg. Self-reported sleep disorders and duration were categorized from a single household interview question, and sleep quality was determined from several questions on sleeping habits. The prevalence of hypertension was 30.2% and 7.5%, and 33.0% and 52.1% reported having sleep disorders, short sleep, and poor sleep, respectively. After adjustment for demographic characteristics and comorbidities, having sleep disorders only was not significantly associated with hypertension (odds ratio [OR], 1.65; 95% confidence interval [CI], 0.73-3.77). However, this association was modified by sleep duration: significant associations were observed among adults with concurrent sleep disorders and short sleep (OR, 2.30; 95% CI, 1.49-3.56) and with sleep disorders, short sleep, and poor sleep (OR, 1.84; 95% CI, 1.13-2.98). These findings indicate an association between a combination of sleep problems and hypertension, but prospective studies are needed to understand the complex interplay between them. J Clin Hypertens (Greenwich). 2011;13:739-743. (C) 2011 Wiley Periodicals, Inc. C1 [Bansil, Pooja; Kuklina, Elena V.; Merritt, Robert K.; Yoon, Paula W.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Bansil, P (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Highway NE,MS K47, Atlanta, GA 30341 USA. EM pbansil@cdc.gov NR 23 TC 49 Z9 52 U1 0 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD OCT PY 2011 VL 13 IS 10 BP 739 EP 743 DI 10.1111/j.1751-7176.2011.00500.x PG 5 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 828TH UT WOS:000295525200008 PM 21974761 ER PT J AU Dobbs, T Liu, X Anderson, R Nkengasong, J Parekh, BS AF Dobbs, Trudy Liu, Xin Anderson, Rebecca Nkengasong, John Parekh, Bharat S. TI A Comprehensive Evaluation of the Proficiency Testing Program for the HIV-1 BED Incidence Assay SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID QUALITY-ASSURANCE PROGRAM; INJECTION-DRUG USERS; ENZYME-IMMUNOASSAY; PERFORMANCE-CHARACTERISTICS; TYPE-1 SEROCONVERSION; INFECTION; SEROINCIDENCE; SPECIMENS; STRATEGY; TRENDS AB The HIV-1 BED incidence assay was developed at the Centers for Disease Control and Prevention and since 2005 has been available as a commercial kit for use in HIV-1 incidence surveillance. A BED-specific proficiency testing (PT) program was initiated in 2006 that included a panel of eight coded specimens (six unique and two duplicates) to participating laboratories. The number of participating laboratories increased from 12 to 38 from 2006 to 2009. Overall, 96.1% of the laboratories reported results, and 95.4% of those reporting achieved a 100% score. The observed mean normalized optical density (OD-n) values of all participants correlated well with the expected OD-n values for all specimens (R(2) = 0.98) used for seven PT rounds. BED testing demonstrated high reproducibility among all laboratories, with an agreement of 99.3% (574/578) between initial and confirmatory classification and regression statistics of R(2) = 0.96, slope = 1.022, and intercept = 0.0066. Reproducibility among duplicate specimens was very high during each PT round, with mean deviation of 1.8%. Analysis of controls and calibrator specimen for all 343 runs showed a coefficient of variation of ca. 20% for raw ODs in the dynamic range, which was reduced to < 10% when the OD was normalized (OD-n). Most laboratories that failed the PT assessment had transcriptional errors, kit reagent problems, or specimen handling errors. Thus, the BED-specific PT program enabled us to track performance of different laboratories conducting the BED assay while identifying areas for improvements. This program will also serve as a template for future PT programs for new incidence assays as they become available. C1 [Dobbs, Trudy; Liu, Xin; Anderson, Rebecca; Nkengasong, John; Parekh, Bharat S.] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Atlanta, GA 30329 USA. RP Parekh, BS (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Bldg 15,Room 2611,Mail Stop G19,1600 Clifton Rd, Atlanta, GA 30329 USA. EM bparekh@cdc.gov NR 30 TC 4 Z9 4 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2011 VL 49 IS 10 BP 3470 EP 3473 DI 10.1128/JCM.01122-11 PG 4 WC Microbiology SC Microbiology GA 826NK UT WOS:000295360700005 PM 21832016 ER PT J AU Tveit, AH Bruce, MG Bruden, DL Morris, J Reasonover, A Hurlburt, DA Hennessy, TW McMahon, B AF Tveit, Adrienne H. Bruce, Michael G. Bruden, Dana L. Morris, Julie Reasonover, Alisa Hurlburt, Debby A. Hennessy, Thomas W. McMahon, Brian TI Alaska Sentinel Surveillance Study of Helicobacter pylori Isolates from Alaska Native Persons from 2000 to 2008 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PEPTIC-ULCER DISEASE; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; UNITED-STATES; RISK-FACTORS; INFECTION; STRAINS; PREVALENCE; ERADICATION; FEATURES AB Helicobacter pylori infection is more common in Alaska Native persons than in the general U. S. population, with seroprevalence to H. pylori approaching 75%. Previous studies in Alaska have demonstrated elevated proportions of antimicrobial resistance among H. pylori isolates. We analyzed H. pylori data from the Centers for Disease Control and Prevention's sentinel surveillance in Alaska from January 2000 to December 2008 to determine the proportion of culture-positive biopsy specimens with antimicrobial resistance from Alaska Native persons undergoing endoscopy. The aim of the present study was to monitor antimicrobial resistance of H. pylori isolates over time and by region in Alaska Native persons. Susceptibility testing of H. pylori isolates to metronidazole, clarithromycin, amoxicillin, and tetracycline was performed using agar dilution. Susceptibility testing for levofloxacin was performed by Etest. Overall, 45% (532/1,181) of persons undergoing upper endoscopy were culture positive for H. pylori. Metronidazole resistance was demonstrated in isolates from 222/531 (42%) persons, clarithromycin resistance in 159/531 (30%) persons, amoxicillin resistance in 10/531 (2%) persons, and levofloxacin resistance in 30/155 (19%) persons; no tetracycline resistance was documented. The prevalence of metronidazole, clarithromycin, and levofloxacin resistance varied by region. Female patients were more likely than male patients to demonstrate metronidazole (P < 0.05) and clarithromycin (P < 0.05) resistance. No substantial change in the proportion of persons with resistant isolates was observed over time. Resistance to metronidazole, clarithromycin, and levofloxacin is more common among H. pylori isolates from Alaska Native persons than those from elsewhere in the United States. C1 [Bruce, Michael G.; Bruden, Dana L.; Morris, Julie; Reasonover, Alisa; Hurlburt, Debby A.; Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program, Alaska Native Med Ctr, Anchorage, AK 99508 USA. RP Bruce, MG (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Alaska Native Med Ctr, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM zwa8@cdc.gov NR 28 TC 16 Z9 17 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2011 VL 49 IS 10 BP 3638 EP 3643 DI 10.1128/JCM.01067-11 PG 6 WC Microbiology SC Microbiology GA 826NK UT WOS:000295360700032 PM 21813726 ER PT J AU Sullivan, TJ Patel, P Hutchinson, A Ethridge, SF Parker, MM AF Sullivan, Timothy J. Patel, Pragna Hutchinson, Angela Ethridge, Steven F. Parker, Monica M. TI Evaluation of Pooling Strategies for Acute HIV-1 Infection Screening Using Nucleic Acid Amplification Testing SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; RNA; ASSAY AB A 128-member specimen pooling scheme for acute HIV infection (AHI) detection was evaluated using 21 AHI specimens (range, 1,520 to 500,000 copies/ml) previously identified by RNA testing of 16-member plasma pools. HIV-1 RNA was detectable in 128-member pools for all 21 specimens; however, one pool created from a specimen with 1,827 copies/ml was nonreactive in one of three replicates. C1 [Sullivan, Timothy J.; Parker, Monica M.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA. [Patel, Pragna; Hutchinson, Angela; Ethridge, Steven F.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Parker, MM (reprint author), New York State Dept Hlth, Wadsworth Ctr, POB 22002, Albany, NY 12201 USA. EM mmp09@health.state.ny.us OI Sullivan, Timothy/0000-0003-3144-9188 FU CDC [1UA1 PS000063] FX This work was supported by grant 1UA1 PS000063 from the CDC. NR 9 TC 6 Z9 6 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2011 VL 49 IS 10 BP 3667 EP 3668 DI 10.1128/JCM.00650-11 PG 2 WC Microbiology SC Microbiology GA 826NK UT WOS:000295360700040 PM 21832020 ER PT J AU Blake, R Corso, L Bender, K AF Blake, Rob Corso, Liza Bender, Kaye TI Public Health Department Accreditation and Environmental Public Health: A Logical Collaboration SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID QUALITY IMPROVEMENT AB NEHA strives to provide up-to-date and relevant information on environmental health and to build partnerships in the profession. In pursuit of these goals, we feature a column from the Environmental Health Services Branch (EHSB) of the Centers for Disease Control and Prevention (CDC) in every issue of the Journal. In this column, EHSB and guest authors from across CDC will highlight a variety of concerns, opportunities, challenges, and successes that we all share in environmental public health. EHSB's objective is to strengthen the role of state, local, and national environmental health programs and professionals to anticipate, identify, and respond to adverse environmental exposures and the consequences of these exposures for human health. The services being developed through EHSB include access to topical, relevant, and scientific information; consultation; and assistance to environmental health specialists, sanitarians, and environmental health professionals and practitioners. The conclusions in this article are those of the author(s) and do not necessarily represent the views of the Centers for Disease Control and Prevention. Rob Blake is chief of the Environmental Health Services Branch at CDC and has been working in the environmental health field for more than 30 years. Liza Corso is acting branch chief for CDC's Agency and Systems Improvement Branch within the Office for State, Tribal, Local and Territorial Support. Kaye Bender is the president and CEO for the Public Health Accreditation Board, the organization that oversees the voluntary accreditation of health departments across the country. C1 [Blake, Rob] Natl Ctr Environm Hlth, Environm Hlth Serv Branch, Div Emergency, Atlanta, GA 30341 USA. RP Blake, R (reprint author), Natl Ctr Environm Hlth, Environm Hlth Serv Branch, Div Emergency, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA. EM rgblake@cdc.gov FU CLC NIH HHS [NIH0010192010] NR 4 TC 3 Z9 3 U1 0 U2 1 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2011 VL 74 IS 3 BP 28 EP 30 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 826XF UT WOS:000295388200006 PM 22010331 ER PT J AU Pimenta, FC Carvalho, MDS Gertz, RE Bastos-Rocha, CGB Oliveira, LSC Pigosso, LL Lima, JA Franco, CM Andrade, AL Beall, BW AF Pimenta, Fabiana C. Carvalho, Maria da Gloria S. Gertz, Robert E., Jr. Bastos-Rocha, Cristyane G. B. Oliveira, Luciana S. C. Pigosso, Laurine Lacerda Lima, Juliane A. Franco, Caritas Marquez Andrade, Ana Lucia Beall, Bernard W. TI Serotype and genotype distributions of pneumococcal carriage isolates recovered from Brazilian children attending day-care centres SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID DETERMINING CAPSULAR SEROTYPES; SEQUENTIAL MULTIPLEX PCR; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; MOLECULAR EPIDEMIOLOGY; RESISTANT CLONES; 6C; VACCINES; DISEASE; 19A AB Pneumococcal nasopharyngeal carriage isolates recovered from Brazilian children attending day-care centres in 2005 were assessed for serotype, genotype and penicillin susceptibility phenotype. As 124 of the 253 isolates (49%) were characterized previously with respect to serotype and penicillin susceptibility, the primary objectives were to examine clonal associations and penicillin susceptibility within major serotypes and to assess the suitability of conventional multiplex PCR for deducing carriage serotypes within this population. Using a combination of PCR-based serotyping and the Quellung reaction, serotypes were identified for 81% (205/253) of the isolates, with serogroups or types 14, 6, 23F, 19F and 18 being predominant. Included within the 205 isolates successfully serotyped by PCR were 28 isolates that had become non-viable. Forty-eight isolates were non-typable using both the PCR method and the Quellung reaction. Penicillin non-susceptibility was observed within 16 of the 18 multilocus sequence types detected. Thus, this study provides further evidence from a diverse collection of pneumococcal clones that PCR-based serotype deduction is useful for providing supportive evidence for pneumococcal conjugate vaccine implementation. C1 [Pimenta, Fabiana C.; Carvalho, Maria da Gloria S.; Gertz, Robert E., Jr.; Beall, Bernard W.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. [Pimenta, Fabiana C.; Bastos-Rocha, Cristyane G. B.; Oliveira, Luciana S. C.; Pigosso, Laurine Lacerda; Lima, Juliane A.; Andrade, Ana Lucia] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil. [Franco, Caritas Marquez] Municipal Goiania, Goiania, Go, Brazil. RP Beall, BW (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. EM BBeall@cdc.gov RI Iats, Inct/K-2300-2013; Andrade, Ana Lucia/L-5751-2013 FU Brazilian National Research Council [CNPq-301646/2006-6, 473880/2006-7]; American Society for Microbiology; Brazilian Council for Scientific and Technological Development (CNPq) [306096/2010-2] FX The authors thank Zhongya Li, Alexis Roundtree and Yusra Ahmad (CDC Streptococcus Laboratory) for their help with MLST. This study was supported in part by the Brazilian National Research Council (CNPq-301646/2006-6 and 473880/2006-7) and American Society for Microbiology (Latin American Fellowship, 2007). A. L. A. is a research fellow of the Brazilian Council for Scientific and Technological Development (CNPq) (grant no. 306096/2010-2). NR 21 TC 5 Z9 5 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD OCT PY 2011 VL 60 IS 10 BP 1455 EP 1459 DI 10.1099/jmm.0.031450-0 PG 5 WC Microbiology SC Microbiology GA 833CW UT WOS:000295860400006 PM 21636673 ER PT J AU Samandari, T Moeti, T Talbot, E Agizew, T Nyirenda, S AF Samandari, Taraz Moeti, Themba Talbot, Elizabeth Agizew, Tefera Nyirenda, Samba TI Duration of isoniazid preventive therapy in HIV-infected patients Reply SO LANCET LA English DT Letter ID TUBERCULOSIS; ADULTS; ALASKA C1 [Samandari, Taraz; Talbot, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Moeti, Themba] Minist Hlth, Gaborone, Botswana. [Samandari, Taraz; Talbot, Elizabeth; Agizew, Tefera; Nyirenda, Samba] Botswana USA Partnership BOTUSA, Gaborone, Botswana. [Samandari, Taraz; Talbot, Elizabeth; Agizew, Tefera; Nyirenda, Samba] Botswana USA Partnership BOTUSA, Francistown, Botswana. RP Samandari, T (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM tts0@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD OCT 1 PY 2011 VL 378 IS 9798 BP 1216 EP 1217 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 831IO UT WOS:000295723600017 ER PT J AU Mutebi, JP Lubelczyk, C Eisen, R Panella, N MacMillan, K Godsey, M Swope, B Young, G Smith, RP Kantar, L Robinson, S Sears, S AF Mutebi, John-Paul Lubelczyk, Charles Eisen, Rebecca Panella, Nicholas MacMillan, Katherine Godsey, Marvin Swope, Bethany Young, Ginger Smith, Robert P., Jr. Kantar, Lee Robinson, Sara Sears, Stephen TI Using Wild White-Tailed Deer to Detect Eastern Equine Encephalitis Virus Activity in Maine SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Eastern Equine Encephalitis Virus; Maine; Odocoileus virginianus; PRNT ID ENCEPHALOMYELITIS VIRUS; TRANSMISSION; MOSQUITOS; PATTERNS AB Serum from 226 free-ranging white-tailed deer (Odocoileus virginianus) was screened for Eastern Equine Encephalitis Virus (EEEV) antibodies using plaque reduction neutralization tests. EEEV antibodies were detected in 7.1% of samples. This is the first time EEEV antibodies have been detected in O. virginianus populations in the state of Maine (ME). The highest percentage of EEEV positive sera was in Somerset County (19%) in central ME, and this is the first time that EEEV activity has been detected in that County. EEEV RNA was not detected in any of the 150 harvested deer brain samples submitted to the ME Department of Inland Fisheries and Wildlife as a part of screening for Chronic Wasting Disease. This suggests that screening deer brains is not an efficient method to detect EEEV activity. For each serum sample tested, the geographic location in which the deer was harvested was recorded. Significant spatial clustering of antibody-positive sera samples was not detected. Relative to seronegative deer, seropositive deer were slightly more likely to be harvested in nonforested areas compared with forested areas. Results indicate that screening of free-ranging deer sera can be a useful tool for detecting EEEV activity in ME and other parts of North America. C1 [Mutebi, John-Paul; Eisen, Rebecca; Panella, Nicholas; MacMillan, Katherine; Godsey, Marvin; Swope, Bethany; Young, Ginger] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO 80521 USA. [Lubelczyk, Charles; Smith, Robert P., Jr.] Maine Med Ctr, Vector Borne Dis Lab, Portland, ME USA. [Kantar, Lee] Maine Dept Inland Fisheries & Wildlife, Bangor, ME USA. [Robinson, Sara; Sears, Stephen] Maine Dept Hlth & Human Serv, Augusta, ME USA. RP Mutebi, JP (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM grv0@cdc.gov FU Centers for Disease Control and Prevention (CDC); Maine Medical Center Research Institute (MMCRI) FX The authors thank Leticia Smith and Susan Elias from the Maine Medical Center Research Institute for their logistics, laboratory, and field assistance during this study. They especially thank Dr. Joseph Staples and the students of the University of Southern Maine, Dr. David Knupp and the students of Unity College, Dr. Stephen Hansen and the students of the University of Maine at Fort Kent, the Maine Department of Inland Fisheries and Wildlife, and USDA Wildlife Services for their help in collecting samples at tagging stations. This study was supported by funds from the Centers for Disease Control and Prevention (CDC) and the Maine Medical Center Research Institute (MMCRI). NR 33 TC 10 Z9 10 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD OCT PY 2011 VL 11 IS 10 BP 1403 EP 1409 DI 10.1089/vbz.2011.0643 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 833GN UT WOS:000295870800016 PM 21736489 ER PT J AU Landen, DD Wassell, JT McWilliams, L Patel, A AF Landen, Deborah D. Wassell, James T. McWilliams, Linda Patel, Ami TI Coal Dust Exposure and Mortality From Ischemic Heart Disease Among a Cohort of US Coal Miners SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE coal dust; ischemic heart disease; mortality ID PARTICULATE AIR-POLLUTION; UNITED-STATES; WORKERS-PNEUMOCONIOSIS; CARDIOVASCULAR MORTALITY; COMPETING RISK; FINE; ASSOCIATION; PARTICLES; SUBDISTRIBUTION; PREVALENCE AB Background Particulate exposure from air pollution increases the risk of ischemic heart disease (IHD) mortality. Although coal miners are highly exposed to coal dust particulate, studies of IHD mortality risk among coal miners have had inconsistent results. Previous studies may have been biased by the healthy worker effect. Methods We examined the dose-response relationship between cumulative coal dust exposure, coal rank, and IHD mortality among a cohort of underground coal miners who participated in the National Study of Coal Workers' Pneumoconiosis. Results After adjusting for age, smoking, and body mass index, risk of IHD mortality increased at higher levels of coal dust exposure. Mortality risk was also associated with coal rank region. Conclusion There was an increased risk of mortality from IHD associated with cumulative exposure to coal dust, and with coal rank. The effect of coal rank may be due differences in the composition of coal mine dust particulate. The association of risk of IHD mortality with cumulative particulate exposure is consistent with air pollution studies. Am. J. Ind. Med. 54: 727-733, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Landen, Deborah D.; McWilliams, Linda] NIOSH, Off Mine Safety & Hlth Res, Pittsburgh, PA 15236 USA. [Wassell, James T.] NIOSH, Div Safety Res, Morgantown, WV 26505 USA. [Patel, Ami] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Pittsburgh, PA USA. RP Landen, DD (reprint author), NIOSH, Off Mine Safety & Hlth Res, 626 Cochrans Mill Rd3, Pittsburgh, PA 15236 USA. EM dlanden@cdc.gov NR 47 TC 10 Z9 11 U1 1 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD OCT PY 2011 VL 54 IS 10 BP 727 EP 733 DI 10.1002/ajim.20986 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 824OX UT WOS:000295212800001 PM 21761428 ER PT J AU Plantinga, L Lee, K Inker, LA Saran, R Yee, J Gillespie, B Rolka, D Saydah, S Powe, NR AF Plantinga, Laura Lee, Kathryn Inker, Lesley A. Saran, Rajiv Yee, Jerry Gillespie, Brenda Rolka, Deborah Saydah, Sharon Powe, Neil R. CA CDC CKD Surveillance Team TI Association of Sleep-Related Problems With CKD in the United States, 2005-2008 SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Chronic kidney disease; renal function; sleep duration; leg symptoms; sleep aids ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; QUALITY-OF-LIFE; GLOMERULAR-FILTRATION-RATE; THRICE-WEEKLY HEMODIALYSIS; RESTLESS LEGS SYNDROME; HEART HEALTH; DIALYSIS PATIENTS; SERUM CREATININE; MATCHED CONTROLS AB Background: Sleep-related problems, which have been associated with poor health outcomes, have not been investigated thoroughly in people with chronic kidney disease (CKD). We examined the prevalence of a variety of sleep-related problems in persons with and without CKD. Study Design: National cross-sectional survey (National Health and Nutrition Examination Survey 2005-2008). Setting & Participants: Community-based survey of 9,110 noninstitutionalized US civilian residents 20 years or older. Predictor: CKD, defined as estimated glomerular filtration rate (eGFR) of 15-59 mL/min/1.73 m(2) (stages 3 and 4) or eGFR >= 60 mL/min/1.73 m(2) and albumin-creatinine ratio >= 30 mg/g (stages 1 and 2). Outcome: Sleep quality, defined using self-report in a multi-item sleep questionnaire including items from previously validated instruments. Measurements: Albuminuria and eGFR assessed from urine and blood samples; sleep, demographics, and comorbid conditions assessed using a standardized questionnaire. Results: Inadequate sleep (<= 6 hours per night) differed by CKD severity (37.4%, 43.0%, and 30.9% for no CKD, CKD stages 1 and 2, and CKD stages 3 and 4, respectively; P = 0.003). Frequent sleeping pill use (8.4%, 9.9%, and 16.6%), leg symptoms (39.2%, 48.0%, and 50.9%), and nocturia (20.9%, 35.2%, and 43.6%; P < 0.001 for all) also differed by CKD severity. After adjustment for age, sex, race/ethnicity, obesity, diabetes, and cardiovascular disease, the prevalence of these sleep-related problems remained higher in people with CKD stages 1 and 2 relative to no CKD. Most other measures of sleep quality, disorder, and functional outcomes did not differ by CKD. Limitations: Inability to establish causality and possible unmeasured confounding. Conclusion: Providers should be aware of early sleep-related CKD manifestations, including inadequate sleep, leg symptoms, and nocturia, and of the high rate of reported sleep medication use in this population. Am J Kidney Dis. 58(4): 554-564. (C) 2011 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Plantinga, Laura; Powe, Neil R.] San Francisco Gen Hosp, Dept Med, San Francisco, CA USA. [Lee, Kathryn] Univ Calif San Francisco, Dept Family Hlth Care Nursing, San Francisco, CA 94143 USA. [Inker, Lesley A.] Tufts Med Ctr, Dept Med, Boston, MA USA. [Saran, Rajiv; Gillespie, Brenda] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Yee, Jerry] Henry Ford Hosp, Detroit, MI 48202 USA. [Rolka, Deborah; Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Rolka, Deborah; Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Hyattsville, MD USA. RP Plantinga, L (reprint author), Rollins Sch Publ Hlth, Dept Epidemiol, Claudia Nance Rollins Bldg,3rd Floor,1518 Clifton, Atlanta, GA 30322 USA. EM laura.plantinga@emory.edu FU CDC through the Association of American Medical Colleges (AAMC) [5U36CD319276]; AAMC [MM-1143-10/10]; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland [K24DK02643] FX This project was supported under a cooperative agreement from the CDC through the Association of American Medical Colleges (AAMC), grant number 5U36CD319276, AAMC ID number MM-1143-10/10. Publication and report contents are solely the responsibility of the authors and do not necessarily represent the official views of the AAMC or CDC. Dr Powe is partially supported by grant K24DK02643 from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland. NR 44 TC 25 Z9 27 U1 0 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2011 VL 58 IS 4 BP 554 EP 564 DI 10.1053/j.ajkd.2011.05.024 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 826UE UT WOS:000295379600011 PM 21816524 ER PT J AU Grohskopf, L Uyeki, T Bresee, J Cox, N Bridges, C AF Grohskopf, Lisa Uyeki, Timothy Bresee, Joseph Cox, Nancy Bridges, Carolyn TI Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID 6-TO 23-MONTH-OLD CHILDREN; EGG ALLERGY; ANTIBODY-RESPONSE; IMMUNE-RESPONSE; IMMUNOGENICITY; SAFETY; VACCINATION; REACTOGENICITY; PERSISTENCE; TIME C1 [Grohskopf, Lisa; Uyeki, Timothy; Bresee, Joseph; Cox, Nancy] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Bridges, Carolyn] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Grohskopf, L (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lgrohskopf@cdc.gov NR 35 TC 3 Z9 3 U1 2 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2011 VL 11 IS 10 BP 2250 EP 2255 PG 6 WC Surgery; Transplantation SC Surgery; Transplantation GA 826SO UT WOS:000295375000034 ER PT J AU Alagappan, K Hancock, K Ward, MF De Cicco, S Spencer, R Katz, JM Dawood, FS Silverman, R AF Alagappan, K. Hancock, K. Ward, M. F. De Cicco, S. Spencer, R. Katz, J. M. Dawood, F. S. Silverman, R. TI Demographics of Acute Care Health Care Workers Who Seroconverted After Receiving the 2009 H1N1 Monovalent Vaccine SO ANNALS OF EMERGENCY MEDICINE LA English DT Meeting Abstract CT Annual Research Forum of the American-College-of-Emergency-Physicians CY OCT 15-16, 2011 CL San Francisco, CA SP Amer Coll Emergency Phys C1 Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. N Shore Univ Hosp, Manhasset, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD OCT PY 2011 VL 58 IS 4 SU S BP S290 EP S290 PG 1 WC Emergency Medicine SC Emergency Medicine GA 827ID UT WOS:000295421300333 ER PT J AU Goldblatt, D Plikaytis, BD Akkoyunlu, M Antonello, J Ashton, L Blake, M Burton, R Care, R Durant, N Feavers, I Fernsten, P Fievet, F Giardina, P Jansen, K Katz, L Kierstead, L Lee, L Lin, J Maisonneuve, J Nahm, MH Raab, J Romero-Steiner, S Rose, C Schmidt, D Stapleton, J Carlone, GM AF Goldblatt, D. Plikaytis, B. D. Akkoyunlu, M. Antonello, J. Ashton, L. Blake, M. Burton, R. Care, R. Durant, N. Feavers, I. Fernsten, P. Fievet, F. Giardina, P. Jansen, K. Katz, L. Kierstead, L. Lee, L. Lin, J. Maisonneuve, J. Nahm, M. H. Raab, J. Romero-Steiner, S. Rose, C. Schmidt, D. Stapleton, J. Carlone, G. M. TI Establishment of a New Human Pneumococcal Standard Reference Serum, 007sp SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; IMMUNOGLOBULIN G1; ANTIBODY UNITS; LOT 89-S(F); ASSIGNMENT; POLYSACCHARIDES; QUANTITATION AB Lot 89SF has been the reference standard serum pool used in pneumococcal enzyme-linked immunosorbent assays (ELISAs) since 1990. In 2005, it was estimated that there remained between 2 and 5 years' supply of lot 89SF. Since lot 89SF was the reference standard used in the evaluation of the seven-valent pneumococcal conjugate vaccine Prevnar (PCV7), the link to clinical efficacy would be severed if stocks became completely depleted. Furthermore, demonstration of immune responses comparable to those elicited by PCV7 is a licensure approach used for new pneumococcal conjugate vaccines, so a replacement reference standard was required. A total of 278 volunteers were immunized with the 23-valent unconjugated polysaccharide vaccine Pneumovax II, and a unit of blood was obtained twice within 120 days following immunization. Plasma was prepared, pooled, and confirmed to be free from hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV. The pooled serum was poured at 6 ml per vial into 15,333 vials and lyophilized. Immunological bridging of 007sp to 89SF was used to establish equivalent reference values for 13 pneumococcal capsular serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) by five independent laboratories. Antibody concentrations in 007sp were established relative to the lot 89SF reference preparation using the WHO reference ELISA. Subsequently, 12 existing WHO calibration sera had concentrations reassigned for 13 pneumococcal serotypes using new serum 007sp as the reference, and these were compared to concentrations relative to the original reference serum. Agreement was excellent for the 12 WHO calibration sera. The 007sp preparation has replaced 89SF as the pneumococcal reference standard. Sufficient quantity of this new preparation is available such that, with judicious use, it should be available for at least 25 years. C1 [Goldblatt, D.] UCL, Inst Child Hlth, Immunobiol Unit, London WC1N 1EH, England. [Plikaytis, B. D.; Romero-Steiner, S.; Rose, C.; Schmidt, D.; Carlone, G. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Akkoyunlu, M.; Blake, M.; Lee, L.] US FDA, CBER, Bethesda, MD 20014 USA. [Burton, R.; Lin, J.; Nahm, M. H.] Univ Alabama, Huntsville, AL 35899 USA. [Fernsten, P.; Giardina, P.; Jansen, K.] Pfizer Vaccine Res, Pearl River, NY USA. [Durant, N.; Fievet, F.] GlaxoSmithKline Biol, Rixensart, Belgium. [Care, R.; Feavers, I.] Natl Inst Biol Stand & Controls, Potters Bar, Herts, England. [Kierstead, L.; Raab, J.] PPD Vaccines & Biol Lab, Wayne, PA USA. [Antonello, J.] Sharp & Dohme Corp, Merck, West Point, PA USA. [Maisonneuve, J.] PATH, Seattle, WA USA. [Katz, L.] Mississippi Valley Reg Blood Ctr, Davenport, IA USA. [Stapleton, J.] Univ Iowa, Iowa City, IA USA. RP Goldblatt, D (reprint author), UCL, Inst Child Hlth, Immunobiol Unit, 30 Guilford St, London WC1N 1EH, England. EM d.goldblatt@ich.ucl.ac.uk RI Goldblatt, David/C-5972-2008; Akkoyunlu, Mustafa/I-5712-2012; OI Goldblatt, David/0000-0002-0769-5242; Romero-Steiner, Sandra/0000-0003-4128-7768; Nahm, Moon/0000-0002-6922-1042 FU CBER [06-0093]; USFDA; NIAID; Basic and Clinical Approaches to Controlling Human Respiratory Pathogens [N01-AI-30040] FX This study (study protocol no. 06-0093) was sponsored by CBER, USFDA, and NIAID and supported in part by Basic and Clinical Approaches to Controlling Human Respiratory Pathogens (N01-AI-30040 to J.S.). NR 10 TC 26 Z9 29 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD OCT PY 2011 VL 18 IS 10 BP 1728 EP 1736 DI 10.1128/CVI.05252-11 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 826NQ UT WOS:000295361300018 PM 21852547 ER PT J AU Kato, K Wong, LY Jia, LT Kuklenyik, Z Calafat, AM AF Kato, Kayoko Wong, Lee-Yang Jia, Lily T. Kuklenyik, Zsuzsanna Calafat, Antonia M. TI Trends in Exposure to Polyfluoroalkyl Chemicals in the US Population: 1999-2008 SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID PERFLUORINATED COMPOUNDS; SERUM CONCENTRATIONS; NATIONAL-HEALTH; TIME TRENDS; PERFLUOROCARBOXYLATES; SAMPLES; ACIDS AB Since 2002, practices in manufacturing polyfluoroalkyl chemicals (PFCs) in the United States have changed. Previous results from the National Health and Nutrition Examination Survey (NHANES) documented a significant decrease in serum concentrations of some PFCs during 1999-2004. To further assess concentration trends of perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), perfluorohexane sulfonate (PFHxS), and perfluorononanoate (PFNA), we analyzed 7876 serum samples collected from a representative sample of the general U.S. population >= 12 years of age during NHANES 1999-2008. We detected PFOS, PFOA, PFNA, and PFHxS in more than 95% of participants. Concentrations differed by sex regardless of age and we observed some differences by race/ethnicity. Since 1999-2000, PFOS concentrations showed a significant downward trend, because of discontinuing industrial production of PFOS, but PFNA concentrations showed a significant upward trend. PFOA concentrations during 1999-2000 were significantly higher than during any other time period examined, but PFOA concentrations have remained essentially unchanged during 2003-2008. PFHxS concentrations showed a downward trend from 1999 to 2006, but concentrations increased during 2007-2008. Additional research is needed to identify the environmental sources contributing to human exposure to PFCs. Nonetheless, these NHANES data suggest that sociodemographic factors may influence exposure and also provide unique information on temporal trends of exposure. C1 [Kato, Kayoko; Wong, Lee-Yang; Jia, Lily T.; Kuklenyik, Zsuzsanna; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Calafat, AM (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM Acalafat@cdc.gov NR 23 TC 205 Z9 211 U1 14 U2 72 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD OCT 1 PY 2011 VL 45 IS 19 BP 8037 EP 8045 DI 10.1021/es1043613 PG 9 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 825BJ UT WOS:000295245600012 PM 21469664 ER PT J AU Vandenplas, O Dressel, H Wilken, D Jamart, J Heederik, D Maestrelli, P Sigsgaard, T Henneberger, P Baur, X AF Vandenplas, O. Dressel, H. Wilken, D. Jamart, J. Heederik, D. Maestrelli, P. Sigsgaard, T. Henneberger, P. Baur, X. TI Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence SO EUROPEAN RESPIRATORY JOURNAL LA English DT Review DE Asthma; occupational disease ID WESTERN RED CEDAR; DIISOCYANATE-INDUCED ASTHMA; IMMUNOLOGICAL LUNG-DISEASE; NATURAL-RUBBER LATEX; WORK-RELATED ASTHMA; FOLLOW-UP; TOLUENE DIISOCYANATE; THUJA-PLICATA; BRONCHIAL HYPERRESPONSIVENESS; PERSULFATE SALTS AB Reduction of exposure to sensitising agents causing occupational asthma has been proposed as an alternative to total avoidance in order to minimise the adverse socio-economic impact of the condition. The aim of this systematic review was to compare the effects of these two management options on asthma and socio-economic outcomes. A bibliographic search was conducted to identify studies examining the outcome of workers with occupational asthma after reduction or cessation of exposure to the causal agent. The changes in asthma symptoms and nonspecific bronchial hyperresponsiveness after reduction or cessation of exposure were described in nine and five studies, respectively. The meta-analysis of pooled data showed that a reduction of exposure was associated with a lower likelihood of improvement (OR 0.16, 95% CI 0.03-0.91) and recovery (OR 0.30, 95% CI 0.11-0.84) of asthma symptoms and a higher risk of worsening of the symptoms (OR 10.23, 95% CI 2.97-35.28) and nonspecific bronchial hyperresponsiveness (OR 5.65, 95% CI 1.11-28.82), compared with complete avoidance of exposure. This systematic review indicates that reduction of exposure cannot be routinely recommended as an alternative to cessation of exposure in the management of occupational asthma. However, further investigations are required before drawing evidence-based conclusions on the cost-effectiveness of this approach. C1 [Vandenplas, O.] Catholic Univ Louvain, Mt Godinne Hosp, Dept Chest Med, Yvoir, Belgium. [Jamart, J.] Catholic Univ Louvain, Mt Godinne Hosp, Sci Support Unit, Yvoir, Belgium. [Dressel, H.] Univ Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany. [Wilken, D.; Baur, X.] Univ Med Ctr Hamburg Eppendorf, Inst Occupat & Maritime Med, Hamburg, Germany. [Heederik, D.] Univ Utrecht, IRAS, Environm Epidemiol Div, Utrecht, Netherlands. [Maestrelli, P.] Univ Padua, Dept Environm Med & Publ Hlth, Padua, Italy. [Sigsgaard, T.] Univ Aarhus, Sch Publ Hlth, Dept Environm & Occupat Med, Aarhus, Denmark. [Henneberger, P.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Vandenplas, O (reprint author), Clin Univ Mt Godinne, Serv Pneumol, B-5530 Yvoir, Belgium. EM olivier.vandenplas@uclouvain.be OI Sigsgaard, Torben/0000-0002-2043-7571 FU European Respiratory Society FX This document presents the results of a systematic review on this specific issue, which has been completed as part of a larger review conducted by the ERS task force on the management of work-related asthma. This paper is not considered part of the official task force report; the full, official report will be presented in future issues of the European Respiratory Journal and the European Respiratory Review. The work of the task force on the management of work-related asthma was funded by the European Respiratory Society. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 41 TC 30 Z9 30 U1 0 U2 8 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD OCT PY 2011 VL 38 IS 4 BP 804 EP 811 DI 10.1183/09031936.00177510 PG 8 WC Respiratory System SC Respiratory System GA 827EK UT WOS:000295410200011 PM 21436354 ER PT J AU Bilukha, OO Laurenge, H Danee, L Subedi, KP Becknell, K AF Bilukha, Oleg O. Laurenge, Hugues Danee, Luhar Subedi, Krishna P. Becknell, Kristin TI Injuries and deaths due to victim-activated improvised explosive devices, landmines and other explosive remnants of war in Nepal SO INJURY PREVENTION LA English DT Article ID UNEXPLODED ORDNANCE; LAND MINES; AFGHANISTAN; MOZAMBIQUE; BOSNIA AB Background Following more than a decade of civil conflict, Nepal is among the countries affected by landmines, victim-activated improvised explosive devices (IED) and other explosive remnants of war (ERW). Objectives To assess the magnitude of injuries due to landmines, victim-activated IED and other ERW in Nepal and to describe epidemiological patterns and risk factors for these events. Methods Analysis of surveillance data on civilian injuries due to landmines, victim-activated IED and other ERW between July 2006 and June 2010. Data were collected through active community-based prospective surveillance. Results Of 307 total casualties, 94 (31%) were female and 169 (55%) were children under 18 years of age. The case-fatality ratio was 14%. The highest number of casualties was in the age group 10-14 years. 233 (76%) injuries were caused by victim-activated IED, 13 (4%) by landmines and 44 (14%) by other ERW. Two types of IED, sutali and socket bombs, caused the majority of injuries (28% and 31%, respectively). 117 (38%) of all injuries occurred in victims' homes and 152 (50%) occurred while victims were tampering with explosive devices. Conclusions Substantial numbers of civilians, including women and children, were injured and killed following implementation of the Comprehensive Peace Agreement in 2006. The government of Nepal and humanitarian organisations should continue their efforts to reach communities at highest risk through targeted interventions and nationwide media campaigns to convey the risks of tampering with explosive devices or suspicious objects. C1 [Bilukha, Oleg O.; Becknell, Kristin] Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Ctr Global Hlth, Atlanta, GA 30341 USA. [Laurenge, Hugues; Danee, Luhar] United Nations Childrens Fund, Kathmandu, Nepal. [Subedi, Krishna P.] Informal Sect Serv Ctr, Kathmandu, Nepal. RP Bilukha, OO (reprint author), Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Ctr Global Hlth, CDC 4770 Buford Hwy,MS F-60, Atlanta, GA 30341 USA. EM obilukha1@cdc.gov FU United Nations Children's Fund FX The authors would like to thank the Informal Sector Service Center and the United Nations Children's Fund for providing the data on victims of victim-activated IED, landmines and other ERW in Nepal. NR 18 TC 6 Z9 6 U1 1 U2 6 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD OCT PY 2011 VL 17 IS 5 BP 326 EP 331 DI 10.1136/ip.2010.030312 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 823MB UT WOS:000295125300009 PM 21296800 ER PT J AU Cox, S Kuo, C Jamieson, DJ Kourtis, AP McPheeters, ML Meikle, SF Posner, SF AF Cox, Shanna Kuo, Cassie Jamieson, Denise J. Kourtis, Athena P. McPheeters, Melissa L. Meikle, Susan F. Posner, Samuel F. TI Poisoning hospitalisations among reproductive-aged women in the USA, 1998-2006 SO INJURY PREVENTION LA English DT Article ID EMERGENCY-DEPARTMENT VISITS; ATTEMPTED-SUICIDE; NONMEDICAL USE; UNITED-STATES; INJURY; ASSOCIATION; DRUGS AB Objective To describe poisoning hospitalisations among reproductive-aged women from 1998 to 2006. Methods 1998-2006 data from the Nationwide Inpatient Sample of the Healthcare Cost and Utilisation Project were used to identify hospitalisations for poisonings among US women aged 15-44 years. Differences in hospitalisation characteristics were compared by intent using chi(2) statistics. Trends in poisoning hospitalisation rates were calculated overall and by subgroup. Results There were approximately 636 000 poisoning hospitalisations in women aged 15-44 years during 1998-2006. Hospitalisations for intentionally self-inflicted poisonings had a higher proportion of women aged 15-24 years and privately insured women than did unintentional poisonings (p<0.001). Poisoning hospitalisations in rural areas and those that resulted in death were more likely to be of undetermined intent than those for which intent was specified (p<0.001). Co-diagnoses of substance abuse (34.5%) or mental disorders (66.5%) were high. The rate of poisoning hospitalisations overall and unintentional poisoning hospitalisations increased 6% and 22%, respectively, during this period (p<0.001). The most frequently diagnosed poisoning agent was acetaminophen. Poisonings attributable to acetaminophen, opioids, central nervous system stimulants and benzodiazepines increased, while poisonings attributable to antidepressants decreased (p<0.05). Conclusions The increase in unintentional poisoning hospitalisations among women aged 15-44 years and the changing profile of poisoning agents should inform the healthcare community's poisoning prevention strategies. Poisoning prevention strategies should include a component to address substance abuse and mental health disorders among reproductive-age women. C1 [Cox, Shanna; Kuo, Cassie; Jamieson, Denise J.; Kourtis, Athena P.; Posner, Samuel F.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [McPheeters, Melissa L.] Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, Nashville, TN 37232 USA. [Meikle, Susan F.] NIH, Off Res Womens Hlth, Bethesda, MD 20892 USA. RP Cox, S (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway MS K-20, Atlanta, GA 30341 USA. EM shanna.cox@cdc.hhs.gov OI Posner, Samuel/0000-0003-1574-585X NR 36 TC 8 Z9 8 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD OCT PY 2011 VL 17 IS 5 BP 332 EP 337 DI 10.1136/ip.2010.029793 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 823MB UT WOS:000295125300010 PM 21296799 ER PT J AU Degutis, LC Sattin, RW AF Degutis, Linda C. Sattin, Richard W. TI Injury research: a perspective from the National Center for Injury Prevention and Control SO INJURY PREVENTION LA English DT Editorial Material C1 [Degutis, Linda C.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Sattin, Richard W.] Georgia Hlth Sci Univ, Dept Emergency Med, Augusta, GA USA. [Sattin, Richard W.] Soc Adv Violence & Injury Res, Washington, DC USA. RP Degutis, LC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,MS F63, Atlanta, GA 30341 USA. EM lqd5@cdc.gov NR 3 TC 3 Z9 3 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD OCT PY 2011 VL 17 IS 5 BP 357 EP 357 DI 10.1136/injuryprev-2011-040167 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 823MB UT WOS:000295125300014 PM 21873305 ER PT J AU Gammino, VM Taylor, AB Rich, ML Bayona, J Becerra, MC Bonilla, C Gelmanova, I Hollo, V Jaramillo, E Keshavjee, S Leimane, V Mitnick, CD Quelapio, MID Riektsina, V Tupasi, TE Wells, CD Zignol, M Cegielski, PJ AF Gammino, V. M. Taylor, A. B. Rich, M. L. Bayona, J. Becerra, M. C. Bonilla, C. Gelmanova, I. Hollo, V. Jaramillo, E. Keshavjee, S. Leimane, V. Mitnick, C. D. Quelapio, M. I. D. Riektsina, V. Tupasi, T. E. Wells, C. D. Zignol, M. Cegielski, P. J. TI Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE MDR-TB; culture conversion; treatment monitoring; XDR-TB; culture reversion ID SPUTUM CULTURE CONVERSION; MDR-TB; PREDICTORS AB BACKGROUND: Multidrug-resistant tuberculosis programs in DOTS-Plus pilot sites in five countries. OBJECTIVES: To calculate sputum conversion time and its relationship to treatment outcome, document the frequency of culture reversions and examine concordance of smear and culture to assess the potential consequences of monitoring by smear microscopy alone. DESIGN: Retrospective cohort analysis of 1926 patients receiving individualized, second-line therapy. RESULTS: Among 1385 sputum culture-positive cases at baseline, 1146 (83%) experienced at least one culture conversion during treatment. Conversion, however, was not sustained in all patients: 201 (15%) experienced initial culture conversion and at least one subsequent culture reversion to positive; 1064 (77%) achieved sustained culture conversion. Median time to culture conversion was 3 months. Among 206 patients whose final conversion occurred 7-18 months after the initiation of therapy, 71% were cured or had completed treatment. CONCLUSIONS: Prolonged treatment for patients with delayed conversion may be beneficial, as 71% of late converters still achieved cure or completed treatment. This has implications for programs with defined end points for treatment failure. The interval between first and final conversion among patients whose initial conversion is not sustained raises concern with respect to the ongoing debate regarding duration of treatment and the definition of cure. C1 [Gammino, V. M.; Taylor, A. B.; Wells, C. D.; Cegielski, P. J.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Rich, M. L.] Brigham & Womens Hosp, Div Social Med & Hlth Inequal, Boston, MA 02115 USA. [Bayona, J.] Socios Salud, Lima, Peru. [Becerra, M. C.; Mitnick, C. D.] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA. [Bonilla, C.] Hosp Nacl, Lima, Peru. [Gelmanova, I.] Partners Hlth, Tomsk Project, Boston, MA USA. [Hollo, V.] Minist Hlth, Natl TB Program Estonia, Tallinn, Estonia. [Keshavjee, S.] Partners Hlth, Lesotho Project, Boston, MA USA. [Leimane, V.; Riektsina, V.] State Ctr TB & Lung Dis, Cekule Riga Dist, Latvia. [Quelapio, M. I. D.; Tupasi, T. E.] Trop Dis Fdn, Makati Med Ctr, Makati, Philippines. [Zignol, M.] World Hlth Org, Stop TB Dept, TB HIV & Drug Resistance THD, Geneva, Switzerland. RP Gammino, VM (reprint author), US Ctr Dis Control, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM vmg0@cdc.gov NR 23 TC 15 Z9 15 U1 1 U2 9 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2011 VL 15 IS 10 BP 1315 EP 1322 DI 10.5588/ijtld.10.0221 PG 8 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 825ED UT WOS:000295252800008 PM 22283887 ER PT J AU Hall, IJ Taylor, YJ Ross, LE Richardson, LC Richards, TB Rim, SH AF Hall, Ingrid J. Taylor, Yhenneko J. Ross, Louie E. Richardson, Lisa C. Richards, Thomas B. Rim, Sun Hee TI Discussions About Prostate Cancer Screening Between US Primary Care Physicians and Their Patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE primary care physicians; prostate cancer screening; prostate-specific antigen; physician-patient discussions; prostate cancer ID HEALTH INTERVIEW SURVEY; PATIENTS SELF-REPORTS; ANTIGEN TEST USE; UNITED-STATES; MEN; GUIDELINES; TESTS AB OBJECTIVE: This study examined the likelihood that U.S. primary care physicians (PCPs) discuss and recommend prostate cancer screening with their patients and physician-related and practice-related factors associated with this behavior. METHODS: We analyzed data from the 2007-2008 National Survey of Primary Care Physician Practices Regarding Prostate Cancer Screening (N = 1,256), the most recent and comprehensive survey specifically designed to address issues concerning prostate cancer screening and representing nearly 95,000 PCPs. We evaluated the relationship between PCP behavior regarding prostate cancer screening discussions and covariates, including PCP demographic and practice-related factors. Weighted percentages and Chi-square tests were used to compare use of screening discussions by PCP characteristics. Adjusted odds of discussing screening and recommending the PSA test were determined from logistic regression. RESULTS: Eighty percent of PCPs reported that they routinely discuss prostate cancer screening with all of their male patients, and 64.1% of PCPs who discussed screening with any patients reported that they attempted to talk their patients into getting the PSA test. In multivariate analyses, encouraging PSA testing was more likely among non-Hispanic black PCPs (OR = 2.80, 95% CI [1.88, 4.16]), PCPs serving 100 or more patients per week (OR = 2.16, 95% CI [1.38, 3.37]), and PCPs spending longer hours per week in direct patient care (31-40 hours: OR = 1.90, 95% CI [1.13, 3.20]; 41 or more hours: OR = 2.09, 95% CI [1.12, 3.88]), compared to their referents. PCPs in multi-specialty group practice were more likely to remain neutral or discourage PSA testing compared to PCPs in solo practice. CONCLUSIONS: Both individual and practice-related factors of PCPs were associated with the use of prostate cancer screening discussions by U.S. PCPs. Results from this study may prove valuable to researchers and clinicians and help guide the development and implementation of future prostate cancer screening interventions in the U.S. C1 [Hall, Ingrid J.; Richardson, Lisa C.; Richards, Thomas B.; Rim, Sun Hee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Taylor, Yhenneko J.] Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC 28223 USA. [Ross, Louie E.] Ross Holmes Grp LLC, Raleigh, NC USA. RP Hall, IJ (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. EM iah9@cdc.gov FU Division of Cancer Prevention and Control, Centers for Disease Control and Prevention FX This work was funded by the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention NR 22 TC 11 Z9 11 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2011 VL 26 IS 10 BP 1098 EP 1104 DI 10.1007/s11606-011-1682-0 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 826CS UT WOS:000295329600008 PM 21416405 ER PT J AU Wechsler, H AF Wechsler, Howell TI Special Issue: Dedication This special issue of the Journal of School Health is dedicated to the urban minority youth of America PREFACE SO JOURNAL OF SCHOOL HEALTH LA English DT Editorial Material ID OF-THE-LITERATURE; STUDENT PERFORMANCE; PHYSICAL-EDUCATION; PROGRAMS; POLICIES; SERVICES; ACHIEVEMENT; NUTRITION C1 Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. RP Wechsler, H (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adolescent & Sch Hlth, 4770 Buford Highway,MS K 29, Atlanta, GA 30341 USA. EM Hwechsler@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD OCT PY 2011 VL 81 IS 10 SI SI BP III EP V DI 10.1111/j.1746-1561.2011.00650.x PG 3 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 823AS UT WOS:000295093900001 PM 21923868 ER PT J AU Boekhout, T Balajee, A AF Boekhout, T. Balajee, A. TI Molecular barcoding of fungi SO MYCOSES LA English DT Meeting Abstract C1 [Boekhout, T.] CBS Fungal Biodivers Ctr, Utrecht, Netherlands. [Balajee, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0933-7407 J9 MYCOSES JI Mycoses PD OCT PY 2011 VL 54 SU 2 SI SI BP 47 EP 47 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA 826FB UT WOS:000295336100080 ER PT J AU Rubio, M Sahaza, J Gaviria, M Diaz-Granados, LR Scheel, C Gomez, B Gonzalez, A Cano, LE AF Rubio, M. Sahaza, J. Gaviria, M. Diaz-Granados, L. R. Scheel, C. Gomez, B. Gonzalez, A. Cano, L. E. TI A chemotype II strain of Histoplasma capsulatum yeast cells do not induce a Th17 immune response in BALB/c mice challenged intranasally SO MYCOSES LA English DT Meeting Abstract C1 [Scheel, C.; Gomez, B.] CDC, Mycot Dis Branch, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0933-7407 J9 MYCOSES JI Mycoses PD OCT PY 2011 VL 54 SU 2 SI SI BP 118 EP 118 PG 1 WC Dermatology; Mycology SC Dermatology; Mycology GA 826FB UT WOS:000295336100265 ER PT J AU Black, MH Anderson, A Bell, RA Dabelea, D Pihoker, C Saydah, S Seid, M Standiford, DA Waitzfelder, B Marcovina, SM Lawrence, JM AF Black, Mary Helen Anderson, Andrea Bell, Ronny A. Dabelea, Dana Pihoker, Catherine Saydah, Sharon Seid, Michael Standiford, Debra A. Waitzfelder, Beth Marcovina, Santica M. Lawrence, Jean M. TI Prevalence of Asthma and Its Association With Glycemic Control Among Youth With Diabetes SO PEDIATRICS LA English DT Article DE asthma; diabetes mellitus; diabetes type 1; diabetes type 2; obesity ID UNITED-STATES; INSULIN-RESISTANCE; NATIONAL-HEALTH; LUNG-FUNCTION; US CHILDREN; OBESITY; ADOLESCENTS; MELLITUS; COMPLICATIONS; DISEASE AB OBJECTIVE: To estimate the prevalence of asthma among youth with types 1 and 2 diabetes and examine associations between asthma and glycemic control. METHODS: This was a cross-sectional analysis of data from the SEARCH for Diabetes in Youth study, which included youth diagnosed with type 1 (n = 1683) and type 2 (n = 311) diabetes from 2002 through 2005. Asthma status and medications were ascertained from medical records and self-administered questionnaires, and glycemic control was assessed from hemoglobin A1c measured at the study visit. RESULTS: Prevalence of asthma among all youth with diabetes was 10.9% (95% confidence interval [CI]: 9.6%-12.3%). The prevalence was 10.0% (95% CI: 8.6%-11.4%) among youth with type 1 and 16.1% (95% CI: 12.0%-20.2%) among youth with type 2 diabetes and differed according to race/ethnicity. Among youth with type 1 diabetes, those with asthma had higher mean A1c levels than those without asthma, after adjustment for age, gender, race/ethnicity, and BMI (7.77% vs 7.49%; P=.034). Youth with asthma were more likely to have poor glycemic control, particularly those with type 1 diabetes whose asthma was not treated with pharmacotherapy, although this association was attenuated by adjustment for race/ethnicity. CONCLUSIONS: Prevalence of asthma may be elevated among youth with diabetes relative to the general US population. Among youth with type 1 diabetes, asthma is associated with poor glycemic control, especially if asthma is untreated. Specific asthma medications may decrease systemic inflammation, which underlies the complex relationship between pulmonary function, BMI, and glycemic control among youth with diabetes. Pediatrics 2011;128:e839-e847 C1 [Black, Mary Helen; Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Anderson, Andrea; Bell, Ronny A.] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA. [Dabelea, Dana] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA. [Pihoker, Catherine] Childrens Hosp & Reg Med Ctr, Seattle, WA USA. [Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Seid, Michael] Childrens Hosp, Med Ctr, Div Pulm Med, Cincinnati, OH 45229 USA. [Standiford, Debra A.] Childrens Hosp, Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA. [Waitzfelder, Beth] Kaiser Permanente, Ctr Hlth Res Hawaii, Honolulu, HI USA. [Marcovina, Santica M.] Univ Washington, Dept Med, Seattle, WA USA. RP Lawrence, JM (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, 100 S Los Robles,4th Floor, Pasadena, CA 91101 USA. EM jean.m.lawrence@kp.org FU Centers for Disease Control and Prevention [PA 00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; General Clinical Research Centers at the Medical University of South Carolina [M01 RR01070]; Seattle Children's and the University of Washington School of Medicine [M01RR00037, M01RR001271]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Institutional Clinical and Translational Science Award; National Institutes of Health/National Center for Research Resources at the University of Cincinnati [1UL1RR026314-01] FX SEARCH is funded by the Centers for Disease Control and Prevention (PA 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases.; We acknowledge the involvement of General Clinical Research Centers at the Medical University of South Carolina (grant M01 RR01070); Seattle Children's and the University of Washington School of Medicine (grant M01RR00037 and M01RR001271); Colorado Pediatric General Clinical Research Center (grant M01 RR00069); and the Institutional Clinical and Translational Science Award and National Institutes of Health/National Center for Research Resources at the University of Cincinnati (grant 1UL1RR026314-01) NR 34 TC 12 Z9 12 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD OCT PY 2011 VL 128 IS 4 BP E839 EP E847 DI 10.1542/peds.2010-3636 PG 9 WC Pediatrics SC Pediatrics GA 827DH UT WOS:000295406800009 PM 21949144 ER PT J AU Nasrullah, M Mazurek, JM Wood, JM Bang, KM Kreiss, K AF Nasrullah, Muazzam Mazurek, Jacek M. Wood, John M. Bang, Ki Moon Kreiss, Kathleen TI Silicosis Mortality With Respiratory Tuberculosis in the United States, 1968-2006 SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE industry; mortality; occupational exposure; occupations; silicosis; tuberculosis ID DEATH CERTIFICATES; OCCUPATIONAL-HEALTH; FOUNDRY WORKERS; INDUSTRY DATA; TRENDS; EPIDEMIOLOGY; ACCURACY AB The presence of tuberculosis (TB) in patients with silicosis increases mortality risk. To characterize silicosis-respiratory TB comortality in the United States, the authors used 1968-2006 National Center for Health Statistics multiple cause-of-death data for decedents aged >= 25 years. The authors calculated proportionate mortality ratios (PMRs) using available information on decedents' industries and occupations reported from 26 states from 1985 through 1999. Among 16,648 silicosis deaths, 2,278 (13.7%) had respiratory TB listed on the death certificate. Of silicosis-respiratory TB deaths, 1,666 decedents (73.1%) were aged >= 65 years, 2,255 (99.0%) were male, and 1,893 (83.1%) were white. Silicosis-respiratory TB deaths declined 99.5% during the study period (P < 0.001 for time-related trend), from 239.8 per year during 1968-1972 to 1.2 per year during 2002-2006, with no reported deaths in 2006. Silicosis-respiratory TB deaths reported from Pennsylvania (n = 525; 1.29 per million population), Ohio (n = 258; 0.81 per million), and West Virginia (n = 146; 2.35 per million) accounted for 40.8% of all such deaths in the United States. The highest PMR for silicosis-respiratory TB death was associated with the "miscellaneous nonmetallic mineral and stone products" industry (PMR = 73.7, 95% confidence interval: 33.8, 139.8). In the United States, 2006 marked the first year since 1968 with no silicosis-respiratory TB deaths. The substantial decline in silicosis-respiratory TB comortality probably reflects prevention and control measures for both diseases. C1 [Nasrullah, Muazzam] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Nasrullah, Muazzam; Mazurek, Jacek M.; Wood, John M.; Bang, Ki Moon; Kreiss, Kathleen] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA. RP Nasrullah, M (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,Mailstop E46, Atlanta, GA 30333 USA. EM snasrullah@cdc.gov NR 42 TC 5 Z9 5 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 1 PY 2011 VL 174 IS 7 BP 839 EP 848 DI 10.1093/aje/kwr159 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 823ZC UT WOS:000295166500010 PM 21828370 ER PT J AU Goff, BA Matthews, B Andrilla, CHA Miller, JW Trivers, KF Berry, D Lishner, DM Baldwin, LM AF Goff, Barbara A. Matthews, Barbara Andrilla, C. Holly A. Miller, Jacqueline W. Trivers, Katrina F. Berry, Donna Lishner, Denise M. Baldwin, Laura-Mae TI How Are Symptoms of Ovarian Cancer Managed? A Study of Primary Care Physicians SO CANCER LA English DT Article DE primary care physicians; screening; symptoms; ovarian cancer; CA125; transvaginal ultrasound ID UNITED-STATES; DIAGNOSIS; WOMEN; POPULATION; INDEX; EARLIER; RISK AB BACKGROUND: A study was undertaken to identify the diagnostic approaches that primary care physicians and gynecologists undertake in women with symptoms associated with ovarian cancer. METHODS: A vignette-based survey was mailed to 3200 primary care physicians from the American Medical Association Physician Masterfile. The vignette described a 55-year-old woman with symptoms associated with ovarian cancer, although ovarian cancer was never mentioned. The authors evaluated patient, physician, and practice characteristics associated with a workup that could detect ovarian cancer. RESULTS: The survey response rate was 61.7%. After exclusions, 1532 physicians were included. Overall, 89.5% of physicians reported that they would recommend testing that can detect ovarian cancer ( 71.2% ultrasound; 25.4% pelvic computed tomography; 26.5% CA125). In adjusted analysis, the only patient factor associated with ovarian cancer testing was symptom type, genitourinary versus gastrointestinal ( risk ratio, 1.07; 95% confidence interval, 1.03-1.11). Physician and practice characteristics associated with recommending of ovarian cancer testing included specialty ( gynecologists > family physicians and internists); type of practice ( group > solo); clinical teaching ( yes > no); and within Census division, location of practice, with all Central ( East, West, North, and South) and Atlantic ( Middle and South) areas having a lower likelihood than New England. CONCLUSIONS: On the basis of a vignette in which a woman reported symptoms associated with ovarian cancer, the majority of primary care physicians and gynecologists would not recommend CA125, but would recommend imaging of the pelvis. Gynecologists, physicians involved with clinical teaching, and those in group practices were significantly more likely to recommend testing that could lead to an ovarian cancer diagnosis. Cancer 2011; 117: 4414-23. (C) 2011 American Cancer Society. C1 [Goff, Barbara A.] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Matthews, Barbara; Andrilla, C. Holly A.; Lishner, Denise M.; Baldwin, Laura-Mae] Univ Washington, Dept Family Med, Seattle, WA 98195 USA. [Miller, Jacqueline W.; Trivers, Katrina F.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Berry, Donna] Dana Farber Canc Inst, Phyllis F Cantor Ctr, Boston, MA 02115 USA. RP Goff, BA (reprint author), Univ Washington, Sch Med, Dept Obstet & Gynecol, Box 356460, Seattle, WA 98195 USA. EM bgoff@uw.edu FU Centers for Disease Control and Prevention (CDC) through the University of Washington Health Promotion Research Centers [U48DP001911]; Centers for Disease Control and Prevention (CDC) through the Alliance for Reducing Cancer, Northwest; CDC [U48DP001911]; National Cancer Institute FX This project was funded by the Centers for Disease Control and Prevention (CDC) through the University of Washington Health Promotion Research Centers Cooperative Agreement U48DP001911, and through the Alliance for Reducing Cancer, Northwest, funded by both the CDC (grant U48DP001911, V. Taylor, principal investigator) and the National Cancer Institute. The findings and conclusions in this journal article are those of the authors and do not necessarily represent the official position of the CDC. NR 36 TC 9 Z9 9 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2011 VL 117 IS 19 BP 4414 EP 4423 DI 10.1002/cncr.26035 PG 10 WC Oncology SC Oncology GA 824TN UT WOS:000295225200013 PM 21413001 ER PT J AU Wu, FT Banyai, K Huang, JC Wu, HS Chang, FY Hsiung, CA Huang, YC Lin, JS Hwang, KP Jiang, B Gentsch, JR AF Wu, F. -T. Banyai, K. Huang, J. C. Wu, H. -S. Chang, F. -Y. Hsiung, C. A. Huang, Y. -C. Lin, J. -S. Hwang, K. -P. Jiang, B. Gentsch, J. R. TI Human infection with novel G3P[25] rotavirus strain in Taiwan SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article DE Genotype; phylogenetic analysis; reassortment; Taiwan; zoonosis ID GROUP-A ROTAVIRUS; SEROTYPE G12 ROTAVIRUSES; MOLECULAR CHARACTERIZATION; G9 ROTAVIRUS; DIARRHEA; CHILDREN; EMERGENCE; GENOTYPE; INDIA; EPIDEMIOLOGY AB Genotype P[25] rotaviruses are rare and to date have been reported to occur only in a few countries of mainland Asia. Here we report the molecular characterization of a novel human rotavirus genotype combination, G3P[25], detected in a 17-month-old child hospitalized due to severe gastroenteritis during 2009 in central Taiwan. Sequencing and phylogenetic analysis of the VP4 gene demonstrated a distinct origin from other strains bearing the P[25] VP4 gene, whereas the VP7, VP6 and NSP4 gene phylogenies identified common origins with cognate genes of other, presumed human-porcine reassortment Taiwanese strains. These results suggest that interactions between human and animal strains appear to contribute to the generation of genetic and antigenic diversity of rotavirus strains, with potential public health importance in Taiwan. C1 [Wu, F. -T.; Wu, H. -S.; Chang, F. -Y.] Natl Yang Ming Univ, Ctr Res & Diagnost, Ctr Dis Control, Dept Hlth, Taipei 112, Taiwan. [Wu, F. -T.; Huang, J. C.] Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan. [Banyai, K.] Hungarian Acad Sci, Vet Med Res Inst, H-1581 Budapest, Hungary. [Wu, H. -S.] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan. [Hsiung, C. A.] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan. [Huang, Y. -C.] Chang Gung Univ, Coll Med, Chang Gung Childrens Hosp, Div Paediat Infect Dis, Tao Yuan, Taiwan. [Lin, J. -S.] Changhua Christian Hosp, Div Paediat Infect Dis, Changhua, Taiwan. [Lin, J. -S.] Changhua Christian Hosp, Dept Lab Med, Changhua, Taiwan. [Hwang, K. -P.] Chang Gung Univ, Coll Med, Div Paediat Infect Dis, Dept Paediat,Chang Gung Mem Hosp,Kaohsiung Med, Kaohsiung, Taiwan. [Hwang, K. -P.] China Med Univ & Hosp, Sch Med, Childrens Hosp, Taichung, Taiwan. [Jiang, B.; Gentsch, J. R.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Wu, FT (reprint author), Natl Yang Ming Univ, Ctr Res & Diagnost, Ctr Dis Control, Dept Hlth, Taipei 112, Taiwan. EM fang@cdc.gov.tw RI Hsiung, Chao Agnes/E-3994-2010; OI Banyai, Krisztian/0000-0002-6270-1772 FU Hungarian Scientific Research Fund (OTKA) [PD76364]; Centers for Disease Control, Department of Health, Taiwan [DOH97-DC-1102] FX K.B. was supported by the Hungarian Scientific Research Fund (OTKA, PD76364). This study was financially supported in part by research grant of DOH97-DC-1102 from Centers for Disease Control, Department of Health, Taiwan. We thank Chen-Fu Yang for discussion and Ching-Yi Wu for assistance in performing data management and molecular analysis. NR 25 TC 8 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD OCT PY 2011 VL 17 IS 10 BP 1570 EP 1573 DI 10.1111/j.1469-0691.2011.03531.x PG 4 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 822YI UT WOS:000295086100022 PM 21851477 ER PT J AU Yu, W Yesupriya, A Wulf, A Hindorff, LA Dowling, N Khoury, MJ Gwinn, M AF Yu, Wei Yesupriya, Ajay Wulf, Anja Hindorff, Lucia A. Dowling, Nicole Khoury, Muin J. Gwinn, Marta TI GWAS Integrator: a bioinformatics tool to explore human genetic associations reported in published genome-wide association studies SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article DE genome-wide association studies; database; bioinformatics ID EPIDEMIOLOGY; KNOWLEDGE; DISEASE AB Genome-wide association studies (GWAS) have successfully identified numerous genetic loci that are associated with phenotypic traits and diseases. GWAS Integrator is a bioinformatics tool that integrates information on these associations from the National Human Genome Research institute (NHGRI) Catalog, SNAP (SNP Annotation and Proxy Search), and the Human Genome Epidemiology (HuGE) Navigator literature database. This tool includes robust search and data mining functionalities that can be used to quickly identify relevant associations from GWAS, as well as proxy single-nucleotide polymorphisms (SNPs) and potential candidate genes. Query-based University of California Santa Cruz (UCSC) Genome Browser custom tracks are generated dynamically on the basis of users' selected GWAS hits or candidate genes from HuGE Navigator literature database (http://www.hugenavigator.net/HuGENavigator/gWAHitStartPage.do). The GWAS Integrator may help enhance inference on potential genetic associations identified from GWAS studies. European Journal of Human Genetics (2011) 19, 1095-1099; doi:10.1038/ejhg.2011.91; published online 25 May 2011 C1 [Yu, Wei; Yesupriya, Ajay; Wulf, Anja; Dowling, Nicole; Khoury, Muin J.; Gwinn, Marta] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30341 USA. [Hindorff, Lucia A.] NHGRI, Office Populat Genom, NIH, Bethesda, MD 20892 USA. RP Yu, W (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 4770 Buford Highway,MS K-89, Atlanta, GA 30341 USA. EM wby0@cdc.gov NR 6 TC 21 Z9 21 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD OCT PY 2011 VL 19 IS 10 BP 1095 EP 1099 DI 10.1038/ejhg.2011.91 PG 5 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 823KG UT WOS:000295120500016 PM 21610748 ER PT J AU Lanier, WA Hall, JM Herlihy, RK Rolfs, RT Wagner, JM Smith, LH Hyytia-Trees, EK AF Lanier, William A. Hall, Julia M. Herlihy, Rachel K. Rolfs, Robert T. Wagner, Jennifer M. Smith, Lori H. Hyytia-Trees, Eija K. TI Outbreak of Shiga-Toxigenic Escherichia coli O157:H7 Infections Associated with Rodeo Attendance, Utah and Idaho, 2009 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID LIVESTOCK; FAIR AB Objectives: In summer 2009, the Utah Department of Health investigated an outbreak of Shiga-toxigenic Escherichia coli (STEC) O157:H7 (O157) illness associated with attendance at multiple rodeos. Materials and Methods: Patients were interviewed regarding exposures during the week before illness onset. A ground beef traceback investigation was performed. Ground beef samples from patient homes and a grocery store were tested for STEC O157. Rodeo managers were interviewed regarding food vendors present and cattle used at the rodeos. Environmental samples were collected from rodeo grounds. Two-enzyme pulsed-field gel electrophoresis (PFGE) and multiple-locus variable-number tandem repeat analysis (MLVA) were performed on isolates. Results: Fourteen patients with primary STEC O157 illness were reported in this outbreak. Isolates from all patients were indistinguishable by PFGE. Isolates from nine patients had identical MLVA patterns (main outbreak strain), and five had minor differences. Thirteen (93%) patients reported ground beef consumption during the week before illness onset. Results of the ground beef traceback investigation and ground beef sampling were negative. Of 12 primary patients asked specifically about rodeo attendance, all reported having attended a rodeo during the week before illness onset; four rodeos were mentioned. All four rodeos had used bulls from the same cattle supplier. An isolate of STEC O157 identified from a dirt sample collected from the bullpens of one of the attended rodeos was indistinguishable by PFGE and MLVA from the main outbreak strain. Discussion: Recommendations were provided to rodeo management to keep livestock and manure separate from rodeo attendees. This is the first reported STEC O157 outbreak associated with attendance at multiple rodeos. Public health officials should be aware of the potential for rodeo-associated STEC illness. C1 [Lanier, William A.; Hall, Julia M.; Herlihy, Rachel K.; Rolfs, Robert T.] Utah Dept Hlth, Bur Epidemiol, Salt Lake City, UT 84114 USA. [Lanier, William A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Lanier, William A.] US PHS, Rockville, MD USA. [Wagner, Jennifer M.; Smith, Lori H.] Utah Dept Hlth, Unified State Labs Publ Hlth, Taylorsville, UT USA. [Hyytia-Trees, Eija K.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Lanier, WA (reprint author), Utah Dept Hlth, Bur Epidemiol, POB 142104, Salt Lake City, UT 84114 USA. EM wlanier@utah.gov NR 8 TC 4 Z9 4 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD OCT PY 2011 VL 8 IS 10 BP 1131 EP 1133 DI 10.1089/fpd.2011.0884 PG 3 WC Food Science & Technology SC Food Science & Technology GA 823WR UT WOS:000295158500012 PM 21657937 ER PT J AU Jordan, IK Conley, AB Antonov, IV Arthur, RA Cook, ED Cooper, GP Jones, BL Knipe, KM Lee, KJ Liu, X Mitchell, GJ Pande, PR Petit, RA Qin, SP Rajan, VN Sarda, S Sebastian, A Tang, SY Thapliyal, R Varghese, NJ Ye, TJ Katz, LS Wang, X Rowe, L Frace, M Mayer, LW AF Jordan, I. King Conley, Andrew B. Antonov, Ivan V. Arthur, Robert A. Cook, Erin D. Cooper, Guy P. Jones, Bernard L. Knipe, Kristen M. Lee, Kevin J. Liu, Xing Mitchell, Gabriel J. Pande, Pushkar R. Petit, Robert A. Qin, Shaopu Rajan, Vani N. Sarda, Shruti Sebastian, Aswathy Tang, Shiyuyun Thapliyal, Racchit Varghese, Neha J. Ye, Tianjun Katz, Lee S. Wang, Xin Rowe, Lori Frace, Michael Mayer, Leonard W. TI Genome Sequences for Five Strains of the Emerging Pathogen Haemophilus haemolyticus SO JOURNAL OF BACTERIOLOGY LA English DT Article ID INFLUENZAE; ENDOCARDITIS AB We report the first whole-genome sequences for five strains, two carried and three pathogenic, of the emerging pathogen Haemophilus haemolyticus. Preliminary analyses indicate that these genome sequences encode markers that distinguish H. haemolyticus from its closest Haemophilus relatives and provide clues to the identity of its virulence factors. C1 [Katz, Lee S.; Wang, Xin; Mayer, Leonard W.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. [Jordan, I. King] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Jordan, I. King; Conley, Andrew B.; Antonov, Ivan V.; Arthur, Robert A.; Cook, Erin D.; Cooper, Guy P.; Jones, Bernard L.; Knipe, Kristen M.; Lee, Kevin J.; Liu, Xing; Mitchell, Gabriel J.; Pande, Pushkar R.; Petit, Robert A.; Qin, Shaopu; Rajan, Vani N.; Sarda, Shruti; Sebastian, Aswathy; Tang, Shiyuyun; Thapliyal, Racchit; Varghese, Neha J.; Ye, Tianjun] Georgia Inst Technol, Computat Genom Grp, Atlanta, GA 30332 USA. [Jordan, I. King] PanAmer Bioinformat Inst, Santa Marta, Magdalena, Colombia. [Rowe, Lori; Frace, Michael] CDC, Biotechnol Core Facil Branch, Div Sci Resources, NCPDCID, Atlanta, GA 30333 USA. RP Mayer, LW (reprint author), Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. EM lwm1@cdc.gov OI Petit, Robert/0000-0002-1350-9426; Sarda, Shrutii/0000-0002-1832-2310; Jones, Bernard/0000-0001-7169-559X FU Alfred P. Sloan Research Fellowship in Computational and Evolutionary Molecular Biology [BR-4839]; Georgia Research Alliance [GRA.VAC09.O]; Georgia Tech graduate programs in bioinformatics FX This work was supported by an Alfred P. Sloan Research Fellowship in Computational and Evolutionary Molecular Biology (grant BR-4839 to I.K.J.) and by the Georgia Research Alliance (GRA.VAC09.O to I.K.J. and L.W.M.).; We acknowledge the support of the Georgia Tech graduate programs in bioinformatics. We thank the Active Bacterial Core surveillance team, Roman Golash from the Illinois Department of Health, and the Texas Department of State Health Services for providing strains. NR 12 TC 13 Z9 13 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD OCT PY 2011 VL 193 IS 20 BP 5879 EP 5880 DI 10.1128/JB.05863-11 PG 2 WC Microbiology SC Microbiology GA 825FJ UT WOS:000295256100042 PM 21952546 ER PT J AU Hamner, HC Cogswell, ME Johnson, MA AF Hamner, Heather C. Cogswell, Mary E. Johnson, Mary Ann TI Acculturation Factors Are Associated with Folate Intakes among Mexican American Women SO JOURNAL OF NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; NEURAL-TUBE DEFECTS; FOLIC-ACID FORTIFICATION; SURVEY NHANES 2001-2006; 3RD NATIONAL-HEALTH; UNITED-STATES; SPINA-BIFIDA; INTAKE DISTRIBUTIONS; NUTRIENT INTAKE; BIRTH-DEFECTS AB Folic acid can prevent neural tube defects (NTD). Hispanic women have a higher prevalence of NTD than non-Hispanic white (NHW) women and consume less folic acid. Among Hispanics, acculturation has been associated with lower intakes of natural folate. It is unknown if this same relationship is seen for fortified foods. This article describes the associations of acculturation factors with usual folate intakes from foods and supplements and compares the proportion that meets recommended intakes of folic acid of US Mexican American (MA) women with those of NHW women. For US NHW and MA women aged 15-44 y (n = 3167), usual folate intakes (i.e., natural food folate, folic acid from food, total folic acid [fortified foods plus supplements], and total folate) were estimated using measurement er-or models from NHANES 2001-2008. Compared with NHW women, MA women did not differ in their intake of natural food folate or folic acid from food. Similarly, compared with NHW women (332 +/- 17.3 mu g/d), the mean total usual folic acid intakes were lower among MA women who reported speaking Spanish (224 +/- 24.9 mu g/d) but not for MA women who reported speaking English (283 +/- 36.2 mu g/d). MA women were more likely than NHW women to consume a total folic acid intake <400 mu g/d. MA women with lower acculturation factors were the most likely to have an intake <400 mu g/d compared to NHW women. Public health efforts should focus on increasing total folic acid intake among MA women, emphasizing those with lower acculturation factors (e.g., MA women who report speaking Spanish). J. Nutr. 141: 1889-1897, 2011. C1 [Hamner, Heather C.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Cogswell, Mary E.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Johnson, Mary Ann] Univ Georgia, Dept Food & Nutr, Coll Family & Consumer Sci, Athens, GA 30602 USA. RP Hamner, HC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM hfc2@cdc.gov NR 40 TC 6 Z9 6 U1 0 U2 2 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD OCT PY 2011 VL 141 IS 10 BP 1889 EP 1897 DI 10.3945/jn.111.143412 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 824HM UT WOS:000295193000018 PM 21865570 ER PT J AU Blanchard, EG Miao, CR Haupt, TE Anderson, LJ Haynes, LM AF Blanchard, Elisabeth G. Miao, Congrong Haupt, Thomas E. Anderson, Larry J. Haynes, Lia M. TI Development of a recombinant truncated nucleocapsid protein based immunoassay for detection of antibodies against human coronavirus OC43 SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Coronavirus; Immunoassay; Nucleocapsid; Serology; HCoV-OC43 ID ACUTE-RESPIRATORY-SYNDROME; VIRUS-INFECTIONS; HCOV-OC43; ILLNESS; ADULTS; SPIKE; ASSAY AB Human coronaviruses are one of the main causes of upper respiratory tract infections in humans. While more often responsible for mild illness, they have been associated with illnesses that require hospitalization. In this study, an assay for one of the human coronaviruses, OC43, was developed using a truncated recombinant nucleocapsid (N) protein antigen in an enzyme immunosorbent assay (ELISA) and evaluated using serum collected from HCoV-OC43-infected patients, healthy adults, and patients with other respiratory virus infections. Results showed that the diagnostic sensitivity and specificity of the assay were 90.9% (10/11) and 82.9% (39/47), respectively. To evaluate the clinical utility of the ELISA, serum samples collected from patients during an outbreak of HCoV-OC43 infection and previously identified as positive by HCoV-OC43 whole N ELISA were screened resulting in 100% diagnosis agreement between the testing methods. These results suggest that this assay offers a reliable method to detect HCoV-OC43 infection and may be a useful tool in coronavirus seroepidemiological studies. Published by Elsevier B.V. C1 [Blanchard, Elisabeth G.; Miao, Congrong; Haynes, Lia M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat Resp Dis, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA 30333 USA. [Haupt, Thomas E.] Wisconsin Div Publ Hlth DPH, Madison, WI 53701 USA. [Anderson, Larry J.] Emory Childrens Ctr, Div Pediat Infect Dis, Atlanta, GA 30329 USA. RP Haynes, LM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat Resp Dis, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, 1600 Clifton Rd NE,Mailstop G-18, Atlanta, GA 30333 USA. EM HZQ0@cdc.gov; bdu7@cdc.gov; Thomas.Haupt@dhs.wisconsin.gov; larry.anderson@emory.edu; loh5@cdc.gov FU Centers for Disease Control and Prevention FX This research was also supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy and CDC. The authors wish to thank Dr. Ann Falsey (Univ. of Rochester School of Medicine, Rochester, NY) for providing sera from patients with HCoV-229E and HCoV-OC43 infections. Thanks also to Dr. Suxiang Tong (CDC) for technical assistance with HCoV fragments and Dr. Dean Erdman (CDC) for the HCoV-OC43 virus stock. NR 23 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD OCT PY 2011 VL 177 IS 1 BP 100 EP 106 DI 10.1016/j.jviromet.2011.07.005 PG 7 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 823HL UT WOS:000295113000016 PM 21801752 ER PT J AU Tripp, K Perrine, CG de Campos, P Knieriemen, M Hartz, R Ali, F Jefferds, MED Kupka, R AF Tripp, Katie Perrine, Cria G. de Campos, Pascal Knieriemen, Marily Hartz, Rebecca Ali, Farah Jefferds, Maria Elena D. Kupka, Roland TI Formative research for the development of a market-based home fortification programme for young children in Niger SO MATERNAL AND CHILD NUTRITION LA English DT Article DE micronutrient powder; lipid-based nutrient supplement; Niger; undernutrition; formative; acceptability; market-based ID MICRONUTRIENT SPRINKLES; COMPLEMENTARY FOODS; HEALTH; UNDERNUTRITION; CONSEQUENCES; SUPPLEMENTS; GROWTH; TRIAL AB The objective of this formative research was to assess the acceptability of a micronutrient powder (Sprinkles (R)) and a lipid-based nutrient supplement (Nutributter (R)), and to explore people's willingness to pay for these products in a resource-poor context like Niger. In four sites, 84 focus group discussions among mothers, fathers and grandmothers of children 6-23 months were conducted, as well as 80 key informant interviews of mothers who participated in a home study where their children 6-23 months were given either Sprinkles (R) or Nutributter (R) to use either for a period of 4 weeks, or they were given both products over the 4-week period, i.e. Sprinkles (R) for 2 weeks and Nutributter (R) for an additional 2 weeks. The mothers understood how to use the products and generally used the products correctly. Both products were highly acceptable to adults and most children. In Niamey, where the 4-week home study used both products for 2 weeks each, the mothers tended to prefer Nutributter (R). The mothers who used either product were pleased with the improvements they saw in their children's health, including increased appetite, weight gain and increased energy and activity. A few mothers were concerned with how they would be able to provide for their child's increased appetite. Most participants across all four sites reported that they would be willing and able to afford to buy a single sachet of either Sprinkles (R) at a cost of US$0.03 or Nutributter (R) at a cost of US$0.08 several times a week. This study provides evidence that both of these products were are highly acceptable in different settings in Niger and suggests that delivery of Nutributter (R) or Sprinkles (R) at a low or subsidized cost through amarket-based system may be possible in Niger, if an appropriate distribution system can be identified. C1 [Tripp, Katie; Perrine, Cria G.; Hartz, Rebecca; Jefferds, Maria Elena D.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [de Campos, Pascal; Knieriemen, Marily] Helen Keller Int, Niger Country Off, Niamey, Niger. [Ali, Farah] UNICEF, Niger Country Off, Niamey, Niger. [Kupka, Roland] UNICEF, W & Cent Africa Reg Off, Dakar, Senegal. [Kupka, Roland] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. RP Tripp, K (reprint author), 4770 Buford Hwy NE,Mailstop K-25, Atlanta, GA 30306 USA. EM ktripp@cdc.gov FU Directorate of Nutrition at the Niger Ministry of Health FX This work was administered under a cooperative agreement between UNICEF and the Centers for Disease Control and Prevention with Helen Keller International as an implementing partner, and with support from the Directorate of Nutrition at the Niger Ministry of Health. NR 21 TC 14 Z9 14 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1740-8695 J9 MATERN CHILD NUTR JI Matern. Child Nutr. PD OCT PY 2011 VL 7 SU 3 SI SI BP 82 EP 95 DI 10.1111/j.1740-8709.2011.00352.x PG 14 WC Nutrition & Dietetics; Pediatrics SC Nutrition & Dietetics; Pediatrics GA 822NJ UT WOS:000295054800006 PM 21929637 ER PT J AU Goff, BA Miller, JW Matthews, B Trivers, KF Andrilla, CHA Lishner, DM Baldwin, LM AF Goff, Barbara A. Miller, Jacqueline W. Matthews, Barbara Trivers, Katrina F. Andrilla, C. Holly A. Lishner, Denise M. Baldwin, Laura-Mae TI Involvement of Gynecologic Oncologists in the Treatment of Patients With a Suspicious Ovarian Mass SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID CANCER; CARE; SPECIALTY; SURVIVAL; PATTERNS; OUTCOMES; SURGERY; QUALITY; VOLUME; RATES AB OBJECTIVE: To identify the factors associated with inclusion of a gynecologic oncologist in managing the care of a woman with suspected ovarian cancer. METHODS: A vignette-based survey was mailed to 3,200 physicians aged 64 and younger who were randomly sampled from family physician, general internist, and obstetrician-gynecologist (ob-gyn) lists from the American Medical Association Physician Masterfile. The vignette described a 57-year-old woman with pain, bloating, and a suspicious right adnexal mass with ascites. Using multivariable analysis we evaluated patient, physician, and practice characteristics associated with a self-reported referral or inclusion of a gynecologic oncologist in the patient's care. RESULTS: The response rate was 61.7%. After exclusions we included 569 ob-gyns, 591 family physicians, and 414 general internists. Gynecologic oncologist referral and consultation was self reported by 39.3% of family physicians and 51.0% of general internists (P=.01). Among ob-gyns, 33.7% indicated they would perform surgery and 66.3% recommended consultation or referral. Factors associated with not referring and consulting included patients having Medicaid insurance (family physicians), providers' weekly average number of patients being more than 91 (family physicians and general internists), male sex (family physicians), a rural practice location (general internists), and solo practice (general internists). Factors associated with primary surgical management for ob-gyns were small and remote rural practice locations and Census division. CONCLUSION: When presented with a patient with a suspicious ovarian mass, the majority of primary care physicians do not self-report direct referral to a gynecologic oncologist. This may contribute to the high rates of noncomprehensive surgery for ovarian cancer patients in the United States. (Obstet Gynecol 2011;118:854-62) DOI: 10.1097/AOG.0b013e31822dabc6 C1 [Goff, Barbara A.] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. Univ Washington, Dept Family Med, Seattle, WA 98195 USA. Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Goff, BA (reprint author), Univ Washington, Sch Med, Dept Obstet & Gynecol, Box 356460, Seattle, WA 98195 USA. EM bgoff@uw.edu FU Centers for Disease Control and Prevention (CDC) through the University of Washington Health Promotion Research Centers [U48DP001911]; Alliance for Reducing Cancer, Northwest (ARC NW); Centers for Disease Control and Prevention (CDC) [U48DP001911]; National Cancer Institute (NCI) FX Funded by the Centers for Disease Control and Prevention (CDC) through the University of Washington Health Promotion Research Centers Cooperative Agreement U48DP001911, and through the Alliance for Reducing Cancer, Northwest (ARC NW), funded by both the Centers for Disease Control and Prevention (CDC; Grant U48DP001911, V. Taylor, PI) and the National Cancer Institute (NCI). NR 25 TC 12 Z9 12 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2011 VL 118 IS 4 BP 854 EP 862 DI 10.1097/AOG.0b013e31822dabc6 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 823JJ UT WOS:000295118000013 PM 21934449 ER PT J AU Klevens, J Trick, WE Kee, R Angulo, F Garcia, D Sadowski, LS AF Klevens, Joanne Trick, William E. Kee, Romina Angulo, Francisco Garcia, Diana Sadowski, Laura S. TI Concordance in the measurement of quality of life and health indicators between two methods of computer-assisted interviews: self-administered and by telephone SO QUALITY OF LIFE RESEARCH LA English DT Article DE Assessment; Reliability; Quality of life; Disability ID CORRELATION-COEFFICIENT; CATEGORICAL-DATA; RISK BEHAVIORS; DRUG-USE; AGREEMENT; VIOLENCE; SCALES AB The aim of this study was to establish the concordance for quality of life (QOL), disability, and use of health service indicators between two modes of computer-assisted interviews: audio-computer-assisted self-interview (A-CASI) and computer-assisted telephone interview (CATI). High concordance between these modes of data collection would allow comparisons and interchangeable use in cross-sectional or longitudinal assessments. Adult English-speaking women (n = 126) were enrolled from women's health clinics at a public hospital. QOL using the short form 12 version 2, disability (days missed from work, inability to do household activities), and utilization of health services (number of emergency room visits and hospitalizations) were assessed first with A-CASI at the time of enrollment and again (n = 102) with CATI 1 week later. Participants assessed with both modes were 38 years old on average, predominantly African-American, 41% had a high school education or less, and 61% were uninsured. Lin's concordance correlation coefficient or Cohen's kappa was calculated to establish concordance between paired A-CASI and CATI assessments. Concordance between the two interview methods ranged from fair to substantial for the QOL components, (concordance correlation coefficient [CCC] of .76 and .87, respectively), the QOL subscales, and disability indices (CCC range; .53-.91). For health services utilization, there was moderate concordance for emergency room visits (CCC = .70) but only slight concordance for the number of hospitalizations in the past year (CCC = .37). Administering surveys through a telephone or self-administered computer-assisted interview resulted in moderate to substantial agreement for the short form QOL components and fair to substantial for the QOL subscales and disability measures. These findings suggest A-CASI and CATI can be used interchangeably for some QOL scales. C1 [Klevens, Joanne] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. [Trick, William E.; Kee, Romina; Angulo, Francisco; Garcia, Diana; Sadowski, Laura S.] John H Stroger Hosp, Collaborat Res Unit, Chicago, IL USA. RP Klevens, J (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Hwy,Mailstop F-63, Atlanta, GA 30333 USA. EM jklevens@cdc.gov FU Center for Disease Control; Center for Disease Prevention FX This study was funded by the Centers for Disease Control and Prevention. We are grateful to Celia Almazan, Jennifer Nowicki, and Katherine Jorgenson (research field staff), to Stephanie Love Patterson (Executive Director of the Hospital Crisis Intervention Project), to Dr. Ashleisha Patel (Director of Reproductive Health Services, Department of Obstetrics & Gynecology), and to Jim Martindale (CDC Project Officer), for their valuable collaboration. NR 22 TC 3 Z9 3 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD OCT PY 2011 VL 20 IS 8 BP 1179 EP 1186 DI 10.1007/s11136-011-9862-2 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 823PY UT WOS:000295136500003 PM 21318647 ER PT J AU Mukanga, D Babirye, R Peterson, S Pariyo, GW Ojiambo, G Tibenderana, JK Nsubuga, P Kallander, K AF Mukanga, D. Babirye, R. Peterson, S. Pariyo, G. W. Ojiambo, G. Tibenderana, J. K. Nsubuga, P. Kallander, K. TI Can lay community health workers be trained to use diagnostics to distinguish and treat malaria and pneumonia in children? Lessons from rural Uganda SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE community health worker; performance; integrated community case management for malaria and pneumonia; diagnostics; rapid diagnostic test; respiratory rate timer; Uganda ID HOME-BASED MANAGEMENT; INTEGRATED MANAGEMENT; COMBINATION THERAPY; BRAZILIAN AMAZON; RANDOMIZED-TRIAL; CARE FACILITIES; BURKINA-FASO; UNDER-FIVES; QUALITY; ILLNESS AB OBJECTIVE To determine the competence of community health workers (CHWs) to correctly assess, classify and treat malaria and pneumonia among under-five children after training. METHODS Consultations of 182 under-fives by 14 CHWs in Iganga district, Uganda, were observed using standardised checklists. Each CHW saw 13 febrile children. Two paediatricians observed CHWs' assessment, classification and prescription of treatment, while a laboratory scientist assessed CHW use of malaria rapid diagnostic tests (RDTs). The validity of CHWs' use of RDTs to detect malaria and respiratory timers to diagnose pneumonia was estimated using a laboratory scientist's RDT repeat reading and a paediatrician's repeat count of the respiratory rate, respectively. RESULTS From the 182 consultations, overall CHWs' performance was adequate in taking history (97%), use (following procedures prior to reading result) of timers (96%) and use of RDTs (96%), but inadequate in classification (87%). Breath readings (classified as fast or normal) were 85% in agreement with the paediatrician (kappa = 0.665, P < 0.001). All RDT readings were in agreement with those obtained by the laboratory scientist. Ninety-six per cent (85/89) of children with a positive RDT were prescribed an antimalarial drug, 40% (4/10) with fast breathing (gold standard) were prescribed an antibiotic and 91% (48/53) with both were prescribed both medicines. CONCLUSION Community health workers can be trained to use RDTs and timers to assess and manage malaria and pneumonia in children. We recommend integration of these diagnostics into community case management of fever. CHWs require enhanced practice in counting respiratory rates and simple job aides to enable them make a classification without thinking deeply about several assessment results. C1 [Mukanga, D.; Kallander, K.] Makerere Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Kampala, Uganda. [Mukanga, D.; Peterson, S.; Kallander, K.] Karolinska Inst, Dept Publ Hlth Sci, Div Global Hlth, Stockholm, Sweden. [Mukanga, D.; Babirye, R.; Ojiambo, G.] African Field Epidemiol Network, Kampala, Uganda. [Peterson, S.] Uppsala Univ, Int Maternal & Child Hlth Unit, Uppsala, Sweden. [Peterson, S.; Pariyo, G. W.] Makerere Univ, Sch Publ Hlth, Dept Hlth Policy Planning & Management, Kampala, Uganda. [Tibenderana, J. K.; Kallander, K.] Malaria Consortium Africa, Kampala, Uganda. [Nsubuga, P.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Mukanga, D (reprint author), Makerere Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, POB 7072, Kampala, Uganda. EM dmukanga@afenet.net OI Pariyo, George/0000-0002-4411-2309; Kallander, Karin/0000-0002-5778-5780 FU UNICEF/UNDP/World Bank/WHO; Division for International Development DfID; Malaria Consortium; Ministry of Health Uganda FX This study received financial support from UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR), and two separate grants from the Division for International Development DfID to the Makerere University School of Public Health (DeLPHE) and the Malaria Consortium. Its contents are solely the responsibility of the authors and do not reflect the views of TDR, DfID or the authors' institutions of affiliation. We thank in a special way Dr Franco Pagnoni of TDR for his invaluable support and guidance. The study participants, the community health workers, the three trainers, two paediatricians, laboratory scientists, health workers at the three health facilities used for this study, the health facility incharges, Iganga district, local council officials and Ministry of Health Uganda are all acknowledged for their support and contribution. NR 45 TC 45 Z9 45 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2011 VL 16 IS 10 BP 1234 EP 1242 DI 10.1111/j.1365-3156.2011.02831.x PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 822MN UT WOS:000295052000005 PM 21752163 ER PT J AU Ma, Q AF Ma, Qiang TI Influence of light on aryl hydrocarbon receptor signaling and consequences in drug metabolism, physiology and disease SO EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY LA English DT Review DE AH receptor; AHR ligand; CYP1A1 induction; FICZ; tryptophan photoreaction; UV response ID REGULATORY T-CELLS; CYP1A1 GENE-EXPRESSION; NF-KAPPA-B; PROTEIN-TYROSINE PHOSPHATASES; HEMATOPOIETIC STEM-CELLS; MESSENGER-RNA EXPRESSION; GROWTH-FACTOR RECEPTOR; DNA ADDUCT FORMATION; AH-RECEPTOR; IN-VIVO AB Introduction: A key to understanding the biological function(s) of the aryl hydrocarbon receptor (AHR) - a xenobiotic-activated receptor - is to identify its endogenous ligand(s). The discovery of a tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) as an endogenous, high affinity agonist of AHR filled this knowledge gap in the context of skin physiology and pathology in response to light and opened several new directions for research on AHR. Area covered: This paper reviews major developments in the study of light-elicited AHR signaling and its impact on drug metabolism, skin physiology and disease with a focus on the identification of AHR ligands from Trp photoproducts and the AHR-mediated UV response. This review consists of material obtained from Medline and PubMed literature searches up to May 2011. Expert opinion: The recognition of FICZ as a potent, endogenous ligand of AHR provided a molecular link between light exposure and AHR signaling and function. The uncovering of the bifurcated signaling pathway of AHR in the mammalian UV response - that is, activation of the cytoplasmic AHR by light via FICZ leads to: i) AHR/AH response element-dependent transcription to induce CYP1A1 and ii) activation of the AHR-pp60(src)-EGFR pathway to induce Cox-2 - put forward a working model for the multiple roles of AHR in skin function and disease that include drug metabolism, circadian oscillation, melanogenesis, inflammation, immunosuppression and cancer. Such findings suggest AHR as a therapeutic target for cancer, autoimmune dysfunction, inflammatory disease and stem cell therapy. C1 Ctr Dis Control & Prevent, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,NIOSH, Morgantown, WV 26505 USA. RP Ma, Q (reprint author), Ctr Dis Control & Prevent, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,NIOSH, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM qam1@cdc.gov FU National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention FX This research was supported by the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. The author declares no other conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 181 TC 23 Z9 24 U1 1 U2 18 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1742-5255 J9 EXPERT OPIN DRUG MET JI Expert Opin. Drug Metab. Toxicol. PD OCT PY 2011 VL 7 IS 10 BP 1267 EP 1293 DI 10.1517/17425255.2011.614947 PG 27 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 821IB UT WOS:000294967200006 PM 21883026 ER PT J AU Wallace, SA McLellan-Lemal, E Harris, MJ Townsend, TG Miller, KS AF Wallace, Scyatta A. McLellan-Lemal, Eleanor Harris, Muriel J. Townsend, Tiffany G. Miller, Kim S. TI Why Take an HIV Test? Concerns, Benefits, and Strategies to Promote HIV Testing Among Low-Income Heterosexual African American Young Adults SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE HIV testing; young adult; African American ID UNITED-STATES; INFECTION; RISK AB A qualitative study examined perceptions of HIV testing and strategies to enhance HIV testing among HIV-negative African American heterosexual young adults (ages 18-25 years). Twenty-six focus groups (13 male groups, 13 female groups) were conducted in two low-income communities (urban and rural). All sessions were audio-recorded and transcribed. Data analysis was completed using AnSWR software. Many participants expressed that learning one's HIV status, regardless of the result, was a benefit of taking an HIV test because this was perceived to produce emotional relief. Additional benefits included the avoidance of unknowingly spreading the virus, being offered treatment access if HIV-positive, and taking time to assess and modify risky sexual behaviors if HIV-negative. If diagnosed HIV-positive, HIV testing concerns included the recognition of one's mortality, the experience of social stigma, and concerns about accessing affordable treatment. Recommended promotion strategies included the use of HIV-positive individuals, pop culture icons, and the media to promote HIV testing messages. C1 [Wallace, Scyatta A.; McLellan-Lemal, Eleanor; Miller, Kim S.] US Ctr Dis Control & Prevent, Epidemiol Branch, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STID & TB Prevent, Atlanta, GA USA. [Harris, Muriel J.] Univ S Carolina, Columbia, SC 29208 USA. [Townsend, Tiffany G.] Penn State Univ, University Pk, PA 16802 USA. RP Wallace, SA (reprint author), 8000 Utopia Pkwy, Queens, NY 11439 USA. EM wallaces@stjohns.edu OI McLellan-Lemal, Eleanor/0000-0002-1884-9315 FU PHS HHS [200-2003-03090] NR 35 TC 9 Z9 9 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD OCT PY 2011 VL 38 IS 5 BP 462 EP 470 DI 10.1177/1090198110382501 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 822EJ UT WOS:000295026400005 PM 21464204 ER PT J AU Dotson, GS Chen, CP Gadagbui, B Maier, A Ahlers, HW Lentz, TJ AF Dotson, G. Scott Chen, Chen-Peng Gadagbui, Bernard Maier, Andrew Ahlers, Heinz W. Lentz, Thomas J. TI The evolution of skin notations for occupational risk assessment: A new NIOSH strategy SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Skin notations; Skin; Chemicals; Occupational; Hazard characterization; Risk assessment ID DERMAL EXPOSURE LIMITS; ACRYLAMIDE; CRITERIA; WORKERS; ENVIRONMENTS; CHEMICALS; WORKSHOP; PROPOSAL; MOUSE; MICE AB This article presents an overview of a strategy for assignment of hazard-specific skin notations (SK), developed by the National Institute for Occupational Safety and Health (NIOSH). This health hazard characterization strategy relies on multiple SKs capable of delineating systemic (SYS), direct (DIR), and immune-mediated (SEN) adverse effects caused by dermal exposures to chemicals. One advantage of the NIOSH strategy is the ability to combine SKs when it is determined that a chemical may cause multiple adverse effects following dermal contact (e.g., SK: SYS-DIR-SEN). Assignment of the SKs is based on a weight-of-evidence (WOE) approach, which refers to the critical examination of all available data from diverse lines of evidence and the derivation of a scientific interpretation based on the collective body of data including its relevance, quality, and reported results. Numeric cutoff values, based on indices of toxic potency, serve as guidelines to aid in consistently determining a chemical's relative toxicity and hazard potential. The NIOSH strategy documents the scientific rationale for determination of the hazard potential of a chemical and the subsequent assignment of SKs. A case study of acrylamide is presented as an application of the NIOSH strategy. Published by Elsevier Inc. C1 [Dotson, G. Scott; Lentz, Thomas J.] Ctr Dis Control & Prevent CDC, NIOSH, EID, Cincinnati, OH 45227 USA. [Chen, Chen-Peng] China Med Univ, Coll Publ Hlth, Dept Occupat Safety & Hlth, Taichung, Taiwan. [Gadagbui, Bernard; Maier, Andrew] TERA, Cincinnati, OH USA. [Ahlers, Heinz W.] CDC, NIOSH, NPPTL, Pittsburgh, PA USA. RP Dotson, GS (reprint author), Ctr Dis Control & Prevent CDC, NIOSH, EID, 4676 Columbia Pkwy,MS C32, Cincinnati, OH 45227 USA. EM fya8@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH) FX The authors declare that there are no conflicts of interest. This project was funded by the National Institute for Occupational Safety and Health (NIOSH). NR 59 TC 1 Z9 1 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD OCT PY 2011 VL 61 IS 1 BP 53 EP 62 DI 10.1016/j.yrtph.2011.06.002 PG 10 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA 820WO UT WOS:000294937000007 PM 21689711 ER PT J AU Chen, CP Ahlers, HW Dotson, GS Lin, YC Chang, WC Maier, A Gadagbui, B AF Chen, Chen-Peng Ahlers, Heinz W. Dotson, G. Scott Lin, Yi-Chun Chang, Wei-Chen Maier, Andrew Gadagbui, Bernard TI Efficacy of predictive modeling as a scientific criterion in dermal hazard identification for assignment of skin notations SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Occupational skin exposure; Skin notation; Hazard characterization; Predictive modeling; Dermal lethal dose 50%; Octanol-water partition coefficient; Globally Harmonized System of; Classification and Labeling of Chemicals; Hazard ranking ID ABSORPTION; CHEMICALS; EXPOSURE AB Skin notations (SNs) represent a hazard characterization tool for alerting workers of health hazards associated with dermal contact with chemicals. This study evaluated the efficacy of a predictive model utilized by the National Institute for Occupational Safety and Health to identify dermal hazards based on potential of systemic absorption compared to hazard assignments based on dermal lethal dose 50% or logarithm of octanol-water partition coefficient. A total of 480 chemicals assigned an SN from at least one of seven institutes were selected and partitioned into seven hazard categories by frequency of SN assignment to provide a basis of evaluation for the predictivity of the examined criteria. We find that all three properties serve as a qualitative indicator in support of a dichotomous decision on dermal hazard; the predictive modeling was identified from a multiple regression analysis as the most significant indicator. The model generated estimates that corresponded to anticipated hazard potentials, suggesting a role of the model to further serve as a hazard-ranking tool. The hazard-ranking capability of the model was consistent with the scheme of acute toxicity classification in the Globally Harmonized System of Classification and Labeling of Chemicals. (C) 2011 Elsevier Inc. All rights reserved. C1 [Chen, Chen-Peng; Lin, Yi-Chun; Chang, Wei-Chen] China Med Univ, Dept Occupat Safety & Hlth, Taichung 40402, Taiwan. [Ahlers, Heinz W.] Ctr Dis Control & Prevent, NIOSH, Natl Personal Protect Technol Lab, Pittsburgh, PA 15236 USA. [Dotson, G. Scott] Ctr Dis Control & Prevent, NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Maier, Andrew; Gadagbui, Bernard] Toxicol Excellence Risk Assessment, Cincinnati, OH 45211 USA. RP Chen, CP (reprint author), China Med Univ, Dept Occupat Safety & Hlth, 91 Hsueh Shih Rd, Taichung 40402, Taiwan. EM chencp@mail.cmu.edu.tw FU National Science Council, Taiwan, ROC [NSC 96-2221-E-039-003-MY2]; China Medical University [CMU95-183] FX The authors are grateful to the assistance of the following individuals: Mr. Chieh-Ming Wu of the China Medical University for assistance in statistical analysis; Drs. Frederick Frasch and Matthew Wheeler of the NIOSH; Dr. Youcheng Liu of the University of North Texas Health Science Center; and Ms. Jennifer Sahmel of the ChemRisk, LLC, for providing technical comments; and Dr. Cathy Rotunda of the NIOSH for editorial review. The funding for this study was supported by the National Science Council, Taiwan, ROC, under project number NSC 96-2221-E-039-003-MY2 and by the China Medical University under number CMU95-183. The funding sources were not involved in the study design, the collection, analysis and interpretation of data, the writing of report, or the decision to submit the paper for publication. NR 36 TC 3 Z9 3 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD OCT PY 2011 VL 61 IS 1 BP 63 EP 72 DI 10.1016/j.yrtph.2011.05.013 PG 10 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA 820WO UT WOS:000294937000008 PM 21712060 ER PT J AU Chesson, HW Gift, TL Owusu-Edusei, K Tao, GY Johnson, AP Kent, CK AF Chesson, Harrell W. Gift, Thomas L. Owusu-Edusei, Kwame, Jr. Tao, Guoyu Johnson, Ana P. Kent, Charlotte K. TI A Brief Review of the Estimated Economic Burden of Sexually Transmitted Diseases in the United States: Inflation-Adjusted Updates of Previously Published Cost Studies SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID INSURED POPULATION; AMERICAN YOUTH; MEDICAL COST; PREVALENCE; SEROPREVALENCE; INFECTIONS; HIV; HEALTH; TYPE-2; WOMEN AB We conducted a literature review of studies of the economic burden of sexually transmitted diseases in the United States. The annual direct medical cost of sexually transmitted diseases (including human immunodeficiency virus) has been estimated to be $16.9 billion (range: $13.9-$23.0 billion) in 2010 US dollars. C1 [Chesson, Harrell W.; Gift, Thomas L.; Owusu-Edusei, Kwame, Jr.; Tao, Guoyu; Kent, Charlotte K.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Johnson, Ana P.] Queens Univ, Kingston, ON, Canada. RP Chesson, HW (reprint author), CDC, 1600 Clifton Rd,Mailstop E-80, Atlanta, GA 30333 USA. EM hbc7@cdc.gov FU Canada Research Chairs Program FX The authors acknowledge funding from the Canada Research Chairs Program for Ana P. Johnson. NR 27 TC 21 Z9 21 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2011 VL 38 IS 10 BP 889 EP 891 DI 10.1097/OLQ.0b013e318223be77 PG 3 WC Infectious Diseases SC Infectious Diseases GA 821RS UT WOS:000294992700001 PM 21934557 ER PT J AU Gallo, MF Sobel, JD Rompalo, AM Cu-Uvin, S Schoenbaum, E Jamieson, DJ AF Gallo, Maria F. Sobel, Jack D. Rompalo, Anne M. Cu-Uvin, Susan Schoenbaum, Ellie Jamieson, Denise J. TI Discordance Between Spermatozoa Detection and Self-Reported Semen Exposure SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; PROSTATE-SPECIFIC ANTIGEN; CONDOM USE; BEHAVIORAL INTERVENTIONS; DEVELOPING-COUNTRIES; YOUNG-ADOLESCENTS; INDIVIDUAL-LEVEL; CONTROLLED-TRIAL; HIV-INFECTION; SEX WORKERS AB An analysis of data from a prospective study of 1257 high-risk women revealed 7 predictors of discordance between self-reported lack of recent exposure to semen and detection of spermatozoa on Gram stain, suggesting that inaccuracies in the reporting of sexual behaviors cannot be assumed to be distributed randomly. C1 [Gallo, Maria F.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Sobel, Jack D.] Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA. [Rompalo, Anne M.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Cu-Uvin, Susan] Brown Univ, Miriam Hosp, Providence, RI USA. [Schoenbaum, Ellie] Albert Einstein Coll Med, Einstein Montefiore Inst Clin & Translat Res, Bronx, NY 10467 USA. RP Gallo, MF (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,Mail Stop K-34, Atlanta, GA 30341 USA. EM mgallo@cdc.gov FU Centers for Disease Control and Prevention [U64/CCU106795, U64/CCU206798, U64/CCU306802, U64/CCU506831] FX Supported by Centers for Disease Control and Prevention cooperative agreement numbers U64/CCU106795, U64/CCU206798, U64/CCU306802, and U64/CCU506831. NR 34 TC 10 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2011 VL 38 IS 10 BP 909 EP 912 DI 10.1097/OLQ.0b013e318223be4b PG 4 WC Infectious Diseases SC Infectious Diseases GA 821RS UT WOS:000294992700006 PM 21934562 ER PT J AU Yu, YY Frasure-Williams, JA Dunne, EF Bolan, G Markowitz, L Bauer, HM AF Yu, Ying-Ying Frasure-Williams, Jessica A. Dunne, Eileen F. Bolan, Gail Markowitz, Lauri Bauer, Heidi M. TI Chlamydia Partner Services for Females in California Family Planning Clinics SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; RANDOMIZED CONTROLLED-TRIAL; TRICHOMONAS-VAGINALIS; TRACHOMATIS INFECTION; RECURRENT; WOMEN; GONORRHEA; NOTIFICATION; PERSISTENT; THERAPY AB Background: Prompt treatment of exposed partners is critical for preventing further transmission of chlamydia, reinfection, and sequelae among females. Patient-delivered partner therapy (PDPT) has been allowable in California since 2001; however, few data are available regarding PDPT use and treatment outcomes. Methods: Eight family planning clinics participated in a partner services evaluation from 2005 to 2006. Females aged 16 to 35 years with chlamydia were interviewed to determine the partner service received and partner treatment outcomes; a subset of partners was also interviewed. Determinants of reported partner treatment were assessed using multivariate logistic regression. Selected medical records were reviewed to assess reinfection rates. Results: Overall, 743 female patients disclosed 952 partners; 58% of whom were identified as steady partners. Reported partner services included concurrent patient-partner treatment visits (15% of partners), PDPT (19%), patient referral (55%), health department referral (0.1%), and no partner management (11%). On the basis of patient report, 82% of partners were notified and 54% received treatment. Of the 166 (17%) partners interviewed, 139 (84%) reported that they had received treatment, which correlated well with patient report. Reported partner treatment was higher for concurrent treatment visits and PDPT (79% and 80%, respectively) compared to patient referral (44%, P < 0.0001). Adjusted for clinic and relationship status, partners managed with concurrent treatment visits or PDPT were more likely to receive treatment compared with partners managed with patient referral (adjusted odds ratios, 3.5; 95% confidence interval, 2.1-5.8 and adjusted odds ratios, 4.3; 95% confidence interval, 2.6-7.2, respectively). Among the patients retested within 6 months after treatment, 18% were reinfected; reinfection rates did not differ by type of partner service. Conclusions: Although overall rates of reported partner treatment were low, concurrent patient-partner treatment visits and PDPT were associated with significantly higher rates of partner treatment. However, these methods may be underutilized in California family planning settings. C1 [Yu, Ying-Ying; Frasure-Williams, Jessica A.; Bolan, Gail; Bauer, Heidi M.] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, STD Control Branch, Richmond, CA 94804 USA. [Yu, Ying-Ying] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv Program, Field Assignments Branch, Off Workforce & Career Dev, Atlanta, GA USA. [Dunne, Eileen F.; Markowitz, Lauri] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Bauer, HM (reprint author), Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, STD Control Branch, 850 Marina Bay Pkwy,Bldg P,2nd Floor, Richmond, CA 94804 USA. EM heidi.bauer@cdph.ca.gov FU Centers for Disease Control and Prevention through the Office of Women's Health [H25/CCH904362-13-05]; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention FX Supported by funds from the Centers for Disease Control and Prevention, Cooperative Agreement (H25/CCH904362-13-05), through the Office of Women's Health and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. NR 28 TC 14 Z9 14 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2011 VL 38 IS 10 BP 913 EP 918 DI 10.1097/OLQ.0b013e3182240366 PG 6 WC Infectious Diseases SC Infectious Diseases GA 821RS UT WOS:000294992700007 PM 21934563 ER PT J AU Anderson, JE Warner, L Macaluso, M AF Anderson, John E. Warner, Lee Macaluso, Maurizio TI Condom Use Among US Adults at Last Sexual Intercourse, 1996-2008: An Update From National Survey Data SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HIV RISK AB The prevalence of condom use at last intercourse, estimated from questions added to a national survey, was estimated to be 20.2%. Use of condom was significantly higher for sex outside ongoing relationships and among those with 2 or more past-year sex partners and its use increased slightly but significantly from 1996 to 2008. C1 [Anderson, John E.; Warner, Lee; Macaluso, Maurizio] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Anderson, JE (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,Mailstop E-34, Atlanta, GA 30341 USA. EM Jea1@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 13 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2011 VL 38 IS 10 BP 919 EP 921 DI 10.1097/OLQ.0b013e31822545d9 PG 3 WC Infectious Diseases SC Infectious Diseases GA 821RS UT WOS:000294992700008 PM 21934564 ER PT J AU Taylor, MM Reilley, B Tulloch, S Winscott, M Dunnigan, A Russell, M Redd, JT AF Taylor, Melanie M. Reilley, Brigg Tulloch, Scott Winscott, Michelle Dunnigan, Anthony Russell, Marie Redd, John T. TI Identifying Opportunities for Chlamydia Screening Among American Indian Women SO SEXUALLY TRANSMITTED DISEASES LA English DT Article AB Medical record review was used to identify missed opportunities for chlamydia screening among 103 American Indian/Alaska Native women. Of these, 69% had received a pregnancy test and 74% had received a urine test in the previous 12 months. Chlamydia screening may increase if linked to the other routine clinical testing. C1 [Taylor, Melanie M.; Tulloch, Scott] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, Melanie M.; Tulloch, Scott; Redd, John T.] Indian Hlth Serv, Natl STD Program, Albuquerque, NM USA. [Taylor, Melanie M.; Winscott, Michelle] Arizona Dept Hlth Serv, STD Control Program, Phoenix, AZ 85007 USA. [Reilley, Brigg] Indian Hlth Serv, Div Epidemiol, Albuquerque, NM USA. [Dunnigan, Anthony; Russell, Marie] Phoenix Indian Med Ctr, Indian Hlth Serv, Phoenix, AZ USA. RP Taylor, MM (reprint author), CDC, NCHHSTP, DSTDP, Maricopa Dept Publ Hlth, 1645 E Roosevelt, Phoenix, AZ 85006 USA. EM MDT7@cdc.gov NR 10 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2011 VL 38 IS 10 BP 947 EP 948 DI 10.1097/OLQ.0b013e318222f126 PG 2 WC Infectious Diseases SC Infectious Diseases GA 821RS UT WOS:000294992700014 PM 21934570 ER PT J AU Owusu-Edusei, K Doshi, SR AF Owusu-Edusei, Kwame, Jr. Doshi, Sonal R. TI County-Level Sexually Transmitted Disease Detection and Control in Texas: Do Sexually Transmitted Diseases and Family Planning Clinics Matter? SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SPATIAL DATA-ANALYSIS; MANAGED CARE; HEALTH-CARE; GONORRHEA; SYPHILIS; CHLAMYDIA; IMPACT; RATES; STATE AB Background: Sexually transmitted disease (STD) detection and control have traditionally been performed by STD and family planning (FP) clinics. However, the magnitude of their impact (or the lack thereof) has not been examined. We examine the association between having STD and/or FP clinics and county-level STD detection and control in the state of Texas. Methods: We used county-level STD (chlamydia, gonorrhea, and primary and secondary syphilis) morbidity data from the National Electronic Telecommunications System for Surveillance for 2000 and 2007. We applied spatial regression techniques to examine the impact of the presence of STD/FP clinic(s) (included as dichotomous variables) on STD detection (i.e., morbidity) and control. We included county-level demographic characteristics as control variables. Results: Our results indicated that counties with STD or FP clinics were associated with at least 8% (P < 0.05) increase in the transformed chlamydia and gonorrhea rates, 20% (P < 0.01) increase in transformed syphilis rates in 2000, and at least 6% (P < 0.05) increase in transformed gonorrhea and Chlamydia rates in 2007. From 2000 to 2007, the transformed incidence rates of chlamydia declined by 4% (P < 0.10), 8% (P < 0.01) for gonorrhea, and 8% (P < 0.05) for primary and secondary syphilis for the counties that had at least 1 STD or FP clinic. Conclusions: The results from this ecological study are associations and do not establish a causal relationship between having an STD/FP clinic and improved STD detection and control. Finer level analyses (such as census block or cities) may be able to provide more detail information. C1 [Owusu-Edusei, Kwame, Jr.; Doshi, Sonal R.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 30 TC 5 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2011 VL 38 IS 10 BP 970 EP 975 DI 10.1097/OLQ.0b013e3182215615 PG 6 WC Infectious Diseases SC Infectious Diseases GA 821RS UT WOS:000294992700019 PM 21934575 ER PT J AU Bosserman, EA Helms, DJ Mosure, DJ Secor, WE Workowski, KA AF Bosserman, Elizabeth A. Helms, Donna J. Mosure, Debra J. Secor, W. Evan Workowski, Kimberly A. TI Utility of Antimicrobial Susceptibility Testing in Trichomonas vaginalis-Infected Women With Clinical Treatment Failure SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; UNITED-STATES; METRONIDAZOLE; RESISTANT; PREVALENCE; TINIDAZOLE AB Background: Antimicrobial resistance is one of the causes of treatment failure in women after standard nitroimidazole therapy for Trichomonas vaginalis infections. The Centers for Disease Control and Prevention provides drug susceptibility testing and guidance for treatment failures but the efficacy of the alternate recommendations has not been assessed. Methods: T. vaginalis isolates from women who had failed at least 2 courses of standard therapy for trichomoniasis were submitted to the Centers for Disease Control and Prevention for susceptibility testing. Alternative treatment recommendations were provided based on in vitro drug susceptibility results and clinical outcomes were collected. Results: Drug susceptibility results were available for 175 women tested between January 2002 and January 2008. In vitro, 115 of the 175 isolates demonstrated metronidazole resistance. For all isolates resistant to metronidazole, in vitro resistance to tinidazole was similar or lower. Clinical treatment outcomes were available for 72 women. Of the women receiving an alternative recommended nitroimidazole regimen, 30 (83%) of 36 were cured compared with 8 (57%) of 14 women who received a lower dose than recommended. Clinical and microbiologic success was attained in 59 (82%) of 72 women whose follow-up information was available, with some women requiring multiple treatment courses. Conclusions: Clinical and microbiologic cure rates were higher for women who were treated in accordance with the recommendation provided after in vitro testing compared with those who received a lower dose or a different drug. Susceptibility testing leading to tailored treatment may have a beneficial role for management of women with persistent trichomoniasis. C1 [Bosserman, Elizabeth A.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. [Bosserman, Elizabeth A.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Workowski, Kimberly A.] Emory Univ, Div Infect Dis, Atlanta, GA 30322 USA. RP Bosserman, EA (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 4770 Buford Hwy NE,MS-F22, Atlanta, GA 30341 USA. EM ebosserman@cdc.gov NR 29 TC 18 Z9 19 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2011 VL 38 IS 10 BP 983 EP 987 DI 10.1097/OLQ.0b013e318224db39 PG 5 WC Infectious Diseases SC Infectious Diseases GA 821RS UT WOS:000294992700021 PM 21934577 ER PT J AU Galbraith, JS Herbst, JH Whittier, DK Jones, PL Smith, BD Uhl, G Fisher, HH AF Galbraith, Jennifer S. Herbst, Jeffrey H. Whittier, David K. Jones, Patricia L. Smith, Bryce D. Uhl, Gary Fisher, Holly H. TI Taxonomy for strengthening the identification of core elements for evidence-based behavioral interventions for HIV/AIDS prevention SO HEALTH EDUCATION RESEARCH LA English DT Article ID SEXUAL RISK BEHAVIOR; SELF-EFFICACY; PROGRAM IMPLEMENTATION; METAANALYTIC EVIDENCE; ABUSE PREVENTION; UNITED-STATES; DRUG-ABUSE; HIV; POPULATIONS; DIFFUSION AB The concept of core elements was developed to denote characteristics of an intervention, such as activities or delivery methods, presumed to be responsible for the efficacy of evidence-based behavioral interventions (EBIs) for HIV/AIDS prevention. This paper describes the development of a taxonomy of core elements based on a literature review of theoretical approaches and characteristics of EBIs. Sixty-one categories of core elements were identified from the literature and grouped into three distinct domains: implementation, content and pedagogy. The taxonomy was tested by categorizing core elements from 20 HIV prevention EBIs disseminated by Centers for Disease Control and Prevention. Results indicated that core elements represented all three domains but several were difficult to operationalize due to vague language or the inclusion of numerous activities or constructs. A process is proposed to describe core elements in a method that overcomes some of these challenges. The taxonomy of core elements can be used to identify core elements of EBIs, strengthen the translation of EBIs from research to practice and guide future research seeking to identify essential core elements in prevention interventions. C1 [Galbraith, Jennifer S.; Herbst, Jeffrey H.; Whittier, David K.; Jones, Patricia L.; Smith, Bryce D.; Uhl, Gary; Fisher, Holly H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Galbraith, JS (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM jgalbraith@cdc.gov NR 60 TC 16 Z9 16 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1153 J9 HEALTH EDUC RES JI Health Educ. Res. PD OCT PY 2011 VL 26 IS 5 BP 872 EP 885 DI 10.1093/her/cyr030 PG 14 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 819FB UT WOS:000294809700010 PM 21536712 ER PT J AU Morata, TC Sliwinska-Kowalska, M Johnson, AC Starck, J Pawlas, K Zamyslowska-Szmytke, E Nylen, P Toppila, E Krieg, E Pawlas, N Prasher, D AF Morata, Thais C. Sliwinska-Kowalska, Mariola Johnson, Ann-Christin Starck, Jukka Pawlas, Krystyna Zamyslowska-Szmytke, Ewa Nylen, Per Toppila, Esko Krieg, Edward Pawlas, Natalia Prasher, Deepak TI A multicenter study on the audiometric findings of styrene-exposed workers SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article DE Pure-tone audiometry; Otologically unscreened; Noise; Hearing loss ID HEARING THRESHOLD LEVELS; ORGANIC-SOLVENTS; OCCUPATIONAL EXPOSURE; GENDER-DIFFERENCES; UPPER LIMIT; NOISE; OTOTOXICITY; TOLUENE; PROTECTION; HEALTH AB Objective: The objective of this study was to evaluate hearing loss among workers exposed to styrene, alone or with noise. Design: This cross-sectional study was conducted as part of NoiseChem, a European Commission 5th Framework Programme research project, by occupational health institutes in Finland, Sweden, and Poland. Study sample: Participants' ages ranged from 18-72 years (n = 1620 workers). Participants exposed to styrene, alone or with noise, were from reinforced fiberglass products manufacturing plants (n = 862). Comparison groups were comprised of workers noise-exposed (n = 400) or controls (n = 358). Current styrene exposures ranged from 0 to 309 mg/m(3), while mean current noise levels ranged from 70-84 dB(A). Hearing thresholds of styrene-exposed participants were compared with Annexes A and B from ANSI S3.44, 1996. Results: The audiometric thresholds of styrene exposed workers were significantly poorer than those in published standards. Age, gender, and styrene exposure met the significance level criterion in the multiple logistic regression for the binary outcome 'hearing loss' (P = 0.0000). Exposure to noise (<85 dBA p = 0.0001; >= 85 dB(A) p = 0.0192) interacted significantly with styrene exposure. Conclusions: Occupational exposure to styrene is a risk factor for hearing loss, and styrene-exposed workers should be included in hearing loss prevention programs. C1 [Morata, Thais C.; Krieg, Edward] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Sliwinska-Kowalska, Mariola; Zamyslowska-Szmytke, Ewa] Nofer Inst Occupat Med, Dept Audiol & Phoniatr, Lodz, Poland. [Johnson, Ann-Christin] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden. [Starck, Jukka; Toppila, Esko] Finnish Inst Occupat Hlth, Dept Phys Hazards, Helsinki, Finland. [Pawlas, Krystyna] Inst Occupat Med & Environm Hlth, Dept Phys Agents, Sosnowiec, Poland. [Nylen, Per] Natl Inst Working Life, Dept Neuromed, Solna, Sweden. [Pawlas, Natalia] Inst Occupat Med & Environm Hlth, Dept Chem Hazards & Genet Toxicol, Sosnowiec, Poland. [Prasher, Deepak] Royal Surrey Cty Hosp, Dept Audiol, Guildford, Surrey, England. RP Morata, TC (reprint author), NIOSH, Div Appl Res & Technol, 4676 Columbia Pkwy,C27, Cincinnati, OH 45226 USA. EM tmorata@cdc.gov RI Sliwinska-Kowalska, Mariola/F-6119-2010; Zamyslowska-Szmytke, Ewa/G-3696-2010; Pawlas, Natalia/H-5796-2013 OI Sliwinska-Kowalska, Mariola/0000-0001-7569-3882; FU EU [QLK4-CT-2000-00293]; Swedish Council for Working Life and Social Research [2006-1526]; US National Institute for Occupational Safety and Health [0009736801] FX This paper is dedicated to the memory of Dr. Derek E. Dunn. Ms. Susan Afanuh, Drs. Rickie Davis and Sang Woo Tak from the US National Institute for Occupational Safety and Health, and Dr. Soren Peter Lund from the National Research Centre on the Working Environment, Denmark, provided helpful critiques of the manuscript. The authors wish to thank those who agreed to participate in the study for their time, interest, and cooperation. The study was supported by grants from EU Research project NoiseChem, Contract number QLK4-CT-2000-00293, from the Swedish Council for Working Life and Social Research, Contract number 2006-1526 and from the US National Institute for Occupational Safety and Health, Contract number 0009736801. NR 49 TC 17 Z9 20 U1 1 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1499-2027 J9 INT J AUDIOL JI Int. J. Audiol. PD OCT PY 2011 VL 50 IS 10 BP 652 EP 660 DI 10.3109/14992027.2011.588965 PG 9 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 820QD UT WOS:000294919600002 PM 21812635 ER PT J AU Olds, T Maher, C Shi, ZM Peneau, S Lioret, S Castetbon, K Bellisle de Wilde, J Hohepa, M Maddison, R Lissner, L Sjoberg, A Zimmermann, M Aeberli, I Ogden, C Flegal, K Summerbell, C AF Olds, Tim Maher, Carol Shi Zumin Peneau, Sandrine Lioret, Sandrine Castetbon, Katia Bellisle de Wilde, Jeroen Hohepa, Maea Maddison, Ralph Lissner, Lauren Sjoberg, Agneta Zimmermann, Michael Aeberli, Isabelle Ogden, Cynthia Flegal, Katherine Summerbell, Carolyn TI Evidence that the prevalence of childhood overweight is plateauing: data from nine countries SO INTERNATIONAL JOURNAL OF PEDIATRIC OBESITY LA English DT Review DE Child; adolescent; obesity; overweight; prevalence; international ID BODY-MASS INDEX; RISK-FACTORS; US CHILDREN; DECREASING PREVALENCE; OBESITY PREVALENCE; REFERENCE VALUES; UNITED-STATES; TRENDS; ADOLESCENTS; SCHOOLCHILDREN AB Until quite recently, there has been a widespread belief in the popular media and scientific literature that the prevalence of childhood obesity is rapidly increasing. However, high quality evidence has emerged from several countries suggesting that the rise in the prevalence has slowed appreciably, or even plateaued. This review brings together such data from nine countries (Australia, China, England, France, Netherlands, New Zealand, Sweden, Switzerland and USA), with data from 467,294 children aged 2-19 years. The mean unweighted rate of change in prevalence of overweight and obesity was +0.00 (0.49)% per year across all age X sex groups and all countries between 1995 and 2008. For overweight alone, the figure was +0.01 (0.56)%, and for obesity alone -0.01 (0.24)%. Rates of change differed by sex, age, socioeconomic status and ethnicity. While the prevalence of overweight and obesity appears to be stabilizing at different levels in different countries, it remains high, and a significant public health issue. Possible reasons for the apparent flattening are hypothesised. C1 [Olds, Tim; Maher, Carol] Univ S Australia, Hlth & Use Time Grp, Sansom Inst, Adelaide, SA 5001, Australia. [Shi Zumin] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing 210009, Jiangsu Prov, Peoples R China. [Shi Zumin] Univ Adelaide, Sch Med, Adelaide, SA, Australia. [Peneau, Sandrine; Bellisle] Unite Rech Epidemiol Nutr, Bobigny, France. [Lioret, Sandrine] French Food Safety Agcy, Dietary Survey Unit Nutr Epidemiol, Maisons Alfort, France. [Castetbon, Katia] Univ Paris 13, French Inst Hlth Surveillance InVS, Unite Surveillance & Epidemiol Nutr, Bobigny, France. [de Wilde, Jeroen] Municipal Hlth Serv Hague, Dept Epidemiol, Dept Sch Hlth Care, The Hague, Netherlands. [Hohepa, Maea] Sport & Recreat New Zealand, Wellington, New Zealand. [Maddison, Ralph] Univ Auckland, Clin Trials Res Unit, Auckland 1, New Zealand. [Lissner, Lauren; Sjoberg, Agneta] Univ Gothenburg, Dept Publ Hlth & Community Med, Publ Hlth Epidemiol Unit, Sahlgrenska Acad, Gothenburg, Sweden. [Zimmermann, Michael; Aeberli, Isabelle] Swiss Fed Inst Technol, Inst Food Nutr & Hlth, Human Nutr Lab, Zurich, Switzerland. [Aeberli, Isabelle] Univ Zurich Hosp, Clin Endocrinol Diabet & Clin Nutr, Zurich, Switzerland. [Ogden, Cynthia; Flegal, Katherine] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Summerbell, Carolyn] John Snow Coll, Wolfson Res Inst, Sch Med & Hlth, Stockton On Tees, England. RP Maher, C (reprint author), Univ S Australia, Hlth & Use Time Grp, Sansom Inst, GPO Box 2471, Adelaide, SA 5001, Australia. EM carol.maher@unisa.edu.au RI Olds, Timothy/A-1223-2008; Shi, Zumin/A-1093-2009; Flegal, Katherine/A-4608-2013; Herter-Aeberli, Isabelle/C-8580-2013; Maher, Carol/C-8169-2009; Zimmermann, Michael/C-3062-2016; Summerbell, Carolyn/O-3759-2015; Summerbell, Carolyn/O-3001-2015; OI Shi, Zumin/0000-0002-3099-3299; Maddison, Ralph/0000-0001-8564-5518; Herter-Aeberli, Isabelle/0000-0003-0134-6217; Summerbell, Carolyn/0000-0003-1910-9383; Summerbell, Carolyn/0000-0003-1910-9383; Flegal, Katherine/0000-0002-0838-469X NR 64 TC 231 Z9 236 U1 25 U2 67 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1747-7166 J9 INT J PEDIATR OBES JI Int. J. Pediatr. Obes. PD OCT PY 2011 VL 6 IS 5-6 BP 342 EP 360 DI 10.3109/17477166.2011.605895 PG 19 WC Pediatrics SC Pediatrics GA 820LB UT WOS:000294906100003 PM 21838570 ER PT J AU Pastor, PN Reuben, CA AF Pastor, Patricia N. Reuben, Cynthia A. TI Emotional/behavioral difficulties and adolescent obesity: effect of sex and Hispanic origin/race SO INTERNATIONAL JOURNAL OF PEDIATRIC OBESITY LA English DT Article DE Obesity; emotion; behavior; adolescence; cross-sectional survey ID DEPRESSIVE SYMPTOMS; UNITED-STATES; OVERWEIGHT; CHILDHOOD; WEIGHT; HEALTH; ACCULTURATION; QUESTIONNAIRE; PREVENTION; STRENGTHS AB This study examines the relationship between emotional/behavioral difficulties and obesity among US adolescents aged 12-17 using parent-reported data for 11,042 adolescents in the National Health Interview Survey. Obesity was defined as body mass index (BMI) >= sex/age-specific 95th percentile BMI cut-points from the 2000 CDC Growth Charts. Types of emotional/behavioral difficulties were identified using the Strengths and Difficulties Questionnaire. Among females, emotional/behavioral difficulties were associated with obesity among non-Hispanic (NH) white and Hispanic adolescents (both those with interviews in English and interviews in Spanish). Among males, emotional/behavioral difficulties were associated with obesity among NH white adolescents and Hispanic males with interviews in English. No association between any difficulties and obesity was found among NH black adolescents, either male or female, or Hispanic males with interviews in Spanish. Awareness of the differing association between emotional/behavioral difficulties and obesity among subgroups of adolescents may aid in the development of targeted obesity interventions. C1 [Pastor, Patricia N.; Reuben, Cynthia A.] Ctr Dis Control & Prevent, CDC, NCHS, Hyattsville, MD 20782 USA. RP Pastor, PN (reprint author), Ctr Dis Control & Prevent, CDC, NCHS, 3311 Toledo Rd,Room 6437, Hyattsville, MD 20782 USA. EM php3@cdc.gov NR 19 TC 2 Z9 2 U1 3 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1747-7166 J9 INT J PEDIATR OBES JI Int. J. Pediatr. Obes. PD OCT PY 2011 VL 6 IS 5-6 BP 462 EP 466 DI 10.3109/17477166.2011.590207 PG 5 WC Pediatrics SC Pediatrics GA 820LB UT WOS:000294906100015 PM 21790263 ER PT J AU Koppenhaver, RT Sorensen, SW Farnham, PG Sansom, SL AF Koppenhaver, Robert T. Sorensen, Stephen W. Farnham, Paul G. Sansom, Stephanie L. TI The Cost-Effectiveness of Pre-Exposure Prophylaxis in Men Who Have Sex With Men in the United States: An Epidemic Model SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter C1 [Koppenhaver, Robert T.; Sorensen, Stephen W.; Farnham, Paul G.; Sansom, Stephanie L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Koppenhaver, RT (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. NR 6 TC 28 Z9 28 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2011 VL 58 IS 2 BP E51 EP E52 DI 10.1097/QAI.0b013e31822b74fe PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 821AL UT WOS:000294947100010 PM 21921730 ER PT J AU Boulet, SL Schieve, LA Boyle, CA AF Boulet, Sheree L. Schieve, Laura A. Boyle, Coleen A. TI Birth Weight and Health and Developmental Outcomes in US Children, 1997-2005 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Birth weight; Developmental disabilities; Mental retardation; Autistic disorder; Attention-deficit/hyperactivity disorder; Cerebral palsy; Deafness; Learning disorders; Epilepsy; Stuttering ID SCHOOL-AGED CHILDREN; LATE PRETERM INFANTS; FUNCTIONAL LIMITATIONS; GESTATIONAL-AGE; UNITED-STATES; CARE USE; BORN; PERFORMANCE; DISABILITIES; METAANALYSIS AB The primary goal of this study was to assess the association between the full birth weight distribution and prevalence of specific developmental disabilities and related measures of health and special education services utilization in US children. Using data from the 1997-2005 National Health Interview Survey (NHIS) Sample Child Core, we identified 87,578 children 3-17 years of age with parent-reported information on birth weight. We estimated the prevalences of DDs (attention-deficit/hyperactivity disorder [ADHD], autism, cerebral palsy, hearing impairment, learning disability without mental retardation, mental retardation, seizures, stuttering/stammering, and other developmental delay) and several indicators of health services utilization within a range of birth weight categories. We calculated odds ratios adjusted for demographic factors (AOR). We observed trends of decreasing disability/indicator prevalence with increasing birth weight up to a plateau. Although associations were strongest for very low birth weight, children with "normal" birth weights of 2,500-2,999 g were more likely than those with birth weights of 3,500-3,999 g to have mental retardation (AOR 1.9 [95% CI: 1.4-2.6]), cerebral palsy (AOR 2.4 [95% CI: 1.5-3.8]), learning disability without mental retardation (AOR 1.2 [95% CI: 1.1-1.4]), ADHD (AOR 1.2 [95% CI: 1.1-1.3]), and other developmental delay (AOR 1.3 [95% CI: 1.1-1.5]) and to receive special education services (AOR 1.3 [95% CI: 1.2-1.5]). While much research has focused on the health and developmental outcomes of low and very low birth weight children, these findings suggest that additional study of a continuous range of birth weights may be warranted. C1 [Boulet, Sheree L.; Schieve, Laura A.; Boyle, Coleen A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Boulet, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-D02, Atlanta, GA 30333 USA. EM sboulet@cdc.gov NR 35 TC 29 Z9 30 U1 0 U2 15 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2011 VL 15 IS 7 BP 836 EP 844 DI 10.1007/s10995-009-0538-2 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 819LD UT WOS:000294825900002 PM 19902344 ER PT J AU Park, S Sappenfield, WM Bish, C Bensyl, DM Goodman, D Menges, J AF Park, Sohyun Sappenfield, William M. Bish, Connie Bensyl, Diana M. Goodman, David Menges, Jane TI Reliability and Validity of Birth Certificate Prepregnancy Weight and Height Among Women Enrolled in Prenatal WIC Program: Florida, 2005 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Reliability; Validity; Birth certificate; Prepregnancy weight; Prepregnancy height; Prepregnancy BMI; WIC ID SELF-REPORTED WEIGHT; BODY-MASS INDEX; MATERNAL OBESITY; UNITED-STATES; PREGNANCY; VALIDATION; CATEGORIES; RECORDS; HEALTH; GAIN AB To investigate the reliability and validity of weight, height, and body mass index (BMI) from birth certificates with directly measured values from the Women, Infants, and Children (WIC) Program. Florida birth certificate data were linked and compared with first trimester WIC data for women with a live birth during the last quarter of calendar year 2005 (n = 23,314 women). Mean differences for weight, height, and BMI were calculated by subtracting birth certificate values from WIC values. Reliability was estimated by Pearson's correlation. Validity was measured by sensitivity and specificity using WIC data as the reference. Overall mean differences plus or minus standard error (SE) were 1.93 +/- A 0.04 kg for weight, -1.03 +/- A 0.03 cm for height, and 1.07 +/- A 0.02 kg/m(2) for BMI. Pearson's correlation ranged from 0.83 to 0.95, which indicates a strong positive association. Compared with other categories, women in the second weight group (56.7-65.8 kg), the highest height group (a parts per thousand yen167.6 cm), or BMI < 18.5 had the greatest mean differences for weight (2.2 +/- A 0.08 kg), height (-2.4 +/- A 0.05 cm), and BMI (1.5 +/- A 0.06), respectively. Mean differences by maternal characteristics were similar, but statistically significant, likely in part from the large sample size. The sensitivity for birth certificate data was 77.3% (+/- 1.42) for underweight (BMI < 18.5) and 76.4% (+/- 0.51) for obesity (BMI a parts per thousand yen 30). Specificity was 96.8% (+/- 0.12) for underweight and 97.5% (+/- 0.12) for obesity. Birth certificate data had higher underweight prevalence (6 vs. 4%) and lower obesity prevalence (24 vs. 29%), compared with WIC data. Although birth certificate data overestimated underweight and underestimated obesity prevalence, the difference was minimal and has limited impact on the reliability and validity for population-based surveillance and research purposes related to recall or reporting bias. C1 [Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, NCCDPHP, Atlanta, GA 30341 USA. [Sappenfield, William M.; Menges, Jane] Florida Dept Hlth, Div Family Hlth Serv, Tallahassee, FL USA. [Bish, Connie; Goodman, David] Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, Atlanta, GA 30341 USA. [Bensyl, Diana M.] Ctr Dis Control & Prevent, EIS, Field Assignments Branch, CDD OWCD OD, Atlanta, GA 30341 USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, NCCDPHP, 4770 Buford Highway NE,Mailstop K-26, Atlanta, GA 30341 USA. EM spark3@cdc.gov NR 30 TC 34 Z9 34 U1 3 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2011 VL 15 IS 7 BP 851 EP 859 DI 10.1007/s10995-009-0544-4 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 819LD UT WOS:000294825900004 PM 19937268 ER PT J AU Cox, RG Zhang, L Zotti, ME Graham, J AF Cox, Reagan G. Zhang, Lei Zotti, Marianne E. Graham, Juanita TI Prenatal Care Utilization in Mississippi: Racial Disparities and Implications for Unfavorable Birth Outcomes SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Preterm birth; Low birth weight; Infant mortality; Prenatal care utilization; Racial disparities ID HIGH-RISK CONDITIONS; PRECONCEPTION CARE; PRETERM BIRTH; UNITED-STATES; HEALTHSTART PROGRAM; PREGNANCY OUTCOMES; CERTIFICATE DATA; WOMEN; WEIGHT; ADEQUACY AB The objective of the study is to identify racial disparities in prenatal care (PNC) utilization and to examine the relationship between PNC and preterm birth (PTB), low birth weight (LBW) and infant mortality in Mississippi. Retrospective cohort from 1996 to 2003 linked Mississippi birth and infant death files was used. Analysis was limited to live-born singleton infants born to non-Hispanic white and black women (n = 292,776). PNC was classified by Kotelchuck's Adequacy of Prenatal Care Utilization Index. Factors associated with PTB, LBW and infant death were identified using multiple logistic regression after controlling for maternal age, education, marital status, place of residence, tobacco use and medical risk. About one in five Mississippi women had less than adequate PNC, and racial disparities in PNC utilization were observed. Black women delayed PNC, received too few visits, and were more likely to have either "inadequate PNC" (P < 0.0001) or "no care" (P < 0.0001) compared to white women. Furthermore, among women with medical conditions, black women were twice as likely to receive inadequate PNC compared to white women. Regardless of race, "no care" and "inadequate PNC" were strong risk factors for PTB, LBW and infant death. We provide empirical evidence to support the existence of racial disparities in PNC utilization and infant birth outcomes in Mississippi. Further study is needed to explain racial differences in PNC utilization. However, this study suggests that public health interventions designed to improve PNC utilization among women might reduce unfavorable birth outcomes especially infant mortality. C1 [Cox, Reagan G.] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Jackson, MS 39215 USA. [Zhang, Lei] Mississippi Dept Hlth, Off Hlth Data & Res, Jackson, MS 39215 USA. [Zotti, Marianne E.] Ctr Dis Control & Prevent, ASB, DRH, NCCDPHP, Atlanta, GA 30341 USA. [Graham, Juanita] Mississippi Dept Hlth, Hlth Serv Chief Nurse, Jackson, MS 39215 USA. RP Zhang, L (reprint author), Mississippi Dept Hlth, Off Hlth Data & Res, 570 E Woodrow Wilson, Jackson, MS 39215 USA. EM reagan.j.cox@vanderbilt.edu; Lei.Zhang@msdh.state.ms.us; mbz1@cdc.gov; Juanita.Graham@msdh.state.ms.us NR 50 TC 19 Z9 19 U1 0 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2011 VL 15 IS 7 BP 931 EP 942 DI 10.1007/s10995-009-0542-6 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 819LD UT WOS:000294825900013 PM 19943096 ER PT J AU Tran, T Roberson, E Borstell, J Hoyert, DL AF Tran, Tri Roberson, Emily Borstell, Joan Hoyert, Donna L. TI Evaluation of Pregnancy Mortality in Louisiana Using Enhanced Linkage and Different Indicators Defined by WHO and CDC/ACOG: Challenging and Practical Issues SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Pregnancy mortality; Maternal mortality; Surveillance; Data linkage; Trend ID MATERNAL MORTALITY; UNITED-STATES; DEATHS AB Differences in definitions and methods of data collection on deaths occurring during or shortly after pregnancy have created confusion and challenges in evaluating research findings. The study aimed to determine if the use of enhanced linkage procedures improve data collection of deaths occurring during or shortly after pregnancy, and how different definitions of those deaths changed the results of data analysis. The study used 2000-2005 Louisiana Pregnancy Mortality Surveillance System (LPMSS) and 2000-2005 death certificates linked with 1999-2005 live birth and fetal death certificates. Five indicators of deaths occurring during or shortly after pregnancy using WHO and CDC/ACOG definitions were estimated. One-sided Spearman rank test was used to analyze maternal mortality trends from 2000 to 2005. Of 345 women who died within 1 year of pregnancy, 187 were identified through linkage; 38 of those were missed by the LPMSS. Total mortality ratios of deaths occurring within 1 year of pregnancy ranged from 13.4 to 88.9 per 100,000 live births depending on the indicator used. CDC/ACOG pregnancy-related death and pregnancy-associated death statistically increased, whereas WHO pregnancy-related death decreased between 2000 and 2005. The most common causes of death differed by indicator. Universal adoption of linkage procedures could improve data on deaths occurring during or shortly after pregnancy. Estimates, trends, and most common causes of death were markedly different depending on which indicator was used. Additionally, the use of different mortality indicators during analysis provides a more detailed picture of potential target areas for future research and interventions. C1 [Tran, Tri] Louisiana Off Publ Hlth, Maternal & Child Hlth Program, New Orleans, LA USA. [Tran, Tri] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Pediat, New Orleans, LA USA. [Roberson, Emily] Hawaii Dept Hlth, Family Hlth Serv Div, Honolulu, HI USA. [Borstell, Joan] Ctr Hlth Stat & Vital Records, Louisiana Off Publ Hlth, New Orleans, LA USA. [Hoyert, Donna L.] Ctr Dis Control & Prevent, Mortal Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Tran, T (reprint author), Louisiana Off Publ Hlth, Maternal & Child Hlth Program, New Orleans, LA USA. EM tri.tran@la.gov NR 15 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2011 VL 15 IS 7 BP 955 EP 963 DI 10.1007/s10995-010-0564-0 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 819LD UT WOS:000294825900016 PM 20091108 ER PT J AU Koumans, EH Lane, SD Aubry, R DeMott, K Webster, N Levandowski, BA Berman, S Markowitz, LE AF Koumans, Emilia H. Lane, Sandra D. Aubry, Richard DeMott, Kathleen Webster, Noah Levandowski, Brooke A. Berman, Stuart Markowitz, Lauri E. TI Evaluation of Syracuse Healthy Start's Program for Abnormal Flora Management to Reduce Preterm Birth Among Pregnant Women SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Premature birth; Vaginosis, bacterial; Prenatal care ID ASYMPTOMATIC BACTERIAL VAGINOSIS; LATE MISCARRIAGE; VAGINAL FLORA; GENITAL-TRACT; CLINDAMYCIN; DELIVERY; METRONIDAZOLE; BEHAVIORS AB Randomized trials of bacterial vaginosis (BV) treatment among pregnant women to reduce preterm birth have had mixed results. Among non-pregnant women, BV recurs frequently after treatment. Randomized trials of early BV treatment for pregnant women in which recurrence was retreated have shown promise in reducing preterm birth. Syracuse's Healthy Start (SHS) program began in 1997; in 1998 prenatal care providers for pregnant women living in high infant mortality zip codes were encouraged to screen for abnormal vaginal flora at the first prenatal visit. Vaginal swabs were sent to a referral hospital laboratory for Gram staining and interpretation. SHS encouraged providers to treat and rescreen women with bacterial vaginosis or abnormal flora (BV). We abstracted prenatal and hospital charts of live births between January 2000 and March 2002 for maternal conditions and treatments. We merged abstracted data with local electronic data. We evaluated the effect of BV screening before 22 weeks gestation, treatment, and rescreening using a retrospective cohort study design. Among 838 women first screened before 22 weeks, 346 (41%) had normal flora and 492 (59%) women had BV at a mean of 13 weeks gestation; 202 (24%) did not have treatment documented and 290 (35%) received treatment at a mean of 15 weeks gestation; 267 (92%) of those treated were re-screened. Among pregnant women with early BV, 42 (21%) untreated women and 28 (10%) treated women delivered preterm (Odds Ratio [OR] 0.4, 95% confidence interval [CI] 0.2-0.7)). After adjustment for age, race, prior preterm birth and other possible confounders, treatment remained associated with a reduced risk of preterm birth compared to no treatment (aOR = 0.5, 95% CI 0.3-0.9); the aOR for women with normal flora was not significantly different. Conclusion: Screening, treatment, and rescreening for BV/abnormal flora between the first prenatal visit and 22 weeks gestation showed promise in reducing preterm births and deserves further study. C1 [Koumans, Emilia H.; Berman, Stuart; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Lane, Sandra D.] Syracuse Univ, Dept Hlth, Syracuse, NY USA. [Lane, Sandra D.] Syracuse Univ, Dept Wellness, Syracuse, NY USA. [Aubry, Richard] SUNY Upstate Med Univ, Ctr Maternal & Child Hlth, Syracuse, NY USA. [Aubry, Richard] SUNY Upstate Med Univ, Dept Obstet & Gynecol, Syracuse, NY USA. [DeMott, Kathleen] Royal Coll Physicians, London NW1 4LE, England. [Webster, Noah] Syracuse Hlth Start Case Western Univ, Cleveland, OH USA. [Levandowski, Brooke A.] Syracuse Hlth Start Ipas, Chapel Hill, NC USA. RP Koumans, EH (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM ekoumans@cdc.gov NR 22 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2011 VL 15 IS 7 BP 1020 EP 1028 DI 10.1007/s10995-010-0661-0 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 819LD UT WOS:000294825900024 PM 20824320 ER PT J AU Aburto, NJ Fulton, JE Safdie, M Duque, T Bonvecchio, A Rivera, JA AF Aburto, Nancy Jennings Fulton, Janet E. Safdie, Margarita Duque, T. Bonvecchio, Annabelle Rivera, Juan A. TI Effect of a School-Based Intervention on Physical Activity: Cluster-Randomized Trial SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE MEXICO; PHYSICAL ACTIVITY; PHYSICAL FITNESS; ENVIRONMENT; SCHOOLS ID CARDIOVASCULAR HEALTH; OBESITY PREVENTION; EDUCATION-PROGRAM; ADOLESCENT TRIAL; CHILDREN; FITNESS; NUTRITION; RISK; OVERWEIGHT; TRACKING AB ABURTO, N. J., J. E. FULTON, M. SAFDIE, T. DUQUE, A. BONVECCHIO, and J. A. RIVERA. Effect of a School-Based Intervention on Physical Activity: Cluster-Randomized Trial. Med. Sci. Sports Exerc., Vol. 43, No. 10, pp. 1898-1906, 2011. Purpose: Physical activity in childhood has many health benefits; however, the majority of children in many countries, including Mexico, are insufficiently active. The objective of this investigation was to test the effect of a school-based environmental intervention on the physical activity and physical fitness of students attending public primary schools in Mexico City. Methods: Twenty-seven schools were randomly assigned to basic or plus intervention or control. The basic and plus groups were exposed to school environment and policy changes to enhance physical activity. Physical activity was evaluated in 699 randomly selected fourth-and fifth-grade students by measuring school-day and all-day (24 h) steps using pedometers worn for 5 d before and after the 6-month intervention. Physical fitness was assessed by measuring the 9-min run, flexibility, and sit-ups. We calculated the average change in school-day and all-day steps and fitness measures from baseline to follow-up. Using linear regression, we tested the effect of intervention on change controlling for baseline measures and covariates and accounting for the design effect of school. Using logistic regression, we tested the effect of intervention on reaching step cutoffs at baseline and follow-up. Results: The plus group significantly (P < 0.05) increased school-day steps relative to control (change = 687 vs -639). Significantly (P < 0.05) more participants in the basic (25.8%) and plus (36.4%) groups reached step cutoffs during school relative to control (12.0%). The basic group significantly (P < 0.05) increased all-day steps relative to control (change = 581 vs -419). The plus group significantly (P = 0.05) increased sit-ups relative to control (change = 0.3 vs -1.7). Conclusions: A school-based environmental intervention improved student physical activity during school in public schools in Mexico City. C1 [Aburto, Nancy Jennings; Fulton, Janet E.; Duque, T.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Aburto, Nancy Jennings; Safdie, Margarita; Duque, T.; Bonvecchio, Annabelle; Rivera, Juan A.] Nutr & Hlth Res Ctr, Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. RP Safdie, M (reprint author), Queens Univ, Sch Kinesiol & Hlth Studies, 28 Div St, Kingston, ON K7L 3N6, Canada. EM margarita.safdie@queensu.ca FU International Life Sciences Institute; Pan American Health Organization FX This investigation was funded in part by the International Life Sciences Institute and the Pan American Health Organization as part of the Healthy People/Healthy Lifestyles Project. NR 36 TC 10 Z9 10 U1 1 U2 35 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD OCT PY 2011 VL 43 IS 10 BP 1898 EP 1906 DI 10.1249/MSS.0b013e318217ebec PG 9 WC Sport Sciences SC Sport Sciences GA 821DT UT WOS:000294955800011 PM 21407129 ER PT J AU Mansergh, G Koblin, B Colfax, GN Flores, SA Hudson, SM AF Mansergh, G. Koblin, B. Colfax, G. N. Flores, S. A. Hudson, S. M. CA Project MIX Study Team TI 'Less education' is associated with use and sharing of antiretroviral medications for prophylaxis of HIV infection by US men who have sex with men SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Letter C1 [Mansergh, G.; Flores, S. A.] CDC Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA 30333 USA. [Koblin, B.] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA. [Colfax, G. N.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Colfax, G. N.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hudson, S. M.] Hlth Res Assoc, Los Angeles, CA USA. RP Mansergh, G (reprint author), CDC Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd NE,Mailstop E37, Atlanta, GA 30333 USA. EM gcm2@cdc.gov NR 5 TC 2 Z9 2 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD OCT PY 2011 VL 87 IS 6 BP 510 EP 510 DI 10.1136/sextrans-2011-050188 PG 1 WC Infectious Diseases SC Infectious Diseases GA 819ID UT WOS:000294817700019 PM 21873470 ER PT J AU Mor, Z Davidovich, U Bessudu-Manor, N McFarlane, M Feldshtein, G Chemtob, D AF Mor, Zohar Davidovich, Udi Bessudu-Manor, Niva McFarlane, Mary Feldshtein, Gil Chemtob, Daniel TI High-risk behaviour in steady and in casual relationships among men who have sex with men in Israel SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID GAY MEN; HIV-INFECTION; BISEXUAL MEN; PARTNERS; TRENDS; PREVENTION; MSM AB Objective To explore the differences in sexual risk behaviour between men who have sex with men (MSM) with steady partners versus casual partner(s) in the gay community. Methods This online cross-sectional convenience-sampling study assessed MSM practices, their knowledge and their motivation regarding safe sex. Participants not knowing their HIV status or who performed insertive or receptive unprotected anal intercourse (UAI) or with a sex partner whose HIV status was unknown or discordant were considered 'at-risk'. Results Of all 2569 participants who completed the questionnaire, 907/2569 (35.3%) had a steady partner, and 896/2569 (34.9%) had a casual partner(s) in the past 6 months. 262/907 (28.9%) with steady partners and 248/896 (27.7%) with casual partners demonstrated at-risk sexual behaviour. Of all participants with steady partners, 108/907 (11.9%) performed UAI with their partner without undergoing mutual HIV testing. Of all participants with steady partners, 476/907 (52.5%) had a concurrent casual partner, and 144/476 (30.3%) performed UAI with both the steady and the casual partner. Of all participants with steady partners, 775/907 (85.4%) negotiated the possibility of sex outside their relationship with their main partner. The length of the steady relationship correlated with the number of concurrent casual partners. Conclusions At-risk sexual behaviour was associated with insufficient negotiation skills, difficulties in condom use and a general risk-taking profile. Health educators should encourage MSM with steady partners to perform HIV testing before practising UAI, to improve their negotiation skills during the contact and to support open discussions with regard to sexual contact besides the steady relationship, as it may not be monogamous. C1 [Mor, Zohar; Bessudu-Manor, Niva; Chemtob, Daniel] Minist Hlth, Dept TB & AIDS, IL-91010 Jerusalem, Israel. [Davidovich, Udi] Amsterdam Hlth Serv, Dept Res, Amsterdam, Netherlands. [McFarlane, Mary] CDC, Div STD Prevent, Atlanta, GA 30333 USA. [Feldshtein, Gil] Assoc Gays Lesbians Bisexuals & Transgenders, Tel Aviv, Israel. RP Mor, Z (reprint author), Minist Hlth, Dept TB & AIDS, 33 Pierre Koenig St,POB 1176, IL-91010 Jerusalem, Israel. EM zohar.mor@rml.health.gov NR 20 TC 10 Z9 10 U1 1 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD OCT PY 2011 VL 87 IS 6 BP 532 EP 537 DI 10.1136/sextrans-2011-050048 PG 6 WC Infectious Diseases SC Infectious Diseases GA 819ID UT WOS:000294817700024 PM 21917699 ER PT J AU Koeppe, J Lichtenstein, K Armon, C Chmiel, JS Buchacz, K Wood, K Brooks, JT AF Koeppe, John Lichtenstein, Kenneth Armon, Carl Chmiel, Joan S. Buchacz, Kate Wood, Kathy Brooks, John T. CA HOPS Investigators TI Factors Associated With Initiation of Prolonged Analgesic Use Among Patients in the HIV Outpatient Study (HOPS) SO CLINICAL JOURNAL OF PAIN LA English DT Article DE HIV; pain; analgesics; opioids ID PRESCRIPTION OPIOID USE; NEWLY EMPLOYED WORKERS; LOW-BACK-PAIN; UNITED-STATES; PSYCHOSOCIAL FACTORS; SELF-EFFICACY; OLDER-ADULTS; PRIMARY-CARE; RISK-FACTORS; DRUG-USE AB Background: Analgesic use is common but remains poorly described among human immunodeficiency virus (HIV)-infected persons in the highly active antiretroviral therapy era. Methods: We studied HIV Outpatient Study participants during 1996 to 2008. We used Cox proportional hazards regression to assess variables associated with initiation of prolonged analgesia (>= 90 consecutive days of analgesics); logistic regression to explore variables associated with initiation of prolonged opioid analgesia among those taking any prolonged analgesia; and linear regression to determine temporal trends in prolonged analgesia. Results: Among 4180 patients, 931 (22%) initiated prolonged analgesia. Factors independently associated (P < 0.05) with prolonged analgesia included: age above 40 years (hazard ratio = 1.20), female sex (1.43), injection drug use as an HIV risk factor (1.33), public healthcare payer (1.88), nadir CD4+ less than 200 cells/mm(3) (1.29), tobacco use (1.43), prior opportunistic infection(s) (1.25), antidepressant use (1.76), and anxiolytic use (1.51). Independent correlates of prolonged opioid analgesia were white race (odds ratio = 1.64), baseline CD4+ less than 350 cells/mm(3) (1.88), and anxiolytic use (1.87). Prolonged analgesia ranged from 11% to 15% each year. Conclusions: In the highly active antiretroviral therapy era, up to 15% of HIV Outpatient Study patients used prolonged analgesic therapy each year. Variables associated with the initiation of prolonged analgesia included IIIV and non-IIIV-related factors. C1 [Koeppe, John] Univ Colorado Denver, Dept Internal Med, Div Infect Dis, Aurora, CO 80045 USA. [Lichtenstein, Kenneth] Natl Jewish Hlth, Dept Internal Med, Div Infect Dis, Denver, CO USA. [Armon, Carl; Wood, Kathy] Cerner Corp, Res Div Life Sci, Vienna, Austria. [Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent, Epidemiol Branch, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis TB & STD Prevent, Atlanta, GA USA. RP Koeppe, J (reprint author), Univ Colorado Denver, Dept Internal Med, Div Infect Dis, 1635 Aurora Court,B-163, Aurora, CO 80045 USA. EM John.Koeppe@ucdenver.edu FU Centers for Disease Control and Prevention, Atlanta, GA [200-2001-00133, 200-2006-18797]; Merck; TaiMed (TaiMed Biologics, Inc. Irvine, CA; ViiV, Brentford Middlesex, UK); (Merck & Co., Inc Whitehouse Station, NJ) Pfizer FX Centers for Disease Control and Prevention, Atlanta, GA (contract nos. 200-2001-00133 and 200-2006-18797).; Dr Lichtenstein receives research support from Merck, (Merck & Co., Inc Whitehouse Station, NJ) Pfizer, and TaiMed (TaiMed Biologics, Inc. Irvine, CA; ViiV, Brentford Middlesex, UK). He serves on advisory boards for Abbott, Merck, Bristol-Myers Squibb, Gilead (Gilead Sciences, Inc. Foster City, CA), and Tibotec. All other authors have no conflict of interest. NR 43 TC 3 Z9 3 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-8047 J9 CLIN J PAIN JI Clin. J. Pain PD OCT PY 2011 VL 27 IS 8 BP 699 EP 706 DI 10.1097/AJP.0b013e3182169012 PG 8 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA 817XF UT WOS:000294709700007 PM 21540742 ER PT J AU Koenig, LJ Nesheim, S Abramowitz, S AF Koenig, Linda J. Nesheim, Steven Abramowitz, Susan TI Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY LA English DT Article DE adherence; adolescents; long-term survivors; perinatally acquired HIV; sexual risk behaviors ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; INTIMA-MEDIA THICKNESS; INFECTED CHILDREN; YOUNG-ADULTS; METABOLIC ABNORMALITIES; PSYCHIATRIC-SYMPTOMS; LONGITUDINAL CHANGES; SEXUAL-BEHAVIORS; OLDER CHILDREN AB Purpose of review Because of widespread availability of highly active antiretroviral therapy in the developed world, a large proportion of children with perinatally acquired HIV have survived to adolescence and young adulthood. Although their survival is remarkable, many now experience the long-term effects of HIV infection and its treatment. Further, as these youths have entered adolescence, more is known about the impact of normative developmental transitions on health maintenance behaviors. Recent findings Although perinatally infected adolescents are healthier than they were a decade or more ago, they are significantly experienced with antiretroviral therapy, with increased virological resistance and other consequences of extended antiretroviral use. Three behavioral health challenges have been documented in the first cohort of long-term survivors: decreased medication adherence, sexual debut and accompanying pregnancy and transmission risk, and mental health problems. These issues are consistent with a developmental press for autonomy, mature sexual relationships and future planning, but must be carefully managed to preserve health. Summary Adolescents with perinatally acquired HIV require coordinated multidisciplinary support services - including adherence support, reproductive health counseling addressing both pregnancy planning and disease transmission, and mental health and educational/vocational planning - so that they can fully benefit from treatment advances. C1 [Koenig, Linda J.; Nesheim, Steven] Ctr Dis Control & Prevent, Div HIV AIDS, Atlanta, GA 30333 USA. [Abramowitz, Susan] NYU, Sch Med, New York, NY USA. RP Koenig, LJ (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS, 1600 Clifton Rd,Mailstop D-27, Atlanta, GA 30333 USA. EM LKoenig@cdc.gov NR 61 TC 30 Z9 30 U1 4 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-872X J9 CURR OPIN OBSTET GYN JI Curr. Opin. Obstet. Gynecol. PD OCT PY 2011 VL 23 IS 5 BP 321 EP 327 DI 10.1097/GCO.0b013e32834a581b PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 817MY UT WOS:000294678900003 PM 21836510 ER PT J AU Rein, DB Wittenborn, JS Zhang, XZ Allaire, BA Song, MS Klein, R Saaddine, JB AF Rein, David B. Wittenborn, John S. Zhang, Xinzhi Allaire, Benjamin A. Song, Michael S. Klein, Ronald Saaddine, Jinan B. CA Vision Cost-Effectiveness Study Gr TI The Cost-Effectiveness of Three Screening Alternatives for People with Diabetes with No or Early Diabetic Retinopathy SO HEALTH SERVICES RESEARCH LA English DT Article DE Cost-effectiveness; diabetes care; ophthalmology; telemedicine; simulation modeling ID RANDOMIZED CLINICAL-TRIALS; MANIFEST GLAUCOMA TRIAL; LOGMAR VISUAL-ACUITY; MACULAR DEGENERATION; EYE DISEASE; FUNDUS PHOTOGRAPHY; REFRACTIVE ERRORS; UTILITY ANALYSIS; UNITED-STATES; RISK-FACTORS AB Objective. To determine whether biennial eye evaluation or telemedicine screening are cost-effective alternatives to current recommendations for the estimated 10 million people aged 30-84 with diabetes but no or minimal diabetic retinopathy. Data Sources. United Kingdom Prospective Diabetes Study, National Health and Nutrition Examination Survey, American Academy of Ophthalmology Preferred Practice Patterns, Medicare Payment Schedule. Study Design. Cost-effectiveness Monte Carlo simulation. Data Collection/Extraction Methods. Literature review, analysis of existing surveys. Principal Findings. Biennial eye evaluation was the most cost-effective treatment option when the ability to detect other eye conditions was included in the model. Telemedicine was most cost-effective when other eye conditions were not considered or when telemedicine was assumed to detect refractive error. The current annual eye evaluation recommendation was costly compared with either treatment alternative. Self-referral was most cost-effective up to a willingness to pay (WTP) of U.S.$37,600, with either biennial or annual evaluation most cost-effective at higher WTP levels. Conclusions. Annual eye evaluations are costly and add little benefit compared with either plausible alternative. More research on the ability of telemedicine to detect other eye conditions is needed to determine whether it is more cost-effective than biennial eye evaluation. C1 [Rein, David B.] RTI Int, Atlanta, GA 30341 USA. [Wittenborn, John S.; Allaire, Benjamin A.; Song, Michael S.] RTI Int, Triangle, NC USA. [Zhang, Xinzhi; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA USA. [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth Madison, Madison, WI USA. RP Rein, DB (reprint author), RTI Int, 2951 Flowers Rd, Atlanta, GA 30341 USA. EM drein@rti.org OI Klein, Ronald/0000-0002-4428-6237 FU Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA [200-2002-00776]; National Eye Institute [R21 EY019173] FX This study was funded by the Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA (contract no. 200-2002-00776), and the National Eye Institute (award no. R21 EY019173). The content is solely the responsibility of the authors and does not necessarily represent the official position of the Centers for Disease Control and Prevention or the official views of the National Eye Institute or the National Institutes of Health. Dr. Klein has previously worked as a consultant regarding design and/or analyses of resultant data on DR as an outcome for Astra-Zeneca, Lilly, Novartis, Merck, GlaxoSmithKline, and Pfizer. The authors have no other conflicts of interest to disclose. We thank Susan Murchie for her editorial assistance. NR 77 TC 20 Z9 20 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2011 VL 46 IS 5 BP 1534 EP 1561 DI 10.1111/j.1475-6773.2011.01263.x PG 28 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 818GN UT WOS:000294739800011 PM 21492158 ER PT J AU Gorina, Y Kramarow, EA AF Gorina, Yelena Kramarow, Ellen A. TI Identifying Chronic Conditions in Medicare Claims Data: Evaluating the Chronic Condition Data Warehouse Algorithm SO HEALTH SERVICES RESEARCH LA English DT Article DE CCW; NHEFS; Medicare claims; chronic conditions ID CHRONIC KIDNEY-DISEASE; RHEUMATOLOGIC DIAGNOSES; SENSITIVITY; REPLACEMENT; ACCURACY; DEMENTIA; DEATH AB Objective. To examine the strengths and limitations of the Center for Medicare and Medicaid Services' Chronic Condition Data Warehouse (CCW) algorithm for identifying chronic conditions in older persons from Medicare beneficiary data. Data Sources. Records from participants of the NHANES I Epidemiologic Follow-up Study (NHEFS 1971-1992) linked to Medicare claims data from 1991 to 2000. Study Design. We estimated the percent of preexisting cases of chronic conditions correctly identified by the CCW algorithm during its reference period and the number of years of claims data necessary to find a preexisting condition. Principal Findings. The CCW algorithm identified 69 percent of preexisting diabetes cases but only 17 percent of preexisting arthritis cases. Cases identified by the CCW are a mix of preexisting and newly diagnosed conditions. Conclusions. The prevalence of conditions needing less frequent health care utilization (e.g., arthritis) may be underestimated by the CCW algorithm. The CCW reference periods may not be sufficient for all analytic purposes. C1 [Gorina, Yelena; Kramarow, Ellen A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hyattsville, MD 20782 USA. RP Kramarow, EA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, 3311 Toledo Rd,Room 6332, Hyattsville, MD 20782 USA. EM EKramarow@cdc.gov NR 25 TC 16 Z9 16 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2011 VL 46 IS 5 BP 1610 EP 1627 DI 10.1111/j.1475-6773.2011.01277.x PG 18 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 818GN UT WOS:000294739800015 PM 21649659 ER PT J AU Lopman, BA Curns, AT Yen, C Parashar, UD AF Lopman, Ben A. Curns, Aaron T. Yen, Catherine Parashar, Umesh D. TI Infant Rotavirus Vaccination May Provide Indirect Protection to Older Children and Adults in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNIZATION PRACTICES ACIP; GASTROENTERITIS HOSPITALIZATIONS; ADVISORY-COMMITTEE; US STATES; DIARRHEA; PREVENTION; REDUCTION; COVERAGE AB Following the introduction of rotavirus vaccination in the United States, rotavirus and cause-unspecified gastroenteritis discharges significantly decreased in 2008 in the 0-4, 5-14, and 15-24-year age groups, with significant reductions observed in March, the historic peak rotavirus month, in all age groups. We estimate that 15% of the total 66 000 averted hospitalizations and 20% of the $204 million in averted direct medical costs attributable to the vaccination program were among unvaccinated 5-24 year-olds. This study demonstrates a previously unrecognized burden of severe rotavirus in the population >5 years and the primacy of very young children in the transmission of rotavirus. C1 [Lopman, Ben A.; Curns, Aaron T.; Yen, Catherine; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lopman, BA (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM blopman@cdc.gov NR 24 TC 102 Z9 107 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2011 VL 204 IS 7 BP 980 EP 986 DI 10.1093/infdis/jir492 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 816KA UT WOS:000294595900003 PM 21878425 ER PT J AU Calvert, GM Ruder, AM Petersen, MR AF Calvert, Geoffrey M. Ruder, Avima M. Petersen, Martin R. TI Mortality and end-stage renal disease incidence among dry cleaning workers SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID ISCHEMIC-HEART-DISEASE; UNITED-STATES; OCCUPATIONAL-EXPOSURE; ORGANIC-SOLVENTS; COHORT MORTALITY; CANCER; SMOKING; TETRACHLOROETHYLENE; TRICHLOROETHYLENE; PERCHLOROETHYLENE AB Objective Perchloroethylene (PCE) is a known animal carcinogen and probable human carcinogen. Dry cleaning exposures, particularly PCE, are also associated with renal toxicity. The objective was to follow-up a cohort of dry cleaners to evaluate mortality and assess end-stage renal disease (ESRD) morbidity. Methods This study adds 8 years of mortality follow-up for 1704 dry cleaning workers in four cities. Employees eligible for inclusion worked for >= 1 year before 1960 in a shop using PCE as the primary solvent. Life table analyses for mortality and ESRD morbidity were conducted. Only employees alive on 1 January 1977 were included in ESRD analyses. Results Overall cancer deaths were in significant excess in this cohort (standardised mortality ratio (SMR) 1.22, 95% CI 1.09 to 1.36). Oesophageal, lung and tongue cancers had significant excesses of deaths. Oesophageal cancer risk was highest among those employed in a PCE-using shop for >= 5 years with >= 20 years' latency since first such employment. Deaths from non-malignant underlying diseases of the stomach and duodenum were in significant excess. Hypertensive ESRD morbidity was significantly elevated in the entire cohort (standardised incidence ratio (SIR) 1.98, 95% CI 1.11 to 3.27), and among workers employed only in PCE-using dry cleaning shops for >= 5 years. Conclusion Employment in the dry cleaning industry and occupational exposure to PCE are associated with an increased risk for ESRD and for cancer at several sites. The employment duration findings for oesophageal cancer and hypertensive ESRD further support an association with PCE exposure instead of lifestyle or socioeconomic factors. C1 [Calvert, Geoffrey M.; Ruder, Avima M.; Petersen, Martin R.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Calvert, GM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM jac6@cdc.gov RI Ruder, Avima/I-4155-2012 OI Ruder, Avima/0000-0003-0419-6664 NR 37 TC 16 Z9 16 U1 1 U2 7 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD OCT PY 2011 VL 68 IS 10 BP 709 EP 716 DI 10.1136/oem.2010.060665 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 818SY UT WOS:000294777000002 PM 21172794 ER PT J AU Bradley, JS Byington, CL Shah, SS Alverson, B Carter, ER Harrison, C Kaplan, SL Mace, SE McCracken, GH Moore, MR St Peter, SD Stockwell, JA Swanson, JT AF Bradley, John S. Byington, Carrie L. Shah, Samir S. Alverson, Brian Carter, Edward R. Harrison, Christopher Kaplan, Sheldon L. Mace, Sharon E. McCracken, George H., Jr. Moore, Matthew R. St Peter, Shawn D. Stockwell, Jana A. Swanson, Jack T. TI Executive Summary: The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CONSENSUS; ADULTS AB Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted. C1 [Bradley, John S.] UCSD, Rady Childrens Hosp San Diego, San Diego, CA 92123 USA. [Bradley, John S.] Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA 92103 USA. [Byington, Carrie L.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Shah, Samir S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Shah, Samir S.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Shah, Samir S.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Alverson, Brian] Rhode Isl Hosp, Dept Pediat, Providence, RI USA. [Carter, Edward R.] Seattle Childrens Hosp, Div Pulm, Seattle, WA USA. [Harrison, Christopher] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA. [Kaplan, Sheldon L.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Mace, Sharon E.] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44106 USA. [McCracken, George H., Jr.] Univ Texas SW, Dept Pediat, Dallas, TX USA. [Moore, Matthew R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [St Peter, Shawn D.] Univ Missouri, Kansas City Sch Med, Dept Pediat, Kansas City, MO 64110 USA. [Stockwell, Jana A.] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA. [Swanson, Jack T.] McFarland Clin, Dept Pediat, Ames, IA USA. RP Bradley, JS (reprint author), UCSD, Rady Childrens Hosp San Diego, 3020 Childrens Way,MC 5041, San Diego, CA 92123 USA. EM jbradley@rchsd.org OI Byington, Carrie/0000-0002-7350-9495 FU IDSA; Johnson & Johnson Pharmaceuticals; Cubist; Merck; Sanofi Pasteur; Astellas; National Institutes of Health; Robert Wood Johnson; Wyeth Pharmaceuticals; GlaxoSmithKline FX This work was supported by the IDSA.; J. S. B. has received no pharmaceutical funding or support during the past 36 months for management of pediatric CAP. C. L. B. served as principal investigator on Wyeth/Pfizer clinical trials of PCV13; the funding was to her employer, the University of Utah. C. H. has received honoraria from Sanofi Pasteur, and his employer has received grant funds for research performed by C. H. from Johnson & Johnson Pharmaceuticals, Cubist, Merck, Sanofi Pasteur, Astellas, and GlaxoSmithKline. S. L. K. has served as a consultant for Pfizer, GlaxoSmithKline, and Novartis. S. E. M. has served as principal investigator on a Gebauer clinical trial for vapocoolant and a clinical site investigator for a multicenter Baxter Hylenex clinical trial, the funding for both trials was to her employer, the Cleveland Clinic; she has also served as consultant for Baxter Health Care, Halozyme Therapeutics, Pricara (Ortho-McNeil-Janssen), Rox-888, and Venasite. J. A. S. has given expert testimony for Finley, Alt, Smith, and Schamberg. S. S. S. receives research support from the National Institutes of Health and the Robert Wood Johnson Foundation. He received past research support from Wyeth Pharmaceuticals (completed September 2009); the funding was to his employer. All other authors: No reported conflicts. NR 5 TC 56 Z9 64 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2011 VL 53 IS 7 BP 617 EP 630 DI 10.1093/cid/cir625 PG 14 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 815AJ UT WOS:000294498200008 PM 21890766 ER PT J AU Hicks, LA Chien, YW Taylor, TH Haber, M Klugman, KP AF Hicks, Lauri A. Chien, Yu-Wen Taylor, Thomas H., Jr. Haber, Michael Klugman, Keith P. CA ABCs Team TI Outpatient Antibiotic Prescribing and Nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ACUTE OTITIS-MEDIA; PNEUMOCOCCAL CONJUGATE VACCINE; ANTIMICROBIAL RESISTANCE; MACROLIDE RESISTANCE; PENICILLIN RESISTANCE; AZITHROMYCIN; DISEASE; CARE; METAANALYSIS; INFECTIONS AB Background. Streptococcus pneumoniae infections have become increasingly complicated and costly to treat with the spread of antibiotic resistance. We evaluated the relationship between antibiotic prescribing and nonsusceptibility among invasive pneumococcal disease (IPD) isolates. Methods. Outpatient antibiotic prescription data for penicillins, cephalosporins, macrolides, and trimethoprim-sulfamethoxazole were abstracted from the IMS Health Xponent database to calculate the annual number of prescriptions per capita. We analyzed IPD data from 7 of the Centers for Disease Control and Prevention's Active Bacterial Core surveillance sites (population, 18.6 million) for which data were available for the entire time period under study (1996-2003). Logistic regression models were used to assess whether sites with high antibiotic prescribing rates had a high proportion of nonsusceptible and serotype 19A IPD. Results. Yearly prescribing rates during the period 1996-2003 for children <5 years of age decreased by 37%, from 4.23 to 2.68 prescriptions per capita per year (P < .001), and those for persons >= 5 years of age decreased by 42%, from 0.98 to 0.57 prescriptions per capita per year (P < .001); increases in azithromycin prescribing were noted for both groups. Sites with high rates of antibiotic prescribing had a higher proportion of IPD nonsusceptibility than did low-prescribing sites (P = .003 for penicillin, P < .001 for every other antibiotic class). Cephalosporin and macrolide prescribing were associated with penicillin and multidrug nonsusceptibility and serotype 19A IPD (P < .001). Conclusions. In sites where antibiotic prescribing is high, the proportion of nonsusceptible IPD is also high, suggesting that local prescribing practices contribute to local resistance patterns. Cephalosporins and macrolides seem to be selecting for penicillin-and multidrug-resistant pneumococci, as well as serotype 19A IPD. Antibiotic use is a major factor contributing to the spread of antibiotic resistance; strategies to reduce antibiotic resistance should continue to include judicious use of antibiotics. C1 [Hicks, Lauri A.; Taylor, Thomas H., Jr.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30329 USA. [Chien, Yu-Wen] Emory Univ, Sch Med, Dept Epidemiol, Atlanta, GA USA. [Haber, Michael] Emory Univ, Sch Med, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA USA. [Klugman, Keith P.] Emory Univ, Sch Med, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA USA. [Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. RP Hicks, LA (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, 1600 Clifton Rd,MS C23, Atlanta, GA 30329 USA. EM lhicks@cdc.gov FU Sanofi-Aventis; Pfizer Vaccines; GlaxoSmithKline FX This work was supported by a Sanofi-Aventis grant.; K. P. K. has received consultant fees and research support from Pfizer Vaccines and GlaxoSmithKline. All other authors report no potential conflicts of interest. NR 39 TC 64 Z9 65 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2011 VL 53 IS 7 BP 631 EP 639 DI 10.1093/cid/cir443 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 815AJ UT WOS:000294498200009 PM 21890767 ER PT J AU Bradley, JS Byington, CL Shah, SS Alverson, B Carter, ER Harrison, C Kaplan, SL Mace, SE McCracken, GH Moore, MR St Peter, SD Stockwell, JA Swanson, JT AF Bradley, John S. Byington, Carrie L. Shah, Samir S. Alverson, Brian Carter, Edward R. Harrison, Christopher Kaplan, Sheldon L. Mace, Sharon E. McCracken, George H., Jr. Moore, Matthew R. St Peter, Shawn D. Stockwell, Jana A. Swanson, Jack T. TI The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; INVASIVE PNEUMOCOCCAL DISEASE; POLYMERASE-CHAIN-REACTION; C-REACTIVE PROTEIN; RESISTANT STAPHYLOCOCCUS-AUREUS; HEMOLYTIC-UREMIC SYNDROME; ASSISTED THORACOSCOPIC SURGERY; RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE-UNIT; INFLUENZA-A H1N1 AB Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted. C1 [Bradley, John S.] Univ Calif San Diego, Rady Childrens Hosp San Diego, San Diego, CA 92123 USA. [Bradley, John S.] Univ Calif San Diego, Dept Pediat, Sch Med, San Diego, CA 92103 USA. [Byington, Carrie L.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Shah, Samir S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Shah, Samir S.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Shah, Samir S.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Alverson, Brian] Rhode Isl Hosp, Dept Pediat, Providence, RI USA. [Carter, Edward R.] Seattle Childrens Hosp, Div Pulm, Seattle, WA USA. [Harrison, Christopher] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA. [Kaplan, Sheldon L.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Mace, Sharon E.] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44106 USA. [McCracken, George H., Jr.] Univ Texas SW, Dept Pediat, Dallas, TX USA. [Moore, Matthew R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [St Peter, Shawn D.] Univ Missouri, Kansas City Sch Med, Dept Pediat, Kansas City, MO 64110 USA. [Stockwell, Jana A.] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA. [Swanson, Jack T.] McFarland Clin, Dept Pediat, Ames, IA USA. RP Bradley, JS (reprint author), Univ Calif San Diego, Rady Childrens Hosp San Diego, 3020 Childrens Way,MC 5041, San Diego, CA 92123 USA. EM jbradley@rchsd.org OI Byington, Carrie/0000-0002-7350-9495 FU IDSA; Johnson & Johnson Pharmaceuticals; Cubist; Merck; Sanofi Pasteur; Astellas; National Institutes of Health; Robert Wood Johnson Foundation; Wyeth Pharmaceuticals; GlaxoSmithKline FX This work was supported by the IDSA.; J.S.B. has received no pharmaceutical funding or support during the past 36 months for management of pediatric CAP. C. L. B. served as principal investigator on Wyeth/Pfizer clinical trials of PCV13; the funding was to her employer, the University of Utah. C. H. has received honoraria from Sanofi Pasteur, and his employer has received grant funds for research performed by C. H. from Johnson & Johnson Pharmaceuticals, Cubist, Merck, Sanofi Pasteur, Astellas, and GlaxoSmithKline. S. L. K. has served as a consultant for Pfizer, GlaxoSmithKline, and Novartis. S. E. M. has served as principal investigator on a Gebauer clinical trial for vapocoolant and a clinical site investigator for a multicenter Baxter Hylenex clinical trial, the funding for both trials was to her employer, the Cleveland Clinic; she has also served as consultant for Baxter Health Care, Halozyme Therapeutics, Pricara (Ortho-McNeil-Janssen), Rox 888, and Venasite. J. A. S. has given expert testimony for Finley, Alt, Smith, and Schamberg. S. S. S. receives research support from the National Institutes of Health and the Robert Wood Johnson Foundation. He received past research support from Wyeth Pharmaceuticals (completed September 2009); the funding was to his employer. All other authors: No reported conflicts. NR 341 TC 246 Z9 269 U1 2 U2 20 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2011 VL 53 IS 7 BP E25 EP E76 DI 10.1093/cid/cir531 PG 52 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 815AJ UT WOS:000294498200004 PM 21880587 ER PT J AU LaRocque, RC Jentes, ES AF LaRocque, Regina C. Jentes, Emily S. TI Health recommendations for international travel: a review of the evidence base of travel medicine SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE evidence-based medicine; international travel; travel medicine ID RABIES POSTEXPOSURE PROPHYLAXIS; 4-DOSE VACCINE SCHEDULE; ILL RETURNED TRAVELERS; MALARIA CHEMOPROPHYLAXIS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; DIARRHEA; CHILDREN; TRIAL; SURVEILLANCE AB Purpose of review International travel is increasing, including travel to countries with emerging economies. Travel may pose health risks for the individual and contribute to the global spread of infectious diseases. The specialty of travel medicine is aimed at minimizing health risks associated with international travel. The field has emerged in the past 25 years, and the evidence base supporting its clinical practice is growing. This review will describe the evidence base underlying travel medicine, highlight recently updated travel medicine guidelines, and outline future research priorities. Recent findings Recommendations for a number of common vaccines for travelers have been updated recently. More sophisticated detection methods are leading to the identification of a wider spectrum of pathogens associated with travelers' diarrhea, and antibiotic resistance is increasingly being identified. New treatment options for malaria are available, and a fifth Plasmodium species causing disease in humans has been identified. Summary An evidence base for the practice of travel medicine is emerging. Expert opinion and consensus guidelines continue to play an important role in supporting clinical practice. C1 [LaRocque, Regina C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [LaRocque, Regina C.] Harvard Univ, Sch Med, Boston, MA USA. [Jentes, Emily S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. RP LaRocque, RC (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Gray Jackson 520,55 Fruit St, Boston, MA 02114 USA. EM rclarocque@partners.org FU US Centers for Disease Control and Prevention [U19CI000514] FX R.C.L.R. is supported by funding from the US Centers for Disease Control and Prevention (U19CI000514). The authors are grateful to Dr Edward T. Ryan and Dr Phyllis Kozarsky for critical reading of the manuscript and to Robert Citorik for assistance with the figures. NR 48 TC 5 Z9 5 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD OCT PY 2011 VL 24 IS 5 BP 403 EP 409 DI 10.1097/QCO.0b013e32834a1aef PG 7 WC Infectious Diseases SC Infectious Diseases GA 814UD UT WOS:000294481800001 PM 21788892 ER PT J AU Caffrey, CR Secor, WE AF Caffrey, Conor R. Secor, W. Evan TI Schistosomiasis: from drug deployment to drug development SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE anthelmintic; praziquantel; schistosomiasis; TRND; tropical disease; WHO-TDR ID NEGLECTED TROPICAL DISEASES; HIGH-THROUGHPUT; IN-VITRO; RNA INTERFERENCE; MANSONI; PRAZIQUANTEL; EFFICACY; CHEMOTHERAPY; INFECTIONS; JAPONICUM AB Purpose of review Schistosomiasis is a chronic and morbid disease that affects hundreds of millions of the poorest individuals in (sub) tropical regions, particularly sub-Saharan Africa. Just one drug, praziquantel (PZQ), is available. As discussed, efforts to expand mass drug administration programs may accelerate the emergence of resistance. In addition, PZQ's peculiar pharmacological profile and undefined mechanism of action(s) complicate discriminating incomplete efficacy from true resistance. Accordingly, and in spite of the challenges associated with developing new antischistosomals as discussed herein, alternatives to PZQ should be identified. Various strategies to do this are highlighted here. Recent findings The last 2 years have witnessed more engagement of the necessary infrastructure combined with the application of the latest strategies and technologies to facilitate antischistosomal drug discovery. Preclinical and clinical evaluation of new chemistries has benefited from various consortia and institutions that underwrite drug development for antiparasitics in general. Drug repositioning, target-based drug design, improved automation for compound screening, genomics and functional genomics are just some of the tools now being applied to identify possible new drugs and drug targets. Summary The new momentum toward the discovery of alternatives to PZQ is encouraging but needs to be sustained by a stronger advocacy for drug development, in addition to drug deployment. C1 [Caffrey, Conor R.] Univ Calif San Francisco, Calif Inst Quantitat Biosci, Sandler Ctr Drug Discovery, San Francisco, CA 94158 USA. [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Caffrey, CR (reprint author), Univ Calif San Francisco, Calif Inst Quantitat Biosci, Sandler Ctr Drug Discovery, San Francisco, CA 94158 USA. EM conor.caffrey@ucsf.edu FU Sandler Foundation FX Research by C.R.C. is supported by the Sandler Foundation. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. NR 87 TC 36 Z9 37 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD OCT PY 2011 VL 24 IS 5 BP 410 EP 417 DI 10.1097/QCO.0b013e328349156f PG 8 WC Infectious Diseases SC Infectious Diseases GA 814UD UT WOS:000294481800002 PM 21734570 ER PT J AU Gray, SA Barr, JR Kalb, SR Marks, JD Baird, CL Cangelosi, GA Miller, KD Feldhaus, MJ AF Gray, Sean A. Barr, John R. Kalb, Suzanne R. Marks, James D. Baird, Cheryl L. Cangelosi, Gerard A. Miller, Keith D. Feldhaus, Michael J. TI Synergistic Capture of Clostridium botulinum Type A Neurotoxin by scFv Antibodies to Novel Epitopes SO BIOTECHNOLOGY AND BIOENGINEERING LA English DT Article DE affinity reagents; molecular probes; scFv; antibodies; BoNT/A; yeast display ID YEAST SURFACE DISPLAY; SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; PICHIA-PASTORIS; PHAGE LIBRARIES; BINDING DOMAIN; FLOW-CYTOMETRY; SEROTYPE-A; IMMUNE; DIFFERENTIATION AB A non-immune library of human single chain fragment variable (scFv) antibodies displayed on Saccharomyces cerevisiae was screened for binding to the Clostridium botulinum neurotoxin serotype A binding domain [BoNT/A (Hc)] with the goal of identifying scFv to novel epitopes. To do this, an antibody-mediated labeling strategy was used in which antigen-binding yeast clones were selected after labeling with previously characterized monoclonal antibodies (MAbs) specific to the Hc. Twenty unique scFv clones were isolated that bound Hc. Of these, 3 also bound to full-length BoNT/A toxin complex with affinities ranging from 5 to 48 nM. Epitope binning showed that the three unique clones recognized at least two epitopes distinct from one another as well as from the detection MAbs. After production in E. coli, scFv were coupled to magnetic particles and tested for their ability to capture BoNT/A holotoxin using an Endopep-MS assay. In this assay, toxin captured by scFv coated magnetic particles was detected by incubation of the complex with a peptide containing a BoNT/A-specific cleavage sequence. Mass spectrometry was used to detect the ratio of intact peptide to cleavage products as evidence for toxin capture. When tested individually, each of the scFv showed a weak positive Endopep-MS result. However, when the particles were coated with all three scFv simultaneously, they exhibited significantly higher Endopep-MS activity, consistent with synergistic binding. These results demonstrate novel approaches toward the isolation and characterization of scFv antibodies specific to unlabeled antigens. They also provide evidence that distinct scFv antibodies can work synergistically to increase the efficiency of antigen capture onto a solid support. Biotechnol. Bioeng. 2011; 108: 2456-2467. (C) 2011 Wiley Periodicals, Inc. C1 [Gray, Sean A.; Cangelosi, Gerard A.] Seattle Biomed Res Inst, Seattle, WA 98109 USA. [Barr, John R.; Kalb, Suzanne R.] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA. [Marks, James D.] Univ Calif San Francisco, Dept Anesthesia, San Francisco Gen Hosp, San Francisco, CA 94143 USA. [Baird, Cheryl L.; Miller, Keith D.] Pacific NW Natl Lab, Richland, WA 99352 USA. [Feldhaus, Michael J.] Adimab Inc, Lebanon, NH USA. RP Gray, SA (reprint author), Seattle Biomed Res Inst, 307 Westlake Ave N,Suite 500, Seattle, WA 98109 USA. EM sean.gray@seattlebiomed.org; keith.miller@pnl.gov RI Baird, Cheryl/F-6569-2011; OI Kalb, Suzanne/0000-0002-8067-136X FU Department of Energy; NIAID [R21 AI0744571, U01AI082186] FX Contract grant sponsor: Laboratory Directed Research and Development Program of the Department of Energy; Contract grant sponsor: NIAID; Contract grant number: R21 AI0744571; Contract grant sponsor: NIAID; Contract grant number: U01AI082186 NR 31 TC 2 Z9 2 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0006-3592 J9 BIOTECHNOL BIOENG JI Biotechnol. Bioeng. PD OCT PY 2011 VL 108 IS 10 BP 2456 EP 2467 DI 10.1002/bit.23196 PG 12 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 810EH UT WOS:000294107700021 PM 21538339 ER PT J AU Lucas, CE Taylor, TH Fields, BS AF Lucas, Claressa E. Taylor, Thomas H., Jr. Fields, Barry S. TI Accuracy and precision of Legionella isolation by US laboratories in the ELITE program pilot study SO WATER RESEARCH LA English DT Article DE Proficiency testing; Environmental sampling; Bacteria enumeration; Legionella monitoring ID WATER-SYSTEMS; NOSOCOMIAL LEGIONELLOSIS; ENVIRONMENTAL-SAMPLES; LEGIONNAIRES-DISEASE; PNEUMOPHILA; PREVENTION; RECOVERY; IDENTIFICATION; REQUIREMENTS; SURVEILLANCE AB A pilot study for the Environmental Legionella Isolation Techniques Evaluation (ELITE) Program, a proficiency testing scheme for US laboratories that culture Legionella from environmental samples, was conducted September 1, 2008 through March 31, 2009. Participants (n = 20) processed panels consisting of six sample types: pure and mixed positive, pure and mixed negative, pure and mixed variable. The majority (93%) of all samples (n = 286) were correctly characterized, with 88.5% of samples positive for Legionella and 100% of negative samples identified correctly. Variable samples were incorrectly identified as negative in 36.9% of reports. For all samples reported positive (n = 128), participants underestimated the cfu/ml by a mean of 1.25 logs with standard deviation of 0.78 logs, standard error of 0.07 logs, and a range of 3.57 logs compared to the CDC re-test value. Centering results around the interlaboratory mean yielded a standard deviation of 0.65 logs, standard error of 0.06 logs, and a range of 3.22 logs. Sampling protocol, treatment regimen, culture procedure, and laboratory experience did not significantly affect the accuracy or precision of reported concentrations. Qualitative and quantitative results from the ELITE pilot study were similar to reports from a corresponding proficiency testing scheme available in the European Union, indicating these results are probably valid for most environmental laboratories worldwide. The large enumeration error observed suggests that the need for remediation of a water system should not be determined solely by the concentration of Legionella observed in a sample since that value is likely to underestimate the true level of contamination. Published by Elsevier Ltd. C1 [Lucas, Claressa E.; Taylor, Thomas H., Jr.; Fields, Barry S.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Lucas, CE (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, 1600 Clifton Rd NE,MS G03, Atlanta, GA 30333 USA. EM chl9@cdc.gov FU Division of Environmental Hazards and Health Effects, NCEH FX The authors would like to thank the Safe Water Program of the Division of Environmental Hazards and Health Effects, NCEH for funding the ELITE Program implementation and website administration October 1, 2007 through September 30, 2009. The ELITE Program website URL is https://wwwn.cdc.gov/elite/Public/EliteHome.aspx. NR 38 TC 15 Z9 15 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0043-1354 J9 WATER RES JI Water Res. PD OCT 1 PY 2011 VL 45 IS 15 BP 4428 EP 4436 DI 10.1016/j.watres.2011.05.030 PG 9 WC Engineering, Environmental; Environmental Sciences; Water Resources SC Engineering; Environmental Sciences & Ecology; Water Resources GA 810BV UT WOS:000294101300011 PM 21726887 ER PT J AU Nasrullah, M Muazzam, S AF Nasrullah, Muazzam Muazzam, Sana TI Unintentional Struck by/Struck Against Injury Mortality in the United States, 1999-2006 SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Struck by; Unintentional; Fatal; Trends; United States ID CONSTRUCTION-INDUSTRY; OCCUPATIONAL INJURIES; HEALTH; SAFETY; DEATH AB Our study described demographics and trend analysis in unintentional struck by/struck against fatalities in the United States from 1999 to 2006, and identifies the changes in deaths for specific population subgroups. Mortality data came from the CDC's Web-based Injury Statistics Query and Reporting System. Trends during 1999-2006 were analyzed by gender, age group and race. Annual percentage change in deaths/rates and log-linear regression was used for time-trend analysis from 1999 to 2006, and examines its significance. During 1999-2006, there were 7,049 deaths; 6,236 (88.5%; 0.56 per 100,000) males, 6,180 (87.7%; 0.32 per 100,000) whites, and 1,925 (27.3%) aged 45-59 years. Overall deaths declined by 4.4% during 1999 to 2006 (P = 0.047 for time-related trend). The proportion of deaths was almost similar among males and females (1.1% vs. 0.3%; P = 0.58), and whites and blacks (0.8% vs. 0.7%; P = 0.44). Almost 21% of all deaths occur in only three states of the US i.e., Texas (n = 592; 0.35 per 100,000), California (n = 513; 0.18) and Florida (n = 375; 0.28). Sub-group analysis showed, injury mortality decreased 5% in males and 1% in females, this change was not statistically significant overtime in both sexes. Prevention efforts for struck by/struck against fatalities should be strengthened and surveillance for these deaths should continue to follow future trends. C1 [Nasrullah, Muazzam] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Nasrullah, Muazzam] W Virginia Univ, Dept Community Med, Sch Med, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Muazzam, Sana] Stanford Univ, Stanford Ctr Profess Dev, Stanford, CA 94305 USA. RP Nasrullah, M (reprint author), Ctr Dis Control & Prevent, Mailstop E-46, Atlanta, GA 30333 USA. EM snasrullah@cdc.gov NR 26 TC 0 Z9 0 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2011 VL 13 IS 5 BP 948 EP 953 DI 10.1007/s10903-010-9420-y PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 806ZN UT WOS:000293857400019 PM 21086045 ER PT J AU Menendez, CKC Havea, SA AF Menendez, Cammie K. Chaumont Havea, Solomone A. TI Temporal Patterns in Work-Related Fatalities Among Foreign-Born Workers in the US, 1992-2007 SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Foreign-born; Immigrant; Work-related; Occupational; Fatalities; Injuries ID OCCUPATIONAL-HEALTH; LATINO WORKERS; SAFETY; INJURIES; RISKS AB In the United States, approximately 20% of all workers who died on the job in 2007 were foreign-born. The objective of this study was to describe trends in occupational fatalities among foreign-born workers. An analysis of fatal injuries among foreign-born workers in the US occurring from 1992 through 2007 was conducted using the Bureau of Labor Statistics' Census of Fatal Occupational Injuries. Individual characteristics, employment characteristics, injury events and industry employment were summarized and evaluated for trends. Both the number and proportion of foreign-born workers who died from a traumatic work-related injury increased substantially over the time period studied. The proportion who were men, aged 25-44 years, Hispanic, non self-employed, employed by business establishments with 10 or fewer employees, working at private residences and working in Construction and Services consistently increased throughout the time period. While some trends among foreign-born decedents are improving, others are worsening. More comprehensive research efforts are needed to address the occupational injury and safety issues among foreign-born workers, with a focus on Hispanics. C1 [Menendez, Cammie K. Chaumont] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Havea, Solomone A.] Brigham Young Univ, Provo, UT 84602 USA. RP Menendez, CKC (reprint author), NIOSH, Div Safety Res, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 1811, Morgantown, WV 26505 USA. EM CMenendez@cdc.gov NR 23 TC 3 Z9 3 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD OCT PY 2011 VL 13 IS 5 BP 954 EP 962 DI 10.1007/s10903-010-9379-8 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 806ZN UT WOS:000293857400020 PM 20730494 ER PT J AU Li, Z Sjodin, A Romanoff, LC Horton, K Fitzgerald, CL Eppler, A Aguilar-Villalobos, M Naeher, LP AF Li, Zheng Sjoedin, Andreas Romanoff, Lovisa C. Horton, Kevin Fitzgerald, Christopher L. Eppler, Adam Aguilar-Villalobos, Manuel Naeher, Luke P. TI Evaluation of exposure reduction to indoor air pollution in stove intervention projects in Peru by urinary biomonitoring of polycyclic aromatic hydrocarbon metabolites SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Biomass burning; Solid fuel; Stove intervention; Polycyclic aromatic hydrocarbons; Peru; Biomonitoring ID ACUTE RESPIRATORY-INFECTIONS; DIBENZO-P-DIOXINS; SOLID-FUEL USE; OCCUPATIONAL-EXPOSURE; DEVELOPING-COUNTRIES; BIOMASS COMBUSTION; BIRTH-WEIGHT; WOOD SMOKE; 1-HYDROXYPYRENE; COOKSTOVES AB Burning biomass fuels such as wood on indoor open-pit stoves is common in developing regions. In such settings, exposure to harmful combustion products such as fine particulate matter (PM2.5), carbon monoxide (CO) and polycyclic aromatic hydrocarbons (PAHs) is of concern. We aimed to investigate if the replacement of open pit stoves by improved stoves equipped with a chimney would significantly reduce exposure to PAHs, PM2.5 and CO. Two stove projects were evaluated in Peru. Program A was part of the Juntos National Program in which households built their own stoves using materials provided. In Program B, Barrick Gold Corporation hired a company to produce and install the stoves locally. A total of 30 and 27 homes participated in Program A and B, respectively. We collected personal and kitchen air samples, as well as morning urine samples from women tasked with cooking in the households before and after the installation of the improved stoves. Median levels of PM2.5 and CO were significantly reduced in kitchen and personal air samples by 47-74% after the installation of the new stoves, while the median reduction of 10 urinary hydroxylate PAH metabolites (OH-PAHs) was 19%-52%. The observed OH-PAH concentration in this study was comparable or higher than the 95th percentile of the general U.S. population, even after the stove intervention, indicating a high overall exposure in this population. Published by Elsevier Ltd. C1 [Li, Zheng; Sjoedin, Andreas; Romanoff, Lovisa C.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Horton, Kevin; Fitzgerald, Christopher L.; Eppler, Adam; Naeher, Luke P.] Univ Georgia, Coll Publ Hlth, Athens, GA 30602 USA. [Aguilar-Villalobos, Manuel] Asociac Aire Ambiental, Lima, Peru. RP Li, Z (reprint author), 4770 Buford Highway,F-53, Atlanta, GA 30341 USA. EM ZJLi@cdc.gov RI Sjodin, Andreas/F-2464-2010 FU Barrick; Gobierno Regional de la Libertad; government of Santiago de Chuco FX This study was funded by the Voluntary Contribution of Barrick under an agreement with the Gobierno Regional de la Libertad. We would like to thank Barrick for their support of this project. Our deep appreciation goes to Jose Murgia Zanier and Dr. Pedro Diaz Camacho from the regional Government of La Libertad. We want to thank the local government of Santiago de Chuco for their help and support during this research. We also would like to acknowledge the work by the research team of Maria Antonieta Melendez, Stephen Dorner, Jessica Fitzgerald, Adam Gray, Elizabeth Irvin, and Daniel Pope for sample collection and logistics. Lastly, we would like to recognize Debra Trinidad, Erin Pittman, James Hand, Sandra Lester, Pam Olive, and Dr. Mary Kimberly for laboratory OH-PAH and creatinine measurements. NR 44 TC 37 Z9 39 U1 2 U2 33 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD OCT PY 2011 VL 37 IS 7 BP 1157 EP 1163 DI 10.1016/j.envint.2011.03.024 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA 805LM UT WOS:000293727900001 PM 21524795 ER PT J AU Barker, L Gerzoff, R Crespo, R Shrewsberry, M AF Barker, Lawrence Gerzoff, Robert Crespo, Richard Shrewsberry, Molly TI Age at diagnosis of diabetes in Appalachia SO POPULATION HEALTH METRICS LA English DT Article DE Appalachia; Diabetes: Disparities; Geography ID MELLITUS; CARE AB Background: Appalachia is a region of the United States noted for the poverty and poor health outcomes of its residents. Residents of the poorest Appalachian counties have a high prevalence of diabetes and risk factors (obesity, low income, low education, etc.) for type 2 diabetes. However, diabetes prevalence exceeds what these risk factors alone explain. Based on this, the history of poor health outcomes in Appalachia, and personally observed high rates of childhood obesity and lack of concern about prediabetes, we speculated that people in Appalachia with diagnosed diabetes might tend to be diagnosed younger than their non-Appalachian counterparts. Methods: We used data from the Behavioral Risk Factor Surveillance System (2006-2008). We compared age at diagnosis among counties by Appalachian Regional Commission-defined level of economic development. To account for risk differences, we constructed a model for average age at diagnosis of diabetes, adjusting for county economic development, obesity, income, sedentary lifestyle, and other covariates. Findings: After adjustment for risk factors for diabetes, people in distressed or at-risk counties (the least economically developed) had their diabetes diagnosed two to three years younger than comparable people in non-Appalachian counties. No significant differences between non-Appalachian counties and Appalachian counties at higher levels of economic development remained after adjusting. Conclusions: People in distressed and at-risk counties have poor access to care, and are unlikely to develop diabetes at the same age as their non-Appalachian counterparts but be diagnosed sooner. Therefore, people in distressed and at-risk counties are likely developing diabetes at younger ages. We recommend that steps to reduce health disparities between the poorest Appalachian counties and non-Appalachian counties be considered. C1 [Barker, Lawrence; Gerzoff, Robert] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Crespo, Richard; Shrewsberry, Molly] Marshall Univ, Dept Family & Community Med, Huntington, WV USA. RP Barker, L (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. EM lsb8@cdc.gov NR 21 TC 5 Z9 5 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-7954 J9 POPUL HEALTH METR JI Popul. Health Metr. PD SEP 30 PY 2011 VL 9 AR 54 DI 10.1186/1478-7954-9-54 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 891MC UT WOS:000300220200001 PM 21961697 ER PT J AU Zhao, GX Ford, ES Li, CY Greenlund, KJ Croft, JB Balluz, LS AF Zhao, Guixiang Ford, Earl S. Li, Chaoyang Greenlund, Kurt J. Croft, Janet B. Balluz, Lina S. TI Use of folic acid and vitamin supplementation among adults with depression and anxiety: a cross-sectional, population-based survey SO NUTRITION JOURNAL LA English DT Article DE folic acid; vitamins; depression; anxiety; elevated depressive symptoms; BRFSS ID FACTOR SURVEILLANCE SYSTEM; SERUM FOLATE; RISK-FACTOR; PSYCHIATRIC-PATIENTS; HOMOCYSTEINE LEVELS; MAJOR DEPRESSION; CONTROLLED-TRIAL; NATIONAL-HEALTH; PLASMA FOLATE; GLOBAL BURDEN AB Background: Evidence suggests that folate deficiency may be causatively linked to depressive symptoms. However, little is known on the status of use of folic acid and vitamin supplements among people with mental disorders. This study examined the prevalence and the likelihood of use of folic acid or vitamin supplements among adults with depression and anxiety in comparison to those without these conditions. Methods: Using data from 46, 119 participants (aged >= 18 years) in the 2006 Behavioral Risk Factor Surveillance System survey, we estimated the adjusted prevalence and odds ratios with 95% confidence intervals for taking folic acid and vitamin supplements among those with ever diagnosed depression (n = 8, 019), ever diagnosed anxiety (n = 5, 546) or elevated depressive symptoms (n = 3, 978, defined as having a depression severity score of >= 10 on the Patient Health Questionnaire-8 diagnostic algorithm). Results: Overall, women were more likely than men to take folic acid supplements 1-4 times/day (50.2% versus 38.7%, P < 0.001) and vitamin supplements (62.5% versus 49.8%, P < 0.001). After multivariate adjustment, men with ever diagnosed depression or anxiety were 42% and 83%, respectively, more likely to take folic acid supplements < 1 time/day; 44% and 39%, respectively, more likely to take folic acid supplements 1-4 times/day; and 40% and 46%, respectively, more likely to take vitamin supplements compared to men without these conditions (P < 0.05 for all comparisons). Women with ever diagnosed depression were 13% more likely to take folic acid supplements 1-4 times/day and 15% more likely to take vitamin supplements than women without this condition (P < 0.05 for both comparisons). Use of folic acid and vitamin supplements did not differ significantly by elevated depressive symptoms in either sex. Conclusion: The prevalence and the likelihood of taking folic acid and vitamin supplements varied substantially by a history of diagnosed depression among both men and women and by a history of diagnosed anxiety among men, but not by presence of elevated depressive symptoms in either sex. C1 [Zhao, Guixiang; Ford, Earl S.; Li, Chaoyang; Greenlund, Kurt J.; Croft, Janet B.; Balluz, Lina S.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Zhao, GX (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM gzhao@cdc.gov NR 62 TC 0 Z9 0 U1 0 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2891 J9 NUTR J JI Nutr. J. PD SEP 30 PY 2011 VL 10 AR 102 DI 10.1186/1475-2891-10-102 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 844AJ UT WOS:000296719100001 PM 21962075 ER PT J AU Nater, UM Maloney, E Heim, C Reeves, WC AF Nater, Urs M. Maloney, Elizabeth Heim, Christine Reeves, William C. TI Cumulative life stress in chronic fatigue syndrome SO PSYCHIATRY RESEARCH LA English DT Article DE Stress; Life events; Chronic fatigue syndrome ID POPULATION; DEFINITION; TRAUMA; RISK AB We studied the impact of cumulative life stress on CFS in a population-based study. We found that exposure to stressors was significantly more common in persons with CFS compared to NF controls; those with CFS reported experiencing significantly higher levels of psychological distress. Also, post-traumatic stress disorder was significantly more common in people with CFS. These results not only corroborate findings from other studies but, importantly, extend those by: a) measuring a comprehensive spectrum of stress variables, b) for the first time presenting data on stress in a population-based study, thus minimizing the effects of recruitment bias, and c) diagnosing CFS by means of standardized, validated scales, thus allowing replication and extension of our findings. Stress may be an important factor in the pathophysiology of CFS. Consequently, future studies should provide a more detailed understanding of the processes that lead from stress to CFS using longitudinal designs. Published by Elsevier Ireland Ltd. C1 [Nater, Urs M.; Maloney, Elizabeth; Reeves, William C.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol Proposed, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Nater, Urs M.] Univ Marburg, Dept Psychol, D-35032 Marburg, Germany. [Heim, Christine] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. RP Reeves, WC (reprint author), Ctr Dis Control & Prevent, Publ Hlth Surveillance Program Off, Mail Stop E-97,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM wcr1@cdc.gov RI Heim, Christine/A-1183-2009; Nater, Urs/J-6898-2013; OI Nater, Urs/0000-0002-2430-5090 FU Centers for Disease Control and Prevention; U.S. Department of Energy; Volkswagen Foundation; CDC FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC (UMN). The authors acknowledge the expertise of Abt Associates in managing the study. UMN acknowledges funding by the Volkswagen Foundation. NR 20 TC 15 Z9 15 U1 1 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD SEP 30 PY 2011 VL 189 IS 2 BP 318 EP 320 DI 10.1016/j.psychres.2011.07.015 PG 3 WC Psychiatry SC Psychiatry GA 831RG UT WOS:000295748200028 PM 21840607 ER PT J AU Schotthoefer, AM Bearden, SW Holmes, JL Vetter, SM Montenieri, JA Williams, SK Graham, CB Woods, ME Eisen, RJ Gage, KL AF Schotthoefer, Anna M. Bearden, Scott W. Holmes, Jennifer L. Vetter, Sara M. Montenieri, John A. Williams, Shanna K. Graham, Christine B. Woods, Michael E. Eisen, Rebecca J. Gage, Kenneth L. TI Effects of temperature on the transmission of Yersinia Pestis by the flea, Xenopsylla Cheopis, in the late phase period SO PARASITES & VECTORS LA English DT Article DE Yersinia pestis; Xenopsylla cheopis; biofilm; flea-borne transmission; temperature ID CTENOCEPHALIDES-FELIS; DEPENDENT VARIATIONS; PASTEURELLA-PESTIS; PLAGUE EPIZOOTICS; VECTOR COMPETENCE; RAT FLEA; BIOFILM; SIPHONAPTERA; EFFICIENCY; PULICIDAE AB Background: Traditionally, efficient flea-borne transmission of Yersinia pestis, the causative agent of plague, was thought to be dependent on a process referred to as blockage in which biofilm-mediated growth of the bacteria physically blocks the flea gut, leading to the regurgitation of contaminated blood into the host. This process was previously shown to be temperature-regulated, with blockage failing at temperatures approaching 30 degrees C; however, the abilities of fleas to transmit infections at different temperatures had not been adequately assessed. We infected colony-reared fleas of Xenopsylla cheopis with a wild type strain of Y. pestis and maintained them at 10, 23, 27, or 30 degrees C. Naive mice were exposed to groups of infected fleas beginning on day 7 post-infection (p.i.), and every 3 4 days thereafter until day 14 p.i. for fleas held at 10 degrees C, or 28 days p.i. for fleas held at 23-30 degrees C. Transmission was confirmed using Y. pestis-specific antigen or antibody detection assays on mouse tissues. Results: Although no statistically significant differences in per flea transmission efficiencies were detected between 23 and 30 degrees C, efficiencies were highest for fleas maintained at 23 degrees C and they began to decline at 27 and 30 degrees C by day 21 p.i. These declines coincided with declining median bacterial loads in fleas at 27 and 30 degrees C. Survival and feeding rates of fleas also varied by temperature to suggest fleas at 27 and 30 degrees C would be less likely to sustain transmission than fleas maintained at 23 degrees C. Fleas held at 10 degrees C transmitted Y. pestis infections, although flea survival was significantly reduced compared to that of uninfected fleas at this temperature. Median bacterial loads were significantly higher at 10 C than at the other temperatures. Conclusions: Our results suggest that temperature does not significantly effect the per flea efficiency of Y. pestis transmission by X. cheopis, but that temperature is likely to influence the dynamics of Y. pestis flea-borne transmission, perhaps by affecting persistence of the bacteria in the flea gut or by influencing flea survival. Whether Y. pestis biofilm production is important for transmission at different temperatures remains unresolved, although our results support the hypothesis that blockage is not necessary for efficient transmission. C1 [Schotthoefer, Anna M.; Bearden, Scott W.; Holmes, Jennifer L.; Vetter, Sara M.; Montenieri, John A.; Williams, Shanna K.; Graham, Christine B.; Woods, Michael E.; Eisen, Rebecca J.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot, Ft Collins, CO 80521 USA. [Schotthoefer, Anna M.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. [Vetter, Sara M.] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Woods, Michael E.] Lawrence Livermore Natl Lab, Livermore, CA 94550 USA. RP Schotthoefer, AM (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot, Ft Collins, CO 80521 USA. EM Schotthoefer.Anna@mcrf.mfldclin.edu NR 58 TC 8 Z9 8 U1 2 U2 24 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD SEP 29 PY 2011 VL 4 AR 191 DI 10.1186/1756-3305-4-191 PG 11 WC Parasitology SC Parasitology GA 834LM UT WOS:000295961200001 PM 21958555 ER PT J AU Bern, C AF Bern, Caryn TI Antitrypanosomal Therapy for Chronic Chagas' Disease REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID BENZNIDAZOLE C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Bern, C (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM cxb9@cdc.gov NR 5 TC 0 Z9 0 U1 2 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 29 PY 2011 VL 365 IS 13 BP 1259 EP 1259 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 825YO UT WOS:000295318400026 ER PT J AU Frieden, TR Berwick, DM AF Frieden, Thomas R. Berwick, Donald M. TI The "Million Hearts" Initiative - Preventing Heart Attacks and Strokes SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID DEATHS; US C1 [Frieden, Thomas R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Berwick, Donald M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 5 TC 131 Z9 134 U1 0 U2 11 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 29 PY 2011 VL 365 IS 13 AR UNSP e27 DI 10.1056/NEJMP1110421 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 825YO UT WOS:000295318400004 PM 21913835 ER PT J AU Martin, M Vanichseni, S Suntharasamai, P Sangkum, U Chuachoowong, R Mock, PA Leethochawalit, M Chiamwongpaet, S Kittimunkong, S van Griensven, F McNicholl, JM Paxton, L Choopanya, K AF Martin, Michael Vanichseni, Suphak Suntharasamai, Pravan Sangkum, Udomsak Chuachoowong, Rutt Mock, Philip A. Leethochawalit, Manoj Chiamwongpaet, Sithisat Kittimunkong, Somyot van Griensven, Frits McNicholl, Janet M. Paxton, Lynn Choopanya, Kachit CA Bangkok Tenofovir Study Grp TI Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand SO PLOS ONE LA English DT Article ID HIV VACCINE TRIAL; HUMAN-IMMUNODEFICIENCY-VIRUS; DISOPROXIL FUMARATE; RANDOMIZED-TRIAL; INFECTION; MACAQUES; EMTRICITABINE; PREVENTION; INCARCERATION; CHALLENGES AB Background: The Bangkok Tenofovir Study was launched in 2005 to determine if pre-exposure prophylaxis with tenofovir will reduce the risk of HIV infection among injecting drug users (IDUs). We describe recruitment, screening, enrollment, and baseline characteristics of study participants and contrast risk behavior of Tenofovir Study participants with participants in the 1999-2003 AIDSVAX B/E Vaccine Trial. Methods: The Bangkok Tenofovir Study is an ongoing, phase-3, randomized, double-blind, placebo-controlled, HIV pre-exposure prophylaxis trial of daily oral tenofovir. The Tenofovir Study and the Vaccine Trial were conducted among IDUs at 17 drug-treatment clinics in Bangkok. Tenofovir Study sample size was based on HIV incidence in the Vaccine Trial. Standardized questionnaires were used to collect demographic, risk behavior, and incarceration data. The Tenofovir Study is registered with ClinicalTrials.gov, number-NCT00119106. Results: From June 2005 through July 2010, 4094 IDUs were screened and 2413 enrolled in the Bangkok Tenofovir Study. The median age of enrolled participants was 31 years (range, 20-59), 80% were male, and 63% reported they injected drugs during the 3 months before enrollment. Among those who injected, 53% injected methamphetamine, 37% midazolam, and 35% heroin. Tenofovir Study participants were less likely to inject drugs, inject daily, or share needles (all, p<0.001) than Vaccine Trial participants. Discussion: The Bangkok Tenofovir Study has been successfully launched and is fully enrolled. Study participants are significantly less likely to report injecting drugs and sharing needles than participants in the 1999-2003 AIDSVAX B/E Vaccine Trial suggesting HIV incidence will be lower than expected. In response, the Bangkok Tenofovir Study enrollment was increased from 1600 to 2400 and the study design was changed from a defined 1-year follow-up period to an endpoint-driven design. Trial results demonstrating whether or not daily oral tenofovir reduces the risk of HIV infection among IDUs are expected in 2012. C1 [Martin, Michael; Chuachoowong, Rutt; Mock, Philip A.; van Griensven, Frits; McNicholl, Janet M.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [Martin, Michael; McNicholl, Janet M.; Paxton, Lynn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vanichseni, Suphak; Suntharasamai, Pravan; Sangkum, Udomsak; Choopanya, Kachit] Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Leethochawalit, Manoj; Chiamwongpaet, Sithisat] Bangkok Metropolitan Adm, Bangkok, Thailand. RP Martin, M (reprint author), US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. EM Znd9@cdc.gov RI van Griensven, Frits/G-4719-2013 OI van Griensven, Frits/0000-0002-0971-2843 FU US Centers for Disease Control and Prevention FX Sponsor (US Centers for Disease Control and Prevention) staff had a role in study design, the collection, analysis, and interpretation of data, writing the report, and in the decision to submit the paper for publication. NR 44 TC 28 Z9 29 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 28 PY 2011 VL 6 IS 9 AR e25127 DI 10.1371/journal.pone.0025127 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 834CT UT WOS:000295936900026 PM 21969870 ER PT J AU Lindsey, NP Lehman, JA Weaver, D Campbell, GL Staples, JE Fischer, M AF Lindsey, Nicole P. Lehman, Jennifer A. Weaver, Dustin Campbell, Grant L. Staples, J. Erin Fischer, Marc TI West Nile Virus Disease and Other Arboviral Diseases-United States, 2010 (Reprinted from MMWR vol 60, pg 1009, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID ENCEPHALITIS; EPIDEMIOLOGY C1 [Lindsey, Nicole P.; Lehman, Jennifer A.; Weaver, Dustin; Campbell, Grant L.; Staples, J. Erin; Fischer, Marc] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Lindsey, NP (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM nplindsey@cdc.gov NR 9 TC 0 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 28 PY 2011 VL 306 IS 12 BP 1316 EP 1318 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 825FQ UT WOS:000295257000009 ER PT J AU Denning, PH DiNenno, EA Wiegand, RE AF Denning, Paul H. DiNenno, Elizabeth A. Wiegand, Ryan E. TI Characteristics Associated With HIV Infection Among Heterosexuals in Urban Areas With High AIDS Prevalence-24 Cities, United States, 2006-2007 (Reprinted from MMWR vol 60, pg 1045, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Denning, Paul H.; DiNenno, Elizabeth A.; Wiegand, Ryan E.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Denning, PH (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM pdenning@cdc.gov NR 1 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 28 PY 2011 VL 306 IS 12 BP 1320 EP 1322 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 825FQ UT WOS:000295257000011 ER PT J AU Mattison, DR Plant, TM Lin, HM Chen, HC Chen, JJ Twaddle, NC Doerge, D Slikker, W Patton, RE Hotchkiss, CE Callicott, RJ Schrader, SM Turner, TW Kesner, JS Vitiello, B Petibone, DM Morris, SM AF Mattison, Donald R. Plant, Tony M. Lin, Hui-Min Chen, Hung-Chia Chen, James J. Twaddle, Nathan C. Doerge, Daniel Slikker, William, Jr. Patton, Ralph E. Hotchkiss, Charlotte E. Callicott, Ralph J. Schrader, Steven M. Turner, Terry W. Kesner, James S. Vitiello, Benedetto Petibone, Dayton M. Morris, Suzanne M. TI Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE attention deficit hyperactivity disorder; developmental delay; male puberty ID FOLLICLE-STIMULATING-HORMONE; INHIBIN-B; LUTEINIZING-HORMONE; GONADOTROPIN; TESTOSTERONE; SECRETION; RELEASE; SERTOLI; LEPTIN; RATS AB Juvenile male rhesus monkeys treated with methylphenidate hydrochloride (MPH) to evaluate genetic and behavioral toxicity were observed after 14 mo of treatment to have delayed pubertal progression with impaired testicular descent and reduced testicular volume. Further evaluation of animals dosed orally twice a day with (i) 0.5 mL/kg of vehicle (n = 10), (ii) 0.15 mg/kg of MPH increased to 2.5 mg/kg (low dose, n = 10), or (iii) 1.5 mg/kg of MPH increased to 12.5 mg/kg (high dose, n = 10) for a total of 40 mo revealed that testicular volume was significantly reduced (P < 0.05) at months 15 to 19 and month 27. Testicular descent was significantly delayed (P < 0.05) in the high-dose group. Significantly lower serum testosterone levels were detected in both the low-(P = 0.0017) and high-dose (P = 0.0011) animals through month 33 of treatment. Although serum inhibin B levels were increased overall in low-dose animals (P = 0.0328), differences between groups disappeared by the end of the study. Our findings indicate that MPH administration, beginning before puberty, and which produced clinically relevant blood levels of the drug, impaired pubertal testicular development until similar to 5 y of age. It was not possible to resolve whether MPH delayed the initiation of the onset of puberty or reduced the early tempo of the developmental process. Regardless, deficits in testicular volume and hormone secretion disappeared over the 40-mo observation period, suggesting that the impact of MPH on puberty is not permanent. C1 [Mattison, Donald R.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA. [Plant, Tony M.] Univ Pittsburgh, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA. [Lin, Hui-Min; Chen, Hung-Chia; Chen, James J.; Twaddle, Nathan C.; Doerge, Daniel; Slikker, William, Jr.; Petibone, Dayton M.; Morris, Suzanne M.] Natl Ctr Toxicol Res, Jefferson, AR 72079 USA. [Patton, Ralph E.] Toxicol Pathol Associates, Jefferson, AR 72079 USA. [Hotchkiss, Charlotte E.; Callicott, Ralph J.] Bionet Corp, Jefferson, AR 72079 USA. [Schrader, Steven M.; Turner, Terry W.; Kesner, James S.] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Vitiello, Benedetto] NIMH, Bethesda, MD 20892 USA. RP Mattison, DR (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA. EM mattisod@mail.nih.gov RI Mattison, Donald/L-4661-2013 OI Mattison, Donald/0000-0001-5623-0874 FU Eunice Kennedy Shriver National Institute for Child Health; Development/National Institutes of Health; National Center for Toxicological Research/Food and Drug Administration; National Center for Toxicological Research; National Institute for Occupational Safety and Health; Oak Ridge Institute for Science and Education; National Institute for Child Health and Human Development; National Institutes of Health [R01 HD 013254] FX This work was supported by an InterAgency Agreement between the Eunice Kennedy Shriver National Institute for Child Health and Development/National Institutes of Health and the National Center for Toxicological Research/Food and Drug Administration; an Interagency Agreement between the National Center for Toxicological Research and the National Institute for Occupational Safety and Health; an Interagency Agreement between the Oak Ridge Institute for Science and Education and the National Center for Toxicological Research/Food and Drug Administration (H.-M. L. and H.-C. C.); intramural funds from the National Institute for Child Health and Human Development (to D. R. M.); and National Institutes of Health Grant R01 HD 013254 (to T. M. P.). NR 21 TC 16 Z9 17 U1 1 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD SEP 27 PY 2011 VL 108 IS 39 BP 16301 EP 16306 DI 10.1073/pnas.1102187108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 825FB UT WOS:000295255300038 PM 21930929 ER PT J AU Payne, DC Humiston, S Opel, D Kennedy, A Wikswo, M Downing, K Klein, EJ Kobayashi, A Locke, D Albertin, C Chesley, C Staat, MA AF Payne, Daniel C. Humiston, Sharon Opel, Douglas Kennedy, Allison Wikswo, Mary Downing, Kimberly Klein, Eileen J. Kobayashi, Ana Locke, David Albertin, Christina Chesley, Claudia Staat, Mary A. TI A Multi-Center, Qualitative Assessment of Pediatrician and Maternal Perspectives on Rotavirus Vaccines and the Detection of Porcine circovirus SO BMC PEDIATRICS LA English DT Article DE rotavirus vaccine; RotaTeq (TM)?(TM); Rotarix (R)?(R); porcine circovirus (PCV); adventitious virus; pediatricians; communication development; focus groups ID HEALTH-CARE PROVIDERS; EFFICACY; SAFETY; VACCINATION; GASTROENTERITIS; TRANSMISSION; IMMUNIZATION; RECIPIENTS; ATTITUDES; RISK AB Background: In 2010, researchers using novel laboratory techniques found that US-licensed rotavirus vaccines contain DNA or DNA fragments from Porcine circovirus (PCV), a virus common among pigs but not believed to cause illness in humans. We sought to understand pediatricians' and mothers' perspectives on this finding. Methods: We conducted three iterations of focus groups for pediatricians and non-vaccine hesitant mothers in Seattle, WA, Cincinnati, OH, and Rochester, NY. Focus groups explored perceptions of rotavirus disease, rotavirus vaccination, and attitudes about the detection of PCV material in rotavirus vaccines. Results: Pediatricians understood firsthand the success of rotavirus vaccines in preventing severe acute gastroenteritis among infants and young children. They measured this benefit against the theoretical risk of DNA material from PCV in rotavirus vaccines, determining overall that the PCV finding was of no clinical significance. Particularly influential was the realization that the large, randomized clinical trials that found both vaccines to be highly effective and safe were conducted with DNA material from PCV already in the vaccines. Most mothers supported the ideal of full disclosure regarding vaccination risks and benefits. However, with a scientific topic of this complexity, simplified information regarding PCV material in rotavirus vaccines seemed frightening and suspicious, and detailed information was frequently overwhelming. Mothers often remarked that if they did not understand a medical or technical topic regarding their child's health, they relied on their pediatrician's guidance. Many mothers and pediatricians were also concerned that persons who abstain from pork consumption for religious or personal reasons may have unsubstantiated fears of the PCV finding. Conclusions: Pediatricians considered the detection of DNA material from PCV in rotavirus vaccines a "non-issue" and reported little hesitation in continuing to recommend the vaccines. Mothers desired transparency, but ultimately trusted their pediatrician's recommendation. Both vaccines are currently approved for their intended use, and no risk of human PCV illness has been reported. Communicating this topic to pediatricians and mothers requires sensitivity to a broad range of technical understanding and personal concerns. C1 [Payne, Daniel C.; Wikswo, Mary] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Humiston, Sharon; Albertin, Christina] Univ Rochester, Dept Pediat, Sch Med & Dent, Rochester, NY 14642 USA. [Humiston, Sharon] Childrens Mercy Hosp & Clin, Kansas City, MO USA. [Opel, Douglas; Klein, Eileen J.; Kobayashi, Ana] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Kennedy, Allison] Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Chesley, Claudia] Ctr Dis Control & Prevent, Off Director, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Locke, David; Staat, Mary A.] Univ Cincinnati, Med Ctr, Coll Med, Cincinnati Childrens Hosp,Dept Pediat, Cincinnati, OH 45267 USA. [Downing, Kimberly] Univ Cincinnati, Inst Policy Res, Cincinnati, OH 45267 USA. RP Payne, DC (reprint author), Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM dvp6@cdc.gov FU Merck Research Laboratories, Inc.; Rotavirus Advisory Board for Merck and Company; GlaxoSmithKline, Inc. FX Douglas Opel, MD, MPH No competing interests to declare Allison Kennedy, MPH No competing interests to declare Mary Wikswo, MPH No competing interests to declare Kimberly Downing, PhD No competing interests to declare Eileen J. Klein, MD, MPH No competing interests to declare Ana Kobayashi, MPH No competing interests to declare David Locke No competing interests to declare Christina Albertin, MPH No competing interests to declare Claudia Chesley No competing interests to declare Mary A. Staat, MD, MPH Past research funding from Merck Research Laboratories, Inc. and current funding from GlaxoSmithKline, Inc; Rotavirus Advisory Board for Merck and Company and GlaxoSmithKline, Inc. NR 28 TC 8 Z9 8 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2431 J9 BMC PEDIATR JI BMC Pediatr. PD SEP 26 PY 2011 VL 11 AR 83 DI 10.1186/1471-2431-11-83 PG 11 WC Pediatrics SC Pediatrics GA 832FO UT WOS:000295788400001 PM 21943237 ER PT J AU Palella, FJ Baker, RK Buchacz, K Chmiel, JS Tedaldi, EM Novak, RM Durham, MD Brooks, JT AF Palella, Frank J., Jr. Baker, Rose K. Buchacz, Kate Chmiel, Joan S. Tedaldi, Ellen M. Novak, Richard M. Durham, Marcus D. Brooks, John T. CA HOPS Investigators TI Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment SO AIDS LA English DT Article DE HAART; insurance; mortality; race/ethnicity ID ACTIVE ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; MISSED VISITS; AIDS; CARE; DEATH; RISK; RATES; ERA; IMMUNODEFICIENCY AB Objective: Understanding mortality differences among HIV-infected patients can focus efforts to improve survival. Design: We evaluated death rates, causes, and associated factors among treated patients in the HIV Outpatient Study (HOPS), a large, prospective, multicenter observational cohort of HIV-infected persons seen at a diverse set of US sites of care. Methods: Among 3754 HOPS participants seen during 1996-2007 with at least 6 months of follow-up after initiating HAART and receiving HAART at least 75% of time under observation ('substantially treated'), we calculated hazard ratios for death using proportional hazards regression models. We also examined death causes and comorbidities among decedents. Results: Substantially treated participants, followed a median 4.7 years (interquartile range, 2.2-8.5), experienced 331 deaths. In multivariable analyses, higher mortality was associated with an index CD4 cell count less than 200 cells/mu l [adjusted hazard ratio (aHR), 2.86; 95% confidence interval (CI) 1.95-4.21], older age (aHR, 1.50 per 10 years; 95% CI 1.33-1.70), log(10)HIV RNA (aHR, 1.67 per log(10); 95% CI 1.51-1.85), but not race/ethnicity (aHR, 0.99 for blacks vs. whites, P = 0.92). Mortality was increased among publicly insured (PUB) vs. privately insured participants (PRV) when index CD4 cell count was at least 200 cells/ml (aHR, 2.03; 95% CI 1.32-3.14) but not when index CD4 cell count was less than 200 cells/ml (aHR, 1.3, P = 0.13). By death cause, PUB had significantly more cardiovascular events and hepatic disorders than PRV. Comorbidities more frequent among PUB vs. PRV decedents included cardiovascular disease, renal impairment, and chronic hepatitis. Conclusion: Among HAART-treated participants with CD4 cell counts at least 200 cells/ml, PUB experienced higher death rates than PRV. Non-AIDS death and disease causes predominated among publicly insured decedents, suggesting that treatable comorbidities contributed to survival disparities. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Palella, Frank J., Jr.] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA. [Baker, Rose K.] Cerner Corp, Vienna, VA USA. [Buchacz, Kate; Durham, Marcus D.; Brooks, John T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tedaldi, Ellen M.] Temple Univ, Philadelphia, PA 19122 USA. [Novak, Richard M.] Univ Illinois, Chicago, IL USA. RP Palella, FJ (reprint author), Northwestern Univ, Feinberg Sch Med, Div Infect Dis, 645 N Michigan Ave,Suite 900, Chicago, IL 60611 USA. EM f-palella@northwestern.edu FU Centers for Disease Control and Prevention (CDC) [200-2006-18797] FX The HOPS is funded by the Centers for Disease Control and Prevention (CDC, contract no. 200-2006-18797). CDC authors listed on the masthead were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data, and preparation, review, or approval of the article as indicated below in the section detailing specific author contributions. NR 20 TC 18 Z9 18 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD SEP 24 PY 2011 VL 25 IS 15 BP 1865 EP 1876 DI 10.1097/QAD.0b013e32834b3537 PG 12 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 821AP UT WOS:000294947500007 PM 21811144 ER PT J AU Grabbe, KL Medley, A Bachanas, P Bock, N Marum, E AF Grabbe, Kristina L. Medley, Amy Bachanas, Pamela Bock, Naomi Marum, Elizabeth TI The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda SO AIDS LA English DT Letter ID SEXUAL-BEHAVIOR; COUPLES; INTERVENTIONS; PREVENTION; SEROCONVERSION C1 [Grabbe, Kristina L.; Medley, Amy; Bachanas, Pamela; Bock, Naomi; Marum, Elizabeth] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Grabbe, KL (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM kgrabbe@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD SEP 24 PY 2011 VL 25 IS 15 BP 1931 EP 1932 DI 10.1097/QAD.0b013e32834a9419 PG 2 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 821AP UT WOS:000294947500017 PM 21914980 ER PT J AU Oster, AM Wiegand, RE Sionean, C Miles, IJ Thomas, PE Le, BC Millett, GA AF Oster, Alexandra M. Wiegand, Ryan E. Sionean, Catlainn Miles, Isa J. Thomas, Peter E. Le, Binh C. Millett, Gregorio A. TI Reply to 'Evaluation of sexual networks as a cause for disparate HIV prevalence between blacks and whites: more questions than answers' SO AIDS LA English DT Letter ID RISK BEHAVIOR; PARTNER SELECTION; MEN; INFECTION C1 [Oster, Alexandra M.; Wiegand, Ryan E.; Sionean, Catlainn; Miles, Isa J.; Thomas, Peter E.; Le, Binh C.; Millett, Gregorio A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Oster, AM (reprint author), 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM AOster@cdc.gov NR 14 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD SEP 24 PY 2011 VL 25 IS 15 BP 1934 EP 1936 DI 10.1097/QAD.0b013e32834b35fd PG 3 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 821AP UT WOS:000294947500020 ER PT J AU Osorio, JE Huang, CYH Kinney, RM Stinchcomb, DT AF Osorio, Jorge E. Huang, Claire Y. -H. Kinney, Richard M. Stinchcomb, Dan T. TI Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever SO VACCINE LA English DT Article DE Dengue fever; Vaccine development; Dengue virus; DEN-2 PDK-53 virus; Recombinant viral vaccine ID ANTIBODY-DEPENDENT ENHANCEMENT; THAI CHILDREN; VIRUS-VACCINE; STRAIN 16681; HEMORRHAGIC-FEVER; ADULT VOLUNTEERS; IMMUNOGENICITY; INFECTION; SEROTYPES; SAFETY AB Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned. fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Osorio, Jorge E.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA. [Osorio, Jorge E.; Stinchcomb, Dan T.] Inviragen Inc, Madison, WI 53719 USA. [Osorio, Jorge E.; Stinchcomb, Dan T.] Inviragen Inc, Ft Collins, CO 80525 USA. [Huang, Claire Y. -H.; Kinney, Richard M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Osorio, JE (reprint author), Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA. EM osorio@svm.vetmed.wisc.edu OI Stinchcomb, Dan/0000-0002-3634-7503 FU Intramural CDC HHS [CC999999] NR 48 TC 51 Z9 53 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 23 PY 2011 VL 29 IS 42 SI SI BP 7251 EP 7260 DI 10.1016/j.vaccine.2011.07.020 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 830NA UT WOS:000295662500005 PM 21777638 ER PT J AU Schmitz, J Roehrig, J Barrett, A Hombach, J AF Schmitz, Julia Roehrig, John Barrett, Alan Hombach, Joachim TI Next generation dengue vaccines: A review of candidates in preclinical development SO VACCINE LA English DT Review DE Dengue vaccines; Dengue; Dengue virus ID ELICITS NEUTRALIZING ANTIBODIES; JAPANESE ENCEPHALITIS-VIRUS; RECOMBINANT FUSION PROTEIN; HEALTHY ADULT VOLUNTEERS; TETRAVALENT DNA VACCINE; FLAVIVIRUS-NAIVE ADULTS; B SURFACE-ANTIGEN; IMMUNE-RESPONSE; DOMAIN-III; NONHUMAN-PRIMATES AB Dengue represents a major public health problem of growing global importance. In the absence of specific dengue therapeutics, strategies for disease control have increasingly focused on the development of dengue vaccines. While a licensed dengue vaccine is not yet available, several vaccine candidates are currently being evaluated in clinical trials and are described in detail in accompanying articles. In addition, there are a large variety of candidates in preclinical development, which are based on diverse technologies, ensuring a continued influx of innovation into the development pipeline. Potentially, some of the current preclinical candidates may become next generation dengue vaccines with superior product profiles. This review provides an overview of the various technological approaches to dengue vaccine development and specifically focuses on candidates in preclinical development. (C) 2011 World Health Organization.. Published by Elsevier Ltd. All rights reserved. C1 [Schmitz, Julia; Hombach, Joachim] World Hlth Org, Initiat Vaccine Res, Geneva, Switzerland. [Roehrig, John] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. [Barrett, Alan] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX USA. RP Hombach, J (reprint author), World Hlth Org, Initiat Vaccine Res, Geneva, Switzerland. EM hombachj@who.int OI Roehrig, John/0000-0001-7581-0479 FU Bill and Melinda Gates Foundation FX Participants of the WHO/IVI Informal Consultation on Next Generation Dengue Vaccines and Diagnostics (1-2 November 2010, Atlanta) are thanked for sharing unpublished data. Preclinical stage dengue vaccine candidates were presented at the consultation by Drs. Martin Bachmann (Cytos Biotechnology), Gwong-Jen Chang (CDC), John Dong (GenPhar), Bruce Innis (GSK), Niranjan Y. Sardesai (Inovio Pharmaceuticals) and David B. Weiner (University of Pennsylvania), Alan Shaw (Vaxlnnate), Sathyamangalam Swaminathan (ICGEB), Erich Tauber (Themis Bioscience) and Laura White (UNC). Financial support of the consultation from the Bill and Melinda Gates Foundation is kindly acknowledged. NR 106 TC 66 Z9 69 U1 0 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 23 PY 2011 VL 29 IS 42 SI SI BP 7276 EP 7284 DI 10.1016/j.vaccine.2011.07.017 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 830NA UT WOS:000295662500008 PM 21781998 ER PT J AU Jeisy-Scott, V Davis, WG Patel, JR Bowzard, JB Shieh, WJ Zaki, SR Katz, JM Sambhara, S AF Jeisy-Scott, Victoria Davis, William G. Patel, Jenish R. Bowzard, John Bradford Shieh, Wun-Ju Zaki, Sherif R. Katz, Jacqueline M. Sambhara, Suryaprakash TI Increased MDSC Accumulation and Th2 Biased Response to Influenza A Virus Infection in the Absence of TLR7 in Mice SO PLOS ONE LA English DT Article ID INNATE IMMUNE-SYSTEM; SUPPRESSOR-CELLS; ALVEOLAR MACROPHAGES; STRANDED-RNA; RIG-I; DENDRITIC CELLS; AVIAN H5N1; CROSS-TALK; TNF-ALPHA; RECOGNITION AB Toll-like receptors (TLRs) play an important role in the induction of innate and adaptive immune response against influenza A virus (IAV) infection; however, the role of Toll-like receptor 7 (TLR7) during the innate immune response to IAV infection and the cell types affected by the absence of TLR7 are not clearly understood. In this study, we show that myeloid derived suppressor cells (MDSC) accumulate in the lungs of TLR7 deficient mice more so than in wild-type C57Bl/6 mice, and display increased cytokine expression. Furthermore, there is an increase in production of Th2 cytokines by TLR7(-/-) compared with wildtype CD4+ T-cells in vivo, leading to a Th2 polarized humoral response. Our findings indicate that TLR7 modulates the accumulation of MDSCs during an IAV infection in mice, and that lack of TLR7 signaling leads to a Th2-biased response. C1 [Jeisy-Scott, Victoria; Davis, William G.; Patel, Jenish R.; Bowzard, John Bradford; Katz, Jacqueline M.; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp, Atlanta, GA 30333 USA. [Shieh, Wun-Ju; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Jeisy-Scott, Victoria] Emory Univ, Atlanta, GA 30322 USA. RP Jeisy-Scott, V (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp, Atlanta, GA 30333 USA. EM ssambhara@cdc.gov OI Patel, Jenish/0000-0001-5310-8160; Tripp, Ralph/0000-0002-2924-9956 NR 58 TC 26 Z9 27 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 23 PY 2011 VL 6 IS 9 AR e25242 DI 10.1371/journal.pone.0025242 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 825IZ UT WOS:000295267100033 PM 21966467 ER PT J AU Belser, JA Jayaraman, A Raman, R Pappas, C Zeng, H Cox, NJ Katz, JM Sasisekharan, R Tumpey, TM AF Belser, Jessica A. Jayaraman, Akila Raman, Rahul Pappas, Claudia Zeng, Hui Cox, Nancy J. Katz, Jacqueline M. Sasisekharan, Ram Tumpey, Terrence M. TI Effect of D222G Mutation in the Hemagglutinin Protein on Receptor Binding, Pathogenesis and Transmissibility of the 2009 Pandemic H1N1 Influenza Virus SO PLOS ONE LA English DT Article ID SINGLE-AMINO-ACID; A VIRUSES; EPITHELIAL-CELLS; IN-VITRO; MICE; VIRULENCE; SUBSTITUTION; REPLICATION; INFECTION; HUMANS AB Influenza viruses isolated during the 2009 H1N1 pandemic generally lack known molecular determinants of virulence associated with previous pandemic and highly pathogenic avian influenza viruses. The frequency of the amino acid substitution D222G in the hemagglutinin (HA) of 2009 H1N1 viruses isolated from severe but not mild human cases represents the first molecular marker associated with enhanced disease. To assess the relative contribution of this substitution in virus pathogenesis, transmission, and tropism, we introduced D222G by reverse genetics in the wild-type HA of the 2009 H1N1 virus, A/California/04/09 (CA/04). A dose-dependent glycan array analysis with the D222G virus showed a modest reduction in the binding avidity to human-like (alpha 2-6 sialylated glycan) receptors and an increase in the binding to avian-like (alpha 2-3 sialylated glycan) receptors in comparison with wild-type virus. In the ferret pathogenesis model, the D222G mutant virus was found to be similar to wild-type CA/04 virus with respect to lethargy, weight loss and replication efficiency in the upper and lower respiratory tract. Moreover, based on viral detection, the respiratory droplet transmission properties of these two viruses were found to be similar. The D222G virus failed to productively infect mice inoculated by the ocular route, but exhibited greater viral replication and weight loss than wild-type CA/04 virus in mice inoculated by the intranasal route. In a more relevant human cell model, D222G virus replicated with delayed kinetics compared with wild-type virus but to higher titer in human bronchial epithelial cells. These findings suggest that although the D222G mutation does not influence virus transmission, it may be considered a molecular marker for enhanced replication in certain cell types. C1 [Belser, Jessica A.; Pappas, Claudia; Zeng, Hui; Cox, Nancy J.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jayaraman, Akila; Raman, Rahul; Sasisekharan, Ram] MIT, Harvard MIT Div Hlth Sci & Technol, Singapore MIT Alliance Res & Technol, Dept Biol Engn,Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. RP Belser, JA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tft9@cdc.gov RI Wei, Jianjian/F-7788-2011 OI Wei, Jianjian/0000-0001-8859-8462 FU Centers for Disease Control and Prevention; National Institutes of Health [R37 GM057073-13]; Singapore-MIT Alliance for Research and Technology FX The source of funding for this work was the Centers for Disease Control and Prevention. This work was funded in part by a merit award to RS (R37 GM057073-13) from the National Institutes of Health and the Singapore-MIT Alliance for Research and Technology. The authors acknowledge the Consortium for Functional Glycomics for providing the glycan standards. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 41 Z9 41 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 22 PY 2011 VL 6 IS 9 AR e25091 DI 10.1371/journal.pone.0025091 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 825IJ UT WOS:000295265100053 PM 21966421 ER PT J AU Dondorp, AM Fairhurst, RM Slutsker, L MacArthur, JR Breman, JG Guerin, PJ Wellems, TE Ringwald, P Newman, RD Plowe, CV AF Dondorp, Arjen M. Fairhurst, Rick M. Slutsker, Laurence MacArthur, John R. Breman, Joel G. Guerin, Philippe J. Wellems, Thomas E. Ringwald, Pascal Newman, Robert D. Plowe, Christopher V. TI The Threat of Artemisinin-Resistant Malaria SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID PLASMODIUM-FALCIPARUM; CAMBODIA C1 [Dondorp, Arjen M.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Fairhurst, Rick M.; Wellems, Thomas E.] NIAID, Lab Malaria & Vector Res, Bethesda, MD 20892 USA. [Slutsker, Laurence; MacArthur, John R.] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Breman, Joel G.] NIH, Fogarty Int Ctr, Bethesda, MD USA. [Guerin, Philippe J.] Univ Oxford, Worldwide Antimalarial Resistance Network, Ctr Trop Med, Oxford, England. [Ringwald, Pascal; Newman, Robert D.] World Hlth Org, Global Malaria Program, Geneva, Switzerland. [Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21201 USA. [Plowe, Christopher V.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. RP Dondorp, AM (reprint author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. FU Intramural NIH HHS [ZIA AI001000-06] NR 5 TC 126 Z9 130 U1 0 U2 13 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 22 PY 2011 VL 365 IS 12 BP 1073 EP 1075 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 822WR UT WOS:000295081600005 PM 21992120 ER PT J AU Cortes, JE Curns, AT Tate, JE Cortese, MM Patel, MM Zhou, FJ Parashar, UD AF Cortes, Jennifer E. Curns, Aaron T. Tate, Jacqueline E. Cortese, Margaret M. Patel, Manish M. Zhou, Fangjun Parashar, Umesh D. TI Rotavirus Vaccine and Health Care Utilization for Diarrhea in US Children SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID UNITED-STATES; GASTROENTERITIS; HOSPITALIZATIONS; EFFICACY; SAFETY; BURDEN; RATES AB Background Routine vaccination of U. S. infants with pentavalent rotavirus vaccine (RV5) began in 2006. Methods Using MarketScan databases, we assessed RV5 coverage and diarrhea-associated health care use from July 2007 through June 2009 versus July 2001 through June 2006 in children under 5 years of age. We compared the rates of diarrhea-associated health care use in unvaccinated children in the period from January through June (when rotavirus is most prevalent) in 2008 and 2009 with the prevaccine rates to estimate indirect benefits. We estimated national reductions in the number of hospitalizations for diarrhea, and associated costs, by extrapolation. Results By December 31, 2008, at least one dose of RV5 had been administered in 73% of children under 1 year of age, 64% of children 1 year of age, and 8% of children 2 to 4 years of age. Among children under 5 years of age, rates of hospitalization for diarrhea in 2001-2006, 2007-2008, and 2008-2009 were 52, 35, and 39 cases per 10,000 person-years, respectively, for relative reductions from 2001-2006 by 33% (95% confidence interval [CI], 31 to 35) in 2007-2008 and by 25% (95% CI, 23 to 27) in 2008-2009; rates of hospitalization specifically coded for rotavirus infection were 14, 4, and 6 cases per 10,000 person-years, respectively, for relative reductions in the rate from 2001-2006 by 75% (95% CI, 72 to 77) in 2007-2008 and by 60% (95% CI, 58 to 63) in 2008-2009. In the January-June periods of 2008 and 2009, the respective relative rate reductions among vaccinated children as compared with unvaccinated children were as follows: hospitalization for diarrhea, 44% (95% CI, 33 to 53) and 58% (95% CI, 52 to 64); rotavirus-coded hospitalization, 89% (95% CI, 79 to 94) and 89% (95% CI, 84 to 93); emergency department visits for diarrhea, 37% (95% CI, 31 to 43) and 48% (95% CI, 44 to 51); and outpatient visits for diarrhea, 9% (95% CI, 6 to 11) and 12% (95% CI, 10 to 15). Indirect benefits (in unvaccinated children) were seen in 2007-2008 but not in 2008-2009. Nationally, for the 2007-2009 period, there was an estimated reduction of 64,855 hospitalizations, saving approximately $278 million in treatment costs. Conclusions Since the introduction of rotavirus vaccine, diarrhea-associated health care utilization and medical expenditures for U. S. children have decreased substantially. C1 [Cortes, Jennifer E.; Curns, Aaron T.; Tate, Jacqueline E.; Cortese, Margaret M.; Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Cortes, Jennifer E.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Zhou, Fangjun] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Parashar, UD (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd,MS A-47, Atlanta, GA 30333 USA. EM uparashar@cdc.gov FU NCI NIH HHS [P30 CA016672] NR 25 TC 85 Z9 87 U1 0 U2 6 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 22 PY 2011 VL 365 IS 12 BP 1108 EP 1117 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 822WR UT WOS:000295081600010 PM 21992123 ER PT J AU Groenewold, MR Tak, SW Masterson, E AF Groenewold, Matthew R. Tak, Sang-woo Masterson, Elizabeth TI Severe Hearing Impairment Among Military Veterans-United States, 2010 (Reprinted from MMWR, vol 60, pg 955-958, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Groenewold, Matthew R.; Tak, Sang-woo; Masterson, Elizabeth] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Atlanta, GA 30333 USA. RP Groenewold, MR (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Atlanta, GA 30333 USA. EM mgroenewold@cdc.gov NR 1 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 21 PY 2011 VL 306 IS 11 BP 1192 EP 1194 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 822HB UT WOS:000295033500009 ER PT J AU Fierer, DS Factor, SH Uriel, AJ Carriero, DC Dieterich, DT Mullen, MP Klepper, A van Seggelen, W Childs, K Branch, AD Holtzman, D Ward, JW Khudyakov, Y Holmberg, SD AF Fierer, Daniel S. Factor, Stephanie H. Uriel, Alison J. Carriero, Damaris C. Dieterich, Douglas T. Mullen, Michael P. Klepper, Arielle van Seggelen, Wouter Childs, Kathryn Branch, Andrea D. Holtzman, Deborah Ward, John W. Khudyakov, Yury Holmberg, Scott D. TI Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex With Men-New York City, 2005-2010 (Reprinted from MMWR, vol 60, pg 945-950, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Holtzman, Deborah; Ward, John W.; Khudyakov, Yury; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Fierer, Daniel S.; Factor, Stephanie H.; Uriel, Alison J.; Carriero, Damaris C.; Dieterich, Douglas T.; Mullen, Michael P.; Klepper, Arielle; van Seggelen, Wouter; Childs, Kathryn; Branch, Andrea D.] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Holtzman, D (reprint author), CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM dholtzman@cdc.gov NR 1 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 21 PY 2011 VL 306 IS 11 BP 1194 EP 1196 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 822HB UT WOS:000295033500010 ER PT J AU Stokley, S Stanwyck, C Avey, B Greby, S AF Stokley, Shannon Stanwyck, Carol Avey, Bob Greby, Stacie TI Vaccination Coverage Among Children in Kindergarten-United States, 2009-10 School Year (Reprinted from MMWR, vol 60, pg 700-704, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID NONMEDICAL EXEMPTIONS; MEASLES C1 [Stokley, Shannon; Stanwyck, Carol; Avey, Bob; Greby, Stacie] CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Stokley, S (reprint author), CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM sstokley@cdc.gov NR 11 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 21 PY 2011 VL 306 IS 11 BP 1196 EP 1198 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 822HB UT WOS:000295033500011 ER PT J AU Sonnenfeld, N Decker, SL Schappert, SM AF Sonnenfeld, Nancy Decker, Sandra L. Schappert, Susan M. TI Trends in Emergency Department Visits Among Medicaid Patients SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Sonnenfeld, Nancy; Decker, Sandra L.; Schappert, Susan M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Sonnenfeld, N (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM sdecker@cdc.gov NR 2 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 21 PY 2011 VL 306 IS 11 BP 1202 EP 1203 DI 10.1001/jama.2011.1326 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 822HB UT WOS:000295033500019 PM 21934052 ER PT J AU Ramachandran, S Zhai, XJ Thai, H Campo, DS Xia, GL Ganova-Raeva, LM Drobeniuc, J Khudyakov, YE AF Ramachandran, Sumathi Zhai, Xiangjun Thai, Hong Campo, Davis S. Xia, Guoliang Ganova-Raeva, Lilia M. Drobeniuc, Jan Khudyakov, Yury E. TI Evaluation of Intra-Host Variants of the Entire Hepatitis B Virus Genome SO PLOS ONE LA English DT Article ID DRUG-RESISTANCE MUTATIONS; C VIRUS; DIFFERENT GENOTYPES; HIGH-THROUGHPUT; RECOMBINATION; THERAPY; PCR; POLYMERASE; LAMIVUDINE; EVOLUTION AB Genetic analysis of hepatitis B virus (HBV) frequently involves study of intra-host variants, identification of which is commonly achieved using short regions of the HBV genome. However, the use of short sequences significantly limits evaluation of genetic relatedness among HBV strains. Although analysis of HBV complete genomes using genetic cloning has been developed, its application is highly labor intensive and practiced only infrequently. We describe here a novel approach to whole genome (WG) HBV quasispecies analysis based on end-point, limiting-dilution real-time PCR (EPLD-PCR) for amplification of single HBV genome variants, and their subsequent sequencing. EPLD-PCR was used to analyze WG quasispecies from serum samples of patients (n = 38) infected with HBV genotypes A, B, C, D, E and G. Phylogenetic analysis of the EPLD-isolated HBV-WG quasispecies showed the presence of mixed genotypes, recombinant variants and sub-populations of the virus. A critical observation was that HBV-WG consensus sequences obtained by direct sequencing of PCR fragments without EPLD are genetically close, but not always identical to the major HBV variants in the intra-host population, thus indicating that consensus sequences should be judiciously used in genetic analysis. Sequence-based studies of HBV WG quasispecies should afford a more accurate assessment of HBV evolution in various clinical and epidemiological settings. C1 [Ramachandran, Sumathi; Thai, Hong; Campo, Davis S.; Xia, Guoliang; Ganova-Raeva, Lilia M.; Drobeniuc, Jan; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Zhai, Xiangjun] Jiangsu Ctr Dis Control, Nanjing, Jiangsu, Peoples R China. RP Ramachandran, S (reprint author), Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM dcq6@cdc.gov RI Campo, David S./C-5072-2011 OI Campo, David S./0000-0002-8970-3436 NR 44 TC 9 Z9 10 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 20 PY 2011 VL 6 IS 9 AR e25232 DI 10.1371/journal.pone.0025232 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 825GY UT WOS:000295260400055 PM 21949887 ER PT J AU Roberts, B Morgan, OW Sultani, MG Nyasulu, P Rwebangila, S Sondorp, E Chandramohan, D Checchi, F AF Roberts, Bayard Morgan, Oliver W. Sultani, Mohammed Ghaus Nyasulu, Peter Rwebangila, Sunday Sondorp, Egbert Chandramohan, Daniel Checchi, Francesco TI Economic Feasibility of a New Method to Estimate Mortality in Crisis-Affected and Resource-Poor Settings SO PLOS ONE LA English DT Article AB Introduction: Mortality data provide essential evidence on the health status of populations in crisis-affected and resource-poor settings and to guide and assess relief operations. Retrospective surveys are commonly used to collect mortality data in such populations, but require substantial resources and have important methodological limitations. We evaluated the feasibility of an alternative method for rapidly quantifying mortality (the informant method). The study objective was to assess the economic feasibility of the informant method. Methods: The informant method captures deaths through an exhaustive search for all deaths occurring in a population over a defined and recent recall period, using key community informants and next-of-kin of decedents. Between July and October 2008, we implemented and evaluated the informant method in: Kabul, Afghanistan; Mae La camp for Karen refugees, Thai-Burma border; Chiradzulu District, Malawi; and Lugufu and Mtabila refugee camps, Tanzania. We documented the time and cost inputs for the informant method in each site, and compared these with projections for hypothetical retrospective mortality surveys implemented in the same site with a 6 month recall period and with a 30 day recall period. Findings: The informant method was estimated to require an average of 29% less time inputs and 33% less monetary inputs across all four study sites when compared with retrospective surveys with a 6 month recall period, and 88% less time inputs and 86% less monetary inputs when compared with retrospective surveys with a 1 month recall period. Verbal autopsy questionnaires were feasible and efficient, constituting only 4% of total person-time for the informant method's implementation in Chiradzulu District. Conclusions: The informant method requires fewer resources and incurs less respondent burden. The method's generally impressive feasibility and the near real-time mortality data it provides warrant further work to develop the method given the importance of mortality measurement in such settings. C1 [Roberts, Bayard; Sultani, Mohammed Ghaus; Sondorp, Egbert] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1, England. [Morgan, Oliver W.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Nyasulu, Peter] Med Sans Frontieres France, Malawi Programme, Chiradzulu, Malawi. [Rwebangila, Sunday] United Nations High Commissioner Refugees, Tanzania Off, Kigoma, Tanzania. [Chandramohan, Daniel; Checchi, Francesco] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England. RP Roberts, B (reprint author), London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1, England. EM bayard.roberts@lshtm.ac.uk FU Office of Health, Infectious Disease, and Nutrition; FANTA Project [HRN-A-00-98-00046-00]; Bureau for Global Health; United States Agency for International Development (USAID) [GHN-A-00-08-00001-00] FX This study was funded by the Office of Health, Infectious Disease, and Nutrition, Bureau for Global Health, United States Agency for International Development (USAID), through both the FANTA-2 Project under the terms of Cooperative Agreement Number GHN-A-00-08-00001-00, and the FANTA Project (1998-2008) under the terms of Cooperative Agreement Number HRN-A-00-98-00046-00, managed by the Academy for Educational Development (AED). The contents do not necessarily reflect the views of USAID or the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 13 TC 1 Z9 1 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 19 PY 2011 VL 6 IS 9 AR e25175 DI 10.1371/journal.pone.0025175 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 825FZ UT WOS:000295257900057 PM 21949879 ER PT J AU Neal, COS Richardson, AO Hurst, SF Tortorano, AM Viviani, MA Stevens, DA Balajee, SA AF Neal, Carolyn O. S. Richardson, Aaron O. Hurst, Steven F. Tortorano, Anna Maria Viviani, Maria Anna Stevens, David A. Balajee, S. Arunmozhi TI Global population structure of Aspergillus terreus inferred by ISSR typing reveals geographical subclustering SO BMC MICROBIOLOGY LA English DT Article ID AMPHOTERICIN-B; FUMIGATUS; EPIDEMIOLOGY; MALIGNANCIES; INFECTIONS; INNSBRUCK AB Background: Aspergillus terreus causes invasive aspergillosis (IA) in immunocompromised individuals and can be the leading cause of IA in certain medical centers. We examined a large isolate collection (n = 117) for the presence of cryptic A. terreus species and employed a genome scanning method, Inter-Simple Sequence Repeat (ISSR) PCR to determine A. terreus population structure. Results: Comparative sequence analyses of the calmodulin locus revealed the presence of the recently recognized species A. alabamensis (n = 4) in this collection. Maximum parsimony, Neighbor joining, and Bayesian clustering of the ISSR data from the 113 sequence-confirmed A. terreus isolates demonstrated that one clade was composed exclusively of isolates from Europe and another clade was enriched for isolates from the US. Conclusions: This study provides evidence of a population structure linked to geographical origin in A. terreus. C1 [Neal, Carolyn O. S.; Hurst, Steven F.; Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30329 USA. [Richardson, Aaron O.] Univ Georgia, Dept Plant Biol, Athens, GA 30602 USA. [Tortorano, Anna Maria; Viviani, Maria Anna] Univ Milan, Dipartimento Sanita Publ Microbiol Virol, I-20133 Milan, Italy. [Stevens, David A.] Stanford Univ, Sch Med, Santa Clara Valley Med Ctr, Dept Med,Div Infect Dis, San Jose, CA 95128 USA. RP Balajee, SA (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM fir3@cdc.gov OI Tortorano, Anna Maria/0000-0003-2093-8250 FU Emerging Infectious Diseases Fellowship; Association of Public Health Laboratories; Centers for Disease Control and Prevention FX The authors would like to thank Oliver Clay and Sujatha Seenu for providing assistance with PERL and R scripts. Carolyn Neal was supported by the Emerging Infectious Diseases Fellowship sponsored by the Association of Public Health Laboratories and the Centers for Disease Control and Prevention. NR 18 TC 8 Z9 9 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2180 J9 BMC MICROBIOL JI BMC Microbiol. PD SEP 16 PY 2011 VL 11 AR 203 DI 10.1186/1471-2180-11-203 PG 7 WC Microbiology SC Microbiology GA 835AJ UT WOS:000296005300001 PM 21923908 ER PT J AU Williams, SE Klein, NP Halsey, N Dekker, CL Baxter, RP Marchant, CD LaRussa, PS Sparks, RC Tokars, JI Pahud, BA Aukes, L Jakob, K Coronel, S Choi, H Slade, BA Edwards, KM AF Williams, S. Elizabeth Klein, Nicola P. Halsey, Neal Dekker, Cornelia L. Baxter, Roger P. Marchant, Colin D. LaRussa, Philip S. Sparks, Robert C. Tokars, Jerome I. Pahud, Barbara A. Aukes, Laurie Jakob, Kathleen Coronel, Silvia Choi, Howard Slade, Barbara A. Edwards, Kathryn M. TI Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009 SO VACCINE LA English DT Review DE Adverse event following immunization; Causality ID PNEUMOCOCCAL CONJUGATE VACCINE; INACTIVATED INFLUENZA VACCINE; GUILLAIN-BARRE-SYNDROME; UNITED-STATES; YELLOW-FEVER; VISCEROTROPIC DISEASE; ADVISORY-COMMITTEE; REPORTING SYSTEM; GREEN CHANNEL; SURVEILLANCE AB Background: In 2004 the Clinical Consult Case Review (CCCR) working group was formed within the CDC-funded Clinical Immunization Safety Assessment (CISA) Network to review individual cases of adverse events following immunizations (AEFI). Methods: Cases were referred by practitioners, health departments, or CDC employees. Vaccine Adverse Event Reporting System (VAERS) searches and literature reviews for similar cases were performed prior to review. After CCCR discussion, AEFI were assessed for a causal relationship with vaccination and recommendations regarding future immunizations were relayed back to the referring physicians. In 2010, surveys were sent to referring physicians to determine the utility and effectiveness of the CCCR service. Results: CISA investigators reviewed 76 cases during 68 conference calls between April 2004 and December 2009. Almost half of the cases (35/76) were neurological in nature. Similar AEFI for the specific vaccines received were discovered for 63 cases through VAERS searches and for 38 cases through PubMed searches. Causality assessment using the modified WHO criteria resulted in classifying 3 cases as definitely related to vaccine administration, 12 as probably related, 16 as possibly related, 18 as unlikely related, 10 as unrelated, and 17 had insufficient information to assign causality. The physician satisfaction survey was returned by 30(57.7%) of those surveyed and a majority of respondents (93.3%) felt that the CCCR service was useful. Conclusions: The CCCR provides advice about AEFI to practitioners, assigns potential causality, and contributes to an improved understanding of adverse health events following immunizations. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Williams, S. Elizabeth; Sparks, Robert C.; Edwards, Kathryn M.] Vanderbilt Univ Sch Med, Nashville, TN 37203 USA. [Klein, Nicola P.; Baxter, Roger P.; Aukes, Laurie] No Calif Kaiser Permanente, Oakland, CA USA. [Halsey, Neal; Choi, Howard] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. [Dekker, Cornelia L.; Pahud, Barbara A.] Stanford Univ Med Ctr, Stanford, CA USA. [Marchant, Colin D.; Coronel, Silvia] Boston Med Ctr, Boston, MA USA. [LaRussa, Philip S.; Jakob, Kathleen] Columbia Univ, New York, NY USA. [Tokars, Jerome I.; Slade, Barbara A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Williams, SE (reprint author), Vanderbilt Univ Sch Med, Nashville, TN 37203 USA. EM elizabeth.williams@vanderbilt.edu FU Clinical Immunization and Safety Assessment (CISA) network through Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX We would like to acknowledge the contributions of Dr. Mel Berger, Dr. Steve Dreskin, Dr. Peter Donofrio, Dr. Brian McGeeney, Dr. Gerald Fenichel, Susan Swope, Rosanna Setse, Virginia Frontiero and the Vaccine Healthcare Centers Network, including Dr. Jay Montgomery, Dr. Limone Collins and Dr. Renata Engler. This work was supported by the Clinical Immunization and Safety Assessment (CISA) network through a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). NR 57 TC 12 Z9 12 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 16 PY 2011 VL 29 IS 40 BP 6920 EP 6927 DI 10.1016/j.vaccine.2011.07.044 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 825RT UT WOS:000295300500014 PM 21801776 ER PT J AU Lu, PJ Byrd, KK Murphy, TV Weinbaum, C AF Lu, Peng-jun Byrd, Kathy K. Murphy, Trudy V. Weinbaum, Cindy TI Hepatitis B vaccination coverage among high-risk adults 18-49 years, US, 2009 SO VACCINE LA English DT Article DE Hepatitis B vaccine; Vaccination; Coverage; Adult; High-risk ID UNITED-STATES; MISSED OPPORTUNITIES; PROGRAM AB Background: Approximately 43,000 new hepatitis B virus (HBV) infections occurred in 2007. Although hepB vaccination has been recommended for adults at high-risk for incident HBV infection for many years, coverage remains low. Methods: We used the 2009 National Health Interview Survey to assess self-reported HepB vaccine uptake (>= 1 dose), series completion (>= 3 dose), and independent predictors of vaccination among high-risk adults aged 18-49 years. High-risk adults were defined as those reporting male sex with men; injection drug use; hemophilia with receipt of clotting factors; sexually transmitted disease in prior five years; sex for money or drugs; HIV positive; sex with persons having any above risk factors; or who "felt they were at high risk for HIV". Persons with none of the aforementioned risk factors were considered non-high risk. Bivariate analysis was conducted to assess vaccination coverage. Independent predictors of vaccine uptake and series completion were determined using a logistic regression. Results: Overall, 7.0% adults aged 18-49 years had high-risk behaviors. Unadjusted coverage with >= 1 dose was 50.5% among high-risk compared to 40.5% among non-high-risk adults (p-values <0.001) while series completion (>= 3 doses) was 41.8% and 34.2%, respectively (p-values <0.001). On multivariable analysis, >= 1 dose coverage, but not series completion, was higher (Risk Ratio 1.1, 95% Cl = 1.0-1.2, p-value = 0.021) among high-risk compared to non-high risk adults. Other characteristics independently associated with a higher likelihood of HepB vaccination among persons 18-49 years included younger age groups, females, higher education, >= 2 physician contacts in the past year, ever tested for HIV, health care personnel, received influenza vaccination in the previous year, and ever received hepatitis A vaccination. Vaccine uptake with >= 1 dose increased by 5.1% (p = 0.047) among high-risk adults between 2004 and 2009. Conclusions: A small increase in >= 1 dose HepB vaccination coverage among high-risk adults compared with non-high risk adults was documented for the first time in 2009. Higher coverage among persons 18-30 years may reflect aging of persons vaccinated when they were children and adolescents. To improve protection against hepatitis B among high-risk adults, healthcare providers should offer hepatitis B vaccination to persons at high risk and those who seek vaccination to protect themselves and facilitate timely completion of the three (3) dose HepB series. Published by Elsevier Ltd. C1 [Lu, Peng-jun] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Byrd, Kathy K.; Murphy, Trudy V.; Weinbaum, Cindy] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop E-62, Atlanta, GA 30333 USA. EM plu@cdc.gov NR 39 TC 23 Z9 25 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 16 PY 2011 VL 29 IS 40 BP 7049 EP 7057 DI 10.1016/j.vaccine.2011.07.030 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 825RT UT WOS:000295300500029 PM 21782873 ER PT J AU Griffing, SM Mixson-Hayden, T Sridaran, S Alam, MT McCollum, AM Cabezas, C Quezada, WM Barnwell, JW De Oliveira, AM Lucas, C Arrospide, N Escalante, AA Bacon, DJ Udhayakumar, V AF Griffing, Sean M. Mixson-Hayden, Tonya Sridaran, Sankar Alam, Md Tauqeer McCollum, Andrea M. Cabezas, Cesar Marquino Quezada, Wilmer Barnwell, John W. De Oliveira, Alexandre Macedo Lucas, Carmen Arrospide, Nancy Escalante, Ananias A. Bacon, David J. Udhayakumar, Venkatachalam TI South American Plasmodium falciparum after the Malaria Eradication Era: Clonal Population Expansion and Survival of the Fittest Hybrids SO PLOS ONE LA English DT Article ID SULFADOXINE-PYRIMETHAMINE RESISTANCE; CHLOROQUINE-RESISTANCE; DRUG-RESISTANCE; PERUVIAN AMAZON; MICROSATELLITE MARKERS; MULTIDRUG-RESISTANCE; PARASITIC PROTOZOA; GENETIC DIVERSITY; BRAZILIAN AMAZON; SELECTIVE SWEEPS AB Malaria has reemerged in many regions where once it was nearly eliminated. Yet the source of these parasites, the process of repopulation, their population structure, and dynamics are ill defined. Peru was one of malaria eradication's successes, where Plasmodium falciparum was nearly eliminated for two decades. It reemerged in the 1990s. In the new era of malaria elimination, Peruvian P. falciparum is a model of malaria reinvasion. We investigated its population structure and drug resistance profiles. We hypothesized that only populations adapted to local ecological niches could expand and repopulate and originated as vestigial populations or recent introductions. We investigated the genetic structure (using microsatellites) and drug resistant genotypes of 220 parasites collected from patients immediately after peak epidemic expansion (19992000) from seven sites across the country. The majority of parasites could be grouped into five clonal lineages by networks and AMOVA. The distribution of clonal lineages and their drug sensitivity profiles suggested geographic structure. In 2001, artesunate combination therapy was introduced in Peru. We tested 62 parasites collected in 2006-2007 for changes in genetic structure. Clonal lineages had recombined under selection for the fittest parasites. Our findings illustrate that local adaptations in the post-eradication era have contributed to clonal lineage expansion. Within the shifting confluence of drug policy and malaria incidence, populations continue to evolve through genetic outcrossing influenced by antimalarial selection pressure. Understanding the population substructure of P. falciparum has implications for vaccine, drug, and epidemiologic studies, including monitoring malaria during and after the elimination phase. C1 [Griffing, Sean M.; Mixson-Hayden, Tonya; Sridaran, Sankar; Alam, Md Tauqeer; McCollum, Andrea M.; Barnwell, John W.; De Oliveira, Alexandre Macedo; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Griffing, Sean M.; Mixson-Hayden, Tonya; Alam, Md Tauqeer; McCollum, Andrea M.] Atlanta Res & Educ Fdn, Decatur, GA USA. [Griffing, Sean M.] Emory Univ, Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. [Sridaran, Sankar] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Cabezas, Cesar; Marquino Quezada, Wilmer; Arrospide, Nancy] Inst Nacl Salud, Lima, Peru. [Lucas, Carmen; Bacon, David J.] Naval Med Res Ctr Detachment, Parasitol Program, Lima, Peru. [Escalante, Ananias A.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA. RP Griffing, SM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA. EM vxu0@cdc.gov RI Valle, Ruben/A-7512-2013; OI ARROSPIDE, NANCY/0000-0001-5031-5850 FU National Science Foundation; Association of Public Health Laboratories; American Society for Microbiology; Coordination Centers for Infectious Disease; National Institutes of Health [R01GM084320]; United States Agency for International Development supported Amazon Malaria Initiative; CDC Antimalarial Resistance Working Group FX SMG was supported under a National Science Foundation Graduate Research Fellowship. SS was supported by Emerging Infectious Diseases fellowships from the Association of Public Health Laboratories. TMH and MTA were supported by American Society for Microbiology and Coordination Centers for Infectious Disease postdoctoral fellowship. AAE was supported by grant R01GM084320 from the National Institutes of Health. The authors also thank the United States Agency for International Development supported Amazon Malaria Initiative and the CDC Antimalarial Resistance Working Group for their funding support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 34 Z9 34 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 16 PY 2011 VL 6 IS 9 AR e23486 DI 10.1371/journal.pone.0023486 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 824BI UT WOS:000295173800003 PM 21949680 ER PT J AU Bigham, AW Buckingham, KJ Husain, S Emond, MJ Bofferding, KM Gildersleeve, H Rutherford, A Astakhova, N Perelygin, AA Busch, MP Murray, KO Sejvar, JJ Green, S Kriesel, J Brinton, MA Bamshad, M AF Bigham, Abigail W. Buckingham, Kati J. Husain, Sofia Emond, Mary J. Bofferding, Kathryn M. Gildersleeve, Heidi Rutherford, Ann Astakhova, NataliaM. Perelygin, Andrey A. Busch, Michael P. Murray, Kristy O. Sejvar, James J. Green, Sharone Kriesel, John Brinton, Margo A. Bamshad, Michael TI Host Genetic Risk Factors for West Nile Virus Infection and Disease Progression SO PLOS ONE LA English DT Article ID RECEPTOR 5 GENE; NEW-YORK; IMMUNODEFICIENCY-VIRUS; UNITED-STATES; ENCEPHALITIS; OUTBREAK; EPIDEMIC; ASSOCIATION; DEFICIENCY; DELETION AB West Nile virus (WNV), a category B pathogen endemic in parts of Africa, Asia and Europe, emerged in North America in 1999, and spread rapidly across the continental U. S. Outcomes of infection with WNV range from asymptomatic to severe neuroinvasive disease manifested as encephalitis, paralysis, and/or death. Neuroinvasive WNV disease occurs in less than one percent of cases, and although host genetic factors are thought to influence risk for symptomatic disease, the identity of these factors remains largely unknown. We tested 360 common haplotype tagging and/or functional SNPs in 86 genes that encode key regulators of immune function in 753 individuals infected with WNV including: 422 symptomatic WNV cases and 331 cases with asymptomatic infections. After applying a Bonferroni correction for multiple tests and controlling for population stratification, SNPs in IRF3 (OR 0.54, p = 0.035) and MX1, (OR 0.19, p = 0.014) were associated with symptomatic WNV infection and a single SNP in OAS1 (OR 9.79, p = 0.003) was associated with increased risk for West Nile encephalitis and paralysis (WNE/P). Together, these results suggest that genetic variation in the interferon response pathway is associated with both risk for symptomatic WNV infection and WNV disease progression. C1 [Bigham, Abigail W.; Buckingham, Kati J.; Husain, Sofia; Bofferding, Kathryn M.; Gildersleeve, Heidi; Bamshad, Michael] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Emond, Mary J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Rutherford, Ann; Kriesel, John] Univ Utah, Dept Internal Med, Div Infect Dis, Salt Lake City, UT 84112 USA. [Astakhova, NataliaM.; Perelygin, Andrey A.; Brinton, Margo A.] Georgia State Univ, Dept Biol, Atlanta, GA USA. [Busch, Michael P.] Blood Syst, San Francisco, CA USA. [Murray, Kristy O.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA. [Sejvar, James J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO USA. [Green, Sharone] Univ Massachusetts, Sch Med, Dept Med, Ctr Infect Dis & Vaccine Res, Worcester, MA USA. RP Bigham, AW (reprint author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA. EM awb150@u.washington.edu; mbamshad@u.washington.edu FU Rocky Mountain Regional Center of Excellence (National Institutes of Health [NIH]) [U54 AI-065357]; Centers for Infectious Diseases (CDC) [CI000216]; National Institute of Allergy and Infectious Diseases (NIH) [AI057341]; NIH/National Human Genome Research Institute [T32 HG00035] FX This work was supported by the Rocky Mountain Regional Center of Excellence (National Institutes of Health [NIH] grant # U54 AI-065357), the Centers for Infectious Diseases (CDC grant # CI000216), and the National Institute of Allergy and Infectious Diseases (NIH grant # AI057341). AWB was supported by a training fellowship from the NIH/National Human Genome Research Institute (T32 HG00035). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 42 Z9 42 U1 0 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 15 PY 2011 VL 6 IS 9 AR e24745 DI 10.1371/journal.pone.0024745 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 822JR UT WOS:000295041700054 PM 21935451 ER PT J AU Cummings, KJ Kreiss, K Roggli, VL AF Cummings, Kristin J. Kreiss, Kathleen Roggli, Victor L. TI Indium-Tin Oxide Does Not Induce GM-CSF Autoantibodies SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID PULMONARY ALVEOLAR PROTEINOSIS; INHALATION; WORKERS C1 [Cummings, Kristin J.; Kreiss, Kathleen] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. [Roggli, Victor L.] Duke Univ, Med Ctr, Durham, NC USA. RP Cummings, KJ (reprint author), NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. NR 6 TC 2 Z9 2 U1 1 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2011 VL 184 IS 6 BP 741 EP 742 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 820GO UT WOS:000294893900023 ER PT J AU Blanton, JD Palmer, D Dyer, J Rupprecht, CE AF Blanton, Jesse D. Palmer, Dustyn Dyer, Jessie Rupprecht, Charles E. TI Rabies surveillance in the United States during 2010 SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RACCOON RABIES; PUBLIC-HEALTH; VIRUS; RECOMMENDATIONS; AMERICA; DISEASE; DOGS; BATS AB During 2010, 48 states and Puerto Rico reported 6,154 rabid animals and 2 human rabies cases to the CDC, representing an 8% decrease from the 6,690 rabid animals and 4 human cases reported in 2009. Hawaii and Mississippi did not report any laboratory-confirmed rabid animals during 2010. Approximately 92% of reported rabid animals were wildlife. Relative contributions by the major animal groups were as follows: 2,246 raccoons (36.5%), 1,448 skunks (23.5%), 1,430 bats (23.2%), 429 foxes (6.9%), 303 cats (4.9%), 71 cattle (1.1%), and 69 dogs (1.1%). Compared with 2009, number of reported rabid animals decreased across all animal types with the exception of a 1% increase in the number of reported rabid cats. Two cases of rabies involving humans were reported from Louisiana and Wisconsin in 2010. Louisiana reported an imported human rabies case involving a 19-year-old male migrant farm worker who had a history of a vampire bat (Desmodus rotundus) bite received while in Mexico. This represents the first human rabies case reported in the United States confirmed to have been caused by a vampire bat rabies virus variant. Wisconsin reported a human rabies case involving a 70-year-old male that was confirmed to have been caused by a rabies virus variant associated with tri-colored bats (Perimyotis subflavus). C1 [Blanton, Jesse D.; Palmer, Dustyn; Dyer, Jessie; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Blanton, JD (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM asi5@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 50 Z9 54 U1 1 U2 14 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD SEP 15 PY 2011 VL 239 IS 6 BP 773 EP 783 PG 11 WC Veterinary Sciences SC Veterinary Sciences GA 818YH UT WOS:000294792100007 PM 21916759 ER PT J AU Lopman, B AF Lopman, Ben TI Air Sickness: Vomiting and Environmental Transmission of Norovirus on Aircraft SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID GASTROENTERITIS; OUTBREAK C1 [Lopman, Ben] Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. RP Lopman, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd MS G04, Atlanta, GA 30333 USA. EM blopman@cdc.gov NR 8 TC 2 Z9 2 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2011 VL 53 IS 6 BP 521 EP 522 DI 10.1093/cid/cir486 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 813JQ UT WOS:000294363100010 PM 21832266 ER PT J AU Flores-Figueroa, J Okhuysen, PC von Sonnenburg, F DuPont, HL Libman, MD Keystone, JS Hale, DC Burchard, G Han, PV Wilder-Smith, A Freedman, DO AF Flores-Figueroa, Jose Okhuysen, Pablo C. von Sonnenburg, Frank DuPont, Herbert L. Libman, Michael D. Keystone, Jay S. Hale, Devon C. Burchard, Gerd Han, Pauline V. Wilder-Smith, Annelies Freedman, David O. CA GeoSentinel Surveillance Network TI Patterns of Illness in Travelers Visiting Mexico and Central America: The GeoSentinel Experience SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID DISEASES; SURVEILLANCE; SPECTRUM; MALARIA AB Background. Mexico and Central America are important travel destinations for North American and European travelers. There is limited information on regional differences in travel related morbidity. Methods. We describe the morbidity among 4779 ill travelers returned from Mexico and Central America who were evaluated at GeoSentinel network clinics during December 1996 to February 2010. Results. The most frequent presenting syndromes included acute and chronic diarrhea, dermatologic diseases, febrile systemic illness, and respiratory disease. A higher proportion of ill travelers from the United States had acute diarrhea, compared with their Canadian and European counterparts (odds ratio, 1.9; P < .0001). During the 2009 H1N1 influenza outbreak from March 2009 through February 2010, the proportionate morbidity (PM) associated with respiratory illnesses in ill travelers increased among those returned from Mexico, compared with prior years (196.0 cases per 1000 ill returned travelers vs 53.7 cases per 1000 ill returned travelers; P < .0001); the PM remained constant in the rest of Central America (57.3 cases per 1000 ill returned travelers). We identified 50 travelers returned from Mexico and Central America who developed influenza, including infection due to 2009 H1N1 strains and influenza-like illness. The overall risk of malaria was low; only 4 cases of malaria were acquired in Mexico (PM, 2.2 cases per 1000 ill returned travelers) in 13 years, compared with 18 from Honduras (PM, 79.6 cases per 1000 ill returned travelers) and 14 from Guatemala (PM, 34.4 cases per 1000 ill returned travelers) during the same period. Plasmodium vivax malaria was the most frequent malaria diagnosis. Conclusions. Travel medicine practitioners advising and treating travelers visiting these regions should dedicate special attention to vaccine-preventable illnesses and should consider the uncommon occurrence of acute hepatitis A, leptospirosis, neurocysticercosis, acute Chagas disease, onchocerciasis, mucocutaneous leishmaniasis, neurocysticercosis, HIV, malaria, and brucellosis. C1 [Flores-Figueroa, Jose; Okhuysen, Pablo C.; DuPont, Herbert L.] Univ Texas Houston, Sch Med, Ctr Infect Dis, Sch Publ Hlth, Houston, TX 77030 USA. [Okhuysen, Pablo C.; DuPont, Herbert L.] Univ Texas Hlth Sci Ctr Houston, Div Infect Dis, Sch Med, Houston, TX USA. [Okhuysen, Pablo C.; DuPont, Herbert L.] Baylor Coll Med, Div Infect Dis, Houston, TX 77030 USA. [von Sonnenburg, Frank] Univ Munich, Dept Infect Dis & Trop Med, Munich, Germany. [DuPont, Herbert L.] St Lukes Episcopal Hosp, Internal Med Serv, Houston, TX 77030 USA. [Libman, Michael D.] McGill Univ, JD MacLean Ctr Trop Dis, Div Infect Dis, Montreal, PQ, Canada. [Keystone, Jay S.] Univ Toronto, Toronto, ON, Canada. [Hale, Devon C.] Univ Utah, Div Infect Dis, Salt Lake City, UT USA. [Burchard, Gerd] Bernhard Nocht Inst Trop Med, Hamburg, Germany. [Han, Pauline V.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Wilder-Smith, Annelies] Univ Heidelberg, Inst Publ Hlth, Heidelberg, Germany. [Freedman, David O.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. RP Flores-Figueroa, J (reprint author), Paseo Conquistador 611, Cuernavaca 62240, Morelos, Mexico. EM jose.flores.figueroa@uth.tmc.edu RI Wilder-Smith, Annelies/F-8751-2015; OI Okhuysen, Pablo/0000-0002-1596-3411; Wilder-Smith, Annelies/0000-0003-0362-5375; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330 FU Centers for Disease Control and Prevention [5U50CI000359]; International Society of Travel Medicine; Santarus pharmaceutical company; Salix pharmaceutical company; Intercell Corporation; Sanofi Pasteur FX GeoSentinel is supported by a cooperative agreement (5U50CI000359) from the Centers for Disease Control and Prevention and by an initial pilot grant from the International Society of Travel Medicine.; P. C. O. has received honoraria as a speaker for Forest, Cubist, Salix, Pfizer, Astellas and as a consultant to Intercell pharmaceutical company. Through his University P. C. O. has received research funding from Santarus and Salix pharmaceutical companies. H. L. D. has consulted with, received honoraria for speaking and has received research grants administered through his university from Salix Pharmaceutical Company and has received research grants administered through his university from Intercell Corporation and Santarus Pharmaceutical Company. A. W.-S. has received consulting fees from Sanofi Pasteur and travel support from Novartis. D. O. F. has received travel support from Novartis. All other authors report no potential NR 12 TC 16 Z9 19 U1 1 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2011 VL 53 IS 6 BP 523 EP 531 DI 10.1093/cid/cir468 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 813JQ UT WOS:000294363100011 PM 21832261 ER PT J AU Yen, C Wikswo, ME Lopman, B Vinje, J Parashar, UD Hall, AJ AF Yen, Catherine Wikswo, Mary E. Lopman, Ben A. Vinje, Jan Parashar, Umesh D. Hall, Aron J. TI Impact of an Emergent Norovirus Variant in 2009 on Norovirus Outbreak Activity in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID GASTROENTERITIS; SURVEILLANCE AB In October 2009, a new genogroup II, type 4 (GII.4) norovirus variant was identified in the United States. We collected norovirus outbreak data from 30 states to assess whether this new strain was associated with increased acute gastroenteritis activity. No increase in norovirus outbreaks was observed during the 2009-2010 winter. C1 [Yen, Catherine] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Yen, Catherine; Wikswo, Mary E.; Lopman, Ben A.; Vinje, Jan; Parashar, Umesh D.; Hall, Aron J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Yen, C (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS A-47, Atlanta, GA 30333 USA. EM cyen@cdc.gov OI Vinje, Jan/0000-0002-1530-3675 NR 12 TC 61 Z9 69 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2011 VL 53 IS 6 BP 568 EP 571 DI 10.1093/cid/cir478 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 813JQ UT WOS:000294363100017 PM 21832262 ER PT J AU Smith, BD Drobeniuc, J Jewett, A Branson, BM Garfein, RS Teshale, E Kamili, S Weinbaum, CM AF Smith, Bryce D. Drobeniuc, Jan Jewett, Amy Branson, Bernard M. Garfein, Richard S. Teshale, Eyasu Kamili, Saleem Weinbaum, Cindy M. TI Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; RANDOMIZED-TRIAL; PLUS RIBAVIRIN; DRUG-USERS; OF-CARE; INFECTION; PREVALENCE; SETTINGS; OUTREACH; THERAPY AB Background. The Centers for Disease Control and Prevention (CDC) estimates that 3.2 million Americans are living with chronic hepatitis C virus (HCV) infection and 50%-70% are unaware of their status. Although therapies are available that can suppress or eliminate infection, identifying persons infected with HCV is challenging. Rapid tests could help identify many of these persons more expeditiously. Methods. Three manufacturers, Chembio, OraSure, and MedMira, submitted HCV antibody (anti-HCV) rapid screening assays to the CDC for evaluation and comparison with established anti-HCV screening assays. The panel consisted of 1100 specimens drawn during 1997-1999 from persons reporting injection drug use. Sensitivity and specificity were assessed using 2 reference approaches, one based on the reactivity of samples in an anti-HCV screening assay and the other based on CDC HCV testing algorithm. Results. The sensitivities of the Chembio, MedMira, and OraSure assays across the 2 approaches were 96.2%-98.0%, 86.8%-88.3%, and 97.8%-99.3%, respectively. The 3 assays had specificity of 99.5% or higher with no differences between assays. False rapid assay results were associated with human immunodeficiency virus positivity for both approaches for Chembio and MedMira. Conclusions. Rapid anti-HCV tests can provide sensitive and specific anti-HCV results for high-risk patients. C1 [Jewett, Amy] Oak Ridge Inst Sci & Educ, Clinton, TN USA. [Branson, Bernard M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Garfein, Richard S.] Univ Calif San Diego, Div Global Publ Hlth, Dept Med, San Diego, CA 92103 USA. [Smith, Bryce D.; Drobeniuc, Jan; Teshale, Eyasu; Kamili, Saleem; Weinbaum, Cindy M.] Div Viral Hepatitis, Clinton, TN USA. RP Smith, BD (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM bsmith6@cdc.gov FU Division of Viral Hepatitis at the Centers for Disease Control and Prevention FX This work was supported by the Division of Viral Hepatitis at the Centers for Disease Control and Prevention. All test kits were provided in kind by the manufacturers. NR 34 TC 38 Z9 39 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 15 PY 2011 VL 204 IS 6 BP 825 EP 831 DI 10.1093/infdis/jir422 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 809QJ UT WOS:000294071500004 PM 21849279 ER PT J AU Sterling, TR Lau, B Zhang, JB Freeman, A Bosch, RJ Brooks, JT Deeks, SG French, A Gange, S Gebo, KA Gill, MJ Horberg, MA Jacobson, LP Kirk, GD Kitahata, MM Klein, MB Martin, JN Rodriguez, B Silverberg, MJ Willig, JH Eron, JJ Goedert, JJ Hogg, RS Justice, AC McKaig, RG Napravnik, S Thorne, J Moore, RD AF Sterling, Timothy R. Lau, Bryan Zhang, Jinbing Freeman, Aimee Bosch, Ronald J. Brooks, John T. Deeks, Steven G. French, Audrey Gange, Stephen Gebo, Kelly A. Gill, M. John Horberg, Michael A. Jacobson, Lisa P. Kirk, Gregory D. Kitahata, Mari M. Klein, Marina B. Martin, Jeffrey N. Rodriguez, Benigno Silverberg, Michael J. Willig, James H. Eron, Joseph J. Goedert, James J. Hogg, Robert S. Justice, Amy C. McKaig, Rosemary G. Napravnik, Sonia Thorne, Jennifer Moore, Richard D. CA N American AIDS Cohort Collaborati TI Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HIV-INFECTED PATIENTS; IMMUNE RECONSTITUTION; TREATMENT OUTCOMES; RECURRENCE; RELAPSE; COHORT; AIDS; REINFECTION; MORTALITY; COUNTRIES AB Background. Screening for tuberculosis prior to highly active antiretroviral therapy (HAART) initiation is not routinely performed in low-incidence settings. Identifying factors associated with developing tuberculosis after HAART initiation could focus screening efforts. Methods. Sixteen cohorts in the United States and Canada contributed data on persons infected with human immunodeficiency virus (HIV) who initiated HAART December 1995-August 2009. Parametric survival models identified factors associated with tuberculosis occurrence. Results. Of 37 845 persons in the study, 145 were diagnosed with tuberculosis after HAART initiation. Tuberculosis risk was highest in the first 3 months of HAART (20 cases; 215 cases per 100 000 person-years; 95% confidence interval [CI]: 131-333 per 100 000 person-years). In a multivariate Weibull proportional hazards model, baseline CD4(+) lymphocyte count,200, black race, other nonwhite race, Hispanic ethnicity, and history of injection drug use were independently associated with tuberculosis risk. In addition, in a piece-wise Weibull model, increased baseline HIV-1 RNA was associated with increased tuberculosis risk in the first 3 months; male sex tended to be associated with increased risk. Conclusions. Screening for active tuberculosis prior to HAART initiation should be targeted to persons with baseline CD4 <200 lymphocytes/mm(3) or increased HIV-1 RNA, persons of nonwhite race or Hispanic ethnicity, history of injection drug use, and possibly male sex. C1 [Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, Nashville, TN 37232 USA. [Lau, Bryan; Gebo, Kelly A.; Thorne, Jennifer; Moore, Richard D.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Lau, Bryan; Zhang, Jinbing; Freeman, Aimee; Gange, Stephen; Jacobson, Lisa P.; Kirk, Gregory D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Deeks, Steven G.; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [French, Audrey] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. [Gill, M. John] Univ Calgary, Dept Med, Calgary, AB T2N 1N4, Canada. [Horberg, Michael A.; Silverberg, Michael J.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Kitahata, Mari M.] Univ Washington, Dept Med, Seattle, WA USA. [Klein, Marina B.] McGill Univ, Dept Med, Montreal, PQ, Canada. [Klein, Marina B.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Willig, James H.] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA. [Eron, Joseph J.; Napravnik, Sonia] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Goedert, James J.; McKaig, Rosemary G.] NIH, Bethesda, MD 20892 USA. [Hogg, Robert S.] BC Ctr Excellence & HIV AIDS, Vancouver, BC, Canada. [Hogg, Robert S.] Simon Fraser Univ, Vancouver, BC, Canada. [Justice, Amy C.] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Justice, Amy C.] VA Connecticut Healthcare Syst, New Haven, CT USA. RP Sterling, TR (reprint author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, A2209 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA. EM timothy.sterling@vanderbilt.edu RI Hogg, Robert/B-2783-2012; Rodriguez, Benigno/C-3365-2009; Gill, John/G-7083-2016; OI Rodriguez, Benigno/0000-0001-9736-7957; Gill, John/0000-0002-8546-8790; Gange, Stephen/0000-0001-7842-512X; Hogg, Robert/0000-0003-3463-5488 FU Pfizer; Bristol-Myers Squibb; GlaxoSmithKline; Roche; Gilead; Boehringer-Ingelheim; Merck; Abbott; Tibotec; Canadian Institutes of Health Research; Canadian Institutes of Health Research/Fonds de la Recherche en Sante du Quebec; Canadian HIV Trials Network; Ontario HIV Treatment Network; Schering Plough Canada; Gilead Sciences; National Institutes of Health [U01-AI069918, U01-AA013566, U01-AI-35042, 5-MO1-RR-00052 [GCRC], U01-AI-35043, U01-AI-35039, U01-AI-35040, U01-AI-35041, U01-AI38855: ALLRT, U01-AI38858, U01-AI68634, U01-AI68636, AI-69432, AI-69434, U01-AI-35004, U01-AI-31834]; Centers for Disease Control [CDC 200-2006-18797]; Canadian Institutes for Health Research (CIHR) [TGF-96118, HCP-97105, CBR-86906, CBR-94036, KRS-86251, 169621]; Canadian Trials Network [242] FX T. R. S. reports receiving grant support from Pfizer and Bristol-Myers Squibb. S. G. D. reports receiving consulting fees from GlaxoSmithKline, Roche, Gilead, and Boehringer-Ingelheim and grant support from Merck, Gilead, Bristol-Myers Squibb, and Pfizer. M. J. G. reports receiving consulting fees from Gilead, Abbott, Merck, Boehringer-Ingelheim, Tibotec, and Pfizer and grant support from GlaxoSmithKline, Abbott, Canadian Institutes of Health Research, Tibotec, and Pfizer. M. B. K. reports receiving consulting fees from GlaxoSmithKline, Abbott, Pfizer, and Boehringer-Ingelheim; lecture fees from Abbott, Gilead, Tibotec, Bristol-Myers Squibb, and GlaxoSmithKline; and research support from Canadian Institutes of Health Research/Fonds de la Recherche en Sante du Quebec, Canadian HIV Trials Network, Ontario HIV Treatment Network, and Schering Plough Canada. B. R. reports receiving consulting fees from Gilead and Bristol-Myers Squibb, lecture fees from Bristol-Myers Squibb, and grant support from STERIS. J. H. W. reports receiving consulting fees and/or research funding from Bristol-Myers Squibb, Gilead Sciences, Merck and Tibotec. R. D. M. reports receiving consulting fees from Bristol-Myers Squibb and GlaxoSmithKline, lecture fees from Gilead, and grant support from Pfizer, Merck, Gilead, and Agency for Healthcare Research and Quality. All other authors: no conflicts.; This work was supported by the National Institutes of Health (U01-AI069918, U01-AA013566, U01-AI-35042, 5-MO1-RR-00052 [GCRC], U01-AI-35043, U01-AI-35039, U01-AI-35040, U01-AI-35041, U01-AI38855: ALLRT; U01-AI38858; U01-AI68634; U01-AI68636; AI-69432; AI-69434, U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590, U01-HD-32632, UL1-RR024131, P30-AI27757; K23-AI-61-0320, P30-AI27767, P30-AI50410; RR025747, P30-AI54999, R01-DA04334; R01-DA12568, R01-MH54907, R24-AI067039, N02-CP55504; Z01-CP010176, AHQ290-01-0012, K01-AI071754, K24-00432; R01-DA11602, K01-AI071725, R01-AG026250: Kelly Gebo). This work was also supported by the Centers for Disease Control (CDC 200-2006-18797); the Canadian Institutes for Health Research (CIHR: TGF-96118; HCP-97105; CBR-86906; CBR-94036; KRS-86251; 169621); and the Canadian Trials Network (project number 242). NR 34 TC 16 Z9 16 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 15 PY 2011 VL 204 IS 6 BP 893 EP 901 DI 10.1093/infdis/jir421 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 809QJ UT WOS:000294071500012 PM 21849286 ER PT J AU Labarthe, DR Briss, PA AF Labarthe, Darwin R. Briss, Peter A. TI Urinary Sodium Excretion and Cardiovascular Disease Mortality SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Labarthe, Darwin R.; Briss, Peter A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Labarthe, DR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM pxb5@cdc.gov NR 5 TC 4 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 14 PY 2011 VL 306 IS 10 BP 1084 EP 1085 DI 10.1001/jama.2011.1294 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 819DS UT WOS:000294806200015 PM 21917573 ER PT J AU Gilchrist, J Haileyesus, T Murphy, MW Yard, EE AF Gilchrist, Julie Haileyesus, Tadesse Murphy, Matthew W. Yard, Ellen E. TI Nonfatal Sports and Recreation Heat Illness Treated in Hospital Emergency Departments-United States, 2001-2009 (Reprinted from MMWR, vol 60, pg 977-980, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Yard, Ellen E.] CDC, Atlanta, GA 30333 USA. RP Yard, EE (reprint author), CDC, Atlanta, GA 30333 USA. EM eyard@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 14 PY 2011 VL 306 IS 10 BP 1074 EP 1076 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 819DS UT WOS:000294806200009 ER PT J AU Anderson, T Collinson, J Vap, T Williams, RM Safranek, TJ Leschinsky, DP Bredthauer, AK Gabel, J Buss, BF Sotir, MJ Jentes, ES Munoz-Jordan, JL Hunsperger, EA Arguello, F Pillai, P Sharp, TM AF Anderson, Teresa Collinson, Jeremy Vap, Trina Williams, Robin M. Safranek, Thomas J. Leschinsky, Dennis P. Bredthauer, Annette K. Gabel, Julie Buss, Bryan F. Sotir, Mark J. Jentes, Emily S. Munoz-Jordan, Jorge L. Hunsperger, Elizabeth A. Argueello, Fermin Pillai, Parvathy Sharp, Tyler M. TI Dengue Virus Infections Among Travelers Returning From Haiti-Georgia and Nebraska, October 2010 (Reprinted from MMWR, vol 60, pg 914-917, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Pillai, Parvathy; Sharp, Tyler M.] CDC, Atlanta, GA 30333 USA. [Anderson, Teresa; Collinson, Jeremy; Vap, Trina] Cent Dist Hlth Dept, Grand Isl, NY USA. [Williams, Robin M.] Univ Nebraska Lincoln, Lincoln, NE USA. RP Sharp, TM (reprint author), CDC, Atlanta, GA 30333 USA. EM tsharp@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 14 PY 2011 VL 306 IS 10 BP 1077 EP 1079 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 819DS UT WOS:000294806200010 ER PT J AU Torian, LV Selik, RM Branson, B Owen, SM Granade, T Shouse, RL Joyce, MP Pieniazek, D Kline, R AF Torian, Lucia V. Selik, Richard M. Branson, Bernard Owen, S. Michele Granade, Timothy Shouse, R. Luke Joyce, M. Patricia Pieniazek, Danuta Kline, Richard TI HIV-2 Infection Surveillance-United States, 1987-2009 (Reprinted from MMWR, vol 60, pg 985-988, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Selik, Richard M.; Branson, Bernard; Owen, S. Michele; Granade, Timothy; Shouse, R. Luke; Joyce, M. Patricia; Pieniazek, Danuta; Kline, Richard] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Torian, Lucia V.] New York City Dept Hlth & Mental Hyg, Bur HIV ADIS Prevent & Control, New York, NY USA. RP Selik, RM (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM rselik@cdc.gov NR 1 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 14 PY 2011 VL 306 IS 10 BP 1079 EP 1081 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 819DS UT WOS:000294806200011 ER PT J AU Menzies, NA Berruti, AA Berzon, R Filler, S Ferris, R Ellerbrock, TV Blandford, JM AF Menzies, Nicolas A. Berruti, Andres A. Berzon, Richard Filler, Scott Ferris, Robert Ellerbrock, Tedd V. Blandford, John M. TI The cost of providing comprehensive HIV treatment in PEPFAR-supported programs SO AIDS LA English DT Article DE AIDS; antiretroviral therapy; cost; developing countries; economics; HIV; resource-limited settings ID SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; INTERVENTIONS; COUNTRIES; ECONOMICS; SERVICES; CARE AB Background: PEPFAR, national governments, and other stakeholders are investing unprecedented resources to provide HIV treatment in developing countries. This study reports empirical data on costs and cost trends in a large sample of HIV treatment sites. Design: In 2006-2007, we conducted cost analyses at 43 PEPFAR-supported outpatient clinics providing free comprehensive HIV treatment in Botswana, Ethiopia, Nigeria, Uganda, and Vietnam. Methods: We collected data on HIV treatment costs over consecutive 6-month periods starting from scale-up of dedicated HIV treatment services at each site. The study included all patients receiving HIV treatment and care at study sites [62 512 antiretroviral therapy (ART) and 44 394 pre-ART patients]. Outcomes were costs per patient and total program costs, subdivided by major cost categories. Results: Median annual economic costs were US$ 202 (2009 USD) for pre-ART patients and US$ 880 for ART patients. Excluding antiretrovirals, per patient ART costs were US$ 298. Care for newly initiated ART patients cost 15-20% more than for established patients. Per patient costs dropped rapidly as sites matured, with per patient ART costs dropping 46.8% between first and second 6-month periods after the beginning of scale-up, and an additional 29.5% the following year. PEPFAR provided 79.4% of funding for service delivery, and national governments provided 15.2%. Conclusion: Treatment costs vary widely between sites, and high early costs drop rapidly as sites mature. Treatment costs vary between countries and respond to changes in antiretroviral regimen costs and the package of services. Whereas cost reductions may allow near-term program growth, programs need to weigh the trade-off between improving services for current patients and expanding coverage to new patients. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Menzies, Nicolas A.; Berruti, Andres A.; Filler, Scott; Ellerbrock, Tedd V.; Blandford, John M.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Menzies, Nicolas A.; Berruti, Andres A.] ICF Macro Inc, Atlanta, GA USA. [Berzon, Richard; Ferris, Robert] US Agcy Int Dev, Washington, DC 20523 USA. RP Blandford, JM (reprint author), US Ctr Dis Control & Prevent, MS E30,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jblandford@cdc.gov FU United States President's Emergency Plan for AIDS Relief; PEPFAR; USAID FX The PEPFAR ART Costing Project is a PEPFAR-funded public health evaluation (PHE) study led by the US Centers for Disease Control and Prevention and implemented with ICF-Macro, in collaboration with USAID. J.M.B., N.A.M., R.B., S.F., T.V.E. and R.F. contributed to protocol development and provided study oversight. J.M.B., N.A.M., A.A.B., S.F., and R.B. contributed to instrument design and fieldwork planning, and participated in fieldwork. A.A.B., N.A.M. and J.M.B. analyzed the data and drafted the manuscript. J.M.B., N.A.M., A.A.B., R.B., S.F., T .V.E. and R.F. reviewed and edited the manuscript. N.A.M. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. We would also like to acknowledge the time and effort of the PEPFAR country teams in Botswana, Ethiopia, Nigeria, Uganda and Vietnam, as well as collaborators and participants at health facilities and their supporting organizations. For more information on current PEPFAR evaluation activities, please refer to the website http://www.cdc.gov/globalaids/.; This study was conducted with funding from the United States President's Emergency Plan for AIDS Relief. NR 27 TC 65 Z9 65 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD SEP 10 PY 2011 VL 25 IS 14 BP 1753 EP 1760 DI 10.1097/QAD.0b013e3283463eec PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 814AT UT WOS:000294415200009 PM 21412127 ER PT J AU Whitehead, SJ McLean, C Chaikummao, S Braunstein, S Utaivoravit, W van de Wijgert, JH Mock, PA Siraprapasiri, T Friedland, BA Kilmarx, PH Markowitz, LE AF Whitehead, Sara J. McLean, Catherine Chaikummao, Supaporn Braunstein, Sarah Utaivoravit, Wat van de Wijgert, Janneke H. Mock, Philip A. Siraprapasiri, Taweesap Friedland, Barbara A. Kilmarx, Peter H. Markowitz, Lauri E. TI Acceptability of Carraguard Vaginal Microbicide Gel among HIV-Infected Women in Chiang Rai, Thailand SO PLOS ONE LA English DT Article ID TOPICAL MICROBICIDES; CLINICAL-TRIAL; SAFETY; PLACEBO; COUPLES AB Background: Few studies of microbicide acceptability among HIV-infected women have been done. We assessed CarraguardH vaginal gel acceptability among participants in a randomized, controlled, crossover safety trial in HIV-infected women in Thailand. Methodology/Principal Findings: Participants used each of 3 treatments (Carraguard gel, methylcellulose placebo gel, and no product) for 7 days, were randomized to one of six treatment sequences, and were blinded to the type of gel they received in the two gel-use periods. After both gel-use periods, acceptability was assessed by face-to-face interview. Responses were compared to those of women participating in two previous Carraguard safety studies at the same study site. Sixty women enrolled with a median age of 34 years; 25% were sexually active. Self-reported adherence (98%) and overall satisfaction rating of the gels (87% liked "somewhat'' or "very much'') were high, and most (77%) considered the volume of gel "just right.'' For most characteristics, crossover trial participants evaluated the gels more favorably than women in the other two trials, but there were few differences in the desired characteristics of a hypothetical microbicide. Almost half (48%) of crossover trial participants noticed a difference between Carraguard and placebo gels; 33% preferred Carraguard while 12% preferred placebo (p = 0.01). Conclusions/Significance: Daily Carraguard vaginal gel use was highly acceptable in this population of HIV-infected women, who assessed the gels more positively than women in two other trials at the site. This may be attributable to higher perceived need for protection among HIV-infected women, as well as to study design differences. This trial was registered in the U. S. National Institutes of Health clinical trials registry under registration number NCT00213044. C1 [Whitehead, Sara J.; Chaikummao, Supaporn; Mock, Philip A.; Siraprapasiri, Taweesap] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [McLean, Catherine; Kilmarx, Peter H.; Markowitz, Lauri E.] US Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Braunstein, Sarah; van de Wijgert, Janneke H.; Friedland, Barbara A.] Populat Council, New York, NY 10021 USA. [Utaivoravit, Wat] Chiang Rai Hosp, Chiang Rai, Thailand. [van de Wijgert, Janneke H.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [van de Wijgert, Janneke H.] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands. RP Whitehead, SJ (reprint author), US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. EM svw7@th.cdc.gov OI Kilmarx, Peter/0000-0001-6464-3345 FU Centers for Disease Control and Prevention; Bill and Melinda Gates Foundation FX Funding for this study was provided by the Centers for Disease Control and Prevention (www.cdc.gov) and the Bill and Melinda Gates Foundation (www.gatesfoundation.org). Some authors are employees of the Centers for Disease Control and Prevention and were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript; the Centers for Disease Control and Prevention has no financial or any other competing interest in the Carraguard product. The Bill and Melinda Gates Foundation had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 9 Z9 10 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 7 PY 2011 VL 6 IS 9 AR e14831 DI 10.1371/journal.pone.0014831 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 819CH UT WOS:000294802500001 PM 21915249 ER PT J AU Khan, AS AF Khan, Ali S. TI Public health preparedness and response in the USA since 9/11: a national health security imperative SO LANCET LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, US Dept HHS, Atlanta, GA 30333 USA. RP Khan, AS (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, US Dept HHS, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM askhan@cdc.gov NR 20 TC 14 Z9 14 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD SEP 3 PY 2011 VL 378 IS 9794 BP 953 EP 956 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 818XZ UT WOS:000294791300036 PM 21890060 ER PT J AU Belongia, EA Kieke, BA Donahue, JG Coleman, LA Irving, SA Meece, JK Vandermause, M Lindstrom, S Gargiullo, P Shay, DK AF Belongia, Edward A. Kieke, Burney A. Donahue, James G. Coleman, Laura A. Irving, Stephanie A. Meece, Jennifer K. Vandermause, Mary Lindstrom, Stephen Gargiullo, Paul Shay, David K. TI Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: Comparison of interim and final results SO VACCINE LA English DT Article DE Influenza vaccines; Case-control studies; Vaccines; Inactivated; Epidemiology; Treatment outcome; Reverse transcriptase polymerase chain reaction ID RANDOMIZED CONTROLLED-TRIAL; LIVE ATTENUATED VACCINES; NASOPHARYNGEAL ASPIRATE; HEALTHY-ADULTS; NASAL SWAB; EFFICACY; CHILDREN; MARSHFIELD; PREVENTION; SAFETY AB Background: During the 2007-08 influenza season, we reported an interim vaccine effectiveness (VE) estimate of 44% for preventing medically attended influenza. In this analysis we report results for the entire season and compare them with the interim estimate. Methods: Patients with feverishness, chills, or cough <8 days duration were prospectively recruited over 10 weeks and tested for influenza by real-time reverse transcriptase PCR (rRT-PCR). Case-control analyses were performed using data from patients with rRT-PCR confirmed influenza (cases) and ill patients without influenza (test-negative controls). VE was estimated as 100 X (1 - adjusted odds ratio) in a logistic regression model adjusting for age, week, and high risk medical condition. A sample of influenza isolates was antigenically characterized. Results: Influenza was detected by rRT-PCR in 865 (44%) of 1972 patients; 73% were type A and 27% were type B. VE was 37% (95% Cl, 22-49%) overall and 44% (95% Cl, 27-58%) among participants tested 0-3 days after illness onset. VE was 39% (95% Cl, 2-62%) in children 6-59 months old and 37% (95% CI, -2% to 61%) in adults >= 50 years old. VE was 41% (95% Cl, 24-53%) for influenza A and 31% (95% Cl, 3-51%) for influenza B. All 24 characterized influenza A viruses were antigenically matched to the H3N2 vaccine strain, although 14 viruses exhibited mild antigenic drift. There was a lineage mismatch with the vaccine strain for all 39 characterized influenza B viruses. Conclusions: The 2007-08 influenza vaccine provided modest protection against medically attended influenza in this population. The interim estimate of VE after 17 days closely approximated the final season VE, supporting the potential use of interim VE estimates while influenza seasons are still in progress. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Belongia, Edward A.] Marshfield Clin Res Fdn, Epidemiol Res Ctr ML2, Marshfield, WI 54449 USA. [Lindstrom, Stephen; Gargiullo, Paul; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Belongia, EA (reprint author), Marshfield Clin Res Fdn, Epidemiol Res Ctr ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM belongia.edward@marshfieldclinic.org OI Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention [1 U01 CI000192-01] FX This study was entirely funded by Centers for Disease Control and Prevention cooperative agreement 1 U01 CI000192-01. NR 27 TC 50 Z9 50 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 2 PY 2011 VL 29 IS 38 BP 6558 EP 6563 DI 10.1016/j.vaccine.2011.07.002 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 823TG UT WOS:000295148800021 PM 21767593 ER PT J AU Ray, P Black, S Shinefield, H Dillon, A Carpenter, D Lewis, E Ross, P Chen, RT Klein, NP Baxter, R AF Ray, Paula Black, Steven Shinefield, Henry Dillon, Aileen Carpenter, Diane Lewis, Edwin Ross, Pat Chen, Robert T. Klein, Nicola P. Baxter, Roger CA Vaccine Safety Datalink Team TI Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age SO VACCINE LA English DT Article DE Vaccine; Adverse; Rheumatoid; Arthritis; Vaccination; Hepatitis B; Tetanus; Influenza ID GUILLAIN-BARRE-SYNDROME; RUBELLA IMMUNIZATION; ADULTS; MANIFESTATIONS; EPIDEMIOLOGY; DISEASES; WOMEN AB Background: Associations between vaccinations, particularly hepatitis B, and onset of rheumatoid arthritis (RA) have been reported, but examined in few large-scale studies. Method: Onset of RA cases and dates of vaccination against hepatitis B, tetanus, and influenza were identified in a retrospective chart review of approximately 1 million Kaiser Permanente Northern California members ages 15-59 years from 1997 through 1999. In a cohort analysis, rates of new-onset RA were compared between vaccinated and unvaccinated within 90, 180, and 365 days. In a case-control analysis, rates of vaccination during exposure intervals (90, 180, 365, and 730 days) were compared between cases and controls using conditional logistic regression. Results: 378 RA cases were included in the cohort analysis; 37 additional cases were included in the case-control analysis. In the cohort analysis the relative risks of RA onset within 90, 180, or 365 days of hepatitis B vaccination were not significant (R.R. = 1.44, p = 0.53; R.R. = 1.67, p = 0.22; R.R. = 1.23, p = 0.59 respectively). We found a possible association between RA and influenza vaccine in the previous 180 and 365 days in the cohort analysis (R.R = 1.36, p = 0.03; R.R. = 1.34, p = 0.01 respectively), but in the case-control analysis, cases were no more likely than controls to have received any of the three vaccines. Conclusions: In this large retrospective study we found no statistically significant association between exposure to hepatitis B vaccine and onset of RA. A possible association between RA and influenza vaccination in the cohort study was not borne out in the larger case-control analysis. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Ray, Paula; Lewis, Edwin; Ross, Pat; Klein, Nicola P.; Baxter, Roger] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA 94612 USA. [Black, Steven] Univ Cincinnati, Childrens Hosp, Ctr Global Hlth, Cincinnati, OH USA. [Shinefield, Henry] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Dillon, Aileen] Permanente Med Grp Inc, San Francisco, CA USA. [Carpenter, Diane] Kaiser Permanente, Div Res, Oakland, CA USA. [Chen, Robert T.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Baxter, R (reprint author), Kaiser Permanente, Vaccine Study Ctr, Oakland, CA 94612 USA. EM roger.baxter@kp.org FU Centers for Disease Control and Prevention FX This study was funded by the Centers for Disease Control and Prevention Vaccine Safety Datalink Project. The authors would also like to thank Pat Ross, Patricia Dameron, Marilyn Foley, Karen Forsen, and Frances Sheykhzadeh for their excellent work in collecting data from more than 10,000 medical records. Naomi L. Ruff, PhD, contributed to the writing of this article, for which she received compensation from the Kaiser Permanente Vaccine Study Center. NR 35 TC 13 Z9 13 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 2 PY 2011 VL 29 IS 38 BP 6592 EP 6597 DI 10.1016/j.vaccine.2011.06.112 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 823TG UT WOS:000295148800025 PM 21763385 ER PT J AU McAllister, JC AF McAllister, Janet C. TI AMERICAN MOSQUITO CONTROL ASSOCIATION PRESIDENTIAL ADDRESS: ASSOCIATION ACTIVITIES IN 2010-11 SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO 80521 USA. RP McAllister, JC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, 3150 Rampart Rd, Ft Collins, CO 80521 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2011 VL 27 IS 3 BP 187 EP 190 DI 10.2987/8756-971X-27.3.187 PG 4 WC Entomology SC Entomology GA 973FK UT WOS:000306344300001 PM 22017081 ER PT J AU Jones, RC Weaver, KN Smith, S Blanco, C Flores, C Gibbs, K Markowski, D Mutebi, JP AF Jones, Roderick C. Weaver, Kingsley N. Smith, Shamika Blanco, Claudia Flores, Cristina Gibbs, Kevin Markowski, Daniel Mutebi, John-Paul TI USE OF THE VECTOR INDEX AND GEOGRAPHIC INFORMATION SYSTEM TO PROSPECTIVELY INFORM WEST NILE VIRUS INTERVENTIONS SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE West Nile virus; urban population; Culex mosquito; geographic information system ID CULEX-PIPIENS; MOSQUITOS AB We sought to estimate West Nile virus (WNV) activity in mosquito populations weekly at the census tract level in Chicago, IL, and to provide this information graphically. Each week we calculated a vector index (VI) for each mosquito trap then generated tract estimates using geographic information systems. During June 29-September 13, 2008, a median of 527 (60%) of 874 possible tracts per week had a VI value. Overall, 94% of the weekly VI tract estimates were 0; among those with a VI estimate greater than 0, the median was 0.33 (range 0.003-3.5). Officials deemed risk levels and weather conditions appropriate for adulticide treatments on 3 occasions, resulting in the treatment of approximately 252 linear kilometers of residential streets and alleys. Our analysis successfully converted complex, raw surveillance data into a format that highlighted areas of elevated WNV activity and facilitated the determination of appropriate response procedures. C1 [Jones, Roderick C.; Weaver, Kingsley N.; Smith, Shamika; Blanco, Claudia] Chicago Dept Publ Hlth, Chicago, IL 60612 USA. [Flores, Cristina; Markowski, Daniel] Vector Dis Control Inc, Little Rock, AR 72202 USA. [Gibbs, Kevin] Univ Illinois, Chicago, IL 60608 USA. [Mutebi, John-Paul] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Jones, RC (reprint author), Chicago Dept Publ Hlth, 2160 W Ogden Ave, Chicago, IL 60612 USA. FU Illinois Department of Public Health Mosquito Prevention Program; Centers for Disease Control and Prevention (Epidemiology and Laboratory Capacity) [3U50CI000490-03S1] FX This work was facilitated by the grant support of the Illinois Department of Public Health Mosquito Prevention Program and the Centers for Disease Control and Prevention (Epidemiology and Laboratory Capacity, 3U50CI000490-03S1). For their contributions to the data management, GIS analyses, and public health interventions described in this manuscript, the authors thank Margaret Eaglin, Agata Dryla-Gaca, Susan Gerber, Bill Gloff, Kiran Kumar Gunda, Larry Hanson, Laura Hinojosa, Cort Lohff, Molly Mangan, David Plate, Mehul Shah, Guohe Sun, Bill Vonderhaar, and the staff of the Chicago Department of Public Health's Public Information Office. NR 13 TC 11 Z9 11 U1 1 U2 7 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2011 VL 27 IS 3 BP 315 EP 319 DI 10.2987/10-6098.1 PG 5 WC Entomology SC Entomology GA 973FK UT WOS:000306344300019 PM 22017098 ER PT J AU Little, E Barrera, R Seto, KC Diuk-Wasser, M AF Little, Eliza Barrera, Roberto Seto, Karen C. Diuk-Wasser, Maria TI Co-occurrence Patterns of the Dengue Vector Aedes aegypti and Aedes mediovitattus, a Dengue Competent Mosquito in Puerto Rico SO ECOHEALTH LA English DT Article DE dengue; landscape epidemiology; Puerto Rico; remote sensing; Aedes aegypti; Aedes mediovittatus ID LAND-USE CHANGE; RIO-DE-JANEIRO; HABITAT SEGREGATION; NORTH QUEENSLAND; LARVAL INDEXES; COSTA-RICA; URBAN AREA; CULICIDAE; DIPTERA; TRANSMISSION AB Aedes aegypti is implicated in dengue transmission in tropical and subtropical urban areas around the world. Ae. aegypti populations are controlled through integrative vector management. However, the efficacy of vector control may be undermined by the presence of alternative, competent species. In Puerto Rico, a native mosquito, Ae. mediovittatus, is a competent dengue vector in laboratory settings and spatially overlaps with Ae. aegypti. It has been proposed that Ae. mediovittatus may act as a dengue reservoir during inter-epidemic periods, perpetuating endemic dengue transmission in rural Puerto Rico. Dengue transmission dynamics may therefore be influenced by the spatial overlap of Ae. mediovittatus, Ae. aegypti, dengue viruses, and humans. We take a landscape epidemiology approach to examine the association between landscape composition and configuration and the distribution of each of these Aedes species and their co-occurrence. We used remotely sensed imagery from a newly launched satellite to map landscape features at very high spatial resolution. We found that the distribution of Ae. aegypti is positively predicted by urban density and by the number of tree patches, Ae. mediovittatus is positively predicted by the number of tree patches, but negatively predicted by large contiguous urban areas, and both species are predicted by urban density and the number of tree patches. This analysis provides evidence that landscape composition and configuration is a surrogate for mosquito community composition, and suggests that mapping landscape structure can be used to inform vector control efforts as well as to inform urban planning. C1 [Little, Eliza; Seto, Karen C.; Diuk-Wasser, Maria] Yale Sch Forestry & Environm Studies, New Haven, CT USA. [Barrera, Roberto] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Infect Dis, San Juan, PR USA. [Little, Eliza; Diuk-Wasser, Maria] Yale Sch Publ Hlth, New Haven, CT USA. RP Little, E (reprint author), Yale Sch Publ Hlth, New Haven, CT USA. EM eliza@elizalittle.com RI Seto, Karen/C-2722-2008 FU Intramural CDC HHS [CC999999] NR 57 TC 5 Z9 5 U1 2 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1612-9202 EI 1612-9210 J9 ECOHEALTH JI EcoHealth PD SEP PY 2011 VL 8 IS 3 BP 365 EP 375 DI 10.1007/s10393-011-0708-8 PG 11 WC Biodiversity Conservation; Ecology; Environmental Sciences SC Biodiversity & Conservation; Environmental Sciences & Ecology GA 904HD UT WOS:000301184200011 PM 21989642 ER PT J AU Anderson, LA Day, KL Vandenberg, AE AF Anderson, Lynda A. Day, Kristine L. Vandenberg, Anna E. TI Using a Concept Map as a Tool for Strategic Planning: The Healthy Brain Initiative SO PREVENTING CHRONIC DISEASE LA English DT Article ID COGNITIVE HEALTH; PUBLIC-HEALTH; POPULATION; ISSUE AB Concept mapping is a tool to assist in strategic planning that allows planners to work through a sequence of phases to produce a conceptual framework. Although several studies describe how concept mapping is applied to various public health problems, the flexibility of the methods used in each phase of the process is often overlooked. If practitioners were more aware of the flexibility, more public health endeavors could benefit from using concept mapping as a tool for strategic planning. The objective of this article is to describe how the 6 concept-mapping phases originally outlined by William Trochim guided our strategic planning process and how we adjusted the specific methods in the first 2 phases to meet the specialized needs and requirements to create The Healthy Brain Initiative: A National Public Health Road Map to Maintaining Cognitive Health. In the first stage (phases 1 and 2 of concept mapping), we formed a steering committee, convened 4 work groups over a period of 3 months, and generated an initial set of 42 action items grounded in science. In the second stage (phases 3 and 4), we engaged stakeholders in sorting and rating the action items and constructed a series of concept maps. In the third and final stage (phases 5 and 6), we examined and refined the action items and generated a final concept map consisting of 44 action items. We then selected the top 10 action items, and in 2007, we published The Healthy Brain Initiative: A National Public Health Road Map to Maintaining Cognitive Health, which represents the strategic plan for The Healthy Brain Initiative. C1 [Anderson, Lynda A.; Day, Kristine L.; Vandenberg, Anna E.] Ctr Dis Control & Prevent, Hlth Aging Program, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Anderson, Lynda A.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. RP Anderson, LA (reprint author), Ctr Dis Control & Prevent, Hlth Aging Program, Div Adult & Community Hlth, 4770 Buford Hwy NE,MS K-38, Atlanta, GA 30341 USA. EM laa0@cdc.gov NR 18 TC 8 Z9 8 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2011 VL 8 IS 5 AR A117 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 896JS UT WOS:000300562300027 PM 21843420 ER PT J AU Guy, GP Tai, E Richardson, LC AF Guy, Gery P., Jr. Tai, Eric Richardson, Lisa C. TI Use of Indoor Tanning Devices by High School Students in the United States, 2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID RISK; MELANOMA; SURVEILLANCE; ADOLESCENTS; CANCER AB The objectives of this study were to provide estimates of indoor tanning device use among US high school students and provide baseline data before implementation of a 10% excise tax on indoor tanning device use mandated by recent federal health care reform legislation. We examined the frequency of indoor tanning device use by using data from the 2009 national Youth Risk Behavior Survey. Overall, 15.6% of students used an indoor tanning device during the 12 months before the survey; almost half of those students used an indoor tanning device 10 or more times. Reported use and frequency of use varied by age, sex, and race/ethnicity. Given the high prevalence of indoor tanning device use among US high school students and the associated risk of melanoma, strategies to reduce exposure must be examined. C1 [Guy, Gery P., Jr.; Tai, Eric; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K-52, Atlanta, GA 30341 USA. EM GGuy@cdc.gov FU CDC FX Gery P. Guy, Jr, was supported in part by CDC's Research Participation Program, administered by the Oak Ridge Institute for Science and Education through an inter-agency agreement between the US Department of Energy and CDC. NR 12 TC 18 Z9 18 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2011 VL 8 IS 5 AR A116 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 896JS UT WOS:000300562300026 PM 21843419 ER PT J AU McClure, LA Murphy, HL Roseman, J Howard, G Malarcher, A AF McClure, Leslie A. Murphy, Heather L. Roseman, Jeffrey Howard, George Malarcher, Ann TI Regional and Racial Differences in Smoking and Exposure to Secondhand Smoke: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study SO PREVENTING CHRONIC DISEASE LA English DT Article ID CIGARETTE-SMOKING; UNITED-STATES; PASSIVE SMOKING; ISCHEMIC-STROKE; RISK; ATHEROSCLEROSIS; ADULTS; HEALTH; OLDER AB Introduction Stroke mortality rates differ by race and region, and smoking and exposure to secondhand smoke are associated with stroke. We evaluated regional and racial differences in current smoking and secondhand smoke exposure among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Methods African American and white adults (n = 26,373) aged 45 years or older were recruited during 2003 through 2007. Logistic regression was used to examine the likelihood of current smoking and secondhand smoke exposure by race (African American vs white) and region. We compared the buckle of the stroke belt (the coastal plain region of North Carolina, South Carolina, and Georgia) with the stroke belt (the remainder of North Carolina, South Carolina, and Georgia, plus Alabama, Mississippi, Tennessee, Arkansas, and Louisiana) and compared each of these regions with the remaining contiguous states. Results Among whites, no regional differences in current smoking were seen, but among African Americans, the odds of current smoking were 5% lower in the stroke belt, and 24% lower in the stroke buckle than those in the nonbelt region. Similarly, among whites no regional differences in exposure to secondhand smoke were found, whereas among African Americans, the odds of being exposed to secondhand smoke were 14% lower in the stroke buckle than for nonbelt residents. Conclusions These data suggest that rates of current smoking and secondhand smoke exposure are not higher in regions that have higher stroke mortality and therefore cannot contribute to geographic disparities; nevertheless, given that 15% of our participants reported current smoking and 16% reported secondhand smoke exposure, continued implementation of tobacco control policies is needed. C1 [McClure, Leslie A.] Univ Alabama, Birmingham, AL 35294 USA. [Malarcher, Ann] Ctr Dis Control & Prevent, Atlanta, GA USA. RP McClure, LA (reprint author), Univ Alabama, RPHB 327,1530 3rd Ave S, Birmingham, AL 35294 USA. EM lmc-clure@uab.edu RI McClure, Leslie/P-2929-2015 FU National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services [U01 NS041588] FX This research project is supported by cooperative agreement no. U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. We thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org. NR 23 TC 3 Z9 3 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2011 VL 8 IS 5 AR A108 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 896JS UT WOS:000300562300018 PM 21843411 ER PT J AU Posner, SF AF Posner, Samuel F. TI PCD's First Annual Student Research Contest: Lui and Wallace Examine Hospitalization Rates for At-Risk Populations SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Posner, SF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-85,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM sposner@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2011 VL 8 IS 5 AR A103 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 896JS UT WOS:000300562300013 PM 21843406 ER PT J AU Williams, MM Chen, TH Keane, T Toney, N Toney, S Armbruster, CR Butler, WR Arduino, MJ AF Williams, Margaret M. Chen, Tai-Ho Keane, Tim Toney, Nadege Toney, Sean Armbruster, Catherine R. Butler, W. Ray Arduino, Matthew J. TI Point-of-Use Membrane Filtration and Hyperchlorination to Prevent Patient Exposure to Rapidly Growing Mycobacteria in the Potable Water Supply of a Skilled Nursing Facility SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID POLYMERASE-CHAIN-REACTION; POLYMORPHIC DNA ANALYSIS; PSEUDO-OUTBREAK; NONTUBERCULOUS MYCOBACTERIA; LABORATORY CONTAMINATION; DISTRIBUTION-SYSTEM; IDENTIFICATION; ABSCESSUS; FORTUITUM; CHELONAE AB BACKGROUND. Healthcare-associated outbreaks and pseudo-outbreaks of rapidly growing mycobacteria (RGM) are frequently associated with contaminated tap water. A pseudo-outbreak of Mycobacterium chelonae-M. abscessus in patients undergoing bronchoscopy was identified by 2 acute care hospitals. RGM was identified in bronchoscopy specimens of 28 patients, 25 of whom resided in the same skilled nursing facility (SNF). An investigation ruled out bronchoscopy procedures, specimen collection, and scope reprocessing at the hospitals as sources of transmission. OBJECTIVE. To identify the reservoir for RGM within the SNF and evaluate 2 water system treatments, hyperchlorination and point-ofuse (POU) membrane filters, to reduce RGM. DESIGN. A comparative in situ study of 2 water system treatments to prevent RGM transmission. SETTING. An SNF specializing in care of patients requiring ventilator support. METHODS. RGM and heterotrophic plate count (HPC) bacteria were examined in facility water before and after hyperchlorination and in a subsequent 24-week assessment of filtered water by colony enumeration on Middlebrook and R2A media. results. Mycobacterium chelonae was consistently isolated from the SNF water supply. Hyperchlorination reduced RGM by 1.5 log 10 initially, but the population returned to original levels within 90 days. Concentration of HPC bacteria also decreased temporarily. RGM were reduced below detection level in filtered water, a 3-log(10) reduction. HPC bacteria were not recovered from newly installed filters, although low quantities were found in water from 2-week-old filters. CONCLUSION. POU membrane filters may be a feasible prevention measure for healthcare facilities to limit exposure of sensitive individuals to RGM in potable water systems. Infect Control Hosp Epidemiol 2011;32(9):837-844 C1 [Williams, Margaret M.; Toney, Nadege; Armbruster, Catherine R.; Arduino, Matthew J.] Ctr Dis Control & Prevent CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA. [Chen, Tai-Ho] CDC, Off Surveillance Epidemiol & Lab Serv, Epidemiol Invest Serv Program, Atlanta, GA 30333 USA. [Toney, Sean; Butler, W. Ray] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30333 USA. [Chen, Tai-Ho] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Keane, Tim] Environm Infect Control Consultants, Chalfont, PA USA. RP Williams, MM (reprint author), 1600 Clifton Rd,MS-C16, Atlanta, GA 30333 USA. EM mwilliams7@cdc.gov NR 39 TC 14 Z9 14 U1 1 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2011 VL 32 IS 9 BP 837 EP 844 DI 10.1086/661282 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 876BW UT WOS:000299083000002 PM 21828963 ER PT J AU Miller, BL Lindley, MC Ahmed, F Wortley, PM AF Miller, Brady L. Lindley, Megan C. Ahmed, Faruque Wortley, Pascale M. TI Student Immunity Requirements of Health Professional Schools: Vaccination and Other Means of Fulfillment-United States, 2008 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INFLUENZA VACCINATION; IMMUNIZATION; PROGRAM AB US health professional schools with student immunity requirements for recommended vaccines frequently accept evidence of immunity other than vaccination but vary widely on the types of evidence that are accepted. Exemptions for nonmedical reasons and, to a lesser extent, medical reasons are often obtainable by a student-written document. Infect Control Hosp Epidemiol 2011;32(9):908-911 C1 [Miller, Brady L.; Lindley, Megan C.; Ahmed, Faruque; Wortley, Pascale M.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Miller, BL (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS E-52, Atlanta, GA 30333 USA. EM ion2@cdc.gov NR 10 TC 5 Z9 5 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2011 VL 32 IS 9 BP 908 EP 911 DI 10.1086/661785 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 876BW UT WOS:000299083000011 PM 21828972 ER PT J AU Greer, S Casper, M Kramer, M Schwartz, G Hallisey, E Holt, J Clarkson, L Zhou, YQ Freymann, G AF Greer, Sophia Casper, Michele Kramer, Michael Schwartz, Greg Hallisey, Elaine Holt, James Clarkson, Lydia Zhou, Yueqin Freymann, Gordon TI RACIAL RESIDENTIAL SEGREGATION AND STROKE MORTALITY IN ATLANTA SO ETHNICITY & DISEASE LA English DT Article DE Residential Segregation; Stroke; Mortality; Neighborhood Environment ID BLACK-AND-WHITE; NEW-YORK-CITY; HEALTH DISPARITIES; NEIGHBORHOOD CHARACTERISTICS; UNITED-STATES; ASSOCIATIONS; RISK; WOMEN; US; HYPERTENSION AB Objective: To assess the association between neighborhood-level racial residential segregation and stroke mortality using a spatially derived segregation index. Design: Cross-sectional study Setting: Atlanta Metropolitan Statistical Area Methods: The study population consisted of non-Hispanic Black and White residents of the Atlanta Metropolitan Statistical Area during the time period Jan 1, 2000 to December 31, 2006. Census tract-level stroke death rates for Blacks and Whites were modeled as a function of the segregation index while controlling for two neighborhood-level chronic stressors (poverty, low education). Results: Racial segregation was positively associated with stroke mortality for both Blacks and Whites aged 35-64 years. Among Blacks and Whites aged 65 or older, segregation was negatively associated with stroke mortality after controlling for the two stressors, suggesting that they were pathways between segregation and stroke death rates. Conclusion: Future studies are needed to identify additional pathways between residential segregation and other health outcomes, and to collect data that support a life course approach to understanding the impact of residential segregation on health. (Ethn Dis. 2011;21 (4):437-443) C1 [Casper, Michele; Schwartz, Greg] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Kramer, Michael] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Holt, James] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30341 USA. RP Greer, S (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 2877 Brandywine Rd,Mailstop K-47, Atlanta, GA 30341 USA. EM sgreer@cdc.gov RI Kramer, Michael/A-3195-2013 NR 42 TC 9 Z9 9 U1 2 U2 15 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD FAL PY 2011 VL 21 IS 4 BP 437 EP 443 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 867FH UT WOS:000298439800007 PM 22428347 ER PT J AU Eshbaugh, EM Peterson, CA Wall, S Carta, JJ Luze, G Swanson, M Jeon, HJ AF Eshbaugh, Elaine M. Peterson, Carla A. Wall, Shavaun Carta, Judith J. Luze, Gayle Swanson, Mark Jeon, Hyun-Joo TI Low-Income Parents' Warmth and Parent-Child Activities for Children with Disabilities, Suspected Delays and Biological Risks SO INFANT AND CHILD DEVELOPMENT LA English DT Article DE disabilities; parent-child relations; child health; parental warmth ID EARLY INTERVENTION; MATERNAL RESPONSIVENESS; HOME INVENTORY; DOWN-SYNDROME; SKILLS; BEHAVIORS; MOTHERS; COMPETENCE; PREDICTORS; DEPRESSION AB Warm and responsive parenting is optimal for child development, but this style of parenting may be difficult for some parents to achieve. This study examines how parents' observed warmth and their reported frequency of parent-child activities were related to children's classifications as having biological risks or a range of disability indicators. Children were low-income prekindergarteners who participated in the Early Head Start Research and Evaluation Project Longitudinal Follow-up. Data from parent, early care and education staff reports, and direct child assessments were used to classify children into the following groups: disabilities, suspected delays, biological risks, disabilities and biological risk, suspected delays and biological risk, and no disability indicator. Socioeconomic status ( ethnicity, maternal education and poverty level) and maternal depression were controlled in the analyses. The parents of children with disabilities and suspected delays evidenced significantly lower levels of warmth and less frequent parent-child activities compared with other parents. The parents of children with biological risk factors who did not also have disabilities or suspected delays did not exhibit decreased warmth and less frequent parent-child activities. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Eshbaugh, Elaine M.] Univ No Iowa, Cedar Falls, IA 50614 USA. [Peterson, Carla A.; Luze, Gayle] Iowa State Univ, Ames, IA USA. [Wall, Shavaun] Catholic Univ Amer, Washington, DC 20064 USA. [Carta, Judith J.] Univ Kansas, Lawrence, KS 66045 USA. [Swanson, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jeon, Hyun-Joo] Univ Alabama, Tuscaloosa, AL USA. RP Eshbaugh, EM (reprint author), Univ No Iowa, Cedar Falls, IA 50614 USA. EM elaine.eshbaugh@uni.edu NR 46 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1522-7227 J9 INFANT CHILD DEV JI Infant Child Dev. PD SEP-OCT PY 2011 VL 20 IS 5 BP 509 EP 524 DI 10.1002/icd.717 PG 16 WC Psychology, Developmental SC Psychology GA 865TS UT WOS:000298333800005 ER PT J AU Tong, VT Turcios-Ruiz, RM Dietz, PM England, LJ AF Tong, Van T. Turcios-Ruiz, Reina M. Dietz, Patricia M. England, Lucinda J. TI Patterns and predictors of current cigarette smoking in women and men of reproductive age-Ecuador, El Salvador, Guatemala, and Honduras SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Smoking; women; men; sexual and reproductive health; pregnancy; Ecuador; El Salvador; Guatemala; Honduras ID MIDDLE-INCOME COUNTRIES; TOBACCO USE; EXPOSURE AB Objective. To estimate smoking prevalence by gender, describe patterns of cigarette use, and identify predictors of current smoking in reproductive-age adults in four Latin American countries. Methods. Self-reported smoking was examined using data from Reproductive Health Surveys of women aged 15-49 years in Ecuador (2004), El Salvador (2002-2003), Guatemala (2002), and Honduras (2001), and of men aged 15-59 years in El Salvador, Guatemala, and Honduras for the same years. Current smoking was assessed by demographic characteristics, and independent associations were examined using logistic regression. Data were weighted to be nationally representative of households with reproductive-age women and men. Results. Current smoking prevalence ranged from 2.6% (Guatemala) to 13.1% (Ecuador) for women and from 23.1% (Guatemala) to 34.9% (El Salvador) for men. In Ecuador, 67.6% of female smokers were non-daily users; in other countries, daily use was more prevalent than non-daily use for both men and women. In daily users, the median number of cigarettes smoked per day ranged from 1.9 (Ecuador, Honduras) to 2.3 (Guatemala) for women and from 2.1 (Guatemala) to 3.6 (Honduras) for men. In bivariate analysis, smoking prevalence in all countries was highest in women who lived in urban areas, were previously married, and/or had high socioeconomic status. Risk factors for smoking varied by country and gender. Conclusions. National tobacco control programs in these countries should aggressively target high-risk populations (reproductive-age men) and maintain low prevalence in low-risk populations (reproductive-age women). More research is needed to understand addiction patterns in non-daily smokers. C1 [Tong, Van T.; Turcios-Ruiz, Reina M.; Dietz, Patricia M.; England, Lucinda J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. EM vtong@cdc.gov OI Tong, Van/0000-0002-3970-1440 NR 33 TC 3 Z9 4 U1 0 U2 5 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD SEP PY 2011 VL 30 IS 3 BP 240 EP 247 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 858LD UT WOS:000297797800008 PM 22069071 ER PT J AU Hyttinen, M Rautio, A Pasanen, P Reponen, T Earnest, GS Streifel, A Kalliokoski, P AF Hyttinen, Marko Rautio, Anna Pasanen, Pertti Reponen, Tiina Earnest, G. Scott Streifel, Andrew Kalliokoski, Pentti TI Airborne Infection Isolation Rooms - A Review of Experimental Studies SO INDOOR AND BUILT ENVIRONMENT LA English DT Review DE Isolation room; Airborne infection; Ventilation strategies ID RESPIRATORY ISOLATION ROOMS; EXPEDIENT PATIENT ISOLATION; VENTILATION EFFICIENCY; MIDWESTERN HOSPITALS; AIR IONIZATION; TRANSMISSION; TUBERCULOSIS; FILTRATION; IRRADIATION; PERFORMANCE AB Ventilation guidelines for airborne infection isolation rooms (AIIRs) are highly variable in different countries indicating lack of actual knowledge about the guidance needed. However, US guidelines for AIIRs are extensive and have been widely adopted outside the US. AIIR performance has also been evaluated in numerous studies. For a long time, the aim has mainly been to evaluate how well the existing AIIRs meet US guidelines. For historical reasons, mixing-type ventilation has been emphasised and attention has been paid to air exchange rates, although the use of auxiliary devices, such as portable room-air cleaners and ultraviolet germicidal irradiation systems, has also been examined. Recently, the scope of the investigations has been widened. The most crucial issue is to minimise the potential for disease transmission and prevent the escape of contaminated air from the AIIR. Airflow direction inside the AIIR is also important and AIIRs minimise air leakage to save energy. On the other hand, it has been observed that efficient containment can be achieved even by using simple and inexpensive construction by considering pressure differential and air flow patterns. Nevertheless, additional research is needed to assist hospitals with improving their preparedness to cope with the threat of pandemics by building and using effective AIIRs. C1 [Hyttinen, Marko; Rautio, Anna; Pasanen, Pertti; Kalliokoski, Pentti] Univ Eastern Finland, Dept Environm Sci, FI-70211 Kuopio, Finland. [Reponen, Tiina] Univ Cincinnati, Dept Environm Hlth & Inst, Cincinnati, OH USA. [Earnest, G. Scott] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Streifel, Andrew] Univ Minnesota, Dept Environm Hlth & Safety, Minneapolis, MN USA. RP Hyttinen, M (reprint author), Univ Eastern Finland, Dept Environm Sci, POB 1627, FI-70211 Kuopio, Finland. EM marko.hyttinen@uef.fi NR 72 TC 5 Z9 5 U1 3 U2 12 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1420-326X J9 INDOOR BUILT ENVIRON JI Indoor Built Environ. PD SEP PY 2011 VL 20 IS 6 BP 584 EP 594 DI 10.1177/1420326X11409452 PG 11 WC Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health SC Construction & Building Technology; Engineering; Public, Environmental & Occupational Health GA 858QB UT WOS:000297815700002 ER PT J AU Nakata, A Irie, M Takahashi, M AF Nakata, Akinori Irie, Masahiro Takahashi, Masaya TI Psychological distress, depressive symptoms, and cellular immunity among healthy individuals: A 1-year prospective study SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Article DE Psychological distress; Depressive symptoms; Immune system; Natural killer cells; Lymphocyte ID NATURAL-KILLER-CELLS; ELECTRIC-POWER PLANT; C-REACTIVE PROTEIN; CYTOTOXIC ACTIVITY; T-LYMPHOCYTES; JOB-SATISFACTION; MAJOR DEPRESSION; STRESS; WOMEN; METAANALYSIS AB Cross-sectional and case-control studies have reported that psychological distress and depression are associated with reduced cellular immune competence but the directionality of the relationship remains uncertain. This study investigated whether levels of psychological distress and depressive symptoms are related to subsequent changes in counts of lymphocyte subsets (natural killer (NK), B, and T cell) and/or whether changes of immune markers predict psychological distress/depressive symptoms in a 1-year prospective study design. A total of 105 healthy employees (67 men and 38 women), aged 23-59 (mean 40) years with an average of 15 years of education, underwent a blood draw for the measurement of circulating immune cells and completed the Japanese version of the 28-item General Health Questionnaire (GHQ-28) and the Center for Epidemiologic Studies Depression Scale (CES-D) in April 2002 (time 1) and 2003 (time 2). Hierarchical multiple linear regression analyses revealed that GHQ-28 and CES-D scores at time 1 were significantly (p<.05) and inversely associated with NK cells at time 2 controlling for potential confounders including time 1 NK cells (beta = -.221 and -.177, respectively). In contrast, NK cells and NK cell cytotoxicity at time 1 did not predict GHQ-28 or CES-D score at time 2 controlling for GHQ-28/CES-D score at time 1. GHQ-28 and CES-D scores were not related to T or B cells at times 1 and 2. The present findings indicate that psychological distress and depressive symptoms may precede and predict suppression of NK cell immunity while NK cells did not lead to subsequent psychological distress and depressive symptoms, suggesting an absence of the bi-directional relationships. Published by Elsevier B.V. C1 [Nakata, Akinori] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Irie, Masahiro] Kyushu Univ, Inst Hlth Sci, Fukuoka, Japan. [Takahashi, Masaya] NIOSH, Kawasaki, Kanagawa, Japan. RP Nakata, A (reprint author), NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, MS C24,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM nakataa-tky@umin.ac.jp; irie@ihs.kyushu-u.ac.jp; takaham@hjniosh.go.jp NR 44 TC 4 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD SEP PY 2011 VL 81 IS 3 BP 191 EP 197 DI 10.1016/j.ijpsycho.2011.06.009 PG 7 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 853VT UT WOS:000297454500007 PM 21740930 ER PT J AU Joseph, H Moloney, J Maiava, F McClintock, S Lammie, P Melrose, W AF Joseph, Hayley Moloney, James Maiava, Fuatai McClintock, Shannon Lammie, Patrick Melrose, Wayne TI First evidence of spatial clustering of lymphatic filariasis in an Aedes polynesiensis endemic area SO ACTA TROPICA LA English DT Article DE Filariasis; CELISA; Samoa; Serology; Spatial clustering; SaTScan (TM); Wuchereria ID WUCHERERIA-BANCROFTI INFECTION; AMERICAN-SAMOA; VECTOR CONTROL; TRANSMISSION; ELIMINATION; AEGYPTI; DENGUE; SCHISTOSOMIASIS; HETEROGENEITY; EPIDEMIOLOGY AB Successful elimination of lymphatic filariasis (LF) requires accurate identification of residual foci of transmission and stringent surveillance strategies to combat potential resurgence. This is challenging in areas where the day-bitingAedes polynesiensis is endemic, such as Samoa, since in previous studies no geographical clustering of infection has been demonstrated. Another challenge for this low prevalence phase is the choice of diagnostic assay as testing for circulating filarial antigen (CFA) or microfilariae (Mf) alone may not have adequate sensitivity. This could be solved by using the commercially available filariasis Cellabs enzyme linked immunosorbent assay (CELISA) to measure antibody. In the current study five Samoan villages were chosen based on previous epidemiological assessments to represent a range of infection prevalences. CFA, Mf, and antibody levels in children <10 years had been recorded and results linked to household of residence and/or primary school of attendance. To ascertain the location of exposure, two scenarios based on potential foci of transmission around communities and schools were explored. Both scenarios revealed significant spatial clusters of households with infected individuals and a relationship to antibody positive children when they were included in the spatial analysis. Fasitoo-Tai had the highest LF prevalence and largest geographical spatial clusters for both scenarios. In Falefa, spatial clusters were detected only for the primary school scenario. In Tafua, which spanned an area of 19.5 km(2), no spatial clusters were detected. Lastly, in Siufaga, the village with the lowest LF prevalence, significant clustering of infected individuals was observed and, for the primary school scenario, this was geographically related to exposure. These promising findings are the first published evidence of spatial clustering of LF in a day-biting Ae. polynesiensis endemic area. (C) 2010 Elsevier B,V. All rights reserved. C1 [Joseph, Hayley; Melrose, Wayne] James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, Lymphat Filariasis Support Ctr, Townsville, Qld 4811, Australia. [Moloney, James] James Cook Univ, Sch Earth & Environm Sci, Townsville, Qld 4811, Australia. [McClintock, Shannon; Lammie, Patrick] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Joseph, H (reprint author), James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, Lymphat Filariasis Support Ctr, Townsville, Qld 4811, Australia. EM hayley.joseph@jcu.edu.au; james.moloney@jcu.edu.au; Maiavaf@wpro.who.int; skmcclintock@gmail.com; pjl1@cdc.gov; wayne.melrose@jcu.edu.au RI James Cook University, TESS/B-8171-2012; Pileggi, Shannon/L-1320-2016 OI Pileggi, Shannon/0000-0002-7732-4164 FU GlaxoSmithKline; Division of Parasitic Diseases; National Center for Zoonotic Vector-Borne and Enteric Diseases; Centers for Disease Control and Prevention, Atlanta, GA; Atlanta Research and Education Foundation, Decatur, GA FX "SaTScan (TM) is a trademark of Martin Kulldorff. The SaTScan (TM) software was developed under the joint auspices of (i) Martin Kulldorff, (ii) the National Cancer Institute, and (iii) Farzad Mostashari of the New York City Department of Health and Mental Hygiene". We would like to thank the staff of the Ministry of Health, Samoa and the WHO office in Samoa, for their participation in the fieldwork. We would like to thank the cartographer, Adella Edwards, and her assistant, Julian Lawn, for finalising the maps. Lastly, we would like to thank GlaxoSmithKline for their generous ongoing financial support of our research. We would like to thank Phil Bright, from the Secretariat of the Pacific Community (SPC), for providing the ArcGIS map of Samoa. Shannon McClintock's research is supported by an appointment at the Division of Parasitic Diseases, National Center for Zoonotic Vector-Borne and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA, and the support of Atlanta Research and Education Foundation, Decatur, GA. NR 44 TC 5 Z9 6 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X J9 ACTA TROP JI Acta Trop. PD SEP PY 2011 VL 120 SU 1 SI SI BP S39 EP S47 DI 10.1016/j.actatropica.2010.12.004 PG 9 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA 847DZ UT WOS:000296953400007 PM 21172296 ER PT J AU King, JD Zielinski-Gutierrez, E Pa'au, M Lammie, P AF King, Jonathan D. Zielinski-Gutierrez, Emily Pa'au, Molisamoa Lammie, Patrick TI Improving community participation to eliminate lymphatic filariasis in American Samoa SO ACTA TROPICA LA English DT Article DE Lymphatic filariasis; American Samoa; Mass drug administration ID WUCHERERIA-BANCROFTI; DIETHYLCARBAMAZINE; PROGRAM; TOOLS AB In 2000, the American Samoa Department of Health initiated a campaign of annual mass drug administration (MDA) with albendazole and diethylcarbamazine (DEC) to eliminate transmission of filariasis. Drug coverage was well below prescribed targets in the first three campaigns, ranging from 24 to 52% of the total population. Evaluation findings from a variety of formative research methods identified opportunities to improve MDA coverage and ensuing program modifications resulted in increased drug coverage of 65-71% in the following four annual distributions. Partnering with churches for drug distribution and using multiple media channels for health promotion led to sustained program improvements. With the increased emphasis on the use of mass distribution for delivery of drugs fora number of neglected tropical diseases, other programs may benefit from a similar approach. (C) 2010 Elsevier B.V. All rights reserved. C1 [King, Jonathan D.; Lammie, Patrick] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA. [Zielinski-Gutierrez, Emily] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. [Pa'au, Molisamoa] Amer Samoa Dept Hlth, Pago Pago, AS 96799 USA. RP King, JD (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, 4770 Buford Highway, Atlanta, GA 30341 USA. EM jonathan.king@emory.edu FU US Department of Interior; Council of State and Territorial Epidemiologists; Pacific Island Health Officers Association; Research Corporation of the University of Hawaii; PacELF; CDC; Atlanta Research and Education Foundation FX Funding for this work was provided by the US Department of Interior, the Council of State and Territorial Epidemiologists, the Pacific Island Health Officers Association, Research Corporation of the University of Hawaii, PacELF and CDC's Emerging Infectious Diseases Program. Salary support for Jonathan King was provided by the Atlanta Research and Education Foundation. We are grateful to Tamasoali'i Dr. Joseph Tufa and Uto'ofili Aso Maga for support of the IF elimination program as Directors of Health. We thank all DOH staff who went above and beyond normal duty during MDAs, all the volunteers and church leaders. Also we are grateful to the students and teachers at the American Samoa Community College Departments of Health and Human Services; Community and Social Science; and Nursing. Finally we thank Dr. Kazuyo Ichimori for her role in the development and guidance of PacELF and for her input into the American Samoa IF elimination program during the time period covered in this manuscript. NR 20 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X J9 ACTA TROP JI Acta Trop. PD SEP PY 2011 VL 120 SU 1 SI SI BP S48 EP S54 DI 10.1016/j.actatropica.2010.08.021 PG 7 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA 847DZ UT WOS:000296953400008 PM 20932818 ER PT J AU Weil, GJ Curtis, KC Fischer, PU Won, KY Lammie, PJ Joseph, H Melrose, WD Brattig, NW AF Weil, Gary J. Curtis, Kurt C. Fischer, Peter U. Won, Kimberly Y. Lammie, Patrick J. Joseph, Hayley Melrose, Wayne D. Brattig, Norbert W. TI A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14 SO ACTA TROPICA LA English DT Article DE Filariasis; Brugia; Wuchereria; Antibody; Serology ID BANCROFTIAN FILARIASIS; DIETHYLCARBAMAZINE; MICROFILAREMIA; ELIMINATION; ALBENDAZOLE; DIAGNOSIS; EGYPT AB Antibody tests are useful for mapping the distribution of lymphatic filariasis (LF) in countries and regions and for monitoring progress in elimination programs based on mass drug administration (MDA). Prior antibody tests have suffered from poor sensitivity and/or specificity or from a lack of standardization. We conducted a multicenter evaluation of a new commercial ELISA that detects IgG4 antibodies to the recombinant filarial antigen Bm14. Four laboratories tested a shared panel of coded serum or plasma samples that included 55 samples from people with microfilaremic Wuchereria bancrofti or Brugia infections and 26 control samples. Qualitative results were identical in all four test sites. In addition, each laboratory tested samples from their own serum banks. The test detected antibodies in 32 of 36 samples (91%) from people with Brugian filariasis and in 96 of 98 samples (98%) from people with Bancroftian filariasis. Specificity testing showed that many serum or plasma samples from patients with other filarial infections such as onchocerciasis had positive antibody tests. Specificity was otherwise excellent, although 3 of 30 samples from patients with ascariasis and 4 of 51 with strongyloidiasis had positive antibody tests; it is likely that some or all of these people had previously lived in filariasis-endemic areas. Antibody test results obtained with eluates from blood dried on filter paper were similar to those obtained with plasma tested at the same dilution. This test may be helpful for diagnosing LF in patients with clinical signs of filariasis. It may also be a useful tool for use in IF endemic countries to monitor the progress of filariasis elimination programs and for post-MDA surveillance. (C) 2010 Elsevier B.V.. All rights reserved. C1 [Weil, Gary J.; Curtis, Kurt C.; Fischer, Peter U.] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA. [Won, Kimberly Y.; Lammie, Patrick J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Joseph, Hayley; Melrose, Wayne D.] James Cook Univ, Sch Publ Hlth & Trop Med, Townsville, Qld, Australia. [Brattig, Norbert W.] Bernhard Nocht Inst Trop Med, Hamburg, Germany. RP Weil, GJ (reprint author), Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA. EM gweil@dom.wustl.edu FU NIH [AI 65715]; Barnes-Jewish Hospital Foundation [01251-0608] FX We would like to thank Cellabs Pty Ltd. for providing Filariasis CELISA kits for this evaluation. This work was supported in part by NIH grant AI 65715 and by Barnes-Jewish Hospital Foundation Grant No. 01251-0608. NR 12 TC 13 Z9 14 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X J9 ACTA TROP JI Acta Trop. PD SEP PY 2011 VL 120 SU 1 SI SI BP S19 EP S22 DI 10.1016/j.actatropica.2010.04.010 PG 4 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA 847DZ UT WOS:000296953400004 PM 20430004 ER PT J AU El HaY, MA Reinisch, B Beall, B Sendi, P Brandt, C Spellerberg, B AF El HaY, M. Abd Reinisch, B. Beall, B. Sendi, P. Brandt, C. Spellerberg, B. TI Molecular characterization of Streptococcus agalactiae strains causing streptococcal toxic shock syndrome (STSS) SO INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the German-Society-for-Hygiene-and-Microbiology (DGHM) CY SEP 25-28, 2011 CL Essen, GERMANY SP German Soc Hygiene & Microbiol C1 [El HaY, M. Abd; Reinisch, B.; Spellerberg, B.] Univ Ulm, Inst Med Mikrobiol & Hyg, Ulm, Germany. [Beall, B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sendi, P.] Univ Spital Bern, Inst Infekt Krankheiten, Bern, Switzerland. [Brandt, C.] Goethe Univ Frankfurt, Inst Med Mikrobiol & Krankenhaushyg, Frankfurt, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4221 J9 INT J MED MICROBIOL JI Int. J. Med. Microbiol. PD SEP PY 2011 VL 301 SU 47 BP 95 EP 95 PG 1 WC Microbiology; Virology SC Microbiology; Virology GA 847RS UT WOS:000296990800339 ER PT J AU Kallen, AJ Jernigan, JA Patel, PR AF Kallen, Alexander J. Jernigan, John A. Patel, Priti R. TI Decolonization to Prevent Infections with Staphylococcus aureus in Patients Undergoing Hemodialysis: A Review of Current Evidence SO SEMINARS IN DIALYSIS LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; LONG-TERM HEMODIALYSIS; INTENSIVE-CARE-UNIT; METHICILLIN-RESISTANT; NASAL CARRIAGE; INTRANASAL MUPIROCIN; PERINEAL CARRIAGE; SAFETY NETWORK; COLONIZATION; PROPHYLAXIS AB Staphylococcus aureus infections remain common in patients undergoing hemodialysis, and the consequences of these infections are potentially severe. Although a number of evidence-based practices have been shown to decrease the healthcare-associated infections that this organism can cause, many questions remain about the utility of decolonization as a mechanism to prevent these infections. This brief review describes the current epidemiology of S. aureus infections in patients undergoing hemodialysis and reviews the evidence surrounding decolonization as an infection prevention strategy. C1 [Kallen, Alexander J.; Jernigan, John A.; Patel, Priti R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Kallen, AJ (reprint author), 1600 Clifton Rd NE,MS A-35, Atlanta, GA 30333 USA. EM akallen@cdc.gov NR 50 TC 9 Z9 9 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD SEP-OCT PY 2011 VL 24 IS 5 BP 533 EP 539 DI 10.1111/j.1525-139X.2011.00959.x PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 835GW UT WOS:000296025300012 PM 21883469 ER PT J AU Quinlivan, M Breuer, J Schmidt, DS AF Quinlivan, Mark Breuer, Judith Schmidt, D. Scott TI Molecular studies of the Oka varicella vaccine SO EXPERT REVIEW OF VACCINES LA English DT Review DE attenuation; neurotropism; Oka vaccine; reactivation; SCID-hu mouse; single nucleotide polymorphism; T cell; varicella; varicella zoster virus; zoster ID ZOSTER-VIRUS-INFECTION; POLYMERASE-CHAIN-REACTION; HERPES-SIMPLEX-VIRUS; DORSAL-ROOT GANGLIA; WILD-TYPE STRAINS; SCID-HU MOUSE; TRANSCRIPTIONAL REGULATORY PROTEIN; SINGLE NUCLEOTIDE POLYMORPHISMS; PROGENITOR-CELL TRANSPLANTATION; FRAGMENT-LENGTH-POLYMORPHISM AB Varicella zoster virus (VZV) is one of eight members of the Herpesviridae family for which humans are the primary host; it causes two distinct diseases, varicella (chickenpox) and zoster (shingles). Varicella results from primary infection, during which the virus establishes latency in sensory neurons, a characteristic of all members of the Alphaherpesvirinae subfamily. Zoster is caused by reactivation of latent virus, which typically occurs when cellular immunity is impaired. VZV is the first human herpesvirus for which a vaccine has been licensed. The vaccine preparation, v-Oka, is a live-attenuated virus stock produced by the classic method of tissue culture passage in animal and human cell lines. Over 90 million doses of the vaccine have been administered in countries worldwide, including the USA, where varicella morbidity and mortality has declined dramatically. Over the last decade, several laboratories have been committed to investigating the mechanism by which the Oka vaccine is attenuated. Mutations have accumulated across the genome of the vaccine during the attenuation process; however, studies of the contribution of these changes to vaccine attenuation have been hampered by the lack of a suitable animal model of VZV disease and by the heterogeneity that exists among the viral population within the vaccine preparation. Notwithstanding, a wealth of data has been generated using various laboratory methodologies. Studies of the vaccine virus in human xenografts implanted in severe combined immunodeficiency-hu mice, have enabled analyses of the replication dynamics of the vaccine in dorsal root ganglia, T lymphocytes and skin. In vitro assays have been used to investigate the effect of vaccine mutations on viral gene expression and sequence analysis of vaccine rash viruses has permitted investigations into spread of the vaccine virus in a human host. We present here a review of what has been learned thus far about the molecular and phenotypic characteristics of the Oka vaccine. C1 [Quinlivan, Mark; Schmidt, D. Scott] Ctr Dis Control & Prevent, Herpesvirus Team, MMRHLB, Atlanta, GA 30333 USA. [Quinlivan, Mark; Schmidt, D. Scott] Ctr Dis Control & Prevent, Natl VZV Lab, MMRHLB, Atlanta, GA 30333 USA. [Breuer, Judith] UCL, London W1T 4JF, England. RP Schmidt, DS (reprint author), Ctr Dis Control & Prevent, Herpesvirus Team, MMRHLB, Atlanta, GA 30333 USA. EM sschmid@cdc.gov OI Breuer, Judith/0000-0001-8246-0534 FU Medical Research Council [G0700814] NR 162 TC 8 Z9 8 U1 1 U2 7 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD SEP PY 2011 VL 10 IS 9 BP 1321 EP 1336 DI 10.1586/ERV.11.93 PG 16 WC Immunology SC Immunology GA 835KD UT WOS:000296034400014 PM 21919621 ER PT J AU Smalley, HK Keskinocak, P Engineer, FG Pickering, LK AF Smalley, Hannah K. Keskinocak, Pinar Engineer, Faramroze G. Pickering, Larry K. TI Universal Tool for Vaccine Scheduling: Applications for Children and Adults SO INTERFACES LA English DT Article DE dynamic programming; decision support systems; health care; information systems; scheduling; applications ID CHILDHOOD IMMUNIZATIONS; KNOWLEDGE AB To improve coverage against vaccine-preventable diseases for children and adults, and to aid caretakers and providers in making appropriate and timely vaccination decisions, Georgia Institute of Technology collaborated with the Centers for Disease Control and Prevention to develop decision support tools for creating optimized catch-up immunization schedules for four target groups: children through age 6, adolescents ages 7 through 18, adults ages 19 and over in the United States, and children and adolescents through age 19 in Canada. Our solution to the catch-up scheduling problem for each targeted group determines the best coverage schedule for each individual given his (her) vaccination history and age. If an individual misses one or more doses of a recommended vaccine, a health-care professional is typically responsible for generating a feasible catch-up schedule that optimizes the person's coverage against vaccine-preventable diseases, a task that is often challenging and time consuming. Inappropriate schedules could prevent some individuals from being vaccinated in a timely manner, potentially increasing their risk of contracting a disease. Each decision support tool uses a dynamic programming algorithm to construct recommended immunization schedules in an optimized manner. These tools simplify the tedious process of manually constructing immunization schedules, expedite the process, and eliminate errors. C1 [Smalley, Hannah K.; Keskinocak, Pinar] Georgia Inst Technol, Atlanta, GA 30332 USA. [Engineer, Faramroze G.] Univ Newcastle, Callaghan, NSW 2308, Australia. [Pickering, Larry K.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Smalley, HK (reprint author), Georgia Inst Technol, Atlanta, GA 30332 USA. EM hkolberg3@isye.gatech.edu; pinar@isye.gatech.edu; f.engineer@newcastle.edu.au; larry.pickering@cdc.hhs.gov FU Mary Anne and Harold R. Nash Endowment; Smalley Endowment at Georgia Tech; Health Systems Institute at Georgia Institute of Technology; Centers for Disease Control and Prevention; US Department of Energy; CDC FX We thank Shilpa Kottakapu and Cathy Hogan of the CDC for their assistance in testing and implementing these tools. We also thank Bob Bortolussi and Noni MacDonald for their assistance in developing the Canadian immunization scheduler. This research has been supported in part by the Mary Anne and Harold R. Nash Endowment and the Smalley Endowment at Georgia Tech, as well as the Health Systems Institute at Georgia Institute of Technology. This work has also been supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 14 TC 2 Z9 3 U1 1 U2 10 PU INFORMS PI HANOVER PA 7240 PARKWAY DR, STE 310, HANOVER, MD 21076-1344 USA SN 0092-2102 J9 INTERFACES JI Interfaces PD SEP-OCT PY 2011 VL 41 IS 5 BP 436 EP 454 DI 10.1287/inte.1110.0583 PG 19 WC Management; Operations Research & Management Science SC Business & Economics; Operations Research & Management Science GA 841MG UT WOS:000296515800003 ER PT J AU Smith, JS Brewer, NT Chang, YL Liddon, N Guerry, S Pettigrew, E Markowitz, LE Gottlieb, SL AF Smith, Jennifer S. Brewer, Noel T. Chang, Yuli Liddon, Nicole Guerry, Sarah Pettigrew, Erica Markowitz, Lauri E. Gottlieb, Sami L. TI Acceptability of school requirements for human papillomavirus vaccine SO HUMAN VACCINES LA English DT Article DE Public policy; human papillomavirus; cervical cancer; vaccine; mandates; requirements; implementation ID UNITED-STATES; IMMUNIZATION; LAWS; ADOLESCENTS; COVERAGE; CONTROVERSY; DISEASES; HEALTH AB We characterized parental attitudes regarding school HPV vaccination requirements for adolescent girls. Study participants were 866 parents of 10-18 y-old girls in areas of North Carolina with elevated cervical cancer incidence. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) by logistic regression. Approximately half (47%) of parents agreed that laws requiring HPV immunization for school attendance "are a good idea" when opt-out provisions were not mentioned. Far more agreed that "these laws are okay only if parents can opt out if they want to" (84%). Predictors of supporting requirements included believing HPV vaccine is highly effective against cervical cancer (OR = 2.5, 95% CI: 1.7-5.0) or is more beneficial if provided at an earlier age (OR = 16.1, 95% CI: 8.4-31.0). Parents were less likely to agree with vaccine requirements being a good idea if they expressed concerns related to HPV vaccine safety (OR = 0.3, 95% CI: 0.1-0.5), its recent introduction (OR = 0.3, 95% CI: 0.2-0.6). Parental acceptance of school requirements appears to depend on perceived HPV vaccine safety and efficacy, understanding of the optimal age for vaccine administration, and inclusion of opt-out provisions. C1 [Smith, Jennifer S.] Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Smith, Jennifer S.; Brewer, Noel T.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Brewer, Noel T.; Chang, Yuli] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC 27599 USA. [Liddon, Nicole; Markowitz, Lauri E.; Gottlieb, Sami L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Guerry, Sarah] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Pettigrew, Erica] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Pettigrew, Erica] Univ N Carolina, Sch Law, Chapel Hill, NC USA. RP Smith, JS (reprint author), Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. EM JenniferS@unc.edu NR 38 TC 11 Z9 11 U1 2 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8600 J9 HUM VACCINES JI Hum. Vaccines PD SEP PY 2011 VL 7 IS 9 BP 952 EP 957 DI 10.4161/hv.7.9.15995 PG 6 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 832VN UT WOS:000295837200019 PM 22024912 ER PT J AU Aires, L Pratt, M Lobelo, F Santos, RM Santos, MP Mota, J AF Aires, Luisa Pratt, Michael Lobelo, Felipe Santos, Rute Marina Santos, Maria Paula Mota, Jorge TI Associations of Cardiorespiratory Fitness in Children and Adolescents With Physical Activity, Active Commuting to School, and Screen Time SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE adolescent; health; physical fitness ID SHUTTLE RUN TEST; BODY-MASS INDEX; SEDENTARY BEHAVIORS; SECULAR TRENDS; MEDIA USE; YOUTH; OBESITY; SCHOOLCHILDREN; TELEVISION; FATNESS AB Background: The objective of this study was to analyze associations of cardiorespiratory fitness (CRF) with physical activity, time spent watching television and using computer, mode of commuting to school (CS), and adiposity, by gender. Methods: Participants were 1708 students (53.8% girls), aged 11 to 19 years. CRF was evaluated with a 20-meter shuttle-run test using VO(2)max by previously published equation. Maturation stages determined by Tanner's criteria, body mass index, and skinfolds were measured, and a questionnaire used to assess socioeconomic status, PA, television and computer time, and mode of CS. We conducted a regression analysis using CRF as the dependent variable. Results: CRF was independent and positively associated with physical activity [beta = 0.338 (95% CI = 0.119; 0.188); P < .001] and with maturation [beta = -0.876 (95% CI = 0.666; 1.087); P < .001]; independent and negatively associated with television time [beta = -0.003 (95% Cl = -0.005; -0.002); P < .001] and adiposity [beta = -0.068 (95% CI = -0.076; -0.060); P < .001]. CRF was positively associated with CS [beta = 0.337; (95% CI = 0.014; 0.741); P = .014]. No associations were found for computer time. Conclusions: These findings suggest that increasing overall physical activity levels through interventions in different domains such as active CS, reducing sedentary activities, such as television time, might be effective strategies for improving CRF in youth. C1 [Aires, Luisa; Santos, Rute Marina; Santos, Maria Paula; Mota, Jorge] Univ Porto, Fac Sport, Res Ctr Phys Act Hlth & Leisure, P-4100 Oporto, Portugal. [Pratt, Michael; Lobelo, Felipe] Ctr Dis Control & Prevent, CDC WHO Collaborating Ctr Phys Act & Hlth Promot, Atlanta, GA USA. RP Aires, L (reprint author), Univ Porto, Fac Sport, Res Ctr Phys Act Hlth & Leisure, Rua Campo Alegre 823, P-4100 Oporto, Portugal. RI mota, jorge/B-2980-2013; lobelo, felipe/B-9148-2013; Santos, Rute/A-6401-2012; Santos, Maria Paula/L-7533-2013; OI mota, jorge/0000-0001-7571-9181; Santos, Rute/0000-0002-7604-5753; Santos, Maria Paula/0000-0002-2182-9841; Aires, Luisa/0000-0001-9717-4186 NR 51 TC 12 Z9 15 U1 0 U2 16 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD SEP PY 2011 VL 8 SU 2 BP S198 EP S205 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 825QE UT WOS:000295295600007 PM 21918233 ER PT J AU Arango, CM Parra, DC Eyler, A Sarmiento, O Mantilla, SC Gomez, LF Lobelo, F AF Arango, Carlos Mario Parra, Diana C. Eyler, Amy Sarmiento, Olga Mantilla, Sonia C. Fernando Gomez, Luis Lobelo, Felipe TI Walking or Bicycling to School and Weight Status Among Adolescents From Monteria, Colombia SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE health behavior; physical activity ID CHILDRENS PHYSICAL-ACTIVITY; ACTIVE TRANSPORTATION; CHILDHOOD OBESITY; PROMOTING WALKING; UNITED-STATES; PREVALENCE; BEHAVIOR; URBAN; TRENDS; TRAVEL AB Background: Active school transport (AST) is a recommended strategy to promote physical activity (PA) and prevent overweight (OW) in school-aged children. In many developing countries, such as Colombia, this association has not been well characterized. Objective: To determine the association between AST and weight status in a representative sample of adolescents from Monteria, Colombia. Methods: Participants were 546 adolescents (278 boys) aged 11 to 18 years old from 14 randomly selected schools in Monteria, Colombia in 2008. The PA module of the Global School Health Survey (GSHS-2007) was used to determine the prevalence of AST. To identify OW, participants were classified according to CDC 2000 criteria (BMI >= 85th percentile). Association between AST and OW was determined by binomial logistic regression. Results: Odds ratios adjusted for age, sex, location of school, compliance with PA, and screen time recommendations showed that adolescents who reported AST had a significantly lower likelihood to be OW compared with adolescents who reported nonactive transportation (OR = 0.5, 95% Cl 0.3-0.8, P < .05). Conclusions: These results support the importance of AST as a useful PA domain with potential implications for overweight prevention, in rapidly developing settings. Further epidemiologic and intervention studies addressing AST are needed in the region. C1 [Arango, Carlos Mario; Parra, Diana C.; Eyler, Amy] Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63130 USA. [Arango, Carlos Mario; Parra, Diana C.; Eyler, Amy] Prevent Res Ctr, St Louis, MO USA. [Sarmiento, Olga] Univ Andes, Dept Publ Hlth, Bogota, Colombia. [Mantilla, Sonia C.] Univ Pamplona, Fac Hlth, Pamplona, Colombia. [Fernando Gomez, Luis] Fdn FES Social, Div Hlth, Bogota, Colombia. [Lobelo, Felipe] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Arango, CM (reprint author), Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63130 USA. RI lobelo, felipe/B-9148-2013; Parra, Diana/D-7633-2013; Parra, Diana/B-7761-2015 OI Parra, Diana/0000-0002-9797-6231; Parra, Diana/0000-0002-9797-6231 NR 52 TC 13 Z9 14 U1 5 U2 12 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD SEP PY 2011 VL 8 SU 2 BP S171 EP S177 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 825QE UT WOS:000295295600004 PM 21918230 ER PT J AU Pate, RR Gay, JL Brown, DR Pratt, M AF Pate, Russell R. Gay, Jennifer L. Brown, David R. Pratt, Michael TI Building Capacity in Physical Activity and Public Health SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Editorial Material C1 [Pate, Russell R.] Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Gay, Jennifer L.] Univ Texas Sch Publ Hlth, Dept Hlth Promot & Behav Sci, Brownsville, TX USA. [Brown, David R.; Pratt, Michael] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Pate, RR (reprint author), Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. NR 0 TC 2 Z9 2 U1 0 U2 3 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD SEP PY 2011 VL 8 SU 2 BP S149 EP S150 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 825QE UT WOS:000295295600001 PM 21918227 ER PT J AU Yolton, K Xu, YY Strauss, D Altaye, M Calafat, AM Khoury, J AF Yolton, Kimberly Xu, Yingying Strauss, Donna Altaye, Mekibib Calafat, Antonia M. Khoury, Jane TI Prenatal exposure to bisphenol A and phthalates and infant neurobehavior SO NEUROTOXICOLOGY AND TERATOLOGY LA English DT Article DE Bisphenol A; Infant neurobehavior; Phthalates; Prenatal exposure ID OXIDATIVE METABOLITES; MICE; PREGNANCY; MONOESTER; TOXICITY; CHILDREN; DEHP; LIFE; RAT AB Objective: To examine the association of prenatal exposure to bisphenol A and select common phthalates with infant neurobehavior measured at 5 weeks. Methods: We compared the concentration of maternal urinary metabolites of bisphenol A and phthalates at two distinct time points in pregnancy (16w, 26w) with scores on the NICU Network Neurobehavioral Scale (NNNS) at 5 weeks of age in a cohort of 350 mother/infant pairs. Results: Prenatal exposure to BPA was not significantly associated with neurobehavioral outcomes at 5 weeks. Significant associations between prenatal exposure to measured phthalates and infant neurobehavioral outcomes differed by type of phthalate and were only seen with exposure measured at 26 weeks. Higher total di-butyl phthalate (DBP) metabolites at 26w were associated with improved behavioral organization evidenced by decreased arousal (p = .04), increased self-regulation (p = .052), and decreased handling (p = .02). In males, higher total di-2-ethylhexyl phthalate (DEHP) metabolites at 26w were associated with more nonoptimal reflexes (p = .02). Conclusion: The association between prenatal phthalate exposure and infant neurobehavior differed by type of phthalate and was evident only with exposure measured at 26w. Prenatal exposure to DBP was associated with improved behavioral organization in 5-week-old infants. Prenatal exposure to DEHP was associated with nonoptimal reflexes in male infants. There was no evidence of an association between prenatal BPA exposure and infant neurobehavior. (C) 2011 Elsevier Inc. All rights reserved. C1 [Yolton, Kimberly; Xu, Yingying; Strauss, Donna; Altaye, Mekibib; Khoury, Jane] Cincinnati Childrens Hosp Med Ctr, Div Gen & Community Pediat, Dept Pediat, Cincinnati, OH 45229 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Yolton, K (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Gen & Community Pediat, Dept Pediat, 3333 Burnet Ave,ML 7035, Cincinnati, OH 45229 USA. EM kimberly.yolton@cchmc.org RI Altaye, Mekibib/N-5274-2015; Khoury, Jane/O-2068-2015 FU National Institute of Environmental Health Sciences [R01 ES015517, P01 ES11261] FX This work was partially supported by grants from the National Institute of Environmental Health Sciences (R01 ES015517, P01 ES11261). The study sponsors made no contributions to study design, data collection, analysis, interpretation, authorship, or decisions to submit for publication. We appreciate the support and guidance of Dr. Bruce Lanphear. We acknowledge the technical assistance of X. Ye, A. Bishop, M. Silva, E. Samandar, J. Preau, T. Jia, P. Olive and T. Bernert (Centers for Disease Control and Prevention, Atlanta, GA) in measuring the urinary concentrations of BPA, phthalate metabolites, creatinine, and of serum cotinine. NR 84 TC 72 Z9 76 U1 2 U2 32 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0892-0362 J9 NEUROTOXICOL TERATOL JI Neurotoxicol. Teratol. PD SEP-OCT PY 2011 VL 33 IS 5 BP 558 EP 566 DI 10.1016/j.ntt.2011.08.003 PG 9 WC Neurosciences; Toxicology SC Neurosciences & Neurology; Toxicology GA 841VY UT WOS:000296544500005 PM 21854843 ER PT J AU Bean, JA Fleming, LE Kirkpatrick, B Backer, LC Nierenberg, K Reich, A Cheng, YS Wanner, A Benson, J Naar, J Pierce, R Abraham, WM Kirkpatrick, G Hollenbeck, J Zaias, J Mendes, E Baden, DG AF Bean, Judy A. Fleming, Lora E. Kirkpatrick, Barbara Backer, Lorraine C. Nierenberg, Kate Reich, Andrew Cheng, Yung Sung Wanner, Adam Benson, Janet Naar, Jerome Pierce, Richard Abraham, William M. Kirkpatrick, Gary Hollenbeck, Julie Zaias, Julia Mendes, Eliana Baden, Daniel G. TI Florida red tide toxins (brevetoxins) and longitudinal respiratory effects in asthmatics SO HARMFUL ALGAE LA English DT Article DE Asthma; Harmful algal bloom (HAB); Karenia brevis; Longitudinal health study ID HARMFUL ALGAL BLOOM; HUMAN EXPOSURE; AEROSOLIZED BREVETOXINS; MARINE AEROSOL; HUMAN HEALTH; EVENTS; BEACH; POPULATION; VALUES AB Having demonstrated significant and persistent adverse changes in pulmonary function for asthmatics after 1 h exposure to brevetoxins in Florida red tide (Karenia brevis bloom) aerosols, we assessed the possible longer term health effects in asthmatics from intermittent environmental exposure to brevetoxins over 7 years. 125 asthmatic subjects were assessed for their pulmonary function and reported symptoms before and after 1 h of environmental exposure to Florida red tide aerosols for up to 11 studies over seven years. As a group, the asthmatics came to the studies with normal standardized percent predicted pulmonary function values. The 38 asthmatics who participated in only one exposure study were more reactive compared to the 36 asthmatics who participated in >= 4 exposure studies. The 36 asthmatics participating in >= 4 exposure studies demonstrated no significant change in their standardized percent predicted pre-exposure pulmonary function over the 7 years of the study. These results indicate that stable asthmatics living in areas with intermittent Florida red tides do not exhibit chronic respiratory effects from intermittent environmental exposure to aerosolized brevetoxins over a 7 year period. (C) 2011 Elsevier B.V. All rights reserved. C1 [Bean, Judy A.] Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. [Bean, Judy A.] Univ Cincinnati, Cincinnati, OH 45229 USA. [Fleming, Lora E.; Hollenbeck, Julie] Univ Miami, NSF NIEHS Oceans & Human Hlth Ctr, Miami, FL 33149 USA. [Fleming, Lora E.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. [Kirkpatrick, Barbara; Nierenberg, Kate; Pierce, Richard; Kirkpatrick, Gary] Mote Marine Lab, Sarasota, FL 34236 USA. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Reich, Andrew] Florida Dept Hlth, Tallahassee, FL 32399 USA. [Cheng, Yung Sung; Benson, Janet] Lovelace Resp Inst, Albuquerque, NM 87108 USA. [Wanner, Adam; Abraham, William M.; Mendes, Eliana] Univ Miami, Miller Sch Med, Dept Med, Div Pulm Med, Miami, FL 33136 USA. [Naar, Jerome; Baden, Daniel G.] Univ N Carolina, Ctr Marine Sci, Wilmington, NC 28409 USA. [Abraham, William M.] Mt Sinai Med Ctr, Dept Res, Miami Beach, FL 33140 USA. [Zaias, Julia] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA. [Fleming, Lora E.] Royal Cornwall Hosp, ECEHH, Peninsula Coll Med & Dent, Truro TR1 3HD, Cornwall, England. RP Fleming, LE (reprint author), Royal Cornwall Hosp, ECEHH, Peninsula Coll Med & Dent, Truro TR1 3HD, Cornwall, England. EM lora.fleming@pcmd.ac.uk FU National Institute for Environmental Health Sciences (NIEHS) [P01 ES10594]; Centers for Disease Control and Prevention (CDC); Florida Department of Health; National Science Foundation (NSF)-NIEHS Oceans and Human Health Center at the University of Miami Rosenstiel School of Marine and Atmospheric Sciences [NSF OCE0432368/OCE0911373, NIEHS P50 ES12736]; European Centre for Environment and Human Health (Peninsula College of Medicine and Dentistry, Truro, Cornwall, UK [University of Exeter]; European Union FX This study was funded in part by the National Institute for Environmental Health Sciences (NIEHS) P01 ES10594; the Centers for Disease Control and Prevention (CDC); the Florida Department of Health; the National Science Foundation (NSF)-NIEHS Oceans and Human Health Center at the University of Miami Rosenstiel School of Marine and Atmospheric Sciences (NSF OCE0432368/OCE0911373; NIEHS P50 ES12736); and the European Centre for Environment and Human Health (Peninsula College of Medicine and Dentistry, Truro, Cornwall, UK [University of Exeter]; European Union Convergence Funding).[SS] NR 37 TC 3 Z9 3 U1 0 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-9883 J9 HARMFUL ALGAE JI Harmful Algae PD SEP PY 2011 VL 10 IS 6 BP 744 EP 748 DI 10.1016/j.hal.2011.06.008 PG 5 WC Marine & Freshwater Biology SC Marine & Freshwater Biology GA 836LH UT WOS:000296112700023 PM 22053149 ER PT J AU Crider, KS Berry, RJ Bean, CJ Yang, TP Brant, JO Rasmussen, SA Hao, L Li, Z Maneval, DR Quinlivan, EP Bailey, LB AF Crider, Krista S. Berry, Robert J. Bean, Christopher J. Yang, Thomas P. Brant, Jason O. Rasmussen, Sonja A. Hao, Ling Li, Zhu Maneval, David R. Quinlivan, Eoin P. Bailey, Lynn B. TI Are There Changes in DNA Methylation in Response to Chronic Consumption and Withdrawal of Folic Acid in a Population-Based Trial of Reproductive Age Women? SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE LA English DT Meeting Abstract C1 [Crider, Krista S.; Berry, Robert J.; Bean, Christopher J.; Rasmussen, Sonja A.] CDC, NCBDDD, Atlanta, GA 30333 USA. [Yang, Thomas P.; Brant, Jason O.; Maneval, David R.; Quinlivan, Eoin P.; Bailey, Lynn B.] Univ Florida, Gainesville, FL 32611 USA. [Hao, Ling; Li, Zhu] Peking Univ, Beijing, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2040-1744 J9 J DEV ORIG HLTH DIS JI J. Dev. Orig. Health Dis. PD SEP PY 2011 VL 2 SU 1 BP S126 EP S127 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 837CK UT WOS:000296168500430 ER PT J AU Kim, SY England, LJ Sharma, AJ Njoroge, T AF Kim, Shin Y. England, Lucinda J. Sharma, Andrea J. Njoroge, Terry TI Maternal Gestational Diabetes Mellitus and Risk of Childhood Overweight and Obesity in Offspring: A Systematic Review SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE LA English DT Meeting Abstract C1 [Kim, Shin Y.; England, Lucinda J.; Sharma, Andrea J.; Njoroge, Terry] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2040-1744 J9 J DEV ORIG HLTH DIS JI J. Dev. Orig. Health Dis. PD SEP PY 2011 VL 2 SU 1 BP S86 EP S86 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 837CK UT WOS:000296168500287 ER PT J AU Plantinga, L Grubbs, V Sarkar, U Hsu, CY Hedgeman, E Robinson, B Saran, R Geiss, L Burrows, NR Eberhardt, M Powe, N AF Plantinga, Laura Grubbs, Vanessa Sarkar, Urmimala Hsu, Chi-yuan Hedgeman, Elizabeth Robinson, Bruce Saran, Rajiv Geiss, Linda Burrows, Nilka Rios Eberhardt, Mark Powe, Neil CA CDC CKD Surveillance Team TI Nonsteroidal Anti-Inflammatory Drug Use Among Persons With Chronic Kidney Disease in the United States SO ANNALS OF FAMILY MEDICINE LA English DT Article DE Nonsteroidal anti-inflammatory agents; over-the-counter drugs; chronic kidney failure; medication errors ID GLOMERULAR-FILTRATION-RATE; ANALGESIC USE; RENAL-DISEASE; SERUM CREATININE; NATIONAL-HEALTH; NEPHROPATHY; RISK; HYPERTENSION; POPULATION; EQUATION AB PURPOSE Because avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended for most individuals with chronic kidney disease (CKD), we sought to characterize patterns of NSAID use among persons with CKD in the United States, METHODS A total of 12,065 adult (aged 20 years or older) participants in the cross-sectional National Health and Nutrition Examination Survey (1999-2004) responded to a questionnaire regarding their use of over-the-counter and prescription NSAIDs. NSAIDs (excluding aspirin and acetaminophen) were defined by self-report. CKD was categorized as no CKD, mild CKD (stages 1 and 2; urinary albumin-creatinine ratio of >= 30 mg/g) and moderate to severe CKD (stages 3 and 4; estimated glomerular filtration rate of 15-59 mL/min/1.73 m(2)). Adjusted prevalence was calculated using multivariable logistic regression with appropriate population-based weighting. RESULTS Current use (nearly every day for 30 days or longer) of any NSAID was reported by 2.5%, 2.5%, and 5.0% of the US population with no, mild, and moderate to severe CKD, respectively; nearly all of the NSAIDs used were available over-the-counter. Among those with moderate to severe CKD who were currently using NSAIDs, 10.2% had a current NSAID prescription and 66.1% had used NSAIDs for 1 year or longer. Among those with CKD, disease awareness was not associated with reduced current NSAID use: (3.8% vs 3.9%, aware vs unaware; P = .979). CONCLUSIONS Physicians and other health care clinicians should be aware of use of NSAIDs among those with CKD in the United States and evaluate NSAID use in their CKD patients. C1 [Plantinga, Laura; Grubbs, Vanessa; Sarkar, Urmimala; Hsu, Chi-yuan; Powe, Neil] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Plantinga, Laura; Sarkar, Urmimala; Powe, Neil] San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Hedgeman, Elizabeth; Saran, Rajiv] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Robinson, Bruce] Arbor Res Collaborat Hlth, Ann Arbor, MI USA. [Geiss, Linda; Burrows, Nilka Rios] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Eberhardt, Mark] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Plantinga, L (reprint author), Rollins Sch Publ Hlth, Dept Epidemiol, Claudia Nance Rollins Bldg,3rd Floor,1518 Clifton, Atlanta, GA 30322 USA. EM laura.plantinga@emory.edu FU NIDDK NIH HHS [K24 DK002643, K24 DK092291, K24DK02643]; ODCDC CDC HHS [5U36CD319276, U36 CD319276] NR 34 TC 39 Z9 39 U1 0 U2 10 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 J9 ANN FAM MED JI Ann. Fam. Med. PD SEP-OCT PY 2011 VL 9 IS 5 BP 423 EP 430 DI 10.1370/afm.1302 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 831BQ UT WOS:000295704100008 PM 21911761 ER PT J AU Wong, EM Sullivan, KM Perrine, CG Rogers, LM Pena-Rosas, JP AF Wong, Esther M. Sullivan, Kevin M. Perrine, Cria G. Rogers, Lisa M. Pena-Rosas, Juan Pablo TI Comparison of median urinary iodine concentration as an indicator of iodine status among pregnant women, school-age children, and nonpregnant women SO FOOD AND NUTRITION BULLETIN LA English DT Article DE Iodine deficiency; pregnancy; school-age children; urinary iodine ID LACTATING WOMEN; DEFICIENCY; RECOMMENDATIONS; NUTRITION; FISH AB Background. Most surveys that assess the iodine status of populations target school-age children, whereas others may target nonpregnant women with the assumption that the iodine status of these groups is representative of other groups in the same population. Objective. To assess whether the median urinary iodine concentration (UIC) of school-age children or nonpregnant women can be used to accurately represent the iodine status of pregnant women. Methods. Using the World Health Organization Vitamin and Mineral Nutrition Information System and a literature review, we identified urinary iodine surveys that included pregnant women and school-age children and/or nonpregnant women in the same location and year using estimates from the smallest geographic level to increase the number of data points. Linear regression was used to assess the relationships between the median UIC for the comparisons. Results. There were 48 survey pairs with pregnant women and school-age children (total sample sizes of 8,622 and 16,844, respectively), and 26 pairs with pregnant and nonpregnant women (sample sizes of 3,222 and 5,520, respectively). The country contributing the most data points was China. When the median UIC in school-age children or nonpregnant women indicated iodine intake was adequate or above requirements, approximately half the time pregnant women had inadequate iodine intake. Conclusions. Adequate iodine nutrition status of school-age children or nonpregnant women may not indicate adequate iodine nutrition status among pregnant women. In order to assess the iodine status of pregnant women, the iodine status would need to be assessed in this group. C1 [Sullivan, Kevin M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Sullivan, Kevin M.; Perrine, Cria G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rogers, Lisa M.; Pena-Rosas, Juan Pablo] WHO, Geneva, Switzerland. RP Sullivan, KM (reprint author), Emory Univ, Rollins Sch Publ Hlth, CNR Room 3051,1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM cdckms@emory.edu NR 24 TC 29 Z9 30 U1 0 U2 3 PU INT NUTRITION FOUNDATION PI BOSTON PA 150 HARRISON AVE, BOSTON, MA 02111 USA SN 0379-5721 J9 FOOD NUTR BULL JI Food Nutr. Bull. PD SEP PY 2011 VL 32 IS 3 BP 206 EP 212 PG 7 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA 833DD UT WOS:000295861100004 PM 22073794 ER PT J AU de Pee, S Spiegel, P Kraemer, K Wilkinson, C Bilukha, O Seal, A Macias, K Oman, A Fall, AB Yip, R West, K Zlotkin, S Bloem, MW AF de Pee, Saskia Spiegel, Paul Kraemer, Klaus Wilkinson, Caroline Bilukha, Oleg Seal, Andrew Macias, Kathy Oman, Allison Fall, Ahmed Baba Yip, Ray West, Keith Zlotkin, Stanley Bloem, Martin W. TI Assessing the impact of micronutrient intervention programs implemented under special circumstances-Meeting report SO FOOD AND NUTRITION BULLETIN LA English DT Article DE Adherence; hemoglobin; impact assessment; lipid-based nutrient supplement; micronutrient powder AB Introduction and Objective. The World Food Programme and the Office of the United Nations High Commissioner for Refugees organized a meeting of experts to discuss evaluation of micronutrient interventions under special circumstances, such as emergency and refugee situations. Results. Multimicronutrient interventions for groups with higher needs may include home fortification products for young children or supplements for pregnant and lactating women. The choice of preparation should be guided by target group needs, evidence of efficacy of a product or its compounds, acceptability, and cost-effectiveness. Different designs can be used to assess whether an intervention has the desired impact. First, program implementation and adherence must be ascertained. Then, impact on micronutrient status can be assessed, but design options are often limited by logistic challenges, available budget, security issues, and ethical and practical issues regarding nonintervention or placebo groups. Under these conditions, a plausibility design using pre- and post-intervention cross-sectional surveys, a prospective cohort study, or a step-wedge design, which enrolls groups as they start receiving the intervention, should be considered. Post hoc comparison of groups with different adherence levels may also be useful. Hemoglobin is often selected as an impact indicator because it is easily measured and tends to respond to change in micronutrient status, especially iron. However, it is not a very specific indicator of micronutrient status, because it is also influenced by inflammation, parasitic infestation, physiological status (age, pregnancy), altitude, and disorders such as thalassemia and sickle cell disease. Conclusion. Given the constraints described above, replicability of impact in different contexts is key to the validation of micronutrient interventions. C1 [de Pee, Saskia] World Food Programme, Policy & Strategy Div, Nutr & HIVAIDS Policy Unit, I-00148 Rome, Italy. [Spiegel, Paul; Wilkinson, Caroline; Macias, Kathy; Oman, Allison; Fall, Ahmed Baba] Off United Nations High Commissioner Refugees, Geneva, Switzerland. [Kraemer, Klaus] Sight & Life, Basel, Switzerland. [Bilukha, Oleg] Ctr Dis Control & Prevent, Int Emergency & Refugee Branch, Ctr Global Hlth, Atlanta, GA USA. [Seal, Andrew] UCL, Inst Child Hlth, Ctr Int Hlth & Dev, London, England. [Yip, Ray] Bill & Melinda Gates Fdn, China Off, Beijing, Peoples R China. [West, Keith] Johns Hopkins Univ, Baltimore, MD USA. [Zlotkin, Stanley] Univ Toronto, Toronto, ON, Canada. RP de Pee, S (reprint author), World Food Programme, Policy & Strategy Div, Nutr & HIVAIDS Policy Unit, Via Cesare Giulio Viola 68-70, I-00148 Rome, Italy. EM Saskia.depee@wfp.org RI Seal, Andrew/C-8550-2014 OI Seal, Andrew/0000-0003-3656-4054 NR 6 TC 4 Z9 4 U1 0 U2 7 PU INT NUTRITION FOUNDATION PI BOSTON PA 150 HARRISON AVE, BOSTON, MA 02111 USA SN 0379-5721 J9 FOOD NUTR BULL JI Food Nutr. Bull. PD SEP PY 2011 VL 32 IS 3 BP 256 EP 263 PG 8 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA 833DD UT WOS:000295861100009 PM 22073799 ER PT J AU Bilukha, O Howard, C Wilkinson, C Bamrah, S Husain, F AF Bilukha, Oleg Howard, Christopher Wilkinson, Caroline Bamrah, Sapna Husain, Farah TI Effects of multimicronutrient home fortification on anemia and growth in Bhutanese refugee children SO FOOD AND NUTRITION BULLETIN LA English DT Article DE Anemia; effectiveness; growth; home fortification; micronutrient powder; morbidity ID PLACEBO-CONTROLLED TRIAL; VITAMIN-A-DEFICIENCY; YOUNG-CHILDREN; MICRONUTRIENT SPRINKLES; IRON-DEFICIENCY; COMPLEMENTARY FOODS; INFANTS; HEALTH; SUPPLEMENTS; HEMOGLOBIN AB Background. Anemia remains a significant public health problem in refugee settings. Home fortification with micronutrient powders has been proposed as a feasible option to alleviate micronutrient deficiencies; its efficacy in reducing anemia in children aged 6 to 24 months has been demonstrated in several trials. Objective. To evaluate the effectiveness of a large-scale micronutrient powder distribution program in reducing anemia prevalence and promoting growth in refugee children aged 6 to 59 months. Methods. Four representative cross-sectional surveys were conducted 13 months before and 7, 14, and 26 months after initiation of the supplementation program. Data collected on children aged 6 to 59 months included hemoglobin concentration, anthropometric indicators, morbidity, feeding practices, and information on the micronutrient distribution program. The study had a pre-post design with no control group. Results. The overall prevalence of anemia in children did not change significantly between baseline (43.3%) and endpoint (40.2%). The prevalence of moderate anemia decreased over the same period from 18.9% to 14.4% (p < .05). The levels of severe anemia were negligible (< 1%) in all surveys. The prevalence of stunting decreased significantly from 39.2% at baseline to 23.4% at endpoint (p < .001), a relative decrease of 40%. Reported coverage, use, and acceptance of micronutrient supplements remained consistently high throughout the study. Conclusions. In the absence of a control group, changes in key outcomes should be interpreted with caution. The minor effect on hemoglobin status requires further investigation of underlying causes of anemia in this population. The large positive effect on linear growth may be a significant benefit of supplementation if confirmed by future studies. C1 [Bilukha, Oleg; Howard, Christopher; Bamrah, Sapna; Husain, Farah] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wilkinson, Caroline] Off United Nations High Commissioner Refugees, Geneva, Switzerland. RP Bilukha, O (reprint author), CDC, 4770 Buford Hwy,MS F-60, Atlanta, GA 30341 USA. EM obilukha1@cdc.gov NR 33 TC 11 Z9 11 U1 1 U2 11 PU INT NUTRITION FOUNDATION PI BOSTON PA 150 HARRISON AVE, BOSTON, MA 02111 USA SN 0379-5721 J9 FOOD NUTR BULL JI Food Nutr. Bull. PD SEP PY 2011 VL 32 IS 3 BP 264 EP 276 PG 13 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA 833DD UT WOS:000295861100010 PM 22073800 ER PT J AU Chapman, DP Wheaton, AG Anda, RF Croft, JB Edwards, VJ Liu, Y Sturgis, SL Perry, GS AF Chapman, Daniel P. Wheaton, Anne G. Anda, Robert F. Croft, Janet B. Edwards, Valerie J. Liu, Yong Sturgis, Stephanie L. Perry, Geraldine S. TI Adverse childhood experiences and sleep disturbances in adults SO SLEEP MEDICINE LA English DT Article DE Sleep disturbance; Childhood abuse and neglect; Adverse childhood experiences ID INCREASED NOCTURNAL ACTIVITY; QUALITY-OF-LIFE; HOUSEHOLD DYSFUNCTION; PRIMARY INSOMNIA; INADEQUATE SLEEP; UNITED-STATES; SEXUAL-ABUSE; RISK-FACTOR; CHILDREN; HEALTH AB Background: Sleep disturbances are associated with an increased risk for many chronic diseases and unhealthy behaviors. A history of adverse childhood experiences (ACEs) is also associated with similar adult health outcomes. We studied the relationship between multiple ACEs and the likelihood of experiencing self-reported sleep disturbances in adulthood. Methods: We used data from the adverse childhood experiences (ACE) study, a retrospective cohort study of 17,337 adult health maintenance organization members in California who completed a survey about eight ACEs, which included childhood abuse and growing up with various forms of household dysfunction. The self-reported sleep disturbances measured included ever having trouble falling or staying asleep and feeling tired after a good night's sleep. We used an integer count of the number of ACEs (the ACE score) to assess the cumulative impact of these experiences on the likelihood of self-reported sleep disturbances. Results: Thirty-three percent of the cohort reported trouble falling or staying asleep, while 24% reported feeling tired after sleeping. All eight ACE categories were associated with an increased likelihood of self-reported sleep disturbances (p < 0.05). Compared to persons with an ACE score of 0, those with an ACE score >= 5 were 2.1 (95% Cl: 1.8-2.4) times more likely to report trouble falling or staying asleep and 2.0 (95% Cl: 1.7-2.3) times more likely to report feeling tired even after a good night's sleep. The trend for increasing odds for both types of self-reported sleep disturbance with increasing ACE scores was statistically significant (p < 0.0001). Conclusions: Adverse childhood experiences were associated with self-reported sleep disturbances in adulthood, and the ACE score had a graded relationship to these sleep disturbances. A history of ACEs should be obtained for patients with self-reported sleep disturbances to coordinate services that ameliorate the long-term effects of these events. Published by Elsevier B.V. C1 [Chapman, Daniel P.; Wheaton, Anne G.; Anda, Robert F.; Croft, Janet B.; Edwards, Valerie J.; Liu, Yong; Sturgis, Stephanie L.; Perry, Geraldine S.] Ctr Dis Control & Prevent, Emerging Invest & Analyt Methods Branch, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Chapman, DP (reprint author), Ctr Dis Control & Prevent, Emerging Invest & Analyt Methods Branch, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-67, Atlanta, GA 30341 USA. EM DChapman@cdc.gov NR 56 TC 29 Z9 30 U1 6 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 J9 SLEEP MED JI Sleep Med. PD SEP PY 2011 VL 12 IS 8 BP 773 EP 779 DI 10.1016/j.sleep.2011.03.013 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 831XQ UT WOS:000295764800007 PM 21704556 ER PT J AU Obi, O Braun, KV Baio, J Drews-Botsch, C Devine, O Yeargin-Allsopp, M AF Obi, Obianuju Braun, Kim Van Naarden Baio, Jon Drews-Botsch, Carolyn Devine, Owen Yeargin-Allsopp, Marshalyn TI Effect of Incorporating Adaptive Functioning Scores on the Prevalence of Intellectual Disability SO AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES LA English DT Article ID MENTAL-RETARDATION; DEVELOPMENTAL-DISABILITIES; CHILDREN; EPIDEMIOLOGY; BEHAVIOR; HEALTH; STUDENTS AB Surveillance and epidemiologic research on intellectual disability often do not incorporate adaptive functioning (AF) data. Exclusion of AF data leads to overestimation of the prevalence of intellectual disability, the extent of which is not known. In this study, the authors evaluated the effect of incorporating AF data on overall intellectual disability prevalence according to sociodemographic, economic, and severity characteristics. Between 2002 and 2006, the Metropolitan Atlanta Developmental Disabilities Surveillance Program identified 1,595 8-year-old children who met the study's intellectual disability surveillance-case definition of IQ <= 70. AF scores were not available for 9.2% of the case children, specifically those with mild intellectual disability and low socioeconomic backgrounds. Prevalence estimates showed few substantive changes when incorporating AF data. The authors conclude that use of IQ data alone appears to be appropriate for measuring population intellectual disability prevalence. C1 [Braun, Kim Van Naarden] Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Drews-Botsch, Carolyn] Emory Univ, Atlanta, GA 30322 USA. RP Braun, KV (reprint author), Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM kbn5@cdc.gov NR 34 TC 6 Z9 6 U1 2 U2 3 PU AMER ASSOC INTELLECTUAL DEVELOPMENTAL DISABILITIES PI WASHINGTON PA 444 N CAPITOL ST, NW STE 846, WASHINGTON, DC 20001-1512 USA SN 1944-7515 J9 AJIDD-AM J INTELLECT JI AJIDD-Am. J. Intellect. Dev. Disabil. PD SEP PY 2011 VL 116 IS 5 BP 360 EP 370 DI 10.1352/1944-7558-116.5.360 PG 11 WC Education, Special; Rehabilitation SC Education & Educational Research; Rehabilitation GA 825AJ UT WOS:000295243000003 PM 21905804 ER PT J AU Attanasio, R Scinicariello, F Blount, BC Valentin-Blasini, L Rogers, KA Nguyen, DC Murray, HE AF Attanasio, Roberta Scinicariello, Franco Blount, Benjamin C. Valentin-Blasini, Liza Rogers, Kenneth A. Doan C. Nguyen Murray, H. Edward TI Pendrin mediates uptake of perchlorate in a mammalian in vitro system SO CHEMOSPHERE LA English DT Article DE Iodide; Pendrin; Perchlorate; Thyroid ID SYNDROME GENE; IODIDE TRANSPORTER; SYMPORTER NIS; MAMMARY-GLAND; BREAST-MILK; CELLS; THIOCYANATE; INHIBITION; EXCHANGERS; EXPRESSION AB Perchlorate is a known endocrine disruptor present in groundwater, vegetables and dairy food products in many regions of the United States. It interferes with the uptake of iodide into the thyrocyte by the sodium-iodide symporter at the basolateral surface, thus potentially disrupting the synthesis of thyroid hormone. Because transport of iodide from the thyroid follicular cells to the follicular lumen is mediated by the protein pendrin at the apical surface, we hypothesized that perchlorate may also interact with this protein. Therefore, HeLa cells were transfected with the human SLC26A4 gene, which encodes pendrin, to generate an in vitro mammalian system expressing the recombinant pendrin protein (HeLa-PDS). The HeLa-PDS cells, along with untransfected cells, were then cultured in presence of iodide and/or perchlorate. Intracellular levels of these two chemicals were measured by ion chromatography tandem mass spectrometry. Results from this study show that iodide and perchlorate uptake increases significantly in HeLa-PDS cells as compared to untransfected cells. Thus, recombinant HeLa cells expressing pendrin protein accumulate iodide and perchlorate intracellularly, indicating that pendrin is involved in the uptake of perchlorate. Additional results from this study suggest that iodide and perchlorate competitively inhibit each other for uptake by pendrin. The ability of perchlorate to compete with iodide for uptake by both basal and apical transporters may increase the potential of perturbation of thyroid homeostasis and therefore the estimated risk posed to susceptible human populations. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Attanasio, Roberta; Rogers, Kenneth A.; Doan C. Nguyen] Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA. [Scinicariello, Franco; Murray, H. Edward] Agcy Tox Subst & Dis Registry, Div Toxicol & Environm Med, Atlanta, GA USA. [Blount, Benjamin C.; Valentin-Blasini, Liza] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Attanasio, R (reprint author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30302 USA. EM rattanasio@gsu.edu FU Georgia State University Office of Research and Sponsored Programs; Georgia Research Alliance FX This work was supported in part by the Research Program Enhancement from the Georgia State University Office of Research and Sponsored Programs, and by the Georgia Research Alliance. NR 33 TC 11 Z9 13 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 J9 CHEMOSPHERE JI Chemosphere PD SEP PY 2011 VL 84 IS 10 BP 1484 EP 1488 DI 10.1016/j.chemosphere.2011.04.038 PG 5 WC Environmental Sciences SC Environmental Sciences & Ecology GA 828YX UT WOS:000295542400024 PM 21550633 ER PT J AU de Filippis, AMB Icenogle, J Matus, CR Andrus, JK AF Bispo de Filippis, Ana Maria Icenogle, Joseph Matus, Cuauhtemoc Ruiz Andrus, Jon Kim TI Enhanced Laboratory Surveillance for the Elimination of Rubella and Congenital Rubella Syndrome in the Americas SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID MEASLES ELIMINATION; IGM REACTIVITY; VIRUS; IDENTIFICATION; TRANSMISSION; INFECTION; NETWORK; SAMPLES AB One of the reasons the 1997 Technical Advisory Group on Vaccine-Preventable Diseases recommended acceleration of rubella and congenital rubella syndrome (CRS) prevention efforts was the fact that the enhanced measles surveillance system in the Americas found that 25% of reported measles cases were laboratory-confirmed rubella cases. Until 1997, the laboratory network primarily focused on measles diagnosis. Since 1999, due to the accelerated rubella control and CRS prevention strategy, laboratories have supported the regional measles, rubella, and CRS elimination goals. The measles-rubella laboratory network established in the Americas provides timely confirmation or rejection of suspected measles and rubella cases, and determination of the genotypic characteristics of circulating virus strains, critical information for the programs. A quality assurance process has ensured high-quality performance of procedures in the network. Challenges are occurring, but the measles-rubella laboratory network continues to adapt as the requirements of the program change, demonstrating the high quality of the laboratories in support of public health activities and elimination goals. C1 [Bispo de Filippis, Ana Maria; Matus, Cuauhtemoc Ruiz; Andrus, Jon Kim] Pan Amer Hlth Org, Immunizat Unit, Washington, DC 20037 USA. [Bispo de Filippis, Ana Maria] Inst Oswaldo Cruz, Flavivirus Lab, BR-20001 Rio De Janeiro, Brazil. [Icenogle, Joseph] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP de Filippis, AMB (reprint author), Pan Amer Hlth Org, Immunizat Unit, 525 23rd St NW,Rm 501E, Washington, DC 20037 USA. EM bispoana@paho.org FU Centers for Disease Control and Prevention (CDC); Pan American Health Organization (PAHO) FX The majority of measles-rubella laboratory activities in the Americas have been funded by the Centers for Disease Control and Prevention (CDC) and the Pan American Health Organization (PAHO). NR 34 TC 6 Z9 6 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S652 EP S658 DI 10.1093/infdis/jir405 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800016 ER PT J AU Castillo-Solorzano, C Reef, SE Morice, A Vascones, N Chevez, AE Castalia-Soares, R Torres, C Vizzotti, C Matus, CR AF Castillo-Solorzano, Carlos Reef, Susan E. Morice, Ana Vascones, Nancy Elena Chevez, Ana Castalia-Soares, Rosa Torres, Carlos Vizzotti, Carla Matus, Cuauhtemoc Ruiz TI Rubella Vaccination of Unknowingly Pregnant Women During Mass Campaigns for Rubella and Congenital Rubella Syndrome Elimination, The Americas 2001-2008 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article AB Background. Due to the significant teratogenicity of rubella virus and the use of a live-attentuated vaccine, pregnancy is a contraindication of receipt of rubella vaccine (RCV). Data collected from several countries that have observed susceptible women who had received RCV during pregnancy documented that no infant with congenital rubella syndrome (CRS) has been born, so the risk is theoretical. As part of the regional initiative to eliminate rubella and CRS in the Americas, one of the key strategies was the vaccination of women of childbearing age. The implementation of mass vaccination campaigns targeting women of childbearing age in Argentina, Brazil, Costa Rica, Ecuador, El Salvador, and Paraguay provided an opportunity to further increase the body of knowledge on the safety of rubella vaccine if an unknowingly pregnant woman is vaccinated in early pregnancy. Methods. Using a standard protocol, women who were unknowingly pregnant or become pregnant < 30 days after receiving RCV were evaluated to determine immunity status (eg, susceptible, immune, and unknown) at the time of vaccination. Susceptible pregnant women were observed to determine the outcome of the pregnancy. For pregnancies that resulted in live births, serum samples were obtained from the newborn for rubella immunoglobulin (Ig) M antibody testing. If the newborn's serum sample was IgM positive, the infant was evaluated for manifestations of CRS. Results. During the period 2001-2008, 48748253 women of childbearing age were vaccinated in the region of the Americas, 39542253 (81%) of whom were vaccinated in the 6 selected countries. Of these women, 30139 (0.07%) were pregnant or became pregnant < 1 month after receiving vaccine and were followed up. On the basis of serological evaluation, 2894 (10%) women were classified as susceptible at the time of vaccination; of their pregnancies, 1980 (90%) resulted in a live birth. Sera from 70 (3.5%) of these infants were rubella IgM antibody positive, but none of the infants had features of CRS as a result of rubella vaccination. The maximum theoretical risk for CRS following rubella vaccination of susceptible pregnant women was 0.2%. Conclusions. The results of these studies from 6 select countries provides additional evidence showing an absence of risk of CRS associated with administering rubella vaccine shortly before or during pregnancy. C1 [Castillo-Solorzano, Carlos] Pan Amer Hlth Org, Comprehens Family Immunizat, Family & Community Hlth Area, Washington, DC 20037 USA. [Reef, Susan E.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Castalia-Soares, Rosa] FUNASA, Natl Immunizat Program, Brasilia, DF, Brazil. RP Castillo-Solorzano, C (reprint author), Pan Amer Hlth Org, Comprehens Family Immunizat, Family & Community Hlth Area, 525 23rd St NW, Washington, DC 20037 USA. EM castilsc@paho.org FU Ministries of Health FX This work was supported by the Ministries of Health. NR 15 TC 13 Z9 14 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S713 EP S717 DI 10.1093/infdis/jir489 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800025 PM 21954271 ER PT J AU Castillo-Solorzano, C Reef, SE Morice, A Andrus, JK Matus, CR Tambini, G Gross-Galiano, S AF Castillo-Solorzano, Carlos Reef, Susan E. Morice, Ana Andrus, Jon Kim Matus, Cuauthemoc Ruiz Tambini, Gina Gross-Galiano, Socorro TI Guidelines for the Documentation and Verification of Measles, Rubella, and Congenital Rubella Syndrome Elimination in the Region of the Americas SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article AB In the region of the Americas, goals for the elimination of endemic measles and rubella/congenital rubella syndrome (CRS) by the year 2000 and 2010, respectively were established. The successful implementation of measles elimination strategies in the region of the Americas resulted in the interruption of endemic measles transmission in 2002 and tremendous progress toward rubella and CRS elimination. In October 2007, the 27th Pan American Sanitary Conference adopted Resolution CSP27.R2 urging member states to begin documenting and verifying the interruption of endemic transmission of the measles and rubella viruses in the Americas. To ensure a standardized approach for the process of documentation and verification, the Pan American Health Organization/World Health Organization (PAHO/WHO) developed a regional plan of action to guide countries and their national commissions as they prepare and consolidate evidence of the interruption of endemic measles and rubella transmission. This article summarizes the plan of action including the essential criteria and components of the guidelines. C1 [Castillo-Solorzano, Carlos] Pan Amer Hlth Org, Comprehens Family Immunizat, Washington, DC 20037 USA. [Reef, Susan E.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Castillo-Solorzano, C (reprint author), Pan Amer Hlth Org, Comprehens Family Immunizat, Washington, DC 20037 USA. EM castilsc@paho.org NR 7 TC 19 Z9 20 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S683 EP S689 DI 10.1093/infdis/jir471 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800021 PM 21954267 ER PT J AU de Moraes, JC Toscano, CM de Barros, ENC Kemp, B Lievano, F Jacobson, S Afonso, AMS Strebel, PM Cairns, KL AF de Moraes, Jose Cassio Toscano, Cristiana M. de Barros, Eliana N. C. Kemp, Brigina Lievano, Fabio Jacobson, Steven Afonso, Ana Maria S. Strebel, Peter M. Cairns, K. Lisa CA VigiFex Grp TI Etiologies of Rash and Fever Illnesses in Campinas, Brazil SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; RUBELLA-LIKE ILLNESSES; MONOCLONAL-ANTIBODIES; COMMERCIAL TESTS; MEASLES; DIAGNOSIS; CHILDREN; SURVEILLANCE; IGM AB Background. Few population-based studies of infectious etiologies of fever-rash illnesses have been conducted. This study reports on enhanced febrile-rash illness surveillance in Campinas, Brazil, a setting of low measles and rubella virus transmission. Methods. Cases of febrile-rash illnesses in individuals aged < 40 years that occurred during the period 1 May 2003-30 May 2004 were reported. Blood samples were collected for laboratory diagnostic confirmation, which included testing for adenovirus, dengue virus, Epstein-Barr virus (EBV), enterovirus, human herpes virus 6 (HHV6), measles virus, parvovirus-B19, Rickettsia rickettsii, rubella virus, and group A streptococci (GAS) infections. Notification rates were compared with the prestudy period. Results. A total of 1248 cases were notified, of which 519 (42%) had laboratory diagnosis. Of these, HHV-6 (312 cases), EBV (66 cases), parvovirus (30 cases), rubella virus (30 cases), and GAS (30 cases) were the most frequent causes of infection. Only 10 rubella cases met the rubella clinical case definition currently in use. Notification rates were higher during the study than in the prestudy period (181 vs 52.3 cases per 100,000 population aged < 40 years). Conclusions. Stimulating a passive surveillance system enhanced its sensitivity and resulted in additional rubella cases detected. In settings with rubella elimination goals, rubella testing may be considered for all cases of febrile-rash illness, regardless of suspected clinical diagnosis. C1 [de Moraes, Jose Cassio] Santa Casa Sao Paulo Med Sci Univ, Sao Paulo, Brazil. [Afonso, Ana Maria S.] Inst Adolfo Lutz Sao Paulo, Sao Paulo, Brazil. [Toscano, Cristiana M.] Pan Amer Hlth Org, Brasilia, DF, Brazil. [de Barros, Eliana N. C.; Kemp, Brigina] Municipal Hlth Dept, Campinas, SP, Brazil. [Toscano, Cristiana M.; Lievano, Fabio; Strebel, Peter M.; Cairns, K. Lisa] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Jacobson, Steven] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA. RP Toscano, CM (reprint author), Av T-05,715 Apto,301 Setor Bueno, Goiania, Go, Brazil. EM ctoscano@terra.com.br RI Iats, Inct/K-2300-2013 FU US Centers for Disease Control and Prevention; Pan American Health Organization FX This work was supported by the US Centers for Disease Control and Prevention and the Pan American Health Organization. Laboratory and surveillance personnel were funded by the municipal and state health department. The Campinas Medicine and Surgery Society, State University of Campinas (UNICAMP), and PUC-Campinas University provided funds for the communication strategies and the symposium. NR 36 TC 5 Z9 6 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S627 EP S636 DI 10.1093/infdis/jir490 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800012 PM 21954258 ER PT J AU Icenogle, JP Siqueira, MM Abernathy, ES Lemos, XR Fasce, RA Torres, G Reef, SE AF Icenogle, Joseph P. Siqueira, Marilda M. Abernathy, Emily S. Lemos, Xenia R. Fasce, Rodrigo A. Torres, Graciela Reef, Susan E. TI Virologic Surveillance for Wild-type Rubella Viruses in the Americas SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID ORAL FLUID SAMPLES; OUTBREAK; MEASLES; VACCINE; CANADA; BURDEN; BRAZIL; ASSAY; PERU; IGM AB The goal of eliminating rubella from the Americas by 2010 was established in 2003. Subsequently, a systematic nomenclature for wild-type rubella viruses (wtRVs) was established, wtRVs circulating in the region were catalogued, and importations of wtRVs into a number of countries were documented. The geographic distribution of wtRVs of various genotypes in the Americas, interpreted in the context of the global distribution of these viruses, contributed to the documentation of rubella elimination from some countries. Data from virologic surveillance also contributed to the conclusion that viruses of genotype 2B began circulating endemically in the Americas during 2006-2007. Viruses of one genotype (1C), which are restricted to the Americas, will likely disappear completely from the world as they are eliminated from the Americas. Efforts to expand virologic surveillance for wtRVs in the Americas will also provide additional data aiding the elimination of rubella from the region. For example, identification of vaccine virus in specimens from rash and fever cases found during elimination can identify such cases as vaccine associated. C1 [Icenogle, Joseph P.; Abernathy, Emily S.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Reef, Susan E.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Siqueira, Marilda M.; Lemos, Xenia R.] Fiocruz MS, IOC, Lab Resp Viruses, Oswaldo Cruz Fdn, BR-21045900 Rio De Janeiro, Brazil. [Fasce, Rodrigo A.; Torres, Graciela] Inst Salud Publ Chile, Resp & Exanthemat Viruses Sect, Santiago, Chile. RP Icenogle, JP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mail Stop C-22, Atlanta, GA 30333 USA. EM jci1@cdc.gov NR 33 TC 10 Z9 10 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S647 EP S651 DI 10.1093/infdis/jir431 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800015 PM 21954261 ER PT J AU Rainey, JJ Danovaro-Holliday, MC Magloire, R Kananda, G Lee, CE Chamouillet, H Lacapere, F Mung, K Luman, ET AF Rainey, Jeanette J. Danovaro-Holliday, M. Carolina Magloire, Roc Kananda, Gregoire Lee, Carla E. Chamouillet, Henriette Lacapere, Francois Mung, Kam Luman, Elizabeth T. TI Haiti 2007-2008 National Measles-Rubella Vaccination Campaign: Implications for Rubella Elimination SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article AB Background. A national campaign was conducted in Haiti in 2007-2008 to vaccinate all children and adolescents aged 1-19 years with measles-rubella vaccine in support of achieving the Region of the Americas' 2010 goal of eliminating rubella and congenital rubella syndrome (CRS). Measles-rubella vaccine was introduced into the country's routine childhood immunization schedule after the campaign. Methods. A nationwide, stratified, multistage cluster sample survey of 20859 children was conducted to assess coverage using house-to-house interviews. Results. Estimated national coverage with measles-rubella vaccine was 79.2% (95% confidence interval, 77.6%-80.7%), ranging from 90.2% in Nord-Ouest Department to 70.0% in Cite Soleil Metropolitan Area. National coverage was lower for children aged 1-5 years (76.7%) than for those aged 6-19 years (80.3%) (P < .001) but similar in rural departments (79.4%) and metropolitan areas (78.6%; P = .61). The reasons most frequently cited for nonparticipation in the campaign were that the child was ill or unavailable (18.6%), did not know vaccinations were important (13.8%), did not know when to go or forgot to go (13.3%), and did not have enough time (12.3%). Conclusions. The measles-rubella vaccination campaign was critical for raising rubella immunity levels in children and adolescents in Haiti. To remain free of rubella transmission and CRS, Haiti must also achieve and sustain high routine measles-rubella vaccination coverage and maintain high-quality integrated measles-rubella and CRS surveillance, including laboratory-based confirmation for reported rash illnesses. If routine measles-rubella vaccination coverage is suboptimal or if gaps in coverage are identified, additional mass campaigns with measles-rubella vaccine will be necessary. C1 [Rainey, Jeanette J.; Lee, Carla E.; Luman, Elizabeth T.] US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Danovaro-Holliday, M. Carolina; Kananda, Gregoire] Pan Amer Hlth Org, Comprehens Family Immunizat Project, Washington, DC USA. [Magloire, Roc] Minist Publ Hlth & Populat, DELR, Haiti, Port Au Prince, Haiti. [Lacapere, Francois] Pan Amer Hlth Org World Hlth Org, Expanded Programme Immunizat, Haiti, Port Au Prince, Haiti. [Mung, Kam] Pan Amer Hlth Org World Hlth Org, Epidemiol & Surveillance, Haiti, Port Au Prince, Haiti. RP Rainey, JJ (reprint author), US Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS E-03, Atlanta, GA 30333 USA. EM jkr7@cdc.gov NR 7 TC 10 Z9 10 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S616 EP S621 DI 10.1093/infdis/jir488 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800010 PM 21954256 ER PT J AU Reef, SE Redd, SB Abernathy, E Kutty, P Icenogle, JP AF Reef, Susan E. Redd, Susan B. Abernathy, Emily Kutty, Preeta Icenogle, Joseph P. TI Evidence Used to Support the Achievement and Maintenance of Elimination of Rubella and Congenital Rubella Syndrome in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID AREA VACCINATION COVERAGE; AGED 19-35 MONTHS; TRANSMISSION; POPULATION AB On 29 October 2004, an expert panel was convened to review the status of elimination of rubella and congenital rubella syndrome (CRS) in the United States. Primarily based on 5 types of information presented-epidemiology of reported cases, molecular epidemiology, seroprevalence, vaccine coverage, and adequacy of surveillance-the panel unanimously agreed that rubella virus is no longer endemic in the United States. Since 2004, new data continue to support the conclusion that elimination has been achieved and maintained. In documenting elimination in the United States, each of the 5 types of data provided evidence for elimination and collectively provided much stronger evidence than any one type could individually. As countries document the elimination of rubella and CRS, many sources and types of data will likely be necessary. Rigorous data evaluation must be conducted to look for inconsistencies among the available data. To maintain elimination, countries should maintain high vaccine coverage, adequate surveillance, and rapid response to outbreaks. C1 [Reef, Susan E.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Redd, Susan B.; Abernathy, Emily; Kutty, Preeta; Icenogle, Joseph P.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Reef, SE (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM sreef@cdc.gov NR 18 TC 12 Z9 12 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S593 EP S597 DI 10.1093/infdis/jir420 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800006 PM 21954252 ER PT J AU Segatto, C Samad, S Mengue, SS Rodrigues, G Flannery, B Toscano, CM AF Segatto, Cristina Samad, Samia Mengue, Sotero Serrate Rodrigues, Gilmar Flannery, Brendan Toscano, Cristiana M. TI Historical Analysis of Birth Cohorts Not Vaccinated Against Rubella Prior to National Rubella Vaccination Campaign, Brazil SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID AMERICA AB Background. Brazil conducted mass rubella vaccination campaigns to meet disease elimination goals by 2010. An analysis of rubella vaccination opportunities was conducted to target population groups with concentrations of unvaccinated individuals. Methods. Rubella vaccination strategies for all 27 states were reviewed between 1992 and 2006. Yearly vaccination coverage was calculated by dividing number of doses of measles-rubella or measles-mumps-rubella vaccines administered by census estimates of target populations. For annual birth cohorts (1967-2005), percentages of persons not vaccinated prior to 2007 were estimated by subtracting the highest coverage obtained in any vaccination strategy (routine or campaign) from 100%. Cohort analysis results were compared with rubella incidence by population group. Results. An estimated 28.9 million males and 7.7 million females aged 2-40 years in 2007 remained unvaccinated against rubella, corresponding to 43.0% of males and 11.5% of females of these ages in Brazil. The highest percentages of unvaccinated birth cohorts (93.6%-98.1%) were identified among males aged 26-40 years. In rubella outbreaks reported during 2007, the highest disease incidence (22 cases per 100000 population) occurred among males aged 20-29 years. Conclusions. Analysis of rubella vaccination opportunities identified concentrations of unvaccinated adults and adolescents for targeting mass vaccination to eliminate rubella and congenital rubella syndrome in Brazil. C1 [Segatto, Cristina] Minist Saude, Setor Comercial Sul, Dept Vigilancia Epidemiol, Resp & Vaccine Preventable Dis Surveillan Unit, BR-70304000 Brasilia, DF, Brazil. [Samad, Samia] Minist Saude, Secretariat Hlth Surveillance, Natl Immunizat Program, BR-70304000 Brasilia, DF, Brazil. [Mengue, Sotero Serrate] Univ Fed Rio Grande do Sul, Dept Epidemiol, Porto Alegre, RS, Brazil. [Rodrigues, Gilmar] Minas Gerais State Hlth Dept, Belo Horizonte, MG, Brazil. [Flannery, Brendan; Toscano, Cristiana M.] Pan Amer Hlth Org, Brasilia, DF, Brazil. [Flannery, Brendan; Toscano, Cristiana M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Segatto, C (reprint author), Minist Saude, Setor Comercial Sul, Dept Vigilancia Epidemiol, Resp & Vaccine Preventable Dis Surveillan Unit, Quadra 04,Bloco A, BR-70304000 Brasilia, DF, Brazil. EM cristina.segatto@saude.gov.br RI Iats, Inct/K-2300-2013 FU Pan American Health Organization; Ministry of Health, Brazil FX This work was supported by the Pan American Health Organization and the Ministry of Health, Brazil. NR 18 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S608 EP S615 DI 10.1093/infdis/jir357 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800009 PM 21954255 ER PT J AU Sever, AE Rainey, JJ Zell, ER Hennessey, K Uzicanin, A Castillo-Solorzano, C Dietz, V AF Sever, Adrianne E. Rainey, Jeanette J. Zell, Elizabeth R. Hennessey, Karen Uzicanin, Amra Castillo-Solorzano, Carlos Dietz, Vance TI Measles Elimination in the Americas: A Comparison Between Countries With a One-Dose and Two-Dose Routine Vaccination Schedule SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID MUMPS-RUBELLA VACCINE; LOGISTIC-REGRESSION; MORTALITY REDUCTION; PROPENSITY SCORE; HEALTH OUTCOMES; ERADICATION; STRATEGIES; PROGRESS; POLICY; DETERMINANTS AB Background. The Region of the Americas eliminated measles in 2002 through high first-dose routine measles vaccine coverage and vaccination campaigns every 4-6 years; a second routine dose at school entry was added in some countries. The impact of this second routine dose on measles elimination was evaluated. Methods. Data on socioeconomic factors, demographic characteristics, vaccination coverage, and the estimated proportion of children (< 15 years of age) susceptible to measles were compiled. Countries were grouped using propensity score methods, and Kaplan-Meier curves were used to compare time to measles elimination between countries with a 1-dose schedule and those with a 2-dose schedule. Results. One-dose (n = 14) and 2-dose (n = 7) countries did not differ with respect to median routine first-dose measles vaccine coverage, median coverage for 3 measles campaigns, or estimated percentage of susceptible children after routine first vaccination dose and campaigns. Compared with 1-dose countries, 2-dose countries had higher median gross national income per capita (P =.002), percentage of population living in urban areas (P =.04), and female literacy (P =.01), as well as lower infant mortality (P = .007); however, no differences in time to elimination were found. Conclusions. One-dose and 2-dose countries had similar times to measles elimination despite socioeconomic differences between their populations. A second routine dose might not have hastened measles elimination, because threshold immunity needed to eliminate measles was achieved with high first routine dose coverage and vaccination campaigns. Further research will be needed to determine the applicability of these findings to other regions. C1 [Sever, Adrianne E.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Sever, Adrianne E.; Rainey, Jeanette J.; Hennessey, Karen; Uzicanin, Amra; Dietz, Vance] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Global Immunizat Div, Atlanta, GA 30333 USA. [Zell, Elizabeth R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. [Castillo-Solorzano, Carlos] Pan Amer Hlth Org, Comprehens Family Immunizat Unit, Washington, DC USA. RP Dietz, V (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS-A04, Atlanta, GA 30333 USA. EM vdietz@cdc.gov NR 37 TC 2 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S748 EP S755 DI 10.1093/infdis/jir445 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800031 PM 21954277 ER PT J AU Strebel, PM Gacic-Dobo, M Reef, S Cochi, SL AF Strebel, Peter M. Gacic-Dobo, Marta Reef, Susan Cochi, Stephen L. TI Global Use of Rubella Vaccines, 1980-2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID DEVELOPING-COUNTRIES AB In most developing countries, rubella vaccine has not been included in the Expanded Programme on Immunization because of lack of information on the burden of disease caused by rubella virus, increased cost associated with adding rubella vaccine, and the concern that if high vaccine coverage cannot be achieved and maintained, the risk of congenital rubella syndrome (CRS) may increase. Data for 2009 reported by countries to the World Health Organization (WHO) and United Nations Children's Fund through the annual Joint Reporting Form were used to indicate patterns in the worldwide use of rubella vaccines, describe the number of reported rubella and CRS cases by WHO Region, and explore factors associated with decisions by countries to introduce rubella vaccine in their national childhood immunization programs. The number of WHO Member States using rubella-containing vaccine (RCV) in their national childhood immunization schedule increased from 83 (43%) in 1996 to 130 (67%) in 2009. Although scheduled ages for rubella vaccination vary across countries and regions, most countries have a 2-dose schedule using a combined measles-mumps-rubella vaccine. Among 130 countries using RCV in 2009, median coverage with the first dose of measles-containing vaccine (MCV1) was 95% (interquartile range [IQR], 90%-98%), compared with a median MCV1 coverage of 76% (IQR, 64%-88%) in countries not using RCV. The median per capita gross national income among 130 countries using RCV was US $6300 (IQR, $3227-$20 916), compared with $635 (IQR, $337-$1027) for 63 countries not using RCV. In 2009, 121 344 rubella cases from 167 countries were reported to WHO. However, only 165 CRS cases were reported globally, of which 67 were in the Eastern Mediterranean Region. Further improvements in surveillance are needed to better document the burden of CRS, and new financing mechanisms will be required to catalyze the introduction of rubella vaccine in developing countries that currently meet the coverage criteria for introduction of rubella vaccine. C1 [Strebel, Peter M.; Gacic-Dobo, Marta] World Hlth Org, Expanded Programme Immunizat, Dept Immunizat Vaccines & Biol, Geneva, Switzerland. [Reef, Susan; Cochi, Stephen L.] Natl Ctr Immunizat & Resp Dis, Global Immunizat Div, Atlanta, GA USA. RP Strebel, PM (reprint author), 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM strebelp@who.int NR 13 TC 9 Z9 9 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 SU 2 BP S579 EP S584 DI 10.1093/infdis/jir447 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 828OO UT WOS:000295511800004 PM 21954250 ER PT J AU Oster-Granite, ML Parisi, MA Abbeduto, L Berlin, DS Bodine, C Bynum, D Capone, G Collier, E Hall, D Kaeser, L Kaufmann, P Krischer, J Livingston, M McCabe, LL Pace, J Pfenninger, K Rasmussen, SA Reeves, RH Rubinstein, Y Sherman, S Terry, SF Whitten, MS Williams, S McCabe, ERB Maddox, YT AF Oster-Granite, Mary Lou Parisi, Melissa A. Abbeduto, Leonard Berlin, Dorit S. Bodine, Cathy Bynum, Dana Capone, George Collier, Elaine Hall, Dan Kaeser, Lisa Kaufmann, Petra Krischer, Jeffrey Livingston, Michelle McCabe, Linda L. Pace, Jill Pfenninger, Karl Rasmussen, Sonja A. Reeves, Roger H. Rubinstein, Yaffa Sherman, Stephanie Terry, Sharon F. Whitten, Michelle Sie Williams, Stephen McCabe, Edward R. B. Maddox, Yvonne T. TI Down syndrome: National conference on patient registries, research databases, and biobanks SO MOLECULAR GENETICS AND METABOLISM LA English DT Article DE Down syndrome; Registry; Database; Biobank; Trisomy 21 ID UNITED-STATES; PREVALENCE; PEOPLE AB A December 2010 meeting, "Down Syndrome: National Conference on Patient Registries, Research Databases, and Biobanks," was jointly sponsored by the Eunice Kennedy Shriven National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) in Bethesda, MD, and the Global Down Syndrome Foundation (GDSF)/Linda Crnic Institute for Down Syndrome based in Denver, CO. Approximately 70 attendees and organizers from various advocacy groups, federal agencies (Centers for Disease Control and Prevention, and various NIH Institutes, Centers, and Offices), members of industry, clinicians, and researchers from various academic institutions were greeted by Drs. Yvonne Maddox, Deputy Director of NICHD, and Edward McCabe, Executive Director of the Linda Crnic Institute for Down Syndrome. They charged the participants to focus on the separate issues of contact registries, research databases, and biobanks through both podium presentations and breakout session discussions. Among the breakout groups for each of the major sessions, participants were asked to generate responses to questions posed by the organizers concerning these three research resources as they related to Down syndrome and then to report back to the group at large with a summary of their discussions. This report represents a synthesis of the discussions and suggested approaches formulated by the group as a whole. C1 [Oster-Granite, Mary Lou; Parisi, Melissa A.; Bynum, Dana; Kaeser, Lisa; Pace, Jill; Maddox, Yvonne T.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA. [Abbeduto, Leonard] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA. [Berlin, Dorit S.] Coriell Inst Med Res, Camden, NJ USA. [McCabe, Linda L.; McCabe, Edward R. B.] Univ Colorado Denver, Linda Crnic Inst Syndrome, Aurora, CO USA. [Capone, George] Hugo W Moser Kennedy Krieger Inst, Baltimore, MD USA. [Collier, Elaine] NIH, Natl Ctr Res Resources, Bethesda, MD 20892 USA. [Hall, Dan] NIMH, NIH, Bethesda, MD 20892 USA. [Kaufmann, Petra] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA. [Krischer, Jeffrey] Univ S Florida, Coll Med, Tampa, FL USA. [Livingston, Michelle; Whitten, Michelle Sie] Global Syndrome Fdn, Denver, CO USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Reeves, Roger H.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Rubinstein, Yaffa] NIH, Off Rare Dis Res, Bethesda, MD 20892 USA. [Sherman, Stephanie] Emory Univ, Atlanta, GA 30322 USA. [Terry, Sharon F.] Genet Alliance, Washington, DC USA. [Williams, Stephen] SomaLogic Inc, Boulder, CO USA. RP Parisi, MA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA. EM parisima@mail.nih.gov FU Eunice Kennedy Shriver National Institute of Child Health and Human Development; Global Down Syndrome Foundation; Waisman Intellectual and Developmental Disabilities Research Center [P30HD003552]; NIGMS Human Genetic Cell Repository [HHS-N263-2009-00026C]; Rehabilitation Engineering Research Center for Advancing Cognitive Technologies, National Institute on Disability and Rehabilitation Research, US Department of Energy [H133E090003]; Rare Diseases Clinical Research Network Data Management and Coordinating Center [U54NS064808]; Colorado Clinical and Translational Science Institute, (Aurora) [UL1RR025780]; Coleman Institute for Cognitive Disabilities (Boulder); University of Colorado School of Medicine-Dean's Academic Enrichment; Department of Pediatrics; Health Resources and Services Administration cooperative agreement [U35MC15451]; NICHD [HHS-N275-2009-00011C] FX We thank the conference attendees for active participation and contribution of ideas, Palladian Partners for administrative and logistical support, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Global Down Syndrome Foundation for their organizational and financial support of the conference.; The material presented at the conference was supported, in part, by: the Waisman Intellectual and Developmental Disabilities Research Center (P30HD003552; L Abbeduto); the NIGMS Human Genetic Cell Repository Contract (HHS-N263-2009-00026C; D. Berlin); the Rehabilitation Engineering Research Center for Advancing Cognitive Technologies, National Institute on Disability and Rehabilitation Research, US Department of Energy (H133E090003; C. Bodine); the Rare Diseases Clinical Research Network Data Management and Coordinating Center (U54NS064808; J. Krischer); the Colorado Clinical and Translational Science Institute (UL1RR025780; K. Pfenninger), the Children's Hospital Research Institute (Aurora, CO; K. Pfenninger), the Coleman Institute for Cognitive Disabilities (Boulder, CO; K. Pfenninger), the University of Colorado School of Medicine-Dean's Academic Enrichment fund, and the Department of Pediatrics (K. Pfenninger); the Health Resources and Services Administration cooperative agreement (U35MC15451; S. Terry). Funding for the NICHD Brain and Tissue Bank for Developmental Disorders as discussed by M.Parisi is provided by NICHD contract HHS-N275-2009-00011C. NR 14 TC 17 Z9 18 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD SEP-OCT PY 2011 VL 104 IS 1-2 SI SI BP 13 EP 22 DI 10.1016/j.ymgme.2011.07.005 PG 10 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 823UF UT WOS:000295151300005 PM 21835664 ER PT J AU Shim, SH Park, MS Moon, S Park, KS Song, JW Song, KJ Baek, LJ AF Shim, So Hee Park, Man-Seong Moon, Sungsil Park, Kwang Sook Song, Jin-Won Song, Ki-Joon Baek, Luck Ju TI Comparison of innate immune responses to pathogenic and putative non-pathogenic hantaviruses in vitro SO VIRUS RESEARCH LA English DT Article DE Pathogenic hantaviruses; Putative non-pathogenic hantaviruses; Type-I interferon; Innate immunity ID KOREAN HEMORRHAGIC-FEVER; INTERFERON RESPONSE; ENDOTHELIAL-CELLS; GENE-EXPRESSION; RENAL SYNDROME; HANTAAN VIRUS; THOTTAPALAYAM VIRUS; ANTIVIRAL RESPONSE; ETIOLOGIC AGENT; RNA VIRUSES AB Hantaviruses are human pathogens that cause hemorrhagic fever with renal syndrome or hantavirus cardiopulmonary syndrome. The mechanisms accounting for the differences in virulence between pathogenic and non-pathogenic hantaviruses are not well known. We have examined the pathogenesis of different hantavirus groups by comparing the innate immune responses induced in the host cell following infection by pathogenic (Sin Nombre, Hantaan, and Seoul virus) and putative non-pathogenic (Prospect Hill, Tula, and Thottapalayam virus) hantaviruses. Pathogenic hantaviruses were found to replicate more efficiently in interferon-competent A549 cells than putative non-pathogenic hantaviruses. The former also suppressed the expression of the interferon-beta and myxovirus resistance protein genes, while the transcription level of both genes increased rapidly within 24 h post-infection in the latter. In addition, the induction level of interferon correlated with the activation level of interferon regulatory factor-3. Taken together, these results suggest that the observed differences are correlated with viral pathogenesis and further indicate that pathogenic and putative non-pathogenic hantaviruses differ in terms of early interferon induction via activation of the interferon regulatory factor-3 in infected host cells. (C) 2011 Elsevier B.V. All rights reserved. C1 [Shim, So Hee; Park, Kwang Sook; Song, Jin-Won; Song, Ki-Joon; Baek, Luck Ju] Korea Univ, Coll Med, Dept Microbiol, Inst Viral Dis, Seoul 136705, South Korea. [Park, Man-Seong] Hallym Univ, Coll Med, Dept Microbiol, Chunchon 200702, Kangwon Do, South Korea. [Moon, Sungsil] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Baek, LJ (reprint author), Korea Univ, Coll Med, Dept Microbiol, Inst Viral Dis, 5 Ga, Seoul 136705, South Korea. EM baekmicr@korea.ac.kr FU Ministry of Education and Human Resources Development, Republic of Korea FX This work was supported in part by the Brain Korea 21 Project of the Ministry of Education and Human Resources Development, Republic of Korea. NR 51 TC 11 Z9 11 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD SEP PY 2011 VL 160 IS 1-2 BP 367 EP 373 DI 10.1016/j.virusres.2011.07.013 PG 7 WC Virology SC Virology GA 826HQ UT WOS:000295345600044 PM 21820021 ER PT J AU Schwebel, DC Roth, DL Elliott, MN Visser, SN Toomey, SL Shipp, EM Grunbaum, JA Schuster, MA AF Schwebel, David C. Roth, David L. Elliott, Marc N. Visser, Susanna N. Toomey, Sara L. Shipp, Eva M. Grunbaum, Jo Anne Schuster, Mark A. TI Association of Externalizing Behavior Disorder Symptoms and Injury Among Fifth Graders SO ACADEMIC PEDIATRICS LA English DT Article DE attention-deficit/hyperactivity disorder; behavior disorders; conduct disorder; early adolescence; fifth graders; injury ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; UNINTENTIONAL INJURY; YOUNG-ADULTS; CHILDREN; RISK; ADOLESCENTS; RATES; PSYCHOPATHOLOGY; VISITS AB OBJECTIVE: Injury is the leading cause of death among American youth, killing more 11-year-olds than all other causes combined. Children with symptoms of externalizing behavior disorders such as attention-deficit/hyperactivity disorder (ADHD) and conduct disorder (CD) may have increased risk. Our aims were to determine: (1) whether increasing symptoms of ADHD and CD associate positively with injuries among a community sample of fifth graders; and (2) whether symptoms of ADHD and CD have a multiplicative rather than additive association with injuries among the sample. METHODS: Data were collected from 474.5 fifth graders and their primary caregivers participating in Healthy Passages, a multisite, community-based study of pediatric health risk behaviors and health outcomes. The primary outcome was injury frequency. Primary independent variables were ADHD and CD symptoms. Additional covariates included gender, race/ethnicity, and household income. Ordinal logistic regression examined correlates of injury frequency. The interaction between ADHD and CD symptoms also was examined. RESULTS: In bivariate analyses, the odds of injury increased as ADHD symptoms (odds ratio [OR] 1.29; 95% confidence interval [95% CI] 1.18-1.41) and CD symptoms (OR 1.18; 95% CI 1.07-1.31) increased. However, in multivariate analysis, only ADHD symptoms were significantly associated with injury (OR 1.22; 95% CI 1.10-1.35). There was no statistically significant interaction between ADHD and CD symptoms. CONCLUSIONS: ADHD symptoms are associated with increased odds of injury in fifth graders. Findings have implications for potential injury prevention strategies for mental health practitioners (for example, cognitive training with at-risk youth), pediatricians (ADHD screening), and parents (improved supervision). C1 [Schwebel, David C.] Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. [Roth, David L.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Elliott, Marc N.; Schuster, Mark A.] RAND, Santa Monica, CA USA. [Grunbaum, Jo Anne] Ctr Dis Control & Prevent, Atlanta, GA USA. [Toomey, Sara L.; Schuster, Mark A.] Harvard Univ, Sch Med, Boston, MA USA. [Toomey, Sara L.; Schuster, Mark A.] Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Shipp, Eva M.] Texas A&M Hlth Sci Ctr, Sch Rural Publ Hlth, Dept Epidemiol & Biostat, College Stn, TX USA. RP Schwebel, DC (reprint author), Univ Alabama, Dept Psychol, 1300 Univ Blvd,CH 415, Birmingham, AL 35294 USA. EM schwebel@uab.edu FU Centers for Disease Control and Prevention, Prevention Research Centers [U48DP000046, U48DP000057, U48DP000056] FX The Healthy Passages Study is funded by the Centers for Disease Control and Prevention, Prevention Research Centers (Cooperative Agreements U48DP000046, U48DP000057, and U48DP000056). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Thanks to Martha Hovater for data analysis support. The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 30 TC 12 Z9 13 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD SEP-OCT PY 2011 VL 11 IS 5 BP 427 EP 431 PG 5 WC Pediatrics SC Pediatrics GA 826IF UT WOS:000295347100014 PM 21640681 ER PT J AU Ramadhani, TA Canfield, MA Farag, NH Royle, M Correa, A Waller, DK Scheuerle, A AF Ramadhani, Tunu A. Canfield, Mark A. Farag, Noha H. Royle, Marjorie Correa, Adolfo Waller, D. Kim Scheuerle, Angela CA Natl Birth Defects Prevention Stud TI Do Foreign- and U.S.-born Mothers Across Racial/Ethnic Groups Have a Similar Risk Profile for Selected Sociodemographic and Periconceptional Factors? SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE nativity; periconceptional behavioral factors; health conditions; race/ethnicity; foreign-born; US-born; sociodemographic factors ID UNITED-STATES-BORN; PREGNANCY OUTCOMES; BIRTH-DEFECTS; MATERNAL BIRTHPLACE; PERINATAL OUTCOMES; BLACK-WOMEN; US; POPULATIONS; NATIVITY; WEIGHT AB BACKGROUND: We examined differences in selected pregnancy-related risk factors, including maternal sociodemographic characteristics, health-related conditions, and periconceptional behavioral factors, among foreign-born versus U.S.-born control mothers across race/ethnic groups. METHODS: We used data from the National Birth Defects Prevention Study, and calculated odds ratios (ORs) and 95% confidence intervals (CIs) of the risk factors, for foreign-born Hispanic, non-Hispanic white, non-Hispanic black, and Asian/Pacific Islander (API) mothers, compared to their U.S.-born counterparts. RESULTS: Across all race/ethnic groups, foreign-born mothers were older and had lower odds of obesity compared to their U.S.-born counterparts. With the exception of foreign-born black mothers, foreign-born mothers from other race/ethnic groups had significantly lower odds of binge drinking during the periconceptional period. Compared to U.S.-born, foreign-born Hispanic mothers had twice the odds of gestational diabetes (OR = 2.23; 95% CI = 1.36-3.66). Certain health behaviors were less prevalent in foreign-born black mothers (e.g., folic acid use; OR = 0.54; 95% CI = 0.31-0.96) and foreign-born API mothers (e.g., cigarette smoking; OR = 0.10; 95% CI = 0.02-0.48). CONCLUSIONS: Significant differences in pregnancy related risk factors during the periconceptional period and throughout pregnancy were observed between maternal nativity groups and across race/ethnicity. Prevention efforts for both prepregnancy and after conception should be designed and delivered according to maternal nativity for each racial/ethnic group. Birth Defects Research (Part A) 91:823-830, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Ramadhani, Tunu A.; Canfield, Mark A.; Farag, Noha H.; Scheuerle, Angela] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX 78756 USA. [Farag, Noha H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Royle, Marjorie] State New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [Correa, Adolfo] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Waller, D. Kim] Univ Texas Houston, Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA. [Scheuerle, Angela] Med City Dallas, Tesserae Genet, Dallas, TX USA. RP Canfield, MA (reprint author), Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, 1100 W 49th St, Austin, TX 78756 USA. EM mark.canfield@dshs.state.tx.us FU Texas Center for Birth Defects Research and Prevention [U50/CCU613232]; Centers for Disease Control and Prevention; Texas Department of State Health Services FX This research was supported in part by the Texas Center for Birth Defects Research and Prevention, through a cooperative agreement (No. U50/CCU613232) by the Centers for Disease Control and Prevention with the Texas Department of State Health Services. NR 30 TC 4 Z9 4 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD SEP PY 2011 VL 91 IS 9 BP 823 EP 830 DI 10.1002/bdra.20839 PG 8 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 827BP UT WOS:000295400900003 PM 21656900 ER PT J AU Mao, L Laney, AS Wang, ML Sun, XW Zhou, SW Shi, J Shi, HY AF Mao, Ling Laney, A. Scott Wang, Mei Lin Sun, Xiwen Zhou, Shaowei Shi, Jin Shi, Haiyan TI Comparison of Digital Direct Readout Radiography with Conventional Film-screen Radiography for the Recognition of Pneumoconiosis in Dust-exposed Chinese Workers SO JOURNAL OF OCCUPATIONAL HEALTH LA English DT Article DE Chest radiograph; Digital radiography; Physician; Pneumoconiosis; Radiography; Small opacity AB Comparison of Digital Direct Readout Radiography with Conventional Film-screen Radiography for the Recognition of Pneumoconiosis in Dust-exposed Chinese Workers: Ling MAO, et al. Department of Pneumoconiosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China-Objectives: Pneumoconiosis in China remains a disease with substantial public health significance. Diagnostic standards for the pneumoconioses are based on traditional film-screen radiography (FSR). However, FSR is increasingly being replaced with digital radiographic imaging, which has become the predominant technology available in Chinese clinical practice. To evaluate the applicability of digital direct readout radiography (DR) images in the recognition of pneumoconioses, we compared the profusion of small opacities and large opacities between FSR and DR radiographs. Methods: We enrolled 161 pneumoconioses patients and 31 dust-exposed workers during the course of the study, with FSR and DR images obtained from all participants. Each chest film was interpreted by five readers using the Chinese Diagnostic Criteria classification of radiographs of pneumoconiosis, as were DR images displayed on medical-grade computer monitors. Results: No statistically significant differences were observed when the data were analyzed by small opacity profusion subcategory except for 1/1. The overall intermodality agreement of small opacities was good, with a weighted kappa (kappa) of 0.77. Conclusions: DR images with soft copy display are recognition and classification of small parenchymal lung opacities. Additionally, we observed likeness between modalities with respect to the classification of large opacities. Overall, our study findings demonstrate that in a population of Chinese workers with pneumoconiosis, direct readout digital systems are equivalent to traditional film-screen radiography in the recognition and classification of small pneumoconiotic opacities. (J Occup Health 2011; 53: 320-326) C1 [Mao, Ling; Sun, Xiwen; Zhou, Shaowei; Shi, Jin; Shi, Haiyan] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pneumoconiosis, Shanghai, Peoples R China. [Mao, Ling; Laney, A. Scott; Wang, Mei Lin] Ctr Dis Control & Prevent, Surveillance Branch, Div Resp Dis Studies, NIOSH, Atlanta, GA USA. RP Mao, L (reprint author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pneumoconiosis, 507 Zhengmin Rd, Shanghai, Peoples R China. EM maoling113@sina.com NR 15 TC 7 Z9 9 U1 0 U2 4 PU JAPAN SOC OCCUPATIONAL HEALTH PI TOKYO PA 1-29-8 SHINJUKU, SHINJUKU-KU, TOKYO, 160, JAPAN SN 1341-9145 J9 J OCCUP HEALTH JI J. Occup. Health PD SEP PY 2011 VL 53 IS 5 BP 320 EP 326 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 829BK UT WOS:000295549900003 PM 21778659 ER PT J AU O'Donnell, JK Tobey, M Weiner, DE Stevens, LA Johnson, S Stringham, P Cohen, B Brooks, DR AF O'Donnell, Julie K. Tobey, Matthew Weiner, Daniel E. Stevens, Lesley A. Johnson, Sarah Stringham, Peter Cohen, Bruce Brooks, Daniel R. TI Prevalence of and risk factors for chronic kidney disease in rural Nicaragua SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE chronic kidney disease; epidemiology; Latin America; Nicaragua; prevalence ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; CALIBRATION; CKD; NEPHROPATHY; HEALTH AB Background. Mostly anecdotal reports describe a high prevalence of chronic kidney disease in northwestern Nicaragua, predominantly among younger men, resulting in substantial morbidity and mortality. The true prevalence, nature and aetiology of kidney disease in this region remain unknown. Methods. We performed a population-based prevalence study in Quezalguaque, Nicaragua to assess the frequency of estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m(2), and compared the prevalence of reduced eGFR in Quezalguaque with the USA using the NHANES 1999-2006 data. We also conducted an embedded case-control study in a subset of participants to assess kidney disease risk factors. Results. From 1882 eligible households, 771 individuals from 300 households participated in the prevalence study, 98 (13%) of whom had reduced eGFR. Reduced eGFR was more common among older participants, men and participants living at lower altitudes. Among 18-29-year-old participants, 2.6% had reduced eGFR, and among 30-41-year-old participants, 7.4% had reduced eGFR; this compares with 0.2% and 0.8%, respectively, in NHANES. No individuals in these age groups were diabetic. Among cases, only 27% had dipstick proteinuria of 1+ or greater, compared with 7% of controls. Haematuria did not significantly differ between cases and controls (24% versus 18%). In age-and sex-adjusted models, hypertension and residence at lower altitude were independently associated with reduced eGFR, while occupational history was not associated with reduced eGFR. Conclusions. Kidney disease appears common in residents of Quezalguaque, Nicaragua, particularly in younger men, with features most consistent with tubulointerstitial disease. Further research is needed to elucidate the causes of kidney disease in this region. C1 [Weiner, Daniel E.; Stevens, Lesley A.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [O'Donnell, Julie K.] ASPH CDC Allan Rosenfield Global Hlth Fellowship, Washington, DC USA. [Tobey, Matthew; Stringham, Peter] Boston Univ, Sch Med, Boston, MA 02118 USA. [Johnson, Sarah] Management Sci Hlth, Cambridge, MA USA. [Cohen, Bruce] Massachusetts Dept Publ Hlth, Boston, MA USA. [Brooks, Daniel R.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Weiner, DE (reprint author), Tufts Med Ctr, Div Nephrol, Boston, MA USA. EM dweiner@tuftsmedicalcenter.org OI Brooks, Daniel/0000-0001-6220-6889 FU Sister City Committee in Brookline, MA, USA; Nova Biomedical; East Boston Neighborhood Health Center; Clinical and Translational Research Institute (CTSI) at Tufts University; residents of Quezalguaque FX We would like to acknowledge the assistance of Drs Cecelia Torres and Aurora Aragon of UNAN-Leon who assisted us with the study approval and provided us with the survey instrument that we adapted for use in this study. This study could not have occurred without the efforts of the individuals who performed the screenings in Quezalguaque (Ann Marie Borchelt, Eddy Calderon, Heidi Chase, Fabiola Mendoza, Luisa Silva, Yorlenys Urbina, Tom Van MD and Monica Zigman); the physicians, nurses and technicians who provided logistic support and advice in Nicaragua (Mayra Arias RN, Benjamin Barreto MD, Miriam Cruz, Luzmila Escoto, Francisco Iglesias, Gilberto Moreno MD, Mario Navarette MD and Vera Orozco MD); the advice and assistance of Bijan Roshan MD; the support of the Sister City Committee in Brookline, MA, USA; Nova Biomedical, which donated serum creatinine assays and instruments; ESA Biosciences in Chelmsford, MA, USA, which greatly assisted in lead analyses; the support of the East Boston Neighborhood Health Center; the Clinical and Translational Research Institute (CTSI) at Tufts University; and, most importantly, the residents of Quezalguaque who welcomed us into their community. NR 32 TC 50 Z9 51 U1 2 U2 17 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD SEP PY 2011 VL 26 IS 9 BP 2798 EP 2805 DI 10.1093/ndt/gfq385 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 824VZ UT WOS:000295231600014 PM 20615905 ER PT J AU Waitzfelder, B Pihoker, C Klingensmith, G Case, D Anderson, A Bell, RA Lawrence, JM Mayer-Davis, EJ Imperatore, G Standiford, D Rodriguez, BL Dabelea, D Seid, M AF Waitzfelder, Beth Pihoker, Catherine Klingensmith, Georgeanna Case, Doug Anderson, Andrea Bell, Ronny A. Lawrence, Jean M. Mayer-Davis, Elizabeth J. Imperatore, Giuseppina Standiford, Debra Rodriguez, Beatriz L. Dabelea, Dana Seid, Michael CA Search Diabetes Youth Study Group TI Adherence to Guidelines for Youths With Diabetes Mellitus SO PEDIATRICS LA English DT Article DE quality of care; children and youths; diabetes mellitus ID CHILDRENS HEALTH-CARE; QUALITY-OF-CARE; SOCIOECONOMIC POSITION; TRANSLATING RESEARCH; AMBULATORY-CARE; TYPE-1; COMPLICATIONS; ADOLESCENTS; SEARCH; ADULTS AB OBJECTIVE: To describe demographic and clinical characteristics associated with self-reported receipt of tests and measurements recommended by the American Diabetes Association (ADA) for children and youths with diabetes. METHODS: The study included 1514 SEARCH for Diabetes in Youth study participants who completed a survey about diabetes care received. Quality-of-care measures were based on ADA guidelines for eye examinations and glycohemoglobin (hemoglobin A1c [HbA1c]), lipid level, microalbuminuria, and blood pressure measurements, and a composite variable of these 5 indicators was created. Multivariate logistic regression models were used to assess the association of selected demographic and clinical characteristics with the reported receipt of all recommended tests and measurements according to age and diabetes type subgroups. RESULTS: Overall, 95% of the participants reported having their blood pressure checked at all or most visits, 88% had lipid levels measured, 83% had kidney function tested, 68% underwent HbA1c testing, and 66% underwent an eye examination, in accordance with ADA recommendations. Participants aged 18 years or older, particularly those with type 2 diabetes, tended to have fewer tests of all kinds performed. Age and family income emerged as important correlates of overall quality of care in multivariate models; older age and lower income were associated with not meeting guidelines. CONCLUSIONS: Although there was relatively good adherence to ADA-recommended guidelines for most indicators, efforts are needed to improve rates of HbA1c testing and eye examinations, particularly among older youths. Pediatrics 2011; 128: 531-538 C1 [Waitzfelder, Beth] Kaiser Permanente Ctr Hlth Res Hawaii, Honolulu, HI 96817 USA. [Waitzfelder, Beth] Pacific Hlth Res Inst, Honolulu, HI USA. [Pihoker, Catherine] Childrens Hosp, Dept Pediat Endocrinol, Seattle, WA USA. [Pihoker, Catherine] Reg Med Ctr, Seattle, WA USA. [Klingensmith, Georgeanna] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA. [Dabelea, Dana] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Bell, Ronny A.] Wake Forest Univ, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. [Case, Doug; Anderson, Andrea] Wake Forest Univ, Dept Biostat Sci, Sch Med, Winston Salem, NC 27109 USA. [Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA USA. [Standiford, Debra] Cincinnati Childrens Hosp, Med Ctr, Div Endocrinol, Cincinnati, OH USA. [Seid, Michael] Cincinnati Childrens Hosp, Med Ctr, Div Pulm Med, Cincinnati, OH USA. [Seid, Michael] Cincinnati Childrens Hosp, Med Ctr, Ctr Hlth Care Qual, Cincinnati, OH USA. [Rodriguez, Beatriz L.] Kuakini Med Ctr, Honolulu Heart Program, Honolulu, HI USA. RP Waitzfelder, B (reprint author), Kaiser Permanente Ctr Hlth Res Hawaii, 501 Alakawa St,Suite 201, Honolulu, HI 96817 USA. EM beth.e.waitzfelder@kp.org RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395 FU Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health [UL1RR029882, M01RR00037, M01 RR00069, P30 DK57516, 1UL1RR026314-01] FX The SEARCH for Diabetes in Youth study is funded by the Centers for Disease Control and Prevention (program announcements 00097, DP-05-069, and DP-10-001) and is supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Sites include Kaiser Permanente Southern California (contracts U01 DP000246 and U18DP002714), University of Colorado Denver (contracts U01 DP000247 and U18DP000247-06A1), Kuakini Medical Center (contract U01 DP000245), Children's Hospital Medical Center (Cincinnati, OH) (contracts U01 DP000248 and 1U18DP002709), University of North Carolina at Chapel Hill (contracts U01 DP000254 and U18DP002708-01), University of Washington School of Medicine (contracts U01 DP000244 and U18DP002710-01), and Wake Forest University School of Medicine (contracts U01 DP000250 and 200-2010-35171). We acknowledge the involvement of General Clinical Research Centers at the South Carolina Clinical and Translational Research Institute, Medical University of South Carolina (National Institutes of Health grant UL1RR029882), Children's Hospital and Regional Medical Center (National Institutes of Health grant M01RR00037), Colorado Pediatric General Clinical Research Center (National Institutes of Health grant M01 RR00069), and the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver (National Institutes of Health grant P30 DK57516), as well as the Institutional Clinical and Translational Science Award at the University of Cincinnati (National Institutes of Health grant 1UL1RR026314-01). NR 24 TC 23 Z9 23 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD SEP PY 2011 VL 128 IS 3 BP 531 EP 538 DI 10.1542/peds.2010-3641 PG 8 WC Pediatrics SC Pediatrics GA 827DB UT WOS:000295406100049 PM 21859914 ER PT J AU Unger, ER Fajman, NN Maloney, EM Onyekwuluje, J Swan, DC Howard, L Beck-Sague, CM Sawyer, MK Girardet, RG Sautter, RL Hammerschlag, MR Black, CM AF Unger, Elizabeth R. Fajman, Nancy N. Maloney, Elizabeth M. Onyekwuluje, Juanita Swan, David C. Howard, Laurie Beck-Sague, Consuelo M. Sawyer, Mary K. Girardet, Rebecca G. Sautter, Robert L. Hammerschlag, Margaret R. Black, Carolyn M. TI Anogenital Human Papillomavirus in Sexually Abused and Nonabused Children: A Multicenter Study SO PEDIATRICS LA English DT Article DE HPV; child sexual abuse ID ADOLESCENT POPULATION; UNITED-STATES; INFECTION; EPIDEMIOLOGY; TRANSMISSION; PREVALENCE; CHILDHOOD; WOMEN; AMPLIFICATION; ASSOCIATION AB OBJECTIVES: To characterize the epidemiology of genital human papillomavirus (HPV) infection in children without previous consensual sexual activity, comparing HPV prevalence by certainty of child sexual abuse (CSA). PATIENTS AND METHODS: Patients presenting for evaluation of CSA in 8 sites in Atlanta, Houston, Harrisburg, and New York City were recruited along with patients presenting for unrelated health visits. CSA certainty was classified as definite, probable, possible, or no evidence following published guidelines and the results of history, physical examination, and laboratory tests. Urine and swabs of external genitalia were tested for HPV using L1 consensus polymerase chain reaction. RESULTS: The study included 576 participants (89.9% female) aged 6 months to 13 years (mean: 7.9); 534 of whom were evaluated for CSA and 42 for unrelated reasons. Of those evaluated for CSA, 14 had genital warts. One or more HPV types were detected in 11.8% (61 of 517) of participants with adequate samples. HPV detection was more likely among abused participants (definite, probable, or possible) than among participants without evidence of CSA (13.7% and 1.3%, respectively; P < .0001) and increased with certainty of abuse (8.4%, 15.6%, and 14.5% in participants with possible, probable, and definite CSA, respectively; P < .0001). Participants aged 10 years or older had a higher prevalence of HPV (20.6%) than others (5.6%) (P < .0001). CSA, anogenital warts, and age were independently associated with HPV detection. CONCLUSIONS: HPV detection was associated with CSA and increased with CSA certainty. In this population, genital HPV seemed to behave as a sexually transmitted infection. Pediatrics 2011; 128: e658-e665 C1 [Unger, Elizabeth R.; Maloney, Elizabeth M.; Onyekwuluje, Juanita; Swan, David C.; Howard, Laurie; Beck-Sague, Consuelo M.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Black, Carolyn M.] Ctr Dis Control & Prevent, Div Sci Resources, Atlanta, GA 30333 USA. [Fajman, Nancy N.; Sawyer, Mary K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Girardet, Rebecca G.] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX USA. [Sautter, Robert L.] Pinnacle Hlth, Childrens Resource Ctr, Dept Pediat, Harrisburg, PA USA. [Hammerschlag, Margaret R.] SUNY Hlth Sci Ctr, Dept Pediat, Brooklyn, NY 11203 USA. RP Unger, ER (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, MS G-41, Atlanta, GA 30333 USA. EM eunger@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 FU Centers for Disease Control and Prevention Office of Women's Health [99-155]; National Center for Infectious Diseases Office of Minority and Women's Health; [US6/CCU417921-01]; [US6CCU617918-01]; [US6/CCU217922-01] FX Funding for this project was provided by the Centers for Disease Control and Prevention Office of Women's Health (grant 99-155); Cooperative Agreements US6/CCU417921-01, US6CCU617918-01, and US6/CCU217922-01; and by the National Center for Infectious Diseases Office of Minority and Women's Health. NR 32 TC 11 Z9 11 U1 1 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD SEP PY 2011 VL 128 IS 3 BP E658 EP E665 DI 10.1542/peds.2010-2247 PG 8 WC Pediatrics SC Pediatrics GA 827DB UT WOS:000295406100023 PM 21844060 ER PT J AU Levy, MZ Small, DS Vilhena, DA Bowman, NM Kawai, V del Carpio, JGC Cordova-Benzaquen, E Gilman, RH Bern, C Plotkin, JB AF Levy, Michael Z. Small, Dylan S. Vilhena, Daril A. Bowman, Natalie M. Kawai, Vivian Cornejo del Carpio, Juan G. Cordova-Benzaquen, Eleazar Gilman, Robert H. Bern, Caryn Plotkin, Joshua B. TI Retracing Micro-Epidemics of Chagas Disease Using Epicenter Regression SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID TRYPANOSOMA-CRUZI INFECTION; RURAL NORTHWESTERN ARGENTINA; TRIATOMA-INFESTANS; PERU; AREQUIPA; TRANSMISSION; COMMUNITY; DYNAMICS; STRATEGIES; PATTERNS AB Vector-borne transmission of Chagas disease has become an urban problem in the city of Arequipa, Peru, yet the debilitating symptoms that can occur in the chronic stage of the disease are rarely seen in hospitals in the city. The lack of obvious clinical disease in Arequipa has led to speculation that the local strain of the etiologic agent, Trypanosoma cruzi, has low chronic pathogenicity. The long asymptomatic period of Chagas disease leads us to an alternative hypothesis for the absence of clinical cases in Arequipa: transmission in the city may be so recent that most infected individuals have yet to progress to late stage disease. Here we describe a new method, epicenter regression, that allows us to infer the spatial and temporal history of disease transmission from a snapshot of a population's infection status. We show that in a community of Arequipa, transmission of T. cruzi by the insect vector Triatoma infestans occurred as a series of focal micro-epidemics, the oldest of which began only around 20 years ago. These micro-epidemics infected nearly 5% of the community before transmission of the parasite was disrupted through insecticide application in 2004. Most extant human infections in our study community arose over a brief period of time immediately prior to vector control. According to our findings, the symptoms of chronic Chagas disease are expected to be absent, even if the strain is pathogenic in the chronic phase of disease, given the long asymptomatic period of the disease and short history of intense transmission. Traduccion al espanol disponible en Alternative Language Text S1/A Spanish translation of this article is available in Alternative Language Text S1. C1 [Levy, Michael Z.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Dept Stat, Wharton Sch, Philadelphia, PA 19104 USA. [Vilhena, Daril A.; Plotkin, Joshua B.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA. [Bowman, Natalie M.] Johns Hopkins Univ, Johns Hopkins Hosp, Baltimore, MD USA. [Kawai, Vivian] Asociac Benef PRISMA, Lima, Peru. [Cornejo del Carpio, Juan G.] Gerencia Reg Minist Salud, Cercado Arequipa, Peru. [Cordova-Benzaquen, Eleazar] Univ Nacl de San Agustin, Dept Microbiol, Fac Med, Arequipa, Peru. [Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Bern, Caryn] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Levy, MZ (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. EM mzlevy@mail.med.upenn.edu RI Plotkin, Joshua/E-6947-2013 FU NIH [5K01 AI079162-03, 04, 3K01AI079162-02S1, 03S1, P50 AI074285-03]; Burroughs Wellcome Fund; James S. McDonnell Foundation; David & Lucille Packard Foundation FX Funding for this study came from NIH 5K01 AI079162-03 and 04, NIH 3K01AI079162-02S1 and 03S1, NIH P50 AI074285-03, and 04. JBP is supported by the Burroughs Wellcome Fund, the James S. McDonnell Foundation, and the David & Lucille Packard Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 10 Z9 10 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD SEP PY 2011 VL 7 IS 9 AR e1002146 DI 10.1371/journal.pcbi.1002146 PG 9 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA 827CU UT WOS:000295404900007 PM 21935346 ER PT J AU Rudan, I El Arifeen, S Bhutta, ZA Black, RE Brooks, A Chan, KY Chopra, M Duke, T Marsh, D Pio, A Simoes, EAF Tamburlini, G Theodoratou, E Weber, MW Whitney, CG Campbell, H Qazi, SA AF Rudan, Igor El Arifeen, Shams Bhutta, Zulfiqar A. Black, Robert E. Brooks, Abdullah Chan, Kit Yee Chopra, Mickey Duke, Trevor Marsh, David Pio, Antonio Simoes, Eric A. F. Tamburlini, Giorgio Theodoratou, Evropi Weber, Martin W. Whitney, Cynthia G. Campbell, Harry Qazi, Shamim A. CA WHO CHNRI Expert Grp Childhood TI Setting Research Priorities to Reduce Global Mortality from Childhood Pneumonia by 2015 SO PLOS MEDICINE LA English DT Review ID HEALTH RESEARCH INVESTMENTS; CHILDREN YOUNGER; DISEASE; BURDEN; DIARRHEA C1 [Rudan, Igor; Theodoratou, Evropi; Campbell, Harry] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland. [Rudan, Igor] Univ Split, Fac Med, Croatian Ctr Global Hlth, Split, Croatia. [El Arifeen, Shams; Brooks, Abdullah] B Ctr Hlth & Populat Res, ICDDR B, Dhaka, Bangladesh. [Bhutta, Zulfiqar A.] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan. [Black, Robert E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Chan, Kit Yee] Univ Melbourne, Nossal Inst Global Hlth, Melbourne, Vic, Australia. [Chopra, Mickey] UNICEF, Dept Hlth, New York, NY USA. [Duke, Trevor] Univ Melbourne, Ctr Int Child Hlth, Parkville, Vic 3052, Australia. [Marsh, David] Save Children, Amherst, MA USA. [Simoes, Eric A. F.] Childrens Hosp, Dept Pediat Infect Dis, Denver, CO 80218 USA. [Tamburlini, Giorgio] Inst Child Hlth IRCCS Burlo Garofolo, Trieste, Italy. [Weber, Martin W.] WHO Country Off, Jakarta, Indonesia. [Whitney, Cynthia G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Qazi, Shamim A.] World Hlth Org, Dept Child & Adolescent Hlth & Dev, Geneva, Switzerland. RP Rudan, I (reprint author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland. EM Igor.Rudan@ed.ac.uk; qazis@who.int RI Rudan, Igor/I-1467-2012; Theodoratou, Evropi/C-3430-2014; OI Rudan, Igor/0000-0001-6993-6884; Thea, Donald/0000-0002-6933-1030; Theodoratou, Evropi/0000-0001-5887-9132; Black, Robert/0000-0001-9926-7984; Kallander, Karin/0000-0002-5778-5780; English, Mike/0000-0002-7427-0826 FU Child Health Research and Nutrition Initiative (CHNRI) of Global Forum for Health Research for development and implementation of CHNRI methodology FX The first author (IR) has received support as a consultant of the Child Health Research and Nutrition Initiative (CHNRI) of Global Forum for Health Research for development and implementation of CHNRI methodology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 27 TC 46 Z9 46 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD SEP PY 2011 VL 8 IS 9 AR e1001099 DI 10.1371/journal.pmed.1001099 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 825ZW UT WOS:000295321900015 PM 21980266 ER PT J AU Gonzalez, C Layon, A Arguin, P Barnwell, J Wilkins, P Leiby, DA Nguyen, M Lendio, P Studemeister, A Galel, SA AF Gonzalez, C. Layon, A. Arguin, P. Barnwell, J. Wilkins, P. Leiby, D. A. Nguyen, M. Lendio, P. Studemeister, A. Galel, S. A. TI Transfusion-Transmitted Falciparum Malaria from an Asymptomatic Donor SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting and CTTXPO CY OCT 22-25, 2011 CL San Diego, CA SP AABB C1 [Gonzalez, C.; Layon, A.; Lendio, P.; Galel, S. A.] Stanford Blood Ctr, Palo Alto, CA USA. [Gonzalez, C.; Layon, A.; Lendio, P.; Galel, S. A.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA. [Arguin, P.; Barnwell, J.; Wilkins, P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Leiby, D. A.; Nguyen, M.] Amer Red Cross, Holland Lab, Rockville, MD 90034 USA. [Studemeister, A.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA. EM JoeySarah@sbcglobal.net NR 0 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD SEP PY 2011 VL 51 SU 3 SI SI BP 197A EP 197A PG 1 WC Hematology SC Hematology GA 822YC UT WOS:000295085500505 ER PT J AU Keating, SM Hanson, D Lebedeva, M Owens, M Garrett, PE Pilcher, C Laeyendecker, O Ali-Napo, NL Norris, PJ Busch, MP AF Keating, S. M. Hanson, D. Lebedeva, M. Owens, M. Garrett, P. E. Pilcher, C. Laeyendecker, O. Ali-Napo, N. L. Norris, P. J. Busch, M. P. TI Estimating Incidence and Detecting Early Infection with Less Sensitive and Avidity Protocols for the VITROS Immunodiagnostic Products Anti-HIV-1+2 Assay: Using Repeat Blood Donor Samples for Optimization and Calibration SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting and CTTXPO CY OCT 22-25, 2011 CL San Diego, CA SP AABB C1 [Keating, S. M.; Lebedeva, M.; Norris, P. J.; Busch, M. P.] Blood Syst Res Inst, San Francisco, CA USA. [Keating, S. M.; Pilcher, C.; Norris, P. J.; Busch, M. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hanson, D.; Owens, M.] Ctr Dis Control, Atlanta, GA 30333 USA. [Laeyendecker, O.] Johns Hopkins Sch Med, Baltimore, MD USA. [Garrett, P. E.] Seracare Life Sci, Milford, MA USA. [Ali-Napo, N. L.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. EM skeating@bloodsystems.org RI Laeyendecker, Oliver/B-9331-2009; Keating, Sheila/B-1652-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD SEP PY 2011 VL 51 SU 3 SI SI BP 214A EP 215A PG 2 WC Hematology SC Hematology GA 822YC UT WOS:000295085500551 ER PT J AU Okonji, JA Basavaraju, SV Shiraishi, RW Pitman, JP Ou, C Zeh, C AF Okonji, J. A. Basavaraju, S. V. Shiraishi, R. W. Pitman, J. P. Ou, C. Zeh, C. TI Comparison of HIV-1 Detection in Plasma Specimens and Dried Blood Spots Using the Roche COBAS Ampliscreen HIV-1 Test: Implications for Blood Banking in Resource-Limited Settings SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting and CTTXPO CY OCT 22-25, 2011 CL San Diego, CA SP AABB C1 [Okonji, J. A.] Kenya Govt Med Res Ctr, Ctr Biomed Res & Technol, Kisumu, Kenya. [Basavaraju, S. V.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div HIV AIDS, HIV Prevent Branch, Atlanta, GA USA. [Shiraishi, R. W.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Epidemiol & Strateg Informat Branch, Atlanta, GA USA. [Pitman, J. P.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Windhoek, Namibia. [Ou, C.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Beijing, Peoples R China. [Zeh, C.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, HIV R Lab, Kisumu, Kenya. EM jokonji@ke.cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD SEP PY 2011 VL 51 SU 3 SI SI BP 216A EP 216A PG 1 WC Hematology SC Hematology GA 822YC UT WOS:000295085500554 ER PT J AU Herman, EK Greninger, A Vishvesvara, G Marciano-Cabral, F Chiu, C Dacks, JB AF Herman, E. K. Greninger, A. Vishvesvara, G. Marciano-Cabral, F. Chiu, C. Dacks, J. B. TI INITIAL INSIGHTS FROM THE NAEGLERIA FOWLERI GENOME INITIATIVE SO JOURNAL OF PHYCOLOGY LA English DT Meeting Abstract C1 [Herman, E. K.; Dacks, J. B.] Univ Alberta, Edmonton, AB T6G 2M7, Canada. [Greninger, A.; Chiu, C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Vishvesvara, G.] Ctr Dis Control & Prevent, Druid Hills, GA USA. [Marciano-Cabral, F.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. EM joel.dacks@ualberta.ca; joel.dacks@ualberta.ca NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3646 J9 J PHYCOL JI J. Phycol. PD SEP PY 2011 VL 47 SU 2 SI SI BP S21 EP S22 PG 2 WC Plant Sciences; Marine & Freshwater Biology SC Plant Sciences; Marine & Freshwater Biology GA 822ZO UT WOS:000295090200065 ER PT J AU Ford, ES Anda, RF Edwards, VJ Perry, GS Zhao, GX Li, CY Croft, JB AF Ford, Earl S. Anda, Robert F. Edwards, Valerie J. Perry, Geraldine S. Zhao, Guixiang Li, Chaoyang Croft, Janet B. TI Adverse childhood experiences and smoking status in five states SO PREVENTIVE MEDICINE LA English DT Article DE Child abuse; Divorce; Domestic violence; Mentally ill; Sexual abuse; Smoking; Substance abuse ID SEXUAL-ABUSE; HOUSEHOLD DYSFUNCTION; RETROSPECTIVE REPORTS; FAMILY-STRUCTURE; PHYSICAL ABUSE; UNITED-STATES; UK TEENAGERS; ADULTS; ADOLESCENTS; DEATH AB Objective. Our objective was to examine the associations between adverse childhood experiences (ACEs) and smoking behavior among a random sample of adults living in five U.S. states. Methods. We used data from 25,809 participants of the 2009 Behavioral Risk Factor Surveillance System to assess the relationship of each of the 8 adverse childhood experiences and the adverse childhood experience score to smoking status. Results and conclusions. Some 59.4% of men and women reported at least one adverse childhood experience. Each of the eight adverse childhood experiences measures was significantly associated with smoking status after adjustment for demographic variables. The prevalence ratios for current and ever smoking increased in a positive graded fashion as the adverse childhood experience score increased. Among adults who reported no adverse childhood experiences, 13.0% were currently smoking and 38.3% had ever smoked. Compared to participants with an adverse childhood experience score of 0, those with an adverse childhood experience score of 5 or more were more likely to be a current smoker (adjusted prevalence ratio (aPR): 2.22, 95% confidence interval [CI]: 1.92-2.57) and to have ever smoked (aPR: 1.80, 95% CI: 1.67-1.93). Further research is warranted to determine whether the prevention of and interventions for adverse childhood experiences might reduce the burden of smoking-related illness in the general population. Published by Elsevier Inc. C1 [Ford, Earl S.; Edwards, Valerie J.; Perry, Geraldine S.; Zhao, Guixiang; Li, Chaoyang; Croft, Janet B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Anda, Robert F.] Carter Consulting Inc, Atlanta, GA USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov NR 48 TC 38 Z9 39 U1 1 U2 18 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD SEP 1 PY 2011 VL 53 IS 3 BP 188 EP 193 DI 10.1016/j.ypmed.2011.06.015 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 824LO UT WOS:000295203600022 PM 21726575 ER PT J AU Mainous, AG Diaz, VA Everett, CJ Knoll, ME Hulihan, MM Grant, AM McLaren, CE McLaren, GD AF Mainous, Arch G., III Diaz, Vanessa A. Everett, Charles J. Knoll, Michele E. Hulihan, Mary M. Grant, Althea M. McLaren, Christine E. McLaren, Gordon D. TI IRon Overload ScreeNing tool (IRON): Development of a tool to guide screening in primary care SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID HEREDITARY HEMOCHROMATOSIS; AMERICAN-COLLEGE; CORONARY RISK; DISEASE; HEALTH; GENE AB Iron overload is associated with significant morbidity and mortality yet is easily treated. The objective of this study was to create a tool that could be easily adapted to clinical practice that indicates the likelihood of a patient having undetected iron overload. We used the National Health and Nutrition Examination Survey (NHANES) 1999-2002 for US adults aged 20 years and older to build a model (unweighted n=8,779). We chose potential variables for inclusion that could be gathered by self-report or measured without laboratory data and were suggested by past literature on hemochromatosis and iron overload. We computed logistic regressions to create the scores by initially evaluating the variables' relationship with elevated ferritin and elevated transferrin saturation and then using odds ratios to correspond to scores. The resulting score on the IRon Overload ScreeNing Tool (IRON) was then validated with data on 13,844 adults in the NHANES III, 1988-94. Predictors in the final tool were age, gender, previous diagnoses of liver condition, osteoporosis or thyroid disease. The IRON score yielded an area under the curve (AUC) in the NHANES 1999-02 of 0.720 and an AUC of 0.685 in the NHANES III validation sample. The IRON score is a tool to assist in identification of patients with iron overload that has several qualities that make it attractive for use in clinical practice with an undifferentiated patient population including brevity, easily collected information and predictive ability comparable to other tools that help in directing screening. Am. J. Hematol. 86:733-737, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Mainous, Arch G., III; Diaz, Vanessa A.; Everett, Charles J.; Knoll, Michele E.] Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA. [Hulihan, Mary M.; Grant, Althea M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [McLaren, Christine E.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. [McLaren, Gordon D.] Univ Calif Irvine, Div Hematol Oncol, Irvine, CA USA. [McLaren, Gordon D.] VA Long Beach Healthcare Syst, Long Beach, CA USA. RP Mainous, AG (reprint author), Med Univ S Carolina, Dept Family Med, 295 Calhoun St, Charleston, SC 29425 USA. EM mainouag@musc.edu OI Mainous, Arch/0000-0002-2535-7685 FU Centers for Disease Control and Prevention [MM1144]; National Heart, Lung, and Blood Institute [R01 HL083328]; Centers of Disease Control; R01 grant FX Contract grant sponsor: Centers for Disease Control and Prevention; Contract grant number: MM1144 (Cooperative Agreement).; Contract grant sponsor: National Heart, Lung, and Blood Institute; Contract grant number: R01 HL083328.; As a cooperative agreement authors Mary M. Hulihan and Althea M. Grant from the Centers of Disease Control and from the R01 grant authors Christine E. McLaren and Gordon D. McLaren, MD helped in all aspects of this study. NR 28 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD SEP PY 2011 VL 86 IS 9 BP 733 EP 737 DI 10.1002/ajh.22082 PG 5 WC Hematology SC Hematology GA 821VZ UT WOS:000295003800002 PM 21800355 ER PT J AU Ali, MK Bullard, KM Beckles, GL Stevens, MR Barker, L Narayan, KMV Imperatore, G AF Ali, Mohammed K. Bullard, Kai McKeever Beckles, Gloria L. Stevens, Mark R. Barker, Lawrence Narayan, K. M. Venkat Imperatore, Giuseppina TI Household Income and Cardiovascular Disease Risks in US Children and Young Adults Analyses from NHANES 1999-2008 SO DIABETES CARE LA English DT Article ID CORONARY-HEART-DISEASE; SOCIOECONOMIC POSITION; CHILDHOOD; HEALTH; DENSITY; OBESITY; LIFE AB OBJECTIVE-To assess the cardiovascular risk profile of youths across socioeconomic groups in the U.S. RESEARCH DESIGN AND METHODS-Analysis of 1999-2008 National Health and Nutrition Examination Surveys (NHANES) including 16,085 nonpregnant 6- to 24-year-olds to estimate race/ethnicity-adjusted prevalence of obesity, central obesity, sedentary behaviors, tobacco exposure, elevated systolic blood pressure, glycated hemoglobin, non-HDL cholesterol (non-HDL-C), and high-sensitivity C-reactive protein according to age-group, sex, and poverty-income ratio (PIR) tertiles. RESULTS-Among boys aged 6-11 years, 19.9% in the lowest PIR tertile were obese and 30.0% were centrally obese compared with 13.2 and 21.6%, respectively, in the highest-income tertile households (P-obesity < 0.05 and P-central obesity < 0.01). Boys aged 12-17 years in lowest-income households were more likely than their wealthiest family peers to be obese (20.6 vs. 15.6%, P < 0.05), sedentary (14.8 vs. 9.3%, P < 0.05), and exposed to tobacco (19.0 vs. 6.5%, P < 0.01). Compared with girls aged 12-17 years in highest-income households, lowest-income household girls had higher prevalence of obesity (17.9. vs. 13.1%, P < 0.05), central obesity (41.5 vs. 29.2%, P < 0.01), sedentary behaviors (20.4 vs. 9.4%, P < 0.01), and tobacco exposure (14.1 vs. 5.9%, P < 0.01). Apart from higher prevalence of elevated non-HDL-C among low-income women aged 18-24 years (23.4 vs. 15.8%, P < 0.05), no other cardiovascular disease risk factor prevalence differences were observed between lowest- and highest-income background young adults. CONCLUSIONS-Independent of race/ethnicity, 6- to 17-year-olds from low-income families have higher prevalence of obesity, central obesity, sedentary behavior, and tobacco exposure. Multifaceted cardiovascular health promotion policies are needed to reduce health disparities between income groups. C1 [Ali, Mohammed K.; Narayan, K. M. Venkat] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Ali, Mohammed K.; Bullard, Kai McKeever; Beckles, Gloria L.; Barker, Lawrence; Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Stevens, Mark R.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Ali, MK (reprint author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM mkali@emory.edu RI Narayan, K.M. Venkat /J-9819-2012 OI Narayan, K.M. Venkat /0000-0001-8621-5405 FU Department of Health and Human Services FX Data collection for NHANES is sponsored by the Department of Health and Human Services. These secondary study analyses were not supported by grants or any specific funding source. NR 24 TC 20 Z9 21 U1 1 U2 12 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2011 VL 34 IS 9 BP 1998 EP 2004 DI 10.2337/dc11-0792 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 824IH UT WOS:000295195100020 PM 21868776 ER PT J AU Thurman, DJ Beghi, E Begley, CE Berg, AT Buchhalter, JR Ding, D Hesdorffer, DC Hauser, WA Kazis, L Kobau, R Kroner, B Labiner, D Liow, K Logroscino, G Medina, MT Newton, CR Parko, K Paschal, A Preux, PM Sander, JW Selassie, A Theodore, W Tomson, T Wiebe, S AF Thurman, David J. Beghi, Ettore Begley, Charles E. Berg, Anne T. Buchhalter, Jeffrey R. Ding, Ding Hesdorffer, Dale C. Hauser, W. Allen Kazis, Lewis Kobau, Rosemarie Kroner, Barbara Labiner, David Liow, Kore Logroscino, Giancarlo Medina, Marco T. Newton, Charles R. Parko, Karen Paschal, Angelia Preux, Pierre-Marie Sander, Josemir W. Selassie, Anbesaw Theodore, William Tomson, Torbjorn Wiebe, Samuel CA ILAE Commission Epidemiology TI Standards for epidemiologic studies and surveillance of epilepsy SO EPILEPSIA LA English DT Article DE Epidemiology; Surveillance; Epilepsy ID QUALITY-OF-LIFE; SEIZURE SEVERITY SCALE; INCIDENT UNPROVOKED SEIZURES; ACTIVE CONVULSIVE EPILEPSY; ACUTE SYMPTOMATIC SEIZURE; SUDDEN UNEXPECTED DEATH; POPULATION-BASED COHORT; HEALTH INTERVIEW SURVEY; ILLNESS RATING-SCALE; WELL-BEING MEASURES AB Worldwide, about 65 million people are estimated to have epilepsy. Epidemiologic studies are necessary to define the full public health burden of epilepsy; to set public health and health care priorities; to provide information needed for prevention, early detection, and treatment; to identify education and service needs; and to promote effective health care and support programs for people with epilepsy. However, different definitions and epidemiologic methods complicate the tasks of these studies and their interpretations and comparisons. The purpose of this document is to promote consistency in definitions and methods in an effort to enhance future population-based epidemiologic studies, facilitate comparison between populations, and encourage the collection of data useful for the promotion of public health. We discuss: (1) conceptual and operational definitions of epilepsy, (2) data resources and recommended data elements, and (3) methods and analyses appropriate for epidemiologic studies or the surveillance of epilepsy. Variations in these are considered, taking into account differing resource availability and needs among countries and differing purposes among studies. C1 [Thurman, David J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Beghi, Ettore] Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, Milan, Italy. [Begley, Charles E.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Dept Management & Policy Sci, Houston, TX USA. [Begley, Charles E.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Ctr Hlth Serv Res, Houston, TX USA. [Berg, Anne T.] No Illinois Univ, Dept Biol, De Kalb, IL 60115 USA. [Berg, Anne T.] Chicago NW Childrens Mem Hosp, Epilepsy Ctr, Chicago, IL USA. [Buchhalter, Jeffrey R.] Mayo Clin, Dept Child & Adolescent Neurol, Scottsdale, AZ USA. [Ding, Ding] Fudan Univ, Inst Neurol, Dept Biostat & Epidemiol, Shanghai 200433, Peoples R China. [Hesdorffer, Dale C.; Hauser, W. Allen] Columbia Univ, Dept Epidemiol, New York, NY USA. [Hesdorffer, Dale C.; Hauser, W. Allen] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA. [Hauser, W. Allen] Columbia Univ, Dept Neurol, New York, NY USA. [Kazis, Lewis] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Kroner, Barbara] RTI Int, Rockville, MD USA. [Labiner, David] Univ Arizona, Dept Neurol, Tucson, AZ USA. [Liow, Kore] Univ Hawaii, John A Burns Sch Med, Dept Internal Med Neurol, Honolulu, HI 96822 USA. [Logroscino, Giancarlo] Univ Bari, Dept Neurol, Bari, Italy. [Medina, Marco T.] Natl Autonomous Univ Honduras, Fac Med Sci, Tegucigalpa, Honduras. [Newton, Charles R.] Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Programme, Kilifi, Kenya. [Newton, Charles R.] UCL, Inst Child Hlth, London, England. [Parko, Karen] UCSF Sch Med, Dept Neurol, San Francisco, CA USA. [Paschal, Angelia] Mississippi Univ Women, Dept Hlth & Kinesiol, Columbus, MS USA. [Preux, Pierre-Marie] Univ Limoges, Inst Neuroepidemiol & Trop Neurol & Trop & Compar, Limoges, France. [Sander, Josemir W.] UCL Inst Neurol, London WC1N 3BG, England. [Sander, Josemir W.] Netherlands Fdn, SEIN Epilepsy Inst, Heemstede, Netherlands. [Selassie, Anbesaw] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Theodore, William] NIH, Clin Epilepsy Sect, Bethesda, MD 20892 USA. [Tomson, Torbjorn] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden. [Wiebe, Samuel] Univ Calgary, Dept Clin Neurol Sci, Calgary, AB, Canada. [Wiebe, Samuel] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. RP Thurman, DJ (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K51, Atlanta, GA 30333 USA. EM dxt9@cdc.gov RI Sander, Josemir/C-1576-2008; PREUX, Pierre-Marie/B-8393-2014; LOGROSCINO, GIANCARLO/K-5148-2016; OI Sander, Josemir/0000-0001-6041-9661; PREUX, Pierre-Marie/0000-0002-2171-2977; LOGROSCINO, GIANCARLO/0000-0003-0423-3242; Kazis, Lewis/0000-0003-1800-5849; Newton, Charles/0000-0002-6999-5507 FU Kedrion Pharma Company; Eisai; Sanofi-Aventis; UCB Pharma; GlaxoSmithKline; UCB; Dow Agro Science; Ovation Pharmaceuticals; Pfizer; General Electric; Amgen Inc.; Genzyme; Eli Lilly and Company; Bristol Meyers Squibb; Boerhringer-Ingelheim; Astra Zeneca; Cyberonics; Esai; Ortho McNeil; Janssen-Gilag; Novartis FX The authors declare the following associations as potential conflicts of interest: David J. Thurman - None; Ettore Beghi - Honoraria/research grants from Kedrion Pharma Company, Eisai, Sanofi-Aventis, UCB Pharma, GlaxoSmithKline; Charles E. Begley - None; Anne T. Berg - Travel funding/honoraria/consulting fees from Eisai, UCB, Dow Agro Science; Jeffrey R. Buchhalter - Research grants from Ovation Pharmaceuticals, Pfizer; Ding Ding - None; Dale C. Hesdorffer - Honoraria/travel funds/stock Pfizer, GlaxoSmithKline, General Electric; W. Allen Hauser - Consultant Neuropace; Lewis Kazis - Research grants Amgen Inc., Genzyme, Eli Lilly and Company, Bristol Meyers Squibb, Sanofi-Aventis, Boerhringer-Ingelheim, and Astra Zeneca; Rosemarie Kobau - None; Barbara Kroner - None; David Labiner - Consultant/Speaker/Research grants from Cyberonics, Esai and Ortho McNeil; Kore Liow - Honoraria from UCB Pharma; Giancarlo Logroscino - None; Marco T. Medina - None; Charles R. Newton - None; Karen Parko - None; Angelia Paschal - None; Pierre-Marie Preux - None; Josemir W. Sander - Honoraria/grants/travel grants from UCB, Janssen-Gilag, Eisai, and GlaxoSmithKline; Anbesaw Selassie - None; William Theodore - Honoraria/stock Elseveir, General Electric; Torbjorn Tomson - Research grants/honoraria from Eisai, GlaxoSmithKline, Janssen-Cilag, Novartis, Pfizer, Sanofi-Aventis, UCB Pharma; Samuel Wiebe None. NR 195 TC 215 Z9 220 U1 10 U2 47 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD SEP PY 2011 VL 52 SU 7 SI SI BP 2 EP 26 DI 10.1111/j.1528-1167.2011.03121.x PG 25 WC Clinical Neurology SC Neurosciences & Neurology GA 821JO UT WOS:000294971500002 PM 21899536 ER PT J AU Keck, J Miernyk, K Bulkow, L Kelly, J McMahon, B Sacco, F Hennessy, T Bruce, MG AF Keck, J. Miernyk, K. Bulkow, L. Kelly, J. McMahon, B. Sacco, F. Hennessy, T. Bruce, M. G. TI HELICOBACTER PYLORI INFECTION AND MARKERS OF GASTRIC CANCER RISK IN ALASKA NATIVE PEOPLE SO HELICOBACTER LA English DT Meeting Abstract CT 24th International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer CY SEP 11-13, 2011 CL Dublin, IRELAND C1 [Keck, J.; Miernyk, K.; Bulkow, L.; Hennessy, T.; Bruce, M. G.] Ctr Dis Control & Prevent, Anchorage, AK USA. [Kelly, J.; McMahon, B.; Sacco, F.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD SEP PY 2011 VL 16 SU 1 SI SI BP 79 EP 79 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 820ZF UT WOS:000294943900013 ER PT J AU Faul, M Weller, NF Jones, JA AF Faul, Mark Weller, Nancy F. Jones, Julie A. TI INJURIES AFTER HURRICANE KATRINA AMONG GULF COAST EVACUEES SHELTERED IN HOUSTON, TEXAS SO JOURNAL OF EMERGENCY NURSING LA English DT Article DE Disaster response; Injury; Hurricane; Triage; Shelter; Vaccination ID NATURAL DISASTER; EMERGENCY; LOUISIANA; VISITS; ANDREW; ISABEL AB Introduction: After Hurricane Katrina and a decline in the living conditions at a major temporary shelter in New Orleans, Louisiana, residents were offered transport to a Mega-Shelter in Houston, Texas. Approximately 200,000 Gulf Coast residents were transported to Houston's Astrodome/Reliant Center Complex for appropriate triage and transfer to other shelter facilities. The Katrina Clinic was quickly organized to treat evacuees with acute injuries and illnesses as well as chronic medical conditions. Clinic physicians documented 1130 hurricane-related injuries during Katrina Clinic's operational interval, September 1-22, 2005. Methods: This article documents the nature, extent, and location of injuries treated at that clinic. We compare the frequency of injury among Katrina evacuees who visited the clinic to that of injuries among clinic outpatient records recorded in a nationally representative database. Using the Barell Matrix system and codes from the International Classification of Diseases, Ninth Revision, we classify Katrina injuries by body region and nature of injury; we also document the large number of hurricane-related immunizations distributed at the temporary outpatient clinic. Results: The results show a 42% higher injury proportion among Katrina evacuees and that approximately half of all of the evacuees required immunizations. Lower leg extremity injuries were among the most frequent injuries. Discussion: Future planning for hurricanes should take into account nonfatal injuries requiring medical treatment and other supportive care. C1 [Faul, Mark] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Weller, Nancy F.; Jones, Julie A.] Baylor Coll Med, Houston, TX 77030 USA. RP Faul, M (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F-62, Atlanta, GA 30333 USA. EM mgf7@cdc.gov NR 31 TC 6 Z9 6 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0099-1767 J9 J EMERG NURS JI J. Emerg. Nurs. PD SEP PY 2011 VL 37 IS 5 BP 460 EP 468 DI 10.1016/j.jen.2010.12.019 PG 9 WC Emergency Medicine; Nursing SC Emergency Medicine; Nursing GA 821XH UT WOS:000295007200012 PM 21549416 ER PT J AU Hedeland, M Moura, H Baverud, V Woolfitt, AR Bondesson, U Barr, JR AF Hedeland, Mikael Moura, Hercules Baverud, Viveca Woolfitt, Adrian R. Bondesson, Ulf Barr, John R. TI Confirmation of botulism in birds and cattle by the mouse bioassay and Endopep-MS SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID IN-VITRO ASSAYS; CLOSTRIDIUM-BOTULINUM; C BOTULISM; MASS-SPECTROMETRY; SMALL-INTESTINE; NEUROTOXIN; TOXIN; FOODS; DIFFERENTIATION; PROTEOMICS AB There have been several outbreaks of botulism among poultry and wild birds in Sweden in recent years. The National Veterinary Institute of Sweden (SVA) has identified botulinum neurotoxin (BoNT)/C1 or the mosaic BoNT/C1D using the mouse bioassay. This is believed to be the first report on the application of the Endopep mass spectrometry (Endopep-MS) method to selected clinical animal (serum and liver) samples and a feed sample that had previously given positive test results with the mouse bioassay. In the mouse bioassay eight of the eleven samples were found to be neutralized by both BoNT/C1 and /D antitoxins; the other three were neutralized only by BoNT/C1 antitoxin, but the mice showed a prolonged survival time when the samples had been treated with /D antitoxin. The Endopep-MS analysis, on the other hand, demonstrated only BoNT/C1 activity for all eleven samples. This suggests that at least eight of the samples were of the chimeric toxin type BoNT/C1D, where the enzymically active site is identical to that of BoNT/C1, while other parts of the protein contain sequences of BoNT/D. This is the first step of a cross-validation between the established mouse bioassay and the Endopep-MS of serotypes BoNT/C1 and /C1D. Endopep-MS is concluded to have potential as an attractive alternative to the mouse bioassay. C1 [Hedeland, Mikael; Bondesson, Ulf] Natl Vet Inst SVA, Dept Chem Environm & Feed Hyg, SE-75189 Uppsala, Sweden. [Hedeland, Mikael; Bondesson, Ulf] Uppsala Univ, Div Analyt Pharmaceut Chem, Biomed Ctr, SE-75123 Uppsala, Sweden. [Moura, Hercules; Woolfitt, Adrian R.; Barr, John R.] Ctr Dis Control & Prevent, NCEH DLS, Atlanta, GA 30341 USA. [Baverud, Viveca] Natl Vet Inst SVA, Dept Bacteriol, SE-75189 Uppsala, Sweden. RP Hedeland, M (reprint author), Natl Vet Inst SVA, Dept Chem Environm & Feed Hyg, SE-75189 Uppsala, Sweden. EM mikael.hedeland@sva.se RI Hedeland, Mikael/I-4327-2013; OI Hedeland, Mikael/0000-0001-8962-2815 FU Swedish Animal Welfare Agency FX The Swedish Animal Welfare Agency is gratefully acknowledged for financial support of this project. This sponsor had no influence on the study design, collection or interpretation of data or writing of the manuscript. References to specific commercial products, processes, services, manufacturers or companies do not constitute an endorsement or a recommendation by the US Government or by the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of CDC. NR 28 TC 9 Z9 9 U1 0 U2 5 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD SEP PY 2011 VL 60 IS 9 BP 1299 EP 1305 DI 10.1099/jmm.0.031179-0 PG 7 WC Microbiology SC Microbiology GA 822BM UT WOS:000295018700011 PM 21566090 ER PT J AU Smith, AM Keddy, KH Ismail, H Thomas, J van der Gryp, R Manamela, MJ Huma, M Sooka, A Theobald, LK Mennen, MA O'Reilly, LC AF Smith, Anthony M. Keddy, Karen H. Ismail, Husna Thomas, Juno van der Gryp, Rina Manamela, Morubula J. Huma, Mmampedi Sooka, Arvinda Theobald, Lisa K. Mennen, Maria A. O'Reilly, Lyn C. CA Grp Enteric Resp & Meningeal Dis TI International collaboration tracks typhoid fever cases over two continents from South Africa to Australia SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Letter ID OUTBREAK; SALMONELLA C1 [Smith, Anthony M.; Keddy, Karen H.; Ismail, Husna; Sooka, Arvinda] NICD, Enter Dis Reference Unit, Johannesburg, South Africa. [Smith, Anthony M.; Keddy, Karen H.; Ismail, Husna] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Thomas, Juno] NICD, Outbreak Response Unit, Johannesburg, South Africa. [van der Gryp, Rina] Hlth & Social Dev Dept, Pretoria, South Africa. [Manamela, Morubula J.] NICD, S African Field Epidemiol & Lab Training Programm, Johannesburg, South Africa. [Huma, Mmampedi] NHLS, No Branch, Pretoria, South Africa. [Theobald, Lisa K.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. [Mennen, Maria A.] Lancet Labs, Pretoria, South Africa. RP Smith, AM (reprint author), NICD, Enter Dis Reference Unit, Johannesburg, South Africa. EM anthonys@nicd.ac.za NR 5 TC 7 Z9 7 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD SEP PY 2011 VL 60 IS 9 BP 1405 EP 1407 DI 10.1099/jmm.0.030700-0 PG 3 WC Microbiology SC Microbiology GA 822BM UT WOS:000295018700028 PM 21474612 ER PT J AU van Gelder, MMHJ Reefhuis, J Herron, AM Williams, ML Roeleveld, N AF van Gelder, Marleen M. H. J. Reefhuis, Jennita Herron, Anne M. Williams, Mark L. Roeleveld, Nel TI Reproductive Health Characteristics of Marijuana And Cocaine Users: Results from the 2002 National Survey of Family Growth SO PERSPECTIVES ON SEXUAL AND REPRODUCTIVE HEALTH LA English DT Article ID RISKY SEXUAL-BEHAVIOR; ABUSE TREATMENT PROGRAMS; ADOLESCENT SUBSTANCE USE; ILLICIT DRUG-USE; CANNABIS USE; HUMAN-PAPILLOMAVIRUS; YOUNG ADULTHOOD; UNITED-STATES; METAANALYSIS; INTERVENTIONS AB CONTEXT: Illicit drug use is associated with risky sexual behaviors in adolescents and young adults. However, few studies have examined these associations among drug users of all reproductive ages, using a control group of nonusers. METHODS: Associations between marijuana and cocaine use, and outcomes related to sexual behaviors and reproductive health, were assessed using data from the 2002 National Survey of Family Growth. Overall, 4,928 men and 7,643 women aged 15-44 were interviewed. Chi-square tests, t tests and multivariable logistic regression analyses were used; in supplementary analyses, men and women were stratified by age-group (25 or younger, and older than 25), to capture the understudied older adults who use drugs. RESULTS: Twenty-seven percent of men and 16% of women reported use of marijuana or cocaine in the last year. Drug users were younger than nonusers at first vaginal sex (mean, 15.2-16.1 vs. 17.3-17.5 years) and were more likely to have engaged in risky sexual behaviors in the last year, including having had sex with a nonmonogamous partner (odds ratios, 3.3-5.2 for men and 2.9-6.5 for women), while high on alcohol or drugs (10.1-18.0 and 8.1-24.2), or in exchange for money or drugs (2.7-2.8 and 2.3-9.2). They also were more likely to have undergone STD testing or treatment. Drug use was associated with risky sexual behaviors in both age-groups. CONCLUSION: Programs aimed at reducing sexual risks among drug users should address the behaviors of men and women of all reproductive ages. Perspectives on Sexual and Reproductive Health, 2011, 43(3):164-172, doi: 10.1363/4316411 C1 [van Gelder, Marleen M. H. J.; Roeleveld, Nel] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6525 ED Nijmegen, Netherlands. [Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Herron, Anne M.] Subst Abuse & Mental Hlth Serv Adm, Ctr Subst Abuse Treatment, Rockville, MD USA. [Williams, Mark L.] Univ Texas Hlth Sci Ctr, Ctr Hlth Promot & Prevent Res, Houston, TX USA. RP van Gelder, MMHJ (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6525 ED Nijmegen, Netherlands. EM M.vanGelder@ebh.umcn.nl RI van Gelder, Marleen/P-9473-2015; Roeleveld, Nel/B-4242-2008 OI van Gelder, Marleen/0000-0003-4853-4434; Roeleveld, Nel/0000-0002-3390-4466 NR 44 TC 4 Z9 4 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-6341 J9 PERSPECT SEX REPRO H JI Perspect. Sex Reprod. Health PD SEP PY 2011 VL 43 IS 3 BP 164 EP 172 DI 10.1363/4316411 PG 9 WC Demography; Family Studies SC Demography; Family Studies GA 822AW UT WOS:000295016700004 PM 21884384 ER PT J AU SteelFisher, G Blendon, R Ross, LJ Collins, BC Ben-Porath, EN Bekheit, MM Mailhot, JR AF SteelFisher, Gillian Blendon, Robert Ross, Laura J. Collins, Blanche C. Ben-Porath, Eran N. Bekheit, Mark M. Mailhot, Johanna R. TI PUBLIC RESPONSE TO AN ANTHRAX ATTACK: REACTIONS TO MASS PROPHYLAXIS IN A SCENARIO INVOLVING INHALATION ANTHRAX FROM AN UNIDENTIFIED SOURCE SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Article ID UNITED-STATES; POSTEXPOSURE PROPHYLAXIS; POSTAL WORKERS; SARS OUTBREAK; BIOTERRORISM; ATTITUDES; COMMUNICATION; MANAGEMENT; QUARANTINE; ADHERENCE AB An attack with Bacillus anthracis ("anthrax'') is a known threat to the United States. When weaponized, it can cause inhalation anthrax, the deadliest form of the disease. Due to the rapid course of inhalation anthrax, delays in initiation of antibiotics may decrease survival chances. Because a rapid response would require cooperation from the public, there is a need to understand the public's response to possible mass dispensing programs. To examine the public's response to a mass prophylaxis program, this study used a nationally representative poll of 1,092 adults, supplemented by a targeted focus on 3 metropolitan areas where anthrax attacks occurred in 2001: New York City (n = 517), Washington, DC (n = 509), and Trenton/Mercer County, NJ (n = 507). The poll was built around a "worst-case scenario'' in which cases of inhalation anthrax are discovered without an identified source and the entire population of a city or town is asked to receive antibiotic prophylaxis within a 48-hour period. Findings from this poll provide important signs of public willingness to comply with public health recommendations for obtaining antibiotics from a dispensing site, although they also indicate that public health officials may face several challenges to compliance, including misinformation about the contagiousness of inhalation anthrax; fears about personal safety in crowds; distrust of government agencies to provide sufficient, safe, and effective medicine; and hesitation about ingesting antibiotic pills after receiving them. In general, people living in areas where anthrax attacks occurred in 2001 had responses similar to those of the nation as a whole. C1 [SteelFisher, Gillian] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Harvard Opin Res Program, Boston, MA 02115 USA. [Blendon, Robert] Harvard Univ, Kennedy Sch Govt, Boston, MA 02115 USA. [Blendon, Robert] Harvard Univ, Kennedy Sch Govt, Cambridge, MA 02138 USA. [Ross, Laura J.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Div Strateg Natl Stockpile, Atlanta, GA USA. [Collins, Blanche C.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Ben-Porath, Eran N.] Social Sci Res Solut, Media, PA USA. RP SteelFisher, G (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Harvard Opin Res Program, 4th Floor,677 Huntington Ave, Boston, MA 02115 USA. EM gsteel@hsph.harvard.edu NR 51 TC 8 Z9 8 U1 0 U2 8 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD SEP PY 2011 VL 9 IS 3 BP 239 EP 250 DI 10.1089/bsp.2011.0005 PG 12 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA 818PU UT WOS:000294767100007 PM 21819225 ER PT J AU Florescu, SA Popescu, CP Calistru, P Ceausu, E Nica, M Toderan, A Zaharia, M Parola, P AF Florescu, S. A. Popescu, C. P. Calistru, P. Ceausu, E. Nica, M. Toderan, A. Zaharia, M. Parola, P. TI Plasmodium vivax malaria in a Romanian traveller returning from Greece, August 2011 SO EUROSURVEILLANCE LA English DT Article ID AUTOCHTHONOUS MALARIA; NORTHERN GREECE; EVROS PROVINCE C1 [Florescu, S. A.; Popescu, C. P.; Calistru, P.; Ceausu, E.; Nica, M.; Toderan, A.; Zaharia, M.] Carol Davila Univ Med & Pharm, Bucharest, Romania. [Florescu, S. A.; Popescu, C. P.; Calistru, P.; Ceausu, E.; Nica, M.] Dr Victor Babes Hosp Infect & Trop Dis, Bucharest, Romania. [Popescu, C. P.; Parola, P.] European Ctr Dis Prevent & Control ECDC, EuroTravNet, European Travel & Trop Med Network, Stockholm, Sweden. [Parola, P.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Parola, P.] Aix Marseille Univ, Fac Med, Marseille, France. RP Florescu, SA (reprint author), Carol Davila Univ Med & Pharm, Bucharest, Romania. EM philippe.parola@univmed.fr NR 13 TC 0 Z9 0 U1 8 U2 9 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD SEP 1 PY 2011 VL 16 IS 35 BP 2 EP 4 PG 3 WC Infectious Diseases SC Infectious Diseases GA 817RO UT WOS:000294692000001 ER PT J AU Loustalot, F Wyatt, SB Sims, M Ellison, CG Taylor, HA Underwood, L AF Loustalot, Fleetwood Wyatt, Sharon B. Sims, Mario Ellison, Christopher G. Taylor, Herman A. Underwood, Lynn TI Psychometric Testing of the Daily Spiritual Experiences Scale Among African Americans in the Jackson Heart Study SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Daily Spiritual Experiences Scale; Spirituality; Psychometrics; African American; Jackson Heart Study ID HEALTH; RELIGION; ADULTS; RELIABILITY; VALIDITY AB This study provided the first examination of the psychometric properties of the 6-item Daily Spiritual Experiences Scale (DSES) in a large African American sample, the Jackson Heart Study (JHS). The JHS included measures of spiritual (DSES) and religious practices. Internal reliability, dimensionality, fit indices, and correlation were assessed. DSES scores reflected frequent daily spiritual experiences (12.84 +/- A 4.72) and reliability scores were high (alpha A = 0.85; 95% CI 0.84-0.86). The DSES loaded on a single factor, with significant goodness-of-fit scores (RMSEA = 0.094, P < 0.01). Moderate significant correlations were noted among DSES items. Our findings confirm that the 6-item DSES had excellent psychometric properties in this sample. C1 [Loustalot, Fleetwood] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Loustalot, Fleetwood; Wyatt, Sharon B.] Univ Mississippi, Med Ctr, Sch Nursing, Jackson, MS 39216 USA. [Wyatt, Sharon B.] Univ Mississippi, Med Ctr, Sch Med, Div Hypertens & Internal Med, Jackson, MS 39216 USA. [Wyatt, Sharon B.; Sims, Mario; Taylor, Herman A.] Univ Mississippi, Med Ctr, Jackson Heart Study Examinat Ctr, Jackson, MS 39216 USA. [Ellison, Christopher G.] Univ Texas Austin, Dept Sociol, Austin, TX 78712 USA. [Taylor, Herman A.] Univ Mississippi, Med Ctr, Sch Med, Div Cardiol, Jackson, MS 39216 USA. [Underwood, Lynn] Hiram Coll, Dept Biomed Humanities, Hiram, OH USA. RP Loustalot, F (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS-K-46, Atlanta, GA 30341 USA. EM floustalot@cdc.gov FU NHLBI NIH HHS [N01HC95172, N01-HC-95172, N01HC95170, N01 HC095171, N01-HC-95170, N01-HC-95171, N01HC95171] NR 32 TC 5 Z9 6 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 J9 J RELIG HEALTH JI J. Relig. Health PD SEP PY 2011 VL 50 IS 3 BP 675 EP 685 DI 10.1007/s10943-009-9278-2 PG 11 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA 819OT UT WOS:000294836900019 PM 19693673 ER PT J AU Rethman, MP Beltran-Aguilar, ED Billings, RJ Burne, RA Clark, M Donly, KJ Hujoel, PP Katz, BP Milgrom, P Sohn, W Stamm, JW Watson, G Wolff, M Wright, JT Zero, D Aravamudhan, K Frantsve-Hawley, J Meyer, DM AF Rethman, Michael P. Beltran-Aguilar, Eugenio D. Billings, Ronald J. Burne, Robert A. Clark, Melinda Donly, Kevin J. Hujoel, Philippe P. Katz, Barry P. Milgrom, Peter Sohn, Woosung Stamm, John W. Watson, Gene Wolff, Mark Wright, J. Tim Zero, Domenick Aravamudhan, Krishna Frantsve-Hawley, Julie Meyer, Daniel M. CA Amer Dent Assoc Council Sci Affair TI Nonfluoride caries-preventive agents Executive summary of evidence-based clinical recommendations SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Caries; xylitol; chlorhexidine; acidulated phosphate fluoride; evidence-based dentistry; clinical recommendations ID CHLORHEXIDINE-THYMOL VARNISH; XYLITOL CHEWING GUM; DENTAL-CARIES; MUTANS STREPTOCOCCI; PRESCHOOL-CHILDREN; CONTROLLED-TRIAL; SCHOOLCHILDREN; FLUORIDE; SEALANTS; LESIONS AB Background. In this article, the authors present evidence-based clinical recommendations regarding the use of nonfluoride caries-preventive agents. The recommendations were developed by an expert panel convened by the American Dental Association (ADA) Council on Scientific Affairs. The panel addressed several questions regarding the efficacy of nonfluoride agents in reducing the incidence of caries and arresting or reversing the progression of caries. Types of Studies Reviewed. A panel of experts convened by the ADA Council on Scientific Affairs, in collaboration with ADA Division of Science staff, conducted a MEDLINE search to identify all randomized and nonrandomized clinical studies regarding the use of nonfluoride caries-preventive agents. Results. The panel reviewed evidence from 50 randomized controlled trials and 15 nonrandomized studies to assess the efficacy of various nonfluoride caries-preventive agents. Clinical Implications. The panel concluded that certain nonfluoride agents may provide some benefit as adjunctive therapies in children and adults at higher risk of developing caries. These recommendations are presented as a resource for dentists to consider in the clinical decision-making process. As part of the evidence-based approach to care, these clinical recommendations should be integrated with the practitioner's professional judgment and the patient's needs and preferences. (The full report can be accessed at "http://ebd.ada.org/ClinicalRecommendations.aspx".) C1 [Frantsve-Hawley, Julie] Amer Dent Assoc, Res Inst, Chicago, IL 60611 USA. [Aravamudhan, Krishna; Frantsve-Hawley, Julie] Amer Dent Assoc, Ctr Evidence Based Dent, Div Sci, Chicago, IL 60611 USA. [Rethman, Michael P.] Ohio State Univ, Coll Dent, Columbus, OH 43210 USA. [Rethman, Michael P.] Univ Maryland, Baltimore Coll Dent Surg, Baltimore, MD USA. [Rethman, Michael P.] ADA Fdn, Chicago, IL USA. [Rethman, Michael P.] Amer Dent Assoc, Council Sci Affairs, Chicago, IL 60611 USA. [Beltran-Aguilar, Eugenio D.] Ctr Dis Control & Prevent, Div Oral Hlth, Atlanta, GA USA. [Billings, Ronald J.; Watson, Gene] Univ Rochester, Dept Dent, Sch Med & Dent, Rochester, NY 14627 USA. [Billings, Ronald J.] Univ Rochester, Dept Community & Prevent Med, Sch Med & Dent, Rochester, NY 14627 USA. [Burne, Robert A.] Univ Florida, Coll Dent, Dept Oral Biol, Gainesville, FL 32610 USA. [Clark, Melinda] Albany Med Ctr, Albany, NY USA. [Donly, Kevin J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat Dent, Sch Dent, San Antonio, TX USA. [Hujoel, Philippe P.; Milgrom, Peter] Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA. [Katz, Barry P.] Indiana Univ, Sch Med, Dept Biostat, Indianapolis, IN USA. [Sohn, Woosung] Univ Michigan, Sch Dent, Dept Cariol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA. [Stamm, John W.] Univ N Carolina, Sch Dent, Dept Dent Ecol, Chapel Hill, NC 27599 USA. [Wolff, Mark] NYU, Coll Dent, Dept Cariol & Comprehens Care, New York, NY USA. [Wright, J. Tim] Univ N Carolina, Sch Dent, Dept Pediat Dent, Chapel Hill, NC USA. [Zero, Domenick] Indiana Univ, Sch Dent, Dept Prevent & Community Dent, Indianapolis, IN USA. [Zero, Domenick] Indiana Univ, Sch Dent, Oral Hlth Res Inst, Indianapolis, IN USA. RP Frantsve-Hawley, J (reprint author), Amer Dent Assoc, Res Inst, 211 E Chicago Ave, Chicago, IL 60611 USA. EM frantsvej@ada.org OI Milgrom, Peter/0000-0003-0784-9181; Burne, Robert/0000-0002-4234-0316 FU BISCO, Schaumburg, Ill.; Church and Dwight, Princeton, N.J.; Dentsply, York, Pa.; Health Resources and Services Administration, Rockville, Md.; Ivoclar Vivadent, Schaan, Liechtenstein; National Institute of Dental and Craniofacial Research, Bethesda, Md.; 3M ESPE, St. Paul, Minn.; Oral B, Cincinnati; Philips, Andover, Mass.; Procter & Gamble, Cincinnati FX Drs. Burne and Rethman are consultants for Colgate, New York City. Dr. Donly has received financial research support from BISCO, Schaumburg, Ill.; Church and Dwight, Princeton, N.J.; Dentsply, York, Pa.; the Health Resources and Services Administration, Rockville, Md.; Ivoclar Vivadent, Schaan, Liechtenstein; the National Institute of Dental and Craniofacial Research, Bethesda, Md.; 3M ESPE, St. Paul, Minn.; Oral B, Cincinnati; Philips, Andover, Mass.; and Procter & Gamble, Cincinnati. Dr. Milgrom is the scientific director of ADP Silver Dental Arrest, Redmond, Ore.; is a member of the Cadbury Global Oral Health Advisory Committee, Parsippany, N.J.; and is a consultant for the U.S. Food and Drug Administration, Silver Spring, Md. Dr. Zero consults with and conducts studies for GlaxoSmithKline, Research Triangle Park, N.C.; Johnson & Johnson, New Brunswick, N.J.; Procter & Gamble; and Wrigley, Chicago. None of the other authors reported any disclosures. NR 56 TC 26 Z9 28 U1 1 U2 13 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD SEP PY 2011 VL 142 IS 9 BP 1065 EP 1071 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 821KD UT WOS:000294973000018 PM 21987836 ER PT J AU Stewart, SL Rim, SH Richards, TB AF Stewart, Sherri L. Rim, Sun Hee Richards, Thomas B. TI Gynecologic Oncologists and Ovarian Cancer Treatment: Avenues for Improved Survival SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GEOGRAPHIC ACCESS; UNITED-STATES; CARE; PATTERNS; STAGE; AGE AB Ovarian cancer is the deadliest gynecologic malignancy in the United States. Evidence-based interventions for the prevention and early detection of ovarian cancer do not currently exist. However, several treatment guidelines, including the receipt of treatment from a gynecologic oncologist, have been shown to result in improved survival from ovarian cancer. C1 [Stewart, Sherri L.; Rim, Sun Hee; Richards, Thomas B.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Stewart, SL (reprint author), 4770 Buford Highway,K-57, Atlanta, GA 30341 USA. EM sstewart@cdc.gov NR 24 TC 9 Z9 9 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD SEP PY 2011 VL 20 IS 9 BP 1257 EP 1260 DI 10.1089/jwh.2011.3053 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 819EH UT WOS:000294807700001 PM 21819252 ER PT J AU Courtney-Long, E Armour, B Frammartino, B Miller, J AF Courtney-Long, Elizabeth Armour, Brian Frammartino, Brunella Miller, Jacqueline TI Factors Associated with Self-Reported Mammography Use for Women With and Women Without a Disability SO JOURNAL OF WOMENS HEALTH LA English DT Article ID BREAST-CANCER-TREATMENT; PHYSICAL-DISABILITIES; PREVENTIVE SERVICES; SCREENING SERVICES; UNITED-STATES; SURVIVAL; ETHNICITY; ACCESS; RACE; EXPERIENCES AB Background: Although their risk of breast cancer is similar to that of women without a disability, women with a disability might be less likely to obtain a mammogram within the recommended time frame. The purpose of this study was to expand our knowledge of the association between mammography use and having a disability by controlling for sociodemographic and health variables. Methods: Data from the 2008 Behavioral Risk Factor Surveillance System (BRFSS) were used to obtain prevalence of self-reported mammography use in the past 2 years among U.S. women >= 40 years of age (n = 204,981) as well as women 50-74 years of age (n = 122,374). Logistic regression was used to estimate associations between disability and obtaining a mammogram for each age cohort, controlling for sociodemographic factors. Results: Prevalence of self-reported mammography use is lower for women with a disability (72.2% for women >= 40 years of age and 78.1% for women 50-74 years of age) than women without a disability (77.8% and 82.6%, respectively). Women with a disability had lower odds of mammography use than women without a disability for both age cohorts (>= 40, adjusted odds ratio [aOR] 0.92, p = 0.01; 50-74 years, aOR 0.92, p = 0.03). Conclusions: Disparities in obtaining a mammogram at recommended screening intervals persist for women with disabilities. This demonstrates the need for continued health promotion and prevention activities directed toward women with a disability to improve their accessibility to obtaining a mammogram. C1 [Courtney-Long, Elizabeth; Armour, Brian] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Frammartino, Brunella; Miller, Jacqueline] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Courtney-Long, E (reprint author), Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-88, Atlanta, GA 30333 USA. EM gmr9@cdc.gov NR 39 TC 18 Z9 19 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD SEP PY 2011 VL 20 IS 9 BP 1279 EP 1286 DI 10.1089/jwh.2010.2609 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 819EH UT WOS:000294807700004 PM 21732810 ER PT J AU Collier, SA Mulholland, C Williams, J Mersereau, P Turay, K Prue, C AF Collier, Sarah A. Mulholland, Celene Williams, Jennifer Mersereau, Patricia Turay, Khadija Prue, Christine TI A Qualitative Study of Perceived Barriers to Management of Diabetes Among Women with a History of Diabetes During Pregnancy SO JOURNAL OF WOMENS HEALTH LA English DT Article ID PRE-CONCEPTION CARE; PERINATAL-MORTALITY; MELLITUS; MALFORMATIONS; TYPE-1 AB Background: Uncontrolled diabetes during pregnancy can cause adverse maternal and infant outcomes. This study explored barriers to glycemic control before, during, and after pregnancy and describes knowledge, attitudes, and behaviors among pregnant women with pregestational diabetes (PGDM) or gestational diabetes (GDM). Methods: Focus groups were conducted in the Atlanta area among white, black, and Hispanic women who had diabetes during a recent pregnancy. Participants were a convenience sample drawn from a variety of sources. Nine focus groups were held with womenwho had GDM, and seven focus groups were held with womenwho had PGDM. Results: Participants identified five main areas of barriers to management of diabetes during pregnancy: financial barriers and difficulties accessing care, barriers to maintaining a healthy diet and exercising, communication difficulties, lack of social support, and barriers related to diabetes care. Participants with GDM had general awareness of possible diabetes complications but frequently could not name specific effects of diabetes on the woman or child during and after pregnancy. Most were unaware of their risk for developing type 2 diabetes later. Participants with PGDM expressed concern about the increased risk of adverse outcomes for the baby; most knew the importance of maintaining glycemic control during pregnancy. Low rates of pregnancy planning were reported in both groups. Pregnancy planning was not identified as a strategy to ensure a healthy baby. Conclusions: The barriers to achieving glycemic control during pregnancy identified in this study could help inform future efforts to assist women in achieving optimal prepregnancy and intrapregnancy glycemic control. C1 [Mersereau, Patricia] CDC, SciMetrika LLC, NCBDDD, Atlanta, GA 30333 USA. [Collier, Sarah A.] Ctr Dis Control & Prevent, Atlanta Res & Educ Fdn, CDC, NCEZID, Atlanta, GA 30333 USA. [Mulholland, Celene] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Turay, Khadija] Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA. RP Mersereau, P (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM pmersereau@cdc.gov NR 35 TC 17 Z9 17 U1 2 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD SEP PY 2011 VL 20 IS 9 BP 1333 EP 1339 DI 10.1089/jwh.2010.2676 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 819EH UT WOS:000294807700010 PM 21740191 ER PT J AU White, G Ottendorfer, C Graham, S Unnasch, TR AF White, Gregory Ottendorfer, Christy Graham, Sean Unnasch, Thomas R. TI Competency of Reptiles and Amphibians for Eastern Equine Encephalitis Virus SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ENCEPHALOMYELITIS VIRUS; CULISETA-MELANURA; FEEDING PATTERNS; CENTRAL ALABAMA; NEW-YORK; VECTORS; FOCUS; IDENTIFICATION; EVOLUTION; MOSQUITOS AB Eastern equine encephalitis virus (EEEV) is endemic throughout most of the eastern United States. Although it is transmitted year round in Florida, transmission elsewhere is seasonal. The mechanism that enables EEEV to overwinter in seasonal foci remains obscure. In previous field studies, early season EEEV activity was detected in mosquito species that feed primarily upon ectothermic hosts, suggesting that reptiles and amphibians might represent overwintering reservoir hosts for EEEV. To determine if this might be possible, two commonly fed upon amphibian and reptile species were evaluated as hosts for the North American subtype I strain of EEEV. Neither amphibian species was a competent host. However, circulating viremias were detected in both reptile species examined. Hibernating infected garter snakes remained viremic after exiting hibernation. These data suggest that snakes may represent an overwintering host for North American EEEV. C1 [Unnasch, Thomas R.] Univ S Florida, Coll Publ Hlth, Dept Global Hlth, Global Hlth Infect Dis Res Program, Tampa, FL 33612 USA. [Graham, Sean] Auburn Univ, Dept Biol Sci, Auburn, AL 36849 USA. [White, Gregory] Coachella Valley Mosquito & Vector Control Dist, Indio, CA USA. [Ottendorfer, Christy] Ctr Dis Control & Prevent, Div Select Agents & Toxins, Atlanta, GA USA. RP Unnasch, TR (reprint author), Univ S Florida, Coll Publ Hlth, Dept Global Hlth, Global Hlth Infect Dis Res Program, 3720 Spectrum Blvd,Suite 304, Tampa, FL 33612 USA. EM gwhite@cvmvcd.org; cottendorfer@gmail.com; thronateeska@yahoo.com; tunnasch@health.usf.edu FU National Institute of Allergy and Infectious Diseases [R01AI049724] FX This work was supported by a grant from the National Institute of Allergy and Infectious Diseases (Project # R01AI049724) to TRU. NR 30 TC 10 Z9 10 U1 0 U2 10 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2011 VL 85 IS 3 BP 421 EP 425 DI 10.4269/ajtmh.2011.11-0006 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 816EL UT WOS:000294581400007 PM 21896798 ER PT J AU Lu, Z Fu, SH Wang, FT Nasci, RS Tang, Q Liang, GD AF Lu, Zhi Fu, Shi-Hong Wang, Feng-Tian Nasci, Roger S. Tang, Qing Liang, Guo-Dong TI Short Report: Circulation of Diverse Genotypes of Tahyna Virus in Xinjiang, People's Republic of China SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ORTHOBUNYAVIRUS; BUNYAVIRIDAE; GLYCOPROTEINS; INFECTION; FAMILY AB Tahyna virus (TAHV) is widely distributed in Europe and Asia. A previous study reported a high level of conservation of the TAHV genome in isolates from Europe. During 2006 and 2007, three Tahyna virus isolates from mosquitoes were obtained from various locations in Xinjiang, People's Republic of China. We analyzed the complete coding sequence of full-length small, medium, and large segments of these isolates. Molecular and phylogenetic analyses of the three complete TAHV genomes showed that sequence identity between isolates from China and Europe was more divergent, and an unexpected level of medium segment diversity was found among isolates from China compared with high levels of sequence conservation for the small and large segments. This study indicated that effects of genotypic diversity on the ecology, transmission, and pathogenicity of TAHV in China should be studied. C1 [Lu, Zhi; Fu, Shi-Hong; Wang, Feng-Tian; Tang, Qing; Liang, Guo-Dong] Chinese Ctr Dis Control & Prevent, Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China. [Nasci, Roger S.] Ctr Dis Control & Prevent, Natl Ctr Zoont Vector Borne & Enter Dis, Div Vector Borne Infect Dis, Publ Hlth Serv, Ft Collins, CO USA. RP Liang, GD (reprint author), Chinese Ctr Dis Control & Prevent, Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, 155 Chang Bai Rd, Beijing 102206, Peoples R China. EM liflit@hotmail.com; shihongfu@hotmail.com; wangft82@163.com; rsn0@cdc.gov; qtang04@sina.com; gdliang@hotmail.com FU Ministry of Science and Technology of China [2008ZX10004-001]; Young Scholar Scientific Research Foundation of China CDC [2010A105]; State Key Laboratory for Infectious Disease Prevention and Control [2008SKLID105]; China CDC-US CDC [U19-GH000004] FX This study was supported by grants from the Ministry of Science and Technology of China (no. 2008ZX10004-001), The Young Scholar Scientific Research Foundation of China CDC (no.2010A105), a Development Grant from the State Key Laboratory for Infectious Disease Prevention and Control (2008SKLID105), and China CDC-US CDC Cooperative Agreement U19-GH000004. NR 12 TC 2 Z9 4 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2011 VL 85 IS 3 BP 442 EP 445 DI 10.4269/ajtmh.2011.10-0368 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 816EL UT WOS:000294581400010 PM 21896801 ER PT J AU Islam, MS Luby, SP Rahman, M Parveen, S Homaira, N Begum, NH Khan, AKMD Sultana, R Akhter, S Gurley, ES AF Islam, M. Saiful Luby, Stephen P. Rahman, Mahmudur Parveen, Shahana Homaira, Nusrat Begum, Nur Har Khan, A. K. M. Dawlat Sultana, Rebeca Akhter, Shammi Gurley, Emily S. TI Social Ecological Analysis of an Outbreak of Pufferfish Egg Poisoning in a Coastal Area of Bangladesh SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TAKIFUGU-OBLONGUS; TETRODOTOXIN; EPIDEMIOLOGY; INCIDENT AB Recurrent outbreaks of marine pufferfish poisoning in Bangladesh highlight the need to understand the context in which the outbreaks occurred. In a recent outbreak investigation, a multidisciplinary team conducted a mixed-method study to identify the demography and clinical manifestation of the victims and to explore different uses of pufferfish, and local buying, selling, and processing practices. The outbreak primarily affected a low income household where an elderly woman collected and cooked pufferfish egg curry. Nine persons consumed the curry, and symptoms developed in 6 (67%) of these persons. Symptoms included vomiting, diarrhea, paresis, and tingling sensation; 2 (22%) persons died. The unstable income of the affected family, food crisis, and the public disposal of unsafe pufferfish byproducts all contributed to the outbreak. A multi-level intervention should be developed and disseminated with the participation of target communities to discourage unsafe discarding of pufferfish scraps and to improve the community knowledge about the risk of consuming pufferfish. C1 [Islam, M. Saiful; Luby, Stephen P.; Homaira, Nusrat; Khan, A. K. M. Dawlat; Sultana, Rebeca; Gurley, Emily S.] Int Ctr Diarrhoeal Dis Res, Hlth Syst & Infect Dis Div, Programme Infect Dis & Vaccine Sci, Dhaka 1212, Bangladesh. [Rahman, Mahmudur; Begum, Nur Har; Akhter, Shammi] Inst Epidemiol Dis Control & Res, Dhaka 1212, Bangladesh. Ctr Dis Control & Prevent, Atlanta, GA USA. [Luby, Stephen P.] US Embassy, Ctr Dis Control & Prevent, Dhaka, Bangladesh. [Rahman, Mahmudur] Natl Influenza Ctr Mohakhali, Dhaka 1212, Bangladesh. RP Islam, MS (reprint author), Int Ctr Diarrhoeal Dis Res, Hlth Syst & Infect Dis Div, Programme Infect Dis & Vaccine Sci, 68 Shahid Tajuddin Ahmed Sharani, Dhaka 1212, Bangladesh. EM saiful@icddrb.org; sluby@icddrb.org; mrahman@citechco.net; shahana@icddrb.org; nhomaira@icddrb.org; dr.nurhar@yahoo.com; dawlat@icddrb.org; rebeca@icddrb.org; bablybd2002@yahoo.com; egurley@icddrb.org RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 FU Centers for Disease Control and Prevention [I-U01-C1000298]; Government of the People's Republic of Bangladesh FX This study was supported by the Centers for Disease Control and Prevention through cooperative award number I-U01-C1000298 and by the Government of the People's Republic of Bangladesh. NR 38 TC 1 Z9 1 U1 1 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2011 VL 85 IS 3 BP 498 EP 503 DI 10.4269/ajtmh.2011.10-0629 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 816EL UT WOS:000294581400020 PM 21896811 ER PT J AU Ozaki, M Islam, S Rahman, KM Rahman, A Luby, SP Bern, C AF Ozaki, Masayo Islam, Shamim Rahman, Kazi Mizanur Rahman, Anisur Luby, Stephen P. Bern, Caryn TI Economic Consequences of Post Kala-Azar Dermal Leishmaniasis in a Rural Bangladeshi Community SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID VISCERAL LEISHMANIASIS; HEALTH-CARE; POVERTY; HOUSEHOLDS; BIHAR; INDIA; NEPAL; COUNTRIES; EFFICACY; PAYMENTS AB Post kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis. Bangladesh national treatment guidelines during the study period called for 120 intramuscular injections of sodium antimony gluconate (SAG). We assessed care-seeking behavior, diagnosis and treatment costs, and coping strategies among 134 PKDL patients; 56 (42%) patients had been treated with SAG, and 78 (58%) remained untreated. The median direct cost per patient treated was US$367 (interquartile range [IQR] = 90-284), more than two times the estimated per capita annual income for the study population. The most common coping strategy was to take a loan; the median amount borrowed was US$98 (IQR = 71-150), with a median interest of US$32 (IQR = 16-95). Households lost a median of 123 work-days per patient treated. The current regimen for PKDL imposes a significant financial burden, reinforcing the link between poverty and visceral leishmaniasis. More practical shorter-course regimens for PKDL are urgently needed to achieve national and regional visceral leishmaniasis elimination goals. C1 [Bern, Caryn] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Islam, Shamim] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA. [Rahman, Kazi Mizanur; Rahman, Anisur; Luby, Stephen P.] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh. [Ozaki, Masayo] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Bern, C (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, 4770 Buford Highway NE,MS F-22, Atlanta, GA 30341 USA. EM masayo.ozaki@gmail.com; sizuba@yahoo.com; mizan@icddrb.org; anis123@icddrb.org; sluby@icddrb.org; cxb9@cdc.gov FU United States Agency for International Development-CDC [GHN-T-00-06-00001-00] FX The study was funded by United States Agency for International Development-CDC interagency agreement GHN-T-00-06-00001-00. NR 31 TC 4 Z9 4 U1 2 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2011 VL 85 IS 3 BP 528 EP 534 DI 10.4269/ajtmh.2011.10-0683 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 816EL UT WOS:000294581400026 PM 21896817 ER PT J AU Kang, HJ Kosoy, MY Shrestha, SK Shrestha, MP Pavlin, JA Gibbons, RV Yanagihara, R AF Kang, Hae Ji Kosoy, Michael Y. Shrestha, Sanjaya K. Shrestha, Mrigendra P. Pavlin, Julie A. Gibbons, Robert V. Yanagihara, Richard TI Short Report: Genetic Diversity of Thottapalayam Virus, a Hantavirus Harbored by the Asian House Shrew (Suncus murinus) in Nepal SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID EURASIAN COMMON SHREW; DISTINCT HANTAVIRUS; SEEWIS-VIRUS; NEWFOUND HANTAVIRUS; HEMORRHAGIC-FEVER; BORNE HANTAVIRUS; UNITED-STATES; KOREA; PHYLOGEOGRAPHY; SEQUENCES AB Despite the recent discovery of genetically divergent hantaviruses in shrews of multiple species in widely separated geographic regions, data are unavailable about the genetic diversity and phylogeography of Thottapalayam virus (TPMV), a hantavirus originally isolated from an Asian house shrew (Suncus murinus) captured in southern India more than four decades ago. To bridge this knowledge gap, the S, M, and L segments of hantavirus RNA were amplified by reverse transcription polymerase chain reaction from archival lung tissues of Asian house shrews captured in Nepal from January to September 1996. Pair-wise alignment and comparison revealed approximately 80% nucleotide and > 94% amino acid sequence similarity to prototype TPMV. Phylogenetic analyses, generated by maximum likelihood and Bayesian methods, showed geographic-specific clustering of TPMV, similar to that observed for rodent- and soricid-borne hantaviruses. These findings confirm that the Asian house shrew is the natural reservoir of TPMV and suggest a long-standing virus host relationship. C1 [Yanagihara, Richard] Univ Hawaii Manoa, Pacific Ctr Emerging Infect Dis Res, John A Burns Sch Med, Dept Pediat, Honolulu, HI 96813 USA. Univ Hawaii Manoa, Dept Trop Med Med Microbiol & Pharmacol, John A Burns Sch Med, Honolulu, HI 96813 USA. [Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO USA. [Shrestha, Sanjaya K.; Shrestha, Mrigendra P.] Walter Reed Armed Forces Res Inst Med Sci, Res Unit Nepal, Kathmandu, Nepal. [Pavlin, Julie A.] Uniformed Serv Univ Hlth Sci, Div Epidemiol & Biostat, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Gibbons, Robert V.] US Army Med Component, Armed Forces Res Inst Med Sci, Dept Virol, Bangkok, Thailand. US Army Med Component, Armed Forces Res Inst Med Sci, Dept Global Emerging Infect, Bangkok, Thailand. RP Yanagihara, R (reprint author), Univ Hawaii Manoa, Pacific Ctr Emerging Infect Dis Res, John A Burns Sch Med, Dept Pediat, 651 Ilalo St,BSB320L, Honolulu, HI 96813 USA. EM hyeyun.kang@gmail.com; mck3@cdc.gov; shresthask@afrims.org; shresthamp@afrims.org; japavlin@gmail.com; Robert.Gibbons@afrims.org; yanagiha@pbrc.hawaii.edu RI Valle, Ruben/A-7512-2013 FU National Institute of Allergy and Infectious Diseases [R01A1075057]; National Center for Research Resources, National Institutes of Health [P20RR018727, G12RR003061] FX This work was supported in part by U.S. Public Health Service Grant R01A1075057 from the National Institute of Allergy and Infectious Diseases and Grants P20RR018727 and G12RR003061 from the National Center for Research Resources, National Institutes of Health. NR 36 TC 11 Z9 11 U1 1 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2011 VL 85 IS 3 BP 540 EP 545 DI 10.4269/ajtmh.2011.11-0034 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 816EL UT WOS:000294581400028 PM 21896819 ER PT J AU de Oliveira, AM Chavez, J de Leon, GP Durand, S Arrospide, N Roberts, J Cabezas, C Marquino, W AF de Oliveira, Alexandre Macedo Chavez, Jorge de Leon, Gabriel Ponce Durand, Salomon Arrospide, Nancy Roberts, Jacquelin Cabezas, Cesar Marquino, Wilmer TI Efficacy and Effectiveness of Mefloquine and Artesunate Combination Therapy for Uncomplicated Plasmodium falciparum Malaria in the Peruvian Amazon SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SULFADOXINE-PYRIMETHAMINE; RESISTANCE; DERIVATIVES; CHALLENGE; NIGERIA; MALAWI; POLICY; CARE AB We evaluated the efficacy and effectiveness of mefloquine (MO) plus artesunate (AS) to treat patients with uncomplicated malaria in the Peruvian Amazon Basin in April 2005 March 2006. Patients >= 1 year of age with fever (axillary temperature >= 37.5 degrees C) or history of fever and Plasmodium falciparum monoinfection were included. Patients received antimalarial treatment with MQ (12.5 mg/kg/day for two days) and AS (4.0 mg/kg/day for three days) either by directly observed therapy or without directly observed therapy. After a 28-day follow-up, treatment efficacy and effectiveness were assessed on the basis of clinical and parasitologic outcomes. Ninety-six patients were enrolled in each study group; nine patients were lost to follow-up. All patients, except for one in the observed group, demonstrated adequate clinical and parasitologic response; none had detectable parasitemia on day 3. The efficacy of MO + AS efficacy was 98.9% (95% confidence interval = 94.1-100.0%) and the effectiveness was 100.0% (95% confidence interval = 95.9-100.0%). Our study shows that MO + AS is highly efficacious in the Peruvian Amazon. C1 [de Oliveira, Alexandre Macedo; de Leon, Gabriel Ponce; Roberts, Jacquelin] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [de Oliveira, Alexandre Macedo; de Leon, Gabriel Ponce; Roberts, Jacquelin] Ctr Dis Control & Prevent, Off Director, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Chavez, Jorge] Univ Cesar Vallejo, Escuela Med Humana, Fac Ciencias Med, Piura, Peru. Naval Med Res Unit 6, Iquitos, Peru. [Durand, Salomon] Naval Med Res Unit NAMRU Unit 6, Iquitos, Peru. [Arrospide, Nancy; Cabezas, Cesar; Marquino, Wilmer] Inst Nacl Salud, Ctr Nacl Salud Publ, Lima 11, Peru. RP de Oliveira, AM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 1600 Clifton Rd,Mailstop A-06, Atlanta, GA 30333 USA. EM acq7@cdc.gov; jorgechavez2708@yahoo.es; gcp1@cdc.gov; sdurandv@yahoo.com; narrospide@hotmail.com; jmr1@cdc.org; salljaruna@yahoo.com; marquinw@nic.ops-oms.org OI durand, salomon/0000-0002-5923-8879; ARROSPIDE, NANCY/0000-0001-5031-5850 FU United States Agency for International Development (USAID) through the Amazon Malaria Initiative (AMI) FX This study was supported by the United States Agency for International Development (USAID) through the Amazon Malaria Initiative (AMI). NR 29 TC 4 Z9 4 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2011 VL 85 IS 3 BP 573 EP 578 DI 10.4269/ajtmh.2011.11-0250 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 816EL UT WOS:000294581400034 PM 21896825 ER PT J AU Humrighouse, BW Adcock, NJ Rice, EW AF Humrighouse, B. W. Adcock, N. J. Rice, E. W. TI Use of Acid Treatment and a Selective Medium To Enhance the Recovery of Francisella tularensis from Water SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID ENVIRONMENTAL-SAMPLES; TAP WATER; LEGIONELLA; TULAREMIA AB Francisella tularensis has been associated with naturally occurring waterborne outbreaks and is also of interest as a potential biological weapon. Recovery of this pathogen from water using cultural methods is challenging due to the organism's fastidious growth requirements and interference by indigenous bacteria. A 15-min acid treatment procedure prior to culture on a selective agar was evaluated for recovery of F. tularensis from seeded water samples. Mean levels of reduction of virulent strains of F. tularensis subsp. holarctica and subsp. tularensis were less than 20% following acid treatment. The attenuated live vaccine strain (LVS) was less resistant to acid exposure. The acid treatment procedure coupled with plating on cystine heart agar with rabbit blood and antibiotics (CHARBab) allowed the isolation of F. tularensis seeded into five natural water samples. C1 [Humrighouse, B. W.] Pegasus Tech Serv Inc, Cincinnati, OH USA. [Adcock, N. J.] Natl Risk Management Res Lab, Cincinnati, OH USA. [Rice, E. W.] US EPA, Natl Homeland Secur Res Ctr, Cincinnati, OH 45268 USA. RP Humrighouse, BW (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop D11, Atlanta, GA 30333 USA. EM vkk7@cdc.gov NR 17 TC 4 Z9 4 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD SEP PY 2011 VL 77 IS 18 BP 6729 EP 6732 DI 10.1128/AEM.05226-11 PG 4 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 817RJ UT WOS:000294691400056 PM 21803910 ER PT J AU MacDorman, MF Declercq, E Mathews, TJ AF MacDorman, Marian F. Declercq, Eugene Mathews, T. J. TI United States Home Births Increase 20 Percent from 2004 to 2008 SO BIRTH-ISSUES IN PERINATAL CARE LA English DT Article DE birth certificate; home birth; out-of-hospital birth; race and ethnic differences ID US AB Background: After a gradual decline from 1990 to 2004, the percentage of births occurring at home increased from 2004 to 2008 in the United States. The objective of this report was to examine the recent increase in home births and the factors associated with this increase from 2004 to 2008. Methods: United States birth certificate data on home births were analyzed by maternal demographic and medical characteristics. Results: In 2008, there were 28,357 home births in the United States. From 2004 to 2008, the percentage of births occurring at home increased by 20 percent from 0.56 percent to 0.67 percent of United States births. This rise was largely driven by a 28 percent increase in the percentage of home births for non-Hispanic white women, for whom more than 1 percent of births occur at home. At the same time, the risk profile for home births has been lowered, with substantial drops in the percentage of home births of infants who are born preterm or at low birthweight, and declines in the percentage of home births that occur to teen and unmarried mothers. Twenty-seven states had statistically significant increases in the percentage of home births from 2004 to 2008; only four states had declines. Conclusion: The 20 percent increase in United States home births from 2004 to 2008 is a notable development that will be of interest to practitioners and policy-makers. (BIRTH 38: 3 September 2011) C1 [MacDorman, Marian F.; Mathews, T. J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Reprod Stat Branch, Div Vital Stat, Hyattsville, MD 20782 USA. [Declercq, Eugene] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA USA. RP MacDorman, MF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Reprod Stat Branch, Div Vital Stat, 3311 Toledo Rd,Room 7318, Hyattsville, MD 20782 USA. OI Declercq, Eugene/0000-0001-5411-3033 NR 32 TC 12 Z9 12 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0730-7659 J9 BIRTH-ISS PERINAT C JI Birth-Issue Perinat. Care PD SEP PY 2011 VL 38 IS 3 BP 185 EP 190 DI 10.1111/j.1523-536X.2011.00481.x PG 6 WC Nursing; Obstetrics & Gynecology; Pediatrics SC Nursing; Obstetrics & Gynecology; Pediatrics GA 816LT UT WOS:000294602400002 PM 21884226 ER PT J AU Zeliadt, SB Penson, DF Moinpour, CM Blough, DK Fedorenko, CR Hall, IJ Smith, JL Ekwueme, DU Thompson, IM Keane, TE Ramsey, SD AF Zeliadt, Steven B. Penson, David F. Moinpour, Carol M. Blough, David K. Fedorenko, Catherine R. Hall, Ingrid J. Smith, Judith Lee Ekwueme, Donatus U. Thompson, Ian M. Keane, Thomas E. Ramsey, Scott D. TI Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer SO BJU INTERNATIONAL LA English DT Article DE shared decision-making; patient-provider communication; family member involvement; provider-partner communication; prostate cancer ID INFORMATION-SEEKING BEHAVIORS; MEN; INVOLVEMENT; EXPERIENCES; THERAPY AB OBJECTIVE To evaluate the degree to which the partners of prostate cancer patients participate in the shared decision-making process with the patients' providers during the time between diagnosis and initiating treatment. PATIENTS AND METHODS We recruited patients with newly diagnosed local-stage prostate cancer and their partners to complete take-home surveys after biopsy but before initiating treatment at urology practices in three states. We asked partners to describe their roles in the decision-making process, including participation in clinic visits, and perceptions of encouragement from providers to participate in the treatment decision-making process. We also asked partners to rate their satisfaction with the patients' providers. RESULTS Family members of 80% of newly diagnosed patients agreed to participate; most (93%) were partners (i.e. spouses or significant others). Most partners (93%) had direct contact with the patients' physicians. Among the partners who had contact with providers, most (67%) were very satisfied with the patients' providers and 80% indicated that the doctor encouraged them to participate in the treatment decision. Overall, 91% of partners reported very frequent discussions with their loved one about the pending treatment decision, and 69% reported that their role was to help the patient make a decision. In multivariate models, provider encouragement of partner participation was associated with higher partner satisfaction (odds ratio 3.4, 95% CI 1.4-8.4) and an increased likelihood of partners reporting very frequent discussions with their loved one (odds ratio 6.1, 95% CI 1.3-27.7). CONCLUSIONS Partners often attended clinic visits and were very involved in discussions about treatment options with both loved ones and providers. Provider encouragement of participation by partners greatly facilitates shared decision-making between patients and partners. C1 [Zeliadt, Steven B.; Moinpour, Carol M.; Blough, David K.; Fedorenko, Catherine R.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Zeliadt, Steven B.] Dept Vet Affairs Med Ctr, Seattle, WA USA. [Zeliadt, Steven B.; Blough, David K.; Ramsey, Scott D.] Univ Washington, Seattle, WA 98195 USA. [Penson, David F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Charleston, SC USA. [Keane, Thomas E.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,M3-B232, Seattle, WA 98109 USA. EM sramsey@fhcrc.org FU Centers for Disease Control and Prevention (CDC) through University of Washington Health Promotion Research Center [SIP 25-04 1-U48-DP-000050]; Cancer Surveillance System of the Fred Hutchinson Cancer Research Center; National Cancer Institute [N01-PC-35142]; Fred Hutchinson Cancer Research Center; State of Washington FX This publication was supported by Cooperative Agreement Number SIP 25-04 1-U48-DP-000050 from the Centers for Disease Control and Prevention (CDC), Prevention Research Centers Program, through the University of Washington Health Promotion Research Center. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. Case ascertainment for the focus group research was supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, which is funded by Contract No. N01-PC-35142 from the Surveillance, Epidemiology and End Results Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington. NR 21 TC 22 Z9 23 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-4096 J9 BJU INT JI BJU Int. PD SEP PY 2011 VL 108 IS 6 BP 851 EP 856 DI 10.1111/j.1464-410X.2010.09945,10540.x PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 819VZ UT WOS:000294862000013 PM 21244609 ER PT J AU Hunt, R Ashkenazi, I Falk, H AF Hunt, Richard Ashkenazi, Isaac Falk, Henry TI A Tale of Cities SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Editorial Material ID INJURIES C1 [Hunt, Richard] CDC, Div Injury Response, NCIPC, Ctr Dis Control & Prevent, Chamblee, GA 30341 USA. [Ashkenazi, Isaac] Harvard Univ, Natl Preparedness Leadership Inst, Cambridge, MA 02138 USA. [Falk, Henry] Ctr Dis Control & Prevent, Off Deputy Director Noncommunicable Dis Injury &, Atlanta, GA USA. RP Hunt, R (reprint author), CDC, Div Injury Response, NCIPC, Ctr Dis Control & Prevent, 4770 Buford Hwy,Bldg 106,Room 08112,MS F62, Chamblee, GA 30341 USA. EM rhunt@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD SEP PY 2011 VL 5 SU 2 BP S185 EP S188 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 817ZH UT WOS:000294716700006 PM 21908697 ER PT J AU Tharp, AT Vasterling, JJ Sullivan, G Han, XT Davis, T Deitch, EA Constans, J AF Tharp, Andra Teten Vasterling, Jennifer J. Sullivan, Greer Han, Xiaotong Davis, Teri Deitch, Elizabeth A. Constans, Joseph TI Effects of Pre- and Post-Katrina Nonviolent and Violent Experiences on Male Veterans' Psychological Functioning SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE disaster; violence; veterans; posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; HURRICANE KATRINA; HEALTH; VICTIMIZATION; METAANALYSIS; POPULATION; DEPRESSION; OUTCOMES; ALCOHOL; TSUNAMI AB Background: Identifying individuals at risk for mental health problems after a disaster often involves assessing potentially traumatic exposures inherent to the disaster. Survivors of disasters also may have been exposed, both before and during the event, to trauma not directly related to the disaster. A substantial literature suggests exposure to interpersonal violence may have more severe negative outcomes than exposure to nonviolent events; however, it is unclear whether violent vs nonviolent exposures before and during a disaster have differential effects on postdisaster psychological functioning. Methods: We examined the associations of violent and nonviolent exposures before and during Hurricane Katrina with postdisaster psychological functioning in a sample of male military veterans. Results: Violent and nonviolent exposures post-Hurricane Katrina as well as pre-Katrina violent exposures were significantly associated with symptoms of posttraumatic stress disorder, panic, and generalized anxiety disorder more than 2 years after the storm. Moreover, veterans who reported violent exposures pre-Katrina were more than 4 times more likely to have reexperienced interpersonal violence during Katrina than those who did not report such exposures. Conclusions: Results suggest assessing disaster-specific experiences in addition to predisaster interpersonal violence may be important for identifying and triaging individuals at risk for postdisaster mental health problems. (Disaster Med Public Health Preparedness. 2011;5:S227-S234) C1 [Tharp, Andra Teten] Baylor Coll Med, Houston, TX 77030 USA. [Vasterling, Jennifer J.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02215 USA. [Sullivan, Greer; Han, Xiaotong; Davis, Teri] Univ Arkansas Med Sci, S Cent VA Mental Illness Res Educ & Clin Ctr, Little Rock, AR 72205 USA. [Deitch, Elizabeth A.] Univ New Orleans, New Orleans, LA 70148 USA. [Constans, Joseph] Tulane Univ, S Cent VA Mental Illness Res Educ & Clin Ctr, SE Louisiana Vet Healthcare Syst, New Orleans, LA 70118 USA. RP Tharp, AT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,MS F-64, Atlanta, GA 30341 USA. EM atharpn@cdc.gov RI Schueter, nicos/A-3625-2014 FU Department of Veterans Affairs' South Central Mental Illness Research, Education, and Clinical Center FX This work was supported by the Department of Veterans Affairs' South Central Mental Illness Research, Education, and Clinical Center. The work does not represent the views of the Department of Veterans Affairs or the US government. Data were collected before Andra Teten Tharp joined the Centers for Disease Control and Prevention. NR 30 TC 3 Z9 3 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD SEP PY 2011 VL 5 SU 2 BP S227 EP S234 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 817ZH UT WOS:000294716700012 PM 21908700 ER PT J AU Atkins, CY Patel, A Taylor, TH Biggerstaff, M Merlin, TL Dulin, SM Erickson, BA Borse, RH Hunkler, R Meltzer, MI AF Atkins, Charisma Y. Patel, Anita Taylor, Thomas H., Jr. Biggerstaff, Matthew Merlin, Toby L. Dulin, Stephanie M. Erickson, Benjamin A. Borse, Rebekah H. Hunkler, Robert Meltzer, Martin I. TI Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NEURAMINIDASE INHIBITOR ZANAMIVIR; INFLUENZA-RELATED COMPLICATIONS; RANDOMIZED CONTROLLED-TRIAL; OSELTAMIVIR TREATMENT; VIRUS-INFECTIONS; EFFICACY; SAFETY; CHILDREN; HOSPITALIZATIONS; BENEFITS AB From April 2009 through March 2010, during the pandemic (H1N1) 2009 outbreak, approximate to 8.2 million prescriptions for influenza neuraminidase-inhibiting antiviral drugs were filled in the United States. We estimated the number of hospitalizations likely averted due to use of these antiviral medications. After adjusting for prescriptions that were used for prophylaxis and personal stockpiles, as well as for patients who did not complete their drug regimen, we estimated the filled prescriptions prevented approximate to 8,400-12,600 hospitalizations (on the basis of median values). Approximately 60% of these prevented hospitalizations were among adults 18-64 years of age, with the remainder almost equally divided between children 0-17 years of age and adults >= 65 years of age. Public health officials should consider these estimates an indication of success of treating patients during the 2009 pandemic and a warning of the need for renewed planning to cope with the next pandemic. C1 [Atkins, Charisma Y.; Patel, Anita; Taylor, Thomas H., Jr.; Biggerstaff, Matthew; Merlin, Toby L.; Dulin, Stephanie M.; Erickson, Benjamin A.; Borse, Rebekah H.; Meltzer, Martin I.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Hunkler, Robert] IMS Hlth, Fountain Hills, AZ USA. RP Meltzer, MI (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D59, Atlanta, GA 30333 USA. EM qzm4@cdc.gov NR 26 TC 17 Z9 17 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2011 VL 17 IS 9 BP 1591 EP 1598 DI 10.3201/eid1709.110295 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817FG UT WOS:000294656100002 PM 21888783 ER PT J AU Simmon, KE Brown-Elliott, BA Ridge, PG Durtschi, JD Mann, LB Slechta, ES Steigerwalt, AG Moser, BD Whitney, AM Brown, JM Voelkerding, KV McGowan, KL Reilly, AF Kim, TJ Butler, WR Edelstein, PH Wallace, RJ Petti, CA AF Simmon, Keith E. Brown-Elliott, Barbara A. Ridge, Perry G. Durtschi, Jacob D. Mann, Linda Bridge Slechta, E. Susan Steigerwalt, Arnold G. Moser, Benjamin D. Whitney, Anne M. Brown, June M. Voelkerding, Karl V. McGowan, Karin L. Reilly, Anne F. Kim, Thomas J. Butler, W. Ray Edelstein, Paul H. Wallace, Richard J., Jr. Petti, Cathy A. TI Mycobacterium chelonae-abscessus Complex Associated with Sinopulmonary Disease, Northeastern USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RAPIDLY GROWING MYCOBACTERIA; SP NOV.; NONTUBERCULOUS MYCOBACTERIA; EMERGING PATHOGEN; GENE SEQUENCE; RIBOSOMAL-RNA; AVIUM COMPLEX; IDENTIFICATION; AMPLIFICATION; MASSILIENSE AB Members of the Mycobacterium chelonae-abscessus complex represent Mycobacterium species that cause invasive infections in immunocompetent and immunocompromised hosts. We report the detection of a new pathogen that had been misidentified as M. chelonae with an atypical antimicrobial drug susceptibility profile. The discovery prompted a multicenter investigation of 26 patients. Almost all patients were from the northeastern United States, and most had underlying sinus or pulmonary disease. Infected patients had clinical features similar to those with M. abscessus infections. Taxonomically, the new pathogen shared molecular identity with members of the M. chelonae-abscessus complex. Multi locus DNA target sequencing, DNA-DNA hybridization, and deep multilocus sequencing (43 full-length genes) support a new taxon for these microorganisms. Because most isolates originated in Pennsylvania, we propose the name M. franklinii sp. nov. This investigation underscores the need for accurate identification of Mycobacterium spp. to detect new pathogens implicated in human disease. C1 [Simmon, Keith E.; Ridge, Perry G.; Durtschi, Jacob D.; Slechta, E. Susan; Voelkerding, Karl V.; Petti, Cathy A.] Associated Reg & Univ Pathologists Inst Clin & Ex, Salt Lake City, UT USA. [Brown-Elliott, Barbara A.; Mann, Linda Bridge; Wallace, Richard J., Jr.] Univ Texas Hlth Sci Ctr, Tyler, TX USA. [Steigerwalt, Arnold G.; Moser, Benjamin D.; Whitney, Anne M.; Brown, June M.; Butler, W. Ray] Ctr Dis Control & Prevent, Atlanta, GA USA. [Voelkerding, Karl V.; Petti, Cathy A.] Univ Utah, Sch Med, Salt Lake City, UT USA. [McGowan, Karin L.; Reilly, Anne F.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA. [Kim, Thomas J.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Edelstein, Paul H.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. RP Simmon, KE (reprint author), Associated Reg & Univ Pathologists Labs, 500 Chipeta Way, Salt Lake City, UT 84108 USA. EM ke.monk@gmail.com FU Isentio US/Software company (non-FDA); Merck Sharpe; Dohme; Novartis Diagnostics FX Barbara A. Brown-Elliott, MS; Perry G. Ridge; Jacob D. Durtschi, BS; Linda Bridge Mann, BS; E. Susan Slechta; Arnold G. Steigerwalt, BS; Benjamin D. Moser; Anne M. Whitney, PhD; June M. Brown, BS; Karl V. Voelkerding, MD; Karin L. McGowan, PhD; Anne F. Reilly, MD, MPH; W. Ray Butler, MS; Paul H. Edelstein, MD; and Richard J. Wallace Jr., MD, have disclosed no relevant financial relationships. Keith E. Simmon, BS, has disclosed the following relevant financial relationships: employed by: Isentio US/Software company (non-FDA). Thomas J. Kim, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Merck Sharpe and Dohme. Cathy A. Petti, MD, has disclosed the following relevant financial relationships: was an employee for Novartis Diagnostics from 2009-2010. NR 36 TC 19 Z9 19 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2011 VL 17 IS 9 BP 1692 EP 1700 DI 10.3201/eid1709.101667 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817FG UT WOS:000294656100016 PM 21888796 ER PT J AU Mead, P Goel, R Kugeler, K AF Mead, Paul Goel, Rohan Kugeler, Kiersten TI Canine Serology as Adjunct to Human Lyme Disease Surveillance SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BORRELIA-BURGDORFERI; STATES; DOGS AB To better define areas of human Lyme disease risk, we compared US surveillance data with published data on the seroprevalence of Borrelia burgdorferi antibodies among domestic dogs. Canine seroprevalence >5% was a sensitive but nonspecific marker of human risk, whereas seroprevalence <= 1% was associated with minimal risk for human infection. C1 [Mead, Paul; Goel, Rohan; Kugeler, Kiersten] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Mead, P (reprint author), Ctr Dis Control & Prevent, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM pfm0@cdc.gov NR 10 TC 15 Z9 18 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2011 VL 17 IS 9 BP 1710 EP 1712 DI 10.3201/1709.110210 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817FG UT WOS:000294656100020 PM 21888800 ER PT J AU Choudhary, MM Metcalfe, MG Arrambide, K Bern, C Visvesvara, GS Pieniazek, NJ Bandea, RD DeLeon-Carnes, M Adem, P Choudhary, MM Zaki, SR Saeed, MU AF Choudhary, Maria M. Metcalfe, Maureen G. Arrambide, Kathryn Bern, Caryn Visvesvara, Govinda S. Pieniazek, Norman J. Bandea, Rebecca D. DeLeon-Carnes, Marlene Adem, Patricia Choudhary, Moaz M. Zaki, Sherif R. Saeed, Musab U. TI Tubulinosema sp Microsporidian Myositis in Immunosuppressed Patient SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TRANSPLANT RECIPIENT; BRACHIOLA-ALGERAE; EPIDEMIOLOGY; PATHOGEN AB The Phylum Microsporidia comprises >1,200 species, only 15 of which are known to infect humans, including the genera Trachipleistophora, Pleistophora, and Brachiola. We report an infection by Tubulinosema sp. in an immunosuppressed patient. C1 [Choudhary, Maria M.] Cleveland Clin Fdn, Dept Internal Med, Cleveland, OH 44195 USA. [Metcalfe, Maureen G.; Bern, Caryn; Visvesvara, Govinda S.; Pieniazek, Norman J.; Bandea, Rebecca D.; DeLeon-Carnes, Marlene; Adem, Patricia; Zaki, Sherif R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Arrambide, Kathryn; Choudhary, Moaz M.; Saeed, Musab U.] So Illinois Univ, Quincy, IL USA. RP Choudhary, MM (reprint author), Cleveland Clin Fdn, Dept Internal Med, 9500 Euclid Fdn,NA10, Cleveland, OH 44195 USA. EM choudhm@ccf.org; choudhm@ccf.org NR 15 TC 20 Z9 23 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2011 VL 17 IS 9 BP 1727 EP 1730 DI 10.3201/eid1709.101926 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817FG UT WOS:000294656100025 PM 21888805 ER PT J AU Kay, MK Perti, TR Duchin, JS AF Kay, Meagan K. Perti, Tara R. Duchin, Jeffrey S. TI Tattoo-associated Mycobacterium haemophilum Skin Infection in Immunocompetent Adult, 2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID IMMUNOCOMPROMISED PATIENTS; OUTBREAK AB After a laboratory-confirmed case of Mycobacterium haemophilum skin infection in a recently tattooed immunocompetent adult was reported, we investigated to identify the infection source and additional cases. We found 1 laboratory-confirmed and 1 suspected case among immunocompetent adults who had been tattooed at the same parlor. C1 [Kay, Meagan K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kay, Meagan K.; Duchin, Jeffrey S.] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Perti, Tara R.] HealthPoint, Renton, WA USA. [Duchin, Jeffrey S.] Univ Washington, Seattle, WA 98195 USA. RP Kay, MK (reprint author), Suite 900,401 5th Ave, Seattle, WA 98104 USA. EM meagan.kay@kingcounty.gov NR 15 TC 10 Z9 11 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2011 VL 17 IS 9 BP 1734 EP 1736 DI 10.3201/eid1709.102011 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817FG UT WOS:000294656100027 PM 21888807 ER PT J AU Cohen, NJ Callahan, DB Gonzalez, V Balaban, V Wang, RT Pordell, P Beato, R Oyervides, O Huang, WT Massoudi, MS AF Cohen, Nicole J. Callahan, David B. Gonzalez, Vanessa Balaban, Victor Wang, Rose T. Pordell, Paran Beato, Ricardo Oyervides, Otilio Huang, Wan-Ting Massoudi, Mehran S. TI Respiratory Illness in Households of School-Dismissed Students during Pandemic (H1N1) 2009 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID INFLUENZA-A H1N1; IMPACT; VIRUS C1 [Cohen, Nicole J.; Callahan, David B.; Gonzalez, Vanessa; Balaban, Victor; Wang, Rose T.; Pordell, Paran; Beato, Ricardo; Oyervides, Otilio; Huang, Wan-Ting; Massoudi, Mehran S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Cohen, NJ (reprint author), Ctr Dis Control & Prevent, Mailstop C01,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ncohen@cdc.gov RI Huang, Wan-Ting/E-3497-2010 OI Huang, Wan-Ting/0000-0002-4344-9567 NR 9 TC 1 Z9 1 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2011 VL 17 IS 9 BP 1756 EP 1757 DI 10.3201/eid1709.101589 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817FG UT WOS:000294656100034 PM 21888814 ER PT J AU Potter, P AF Potter, Polyxeni TI The Monkey's Paw SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2011 VL 17 IS 9 BP 1785 EP 1786 DI 10.3201/eid1709.AC1709 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817FG UT WOS:000294656100056 ER PT J AU Holden, MJ Madej, RM Minor, P Kalman, LV AF Holden, Marcia J. Madej, Roberta M. Minor, Philip Kalman, Lisa V. TI Molecular diagnostics: harmonization through reference materials, documentary standards and proficiency testing SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review DE DNA; documentary standards; external quality assessment; genetic testing; infectious disease diagnostics; molecular methods; NAT; nucleic acid testing; proficiency testing; reference material ID ORGANIZATION INTERNATIONAL STANDARD; EXTERNAL QUALITY ASSESSMENT; GENOMIC REFERENCE MATERIALS; EPSTEIN-BARR-VIRUS; FRAGILE-X-SYNDROME; QUANTITATIVE DETECTION; HUNTINGTONS-DISEASE; RNA CONTROLS; AMPLIFICATION; ASSAYS AB There is a great need for harmonization in nucleic acid testing for infectious disease and clinical genetics. The proliferation of assay methods, the number of targets for molecular diagnostics and the absence of standard reference materials contribute to variability in test results among laboratories. This article provides a comprehensive overview of reference materials, related documentary standards and proficiency testing programs. The article explores the relationships among these resources and provides necessary information for people practicing in this area that is not taught in formal courses and frequently is obtained on an ad hoc basis. The aim of this article is to provide helpful tools for molecular diagnostic laboratories. C1 [Holden, Marcia J.] NIST, Gaithersburg, MD 20899 USA. [Madej, Roberta M.] Cepheid, Sunnyvale, CA 94089 USA. [Minor, Philip] Hlth Protect Agcy, Natl Inst Biol Stand & Control, Potters Bar EN6 3QG, Herts, England. [Kalman, Lisa V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Holden, MJ (reprint author), NIST, 100 Bur Dr,MS 8312, Gaithersburg, MD 20899 USA. EM marcia.holden@nist.gov NR 76 TC 23 Z9 23 U1 1 U2 4 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD SEP PY 2011 VL 11 IS 7 BP 741 EP 755 DI 10.1586/ERM.11.50 PG 15 WC Pathology SC Pathology GA 819RW UT WOS:000294848400015 PM 21902536 ER PT J AU McMahon, BJ Bulkow, LR Singleton, RJ Williams, J Snowball, M Homan, C Parkinson, AJ AF McMahon, Brian J. Bulkow, Lisa R. Singleton, Rosalyn J. Williams, James Snowball, Mary Homan, Chriss Parkinson, Alan J. TI Elimination of Hepatocellular Carcinoma and Acute Hepatitis B in Children 25 Years After a Hepatitis B Newborn and Catch-Up Immunization Program SO HEPATOLOGY LA English DT Article ID VIRUS-INFECTION; VACCINATION PROGRAM; SURFACE-ANTIGEN; NATURAL-HISTORY; ALASKAN NATIVES; TAIWAN; IMPLEMENTATION; PREVALENCE; VILLAGES; DISEASE AB Alaska Native people experience the highest rates of acute and chronic hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) in the United States. We examined the effect of a universal newborn immunization with hepatitis B vaccine and mass population screening immunization program initiated in 1984 on rates of HBV and HCC in children 25 years later. During this time, the population of Alaska Native people grew from an estimated 75,000 to 130,000 persons. A surveillance system to detect acute HBV infection in Alaska Native facilities was established in 1981. Cases of HCC in children under 20 years of age were identified using a National Cancer Institute (NCI)-funded Cancer Registry established in 1969 coupled with an active surveillance program of screening persons with chronic HBV semiannually for alpha-fetoprotein since 1982. The incidence of acute symptomatic HBV infection in persons <20 years of age fell from cases 19/100,000 in 1981-1982 to 0/100,000 in 1993-1994. No cases of acute HBV have occurred in children since 1992. The incidence of HCC in persons <20 years decreased from 3/100,000 in 1984-1988 to zero in 1995-1999 and no cases have occurred since 1999. The number of identified hepatitis B surface antigen-positive children <20 years in the Alaska Native population declined from 657 in 1987 to two in 2008. Conclusion: Universal newborn vaccination coupled with mass screening and immunization of susceptible Alaska Natives has eliminated HCC and acute symptomatic HBV infection among Alaska Native children and this approach is the best way to prevent HBV-related disease in children. (HEPATOLOGY 2011;54:801-807) C1 [McMahon, Brian J.; Singleton, Rosalyn J.; Williams, James; Snowball, Mary; Homan, Chriss] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK 99508 USA. [McMahon, Brian J.; Bulkow, Lisa R.; Singleton, Rosalyn J.; Parkinson, Alan J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. RP McMahon, BJ (reprint author), Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, 4315 Diplomacy Dr, Anchorage, AK 99508 USA. EM bdm9@cdc.gov FU United States Public Health Service/Indian Health Service; Alaska Native Tribal Health Consortium; Centers for Disease Control and Prevention FX Supported by the United States Public Health Service/Indian Health Service, Alaska Native Tribal Health Consortium and the Centers for Disease Control and Prevention. NR 28 TC 66 Z9 67 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD SEP PY 2011 VL 54 IS 3 BP 801 EP 807 DI 10.1002/hep.24442 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 818FZ UT WOS:000294738300008 PM 21618565 ER PT J AU Millett, GA Ding, H Marks, G Jeffries, WL Bingham, T Lauby, J Murrill, C Flores, S Stueve, A AF Millett, Gregorio A. Ding, Helen Marks, Gary Jeffries, William L. Bingham, Trista Lauby, Jennifer Murrill, Christopher Flores, Stephen Stueve, Ann TI Mistaken Assumptions and Missed Opportunities: Correlates of Undiagnosed HIV Infection Among Black and Latino Men Who Have Sex With Men SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE black; HIV; Latino; MSM; undiagnosed; unrecognized ID RISK BEHAVIORS; LOS-ANGELES; UNITED-STATES; BISEXUAL MEN; HEALTH-CARE; YOUNG MEN; PERCEPTIONS; PREVALENCE; TRANSMISSION; DISPARITIES AB Objective: To identify demographic, behavioral, and psychological variables associated with being HIV positive unaware among black and Latino men who have sex with men (MSM). Methods: Participants recruited in 3 cities completed a computer-assisted interview and were tested for HIV infection (OraSure Technologies, Bethlehem, PA). HIV-positive unaware MSM were compared with MSM who tested HIV negative in bivariate and multivariate analyses. Results: Of 1208 MSM (597 black and 611 Latino), 11% were HIV-positive unaware (18% black; 5% Latino). In multivariate analysis of the Latino MSM, being HIV-positive unaware was associated with nongay identity, high perceived risk of currently being HIV positive, and belief that sex with other Latino men reduces HIV transmission risk. Among black MSM, being HIV-positive unaware was associated with gay identity, moderately higher income, having health insurance, sexuality disclosure to a current health care provider, fewer than 3 lifetime HIV tests, high perceived risk of testing HIV positive, and belief that sex with other black men reduces HIV transmission risk. Conclusions: HIV prevention efforts should address misperceptions among those black and Latino MSM who believe that assortative (ie, intraracial) sexual mixing reduces risk of HIV infection. Our findings also revealed missed opportunities to diagnose black MSM with HIV infection who were already engaged in care and had disclosed their sexuality to their health care provider. Clinicians should offer HIV testing to all MSM, particularly black MSM, who disclose engaging in recent sex with other men to facilitate earlier diagnosis of HIV infection and reduce transmission risk to sexual partners. C1 [Millett, Gregorio A.; Marks, Gary; Flores, Stephen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Ding, Helen] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Jeffries, William L.] Ctr Dis Control & Prevent, Div Appl Sci, Epidem Intelligence Serv, Atlanta, GA USA. [Bingham, Trista] Los Angeles Cty Dept Publ Hlth, HIV Epidemiol Program, Seroepidemiol Unit, Los Angeles, CA USA. [Lauby, Jennifer] Publ Hlth Management Corp, Philadelphia, PA USA. [Murrill, Christopher] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. [Stueve, Ann] Educ Dev Ctr, Hlth Program, Boston, MA USA. [Stueve, Ann] Educ Dev Ctr, Human Dev Program, Boston, MA USA. RP Millett, GA (reprint author), Ctr Dis Control & Prevent, 395 E St SW,Suite 9100,MS 06, Washington, DC 20201 USA. EM gmillett@cdc.gov FU US Centers for Disease Control and Prevention FX Supported by fund through a co-operative agreement from the US Centers for Disease Control and Prevention. NR 34 TC 27 Z9 27 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2011 VL 58 IS 1 BP 64 EP 71 DI 10.1097/QAI.0b013e31822542ad PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 816OA UT WOS:000294610600015 PM 21654500 ER PT J AU Mwangi, M Bunnell, R Nyoka, R Gichangi, A Makokha, E Kim, A Kichamu, G Marum, L Ichwara, J Mermin, J AF Mwangi, Mary Bunnell, Rebecca Nyoka, Raymond Gichangi, Anthony Makokha, Ernest Kim, Andrea Kichamu, George Marum, Lawrence Ichwara, Jared Mermin, Jonathan CA 2007 KAIS Study Grp TI Unsafe Sex Among HIV-Infected Adults in Kenya: Results of a Nationally Representative Survey SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE condoms; HIV/AIDS; HIV testing; Kenya; sexual behavior; unsafe sex ID TRANSMISSION RISK; PREVENTION INTERVENTIONS; ANTIRETROVIRAL THERAPY; BEHAVIOR; PEOPLE; METAANALYSIS; AFRICA; UGANDA AB Objective: Assess factors associated with knowledge of HIV status, sexual activity, and unprotected sex with a partner of unknown or negative HIV status (unsafe sex) among HIV-infected adults in Kenya. Design: Nationally representative Kenya AIDS Indicator Survey among adults aged 15-64 years in 2007. Methods: A standardized questionnaire was administered and blood samples tested for HIV. We assessed factors associated with knowledge of HIV infection, sexual activity, and unsafe sex. Analyses took into account stratification and clustering in the survey design and estimates were weighted to account for sampling probability. Results: Of 15,853 participants with blood samples, 1104 (6.9%) were HIV infected. Of these, 83.8% did not know their HIV status (56% had never tested; 27.8% reported their last HIV test was negative), and 80.4% were sexually active. Of 861 sexually active adults, 76.9% reported unsafe sex in the past year. Adults who did not know their HIV status were more likely to be sexually active [never tested adjusted odds ratio (AOR): 5.5, 95% confidence interval (CI): 2.8 to 10.7; ever tested, incorrect knowledge AOR: 6.5, CI: 2.1 to 19.6) and to report unsafe sex (never tested AOR: 51.7, CI: 27.3 to 97.6; ever tested, incorrect knowledge of status AOR: 18.6, CI: 8.6 to 40.5) than those who knew their status. Conclusions: The majority of adults did not know they were infected and engaged in unsafe sex. Adults who knew their HIV status were less likely to be sexually active and report unsafe sex compared with those unaware of their infection. HIV prevention interventions that target HIV-infected adults are urgently needed. C1 [Mwangi, Mary; Bunnell, Rebecca; Gichangi, Anthony; Makokha, Ernest; Mermin, Jonathan] Ctr Dis Control & Prevent, Nairobi, Kenya. [Nyoka, Raymond] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Kim, Andrea] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kichamu, George] Natl Coordinating Agcy Populat & Dev, Nairobi, Kenya. [Marum, Lawrence] Ctr Dis Control & Prevent, Lusaka, Zambia. [Ichwara, Jared] Kenya Natl Bur Stat, Nairobi, Kenya. RP Mwangi, M (reprint author), US Ctr Dis Control & Prevent, 606 00621 Village Market, Nairobi, Kenya. EM mmwangi@ke.cdc.gov RI Mermin, Jonathan/J-9847-2012 FU U.S. President's Emergency Plan for AIDS Relief (PEPFAR) FX Funded by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). NR 21 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2011 VL 58 IS 1 BP 80 EP 88 DI 10.1097/QAI.0b013e3182251001 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 816OA UT WOS:000294610600017 PM 21637108 ER PT J AU Williams, MR Savage, HM AF Williams, Martin R. Savage, Harry M. TI Development of Multiplexed Species Specific Polymerase Chain Reaction Assays for Identification of the Culex (Melanoconion) Species (Diptera: Culicidae) of the Southeastern United States Based on rDNA SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Culex (Melanoconion); internal transcribed spacer; multiplex polymerase chain reaction; mosquito identification ID NILE-VIRUS-INFECTION; EQUINE ENCEPHALOMYELITIS VIRUS; PIPIENS COMPLEX; CENTRAL ALABAMA; SHELBY COUNTY; MOSQUITOS; ENCEPHALITIS; MEMBERS; RATES AB Adult female mosquitoes within the subgenus Culex (Melanoconion) Theobald (Diptera: Culicidae) are difficult to identify to species using external morphological features. We present two multiplexed polymerase chain reaction assays that quickly and accurately identify specimens from the southeastern United States based on sequence differences in the internal transcribed spacers of the ribosomal DNA gene array. One assay identifies all species that occur only in Florida, whereas the second assay identifies species that may occur in other southeastern states. These assays require small amounts of DNA, such as DNA from two sonicated legs, or an individual specimen. These assays also may be run as multiple singleplex reactions to determine the mosquito species composition of virus-positive mosquito pools. Reaction volumes may be as low as 10 mu l, which reduces assay cost. C1 [Williams, Martin R.; Savage, Harry M.] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Savage, HM (reprint author), Ctr Dis Control & Prevent, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM hms1@cdc.gov NR 15 TC 1 Z9 1 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD SEP PY 2011 VL 48 IS 5 BP 961 EP 966 DI 10.1603/ME11081 PG 6 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 816FX UT WOS:000294585200001 PM 21936313 ER PT J AU Saiyasombat, R Bolling, BG Brault, AC Bartholomay, LC Blitvich, BJ AF Saiyasombat, Rungrat Bolling, Bethany G. Brault, Aaron C. Bartholomay, Lyric C. Blitvich, Bradley J. TI Evidence of Efficient Transovarial Transmission of Culex Flavivirus by Culex pipiens (Diptera: Culicidae) SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE flavivirus; Culex flavivirus; Culex pipiens; transovarial transmission; tissue tropisms ID TRANS-OVARIAL TRANSMISSION; WEST-NILE-VIRUS; LA-CROSSE VIRUS; NATURAL MOSQUITO POPULATION; INSECT-SPECIFIC FLAVIVIRUS; LOUIS ENCEPHALITIS-VIRUS; FUSING AGENT VIRUS; YELLOW-FEVER VIRUS; AEDES-TRISERIATUS; VERTICAL TRANSMISSION AB This study determined the transovarial transmission (TOT) potential and tissue tropisms of Culex flavivirus (CxFV), an insect-specific flavivirus, in Cider pipiens (L.). Several hundred mosquito egg rafts were collected in the field, transferred to the insectaries, reared to the fourth larval instar, and identified using morphological characteristics. Cx. pipiens were reared to adults, allowed to oviposit in individual containers, and tested for CxFV RNA by reverse transcription-polymerase chain reaction (RT-PCR) and nucleotide sequencing. Eighteen CxFV RNA-positive females were identified from 26 females that oviposited viable egg rafts. Thirty F(1) adults from each positive female were individually tested by RT-PCR for CxFV RNA. Viral RNA was detected in 526 of 540 progeny, and thus, the filial infection rate was 97.4%. Because all 18 positive females produced infected offspring, the TOT prevalence was 100%. These data indicated that efficient TOT of CxFV occurs in nature. To define the tissue tropisms of CxFV, different tissues (salivary glands, ovaries, testes, head, fat bodies, and midguts) were removed from the remainder of the F(1) and tested by RT-PCR for CxFV RNA. Viral RNA was detected in all tissues. Additionally, uninfected laboratory-colonized Cx. pipiens were infected with CxFV by needle inoculation, and ovaries were collected at 4, 6, 8, and 12 d postinoculation and tested for CxFV RNA by RT-PCR. Viral RNA was detected at all time points, demonstrating that CxFV infects the ovaries as early as 4 cl postinoculation. Surprisingly, however, we were unable to demonstrate transovarial transmission despite the presence of viral RNA in the ovaries. Nevertheless, the experiments performed with field-infected Cx. pipiens demonstrate that TOT is an efficient mechanism by which CxFV is maintained in mosquitoes in nature. C1 [Saiyasombat, Rungrat; Blitvich, Bradley J.] Iowa State Univ, Dept Vet Microbiol & Prevent Med, Coll Vet Med, Ames, IA 50011 USA. [Bolling, Bethany G.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Bartholomay, Lyric C.] Iowa State Univ, Dept Entomol, Coll Agr & Life Sci, Ames, IA 50011 USA. RP Blitvich, BJ (reprint author), Iowa State Univ, Dept Vet Microbiol & Prevent Med, Coll Vet Med, 2116 Vet Med, Ames, IA 50011 USA. EM blitvich@iastate.edu FU Center for Integrated Animal Genomics; Healthy Livestock Initiative at Iowa State University FX We thank Brianne Simonsen and Brendan Dunphy for mosquito rearing; Bradley Tucker and Patrick Jennings for mosquito identification; and Molly Staley, Cecile Mercado-Costa, Grishma Parikh, and Jon Oliver for technical assistance. This work was supported by intramurals grant provided by the Center for Integrated Animal Genomics and the Healthy Livestock Initiative at Iowa State University. NR 43 TC 35 Z9 37 U1 0 U2 10 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 J9 J MED ENTOMOL JI J. Med. Entomol. PD SEP PY 2011 VL 48 IS 5 BP 1031 EP 1038 DI 10.1603/ME11043 PG 8 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 816FX UT WOS:000294585200010 PM 21936322 ER PT J AU Waters, TR Dick, RB Krieg, EF AF Waters, Thomas R. Dick, Robert B. Krieg, Edward F. TI Trends in Work-Related Musculoskeletal Disorders A Comparison of Risk Factors for Symptoms Using Quality of Work Life Data From the 2002 and 2006 General Social Survey SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID LOW-BACK-PAIN; PSYCHOSOCIAL FACTORS AB Objective: To assess trends in risk factors for work-related musculoskeletal disorders (MSDs). Methods: Results from two similar national surveys (2002 and 2006) examined trends in relationships between individual, psychosocial, and physical factors and MSDs. Results: Findings between years were similar, but important differences included a stronger effect of "Work Stress" on "Pain in Arms," and a stronger combined effect of "Hand Movement" and "Work Stress" on "Pain in Arms." Also, two interactions were statistically significant in the 2006 data, but not in the 2002 data, revealing potentially increased risks. These were "Hand Movement" and "Work Stress" on "Back Pain," and "Heavy Lifting" and "Work Stress" on "Pain in Arms." Conclusion: New strategies for preventing both low back and upper extremity MSDs should focus on work stress, heavy lifting, and hand movement, individually and in combination. C1 [Waters, Thomas R.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Waters, TR (reprint author), NIOSH, Div Appl Res & Technol, Mail Stop C-24,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM TRW1@cdc.gov NR 15 TC 12 Z9 13 U1 2 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2011 VL 53 IS 9 BP 1013 EP 1024 DI 10.1097/JOM.0b013e3181fc8493 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 817ZC UT WOS:000294716100009 PM 21278598 ER PT J AU Ma, CC Burchfiel, CM Fekedulegn, D Andrew, ME Charles, LE Gu, JK Mnatsakanova, A Violanti, JM AF Ma, Claudia C. Burchfiel, Cecil M. Fekedulegn, Desta Andrew, Michael E. Charles, Luenda E. Gu, Ja K. Mnatsakanova, Anna Violanti, John M. TI Association of Shift Work With Physical Activity Among Police Officers The Buffalo Cardio-Metabolic Occupational Police Stress Study SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CARDIOVASCULAR-DISEASE; RISK; MORTALITY; CANCER; HEALTH; RECALL; COHORT; ADULTS AB Objective: To examine relations of shift work with occupational, sports, and household physical activity (PA) among police officers. Methods: Self-reported PA was assessed among 350 male and female officers (aged 27 to 66). Day, afternoon, or midnight shift was identified from daily payroll records. Results: Shift work was associated with prevalence of hard-intensity (occupational and sport) PA among men, and very hard-intensity sport PA among women, with afternoon workers reporting the highest prevalence. Shift work was independently associated with total hours of hard-intensity PA among men and very hard-intensity PA among women, with afternoon workers reporting the most hours. Conclusion: Results indicated that hard and very hard-intensity PA varied significantly across shifts with afternoon workers being the most active. C1 [Ma, Claudia C.; Burchfiel, Cecil M.; Fekedulegn, Desta; Andrew, Michael E.; Charles, Luenda E.; Gu, Ja K.; Mnatsakanova, Anna] NIOSH, HELD, BEB, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. RP Ma, CC (reprint author), NIOSH, HELD, BEB, Ctr Dis Control & Prevent, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM iia4@cdc.gov RI Charles, Luenda/H-6008-2011 FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), contract no. 200-2003-01580. NR 31 TC 8 Z9 8 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2011 VL 53 IS 9 BP 1030 EP 1036 DI 10.1097/JOM.0b013e31822589f9 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 817ZC UT WOS:000294716100011 PM 21866054 ER PT J AU Waters, TR Lu, ML Piacitelli, LA Werren, D Deddens, JA AF Waters, Thomas R. Lu, Ming-Lun Piacitelli, Laurie A. Werren, Dwight Deddens, James A. TI Efficacy of the Revised NIOSH Lifting Equation to Predict Risk of Low Back Pain Due to Manual Lifting Expanded Cross-Sectional Analysis SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID MUSCULOSKELETAL SYMPTOMS; PSYCHOSOCIAL FACTORS; PHYSICAL WORK; UNITED-STATES; PREVALENCE; DISORDERS; DISCOMFORT; EXPOSURE; RATIOS; INJURY AB Objective: To evaluate whether the Revised NIOSH Lifting Equation (RNLE) is a valid tool for assessing risk of low back pain (LBP) due to manual lifting by using combined data from two cross-sectional studies of 1-year prevalence. Methods: Results from a symptom and occupational history questionnaire and RNLE analysis for 677 subjects employed in 125 manual lifting jobs at nine industrial sites were combined from two studies. Results: The odds of LBP increased as the lifting index (LI) increased from 1.0 to 3.0. A statistically significant odds ratio (OR) was found for both the 1 < LI <= 2 (OR = 1.81) and the 2 < LI <= 3 categories (OR = 2.26). For jobs with an LI value greater than 3.0, however, the OR remained nonsignificant. The 2 < LI <= 3 group remained statistically significant after adjusting for age, gender, body mass index, and psychosocial factors. Conclusions: It is clear that as the LI increases, the risk of LBP increases. Longitudinal studies are needed. C1 [Waters, Thomas R.; Lu, Ming-Lun; Piacitelli, Laurie A.; Werren, Dwight; Deddens, James A.] NIOSH, Cincinnati, OH 45226 USA. RP Waters, TR (reprint author), NIOSH, C24,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM trw1@cdc.gov NR 34 TC 17 Z9 17 U1 4 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2011 VL 53 IS 9 BP 1061 EP 1067 DI 10.1097/JOM.0b013e31822cfe5e PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 817ZC UT WOS:000294716100015 PM 21866048 ER PT J AU Nakata, A Irie, M Takahashi, M AF Nakata, Akinori Irie, Masahiro Takahashi, Masaya TI Association of General Fatigue With Cellular Immune Indicators Among Healthy White-Collar Employees SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID PSYCHOSOCIAL WORK CHARACTERISTICS; TERM SICKNESS ABSENCE; ELECTRIC-POWER PLANT; AGED MALE WORKERS; PSYCHOLOGICAL DISTRESS; VITAL EXHAUSTION; MAASTRICHT COHORT; MYOCARDIAL-INFARCTION; JAPANESE WORKERS; INDUSTRIAL EMPLOYEES AB Objective: Although fatigue is a common complaint in the working population, underlying immunological mechanisms are not well understood. This study investigated the association of general fatigue with cellular immune indicators. Methods: A total of 148 healthy white-collar employees (70% men) underwent a blood draw for the measurement of natural killer (NK), B, and T cell counts as well as NK cell cytotoxicity (NKCC) and completed two different fatigue scales, that is, Profile of Mood State (POMS) and Maastricht Questionnaire (MQ). Results: Multiple linear regression analyses revealed that POMS fatigue score was significantly associated with decreases of NK cells (beta = -.407) and NKCC (beta = -.215), whereas MQ fatigue score was significantly associated with reduced NK cells (beta = -.290) but not with NKCC (beta = -.127). Conclusion: The results suggest that general fatigue may be related to impaired NK cell competency among healthy employees. C1 [Nakata, Akinori] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Irie, Masahiro] Kyushu Univ, Inst Hlth Sci, Fukuoka 812, Japan. [Takahashi, Masaya] NIOSH, Kawasaki, Kanagawa, Japan. RP Nakata, A (reprint author), NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, MS-C24,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM nakataa-tky@umin.ac.jp FU Japan National Institute of Occupational Safety and Health, Kawasaki, Japan FX This research was partly supported by the base funding of the Japan National Institute of Occupational Safety and Health, Kawasaki, Japan. NR 76 TC 2 Z9 3 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2011 VL 53 IS 9 BP 1078 EP 1086 DI 10.1097/JOM.0b013e318229a938 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 817ZC UT WOS:000294716100017 PM 21860327 ER PT J AU Wong, JB Coates, PM Russell, RM Dwyer, JT Schuttinga, JA Bowman, BA Peterson, SA AF Wong, John B. Coates, Paul M. Russell, Robert M. Dwyer, Johanna T. Schuttinga, James A. Bowman, Barbara A. Peterson, Sarah A. TI Economic analysis of nutrition interventions for chronic disease prevention: methods, research, and policy SO NUTRITION REVIEWS LA English DT Review DE cost-benefit analysis; medical economics; nutrition policy; nutrition therapy; primary prevention ID COST-EFFECTIVENESS ANALYSIS; FOLIC-ACID FORTIFICATION; POLYUNSATURATED FATTY-ACIDS; UNITED-STATES; HEALTH-CARE; MULTIMINERAL SUPPLEMENTS; MYOCARDIAL-INFARCTION; CONTROLLED-TRIAL; VITAMIN THERAPY; ADULTS AB Increased interest in the potential societal benefit of incorporating health economics as a part of clinical translational science, particularly nutrition interventions, led the Office of Dietary Supplements at the National Institutes of Health to sponsor a conference to address key questions about the economic analysis of nutrition interventions to enhance communication among health economic methodologists, researchers, reimbursement policy makers, and regulators. Issues discussed included the state of the science, such as what health economic methods are currently used to judge the burden of illness, interventions, or healthcare policies, and what new research methodologies are available or needed to address knowledge and methodological gaps or barriers. Research applications included existing evidence-based health economic research activities in nutrition that are ongoing or planned at federal agencies. International and US regulatory, policy, and clinical practice perspectives included a discussion of how research results can help regulators and policy makers within government make nutrition policy decisions, and how economics affects clinical guideline development. (C) 2011 International Life Sciences Institute C1 [Wong, John B.] Tufts Univ, Tufts Med Ctr, Sch Med, Div Clin Decis Making, Boston, MA 02111 USA. [Coates, Paul M.; Russell, Robert M.; Dwyer, Johanna T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Dwyer, Johanna T.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Dwyer, Johanna T.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. [Schuttinga, James A.] NIH, Div Program Coordinat Planning & Strateg Initiat, Bethesda, MD 20892 USA. [Bowman, Barbara A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Wong, JB (reprint author), Tufts Univ, Tufts Med Ctr, Sch Med, Div Clin Decis Making, 800 Washington St 302, Boston, MA 02111 USA. EM jwong@tuftsmedicalcenter.org OI Dwyer, Johanna/0000-0002-0783-1769 FU Office of Dietary Supplements; National Center for Complementary and Alternative Medicine; National Cancer Institute; National Institute for Nursing Research, National Institutes of Health FX The workshop was jointly sponsored by the Office of Dietary Supplements, the National Center for Complementary and Alternative Medicine, the National Cancer Institute, and the National Institute for Nursing Research, which belong to the National Institutes of Health. NR 53 TC 3 Z9 4 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0029-6643 J9 NUTR REV JI Nutr. Rev. PD SEP PY 2011 VL 69 IS 9 BP 533 EP 549 DI 10.1111/j.1753-4887.2011.00412.x PG 17 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 815TH UT WOS:000294551900004 PM 21884133 ER PT J AU Smith, SG Breiding, MJ AF Smith, S. G. Breiding, M. J. TI Chronic disease and health behaviours linked to experiences of non-consensual sex among women and men SO PUBLIC HEALTH LA English DT Article DE Sexual violence; Victimisation; BRFSS; Health behaviour; Chronic disease ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; GENERAL-POPULATION; ASSAULT HISTORY; LIFE-EVENTS; SOMATIC SYMPTOMS; RAPE VICTIMS; ALCOHOL-USE; ABUSE; OUTCOMES AB Objectives: Few studies have examined the association between non-consensual sex and health indicators for both women and men. The current study examined this relationship as part of a large public health survey that collected information on a range of health behaviours and health risks. Methods: The Behavioural Risk Factor Surveillance System (BRFSS) is an annual random-digit-dialled telephone survey providing surveillance of health behaviours and health risks among US adults. In 2005, an optional module on sexual violence was available for use at the discretion of each US state/territory. Over 115,000 respondents in 25 states/territories were administered the sexual violence module within the BRFSS. Logistic regression analyses were conducted from January to December 2008. Results: Among both women and men, previous non-consensual sex was associated with health conditions such as high cholesterol, stroke and heart disease, and risk behaviours such as human immunodeficiency virus risk factors, smoking and excessive drinking. Sexually victimized women were more likely to report having had a heart attack or heart disease than non-victims. Conclusions: The experience of non-consensual sex is associated with a number of chronic disease outcomes and risk factors. The development and implementation of effective sexual violence prevention strategies may reduce the risk of chronic conditions among persons who have experienced sexual victimisation. Published by Elsevier Ltd on behalf of The Royal Society for Public Health. C1 [Smith, S. G.; Breiding, M. J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Smith, SG (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ssmith4@cdc.gov NR 42 TC 7 Z9 8 U1 2 U2 14 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0033-3506 J9 PUBLIC HEALTH JI Public Health PD SEP PY 2011 VL 125 IS 9 BP 653 EP 659 DI 10.1016/j.puhe.2011.06.006 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816NE UT WOS:000294608100014 PM 21855097 ER PT J AU Harrison, KM Dean, HD AF Harrison, Kathleen McDavid Dean, Hazel D. TI USE OF DATA SYSTEMS TO ADDRESS SOCIAL DETERMINANTS OF HEALTH: A NEED TO DO MORE SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID VIRAL-HEPATITIS; GLOBAL HEALTH; DISEASE; INEQUALITIES; COLLECTION; HIV/AIDS; EQUITY; POLICY; RATES; HIV C1 [Harrison, Kathleen McDavid] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Hlth Equ, Off Director, Atlanta, GA 30333 USA. RP Harrison, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Hlth Equ, Off Director, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM Kzm2@cdc.gov NR 34 TC 8 Z9 8 U1 1 U2 5 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 SU 3 BP 1 EP 5 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BN UT WOS:000294573800001 PM 21836729 ER PT J AU Colbert, SJJ Harrison, KM AF Colbert, Sha Juan J. Harrison, Kathleen McDavid TI Reflections from the CDC 2010 Health Equity Symposium SO PUBLIC HEALTH REPORTS LA English DT Editorial Material C1 [Colbert, Sha Juan J.; Harrison, Kathleen McDavid] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Harrison, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM kzm2@cdc.gov NR 10 TC 2 Z9 2 U1 0 U2 0 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 SU 3 BP 38 EP 40 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BN UT WOS:000294573800008 PM 21836736 ER PT J AU Beltran, VM Harrison, KM Hall, HI Dean, HD AF Beltran, Victoria M. Harrison, Kathleen McDavid Hall, H. Irene Dean, Hazel D. TI Collection of Social Determinant of Health Measures in U.S. National Surveillance Systems for HIV, Viral Hepatitis, STDs, and TB SO PUBLIC HEALTH REPORTS LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; DISPARITIES GEOCODING PROJECT; AFRICAN-AMERICAN COMMUNITIES; UNITED-STATES; PUBLIC-HEALTH; SOCIOECONOMIC-STATUS; STRUCTURAL FACTORS; LIFE EXPECTANCY; VIRUS-INFECTION; RISK-FACTORS AB Challenges exist in the study of social determinants of health (SDH) because of limited comparability of population-based U.S. data on SDH. This limitation is due to differences in disparity or equity measurements, as well as general data quality and availability. We reviewed the current SDH variables collected for HIV, viral hepatitis, sexually transmitted diseases, and tuberculosis at the Centers for Disease Control and Prevention through its population-based surveillance systems and assessed specific system attributes. Results were used to provide recommendations for a core set of SDH variables to collect that are both feasible and useful. We also conducted an environmental literature scan to determine the status of knowledge of SDH as underlying causes of disease and to inform the recommended core set of SDH variables. C1 [Beltran, Victoria M.; Harrison, Kathleen McDavid; Dean, Hazel D.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Hlth Equ, Off Director, Atlanta, GA 30333 USA. [Hall, H. Irene] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, HIV Incidence & Case Surveillance Branch, Atlanta, GA 30333 USA. RP Harrison, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Hlth Equ, Off Director, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM kzm2@cdc.gov NR 118 TC 17 Z9 18 U1 2 U2 9 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 SU 3 BP 41 EP 53 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BN UT WOS:000294573800009 PM 21836737 ER PT J AU Song, RG Hall, HI Harrison, KM Sharpe, TT Lin, LLS Dean, HD AF Song, Ruiguang Hall, H. Irene Harrison, Kathleen McDavid Sharpe, Tanya Telfair Lin, Lillian S. Dean, Hazel D. TI Identifying the Impact of Social Determinants of Health on Disease Rates Using Correlation Analysis of Area-Based Summary Information SO PUBLIC HEALTH REPORTS LA English DT Article ID DISPARITIES GEOCODING PROJECT; SOCIOECONOMIC MEASURES; INEQUALITIES; US; EQUITY AB Objectives. We developed a statistical tool that brings together standard, accessible, and well-understood analytic approaches and uses area-based information and other publicly available data to identify social determinants of health (SDH) that significantly affect the morbidity of a specific disease. Methods. We specified AIDS as the disease of interest and used data from the American Community Survey and the National HIV Surveillance System. Morbidity and socioeconomic variables in the two data systems were linked through geographic areas that can be identified in both systems. Correlation and partial correlation coefficients were used to measure the impact of socioeconomic factors on AIDS diagnosis rates in certain geographic areas. Results. We developed an easily explained approach that can be used by a data analyst with access to publicly available datasets and standard statistical software to identify the impact of SDH. We found that the AIDS diagnosis rate was highly correlated with the distribution of race/ethnicity, population density, and marital status in an area. The impact of poverty, education level, and unemployment depended on other SDH variables. Conclusions. Area-based measures of socioeconomic variables can be used to identify risk factors associated with a disease of interest. When correlation analysis is used to identify risk factors, potential confounding from other variables must be taken into account. C1 [Song, Ruiguang; Hall, H. Irene; Lin, Lillian S.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Harrison, Kathleen McDavid; Sharpe, Tanya Telfair] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Hlth Equ, Atlanta, GA 30333 USA. [Dean, Hazel D.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, Atlanta, GA 30333 USA. RP Song, RG (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-48, Atlanta, GA 30333 USA. EM RSong@cdc.gov NR 26 TC 16 Z9 16 U1 1 U2 8 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 SU 3 BP 70 EP 80 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BN UT WOS:000294573800012 PM 21836740 ER PT J AU Sutton, MY Hardnett, FP Wright, P Wai, S Pathak, S Warren-Jeanpiere, L Jones, S AF Sutton, Madeline Y. Hardnett, Felicia P. Wright, Pierre Wai, Sagina Pathak, Sonal Warren-Jeanpiere, Lari Jones, Sandra TI HIV/AIDS Knowledge Scores and Perceptions of Risk Among African American Students Attending Historically Black Colleges and Universities SO PUBLIC HEALTH REPORTS LA English DT Article ID TESTING BELIEF INVENTORY; HIV RISK; PREVENTIVE BEHAVIOR; SEXUAL-BEHAVIOR; CONDOM USE; WOMEN; PREVALENCE; TRANSMISSION; PERSPECTIVES; PREDICTORS AB Objective. African American young adults are disproportionately affected by the HIV/AIDS epidemic and often unaware of their personal risk for HIV. Historically black colleges and universities (HBCUs) enroll 25% of college-educated African American young adults and can play an important role in HIV prevention. We examined HIV/AIDS knowledge of students at HBCUs to inform and strengthen our HIV prevention efforts at HBCUs. Methods. African American undergraduate HBCU students completed online surveys assessing HIV/AIDS knowledge and behaviors, and we analyzed data to assess their knowledge and behaviors. Results. A total of 1,051 of 1,230 surveys completed (85.4%) were analyzable. Eighty-two percent of students had average/high HIV knowledge scores. Seventy-nine percent of students surveyed perceived themselves to be at low risk for HIV infection; 64% of those who had at least two or more sex partners had not used a condom at last sex encounter. In the final model, significant independent effects were identified for average/high knowledge of HIV risk, including agreeing with assessing a potential partner's HIV risk by all of the five actions listed (adjusted odds ratio [AOR] = 2.7, 95% confidence interval [CI] 1.7, 4.3) and never using a needle to inject drugs (AOR=5.6, 95% CI 3.2, 9.7). Conclusions. Educating students about effectively assessing sex partner risk will improve HIV knowledge and prevention efforts at HBCUs. C1 [Sutton, Madeline Y.; Hardnett, Felicia P.; Warren-Jeanpiere, Lari] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Wright, Pierre; Wai, Sagina] United Negro Coll Fund Special Programs Corp, Falls Church, VA USA. [Pathak, Sonal] Northrop Grumman Corp, Informat Technol, Atlanta, GA USA. [Jones, Sandra] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Sutton, MY (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,MS E-45, Atlanta, GA 30333 USA. EM zxa3@cdc.gov NR 50 TC 19 Z9 19 U1 4 U2 8 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 IS 5 BP 653 EP 663 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BM UT WOS:000294573700008 PM 21886325 ER PT J AU Nannini, A Lazar, J Berg, C Barger, M Tomashek, K Cabral, H Barfield, W Kotelchuck, M AF Nannini, Angela Lazar, Jane Berg, Cynthia Barger, Mary Tomashek, Kay Cabral, Howard Barfield, Wanda Kotelchuck, Milton TI Rates of Hospital Visits for Assault During Pregnancy and the Year Postpartum: Timing Matters SO PUBLIC HEALTH REPORTS LA English DT Article ID INTIMATE PARTNER VIOLENCE; DOMESTIC VIOLENCE; PRECONCEPTION CARE; UNITED-STATES; HEALTH-CARE; WOMEN; PREVALENCE AB Objective. To clarify the risk of violence for women during pregnancy and the first year postpartum, we examined the timing of hospital visits for assault among a population cohort of women in Massachusetts. Methods. Using linked natality and hospital data from 2001 through 2007 for Massachusetts, we examined the timing of hospital (i.e., emergency, inpatient, and observation) visits for maternal assault during seven time periods: the three prenatal trimesters and four three-month postpartum periods. To describe the risk of assault for each of the time periods, we calculated the rate as the number of such visits per 100,000 person-weeks. We used the denominator of 100,000 person-weeks to adjust for variable lengths of gestation and for postpartum periods shortened by subsequent pregnancies. Results. Rates of hospital visits for maternal assault were highest in the first trimester and lowest in the third trimester, with rates of 16.0 and 5.8 per 100,000 person-weeks, respectively. The four postpartum period rates were higher than the third trimester rate but never reached the levels observed in the first and second trimesters. Conclusions. These findings suggest a changing rate for assault visits during each prenatal trimester and postpartum period. In addition, the importance of violence prevention strategies as part of women's health care across the life span and the need for preconception care initiatives are reaffirmed. C1 [Nannini, Angela] Univ Massachusetts, Dept Nursing, Lowell, MA 01854 USA. [Lazar, Jane] Northeastern Univ, Bouve Coll Hlth Sci, Sch Nursing, Boston, MA 02115 USA. [Berg, Cynthia; Barfield, Wanda] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Barger, Mary] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Tomashek, Kay] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Dengue Branch, San Juan, PR USA. [Cabral, Howard] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Kotelchuck, Milton] Harvard Univ, Sch Med, Boston, MA USA. RP Nannini, A (reprint author), Univ Massachusetts, Dept Nursing, 3 Solomont Way, Lowell, MA 01854 USA. EM angela_nannini@uml.edu FU Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC) [200-2006-M-15729]; Massachusetts Pregnancy to Early Life Longitudinal Database, Association of Schools of Public Health/CDC [S3485-23/24] FX This study was supported by the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC) contract #200-2006-M-15729 and the Massachusetts Pregnancy to Early Life Longitudinal Database, Association of Schools of Public Health/CDC #S3485-23/24. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of CDC. NR 24 TC 2 Z9 3 U1 1 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 IS 5 BP 664 EP 668 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BM UT WOS:000294573700009 PM 21886326 ER PT J AU Bloss, E Holtz, TH Jereb, J Redd, JT Podewils, LJ Cheek, JE McCray, E AF Bloss, Emily Holtz, Timothy H. Jereb, John Redd, John T. Podewils, Laura Jean Cheek, James E. McCray, Eugene TI Tuberculosis in Indigenous Peoples in the U.S., 2003-2008 SO PUBLIC HEALTH REPORTS LA English DT Article ID DIRECTLY OBSERVED THERAPY; UNITED-STATES; SOCIAL DETERMINANTS; DIABETES PREVALENCE; AMERICAN-INDIANS; ALASKA-NATIVES; PUBLIC-HEALTH; RACE/ETHNICITY; POPULATION; TRENDS AB Objectives. We examined trends and epidemiology of tuberculosis (TB) across racial/ethnic groups to better understand TB disparities in the United States, with particular focus on American Indians/Alaska Natives (AI/ANs) and Native Hawaiians/other Pacific Islanders (NH/PIs). Methods. We analyzed cases in the U.S. National Tuberculosis Surveillance System and calculated TB case rates among all racial/ethnic groups from 2003 to 2008. Socioeconomic and health indicators for counties in which TB cases were reported came from the Health Resources and Services Administration Area Resource File. Results. Among the 82,836 TB cases, 914(1.1%) were in AI/ANs and 362 (0.4%) were in NH/PIs. In 2008, TB case rates for AI/ANs and NH/PIs were 5.9 and 14.7 per 100,000 population, respectively, rates that were more than five and 13 times greater than for non-Hispanic white people (1.1 per 100,000 population). From 2003 to 2008, AI/ANs had the largest percentage decline in TB case rates (-27.4%) for any racial/ethnic group, but NH/PIs had the smallest percentage decline (-3.5%). AI/ANs were more likely than other racial/ethnic groups to be homeless, excessively use alcohol, receive totally directly observed therapy, and come from counties with a greater proportion of people living in poverty and without health insurance. A greater proportion of NH/PIs had extrapulmonary disease and came from counties with a higher proportion of people with a high school diploma. Conclusions. There is a need to develop flexible TB-control strategies that address the social determinants of health and that are tailored to the specific needs of AI/ANs and NH/PIs in the U.S. C1 [Bloss, Emily; Holtz, Timothy H.; Podewils, Laura Jean; McCray, Eugene] Ctr Dis Control & Prevent, Div TB Eliminat, Int Res & Programs Branch, Atlanta, GA 30333 USA. [Holtz, Timothy H.] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand. [Jereb, John] Ctr Dis Control & Prevent, Div TB Eliminat, Field Serv & Evaluat Branch, Atlanta, GA 30333 USA. [Redd, John T.; Cheek, James E.] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Albuquerque, NM USA. RP Bloss, E (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Int Res & Programs Branch, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM dpu2@cdc.gov NR 50 TC 12 Z9 12 U1 0 U2 5 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 IS 5 BP 677 EP 689 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BM UT WOS:000294573700011 PM 21886328 ER PT J AU Lowther, SA Miramontes, R Navara, B Sabuwala, N Brueshaber, M Solarz, S Haddad, MB Sodt, D Lynfield, R AF Lowther, Sara A. Miramontes, Roque Navara, Barbara Sabuwala, Nadya Brueshaber, Milayna Solarz, Sarah Haddad, Maryam B. Sodt, Deborah Lynfield, Ruth TI Outbreak of Tuberculosis Among Guatemalan Immigrants in Rural Minnesota, 2008 SO PUBLIC HEALTH REPORTS LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; UNITED-STATES; FOREIGN-BORN; COMMUNITY; COUNTY AB Objectives. We described the outbreak investigation and control measures after the Minnesota Department of Health identified a cluster of tuberculosis (TB) cases among Guatemalan immigrants within three rural Minnesota counties in August 2008. Methods. TB cases were diagnosed by tuberculin skin test followed by chest radiography and sputum testing for Mycobacterium tuberculosis (M. tuberculosis). We reviewed medical records, interviewed patients, and completed a contact investigation for each infectious case. We used isolate genotyping to confirm epidemiologic links between cases. Results. The index case was a six-month-old U.S.-born male with Guatemalan parents. Although he experienced four months of cough and fever, TB was not considered at two medical visits but was diagnosed upon hospitalization in May 2008. The presumed source of infection was a Guatemalan male aged 25 years who sang in a band that practiced in the infant's house and whose pulmonary TB was diagnosed at hospitalization in June 2008, despite his having sought medical attention for symptoms seven months earlier. Among the 16 identified TB cases, 14 were outbreak-related. Three genetically distinct M. tuberculosis strains circulated. Of 150 contacts of the singer, 62 (41%) had latent TB infection and 13 (9%), including 10 children, had TB disease. Conclusions. In this outbreak, delayed diagnoses contributed to M. tuberculosis transmission. Isolate genotyping corroborated the social links between outbreak-related patients. More timely diagnosis of TB among immigrants and their children can prevent TB transmission among communities in rural, low-incidence areas that might have limited resources for contact investigations. C1 [Lowther, Sara A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Lowther, Sara A.; Sabuwala, Nadya; Brueshaber, Milayna; Solarz, Sarah; Sodt, Deborah; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Miramontes, Roque; Haddad, Maryam B.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Navara, Barbara] Nobles Rock Community Hlth Serv, Worthington, MN USA. RP Lowther, SA (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS E-05, Atlanta, GA 30333 USA. EM SGL6@cdc.gov FU Nobles-Rock Community Health Services; Watonwan County Public Health Department; Minnesota Department of Health; Centers for Disease Control and Prevention (CDC) FX The investigation was conducted with the input, advice, support, and collaboration of Nobles-Rock Community Health Services, the Watonwan County Public Health Department, the Minnesota Department of Health, and the Centers for Disease Control and Prevention (CDC). NR 20 TC 3 Z9 3 U1 0 U2 4 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2011 VL 126 IS 5 BP 726 EP 732 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816BM UT WOS:000294573700016 PM 21886333 ER PT J AU Teeguarden, JG Calafat, AM Ye, XY Doerge, DR Churchwell, MI Gunawan, R Graham, MK AF Teeguarden, Justin G. Calafat, Antonia M. Ye, Xiaoyum Doerge, Daniel R. Churchwell, Mona I. Gunawan, Rudy Graham, Morgan K. TI Twenty-Four Hour Human Urine and Serum Profiles of Bisphenol A during High-Dietary Exposure SO TOXICOLOGICAL SCIENCES LA English DT Article DE bisphenol A; pharmacokinetics; exposure; biomonitoring; endocrine disruptors; urine; serum ID SPRAGUE-DAWLEY RATS; MASS-SPECTROMETRIC DETERMINATION; HPLC-MS/MS METHOD; LIQUID-CHROMATOGRAPHY; ENVIRONMENTAL PHENOLS; BLOOD-VISCOSITY; WATER-INTAKE; MONKEYS; PHARMACOKINETICS; DISPOSITION AB By virtue of its binding to steroid hormone receptors, bisphenol A (BPA, the unconjugated bioactive monomer) is hypothesized to be estrogenic when present in sufficient quantities in the body, raising concerns that widespread exposure to BPA may impact human health. To better understand the internal exposure of adult humans to BPA and the relationship between the serum and urinary pharmacokinetics of BPA, a clinical exposure study was conducted. Blood and urine samples were collected approximately hourly over a 24-h period from 20 adult volunteers who ingested 100% of one of three specified meals comprising standard grocery store food items for breakfast, lunch, and dinner. The volunteers' average consumption of BPA, estimated from the urinary excretion of total BPA ((TOT)BPA = conjugated BPA + BPA), was 0.27 mu g/kg body weight (range, 0.03-0.86), 21% greater than the 95th percentile of aggregate exposure in the adult U.S. population. A serum time course of (TOT)BPA was observable only in individuals with exposures 1.3-3.9 times higher than the 95th percentile of aggregate U.S. exposure. The (TOT)BPA urine concentration T(max) was 2.75 h (range, 0.75-5.75 h) post-meal, lagging the serum concentration T(max) by similar to 1 h. Serum (TOT)BPA area under the curve per unit BPA exposure was between 21.5 and 79.0 nM center dot h center dot kg/mu g BPA. Serum (TOT)BPA concentrations ranged from less than or equal to limit of detection (LOD, 1.3 nM) to 5.7 nM and were, on average, 42 times lower than urine concentrations. During these high dietary exposures, (TOT)BPA concentrations in serum were undetectable in 83% of the 320 samples collected and BPA concentrations were determined to be less than or equal to LOD in all samples. C1 [Teeguarden, Justin G.; Gunawan, Rudy; Graham, Morgan K.] Pacific NW Natl Lab, Richland, WA 99352 USA. [Calafat, Antonia M.; Ye, Xiaoyum] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Doerge, Daniel R.; Churchwell, Mona I.] US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA. RP Teeguarden, JG (reprint author), Pacific NW Natl Lab, 902 Battelle Blvd, Richland, WA 99352 USA. EM justin.teeguarden@pnl.gov OI Teeguarden, Justin/0000-0003-3817-4391 FU U.S. Enivronmental Protection Agency (EPA) [R83386701] FX U.S. Enivronmental Protection Agency (EPA), through STAR grant (R83386701). NR 36 TC 111 Z9 112 U1 1 U2 54 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD SEP PY 2011 VL 123 IS 1 BP 48 EP 57 DI 10.1093/toxsci/kfr160 PG 10 WC Toxicology SC Toxicology GA 815VG UT WOS:000294557500005 PM 21705716 ER PT J AU Woskie, SR Kim, H Freund, A Stevenson, L Park, BY Baron, S Herbert, R de Hernandez, MS Teitelbaum, S de la Hoz, RE Wisnivesky, JP Landrigan, P AF Woskie, Susan R. Kim, Hyun Freund, Alice Stevenson, Lori Park, Bo Y. Baron, Sherry Herbert, Robin de Hernandez, Micki Siegel Teitelbaum, Susan de la Hoz, Rafael E. Wisnivesky, Juan P. Landrigan, Phillip TI World Trade Center Disaster: Assessment of Responder Occupations, Work Locations, and Job Tasks SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE World Trade Center; WTC; 9/11; emergency responder; disaster; task; exposure; exposure assessment; emergency planning; occupational health ID HEALTH; PROGRAM; ISSUES AB Background To date there have been no comprehensive reports of the work performed by 9/11 World Trade Center responders. Methods 18,969 responders enrolled in the WTC Medical Monitoring and Treatment Program were used to describe workers' pre-9/11 occupations, WTC work activities and locations from September 11, 2001 to June 2002. Results The most common pre-9/11 occupation was protective services (47%); other common occupations included construction, telecommunications, transportation, and support services workers. 14% served as volunteers. Almost one-half began work on 9/11 and >80% reported working on or adjacent to the "pile'' at Ground Zero. Initially, the most common activity was search and rescue but subsequently, the activities of most responders related to their pre-9/11 occupations. Other major activities included security; personnel support; buildings and grounds cleaning; and telecommunications repair. Conclusions The spatial, temporal, occupational, and task-related taxonomy reported here will aid the development of a job-exposure matrix, assist in assessment of disease risk, and improve planning and training for responders in future urban disasters. Am. J. Ind. Med. 54:681-695, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Woskie, Susan R.] Univ Massachusetts, Dept Work Environm, Lowell, MA USA. [Kim, Hyun; Freund, Alice; Stevenson, Lori; Park, Bo Y.; Herbert, Robin; Teitelbaum, Susan; de la Hoz, Rafael E.; Wisnivesky, Juan P.; Landrigan, Phillip] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Kim, Hyun; Freund, Alice; Stevenson, Lori; Park, Bo Y.; Herbert, Robin; Teitelbaum, Susan; de la Hoz, Rafael E.; Wisnivesky, Juan P.; Landrigan, Phillip] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA. [Baron, Sherry] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [de Hernandez, Micki Siegel] AFL CIO, New York, NY USA. RP Woskie, SR (reprint author), 1 Univ Ave, Lowell, MA 01854 USA. EM susan_woskie@uml.edu OI de la Hoz, Rafael E./0000-0002-8949-9279 FU Centers for Disease Control and NIOSH [UIO 0H008232, U10 OH008225, U10 OH008239, U10OH008275, U10 OH008216, U10 OH008223]; Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health (CDC/NIOSH) [200-2002-0038] FX Contract grant sponsor: Centers for Disease Control and NIOSH; Contract grant numbers: UIO 0H008232; U10 OH008225; U10 OH008239; U10OH008275; U10 OH008216; U10 OH008223;; Contract grant sponsor: Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health (CDC/NIOSH); Contract grant number: 200-2002-0038. NR 17 TC 1 Z9 1 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD SEP PY 2011 VL 54 IS 9 SI SI BP 681 EP 695 DI 10.1002/ajim.20997 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 813IQ UT WOS:000294360500004 PM 23236634 ER PT J AU Lamont, RF Nhan-Chang, CL Sobel, JD Workowski, K Conde-Agudelo, A Romero, R AF Lamont, Ronald F. Nhan-Chang, Chia-Ling Sobel, Jack D. Workowski, Kimberly Conde-Agudelo, Agustin Romero, Roberto TI Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Review DE antibiotic; bacterial vaginosis; clindamycin; late miscarriage; preterm birth ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; INFLAMMATORY RESPONSE SYNDROME; GROUP-B STREPTOCOCCUS; TUMOR-NECROSIS-FACTOR; ASYMPTOMATIC BACTERIAL VAGINOSIS; ULTRASONOGRAPHIC CERVICAL LENGTH; DISEASES TREATMENT GUIDELINES; AMNIOTIC-FLUID INFECTION; GENITAL-TRACT FLORA AB The purpose of this study was to determine whether the administration of clindamycin to women with abnormal vaginal flora at < 22 weeks of gestation reduces the risk of preterm birth and late miscarriage. We conducted a systematic review and metaanalysis of randomized controlled trials of the early administration of clindamycin to women with abnormal vaginal flora at < 22 weeks of gestation. Five trials that comprised 2346 women were included. Clindamycin that was administered at < 22 weeks of gestation was associated with a significantly reduced risk of preterm birth at < 37 weeks of gestation and late miscarriage. There were no overall differences in the risk of preterm birth at < 33 weeks of gestation, low birthweight, very low birthweight, admission to neonatal intensive care unit, stillbirth, peripartum infection, and adverse effects. Clindamycin in early pregnancy in women with abnormal vaginal flora reduces the risk of spontaneous preterm birth at < 37 weeks of gestation and late miscarriage. There is evidence to justify further randomized controlled trials of clindamycin for the prevention of preterm birth. However, a deeper understanding of the vaginal microbiome, mucosal immunity, and the biology of bacterial vaginosis will be needed to inform the design of such trials. C1 [Lamont, Ronald F.; Nhan-Chang, Chia-Ling; Conde-Agudelo, Agustin; Romero, Roberto] Wayne State Univ, Perinatol Res Branch, NICHD, NIH,DHHS,Hutzel Womens Hosp, Detroit, MI 48201 USA. [Lamont, Ronald F.; Nhan-Chang, Chia-Ling; Conde-Agudelo, Agustin; Romero, Roberto] NICHD, Perinatol Res Branch, NIH, DHHS, Bethesda, MD USA. [Lamont, Ronald F.; Nhan-Chang, Chia-Ling] Wayne State Univ, Dept Obstet & Gynecol, Hutzel Hosp, Detroit, MI 48201 USA. [Sobel, Jack D.] Wayne State Univ, Dept Infect Dis, Hutzel Hosp, Detroit, MI 48201 USA. [Workowski, Kimberly] Emory Univ, Atlanta, GA 30322 USA. [Workowski, Kimberly] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Romero, R (reprint author), Wayne State Univ, Perinatol Res Branch, NICHD, NIH,DHHS,Hutzel Womens Hosp, 3990 John R,Box 4, Detroit, MI 48201 USA. EM prbchiefstaff@med.wayne.edu FU Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services FX Supported in part by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services. NR 175 TC 56 Z9 59 U1 1 U2 14 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2011 VL 205 IS 3 BP 177 EP 190 DI 10.1016/j.ajog.2011.03.047 PG 14 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 812YF UT WOS:000294330000016 PM 22071048 ER PT J AU Broussard, CS Rasmussen, SA Friedman, JM AF Broussard, Cheryl S. Rasmussen, Sonja A. Friedman, Jan M. TI Maternal treatment with opioid analgesics and risk for birth defects: additional considerations REPLY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Broussard, Cheryl S.; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Friedman, Jan M.] Child & Family Res Inst, Vancouver, BC, Canada. RP Broussard, CS (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM cbroussard@cdc.gov NR 4 TC 1 Z9 1 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2011 VL 205 IS 3 BP E12 EP E13 DI 10.1016/j.ajog.2011.04.027 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 812YF UT WOS:000294330000011 ER PT J AU Broussard, CS Reefhuis, J Honein, MA AF Broussard, Cheryl S. Reefhuis, Jennita Honein, Margaret A. TI Maternal treatment with opioid analgesics and risk for birth defects REPLY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter ID RECALL C1 [Broussard, Cheryl S.; Reefhuis, Jennita; Honein, Margaret A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Broussard, CS (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM cbroussard@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2011 VL 205 IS 3 BP E10 EP E11 DI 10.1016/j.ajog.2011.06.029 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 812YF UT WOS:000294330000009 ER PT J AU Schwartzman, K Cain, KP AF Schwartzman, Kevin Cain, Kevin P. TI Caveat Emptor? Control of Latent Tuberculosis Infection in the United States SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID MOLECULAR EPIDEMIOLOGY; RISK-FACTORS; POPULATION C1 [Schwartzman, Kevin] McGill Univ, Div Resp, Montreal, PQ, Canada. [Schwartzman, Kevin] McGill Univ, Resp Epidemiol & Clin Res Unit, Montreal, PQ, Canada. [Cain, Kevin P.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Schwartzman, K (reprint author), McGill Univ, Div Resp, Montreal, PQ, Canada. NR 10 TC 0 Z9 0 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 1 PY 2011 VL 184 IS 5 BP 501 EP 502 DI 10.1164/rccm.201107-1241ED PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 814ST UT WOS:000294478200007 PM 21885633 ER PT J AU Logan, J Hall, J Karch, D AF Logan, Joseph Hall, Jeffrey Karch, Debra TI Suicide Categories by Patterns of Known Risk Factors A Latent Class Analysis SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID DEATH REPORTING SYSTEM; LIFE EVENTS; ALCOHOL DEPENDENCE; SEVERE DEPRESSION; PHYSICAL ILLNESS; MENTAL-DISORDERS; DRUG-ABUSE; GENDER; STATES; SURVEILLANCE AB Context: Multiple risk factors contribute to suicides; however, patterns of co-occurrence among these factors have not been fully identified. Objectives: To assess patterns of known suicide-related risk factors, classify suicide decedents by these patterns, track class proportions during a 6-year period, and characterize decedents across the classes to help focus prevention strategies. Design, Setting, and Participants: Latent class analysis was conducted using 2003-2008 data from the National Violent Death Reporting System. The population included 28 703 suicide decedents from 12 US states. Main Outcome Measures: The known risk factors included having the following: mental health conditions; a sad or depressed mood; substance abuse problems; medical problems; recent crises; financial, job, and legal problems; intimate partner and other relationship problems; and perpetrated interpersonal violence. Results: Nine distinct patterns of risk factors emerged. Of these classes, 1 only endorsed mental health-related factors and 1 only endorsed alcohol- and substance abuse-related factors; however, 7 classes of decedents had distinct patterns of factors that spanned multiple domains. For example, 5 of these classes had mental health factors with other risks (eg, substance abuse, financial problems, relationship problems, a recent crisis, and medical problems). Two classes had recent crises with relationship problems; one of these classes also had high probabilities for criminal problems and interpersonal violence. Class proportions differed during the 6 years. Differences across classes by demographic and event characteristics were also found. Conclusions: Most suicide decedents could be classified by patterns of risk factors. Furthermore, most classes revealed a need for more connected services across medical, mental health/substance abuse, and court/social service systems. Reducing fragmentation across these agencies and recruiting family, friend, and community support for individuals experiencing mental health problems and/or other stress might significantly reduce suicides. C1 [Logan, Joseph; Hall, Jeffrey; Karch, Debra] Ctr Dis Control & Prevent, Div Violence Prevent, Etiol & Surveillance Branch, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Logan, J (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Etiol & Surveillance Branch, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,MS-F63, Atlanta, GA 30341 USA. EM ffa3@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 42 TC 35 Z9 36 U1 1 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD SEP PY 2011 VL 68 IS 9 BP 935 EP 941 PG 7 WC Psychiatry SC Psychiatry GA 815OU UT WOS:000294535700009 PM 21893660 ER PT J AU Stokley, S Cohn, A Jain, N McCauley, MM AF Stokley, Shannon Cohn, Amanda Jain, Nidhi McCauley, Mary M. TI Compliance With Recommendations and Opportunities for Vaccination at Ages 11 to 12 Years Evaluation of the 2009 National Immunization Survey-Teen SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; UNITED-STATES; ADOLESCENT IMMUNIZATIONS; COVERAGE; PREVENTION AB Objectives: To determine vaccination coverage at selected ages and by birth cohort and to assess whether all indicated vaccines were administered during vaccination visits. Design: Population-based cross-sectional study. Setting: National Immunization Survey-Teen 2009 telephone interview. Participants: United States adolescents aged 13 to 17 years with provider-reported vaccination histories (N=20 066). Main Outcome Measures: Among all adolescents and by birth cohort: coverage estimates for 3 childhood vaccines (measles-containing, hepatitis B, and varicella) and 3 adolescent vaccines (tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis, meningococcal-containing, and human papillomavirus for girls) at selected ages. Results: By age 11 years, most adolescents had obtained the childhood vaccines. Receipt of a tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis vaccine at ages 11 to 12 years increased significantly from the 1991 to 1996 birth cohort (33.8% vs 68.2%, P < .001); receipt of meningococcal-containing vaccine at ages 11 to 12 years increased significantly from the 1993 to 1996 birth cohort (8.4% vs 50.0%, P < .001). Among girls, receipt of human papillomavirus vaccine at ages 11 to 12 years increased significantly from the 1994 to 1996 birth cohort (11.1% vs 30.5%, P < .001). Overall, 54.9% of adolescents received at least 1 vaccination visit at ages 11 to 12 years. Among adolescents who made a vaccination visit at ages 11 to 12 years and were eligible for vaccination, 19.5% did not receive tetanus-diphtheria and/or tetanus-diphtheria-acellular pertussis, 60.9% did not receive meningococcal-containing, and 62.4% did not receive human papillomavirus vaccines. Conclusions: Receipt of vaccines at the recommended ages of 11 to 12 years appears to be increasing; however, providers often do not administer all indicated vaccines during a vaccination visit. C1 [Stokley, Shannon] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Cohn, Amanda] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [McCauley, Mary M.] Ctr Dis Control & Prevent, Off Director, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Jain, Nidhi] Hlth Resources & Serv Adm, Off Reg Operat, San Francisco, CA USA. RP Stokley, S (reprint author), 1600 Clifton Rd,Mail Stop A-19, Atlanta, GA 30333 USA. EM sstokley@cdc.gov NR 24 TC 12 Z9 12 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD SEP PY 2011 VL 165 IS 9 BP 813 EP 818 PG 6 WC Pediatrics SC Pediatrics GA 815PI UT WOS:000294537100007 PM 21893647 ER PT J AU Patel, RS Al Mheid, I Morris, AA Ahmed, Y Kavtaradze, N Ali, S Dabhadkar, K Brigham, K Hooper, WC Alexander, RW Jones, DP Quyyumi, AA AF Patel, Riyaz S. Al Mheid, Ibhar Morris, Alanna A. Ahmed, Yusuf Kavtaradze, Nino Ali, Sarfraz Dabhadkar, Kaustubh Brigham, Kenneth Hooper, W. Craig Alexander, R. Wayne Jones, Dean P. Quyyumi, Arshed A. TI Oxidative stress is associated with impaired arterial elasticity SO ATHEROSCLEROSIS LA English DT Article DE Oxidative stress; Arterial stiffness; Vascular function; Inflammation; Aging ID PULSE PRESSURE AMPLIFICATION; CORONARY-HEART-DISEASE; ENDOTHELIAL FUNCTION; HEALTHY-ADULTS; VITAMIN-C; STIFFNESS; INFLAMMATION; GLUTATHIONE; HYPERTENSION; DYSFUNCTION AB Aims: Arterial stiffening may lead to hypertension, greater left ventricular after-load and adverse clinical outcomes. The underlying mechanisms influencing arterial elasticity may involve oxidative injury to the vessel wall. We sought to examine the relationship between novel markers of oxidative stress and arterial elastic properties in healthy humans. Methods and results: We studied 169 subjects (mean age 42.6 +/- 14 years, 51.6% male) free of traditional cardiovascular risk factors. Indices of arterial stiffness and wave reflections measured included carotid-femoral Pulse Wave Velocity (PWV), Augmentation Index (Aix) and Pulse Pressure Amplification (PPA). Non-free radical oxidative stress was assessed as plasma oxidized and reduced amino-thiol levels (cysteine/cystine, glutathione/GSSG) and their ratios (redox potentials), and free radical oxidative stress as derivatives of reactive oxygen metabolites (dROMs). Inflammation was assessed as hsCRP and interleukin-6 levels. The non-free radical marker of oxidative stress, cystine was significantly correlated with all arterial indices; PWV (r = 0.38, p < 0.001), Aix (r = 0.35, p < 0.001) and PPA (r = -0.30, p < 0.001). Its redox potential, was also associated with PWV (r = 0.22, p = 0.01), while the free radical marker of oxidative stress dROMS was associated with Aix (r = 0.25, p < 0.01). After multivariate adjustment for age, gender, arterial pressure, height, weight, heart rate and CRP, of these oxidative stress markers, only cystine remained independently associated with PWV (p = 0.03), Aix (p = 0.01) and PPA (p = 0.05). Conclusions: In healthy subjects without confounding risk factors or significant systemic inflammation, a high cystine level, reflecting extracellular oxidant burden, is associated with increased arterial stiffness and wave reflections. This has implications for understanding the role of oxidant burden in pre-clinical vascular dysfunction. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Patel, Riyaz S.; Al Mheid, Ibhar; Morris, Alanna A.; Ahmed, Yusuf; Kavtaradze, Nino; Ali, Sarfraz; Dabhadkar, Kaustubh; Brigham, Kenneth; Alexander, R. Wayne; Jones, Dean P.; Quyyumi, Arshed A.] Emory Univ, Sch Med, Atlanta, GA USA. [Patel, Riyaz S.] Cardiff Univ, Cardiff, S Glam, Wales. [Hooper, W. Craig] CDC, Atlanta, GA 30333 USA. RP Quyyumi, AA (reprint author), Emory Univ Hosp, 1364 Clifton Rd,4th Floor,Suite D403C, Atlanta, GA 30322 USA. EM aquyyum@emory.edu FU American Heart Association; Robert W. Woodruff Health Sciences Center; Emory Predictive Health Institute; NIH (Atlanta Clinical Translational Science Institute) [UL1 RR025008]; NIH [ES011195, P01ES016731, R01AG038746] FX This work was supported by the American Heart Association (Postdoctoral Fellowship for RSP), Robert W. Woodruff Health Sciences Center Fund, the Emory Predictive Health Institute and supported in part by NIH Grant UL1 RR025008 from the Clinical and Translational Science Award program (Atlanta Clinical Translational Science Institute). DPJ was supported in part by NIH Grants ES011195, P01ES016731, R01AG038746. NR 37 TC 46 Z9 49 U1 1 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD SEP PY 2011 VL 218 IS 1 BP 90 EP 95 DI 10.1016/j.atherosclerosis.2011.04.033 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 814RU UT WOS:000294475600015 PM 21605864 ER PT J AU Johnson, BW Kosoy, O Wang, E Delorey, M Russell, B Bowen, RA Weaver, SC AF Johnson, B. W. Kosoy, O. Wang, E. Delorey, M. Russell, B. Bowen, R. A. Weaver, S. C. TI Use of Sindbis/Eastern Equine Encephalitis Chimeric Viruses in Plaque Reduction Neutralization Tests for Arboviral Disease Diagnostics SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID EMBRYO CELL CULTURE; EASTERN; NORTH AB Eastern equine encephalitis virus (EEEV) is a highly virulent, mosquito-borne alphavirus that causes severe and often fatal neurological disease in humans and horses in eastern North American, the Caribbean, and Mexico and throughout Central and South America. EEEV infection is diagnosed serologically by anti-EEEV-specific IgM detection, with confirmation by the plaque reduction neutralization test (PRNT), which is highly specific for alphaviruses. Live virus is used in the PRNT procedure, which currently requires biosafety level 3 containment facilities and select agent security in the case of EEEV. These requirements restrict the ability of public health laboratories to conduct PRNTs. Sindbis virus (SINV)/EEEV recombinant constructs have been engineered to express the immunogenic structural proteins from 2 wild-type EEEV strains in an attenuated form. These SINV/EEEVs, which are not classified as select agents, were evaluated as alternative diagnostic reagents in a PRNT using human, equine, and murine sera. The results indicate that the chimeric viruses exhibit specificity comparable to that of wild-type EEEV, with only a slight reduction in sensitivity. Considering their benefits in increased safety and reduced regulatory requirements, these chimeric viruses should be highly useful in diagnostic laboratories throughout the Americas. C1 [Johnson, B. W.; Kosoy, O.; Delorey, M.; Russell, B.] Ctr Dis Control & Prevent, Diagnost & Reference Lab, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Wang, E.; Weaver, S. C.] Univ Texas Med Branch, Inst Human Infect & Immun, Ctr Biodef & Emerging Infect Dis, Galveston, TX USA. [Wang, E.; Weaver, S. C.] Univ Texas Med Branch, Dept Pathol, Galveston, TX USA. [Bowen, R. A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. RP Johnson, BW (reprint author), Ctr Dis Control & Prevent, Diagnost & Reference Lab, Arboviral Dis Branch, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM bfj9@cdc.gov RI Weaver, Scott/D-6490-2011 FU National Institute of Allergy and Infectious Diseases (NIAID) through the Western Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, National Institutes of Health (NIH) [U54 AIO57156] FX This work was supported by a grant from the National Institute of Allergy and Infectious Diseases (NIAID) through the Western Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, National Institutes of Health (NIH) grant U54 AIO57156. NR 19 TC 5 Z9 6 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD SEP PY 2011 VL 18 IS 9 BP 1486 EP 1491 DI 10.1128/CVI.05129-11 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 814LA UT WOS:000294452800015 PM 21752946 ER PT J AU Nayak, AP Green, BJ Janotka, E Hettick, JM Friend, S Vesper, SJ Schmechel, D Beezhold, DH AF Nayak, Ajay P. Green, Brett J. Janotka, Erika Hettick, Justin M. Friend, Sherri Vesper, Steve J. Schmechel, Detlef Beezhold, Donald H. TI Monoclonal Antibodies to Hyphal Exoantigens Derived from the Opportunistic Pathogen Aspergillus terreus SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID INVASIVE PULMONARY ASPERGILLOSIS; STACHYBOTRYS-CHARTARUM; DELAYED-HYPERSENSITIVITY; FUMIGATUS ANTIGEN; HEMOLYTIC TOXIN; AMPHOTERICIN-B; SINGLE PROTEIN; ASP-HEMOLYSIN; PURIFICATION; INFECTION AB Aspergillus terreus has been difficult to identify in cases of aspergillosis, and clinical identification has been restricted to the broad identification of aspergillosis lesions in affected organs or the detection of fungal carbohydrates. As a result, there is a clinical need to identify species-specific biomarkers that can be used to detect invasive A. terreus disease. Monoclonal antibodies (MAbs) were developed to a partially purified preparation of cytolytic hyphal exoantigens (HEA) derived from A. terreus culture supernatant (CSN). Twenty-three IgG1 isotype murine MAbs were developed and tested for cross-reactivity against hyphal extracts of 54 fungal species. Sixteen MAbs were shown to be specific for A. terreus. HEA were detected in conidia, hyphae, and in CSN of A. terreus. HEA were expressed in high levels in the hyphae during early stages of A. terreus growth at 37 degrees C, whereas at room temperature the expression of HEA peaked by days 4 to 5. Expression kinetics of HEA in CSN showed a lag, with peak levels at later time points at room temperature and 37 degrees C than in hyphal extracts. Serum spiking experiments demonstrated that human serum components do not inhibit detection of the HEA epitopes by MAb enzyme-linked immunosorbent assay (ELISA). Immunoprecipitation and proteomic analysis demonstrated that MAbs 13E11 and 12C4 immunoprecipitated a putative uncharacterized leucine aminopeptidase (Q0CAZ7), while MAb 19B2 recognized a putative dipeptidyl-peptidase V (DPP5). Studies using confocal laser scanning microscopy showed that the uncharacterized leucine aminopeptidase mostly localized to extracellular matrix structures while dipeptidyl-peptidase V was mostly confined to the cytoplasm. C1 [Nayak, Ajay P.; Green, Brett J.; Janotka, Erika; Hettick, Justin M.; Schmechel, Detlef; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Nayak, Ajay P.] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA. [Friend, Sherri] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Vesper, Steve J.] US EPA, Microbial Exposure Res Branch, Microbiol & Chem Exposure Assessment Res Div, Natl Exposure Res Lab,Off Res & Dev, Cincinnati, OH 45268 USA. RP Nayak, AP (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM fyg1@cdc.gov RI Hettick, Justin/E-9955-2010 FU National Institute of Environmental Health Sciences [Y1-ES0001-06] FX This work was supported in part by an interagency agreement with the National Institute of Environmental Health Sciences (Y1-ES0001-06). NR 74 TC 6 Z9 6 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD SEP PY 2011 VL 18 IS 9 BP 1568 EP 1576 DI 10.1128/CVI.05163-11 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 814LA UT WOS:000294452800027 PM 21734068 ER PT J AU Kleerekoper, M Schleicher, RL Eisman, J Bouillon, R Singh, RJ Holick, MF AF Kleerekoper, Michael Schleicher, Rosemary L. Eisman, John Bouillon, Roger Singh, Ravinder J. Holick, Michael F. TI Clinical Applications for Vitamin D Assays: What Is Known and What Is Wished for SO CLINICAL CHEMISTRY LA English DT Editorial Material C1 [Kleerekoper, Michael] Wayne State Univ, St John River Dist Hosp, E China, MI 48054 USA. [Schleicher, Rosemary L.] Ctr Dis Control & Prevent, Nutr Biomarkers Lab, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Eisman, John] Univ New S Wales, Sydney, NSW, Australia. [Eisman, John] St Vincents Hosp, Sydney, NSW 2010, Australia. [Eisman, John] Garvan Inst Med Res, Osteoporosis & Bone Biol Res Program, Sydney, NSW, Australia. [Bouillon, Roger] Katholieke Univ Leuven, Expt Med & Endocrinol Sect, Louvain, Belgium. [Singh, Ravinder J.] Mayo Clin, Dept Lab Med & Pathol, Endocrine Lab, Rochester, MN USA. [Holick, Michael F.] Boston Univ, Sch Med, Gen Clin Res Ctr, Boston, MA 02118 USA. RP Kleerekoper, M (reprint author), Wayne State Univ, St John River Dist Hosp, 4014 S River Rd,Bldg 2B, E China, MI 48054 USA. EM mkleerekoper@med.wayne.edu RI Eisman, John/C-2886-2014; OI Holick, Michael/0000-0001-6023-9062 NR 0 TC 11 Z9 11 U1 0 U2 9 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD SEP PY 2011 VL 57 IS 9 BP 1227 EP 1232 DI 10.1373/clinchem.2010.154997 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 812JE UT WOS:000294288500004 PM 21502313 ER PT J AU Llata, E Blossom, DB Khoury, HJ Rao, CY Wannemuehler, KA Noble-Wang, J Langston, AA Ribner, BS Lyon, GM Arnold, KE Jackson, DR Brandt, ME Chiller, TM Balajee, SA Srinivasan, A Magill, SS AF Llata, Eloisa Blossom, David B. Khoury, H. Jean Rao, Carol Y. Wannemuehler, Kathleen A. Noble-Wang, Judith Langston, Amelia A. Ribner, Bruce S. Lyon, G. Marshall Arnold, Kathryn E. Jackson, Deonne R. Brandt, Mary E. Chiller, Tom M. Balajee, S. Arunmozhi Srinivasan, Arjun Magill, Shelley S. TI A cluster of mucormycosis infections in hematology patients: challenges in investigation and control of invasive mold infections in high-risk patient populations SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Zygomycosis; Mucormycosis; Outbreak; Fungal infection ID CELL TRANSPLANT RECIPIENTS; WOODEN TONGUE DEPRESSORS; CARE CANCER CENTER; FUNGAL-INFECTIONS; BREAKTHROUGH ZYGOMYCOSIS; RECEIVING VORICONAZOLE; RHIZOPUS-MICROSPORUS; OUTBREAK; ASPERGILLOSIS; EPIDEMIOLOGY AB Mucormycosis has been reported to be occurring more frequently in hematopoietic stem cell transplant (HSCT) recipients in recent years. We investigated a hospital cluster of mucormycosis cases among patients with hematologic disorders. Case-patients were identified through hospital microbiology and pathology database searches and compared to randomly selected controls matched on underlying disease and hospital discharge date using conditional logistic regression. Environmental assessments, including collection of samples for fungal cultures, were performed. Of 11 case-patients, 6 (55%) had acute myelogenous leukemia and 3 (27%) were allogeneic HSCT recipients. Five case-patients (45%) died. In univariate analysis, case-patients were more likely than controls to have refractory hematologic disease (odds ratio [OR], 13.75; 95% confidence interval [Cl], 1.31-689); neutropenia >14 days (OR, 11.50; 95% Cl, 1.27-558) or to have received voriconazole prophylaxis (OR, 11.26; 95% Cl, 1.11-infinity). A point source was not identified. Factors such as underlying disease state and antifungal prophylaxis type may identify hematology patients at highest risk for mucormycosis. Our investigation highlighted critical knowledge gaps, including strain typing methods, the role of the hospital environment in mucormycosis outbreaks, and hospital environmental infection control measures most likely to reduce exposure of immunosuppressed persons to mucormycetes. Published by Elsevier Inc. C1 [Llata, Eloisa; Blossom, David B.; Rao, Carol Y.; Noble-Wang, Judith; Srinivasan, Arjun] Ctr Dis Control & Prevent CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Llata, Eloisa; Blossom, David B.] CDC, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Khoury, H. Jean; Langston, Amelia A.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30303 USA. [Wannemuehler, Kathleen A.; Brandt, Mary E.; Chiller, Tom M.; Balajee, S. Arunmozhi; Magill, Shelley S.] CDC, Mycot Dis Branch, Atlanta, GA 30333 USA. [Ribner, Bruce S.; Lyon, G. Marshall] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30303 USA. [Arnold, Kathryn E.] Georgia Div Publ Hlth, Atlanta, GA 30303 USA. [Jackson, Deonne R.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30303 USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. EM smagill@cdc.gov FU Office of Workforce and Career Development, Centers for Disease Control and Prevention; Schering-Plough; Astellas; Merck; Pfizer FX Financial support. Office of Workforce and Career Development, Centers for Disease Control and Prevention.; Potential conflicts of interest: A.A.L. has served on advisory boards for Schering-Plough and has participated in clinical research trials sponsored by Schering-Plough and Astellas. G.M.L. has received research support from Astellas, Merck, and Pfizer; has received honoraria from Astellas, Schering-Plough, and Wyeth; and has consulted for Astellas and Merck. S.S.M. consulted for and received grant support from Pfizer and received an honorarium from Astellas, before commencing employment at the Centers for Disease Control and Prevention. All other authors: no conflict. NR 32 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD SEP PY 2011 VL 71 IS 1 BP 72 EP 80 DI 10.1016/j.diagmicrobio.2010.12.022 PG 9 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 812SV UT WOS:000294314100011 PM 21851872 ER PT J AU Belser, JA Katz, JM Tumpey, TM AF Belser, Jessica A. Katz, Jacqueline M. Tumpey, Terrence M. TI The ferret as a model organism to study influenza A virus infection SO DISEASE MODELS & MECHANISMS LA English DT Article ID H5N1 VIRUSES; RECEPTOR SPECIFICITY; SEASONAL INFLUENZA; TRANSMISSION MODEL; ANIMAL-MODELS; GUINEA-PIG; PATHOGENESIS; HUMANS; MICE; IMMUNITY AB Influenza is a human pathogen that continues to pose a public health threat. The use of small mammalian models has become indispensable for understanding the virulence of influenza viruses. Among numerous species used in the laboratory setting, only the ferret model is equally well suited for studying both the pathogenicity and transmissibility of human and avian influenza viruses. Here, we compare the advantages and limitations of the mouse, ferret and guinea pig models for research with influenza A viruses, emphasizing the multifarious uses of the ferret in the assessment of influenza viruses with pandemic potential. Research performed in the ferret model has provided information, support and guidance for the public health response to influenza viruses in humans. We highlight the recent and emerging uses of this species in influenza virus research that are advancing our understanding of virus-host interactions. C1 [Belser, Jessica A.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tft9@cdc.gov NR 58 TC 123 Z9 124 U1 2 U2 16 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 1754-8403 J9 DIS MODEL MECH JI Dis. Model. Mech. PD SEP PY 2011 VL 4 IS 5 BP 575 EP 579 DI 10.1242/dmm.007823 PG 5 WC Cell Biology; Pathology SC Cell Biology; Pathology GA 813ZZ UT WOS:000294411800004 PM 21810904 ER PT J AU Watkins, DJ McClean, MD Fraser, AJ Weinberg, J Stapleton, HM Sjodin, A Webster, TF AF Watkins, Deborah J. McClean, Michael D. Fraser, Alicia J. Weinberg, Janice Stapleton, Heather M. Sjoedin, Andreas Webster, Thomas F. TI Exposure to PBDEs in the Office Environment: Evaluating the Relationships Between Dust, Handwipes, and Serum SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE dust; flame retardants; handwipes; indoor exposure; office; PBDEs ID POLYBROMINATED DIPHENYL ETHERS; BROMINATED FLAME RETARDANTS; IN-HOUSE DUST; INDOOR ENVIRONMENTS; UNITED-STATES; BREAST-MILK AB BACKGROUND: Polybrominated diphenyl ethers (PBDEs) have been widely used as flame retardants in consumer products and are ubiquitous in residential indoor air and dust. However, little is known about exposure in the office environment. OBJECTIVES: We examined relationships between PBDE concentrations in the office environment and internal exposure using concurrent measurements of PBDEs in serum, handwipes, and office dust. METHODS: We collected serum, dust, and handwipe samples from 31 participants who spent at least 20 hr/week in an office. We used a questionnaire to collect information about work and personal habits. RESULTS: We found positive associations between PBDEs in room dust, handwipes (a measure of personal exposure), and serum. PBDE office dust concentrations were weakly correlated with measurements in handwipes: r = 0.35 (p = 0.06) for pentaBDE (sum of BDE congeners 28/33, 47, 99, 100, and 153) and 0.33 (p = 0.07) for BDE-209. Hand washing also predicted pentaBDE levels in handwipes: low hand-washers had 3.3 times the pentaBDE levels in their handwipes than did high hand-washers (p = 0.02). PentaBDE in handwipes predicted pentaBDE levels in serum (p = 0.03): Serum concentrations in the highest handwipe tertile were on average 3.5 times the lowest handwipe tertile. The geometric mean concentration of pentaBDEs in serum was 27 ng/g lipid. We detected BDE-209 in 20% of serum samples, at levels ranging from < 4.8 to 9.7 ng/g lipid. CONCLUSION: Our research suggests that exposure to pentaBDE in the office environment contributes to pentaBDE body burden, with exposure likely linked to PBDE residues on hands. In addition, hand washing may decrease exposure to PBDEs. C1 [Watkins, Deborah J.; McClean, Michael D.; Fraser, Alicia J.; Webster, Thomas F.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02130 USA. [Weinberg, Janice] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02130 USA. [Stapleton, Heather M.] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA. [Sjoedin, Andreas] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Watkins, DJ (reprint author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St,Talbot 4 W, Boston, MA 02130 USA. EM debw@bu.edu RI Sjodin, Andreas/F-2464-2010; McClean, Michael/J-2934-2015; OI McClean, Michael/0000-0002-3902-8823 FU National Institute of Environmental Health Sciences [R01ES015829, T32ES014562] FX This work was supported by grants from the National Institute of Environmental Health Sciences (R01ES015829 and T32ES014562). NR 36 TC 77 Z9 82 U1 6 U2 79 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD SEP PY 2011 VL 119 IS 9 BP 1247 EP 1252 DI 10.1289/ehp.1003271 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 814SV UT WOS:000294478400024 PM 21715243 ER PT J AU Freeman, LEB Rusiecki, JA Hoppin, JA Lubin, JH Koutros, S Andreotti, G Zahm, SH Hines, CJ Coble, JB Barone-Adesi, F Sloan, J Sandler, DP Blair, A Alavanja, MCR AF Freeman, Laura E. Beane Rusiecki, Jennifer A. Hoppin, Jane A. Lubin, Jay H. Koutros, Stella Andreotti, Gabriella Zahm, Shelia Hoar Hines, Cynthia J. Coble, Joseph B. Barone-Adesi, Francesco Sloan, Jennifer Sandler, Dale P. Blair, Aaron Alavanja, Michael C. R. TI Atrazine and Cancer Incidence Among Pesticide Applicators in the Agricultural Health Study (1994-2007) SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE agriculture; atrazine; cancer; cohort study; epidemiology; pesticide ID NON-HODGKINS-LYMPHOMA; HERBICIDE MANUFACTURING WORKERS; RISK-FACTORS; TRIAZINE HERBICIDES; PUBERTAL DEVELOPMENT; THYROID-FUNCTION; WISTAR RATS; EXPOSURE; BREAST; MEN AB BACKGROUND: Atrazine is a triazine herbicide used widely in the United States. Although it is an animal carcinogen, the mechanism in rodents does not appear to operate in humans. Few epidemiologic studies have provided evidence for an association. METHODS: The Agricultural Health Study (AHS) is a prospective cohort that includes 57,310 licensed pesticide applicators. In this report, we extend a previous AHS analysis of cancer risk associated with self-reported atrazine use with six additional years of follow-up and more than twice as many cancer cases. Using Poisson regression, we calculated relative risk estimates and 95% confidence intervals for lifetime use of atrazine and intensity-weighted lifetime days, which accounts for factors that impact exposure. RESULTS: Overall, 36,357 (68%) of applicators reported using atrazine, among whom there were 3,146 cancer cases. There was no increase among atrazine users in overall cancer risk or at most cancer sites in the higher exposure categories compared with the lowest. Based on 29 exposed cases of thyroid cancer, there was a statistically significant risk in the second and fourth quartiles of intensity-weighted lifetime days. There was a similar pattern for lifetime days, but neither the risk estimates nor the trend were statistically significant and for neither metric was the trend monotonic. CONCLUSIONS: Overall, there was no consistent evidence of an association between atrazine use and any cancer site. There was a suggestion of increased risk of thyroid cancer, but these results are based on relatively small numbers and minimal supporting evidence. C1 [Freeman, Laura E. Beane] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Rusiecki, Jennifer A.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Hoppin, Jane A.; Sandler, Dale P.] NIEHS, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Hines, Cynthia J.] NIOSH, Cincinnati, OH 45226 USA. RP Freeman, LEB (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, 6120 Execut Blvd,Room 8112,MSC 7240, Bethesda, MD 20892 USA. EM freemala@mail.nih.gov RI Zahm, Shelia/B-5025-2015; OI Sandler, Dale/0000-0002-6776-0018 FU National Institutes of Health (National Cancer Institute, National Institute of Environmental Health Sciences) [Z01 CP010119, Z01ES049030] FX This study was supported by funds from the Intramural Research Program of the National Institutes of Health (National Cancer Institute Z01 CP010119 and National Institute of Environmental Health Sciences Z01ES049030). NR 52 TC 33 Z9 33 U1 8 U2 53 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD SEP PY 2011 VL 119 IS 9 BP 1253 EP 1259 DI 10.1289/ehp.1103561 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 814SV UT WOS:000294478400025 PM 21622085 ER PT J AU Riojas-Rodriguez, H Schilmann, A Marron-Mares, AT Masera, O Li, Z Romanoff, L Sjodin, A Rojas-Bracho, L Needham, LL Romieu, I AF Riojas-Rodriguez, Horacio Schilmann, Astrid Teresa Marron-Mares, Adriana Masera, Omar Li, Zheng Romanoff, Lovisa Sjoedin, Andreas Rojas-Bracho, Leonora Needham, Larry L. Romieu, Isabelle TI Impact of the Improved Patsari Biomass Stove on Urinary Polycyclic Aromatic Hydrocarbon Biomarkers and Carbon Monoxide Exposures in Rural Mexican Women SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE biomarker of exposure; biomass smoke; carbon monoxide; improved stove; Mexico; polycyclic aromatic hydrocarbons; women ID INDOOR AIR-POLLUTION; US POPULATION; OCCUPATIONAL-EXPOSURE; PARTICULATE MATTER; METABOLITES; WOOD; 1-HYDROXYPYRENE; GUIDELINES; HOUSEHOLDS; GUATEMALA AB BACKGROUND: Cooking with biomass fuels on open fires results in exposure to health-damaging pollutants such as carbon monoxide (CO), polycyclic aromatic hydrocarbons (PAHs), and particulate matter. OBJECTIVE: We compared CO exposures and urinary PAH biomarkers pre- and post-intervention with an improved biomass stove, the Patsari stove. METHODS: In a sub-sample of 63 women participating in a randomized controlled trial in central Mexico, we measured personal CO exposure for 8 hr during the day using continuous monitors and passive samplers. In addition, first-morning urine samples obtained the next day were analyzed for mono-hydroxylated PAH metabolites by gas chromatography/isotope dilution/high-resolution mass spectrometry. Exposure data were collected during the use of an open fire (preintervention) and after installation of the improved stove (post-intervention) for 47 women, enabling paired comparisons. RESULTS: Median pre- and post-intervention values were 4 and 1 ppm for continuous personal CO and 3 and 1 ppm for passive sampler CO, respectively. Postintervention measurements indicated an average reduction of 42% for hydroxylated metabolites of naphthalene, fluorene, phenanthrene, and pyrene on a whole-weight concentration basis (micrograms per liter of urine), and a 34% reduction on a creatinine-adjusted basis (micrograms per gram of creatinine). Pre- and post-intervention geometric mean values for 1-hydroxypyrene were 3.2 and 2.0 mu g/g creatinine, respectively. CONCLUSION: Use of the Patsari stove significantly reduced CO and PAH exposures in women. However, levels of many PAH biomarkers remained higher than those reported among smokers. C1 [Romieu, Isabelle] Int Agcy Res Canc, F-69372 Lyon 08, France. [Riojas-Rodriguez, Horacio; Schilmann, Astrid; Teresa Marron-Mares, Adriana] Natl Inst Publ Hlth, Dept Environm Hlth, Cuernavaca, Morelos, Mexico. [Masera, Omar] Univ Nacl Autonoma Mexico, Ecosyst Res Ctr, Morelia, Michoacan, Mexico. [Masera, Omar] Interdisciplinary Grp Appropriate Rural Technol, Morelia, Michoacan, Mexico. [Li, Zheng; Romanoff, Lovisa; Sjoedin, Andreas; Needham, Larry L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Rojas-Bracho, Leonora] Natl Inst Ecol, Mexico City, DF, Mexico. RP Romieu, I (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France. EM romieui@iarc.fr RI Sjodin, Andreas/F-2464-2010 FU Shell Foundation [20965]; Comision Federal para la Proteccion contra Riesgos Sanitarios; CDC FX This work was supported by the CDC, Shell Foundation (grant 20965), and Comision Federal para la Proteccion contra Riesgos Sanitarios. NR 35 TC 29 Z9 29 U1 1 U2 26 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD SEP PY 2011 VL 119 IS 9 BP 1301 EP 1307 DI 10.1289/ehp.1002927 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 814SV UT WOS:000294478400032 PM 21622083 ER PT J AU Korrick, SA Lee, MM Williams, PL Sergeyev, O Burns, JS Patterson, DG Turner, WE Needham, LL Altshul, L Revich, B Hauser, R AF Korrick, Susan A. Lee, Mary M. Williams, Paige L. Sergeyev, Oleg Burns, Jane S. Patterson, Donald G., Jr. Turner, Wayman E. Needham, Larry L. Altshul, Larisa Revich, Boris Hauser, Russ TI Dioxin Exposure and Age of Pubertal Onset among Russian Boys SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE children; dioxins; furans; growth; PCBs; polychlorinated biphenyls; pubertal stage; puberty; testicular volume ID SECONDARY SEXUAL CHARACTERISTICS; BLOOD LEAD LEVELS; NUTRITION EXAMINATION SURVEY; TOXIC EQUIVALENCY FACTORS; POLYCHLORINATED-BIPHENYLS; HUMAN-SERUM; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ORGANOCHLORINE PESTICIDES; ENDOCRINE DISRUPTORS; LACTATIONAL EXPOSURE AB BACKGROUND: Animal data demonstrate associations of dioxin, furan, and polychlorinated biphenyl (PCB) exposures with altered male gonadal maturation. It is unclear whether these associations apply to human populations. OBJECTIVES: We investigated the association of dioxins, furans, PCBs, and corresponding toxic equivalent (TEQ) concentrations with pubertal onset among boys in a dioxin-contaminated region. METHODS: Between 2003 and 2005, 499 boys 8-9 years of age were enrolled in a longitudinal study in Chapaevsk, Russia. Pubertal onset [stage 2 or higher for genitalia (G2+) or testicular volume (TV) > 3 mL] was assessed annually between ages 8 and 12 years. Serum levels at enrollment were analyzed by the Centers for Disease Control and Prevention, Atlanta, Georgia, USA. We used Cox proportional hazards models to assess age at pubertal onset as a function of exposure adjusted for potential confounders. We conducted sensitivity analyses excluding boys with pubertal onset at enrollment. RESULTS: The median (range) total serum TEQ concentration was 21 (4-175) pg/g lipid, approximately three times higher than values in European children. At enrollment, boys were generally healthy and normal weight (mean body mass index, 15.9 kg/m(2)), with 30% having entered puberty by G2+ and 14% by TV criteria. Higher dioxin TEQs were associated with later pubertal onset by TV (hazard ratio = 0.68, 95% confidence interval, 0.49-0.95 for the highest compared with the lowest quartile). Similar associations were observed for 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin concentrations for TV but not G2+. Results were robust to sensitivity analyses. CONCLUSIONS: Findings support an association of higher peripubertal serum dioxin TEQs and concentrations with later male pubertal onset reflected in delayed testicular maturation. C1 [Korrick, Susan A.; Turner, Wayman E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA 02115 USA. [Korrick, Susan A.; Burns, Jane S.; Altshul, Larisa; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Lee, Mary M.] Univ Massachusetts, Sch Med, Dept Pediat, Pediat Endocrine Div, Worcester, MA USA. [Lee, Mary M.] Univ Massachusetts, Sch Med, Dept Cell Biol, Pediat Endocrine Div, Worcester, MA 01655 USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Sergeyev, Oleg] Samara State Med Univ, Dept Phys Educ & Hlth, Samara, Russia. [Sergeyev, Oleg] Chapaevsk Med Assoc, Chapaevsk, Russia. [Patterson, Donald G., Jr.; Needham, Larry L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Patterson, Donald G., Jr.] Axys Analyt Solut, Sidney, BC, Canada. [Patterson, Donald G., Jr.] FMS, Boston, MA USA. [Patterson, Donald G., Jr.] Exponent Inc, Maynard, MA USA. [Patterson, Donald G., Jr.] EnviroSolut Consulting Inc, Auburn, GA USA. [Turner, Wayman E.] Ctr Dis Control & Prevent Fdn, Atlanta, GA USA. [Altshul, Larisa] Environm Hlth & Engn Inc, Needham, MA USA. [Revich, Boris] Russian Acad Sci, Ctr Demog & Human Ecol, Moscow, Russia. [Revich, Boris] Russian Acad Sci, Inst Forecasting, Moscow, Russia. [Hauser, Russ] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv,Androl Lab, Boston, MA 02115 USA. [Hauser, Russ] Harvard Univ, Sch Med, Massachusetts Gen Hosp, In Vitro Fertilizat Unit, Boston, MA 02115 USA. RP Korrick, SA (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, 181 Longwood Ave, Boston, MA 02115 USA. EM susan.korrick@channing.harvard.edu RI Sergeyev, Oleg/H-8854-2013; OI Sergeyev, Oleg/0000-0002-5745-3348; Lee, Mary/0000-0002-7204-4884 FU U.S. Environmental Protection Agency (EPA) [R82943701]; National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS) [ES014370, ES000002] FX This work was funded by U.S. Environmental Protection Agency (EPA) grant R82943701 and National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS) grants ES014370 and ES000002. M.M.L. is a member of the University of Massachusetts Diabetes and Endocrine Research Center (DK32520). NR 50 TC 18 Z9 18 U1 5 U2 16 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD SEP PY 2011 VL 119 IS 9 BP 1339 EP 1344 DI 10.1289/ehp.1003102 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 814SV UT WOS:000294478400038 PM 21527364 ER PT J AU Bhalla, V Georgiopoulou, VV Azeem, AA Marti, CN Cole, RT Laskar, SR De Staercke, C Hooper, WC Smith, AL Kalogeropoulos, AP Butler, J AF Bhalla, Vikas Georgiopoulou, Vasiliki V. Azeem, Ali A. Marti, Catherine N. Cole, Robert T. Laskar, Sonjoy R. De Staercke, Christine Hooper, W. Craig Smith, Andrew L. Kalogeropoulos, Andreas P. Butler, Javed TI Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Letter DE Heart failure; Matrix metalloproteinases; Outcomes; Tissue inhibitor of metalloproteinases ID DILATED CARDIOMYOPATHY; EXPRESSION; PROGNOSIS; MARKERS; UPDATE; RISK C1 [Bhalla, Vikas; Georgiopoulou, Vasiliki V.; Azeem, Ali A.; Marti, Catherine N.; Cole, Robert T.; Laskar, Sonjoy R.; Smith, Andrew L.; Kalogeropoulos, Andreas P.; Butler, Javed] Emory Univ, Atlanta, GA 30322 USA. [De Staercke, Christine; Hooper, W. Craig] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Butler, J (reprint author), Emory Univ Hosp, Ctr Heart Failure Therapy, 1462 Clifton Rd NE,Suite 504, Atlanta, GA 30322 USA. EM javed.butler@emory.edu RI Bhalla, Vikas/A-9397-2012; Kalogeropoulos, Andreas/A-9494-2009 OI Kalogeropoulos, Andreas/0000-0002-1284-429X FU NCATS NIH HHS [TL1 TR000456, UL1 TR000454, KL2 TR000455]; NCRR NIH HHS [KL2 RR025009, TL1 RR025010, UL1 RR025008] NR 26 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD SEP 1 PY 2011 VL 151 IS 2 BP 237 EP 239 DI 10.1016/j.ijcard.2011.06.048 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 814SB UT WOS:000294476300039 PM 21723628 ER PT J AU Livingston, KA Lobato, MN Sosa, LE Budnick, GE Bernardo, J AF Livingston, K. A. Lobato, M. N. Sosa, L. E. Budnick, G. E. Bernardo, J. CA New England Lab Study Grp TI Mycobacterium tuberculosis testing practices in hospital, commercial and state laboratories in the New England states SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE M. tuberculosis; laboratory capacity; state laboratories ID PULMONARY TUBERCULOSIS; DIAGNOSIS AB SETTING: The mycobacterial laboratory is assuming an increasingly important role in tuberculosis (TB) control in the United States today. OBJECTIVE: To assess mycobacterial laboratory capacity and practices in the New England states, USA. DESIGN: We surveyed 143 hospital and commercial laboratories and five of the six state public health laboratories in New England that offer testing services for Mycobacterium tuberculosis. The survey captured information on types of services offered and volume of testing, use of state laboratories for testing, and promptness of reporting results to TB control programs. RESULTS: State laboratories perform the majority of testing services, particularly for more specialized tests. All state laboratories surveyed perform species identification of acid-fast isolates, culture and first-line drug susceptibility testing. Less than 20% of hospital and commercial laboratories offer these services, and 78.6% of hospitals and commercial laboratories refer specimens to state laboratories for culture. CONCLUSION: Surveys of M. tuberculosis testing capacities in a region can help decision makers ensure maintenance of essential services. Hospital and commercial laboratories with lower testing volume might increase efficiency by referring more specimens to state laboratories. State health departments might consider organizing regional laboratory service networks to monitor the provision of services, improve efficiency and oversee quality improvement initiatives. C1 [Livingston, K. A.] Yale Univ, New Haven, CT USA. [Lobato, M. N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sosa, L. E.; Budnick, G. E.] Connecticut Dept Publ Hlth, Hartford, CT USA. [Bernardo, J.] Boston Univ, Boston, MA 02215 USA. RP Livingston, KA (reprint author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St,9th Floor, Boston, MA 02111 USA. EM kara.livingston@tufts.edu OI Bernardo, John/0000-0002-3922-0559 NR 13 TC 2 Z9 2 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2011 VL 15 IS 9 BP 1218 EP 1222 DI 10.5588/ijtld.10.0640 PG 5 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 815JC UT WOS:000294520900016 PM 21943849 ER PT J AU Winston, CA Navin, TR Becerra, JE LoBue, PA AF Winston, Carla A. Navin, Thomas R. Becerra, Jose E. LoBue, Philip A. TI No rebound in tuberculosis in the United States in 2010 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Letter C1 [Winston, Carla A.; Navin, Thomas R.; Becerra, Jose E.; LoBue, Philip A.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Winston, CA (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM cwinston@cdc.gov RI Becerra, Jose/C-4071-2014 FU Intramural CDC HHS [CC999999] NR 3 TC 0 Z9 0 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2011 VL 15 IS 9 BP 1272 EP 1272 DI 10.5588/ijtld.11.0303 PG 1 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 815JC UT WOS:000294520900026 PM 21943859 ER PT J AU Miernyk, K Morris, J Bruden, D McMahon, B Hurlburt, D Sacco, F Parkinson, A Hennessy, T Bruce, M AF Miernyk, Karen Morris, Julie Bruden, Dana McMahon, Brian Hurlburt, Debby Sacco, Frank Parkinson, Alan Hennessy, Thomas Bruce, Michael TI Characterization of Helicobacter pylori cagA and vacA Genotypes among Alaskans and Their Correlation with Clinical Disease SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID VACUOLATING CYTOTOXIN ALLELES; PEPTIC-ULCER DISEASE; GASTRIC-CANCER; ANTIMICROBIAL RESISTANCE; NATIVE PERSONS; PATHOGENICITY ISLAND; HIGH PREVALENCE; INFECTION; ASSOCIATION; EPIDEMIOLOGY AB Helicobacter pylori infection is common in Alaska. The development of severe H. pylori disease is partially determined by the virulence of the infecting strain. Here we present vacA and cagA genotype data for H. pylori strains isolated from Alaskans and their correlation with clinical disease. We enrolled patients scheduled for esophagogastroduodenoscopy and positive for H. pylori infection. Gastric biopsy specimens from the stomach antrum and fundus were cultured. We performed PCR analysis of the H. pylori vacA gene and for the presence of the cagA gene and cagA empty site. We genotyped 515 H. pylori samples from 220 Native and 66 non-Native Alaskans. We detected the cagA gene in 242/286 (85%) persons; of 222 strains that could be subtyped, 95% (212) were non-Asian cagA and 3% (6) were East Asian cagA. After removing mixed infections (n = 17), 83% of H. pylori strains had either the vacA s1m1 (120/269) or s2m2 (103/269) genotype. Sixty-six percent (68/103) of H. pylori strains with the vacA s2m2 genotype also contained the cagA gene. Infection with an H. pylori strain having the cagA gene or vacA s1m1 genotype (compared with s1m2 and s2m2) was associated with a decreased risk of esophagitis (P = 0.003 and 0.0003, respectively). Infection with an H. pylori strain having the vacA s1m1 genotype (compared with s1m2 and s2m2) was associated with an increased risk of peptic ulcer disease (PUD) (P = 0.003). The majority of H. pylori strains in this study carried the non-Asian cagA gene and either the vacA s1m1 or s2m2 genotype. A majority of H. pylori strains with the vacA s2m2 genotype also contained the cagA gene. There was an association of H. pylori genotype with esophagitis and PUD. C1 [Miernyk, Karen; Morris, Julie; Bruden, Dana; Hurlburt, Debby; Parkinson, Alan; Hennessy, Thomas; Bruce, Michael] Ctr Dis Control & Prevent, Arct Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 99517 USA. [Miernyk, Karen; McMahon, Brian; Sacco, Frank] Ctr Dis Control & Prevent, Alaska Native Tribal Hlth Consortium, Anchorage, AK 99517 USA. RP Miernyk, K (reprint author), Ctr Dis Control & Prevent, Arct Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99517 USA. EM kmiernyk@cdc.gov NR 48 TC 21 Z9 21 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2011 VL 49 IS 9 BP 3114 EP 3121 DI 10.1128/JCM.00469-11 PG 8 WC Microbiology SC Microbiology GA 814AX UT WOS:000294416000002 PM 21752979 ER PT J AU de Almeida, ME Steurer, FJ Koru, O Herwaldt, BL Pieniazek, NJ da Silva, AJ AF de Almeida, Marcos E. Steurer, Francis J. Koru, Ozgur Herwaldt, Barbara L. Pieniazek, Norman J. da Silva, Alexandre J. TI Identification of Leishmania spp. by Molecular Amplification and DNA Sequencing Analysis of a Fragment of rRNA Internal Transcribed Spacer 2 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID POLYMERASE-CHAIN-REACTION; CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; PCR ASSAYS; DIAGNOSIS; NUCLEAR; SAMPLES AB Isoenzyme analysis of cultured parasites is the conventional approach for Leishmania species identification. Molecular approaches have the potential to be more sensitive and rapid. We designed PCR generic primers to amplify a segment of the rRNA internal transcribed spacer 2 (ITS2) from multiple Leishmania species. To validate the selected ITS2 fragment, we tested clinical specimens and compared the species results obtained by the molecular approach (PCR followed by DNA sequencing analysis) with those from the parasitologic approach (in vitro culture followed by isoenzyme analysis). Among the 159 patients with clinical specimens positive by both approaches, a total of eight Leishmania species were identified. The species results were concordant for all but two patients: for one patient, the results were Leishmania (Viannia) guyanensis by the molecular approach versus L. (V.) braziliensis by the parasitologic approach; for the other patient, the results were L. (Leishmania) tropica versus L. (L.) major, respectively. ITS2 PCR, followed by sequencing analysis, can be used to detect and discriminate among Leishmania species. The results confirmed our hypothesis that a region of the ITS2 gene can complement the characterization of Leishmania parasites at the species level. The approach we developed can be used as a diagnostic tool in reference laboratories with adequate infrastructure to perform molecular characterization of pathogens. C1 [de Almeida, Marcos E.; Steurer, Francis J.; Koru, Ozgur; Herwaldt, Barbara L.; Pieniazek, Norman J.; da Silva, Alexandre J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Publ Hlth Serv,US Dept Hlth & HUman Serv, Atlanta, GA 30329 USA. [de Almeida, Marcos E.; Koru, Ozgur] Atlanta Res & Educ Fdn Conjunct Atlanta Vet Adm M, Decatur, GA USA. [Koru, Ozgur] Gulhane Mil Med Acad, Dept Microbiol, Ankara, Turkey. RP da Silva, AJ (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Publ Hlth Serv,US Dept Hlth & HUman Serv, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM abs8@cdc.gov NR 32 TC 23 Z9 24 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2011 VL 49 IS 9 BP 3143 EP 3149 DI 10.1128/JCM.01177-11 PG 7 WC Microbiology SC Microbiology GA 814AX UT WOS:000294416000007 PM 21752983 ER PT J AU Miernyk, K DeByle, C Harker-Jones, M Hummel, KB Hennessy, T Wenger, J Rudolph, K AF Miernyk, Karen DeByle, Carolynn Harker-Jones, Marcella Hummel, Kimberlee Boyd Hennessy, Thomas Wenger, Jay Rudolph, Karen TI Serotyping of Streptococcus pneumoniae Isolates from Nasopharyngeal Samples: Use of an Algorithm Combining Microbiologic, Serologic, and Sequential Multiplex PCR Techniques SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID DETERMINING CAPSULAR SEROTYPES; PNEUMOCOCCAL CONJUGATE VACCINE; RURAL ALASKA; DISEASE; CARRIAGE; COLONIZATION; ACQUISITION; SECRETIONS; CHILDREN; INFANTS AB We evaluated nasopharyngeal carriage of Streptococcus pneumoniae (pneumococci) in nine Alaskan communities and used an algorithm combining microbiologic, serologic, and sequential multiplex PCR (MP-PCR) techniques to serotype the isolates. After microbiological identification as pneumococci, isolates (n = 1,135) were serotyped using latex agglutination and Quellung tests (LA/Q) as well as a series of six sequential MP-PCR assays. Results from the two methods agreed for 94% (1,064/1,135) of samples. Eighty-six percent (61/71) of the discordant results were resolved. Discordant results occurred because (i) the MP-PCR gel was misread (31/61 [51%]), (ii) the LA/Q agglutination was misinterpreted (13/61 [21%]), (iii) two serotypes or sets of serotypes were identified by MP-PCR and only one of the two was identified by LA/Q (9/61 [15%]), (iv) different serotypes or sets of serotypes were identified by LA/Q and MP-PCR and both were correct (7/61 [11%]), and (v) the capsular polysaccharide locus (cps) did not amplify during the initial MP-PCR but was present upon retesting (1/61 [2%]). Overall, isolation of pneumococci followed by MP-PCR quickly and accurately identified pneumococcal serotypes in > 97% of samples and made available isolates for additional tests such as antimicrobial susceptibility. Misinterpretation of the MP-PCR gel was identified as the main source of discordance. Increasing the number of MP-PCRs from six to seven and reducing the number of serotypes in each reaction may reduce this error. This method may be of use to laboratories characterizing large numbers of S. pneumoniae samples, especially when antimicrobial susceptibility data are needed. C1 [Miernyk, Karen; DeByle, Carolynn; Harker-Jones, Marcella; Hummel, Kimberlee Boyd; Hennessy, Thomas; Wenger, Jay; Rudolph, Karen] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 99517 USA. [Miernyk, Karen] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. RP Miernyk, K (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99517 USA. EM kmiernyk@cdc.gov NR 24 TC 18 Z9 19 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2011 VL 49 IS 9 BP 3209 EP 3214 DI 10.1128/JCM.00610-11 PG 6 WC Microbiology SC Microbiology GA 814AX UT WOS:000294416000017 PM 21775540 ER PT J AU Jorgensen, JH McElmeel, ML Fulcher, LC McGee, L Glennen, A AF Jorgensen, James H. McElmeel, M. Leticia Fulcher, Letitia C. McGee, Lesley Glennen, Anita TI Evaluation of Disk Approximation and Single-Well Broth Tests for Detection of Inducible Clindamycin Resistance in Streptococcus pneumoniae SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MANAGEMENT AB This study evaluated an agar disk diffusion D-zone test and an erythromycin-clindamycin (ERY + CLI) single-well broth test for inducible CLI resistance in Streptococcus pneumoniae. The standard CLSI disk approximation test and a single-well combination test incorporating 1 plus 0.5 mu g/ml ERY + CLI detected >96% of isolates containing the ermB determinant. C1 [Jorgensen, James H.; McElmeel, M. Leticia; Fulcher, Letitia C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McGee, Lesley] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Glennen, Anita] Minnesota Dept Hlth, St Paul, MN USA. RP Jorgensen, JH (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM jorgensen@uthscsa.edu FU BD Microbiology Systems; bioMerieux; Pfizer FX J.H.J. has served on advisory boards for BD Microbiology Systems and Rib-X Pharmaceuticals. He has received research support from BD Microbiology Systems, bioMerieux, and Pfizer. All other authors have no conflicts of interest. NR 12 TC 5 Z9 5 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2011 VL 49 IS 9 BP 3332 EP 3333 DI 10.1128/JCM.00960-11 PG 2 WC Microbiology SC Microbiology GA 814AX UT WOS:000294416000036 PM 21775547 ER PT J AU Lu, YN Ma, HY Malone, KE Norman, SA Sullivan-Halley, J Strom, BL Marchbanks, PA Spirtas, R Burkman, RT Deapen, D Folger, SG Simon, MS Press, MF McDonald, JA Bernstein, L AF Lu, Yani Ma, Huiyan Malone, Kathleen E. Norman, Sandra A. Sullivan-Halley, Jane Strom, Brian L. Marchbanks, Polly A. Spirtas, Robert Burkman, Ronald T. Deapen, Dennis Folger, Suzanne G. Simon, Michael S. Press, Michael F. McDonald, Jill A. Bernstein, Leslie TI Obesity and Survival Among Black Women and White Women 35 to 64 Years of Age at Diagnosis With Invasive Breast Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID BODY-MASS INDEX; RECEIVING ADJUVANT CHEMOTHERAPY; AMERICAN WOMEN; RISK-FACTORS; AFRICAN-AMERICAN; WEIGHT-LOSS; LIFE-STYLE; MORTALITY; STAGE; OVERWEIGHT AB Purpose To evaluate the effect of obesity on survival among black women and white women with invasive breast cancer and to determine whether obesity explains the poorer survival of black women relative to white women. Patients and Methods We observed 4,538 (1,604 black, 2,934 white) women who were 35 to 64 years of age when diagnosed with incident invasive breast cancer between 1994 and 1998. Multivariate Cox regression models were used to examine the effect of body mass index (BMI, in kilograms per square meter) 5 years before diagnosis on risk of death from any cause and from breast cancer. Results During a median of 8.6 years of follow-up, 1,053 women died (519 black, 534 white), 828 as a result of breast cancer (412 black, 416 white). Black women were more likely to die than white women (multivariate-adjusted relative risk [RR], 1.33; 95% CI, 1.16 to 1.53). Compared with women with BMI of 20 to 24.9 kg/m(2), those who were obese (BMI >= 30 kg/m(2)) had a greater risk of all-cause mortality (RR, 1.23; 95% CI, 1.04 to 1.47) and breast cancer-specific mortality (RR, 1.20; 95% CI, 0.99 to 1.46). These associations were observed among white women (all-cause RR, 1.54; 95% CI, 1.21 to 1.96; breast cancer RR, 1.46; 95% CI, 1.11 to 1.92), but not among black women (all-cause RR, 1.03; 95% CI, 0.81 to 1.29; breast cancer RR, 1.02; 95% CI, 0.79 to 1.33). Conclusion Obesity may play an important role in mortality among white but not black patients with breast cancer. It is unlikely that differences in obesity distributions between black women and white women account for the poorer survival of black women. J Clin Oncol 29:3358-3365. (C) 2011 by American Society of Clinical Oncology C1 [Lu, Yani] City Hope Natl Med Ctr, Dept Populat Sci, Div Canc Etiol, Beckman Res Inst, Duarte, CA 91010 USA. [Deapen, Dennis; Press, Michael F.] Univ So Calif, Los Angeles, CA USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Norman, Sandra A.; Strom, Brian L.] Univ Penn, Philadelphia, PA 19104 USA. [Marchbanks, Polly A.; Folger, Suzanne G.; McDonald, Jill A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Spirtas, Robert] Natl Inst Child Hlth & Dev, NIH, Bethesda, MD USA. [Burkman, Ronald T.] Tufts Univ, Sch Med, Springfield, MA 01199 USA. [Burkman, Ronald T.] Baystate Med Ctr, Springfield, MA USA. [Simon, Michael S.] Wayne State Univ, Detroit, MI USA. RP Lu, YN (reprint author), City Hope Natl Med Ctr, Dept Populat Sci, Div Canc Etiol, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM yalu@coh.org FU Genentech; Ventana Medical; California Breast Cancer Research Program [15FB-0004]; National Institute of Child Health and Human Development; National Cancer Institute; Emory University [N01-HD-2-3168]; Fred Hutchinson Cancer Research Center [N01-HD-2-3166]; Karmanos Cancer Institute at Wayne State University [N01-HD-3-3174]; University of Pennsylvania [N01-HD-3-3176]; University of Southern California [N01-HD-3-3175]; US Centers for Disease Control and Prevention [Y01-HD-7022]; [N01-PC-67006]; [N01-CN-65064]; [N01-PC-67010]; [N01-CN-05230] FX Research Funding: Michael F. Press, Genentech, Ventana Medical; Supported by the California Breast Cancer Research Program (Grant No. 15FB-0004). The Women's Contraceptive and Reproductive Experiences Study was funded by the National Institute of Child Health and Human Development, with additional support from the National Cancer Institute, through contracts with Emory University (Grant No. N01-HD-2-3168), Fred Hutchinson Cancer Research Center (Grant No. N01-HD-2-3166), Karmanos Cancer Institute at Wayne State University (Grant No. N01-HD-3-3174), the University of Pennsylvania (Grant No. N01-HD-3-3176), and the University of Southern California (Grant No. N01-HD-3-3175), and through an intra-agency agreement with the US Centers for Disease Control and Prevention (Grant No. Y01-HD-7022). Support for use of Surveillance, Epidemiology, and End Results cancer registries for case identification was through Grants No. N01-PC-67006 (Atlanta), N01-CN-65064 (Detroit), N01-PC-67010 (Los Angeles), and N01-CN-05230 (Seattle). NR 46 TC 35 Z9 35 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD SEP 1 PY 2011 VL 29 IS 25 BP 3358 EP 3365 DI 10.1200/JCO.2010.34.2048 PG 8 WC Oncology SC Oncology GA 814EO UT WOS:000294429900012 PM 21788570 ER PT J AU Selman, C AF Selman, Carol TI New Food Safety Training Opportunity Using Cutting Edge Technology! SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 Emergency & Environm Hlth Serv, Environm Hlth Serv Branch, Atlanta, GA 30341 USA. RP Selman, C (reprint author), Emergency & Environm Hlth Serv, Environm Hlth Serv Branch, 4770 Buford Hwy, Atlanta, GA 30341 USA. EM cselman@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD SEP PY 2011 VL 74 IS 2 BP 30 EP 31 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 816IR UT WOS:000294592400005 PM 21949982 ER PT J AU Pearson, W Faul, M Sugerman, D McGuire, L Hunt, R AF Pearson, William Faul, Mark Sugerman, David McGuire, Lisa Hunt, Richard TI Traumatic Brain Injury Emergency Department Visits Meeting Systolic Blood Pressure and Respiratory Rate Criteria of the Centers for Disease Control and Prevention, American College of Surgeons Committee on Trauma Field Triage Guidelines SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Pearson, William; Faul, Mark; Sugerman, David; McGuire, Lisa; Hunt, Richard] Ctr Dis Control & Prevent, Div Injury Response, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD SEP-OCT PY 2011 VL 26 IS 5 MA 0062 BP 425 EP 426 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 814VO UT WOS:000294485500066 ER PT J AU Dulski, T Moss, L Pickelsimer, E Wald, M Pearson, W Lattimore, P AF Dulski, Theresa Moss, LaKissia Pickelsimer, Elisabeth Wald, Marlena Pearson, William Lattimore, Pamela TI Traumatic Brain Injury-Related Training for Correctional Officers and Correctional Health Care Providers; Proof of Concept in a State Prison System SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Dulski, Theresa; Wald, Marlena; Pearson, William] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pickelsimer, Elisabeth] Med Univ S Carolina, Charleston, SC 29425 USA. [Moss, LaKissia] Univ S Carolina, Columbia, SC 29208 USA. [Lattimore, Pamela] Res Triangle Inst, Research Pk, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD SEP-OCT PY 2011 VL 26 IS 5 MA 0066 BP 427 EP 427 PG 1 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 814VO UT WOS:000294485500070 ER PT J AU Lionbarger, M Wald, M Dulski, T McGuire, L AF Lionbarger, Michael Wald, Marlena Dulski, Theresa McGuire, Lisa TI Mapping the Growth of Legislation in the US to Help Improve Traumatic Brain Injury Identification and Management for School-Aged Athletes SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Lionbarger, Michael; Wald, Marlena; McGuire, Lisa] Natl Ctr Injury Prevent & Control NCIPC, Div Injury Response, Ctr Dis Control & Prevent, Atlanta, GA USA. [Dulski, Theresa] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD SEP-OCT PY 2011 VL 26 IS 5 MA 0069 BP 428 EP 429 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 814VO UT WOS:000294485500073 ER PT J AU Vinnard, C Winston, CA Wileyto, EP MacGregor, RR Bisson, GP AF Vinnard, Christopher Winston, Carla A. Wileyto, E. Paul MacGregor, Rob Roy Bisson, Gregory P. TI Multidrug resistant tuberculous meningitis in the United States, 1993-2005 SO JOURNAL OF INFECTION LA English DT Letter ID ADULTS C1 [Vinnard, Christopher] Drexel Univ, Coll Med, Dept Med, Div Infect Dis & HIV Med, Philadelphia, PA 19102 USA. [Winston, Carla A.] Ctr Dis Control & Prevent, Div TB Eliminat, Surveillance Epidemiol & Outbreak Invest Branch, Atlanta, GA USA. [Wileyto, E. Paul] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [MacGregor, Rob Roy; Bisson, Gregory P.] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. RP Vinnard, C (reprint author), Drexel Univ, Coll Med, Dept Med, Div Infect Dis & HIV Med, 245 N 15th St,Mailstop 461,6308 New Coll Bldg, Philadelphia, PA 19102 USA. EM christopher.vinnard@Drexelmed.edu NR 11 TC 5 Z9 6 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 J9 J INFECTION JI J. Infect. PD SEP PY 2011 VL 63 IS 3 BP 240 EP 242 DI 10.1016/j.jinf.2011.07.005 PG 3 WC Infectious Diseases SC Infectious Diseases GA 814JX UT WOS:000294448000009 PM 21784099 ER PT J AU Reynolds, JS Frazer, DG AF Reynolds, Jeffrey S. Frazer, David G. TI Noninvasive pulmonary function screening in spontaneously breathing rodents: An engineering systems perspective SO PHARMACOLOGY & THERAPEUTICS LA English DT Review DE Whole-body plethysmograph; Pulmonary function tests; Respiratory function tests; Lung models; Airway resistance ID AIRWAY RESPONSIVENESS; UNRESTRAINED PLETHYSMOGRAPHY; BAROMETRIC PLETHYSMOGRAPHY; MIDEXPIRATORY FLOW; ALLERGIC MICE; SMALL ANIMALS; TIDAL VOLUME; RESISTANCE; HYPERRESPONSIVENESS; MECHANICS AB Noninvasive pulmonary function measurements made on rodents are commonly used for studies where quick, relatively easy end-points are required. These types of measurements are of particular advantage for studies where large numbers of animals are involved. Using tests that are simple to administer generally translates to more efficient and more accurate data collection. Noninvasive measurements result in less stress placed on the animal and allow repeated testing of the same animals at multiple time points. This review focuses on several noninvasive methods that have been developed for pulmonary function screening, which are analyzed from an engineering systems perspective. An analog model of the respiratory system of a conscious, freely respiring animal is presented in terms of an equivalent electrical circuit. This model is used as a basis to demonstrate the relationship between pulmonary parameters derived from circuit analysis. Published by Elsevier Inc. C1 [Reynolds, Jeffrey S.; Frazer, David G.] NIOSH, Pathol & Physiol Res Branch, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Reynolds, JS (reprint author), NIOSH, Pathol & Physiol Res Branch, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM jreynolds@cdc.gov; dfrazer@cdc.gov NR 41 TC 1 Z9 1 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0163-7258 J9 PHARMACOL THERAPEUT JI Pharmacol. Ther. PD SEP PY 2011 VL 131 IS 3 BP 359 EP 368 DI 10.1016/j.pharmthera.2011.05.003 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 804TQ UT WOS:000293677300009 PM 21635918 ER PT J AU Kuklina, EV Tong, X Bansil, P George, MG Callaghan, WM AF Kuklina, Elena V. Tong, Xin Bansil, Pooja George, Mary G. Callaghan, William M. TI Trends in Pregnancy Hospitalizations That Included a Stroke in the United States From 1994 to 2007 Reasons for Concern? SO STROKE LA English DT Article DE stroke; pregnancy; surveillance ID SEVERE OBSTETRIC MORBIDITY; RISK-FACTORS; PUERPERIUM; DISORDERS AB Background and Purpose-Stroke is an important contributor to maternal morbidity and mortality, but there are no recent data on trends in pregnancy-related hospitalizations that have involved a stroke. This report describes stroke hospitalizations for women in the antenatal, delivery, and postpartum periods from 1994 to 1995 to 2006 to 2007 and analyzes the changes in these hospitalizations over time. Methods-Hospital discharge data were obtained from the Nationwide Inpatient Sample, developed as part of the Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare Research and Quality. Pregnancy-related hospitalizations with stroke were identified according to the International Classification of Diseases, Ninth Revision. All statistical analyses accounted for the complex sampling design of the data source. Results-Between 1994 to 1995 and 2006 to 2007, the rate of any stroke (subarachnoid hemorrhage, intracerebral hemorrhage, ischemic stroke, transient ischemic attack, cerebral venous thrombosis, or unspecified) among antenatal hospitalizations increased by 47% (from 0.15 to 0.22 per 1000 deliveries) and among postpartum hospitalizations by 83% (from 0.12 to 0.22 per 1000 deliveries) while remaining unchanged at 0.27 for delivery hospitalizations. In 2006 to 2007, approximate to 32% and 53% of antenatal and postpartum hospitalizations with stroke, respectively, had concurrent hypertensive disorders or heart disease. Changes in the prevalence of these 2 conditions from 1994 to 1995 to 2006 to 2007 explained almost all of the increase in postpartum hospitalizations with stroke during the same period. Conclusions-Our results have demonstrated an increasing trend in the rate of pregnancy-related hospitalizations with stroke in the United States, especially during the postpartum period, from 1994 to 1995 to 2006 to 2007. (Stroke. 2011;42:2564-2570.) C1 [Kuklina, Elena V.; Tong, Xin; Bansil, Pooja; George, Mary G.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Kuklina, EV (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-37, Atlanta, GA 30341 USA. EM ekuklina@cdc.gov NR 26 TC 56 Z9 61 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD SEP PY 2011 VL 42 IS 9 BP 2564 EP 2570 DI 10.1161/STROKEAHA.110.610592 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 813BX UT WOS:000294342800044 PM 21799174 ER PT J AU Alberts, MJ Latchaw, RE Jagoda, A Wechsler, LR Crocco, T George, MG Connolly, ES Mancini, B Prudhomme, S Gress, D Jensen, ME Bass, R Ruff, R Foell, K Armonda, RA Emr, M Warren, M Baranski, J Walker, MD AF Alberts, Mark J. Latchaw, Richard E. Jagoda, Andy Wechsler, Lawrence R. Crocco, Todd George, Mary G. Connolly, E. S. Mancini, Barbara Prudhomme, Stephen Gress, Daryl Jensen, Mary E. Bass, Robert Ruff, Robert Foell, Kathy Armonda, Rocco A. Emr, Marian Warren, Margo Baranski, Jim Walker, Michael D. CA Brain Attack Coalition TI Revised and Updated Recommendations for the Establishment of Primary Stroke Centers A Summary Statement From the Brain Attack Coalition SO STROKE LA English DT Article DE cerebrovascular disease; disease management; stroke centers; stroke units ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; AMERICAN-HEART-ASSOCIATION; QUALITY-OF-CARE; EMERGENCY-DEPARTMENT EVALUATION; NAEMSP POSITION STATEMENT; REGISTERS-STUDY-GROUP; THROMBOLYTIC THERAPY; CENTER CERTIFICATION; RISK-FACTORS AB Background and Purpose-The formation and certification of Primary Stroke Centers has progressed rapidly since the Brain Attack Coalition's original recommendations in 2000. The purpose of this article is to revise and update our recommendations for Primary Stroke Centers to reflect the latest data and experience. Methods-We conducted a literature review using MEDLINE and PubMed from March 2000 to January 2011. The review focused on studies that were relevant for acute stroke diagnosis, treatment, and care. Original references as well as meta-analyses and other care guidelines were also reviewed and included if found to be valid and relevant. Levels of evidence were added to reflect current guideline development practices. Results-Based on the literature review and experience at Primary Stroke Centers, the importance of some elements has been further strengthened, and several new areas have been added. These include (1) the importance of acute stroke teams; (2) the importance of Stroke Units with telemetry monitoring; (3) performance of brain imaging with MRI and diffusion-weighted sequences; (4) assessment of cerebral vasculature with MR angiography or CT angiography; (5) cardiac imaging; (6) early initiation of rehabilitation therapies; and (7) certification by an independent body, including a site visit and disease performance measures. Conclusions-Based on the evidence, several elements of Primary Stroke Centers are particularly important for improving the care of patients with an acute stroke. Additional elements focus on imaging of the brain, the cerebral vasculature, and the heart. These new elements may improve the care and outcomes for patients with stroke cared for at a Primary Stroke Center. (Stroke. 2011;42:2651-2665.) C1 [Alberts, Mark J.] Northwestern Univ, Sch Med, Chicago, IL 60611 USA. [Latchaw, Richard E.] UC Davis Med Ctr, Davis, CA USA. [Wechsler, Lawrence R.] Univ Pittsburgh, Pittsburgh, PA USA. [Crocco, Todd] W Virginia Univ, Morgantown, WV 26506 USA. [George, Mary G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Connolly, E. S.] Columbia Univ, New York, NY USA. [Gress, Daryl; Jensen, Mary E.] Univ Virginia, Charlottesville, VA 22903 USA. RP Alberts, MJ (reprint author), Northwestern Univ, Sch Med, 710 N Lake Shore Dr, Chicago, IL 60611 USA. EM m-alberts@northwestern.edu NR 163 TC 63 Z9 65 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD SEP PY 2011 VL 42 IS 9 BP 2651 EP 2665 DI 10.1161/STROKEAHA.111.615336 PG 15 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 813BX UT WOS:000294342800062 PM 21868727 ER PT J AU Snyder, S Leibach, EK Shaw, C AF Snyder, Susan Leibach, Elizabeth K. Shaw, Colleen TI Laboratory Medicine Best Practices: Methods for Evidence-Based Patient-Centered Quality Improvement SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT 46th Annual Meeting of the Academy-of-Clinical-Laboratory-Physicians-and-Scientists (ACLPS) CY JUN 09-11, 2011 CL St Louis, MO SP Acad Clin Lab Phys Sci C1 [Snyder, Susan; Shaw, Colleen] Ctr Dis Control & Prevent, Atlanta, GA USA. [Leibach, Elizabeth K.] Georgia Hlth Sci Univ, Dept Biomed & Radiol Technol, Augusta, GA USA. [Leibach, Elizabeth K.] Georgia Hlth Sci Univ, Dept Pathol, Augusta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD SEP PY 2011 VL 136 IS 3 MA 7 BP 459 EP 459 PG 1 WC Pathology SC Pathology GA 809SA UT WOS:000294075800019 ER PT J AU Davidson, CS Green, CF Gibbs, SG Panlilio, AL Jensen, PA Jin, Y Scarpino, PV AF Davidson, Craig S. Green, Christopher F. Gibbs, Shawn G. Panlilio, Adelisa L. Jensen, Paul A. Jin, Yan Scarpino, Pasquale V. TI Feasibility of selected prophylactic barriers in arrestance of airborne bacterial vegetative cells and endospores SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Bioaerosol; insect netting ID PERENNIAL MALARIA TRANSMISSION; INSECTICIDE-TREATED NETS; WESTERN KENYA; REDUCTION; AEROSOLS; AREA AB Background: Transmission of infection by airborne agents is a risk for health care personnel, patients, and visitors. This risk is heightened in regions without access to environmental controls and personal protective equipment. The ability of 2 prophylactic barriers (ie, semitransparent netting for insect control) to arrest bioaerosols was assessed for potential use within the malarial zones. Methods: Barriers (pore sizes of 0.8 mm and 0.25 mm) were challenged with bioaerosols of vegetative cells and endospores of Bacillus anthracis strain Sterne 34F2 using a bioaerosol chamber. Barriers were also challenged with airborne inert polystyrene latex particles of known diameters (0.1, 0.43, 0.6, 1.3, 3.2, and 8.0 mu m), and the arrestance provided by barrier with the 0.25 mm pore size was expressed as a function of aerodynamic diameter of challenge aerosols. Results: Barrier with the 0.8 mm pore size provided no significant arrestance of aerosols, whereas the barrier with the 0.25 mm pore size provided an 8% arrestance of vegetative cells and a 13% arrestance of endospores. No arrestance at or below the 0.6 mu m particle size was observed. Conclusion: The level of arrestance provided by these prophylactic barriers does not justify their use as a sole method of preventing transmission. C1 [Gibbs, Shawn G.] Univ Nebraska, Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, Omaha, NE 68198 USA. [Davidson, Craig S.; Scarpino, Pasquale V.] Univ Cincinnati, Dept Civil & Environm Engn, Cincinnati, OH 45221 USA. [Green, Christopher F.] Univ Cincinnati, Clermont Coll, Sci Math & Engn Div, Batavia, OH USA. [Panlilio, Adelisa L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA USA. [Jensen, Paul A.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Jin, Yan] Univ Cincinnati, Dept Math Sci, Cincinnati, OH 45221 USA. RP Gibbs, SG (reprint author), Univ Nebraska, Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, 985110 Nebraska Med Ctr, Omaha, NE 68198 USA. EM sgibbs@unmc.edu FU Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) FX Supported by the Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). NR 18 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD SEP PY 2011 VL 39 IS 7 BP 581 EP 586 DI 10.1016/j.ajic.2010.10.032 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 810UP UT WOS:000294153300012 PM 21570738 ER PT J AU Miller, A Riehle-Colarusso, T Siffel, C Frias, JL Correa, A AF Miller, Assia Riehle-Colarusso, Tiffany Siffel, Csaba Frias, Jaime L. Correa, Adolfo TI Maternal Age and Prevalence of Isolated Congenital Heart Defects in an Urban Area of the United States SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE congenital heart defects; maternal age; epidemiology of congenital heart defects ID BIRTH-DEFECTS; CARDIOVASCULAR MALFORMATIONS; METROPOLITAN ATLANTA; RISK-FACTORS; POPULATION; INFANTS; EPIDEMIOLOGY; SEX; ASSOCIATION; MORTALITY AB Although maternal age has been associated with a number of birth defects in several reports, the literature on the association of maternal age with isolated congenital heart defect (CHD) phenotypes has been limited. We evaluated CHD prevalence based on a cohort of 5,289 infants and fetuses with isolated CHDs born during the period 1968-2005 and ascertained by the Metropolitan Atlanta Congenital Defects Program (MACDP) among residents of five central counties in Atlanta. For our denominator, we obtained information on births to residents of the same counties from vital records (n = 1,301,143). We calculated prevalence ratios for 23 CHD phenotypes by several maternal age categories, using the group 25-29 years of age as a reference group. We used Poisson regression models to estimate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs), controlling for maternal race, infant sex, and birth cohort. A maternal age of 35 years or older was associated with an increased prevalence for several CHD phenotypes: laterality defects (aPR = 2.06; CI 1.22-3.48), all conotruncal defects (aPR = 1.30; CI 1.03-1.65), and specifically for dextro-transposition of the great arteries (aPR = 1.65; CI 1.10-2.48), coarctation of the aorta (aPR = 1.54; CI 1.10-2.16), ventricular septal defects (aPR = 1.20; CI 1.06-1.36), and atrial septal defects (aPR = 1.36; CI 1.05-1.77). Our findings suggest that the birth prevalence of specific isolated CHDs varies with maternal age. Further studies are warranted to corroborate these observations, taking into account potential confounding by known modifiable risk factors. Published 2011 Wiley-Liss, Inc. C1 [Miller, Assia; Riehle-Colarusso, Tiffany; Siffel, Csaba; Frias, Jaime L.; Correa, Adolfo] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Miller, Assia] Res Triangle Inst Int, Atlanta, GA USA. [Siffel, Csaba] Comp Sci Corp, Atlanta, GA USA. [Frias, Jaime L.] McKing Consulting Corp, Fairfax, VA USA. RP Correa, A (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Mailstop E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM acorrea@cdc.gov NR 52 TC 30 Z9 33 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD SEP PY 2011 VL 155A IS 9 BP 2137 EP 2145 DI 10.1002/ajmg.a.34130 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 811DN UT WOS:000294182500017 PM 21815253 ER PT J AU Schwartz, BS Parker, CL Hess, J Frumkin, H AF Schwartz, Brian S. Parker, Cindy L. Hess, Jeremy Frumkin, Howard TI Public Health and Medicine in an Age of Energy Scarcity: The Case of Petroleum SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID PEAK OIL; CLIMATE-CHANGE; UNITED-STATES; CRUDE-OIL; CHEAP OIL; LIMITS; WORLD; WILL; MECHANISMS; CHALLENGE AB Petroleum supplies have heretofore been abundant and inexpensive, but the world petroleum production peak is imminent, and we are entering an unprecedented era of petroleum scarcity. This fact has had little impact on policies related to climate, energy, the built environment, transportation, food, health care, public health, and global health. Rising prices are likely to spur research and drive efficiency improvements, but such innovations may be unable to address an increasing gap between supply and demand. The resulting implications for health and the environment are explored in the articles we have selected as additional contributions in this special issue. Uncertainty about the timing of the peak, the shape of the production curve, and decline rates should not delay action. The time for quick, decisive, comprehensive action is now. (Am J Public Health. 2011;101:1560-1567. doi:10.2105/AJPH.2010.205187) C1 [Schwartz, Brian S.; Parker, Cindy L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA. [Schwartz, Brian S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Parker, Cindy L.] Johns Hopkins Zanvyl Krieger Sch Arts & Sci, Dept Earth & Planetary Sci, Baltimore, MD USA. [Hess, Jeremy] Natl Ctr Environm Hlth, Atlanta, GA USA. [Hess, Jeremy] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Hess, Jeremy] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA. [Frumkin, Howard] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. RP Schwartz, BS (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room W7041, Baltimore, MD 21205 USA. EM bschwart@jhsph.edu OI Frumkin, Howard/0000-0001-7079-3534 FU National Center for Environmental Health; Johns Hopkins Center for Public Health Preparedness FX This work was supported, in part, by funding from the National Center for Environmental Health and the Johns Hopkins Center for Public Health Preparedness. NR 78 TC 18 Z9 18 U1 1 U2 16 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2011 VL 101 IS 9 BP 1560 EP 1567 DI 10.2105/AJPH.2010.205187 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 809XR UT WOS:000294090500008 PM 21778506 ER PT J AU Thompson, DL Jungk, J Hancock, E Smelser, C Landen, M Nichols, M Selvage, D Baumbach, J Sewell, M AF Thompson, Deborah L. Jungk, Jessica Hancock, Emily Smelser, Chad Landen, Michael Nichols, Megin Selvage, David Baumbach, Joan Sewell, Mack TI Risk Factors for 2009 Pandemic Influenza A (H1N1)-Related Hospitalization and Death Among Racial/Ethnic Groups in New Mexico SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; SOCIOECONOMIC-STATUS; A(H1N1) INFECTION; H1N1 VIRUS; CANADA; AMERICAN; CANCER; HEALTH AB Objectives. We assessed risk factors for 2009 pandemic influenza A (H1N1)-related hospitalization, mechanical ventilation, and death among New Mexico residents. Methods. We calculated population rate ratios using Poisson regression to analyze risk factors for H1N1-related hospitalization. We performed a cross-sectional analysis of hospitalizations during September 14, 2009 through January 13, 2010, using logistic regression to assess risk factors for mechanical ventilation and death among those hospitalized. Results. During the study period, 926 laboratory-confirmed H1N1-related hospitalizations were identified. H1N1-related hospitalization was significantly higher among American Indians (risk ratio [RR]=2.6; 95% confidence interval (CI]=2.2, 3.2), Blacks (RR=1.7; 95% CI=1.2, 2.4), and Hispanics (RR=1.8; 95% CI=1.5, 2.0) than it was among non-Hispanic Whites, and also was higher among persons of younger age and lower household income. Mechanical ventilation was significantly associated with age 25 years and older, obesity, and lack of or delayed antiviral treatment. Death was significantly associated with male gender, cancer during the previous 12 months, and liver disorder. Conclusions. This analysis supports recent national efforts to include American Indian/Alaska Native race as a group at high risk for complications of influenza with respect to vaccination and antiviral treatment recommendations. (Am J Public Health. 2011;101:1776-1784. doi:10.2105/AJPH.2011.300223) C1 [Thompson, Deborah L.; Jungk, Jessica; Hancock, Emily; Smelser, Chad; Landen, Michael; Selvage, David; Baumbach, Joan; Sewell, Mack] New Mexico Dept Hlth, Santa Fe, NM USA. [Nichols, Megin] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Thompson, DL (reprint author), 1190 St,Francis Dr,Suite N1350, Santa Fe, NM 87505 USA. EM deborah.thompson@state.nm.us RI Jungk, Jessica/A-9958-2015 OI Jungk, Jessica/0000-0001-7087-7623 NR 33 TC 16 Z9 16 U1 0 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2011 VL 101 IS 9 BP 1776 EP 1784 DI 10.2105/AJPH.2011.300223 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 809XR UT WOS:000294090500036 PM 21778495 ER PT J AU Sjolund-Karlsson, M Joyce, K Blickenstaff, K Ball, T Haro, J Medalla, FM Fedorka-Cray, P Zhao, SH Crump, JA Whichard, JM AF Sjolund-Karlsson, Maria Joyce, Kevin Blickenstaff, Karen Ball, Takiyah Haro, Jovita Medalla, Felicita M. Fedorka-Cray, Paula Zhao, Shaohua Crump, John A. Whichard, Jean M. TI Antimicrobial Susceptibility to Azithromycin among Salmonella enterica Isolates from the United States SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID UNCOMPLICATED TYPHOID-FEVER; MULTIDRUG-RESISTANT; DECREASED SUSCEPTIBILITY; SEROTYPE TYPHI; CHILDREN; BREAKPOINTS; PARATYPHI; OFLOXACIN; DIARRHEA; GENES AB Due to emerging resistance to traditional antimicrobial agents, such as ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol, azithromycin is increasingly used for the treatment of invasive Salmonella infections. In the present study, 696 isolates of non-Typhi Salmonella collected from humans, food animals, and retail meats in the United States were investigated for antimicrobial susceptibility to azithromycin. Seventy-two Salmonella enterica serotype Typhi isolates from humans were also tested. For each isolate, MICs of azithromycin and 15 other antimicrobial agents were determined by broth microdilution. Among the non-Typhi Salmonella isolates, azithromycin MICs among human isolates ranged from 1 to 32 mu g/ml, whereas the MICs among the animal and retail meat isolates ranged from 2 to 16 mu g/ml and 4 to 16 mu g/ml, respectively. Among Salmonella serotype Typhi isolates, the azithromycin MICs ranged from 4 to 16 mu g/ml. The highest MIC observed in the present study was 32 mu g/ml, and it was detected in three human isolates belonging to serotypes Kentucky, Montevideo, and Paratyphi A. Based on our findings, we propose an epidemiological cutoff value (ECOFF) for wild-type Salmonella of <= 16 mu g/ml of azithromycin. The susceptibility data provided could be used in combination with clinical outcome data to determine tentative clinical breakpoints for azithromycin and Salmonella enterica. C1 [Sjolund-Karlsson, Maria] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, CCID NCZVED DFBMD EDLB, Atlanta, GA 30329 USA. [Blickenstaff, Karen; Zhao, Shaohua] US FDA, Ctr Vet Med, Laurel, MD USA. [Ball, Takiyah; Haro, Jovita; Fedorka-Cray, Paula] USDA ARS, Bacterial Epidemiol & Antimicrobial Resistance Re, Athens, GA 30613 USA. RP Sjolund-Karlsson, M (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, CCID NCZVED DFBMD EDLB, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM fwt4@cdc.gov FU CDC; USDA; FDA Center for Veterinary Medicine (FDA-CVM) FX This work was supported by interagency agreements that the CDC and USDA have with the FDA Center for Veterinary Medicine (FDA-CVM). NR 38 TC 26 Z9 26 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2011 VL 55 IS 9 BP 3985 EP 3989 DI 10.1128/AAC.00590-11 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 808CW UT WOS:000293953900003 PM 21690279 ER PT J AU Lockhart, SR Frade, JP Etienne, KA Pfaller, MA Diekema, DJ Balajee, SA AF Lockhart, Shawn R. Frade, Joao P. Etienne, Kizee A. Pfaller, Michael A. Diekema, Daniel J. Balajee, S. Arunmozhi TI Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A Gene SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ITRACONAZOLE RESISTANCE; INVASIVE ASPERGILLOSIS; CROSS-RESISTANCE; REDUCED SUSCEPTIBILITY; ACQUIRED-RESISTANCE; VORICONAZOLE; MECHANISMS; EVOLUTION; MUTANTS; PATIENT AB We surveyed 497 isolates of Aspergillus fumigatus collected from 2008 to 2009 as part of the ARTEMIS global surveillance study for elevated MIC values to itraconazole, voriconazole, and posaconazole. Sequencing of the cyp51A gene revealed that 8/29 isolates with elevated MIC values to one or more triazoles, all originating in China, contained the TR/L98H mutation associated with resistant European isolates of A. fumigatus. This is the first time the TR/L98H mutation has been identified outside Europe. C1 [Lockhart, Shawn R.; Frade, Joao P.; Etienne, Kizee A.; Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Pfaller, Michael A.; Diekema, Daniel J.] Univ Iowa, Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA. [Diekema, Daniel J.] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA. RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd,Mail Stop G-11, Atlanta, GA 30333 USA. EM gyi2@cdc.gov OI Diekema, Daniel/0000-0003-1273-0724 NR 36 TC 99 Z9 101 U1 1 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2011 VL 55 IS 9 BP 4465 EP 4468 DI 10.1128/AAC.00185-11 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 808CW UT WOS:000293953900081 PM 21690285 ER PT J AU Lee, T Ko, I Lee, I Kim, E Shin, M Roh, S Yoon, D Choi, S Chang, H AF Lee, Taewha Ko, Ilsun Lee, Insook Kim, Eunhyun Shin, Mikyong Roh, Sunghoon Yoon, Dongsup Choi, Seungho Chang, Hangseok TI Effects of Nurse Navigators on Health Outcomes of Cancer Patients SO CANCER NURSING LA English DT Article DE Cancer; Care coordination; Health outcomes; Nurse navigator ID QUALITY-OF-CARE; RANDOMIZED CONTROLLED-TRIAL; COORDINATING CARE; COLORECTAL-CANCER; SURGICAL-PATIENTS; BREAST-CANCER; MANAGEMENT; IMPACT; PAIN; INTERVENTION AB Background: Care coordination has received increased attention in recent years because it critically affects patient safety and care quality across services and settings. Objective: The effectiveness of systematically developed nurse navigator interventions for newly diagnosed cancer patients was evaluated. Methods: Seventy-eight patients participated in a nonequivalent control group pretest-posttest design study. The study design spanned a 3-month period for all participants. Patient outcome measures included quality of life, satisfaction with care, and length of hospital stay. Results: Participants in the experimental program reported significant increases in several components of quality of life and with satisfaction with care and experienced fewer hospital stay days compared with the control group. Conclusion: This study provides evidence that standardized nurse navigator programs can improve patient outcomes in cancer care. Implications for Practice: Positive outcomes of the reduced length of stay and improved quality of life and patient satisfaction may help transform the cancer care delivery model toward more nurse-initiated cost-effective model. C1 [Lee, Taewha; Ko, Ilsun] Yonsei Univ, Coll Nursing, Nursing Policy Res Inst, Seoul 120752, South Korea. [Lee, Insook] Jeju Halla Coll, Dept Nursing, Seoul, South Korea. [Kim, Eunhyun] Severance Hosp, Seoul, South Korea. [Shin, Mikyong] Ctr Dis Control, Atlanta, GA 30333 USA. [Roh, Sunghoon] Yonsei Univ, Coll Med, Dept Gen Surg, Seoul 120752, South Korea. [Yoon, Dongsup; Choi, Seungho; Chang, Hangseok] Gangnam Severance Hosp, Seoul, South Korea. RP Lee, T (reprint author), Yonsei Univ, Coll Nursing, Nursing Policy Res Inst, CPO Box 8044, Seoul 120752, South Korea. EM twlee5@yuhs.ac FU Korea Ministry of Health and Welfare [0520170-1] FX This study was supported by a grant from the Korea Ministry of Health and Welfare (0520170-1). NR 32 TC 13 Z9 13 U1 1 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0162-220X J9 CANCER NURS JI Cancer Nurs. PD SEP-OCT PY 2011 VL 34 IS 5 BP 376 EP 384 DI 10.1097/NCC.0b013e3182025007 PG 9 WC Oncology; Nursing SC Oncology; Nursing GA 810VT UT WOS:000294156700009 PM 21242774 ER PT J AU Jain, S Chaves, SS AF Jain, Seema Chaves, Sandra S. TI Obesity and Influenza SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; A(H1N1) INFECTION; H1N1 INFLUENZA; RISK-FACTOR; A H1N1; VIRUS; HOSPITALIZATION; RECOMMENDATIONS; MORTALITY C1 [Jain, Seema; Chaves, Sandra S.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Jain, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A32, Atlanta, GA 30333 USA. EM bwc8@cdc.gov NR 24 TC 20 Z9 20 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2011 VL 53 IS 5 BP 422 EP 424 DI 10.1093/cid/cir448 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 809PW UT WOS:000294070200007 PM 21844025 ER PT J AU Jackson, ML France, AM Hancock, K Lu, XH Veguilla, V Sun, H Liu, F Hadler, J Harcourt, BH Esposito, DH Zimmerman, CM Katz, JM Fry, AM Schrag, SJ AF Jackson, Michael L. France, Anne M. Hancock, Kathy Lu, Xiuhua Veguilla, Vic Sun, Hong Liu, Feng Hadler, James Harcourt, Brian H. Esposito, Douglas H. Zimmerman, Christopher M. Katz, Jacqueline M. Fry, Alicia M. Schrag, Stephanie J. TI Serologically Confirmed Household Transmission of 2009 Pandemic Influenza A (H1N1) Virus During the First Pandemic Wave-New York City, April-May 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INFECTION; PARAMETERS; OUTBREAK; ANTIBODY; SCHOOL; ASSAYS AB Background. Understanding transmissibility of influenza viruses within households is critical for guiding public health response to pandemics. We studied serologically confirmed infection and disease among household contacts of index case patients with 2009 pandemic influenza A (H1N1) virus (pH1N1) infection in a setting of minimal community pH1N1 transmission. Methods. We defined index case patients as students and staff of a New York City high school with laboratory-confirmed pH1N1 infection during the earliest phase of the pH1N1 outbreak in April 2009. We visited households of index case patients twice, once in early May and again in June/July 2009. At each visit, household members (both index case patents and household contacts) provided serum samples and completed questionnaires about illness and possible risk factors. Serologic testing was performed using microneutralization and hemagglutination-inhibition assays. Results. Of 79 eligible household contacts in 28 households, 19% had serologically confirmed pH1N1 infection, and 28% of those infected were asymptomatic. Serologically confirmed infection varied by age among household contacts: 36% of contacts younger than 10 years were infected, compared with 46% of contacts age 10-18 years, 8% of contacts aged 19-54 years, and 22% of contacts aged 55 years and older. Conclusions. Infection rates were high for household contacts of persons with confirmed pH1N1, particularly for contacts aged 10-18 years, and asymptomatic infection was common. Efforts to reduce household transmission during influenza pandemics are important adjuncts to strategies to reduce community illness. C1 [Jackson, Michael L.; France, Anne M.; Esposito, Douglas H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Jackson, Michael L.; Harcourt, Brian H.; Schrag, Stephanie J.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [France, Anne M.; Hadler, James; Zimmerman, Christopher M.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Hancock, Kathy; Lu, Xiuhua; Veguilla, Vic; Sun, Hong; Liu, Feng; Katz, Jacqueline M.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Jackson, ML (reprint author), Grp Hlth Res Inst, 1730 Minor Ave Ste 1600, Seattle, WA 98101 USA. EM jackson.ml@ghc.org RI Chiang, Vincent, Ming-Hsien/D-4312-2016 OI Chiang, Vincent, Ming-Hsien/0000-0002-2029-7863 FU Centers for Disease Control and Prevention; New York City Department of Health and Mental Hygiene FX This work was supported by the Centers for Disease Control and Prevention and the New York City Department of Health and Mental Hygiene as part of the pandemic response. NR 25 TC 21 Z9 21 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2011 VL 53 IS 5 BP 455 EP 462 DI 10.1093/cid/cir437 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 809PW UT WOS:000294070200012 PM 21844028 ER PT J AU Park, GW Sobsey, MD AF Park, Geun Woo Sobsey, Mark D. TI Simultaneous Comparison of Murine Norovirus, Feline Calicivirus, Coliphage MS2, and GII.4 Norovirus to Evaluate the Efficacy of Sodium Hypochlorite Against Human Norovirus on a Fecally Soiled Stainless Steel Surface SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID ROUND STRUCTURED VIRUSES; TERM-CARE FACILITIES; NORWALK VIRUS; HEALTH-CARE; GASTROENTERITIS; INACTIVATION; DISINFECTION; OUTBREAKS; WATER; TRANSMISSION AB Free chlorine as hypochlorite is recommended to decontaminate fecally contaminated surfaces to control human norovirus (NoV). We evaluated the efficacy of sodium hypochlorite to decontaminate GII.4 NoV and three surrogates of human NoVs, feline calicivirus (FCV), murine norovirus (MNV), and coliphage MS2, on a fecally soiled stainless steel surface. Reduction of infectivity of FCV, MNV, and MS2 was measured by plaque assay and the decline of genomic copy numbers of GII.4 NoV by reverse transcriptase-polymerase chain reaction. Sodium hypochlorite solution at 5000 ppm could inactivate FCV by 3 log(10) plaque forming units after approximately 1.9 minutes of contact time, but required longer exposure times of 3.2 and 4.5 minutes to reduce MNV and MS2 by 3 log(10), respectively. However, detection of viral RNA by reverse transcriptase-polymerase chain reaction assay may not be reliable to estimate the effectiveness of sodium hypochlorite against human NoV. Of three NoV surrogates, FCV is not the most resistant of the virus tested for inactivation by hypochlorite and thus is not the worst-case model for estimating NoV inactivation. Although the use of 5000 ppm of hypochlorite for fecally soiled surfaces is effective, it may require longer exposure times of >= 3 minutes to control NoVs. Surface precleaning before hypochlorite disinfection is recommended to initially reduce the fecal organic load for better virus inactivation and should be a part of the environmental hygiene response measures during an NoV outbreak or where NoV fecal contamination of environmental surfaces is likely or suspected to be present. C1 [Park, Geun Woo; Sobsey, Mark D.] Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC USA. RP Park, GW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM fyt8@cdc.gov NR 31 TC 43 Z9 43 U1 0 U2 18 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD SEP PY 2011 VL 8 IS 9 BP 1005 EP 1010 DI 10.1089/fpd.2010.0782 PG 6 WC Food Science & Technology SC Food Science & Technology GA 812NR UT WOS:000294300700007 PM 21457050 ER PT J AU Johnson, LR Gould, LH Dunn, JR Berkelman, R Mahon, BE AF Johnson, Laura R. Gould, L. Hannah Dunn, John R. Berkelman, Ruth Mahon, Barbara E. CA FoodNet Travel Working Grp TI Salmonella Infections Associated with International Travel: A Foodborne Diseases Active Surveillance Network (FoodNet) Study SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID UNITED-STATES; TYPHOID-FEVER; PARATYPHOID FEVER; ILLNESS; ENTERITIDIS; DIARRHEA AB Salmonella species cause an estimated 1.2 million infections per year in the United States, making it one of the most commonly reported enteric pathogens. In addition, Salmonella is an important cause of travel-associated diarrhea and enteric fever, a systemic illness commonly associated with Salmonella serotypes Typhi and Paratyphi A. We reviewed cases of Salmonella infection reported to the Centers for Disease Control and Prevention's (CDC) Foodborne Diseases Active Surveillance Network (FoodNet), a sentinel surveillance network, from 2004 to 2008. We compared travelers with Salmonella infection to nontravelers with Salmonella infection with respect to demographics, clinical characteristics, and serotypes. Among 23,712 case-patients with known travel status, 11% had traveled internationally in the 7 days before illness. Travelers with Salmonella infection tended to be older (median age, 30 years) than nontravelers (median age, 24 years; p < 0.0001), but were similar with respect to gender. The most common destinations reported were Mexico (38% of travel-associated infections), India (9%), Jamaica (7%), the Dominican Republic (4%), China (3%), and the Bahamas (2%). The proportions of travelers with Salmonella infection hospitalized and with invasive disease were inversely related to the income level of the destination (p < 0.0001). The most commonly reported serotypes, regardless of travel status, were Enteritidis (19% of cases), Typhimurium (14%), Newport (9%), and Javiana (5%). Among infections caused by these four serotypes, 22%, 6%, 5%, and 4%, respectively, were associated with travel. A high index of clinical suspicion for Salmonella infection is appropriate when evaluating recent travelers, especially those who visited Africa, Asia, or Latin America. C1 [Gould, L. Hannah; Mahon, Barbara E.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Johnson, Laura R.; Berkelman, Ruth] Emory Univ, Sch Med, Atlanta, GA USA. [Johnson, Laura R.; Berkelman, Ruth] Rollins Sch Publ Hlth, Atlanta, GA USA. [Dunn, John R.] Tennessee Dept Hlth, Nashville, TN USA. RP Gould, LH (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,MS D63, Atlanta, GA 30333 USA. EM laura122@gmail.com; lgould@cdc.gov FU Centers for Disease Control and Prevention; U.S. Department of Agriculture's Food Safety and Inspection Service; U.S. Food and Drug Administration FX FoodNet Travel Working Group Members at the CDC, the U.S. Department of Agriculture's Food Safety and Inspection Service, the U.S. Food and Drug Administration, and the 10 FoodNet sites (California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee). Pauline Han from CDC's Division of Global Migration and Quarantine, Travelers' Health Branch, for assistance with traveler data. This work was financially supported by Centers for Disease Control and Prevention, U.S. Department of Agriculture's Food Safety and Inspection Service, and the U.S. Food and Drug Administration. NR 27 TC 12 Z9 12 U1 2 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD SEP PY 2011 VL 8 IS 9 BP 1031 EP 1037 DI 10.1089/fpd.2011.0854 PG 7 WC Food Science & Technology SC Food Science & Technology GA 812NR UT WOS:000294300700011 PM 21563923 ER PT J AU MacLeod, JBA Hungerford, DW AF MacLeod, Jana B. A. Hungerford, Daniel W. TI Alcohol-related injury visits: Do we know the true prevalence in US trauma centres? SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE Alcohol; Injuries; Prevalence; Trauma centres; Hazardous drinking ID RISK-FACTORS; DRINKING; ABUSE; INTERVENTIONS; INTOXICATION; ASSOCIATION; DEPENDENCE; MORTALITY; SEVERITY; DISEASE AB Introduction: Alcohol consumption is a significant risk factor for injuries. Further, level I trauma centres are mandated to screen and provide a brief intervention for identified problem drinkers. However, a valid population-based estimate of the magnitude of the problem is unknown. Therefore, the goal of this study is to evaluate the extent to which the present literature provides a valid estimate of the prevalence of alcohol-related visits to U. S. trauma centres. Methods: A Medline search for all articles from 1966 to 2007 that might provide prevalence estimates of alcohol-related visits to U. S. trauma centres yielded 836 articles in English language journals. This review included only papers whose main or secondary goal was to estimate the prevalence of positive blood alcohol concentration (BAC) or acute intoxication. Both a crude aggregate estimate and sample size adjusted estimate were calculated from the included papers and the coverage and comparability of methods were evaluated. Results: Of the 15 studies that met inclusion criteria, incidence estimates of alcohol-related visits ranged from 26.2% to 62.5% and yielded an aggregate, weighted estimate of 32.5%. Target population, capture rate, and threshold for a positive screening result varied considerably across studies. No study provided a comprehensive estimate, i.e., of all trauma patients hospitalised, treated and released, or who died. Conclusions: Although the incidence of alcohol-related visits to U. S. trauma centres appears very high perhaps higher than any other medical setting, the validity of our aggregate estimate is threatened by crucial methodological considerations. The lack of a methodologically valid prevalence estimate hinders efforts to devise appropriate policies for trauma centres and across medical settings. (C) 2010 Elsevier Ltd. All rights reserved. C1 [MacLeod, Jana B. A.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30303 USA. [Hungerford, Daniel W.] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Control & Prevent, Atlanta, GA USA. RP MacLeod, JBA (reprint author), Emory Univ, Sch Med, Dept Surg, 69 Jesse Hill Jr Ave,Suite 315, Atlanta, GA 30303 USA. EM jmacleo@emory.edu; dhungerford@cdc.gov NR 37 TC 21 Z9 22 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 J9 INJURY JI Injury-Int. J. Care Inj. PD SEP PY 2011 VL 42 IS 9 BP 922 EP 926 DI 10.1016/j.injury.2010.01.098 PG 5 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA 811IP UT WOS:000294202400015 PM 22081821 ER PT J AU Han, JS Rogers, ME Nurani, S Rubin, S Blank, S AF Han, Jessica S. Rogers, Meighan E. Nurani, Sophia Rubin, Steven Blank, Susan TI Patterns of Chlamydia/Gonorrhea Positivity Among Voluntarily Screened New York City Public High School Students SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Adolescent; Chlamydia; Gonorrhea; Chlamydia screening; sexually transmitted infection; sexually transmitted disease; high school; school health; self-report; sexual behavior ID RISK BEHAVIOR SURVEY; SEXUAL-BEHAVIOR; SELF-REPORT; CHLAMYDIA; ADOLESCENTS; YOUTH; GONORRHEA; QUESTIONNAIRE; CONSISTENCY; MIDDLE AB Purpose: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are common sexually transmitted infections that disproportionately affect adolescents. Annual screening for CT for sexually active female adolescents is recommended. In 2006, New York City began conducting CT/GC education, screening, and treatment in public high schools. We examine 3-year programmatic outcomes and the relationship between sexual activity, screening, and CT/GC positivity. Methods: We describe the epidemiology of students who screened and those infected with CT/GC. Univariate, bivariate, and multivariate logistic regression analyses were performed to assess relationships between sex, race/ethnicity, age, sexual activity, and screening status; and the relationship between sexually transmitted infection positivity and sexual activity. Results: Between July 2006 and June 2009, we educated 57,418 students and screened 27,353 (47.6%) for CT/GC; 1,736 (6.3%) students were reported to be infected with either organism. Students who screened positive were more likely to be females (8.9%), report black race (8.3%) and be >= 16 years of age (6.6%-9.7%). Screening rates were 70.6% for students who were sexually active, 27.9% for those who had never had sex, and 47.3% for those who did not respond to the sexual activity question; CT/GC positivity was 7.2%, 1.4%, and 6.1%, respectively. Conclusions: Black, older adolescent females were most likely to screen positive for CT/GC in this population. A large proportion of students who did not answer the sexual activity question chose to screen for CT/GC and screened positive. School screening programs should offer screening to all students regardless of reported sexual activity. Programs should target females and older adolescents. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Han, Jessica S.; Rogers, Meighan E.; Nurani, Sophia; Rubin, Steven; Blank, Susan] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. [Rubin, Steven; Blank, Susan] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. RP Han, JS (reprint author), New York City Dept Hlth & Mental Hyg, 40 Worth St,Room 1539, New York, NY 10013 USA. EM han.jessica@gmail.com FU NYC Department of Health and Mental Hygiene Bureau of STD Control; NYC Department of Health and Mental Hygiene Bureau of School Health; NYC Department of Education FX The authors acknowledge the following people who have contributed to the New York City (NYC) high school screening program and to the development of this manuscript: The NYC High school STD Screening Team: Kira Smith, Joyce Wilson, Veronica Rodriguez, Ray R. Ortiz, Jimelle Desouza, Mark Naftel, Alexis Thompson-Middleton, Grace Pabarue, Reginald Jolly, and Miriam Noetzel, MD, MS, for their tireless efforts in providing STD education, screening, treatment, and counseling for NYC high school students; Julia A Schillinger for assistance with evaluation design and data analysis; Margaret Millstone and Preeti Pathela for manuscript review; Ellen Klingler for assistance with data analysis; NYC Department of Health and Mental Hygiene Bureau of STD Control clinic staff for support of the project and for treatment of adolescent clinic patients; and NYC Department of Health and Mental Hygiene Bureau of School Health and NYC Department of Education for project support. This manuscript should be attributed to the Bureau of Sexually Transmitted Diseases Control at the New York City Department of Health and Mental Hygiene. The funding source for this project is the New York City Department of Health and Mental Hygiene. NR 26 TC 12 Z9 13 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD SEP PY 2011 VL 49 IS 3 BP 252 EP 257 DI 10.1016/j.jadohealth.2010.12.006 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 809QF UT WOS:000294071100005 PM 21856516 ER PT J AU Lakhani, NA Shaw, KM Thompson, T Yaroch, AL Glanz, K Hartman, AM Saraiya, M AF Lakhani, Naheed A. Shaw, Kate M. Thompson, Trevor Yaroch, Amy L. Glanz, Karen Hartman, Anne M. Saraiya, Mona TI Prevalence and predictors of total-body skin examination among US adults: 2005 National Health Interview Survey SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter C1 [Lakhani, Naheed A.; Shaw, Kate M.; Thompson, Trevor; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Yaroch, Amy L.] Ctr Human Nutr, Omaha, NE USA. [Glanz, Karen] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Hartman, Anne M.] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. RP Saraiya, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mailstop K-55, Atlanta, GA 30341 USA. EM MSaraiya@cdc.gov NR 4 TC 7 Z9 7 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD SEP PY 2011 VL 65 IS 3 BP 645 EP 648 DI 10.1016/j.jaad.2011.02.028 PG 4 WC Dermatology SC Dermatology GA 810QK UT WOS:000294142000023 PM 21839321 ER PT J AU Liu, AQ Ji, H Wang, ES Liu, JB Xiao, LH Shen, YJ Li, YH Zhang, WZ Ling, H AF Liu, Aiqin Ji, Hong Wang, Ensheng Liu, Jingbo Xiao, Lihua Shen, Yujuan Li, Yihong Zhang, Weizhe Ling, Hong TI Molecular identification and distribution of Cryptosporidium and Giardia duodenalis in raw urban wastewater in Harbin, China SO PARASITOLOGY RESEARCH LA English DT Article ID ZOONOTIC TRANSMISSION; DAIRY-CATTLE; SPP.; GENOTYPES; OUTBREAK; HUMANS; PARVUM; PREVALENCE; MILWAUKEE; DIARRHEA AB Contamination of the water supply by protozoa often causes outbreaks of cryptosporidiosis and giardiasis. The goals of the present study was to investigate the level of Cryptosporidium and Giardia duodenalis in wastewater from wastewater treatment plants in Harbin, China, and to understand the endemic transmission characteristics of cryptosporidiosis and giardiasis. Forty-eight domestic wastewater specimens from the two wastewater treatment plants in Harbin City were collected from April 2009 to March 2010. Cryptosporidium spp. and G. duodenalis assemblages were identified by PCR and sequencing of the 18S ribosomal RNA and the triosephosphate isomerase genes, respectively. In total, 15 wastewater specimens were PCR positive for Cryptosporidium and 23 were PCR positive for G. duodenalis. The prevalence of contamination with G. duodenalis (47.9%) was higher than that of Cryptosporidium (31.3%). Molecular identification showed the presence of two Cryptosporidium spp. (14 belonging to Cryptosporidium andersoni and one belonging to Cryptosporidium ubiquitum) and two G. duodenalis assemblages (18 belonging to assemblage AII and six belonging to assemblage B). In addition, eight specimens contained both Cryptosporidium and G. duodenalis, and one specimen contained G. duodenalis assemblages AII and B. These results suggested humans might be the primary source of G. duodenalis contamination in wastewater in the studied area. In contrast, a low prevalence of C. ubiquitum suggested a reduced risk of human cryptosporidiosis caused by C. ubiquitum via waterborne route. This work provides basic experimental data needed for local wastewater treatment plants to develop protective strategies for water safety and to eliminate waterborne parasites. C1 [Liu, Aiqin; Ji, Hong; Li, Yihong; Zhang, Weizhe; Ling, Hong] Harbin Med Coll, Dept Parasitol, Harbin 150081, Heilongjiang, Peoples R China. [Wang, Ensheng; Liu, Jingbo] Harbin City Drainage Monitoring Stn, Harbin 150026, Heilongjiang, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA. [Shen, Yujuan] Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai 200025, Peoples R China. [Liu, Aiqin; Ji, Hong; Li, Yihong; Zhang, Weizhe; Ling, Hong] Educ Bur Etiol, Key Lab Heilongjiang Prov, Heilongjiang Prov Key Lab Infect & Immun, Harbin 150081, Peoples R China. RP Zhang, WZ (reprint author), Harbin Med Coll, Dept Parasitol, Harbin 150081, Heilongjiang, Peoples R China. EM zhangweizhe526@yahoo.com.cn; yfrling@yahoo.com RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU Natural Science Foundation of Heilongjiang Province, China [D200628]; Heilongjiang postdoctoral Fund [LRB08-303]; Chinese Special Program for Scientific Research of Public Health [200802012] FX This work was supported by the Natural Science Foundation of Heilongjiang Province (grant D200628), China, Heilongjiang postdoctoral Fund (grant LRB08-303) and the Chinese Special Program for Scientific Research of Public Health (No.200802012). NR 44 TC 13 Z9 14 U1 0 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 J9 PARASITOL RES JI Parasitol. Res. PD SEP PY 2011 VL 109 IS 3 BP 913 EP 918 DI 10.1007/s00436-011-2333-4 PG 6 WC Parasitology SC Parasitology GA 811PT UT WOS:000294225700046 PM 21461728 ER PT J AU Herman, W Edelstein, S Ratner, R Montez, M Ackermann, R Orchard, T Foulkes, M Zhang, P Saudek, C Brown, M AF Herman, W. Edelstein, S. Ratner, R. Montez, M. Ackermann, R. Orchard, T. Foulkes, M. Zhang, P. Saudek, C. Brown, M. CA Diabet Prevention Program Res Grp TI The 10-year cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes mellitus: an intent-to-treat analysis of diabetes prevention SO DIABETOLOGIA LA English DT Meeting Abstract CT 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 12-16, 2011 CL Lisbon, PORTUGAL SP European Assoc Study Diabet (EASD) C1 [Herman, W.; Edelstein, S.; Foulkes, M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Herman, W.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Ratner, R.] Medstar Hlth Res Inst, Washington, DC USA. [Montez, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ackermann, R.] Indiana Univ Sch Med, Indianapolis, IN USA. [Orchard, T.] Univ Pittsburgh, Pittsburgh, PA USA. [Zhang, P.] Ctr Dis Control, Atlanta, GA 30333 USA. [Saudek, C.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2011 VL 54 SU 1 MA 904 BP S370 EP S370 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 990ZT UT WOS:000307671302098 ER PT J AU Li, G Zhang, P Wang, J An, Y Gong, Q Gregg, EW Roglic, G Yang, W Zhang, B Hu, Y Bennett, PH AF Li, G. Zhang, P. Wang, J. An, Y. Gong, Q. Gregg, E. W. Roglic, G. Yang, W. Zhang, B. Hu, Y. Bennett, P. H. TI Modifiable predictors of cardiovascular disease and mortality in Chinese with impaired glucose tolerance: 23-year follow-up of the Daqing diabetes prevention study SO DIABETOLOGIA LA English DT Meeting Abstract CT 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 12-16, 2011 CL Lisbon, PORTUGAL SP European Assoc Study Diabet (EASD) C1 [Li, G.; An, Y.; Gong, Q.; Yang, W.; Zhang, B.] China Japan Friendship Hosp, Beijing, Peoples R China. [Zhang, P.; Gregg, E. W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Wang, J.; Hu, Y.] Daqing First Hosp, Daqing, Peoples R China. [Roglic, G.] WHO, CH-1211 Geneva, Switzerland. [Bennett, P. H.] NIH, Phoenix Epidemiol & Clin Res Sect, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2011 VL 54 SU 1 MA 306 BP S133 EP S133 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 990ZT UT WOS:000307671300307 ER PT J AU Panella, NA Crockett, RJK Biggerstaff, BJ Komar, N AF Panella, Nicholas A. Crockett, Rebekah J. Kent Biggerstaff, Brad J. Komar, Nicholas TI THE CENTERS FOR DISEASE CONTROL AND PREVENTION RESTING TRAP: A NOVEL DEVICE FOR COLLECTING RESTING MOSQUITOES SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE Resting mosquitoes; Culex pipiens; Culex tarsalis; resting trap AB Commercially available wood-fiber pots used to collect resting mosquitoes were modified to improve sampling efficiency. The modified traps, called the Centers for Disease Control and Prevention resting traps, collected 16.0 and 5.2 times more adult Culex pipiens and Cx. tarsalis than the conventional wood-fiber pots. The resting trap increases the mean number of resting mosquitoes collected per trap-night and is useful for collecting blood-engorged mosquitoes. C1 [Panella, Nicholas A.; Crockett, Rebekah J. Kent; Biggerstaff, Brad J.; Komar, Nicholas] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Panella, NA (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X FU Intramural CDC HHS [CC999999] NR 11 TC 6 Z9 6 U1 0 U2 5 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2011 VL 27 IS 3 BP 323 EP 325 DI 10.2987/09-5900.1 PG 3 WC Entomology SC Entomology GA 973FK UT WOS:000306344300021 PM 22017100 ER PT J AU Allen, KD Golightly, YM Helmick, CG Ibrahim, SA Kwoh, CK Renner, JB Jordan, JM AF Allen, K. D. Golightly, Y. M. Helmick, C. G. Ibrahim, S. A. Kwoh, C. K. Renner, J. B. Jordan, J. M. TI RACIAL AND GENDER DIFFERENCES IN WILLINGNESS TO UNDERGO TOTAL JOINT REPLACEMENT: THE JOHNSTON COUNTY OSTEOARTHRITIS PROJECT SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract C1 [Allen, K. D.] Duke Univ, Med Ctr, Durham, NC USA. [Allen, K. D.] Durham VA Med Ctr, Durham, NC USA. [Golightly, Y. M.; Renner, J. B.; Jordan, J. M.] Univ N Carolina, Chapel Hill, NC USA. [Helmick, C. G.] CDC, Atlanta, GA 30333 USA. [Ibrahim, S. A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Ibrahim, S. A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kwoh, C. K.] Univ Pittsburgh, Pittsburgh, PA USA. [Kwoh, C. K.] Pittsburgh VA Hlth Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 EI 1522-9653 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD SEP PY 2011 VL 19 SU 1 MA 342 BP S155 EP S156 PG 2 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA V33EH UT WOS:000209001600363 ER PT J AU Lee, J Song, J Hootman, J Semanik, P Chang, R Sharma, L Van Horn, L Bathon, J Eaton, C Hochberg, M Jackson, R Kwoh, C Mysiw, W Nevitt, M Dunlop, D AF Lee, J. Song, J. Hootman, J. Semanik, P. Chang, R. Sharma, L. Van Horn, L. Bathon, J. Eaton, C. Hochberg, M. Jackson, R. Kwoh, C. Mysiw, W. Nevitt, M. Dunlop, D. TI PHYSICAL INACTIVITY CHARACTERISTICS: DATA FROM THE OSTEOARTHRITIS INITIATIVE (OAI) SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract C1 [Lee, J.; Song, J.; Semanik, P.; Chang, R.; Sharma, L.; Van Horn, L.; Dunlop, D.] Northwestern Univ, Chicago, IL 60611 USA. [Hootman, J.] CDC, Atlanta, GA 30333 USA. [Bathon, J.] Columbia Univ, New York, NY USA. [Eaton, C.] Brown Univ, Providence, RI 02912 USA. [Hochberg, M.] Univ Maryland, Baltimore, MD 21201 USA. [Jackson, R.; Mysiw, W.] Ohio State Univ, Columbus, OH 43210 USA. [Kwoh, C.] Univ Pittsburgh, Pittsburgh, PA USA. [Nevitt, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 EI 1522-9653 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD SEP PY 2011 VL 19 SU 1 MA 324 BP S148 EP S149 PG 2 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA V33EH UT WOS:000209001600345 ER PT J AU Welsh, JA Sharma, AJ Grellinger, L Vos, MB AF Welsh, Jean A. Sharma, Andrea J. Grellinger, Lisa Vos, Miriam B. TI Consumption of added sugars is decreasing in the United States SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID BEVERAGE CONSUMPTION; ENERGY; AMERICANS; OBESITY; ADULTS; HEALTH; FOODS; YOUNG; WOMEN; DIET AB Background: The consumption of added sugars (caloric sweeteners) has been linked to obesity, diabetes, and heart disease. Little is known about recent consumption trends in the United States or how intakes compare with current guidelines. Objective: We examined trends in intakes of added sugars in the United States over the past decade. Design: A cross-sectional study of US residents >= 2 y of age (n = 42,316) was conducted by using dietary data from NHANES 1999-2008 (five 2-y cycles) and data for added-sugar contents from the MyPyramid Equivalents Database. Mean intakes of added sugars (grams and percentage of total energy intake) were weighted to obtain national estimates over time across age, sex, and race-ethnic groups. Linear trends were tested by using Wald's F tests. Results: Between 1999-2000 and 2007-2008, the absolute intake of added sugars decreased from a mean (95% CI) of 100.1 g/d (92.8, 107.3 g/d) to 76.7 g/d (71.6, 81.9 g/d); two-thirds of this decrease, from 37.4 g/d (32.6, 42.1 g/d) to 22.8 g/d (18.4, 27.3 g/d), resulted from decreased soda consumption (P-linear trend,0.001 for both). Energy drinks were the only source of added sugars to increase over the study period (P-linear trend = 0.003), although the peak consumption reached only 0.15 g/d (0.08, 0.22 g/d). The percentage of total energy from added sugars also decreased from 18.1% (16.9%, 19.3%) to 14.6% (13.7%, 15.5%) (P-linear trend,0.001). Conclusion: Although the consumption of added sugars in the United States decreased between 1999-2000 and 2007-2008, primarily because of a reduction in soda consumption, mean intakes continue to exceed recommended limits. Am J Clin Nutr 2011;94:726-34. C1 [Welsh, Jean A.; Sharma, Andrea J.; Vos, Miriam B.] Emory Univ, Nutr & Hlth Sci Program, Grad Div Biol & Biomed Sci, Atlanta, GA 30322 USA. [Welsh, Jean A.; Grellinger, Lisa; Vos, Miriam B.] Emory Univ, Sch Med, Dept Pediat Gastroenterol Hepatol & Nutr, Atlanta, GA USA. [Vos, Miriam B.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Sharma, Andrea J.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Sharma, Andrea J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Welsh, JA (reprint author), 2015 Uppergate Dr NE, Atlanta, GA 30332 USA. EM jwelsh1@emory.edu OI Sharma, Andrea/0000-0003-0385-0011 FU National Institute of Diabetes and Digestive and Kidney Diseases [K23DK080953]; Children's Digestive Health and Nutrition Foundation FX No outside funding was obtained for this study. MBV is supported, in part, by a career award from the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK080953) and the Children's Digestive Health and Nutrition Foundation. NR 36 TC 157 Z9 158 U1 4 U2 28 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD SEP PY 2011 VL 94 IS 3 BP 726 EP 734 DI 10.3945/ajcn.111.018366 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 809IX UT WOS:000294047200006 PM 21753067 ER PT J AU Lamb, MM Ogden, CL Carroll, MD Lacher, DA Flegal, KM AF Lamb, Molly M. Ogden, Cynthia L. Carroll, Margaret D. Lacher, David A. Flegal, Katherine M. TI Association of body fat percentage with lipid concentrations in children and adolescents: United States, 1999-2004 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID CARDIOVASCULAR RISK-FACTORS; MASS INDEX; OBESE CHILDREN; US CHILDREN; YOUNG FINNS; CHILDHOOD; HEALTH; PREVALENCE; ADULTHOOD; BMI AB Background: BMI is one factor that is used to determine a child's eligibility for lipid screening and treatment. BMI, which is an indirect measure of body fat, may inadequately represent the biological effect of body fat percentage on lipid concentrations. Objective: We examined the relation between directly measured body fat percentage and lipid concentrations in a representative sample of US youths. Design: Data from 7821 participants aged 8-19 y from the 1999-2004 NHANES were analyzed. Body fat percentage was measured by dual-energy X-ray absorptiometry. Total and HDL-cholesterol concentrations were measured in serum. Serum triglyceride and LDL-cholesterol concentrations were measured in a subsample of 2661 fasting NHANES participants aged 12-19 y. Prevalences of adverse total cholesterol (>200 mg/dL), LDL cholesterol (>130 mg/dL), triglycerides (>150 mg/dL), and HDL cholesterol (<35 mg/dL) were measured. Results: Approximately 10.0% [+/- 0.7% (SE)] of participants had high total cholesterol, 7.0 +/- 0.4% of participants had low HDL cholesterol, 9.7 +/- 1.0% of participants had high triglycerides, and 7.6 +/- 0.7% of participants had high LDL cholesterol. Prevalence of adverse total cholesterol, HDL cholesterol, triglycerides, and LDL cholesterol in US youths with high adiposity (greater than or equal to the age-and sex-specific 75th percentile of body fat percentage) was significantly greater (P < 0.01) than for participants without high adiposity. In multiple linear regressions adjusted for age, survey period, and race-ethnicity, the variance in lipid concentrations explained by body fat percentage was 2-20% (P < 0.001). Conclusion: Adverse lipid concentrations and high adiposity are significantly associated in youths. Am J Clin Nutr 2011;94:877-83. C1 [Lamb, Molly M.; Ogden, Cynthia L.; Carroll, Margaret D.; Lacher, David A.; Flegal, Katherine M.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Lamb, Molly M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Ogden, CL (reprint author), 3311 Toledo Rd,Room 4414, Hyattsville, MD 20782 USA. EM cogden@cdc.gov RI Flegal, Katherine/A-4608-2013; OI Flegal, Katherine/0000-0002-0838-469X FU US Government FX Supported by the US Government. NR 43 TC 24 Z9 27 U1 0 U2 4 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD SEP PY 2011 VL 94 IS 3 BP 877 EP 883 DI 10.3945/ajcn.111.015776 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 809IX UT WOS:000294047200024 PM 21775565 ER PT J AU Vivolo, AM Matjasko, JL Massetti, GM AF Vivolo, Alana M. Matjasko, Jennifer L. Massetti, Greta M. TI Mobilizing Communities and Building Capacity for Youth Violence Prevention: The National Academic Centers of Excellence for Youth Violence Prevention SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article DE Youth violence prevention; Research-community partnerships; Evidence-based programs AB Violence, including its occurrence among youth, results in considerable physical, emotional, social, and economic consequences in the US. Youth violence prevention work at the Division of Violence Prevention (DVP) at the Centers for Disease Control and Prevention (CDC) emphasizes preventing youth violence-related behaviors, injuries, and deaths by collaborating with academic and community partners and stakeholders. In 2000 and 2005, DVP funded the National Academic Centers of Excellence (ACE) for Youth Violence Prevention. Most ACE Centers focus on building community capacity and competence so that evidence-based programs for youth violence prevention can be successfully implemented through effective and supportive research-community partnerships. This commentary provides historical information about the ACE Program, including the development, goals, accomplishments of the Centers, and the utilization of a community-based participatory research approach to prevent youth violence. C1 [Vivolo, Alana M.; Matjasko, Jennifer L.; Massetti, Greta M.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Vivolo, AM (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F-64, Atlanta, GA 30341 USA. EM AVivolo@cdc.gov OI Massetti, Greta/0000-0002-3813-9839 NR 12 TC 9 Z9 9 U1 0 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0562 J9 AM J COMMUN PSYCHOL JI Am. J. Community Psychol. PD SEP PY 2011 VL 48 IS 1-2 BP 141 EP 145 DI 10.1007/s10464-010-9419-5 PG 5 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA 794UF UT WOS:000292926100016 PM 21222150 ER PT J AU Jones, SE Kann, L Pechacek, TF AF Jones, Sherry E. Kann, Laura Pechacek, Terry F. TI Cigarettes Smoked per Day Among High School Students in the US, 1991-2009 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID INTERMITTENT SMOKING; HEALTH CONSEQUENCES; LIGHT; CONSUMPTION AB Background: Recent declines in current cigarette smoking among youth are encouraging, but less is known about the trends in the number of cigarettes smoked per day among youth. Purpose: This study examined trends in the number of cigarettes smoked per day among U. S. high school students during 1991-2009. Methods: Nationally representative data from the 1991-2009 national Youth Risk Behavior Surveys (YRBS) were analyzed in 2010. The YRBS is a biennial, school-based survey representative of 9th-through 12th-grade students in the U. S. Each survey year, students completed anonymous, self-administered questionnaires that included identically worded questions about cigarette use. The number of cigarettes smoked per day on smoking days was categorized as light smoking (< 1-5 cigarettes per day); moderate smoking (6-10 cigarettes per day); and heavy smoking (>= 11 cigarettes per day). Sample sizes ranged from 10,904 to 16,410. Overall response rates ranged from 60% to 71%. Results: During 1991-2009, among current cigarette users overall, light smoking increased from 67.2% to 79.4% and heavy smoking decreased from 18.0% to 7.8%. These trends were found among female and male students overall and white students. Among Hispanic students, light smoking remained stable, but heavy smoking significantly increased from 3.1% in 1991 to 6.4% in 2009. The prevalence of light, moderate, and heavy smoking did not change during 1991-2009 among black students. Conclusions: The finding that during 1991-2009 light smoking increased and heavy smoking decreased among current cigarette users is encouraging; however, even light smoking is detrimental to health and efforts to reduce all cigarette use should continue. (Am J Prev Med 2011; 41(3): 297-299) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Jones, Sherry E.; Kann, Laura] CDC, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Pechacek, Terry F.] CDC, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Jones, SE (reprint author), CDC, Div Adolescent & Sch Hlth, 4770 Buford Highway NE,MS K33, Atlanta, GA 30341 USA. EM sce2@cdc.gov NR 16 TC 4 Z9 4 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2011 VL 41 IS 3 BP 297 EP 299 DI 10.1016/j.amepre.2011.05.018 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 808TW UT WOS:000294002700010 PM 21855744 ER PT J AU Huang, WT Suh, C Campagna, E Broder, KR Daley, MF Crane, LA Stokley, S Kempe, A AF Huang, Wan-Ting Suh, Christina Campagna, Elizabeth Broder, Karen R. Daley, Matthew F. Crane, Lori A. Stokley, Shannon Kempe, Allison TI Adherence to the Advisory Committee on Immunization Practices Recommendation to Prevent Injuries from Postvaccination Syncope A National Physician Survey SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article AB Background: Little is known about physicians' adherence to the 2006 Advisory Committee on Immunization Practices (ACIP) recommendation that providers strongly should consider observing vaccine recipients for 15 minutes to prevent injuries from postvaccination syncope. Purpose: To assess physicians' knowledge, attitudes, and practices toward observing adolescents for 15 minutes postvaccination. Methods: A survey was administered during October 2008-January 2009 to 425 pediatricians (Peds) and 424 family medicine physicians (FPs) from a nationally representative network. Adherence was defined as reporting routinely observing patients for >= 15 minutes after vaccination. Data analysis was completed in 2009. Results: The overall response rate was 73%. A minority of physicians (37% Peds, 24% FPs) were aware that ACIP strongly encourages observing patients for 15 minutes postvaccination, but most physicians (69% Peds, 84% FPs) thought that their practice easily could adhere to this recommendation. Lack of room space (76% Peds, 65% FPs) was the most frequently reported barrier. Seventeen percent of physicians reported adherence to postvaccination observation. Practice in a hospital, university, or community health center compared with private practice (RR = 1.64, 95% CI = 1.05, 2.40); awareness of the ACIP syncope recommendation (RR = 5.55, 95% CI = 3.60, 9.37); and believing that postvaccination syncope can result in serious injuries (RR == 1.74, 95% CI = 1.06, 4.22) were independently associated with self-reported adherence. Conclusions: Few physicians are aware of recommendations for postvaccination observation for syncope and even fewer adhere to them. Strategies to improve this should be developed and tested. (Am J Prev Med 2011; 41(3): 317-321) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Huang, Wan-Ting] CDC, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Huang, Wan-Ting; Broder, Karen R.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Stokley, Shannon] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Suh, Christina; Daley, Matthew F.; Kempe, Allison] Univ Colorado Denver, Dept Pediat, Aurora, CO USA. [Suh, Christina; Campagna, Elizabeth; Daley, Matthew F.; Kempe, Allison] Univ Colorado Denver, Colorado Hlth Outcomes Program, Aurora, CO USA. [Crane, Lori A.] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. [Suh, Christina; Campagna, Elizabeth; Daley, Matthew F.; Crane, Lori A.; Kempe, Allison] Childrens Hosp, Childrens Outcomes Res Program, Aurora, CO USA. RP Broder, KR (reprint author), 1600 Clifton Rd NE,MS D26, Atlanta, GA 30333 USA. EM kbroder@cdc.gov RI Huang, Wan-Ting/E-3497-2010 OI Huang, Wan-Ting/0000-0002-4344-9567 FU CDC through the Rocky Mountain Prevention Research Center, University of Colorado Denver, Aurora CO FX We thank the network physicians for their time and effort in responding to this survey. The study funding was obtained and administered by CDC through the Rocky Mountain Prevention Research Center, University of Colorado Denver, Aurora CO. NR 11 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2011 VL 41 IS 3 BP 317 EP 321 DI 10.1016/j.amepre.2011.04.016 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 808TW UT WOS:000294002700013 PM 21855747 ER PT J AU Rammohan, V Hahn, RA Elder, R Brewer, R Fielding, J Naimi, TS Toomey, TL Chattopadhyay, SK Zometa, C AF Rammohan, Veda Hahn, Robert A. Elder, Randy Brewer, Robert Fielding, Jonathan Naimi, Timothy S. Toomey, Traci L. Chattopadhyay, Sajal K. Zometa, Carlos CA Task Force Community Preventive Se TI Effects of Dram Shop Liability and Enhanced Overservice Law Enforcement Initiatives on Excessive Alcohol Consumption and Related Harms Two Community Guide Systematic Reviews SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID MOTOR-VEHICLE FATALITIES; INTOXICATED PATRONS; PREVENTIVE-SERVICES; BINGE DRINKING; UNITED-STATES; POLICIES; BEHAVIORS; HEALTH; SALES; CIVIL AB Context: Dram shop liability holds the owner or server(s) at a bar, restaurant, or other location where a patron, adult or underage, consumed his or her last alcoholic beverage responsible for harms subsequently inflicted by the patron on others. Liability in a state can be established by case law or statute. Overservice laws prohibit the sale of alcoholic beverages to intoxicated patrons drinking in on-premises retail alcohol outlets (i.e., premises where the alcohol is consumed where purchased); enhanced enforcement of these laws is intended to ensure compliance by premises personnel. Both of these interventions are ultimately designed to promote responsible beverage service by reducing sales to intoxicated patrons, underage youth, or both. This review assesses the effectiveness of dram shop liability and the enhanced enforcement of overservice laws for preventing excessive alcohol consumption and related harms. Evidence acquisition: Studies assessing alcohol-related harms in states adopting dram shop laws were evaluated, as were studies assessing alcohol-related harms in regions with enhanced overservice enforcement. Methods previously developed for systematic reviews for the Guide to Community Preventive Services were used. Evidence synthesis: Eleven studies assessed the association of state dram shop liability with various outcomes, including all-cause motor vehicle crash deaths, alcohol-related motor vehicle crash deaths (the most common outcome assessed in the studies reviewed), alcohol consumption, and other alcohol-related harms. There was a median reduction of 6.4% (range of values 3.7% to 11.3% reduction) in alcohol-related motor vehicle fatalities associated with the presence of dram shop liability in jurisdictions where premises are licensed. Other alcohol-related outcomes also showed a reduction. Only two studies assessed the effects of enhanced enforcement initiatives on alcohol-related outcomes; findings were inconsistent, some indicating benefit and others none. Conclusions: According to Community Guide rules of evidence, the number and consistency of findings indicate strong evidence of the effectiveness of dram shop laws in reducing alcohol-related harms. It will be important to assess the possible effects of legal modifications to dram shop proceedings, such as the imposition of statutes of limitation, increased evidentiary requirements, and caps on recoverable amounts. According to Community Guide rules of evidence, evidence is insufficient to determine the effectiveness of enhanced enforcement of overservice laws for preventing excessive alcohol consumption and related harms. (Am J Prev Med 2011; 41(3): 334-343) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Rammohan, Veda; Hahn, Robert A.; Elder, Randy; Chattopadhyay, Sajal K.; Zometa, Carlos] CDC, Community Guide Branch, Epidemiol & Anal Program Off, Atlanta, GA 30333 USA. [Brewer, Robert] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Fielding, Jonathan] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Toomey, Traci L.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Naimi, Timothy S.] Boston Med Ctr, Gen Internal Med Sect, Boston, MA USA. RP Hahn, RA (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Epidemiol & Anal Program Off, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30333 USA. EM rhahn@cdc.gov NR 38 TC 26 Z9 26 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2011 VL 41 IS 3 BP 334 EP 343 DI 10.1016/j.amepre.2011.06.027 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 808TW UT WOS:000294002700015 PM 21855749 ER PT J AU Hahn, RA AF Hahn, Robert A. CA Task Force Community Preventive Se TI Recommendations on Dram Shop Liability and Overservice Law Enforcement Initiatives to Prevent Excessive Alcohol Consumption and Related Harms SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article AB The Task Force on Community Preventive Services recommends the use of dram shop liability laws, on the basis of strong evidence of effectiveness in preventing and reducing alcohol-related harms. The Task Force found insufficient evidence to determine the effectiveness of overservice law enforcement initiatives as a means to reduce excessive alcohol consumption and related harms, because too few studies were identified and findings were inconsistent. (Am J Prev Med 2011; 41(3): 344-346) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Hahn, Robert A.] Ctr Dis Control & Prevent, Community Guide Branch, Epidemiol & Anal Program Off, Atlanta, GA 30333 USA. RP Hahn, RA (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Epidemiol & Anal Program Off, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30333 USA. EM rhahn@cdc.gov NR 8 TC 4 Z9 4 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2011 VL 41 IS 3 BP 344 EP 346 DI 10.1016/j.amepre.2011.05.024 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 808TW UT WOS:000294002700016 ER PT J AU Janssens, ACJW Ioannidis, JPA van Duijn, CM Little, J Khoury, MJ AF Janssens, A. Cecile J. W. Ioannidis, John P. A. van Duijn, Cornelia M. Little, Julian Khoury, Muin J. CA GRIPS Grp TI Strengthening the reporting of genetic risk prediction studies: the GRIPS statement SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID EPIDEMIOLOGY; MARKER; ASSOCIATION; ELABORATION; EXPLANATION; GUIDELINES; MODELS; STROBE; IMPACT; CURVE AB The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but the quality and completeness of reporting vary. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency of study reporting and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. A detailed Explanation and Elaboration document is published as an accompanying article [1]. C1 [Janssens, A. Cecile J. W.; van Duijn, Cornelia M.] Erasmus Univ, Dept Epidemiol, Med Ctr, Rotterdam, Netherlands. [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. [Ioannidis, John P. A.] Fdn Res & Technol, Biomed Res Inst, Ioannina, Greece. [Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, John P. A.] Tufts Med Ctr, Ctr Genet Epidemiol & Modeling, Boston, MA USA. [Ioannidis, John P. A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Tufts CTSI, Boston, MA USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA USA. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Janssens, ACJW (reprint author), Erasmus Univ, Dept Epidemiol, Med Ctr, Rotterdam, Netherlands. EM a.janssens@erasmusmc.nl RI Ioannidis, John/G-9836-2011; janssens, cecile/L-1075-2015; OI Janssens, A Cecile/0000-0002-6153-4976 FU Centers for Disease Control and Prevention; Erasmus University Medical Center Rotterdam; Center for Medical Systems Biology; Netherlands Organisation for Scientific Research (NWO); National Institutes of Health/National Center for Research Resources [UL1 RR025752] FX Workshop was sponsored by the Centers for Disease Control and Prevention on behalf of the Human Genome Epidemiology Network (HuGENet). The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Department of Health and Human Services. A. Cecile J.W. Janssens is financially supported by grants from the Erasmus University Medical Center Rotterdam, the Center for Medical Systems Biology in the framework of the Netherlands Genomics Initiative (NGI) and the VIDI grant of the Netherlands Organisation for Scientific Research (NWO). John P. A. Ioannidis: Tufts CTSI is supported by the National Institutes of Health/National Center for Research Resources (UL1 RR025752). Opinions in this paper are those of the authors and do not necessarily represent the official position or policies of the Tufts CTSI. Julian Little holds a Canada Research Chair in Human Genome Epidemiology. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 26 TC 20 Z9 20 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0014-2972 J9 EUR J CLIN INVEST JI Eur. J. Clin. Invest. PD SEP PY 2011 VL 41 IS 9 BP 1004 EP 1009 DI 10.1111/j.1365-2362.2011.02494.x PG 6 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 802KJ UT WOS:000293509200012 PM 21434891 ER PT J AU Janssens, ACJW Ioannidis, JPA Bedrosian, S Boffetta, P Dolan, SM Dowling, N Fortier, I Freedman, AN Grimshaw, JM Gulcher, J Gwinn, M Hlatky, MA Janes, H Kraft, P Melillo, S O'Donnell, CJ Pencina, MJ Ransohoff, D Schully, SD Seminara, D Winn, DM Wright, CF van Duijn, CM Little, J Khoury, MJ AF Janssens, A. Cecile J. W. Ioannidis, John P. A. Bedrosian, Sara Boffetta, Paolo Dolan, Siobhan M. Dowling, Nicole Fortier, Isabel Freedman, Andrew N. Grimshaw, Jeremy M. Gulcher, Jeffrey Gwinn, Marta Hlatky, Mark A. Janes, Holly Kraft, Peter Melillo, Stephanie O'Donnell, Christopher J. Pencina, Michael J. Ransohoff, David Schully, Sheri D. Seminara, Daniela Winn, Deborah M. Wright, Caroline F. van Duijn, Cornelia M. Little, Julian Khoury, Muin J. TI Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID GENOME-WIDE ASSOCIATION; HEART-DISEASE RISK; OPERATING CHARACTERISTIC CURVE; TYPE-2 DIABETES RISK; COMMON DISEASES; RECLASSIFICATION MEASURES; MACULAR DEGENERATION; DIAGNOSTIC-ACCURACY; CARDIOVASCULAR RISK; RANDOMIZED-TRIALS AB The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. C1 [Janssens, A. Cecile J. W.; van Duijn, Cornelia M.] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands. [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. [Ioannidis, John P. A.] Fdn Res & Technol, Biomed Res Inst, Ioannina, Greece. [Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, John P. A.] Tufts Med Ctr, Ctr Genet Epidemiol & Modeling, Boston, MA USA. [Ioannidis, John P. A.] Tufts Med Ctr, Tufts CTSI, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA USA. [Bedrosian, Sara; Dowling, Nicole; Gwinn, Marta; Melillo, Stephanie; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. [Boffetta, Paolo] Int Prevent Res Inst, Lyon, France. [Dolan, Siobhan M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA. [Fortier, Isabel] Publ Populat Project Genom P3G, Montreal, PQ, Canada. [Freedman, Andrew N.; Kraft, Peter; Schully, Sheri D.; Seminara, Daniela; Winn, Deborah M.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Grimshaw, Jeremy M.] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Gulcher, Jeffrey] DeCODE Genet, Reykjavik, Iceland. [Hlatky, Mark A.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. [Janes, Holly] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98104 USA. [Janes, Holly] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA. [O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Div Cardiol, Sch Med, Boston, MA USA. [Pencina, Michael J.] Boston Univ, Dept Biostat, Harvard Clin Res Inst, Boston, MA 02215 USA. [Ransohoff, David] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Wright, Caroline F.] PHG Fdn, Cambridge, England. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Janssens, ACJW (reprint author), Erasmus Univ, Med Ctr, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM a.janssens@erasmusmc.nl RI Ioannidis, John/G-9836-2011; Grimshaw, Jeremy/D-8726-2013; janssens, cecile/L-1075-2015; Wright, Caroline/N-5355-2015; OI Janssens, A Cecile/0000-0002-6153-4976; Wright, Caroline/0000-0003-2958-5076; Grimshaw, Jeremy/0000-0001-8015-8243 FU National Heart, Lung, and Blood Institute; National Cancer Institute, National Institutes of Health; Donald W. Reynolds Foundation; Leducq Foundation FX This study was supported by grants from the National Heart, Lung, and Blood Institute and National Cancer Institute, National Institutes of Health; the Donald W. Reynolds Foundation; and the Leducq Foundation. Additional support for DNA extraction, reagents, and data analysis was provided by Roche Diagnostics and Amgen. Genotyping of the 9p21.3 variant was performed by Celera. The funding sources had no role in the design, conduct, or reporting of this study or the decision to submit the manuscript for publication' [53]. NR 92 TC 16 Z9 17 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0014-2972 J9 EUR J CLIN INVEST JI Eur. J. Clin. Invest. PD SEP PY 2011 VL 41 IS 9 BP 1010 EP 1035 DI 10.1111/j.1365-2362.2011.02493.x PG 26 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 802KJ UT WOS:000293509200013 PM 21434890 ER PT J AU Farfan, EB Gaschak, SP Maksymenko, AM Donnelly, EH Bondarkov, MD Jannik, GT Marra, JC AF Farfan, Eduardo B. Gaschak, Sergey P. Maksymenko, Andrey M. Donnelly, Elizabeth H. Bondarkov, Mikhail D. Jannik, G. Tim Marra, James C. TI ASSESSMENT OF (SR)-S-90 AND (CS)-C-137 PENETRATION INTO REINFORCED CONCRETE (EXTENT OF "DEEPENING") UNDER NATURAL ATMOSPHERIC CONDITIONS SO HEALTH PHYSICS LA English DT Article DE Cs-137; Sr-90, Chernobyl; contamination, environmental AB When assessing the feasibility of remediation following the detonation of a radiological dispersion device or improvised nuclear device in a large city, several issues should be considered, including the levels and characteristics of the radioactive contamination, the availability of resources required for decontamination and the planned future use of the city's structures and buildings. Currently, little is known about radionuclide penetration into construction materials in an urban environment. Knowledge in this area would be useful when considering costs of a thorough decontamination of buildings, artificial structures and roads in an affected urban environment. Pripyat, a city substantially contaminated by the Chernobyl Nuclear Power Plant accident in April 1986, may provide some answers. The main objective of this study was to assess the depth of Sr-90 and Cs-137 penetration into reinforced concrete structures in a highly contaminated urban environment under natural weather conditions. Thirteen reinforced concrete core samples were obtained from external surfaces of a contaminated building in Pripyat. The concrete cores were drilled to obtain sample layers of 0-5, 5-10, 10-15, 15-20, 20-30, 30-40 and 40-50 mm. Both Sr-90 and Cs-137 were detected in the entire 0-50 mm profile of the reinforced cores sampled. In most of the cores, over 90% of the total Cs-137 inventory and 70% of the total Sr-90 inventory was found in the first 0-5 mm layer of the reinforced concrete. Strontium-90 (Sr-90) had penetrated markedly deeper into the reinforced concrete structures than Cs-137. Health Phys. 101(3):311-320; 2011 C1 [Farfan, Eduardo B.] Savannah River Nucl Solut LLC, Environm Dosimetry Grp, Environm Sci & Biotechnol, Savannah River Natl Lab, Aiken, SC 29808 USA. [Gaschak, Sergey P.; Maksymenko, Andrey M.; Bondarkov, Mikhail D.] Int Radioecol Lab, Chernobyl Ctr Nucl Safety Radioact Waste & Radioe, UA-07100 Slavutych, Ukraine. [Donnelly, Elizabeth H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Farfan, EB (reprint author), Savannah River Nucl Solut LLC, Environm Dosimetry Grp, Environm Sci & Biotechnol, Savannah River Natl Lab, Bldg 773-42A,Room 236, Aiken, SC 29808 USA. EM Eduardo.Farfan@srnl.doe.gov FU U.S. Department of Energy Office of Environmental Management; SRNL's Laboratory Directed Research and Development (LDRD) [DE-AC09-08SR22470]; U.S. Department of Energy [DE-AC09-08SR22470] FX The authors would like to thank Ines Triay, Cynthia Anderson, Yvette Collazo, Kurt Gerdes, and Ana Han for their support of the U.S. Department of Energy Office of Environmental Management's International Cooperative Program with IRL. The authors would also like to thank Jason Davis (SRNL Records and Document Control) for his help with the development of graphical representations and Tatyana Albert (Thomas E. Albert and Associates, Inc.) for translating documents and reports prepared at IRL. This research was supported by the SRNL's Laboratory Directed Research and Development (LDRD) program in conjunction with work accomplished under contract No. DE-AC09-08SR22470 with the U.S. Department of Energy.; Disclaimer-This manuscript has been co-authored by Savannah River Nuclear Solutions, LLC under Contract No. DE-AC09-08SR22470 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting this article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published form of this work, or allow others to do so, for United States Government purposes. Mention of trade names or commercial products does not constitute endorsement or recommendation for use by the authors or their corresponding organizations. Mention of trade names or commercial products does not constitute endorsement or recommendation for use by the authors or their corresponding organizations. NR 13 TC 2 Z9 2 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0017-9078 EI 1538-5159 J9 HEALTH PHYS JI Health Phys. PD SEP PY 2011 VL 101 IS 3 BP 311 EP 320 DI 10.1097/HP.0b013e3182103242 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 799EH UT WOS:000293266100010 PM 21799347 ER PT J AU Colonne, PM Eremeeva, ME Sahni, SK AF Colonne, Punsiri M. Eremeeva, Marina E. Sahni, Sanjeev K. TI Beta Interferon-Mediated Activation of Signal Transducer and Activator of Transcription Protein 1 Interferes with Rickettsia conorii Replication in Human Endothelial Cells SO INFECTION AND IMMUNITY LA English DT Article ID MEDITERRANEAN SPOTTED-FEVER; KAPPA-B ACTIVATION; TARGETED DISRUPTION; POSITIVE FEEDBACK; GAMMA-INTERFERON; NITRIC-OXIDE; INFECTION; ALPHA; EXPRESSION; INDUCTION AB Infection of the endothelial cell lining of blood vessels with Rickettsia conorii, the causative agent of Mediterranean spotted fever, results in endothelial activation. We investigated the effects of R. conorii infection on the status of the Janus kinase (JAK)-signal transducer and activator of transcription protein (STAT) signaling pathway in human microvascular endothelial cells (HMECs), the most relevant host cell type, in light of rickettsial tropism for microvascular endothelium in vivo. R. conorii infection induced phosphorylation of STAT1 on tyrosine 701 and serine 727 at 24, 48, and 72 h postinfection in HMECs. Employing transcription profile analysis and neutralizing antibodies, we further determined that beta interferon (IFN-beta) production and secretion are critical for STAT1 activation. Secreted IFN-beta further amplified its own expression via a positive-feedback mechanism, while expression of transcription factors interferon regulatory factor 7 (IRF7) and IRF9, implicated in the IFN-beta-STAT1 feedback loop, was also induced. Metabolic activity of rickettsiae was essential for the IFN-beta-mediated response(s) because tetracycline treatment inhibited R. conorii replication, IFN-beta expression, and STAT1 phosphorylation. Inclusion of IFN-beta-neutralizing antibody during infection resulted in significantly enhanced R. conorii replication, whereas addition of exogenous IFN-beta had the opposite inhibitory effect. Finally, small interfering RNA-mediated knockdown further confirmed a protective role for STAT1 against intracellular R. conorii replication. In concert, these findings implicate an important role for IFN-beta-mediated STAT1 activation in innate immune responses of vascular endothelium to R. conorii infection. C1 [Colonne, Punsiri M.; Sahni, Sanjeev K.] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA. [Colonne, Punsiri M.] Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA. [Eremeeva, Marina E.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. RP Sahni, SK (reprint author), Univ Texas Med Branch, Dept Pathol, MMNP 5 210, Mail Route 0428,301 Univ Blvd, Galveston, TX 77555 USA. EM sksahni@utmb.edu FU USPHS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Bethesda, MD [AI040689, AI067613, AI076697] FX This research was supported in part by USPHS grants AI040689, AI067613, and AI076697 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Bethesda, MD. NR 49 TC 8 Z9 8 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD SEP PY 2011 VL 79 IS 9 BP 3733 EP 3743 DI 10.1128/IAI.05008-11 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 807IV UT WOS:000293891000025 PM 21690236 ER PT J AU Eke, PI AF Eke, P. I. TI Using Social Media for Research and Public Health Surveillance SO JOURNAL OF DENTAL RESEARCH LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Eke, PI (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM peke@cdc.gov NR 10 TC 8 Z9 8 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD SEP PY 2011 VL 90 IS 9 BP 1045 EP 1046 DI 10.1177/0022034511415277 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 807FT UT WOS:000293882400001 PM 21768305 ER PT J AU Wang, GJ Labarthe, D AF Wang, Guijing Labarthe, Darwin TI The cost-effectiveness of interventions designed to reduce sodium intake SO JOURNAL OF HYPERTENSION LA English DT Review DE cost-effectiveness; hypertension; salt consumption ID HIGH BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; PUBLIC-HEALTH; AMERICAN DIET; SALT INTAKE; POPULATION; HYPERTENSION; REDUCTIONS; BURDEN; METAANALYSIS AB Background To guide resource allocation, policy makers need evidence of the cost-effectiveness of interventions. We summarized such evidence on selected interventions to reduce sodium intake that would be intended as population-wide approaches to control hypertension. Methods We conducted a comprehensive literature review of journal articles published in English from January 2000 to May 2010 by searching the databases of PubMed, EMBASE, MEDLINE, and EconLit. We selected original research articles for abstracting the evidence on cost-effectiveness of interventions, cost savings and the costs of intervention implementation. Results From the 53 references obtained from the literature search, we identified 11 original research articles that provided relevant information on the medical cost savings, implementation costs, or cost-effectiveness of interventions to reduce sodium intake. The interventions were low in cost, e. g., one study showed that the cost ranged from US$ 0.03 to 0.32 per person per year for awareness campaign through mass media outlets and government regulations on food products in low and middle-income countries. Population-wide interventions for salt reduction are very cost-effective such as only ARS$ 151 per disability-adjusted life-year (DALY) saved in Argentina, whereas statin therapy to lower high cholesterol was $ 70 994 per DALY saved. Another study showed that sodium reduction could save US$ 18 billion in annual US healthcare costs by reducing sodium intake to 2300 mg/day. Conclusion The literature provided economic evidence that was in favor of population-wide interventions designed to reduce sodium intake. Reducing the intake of sodium through such initiatives might be one of the best buys in public health. However, the small body of literature and hypothetical scenarios in most studies might limit policy implications of the findings. J Hypertens 29:1693-1699 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Wang, Guijing; Labarthe, Darwin] Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Wang, GJ (reprint author), Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K-47, Atlanta, GA 30341 USA. EM gbw9@cdc.gov FU Intramural CDC HHS [CC999999] NR 28 TC 28 Z9 29 U1 2 U2 19 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD SEP PY 2011 VL 29 IS 9 BP 1693 EP 1699 DI 10.1097/HJH.0b013e328349ba18 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 806QS UT WOS:000293825600004 PM 21785366 ER PT J AU Le Hello, S Hendriksen, RS Doublet, B Fisher, I Nielsen, EM Whichard, JM Bouchrif, B Fashae, K Granier, SA Silva, NJD Cloeckaert, A Threlfall, EJ Angulo, FJ Aarestrup, FM Wain, J Weill, FX AF Le Hello, Simon Hendriksen, Rene S. Doublet, Benoit Fisher, Ian Nielsen, Eva Moller Whichard, Jean M. Bouchrif, Brahim Fashae, Kayode Granier, Sophie A. Silva, Nathalie Jourdan-Da Cloeckaert, Axel Threlfall, E. John Angulo, Frederick J. Aarestrup, Frank M. Wain, John Weill, Francois-Xavier TI International Spread of an Epidemic Population of Salmonella enterica Serotype Kentucky ST198 Resistant to Ciprofloxacin SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SEROVAR TYPHIMURIUM DT104; FLUOROQUINOLONE RESISTANCE; NONTYPHOIDAL SALMONELLA; ESCHERICHIA-COLI; UNITED-STATES; AQUACULTURE; HEALTH; CONSEQUENCES; EMERGENCE; SEQUENCE AB National Salmonella surveillance systems from France, England and Wales, Denmark, and the United States identified the recent emergence of multidrug-resistant isolates of Salmonella enterica serotype Kentucky displaying high-level resistance to ciprofloxacin. A total of 489 human cases were identified during the period from 2002 (3 cases) to 2008 (174 cases). These isolates belonged to a single clone defined by the multilocus sequence type ST198, the XbaI-pulsed-field gel electrophoresis cluster X1, and the presence of the Salmonella genomic island 1 variant SGI1-K. This clone was probably selected in 3 steps in Egypt during the 1990s and the early 2000s and has now spread to several countries in Africa and, more recently, in the Middle East. Poultry has been identified as a potential major vehicle for infection by this clone. Continued surveillance and appropriate control measures should be implemented by national and international authorities to limit the spread of this strain. C1 [Weill, Francois-Xavier] WHO, Collaborating Ctr Reference & Res Salmonella, Inst Pasteur, Unite Bacteries Pathogenes Enter,Ctr Natl Referen, F-75724 Paris 15, France. [Hendriksen, Rene S.; Aarestrup, Frank M.] Tech Univ Denmark, WHO, Collaborating Ctr Antimicrobial Resistance Food B, Copenhagen, Denmark. [Hendriksen, Rene S.; Aarestrup, Frank M.] Tech Univ Denmark, EU Community Reference Lab Antimicrobial Resistan, Natl Food Inst, Copenhagen, Denmark. [Doublet, Benoit; Cloeckaert, Axel] INRA, UR 1282, F-37380 Nouzilly, France. [Fisher, Ian; Threlfall, E. John; Wain, John] Ctr Infect, Lab Gastrointestinal Infect, Hlth Protect Agcy, London, England. [Nielsen, Eva Moller] Statens Serum Inst, Dept Microbiol Surveillance & Res, DK-2300 Copenhagen, Denmark. [Whichard, Jean M.; Angulo, Frederick J.] Ctr Dis Control & Prevent, Div Foodborne, Atlanta, GA USA. [Bouchrif, Brahim] Inst Pasteur Maroc, Casablanca, Morocco. [Fashae, Kayode] Univ Ibadan, Dept Microbiol, Ibadan, Nigeria. [Granier, Sophie A.] Lab Securite Aliments Maisons Alfort, Agence Natl Securite Sanit Alimentat, Unite Caracterisat & Epidemiol Bacterienne, Maisons Alfort, France. [Silva, Nathalie Jourdan-Da] Inst Veille Sanit, Dept Maladies Infect, St Maurice, France. RP Weill, FX (reprint author), WHO, Collaborating Ctr Reference & Res Salmonella, Inst Pasteur, Unite Bacteries Pathogenes Enter,Ctr Natl Referen, F-75724 Paris 15, France. EM fxweill@pasteur.fr RI Nielsen, Eva Moller/B-9157-2011; Hendriksen, Rene/A-5755-2013; Wain, John/B-3446-2013; OI Nielsen, Eva Moller/0000-0002-5349-7802; Wain, John/0000-0002-1257-1148; Weill, Francois-Xavier/0000-0001-9941-5799 FU Institut Pasteur; Danish Research Agency [274-05-0117]; World Health Organization Global Foodborne Infections Network; Institut National de la Recherche Agronomique; Health Protection Agency; Statens Serum Institute; Centers for Disease Control and Prevention; Institut Pasteur du Maroc; University of Ibadan; Agence Francaise de Securite Sanitaire des Aliments; Reseau international des Instituts Pasteur et instituts associes; Institut de Veille Sanitaire; Science Foundation of Ireland [05/FE1/B882] FX This work was supported by the Institut Pasteur; the Danish Research Agency (274-05-0117); the World Health Organization Global Foodborne Infections Network; the Institut National de la Recherche Agronomique; the Health Protection Agency; the Statens Serum Institute; the Centers for Disease Control and Prevention; the Institut Pasteur du Maroc; the University of Ibadan; the Agence Francaise de Securite Sanitaire des Aliments; the Reseau international des Instituts Pasteur et instituts associes; and the Institut de Veille Sanitaire.; Permanent financial support came from the institutes, universities, or national agencies of the authors. The work conducted at the National Food Institute, Technical University of Denmark was supported by the World Health Organization Global Foodborne Infections Network (www.who.int/gfn) and the Danish Research Agency (274-05-0117).; The MLST data are publicly available at http://mlst.ucc.ie, which is currently funded by a grant from the Science Foundation of Ireland (05/FE1/B882). NR 44 TC 84 Z9 86 U1 1 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 IS 5 BP 675 EP 684 DI 10.1093/infdis/jir409 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 809QB UT WOS:000294070700004 PM 21813512 ER PT J AU Kelley, CF Haaland, RE Patel, P Evans-Strickfaden, T Farshy, C Hanson, D Mayer, K Lennox, JL Brooks, JT Hart, CE AF Kelley, Colleen F. Haaland, Richard E. Patel, Pragna Evans-Strickfaden, Tammy Farshy, Carol Hanson, Debra Mayer, Kenneth Lennox, Jeffrey L. Brooks, John T. Hart, Clyde E. TI HIV-1 RNA Rectal Shedding Is Reduced in Men With Low Plasma HIV-1 RNA Viral Loads and Is Not Enhanced by Sexually Transmitted Bacterial Infections of the Rectum SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR EXPRESSION; FEMALE GENITAL-TRACT; ANTIRETROVIRAL THERAPY; HOMOSEXUAL-MEN; SEMINAL PLASMA; BLOOD; TRANSMISSION; SEX; SEMEN AB Background. Among human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) taking combination antiretroviral therapy (cART), the impact of rectal sexually transmitted infections (STIs) on rectal HIV-1 shedding is unknown. Methods. Human immunodeficiency virus type 1 (HIV-1) RNA was quantified from rectal swabs collected for Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT) screening of HIV-1-infected MSM. Correlations of STIs with rectal viral load were explored using multinomial regression modeling. HIV-1 coreceptor tropism was predicted from sequencing in a subset of men. Results. Thirty-one (39%) of 80 men (59 prescribed combination antiretroviral therapy [cART]) had HIV detected in 38 (42%) of 91 rectal swabs. Rectal HIV detection was associated with plasma virus loads above 3.15 log(10) copies/mL (95% confidence limit [CL] 2.73, 3.55) and paired rectal viral loads and plasma viral loads were correlated (Kendall's tau [tau] 0.68, Spearman rho [P] = .77). Rectal STIs and abnormal anal cytology were not associated with rectal viral load. HIV coreceptor distribution was very similar between the plasma and rectum in 3 of 4 men. Conclusions. Plasma and rectal viral load were correlated, and rectal STIs did not increase the likelihood of detecting HIV in the rectal secretions in MSM, including those with low or undetectable plasma viral load. Suppressing plasma viral load is likely to reduce risk of HIV transmission to insertive partners. C1 [Kelley, Colleen F.; Haaland, Richard E.; Patel, Pragna; Evans-Strickfaden, Tammy; Farshy, Carol; Hanson, Debra; Brooks, John T.; Hart, Clyde E.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Kelley, Colleen F.; Lennox, Jeffrey L.] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Mayer, Kenneth] Brown Univ, Dept Med, Providence, RI 02912 USA. RP Kelley, CF (reprint author), Grady Ponce de Leon Ctr, 341 Ponce Leon Ave, Atlanta, GA 30308 USA. EM colleen.kelley@emory.edu RI Lennox, Jeffrey/D-1654-2014; Kelley, Colleen/O-4819-2016 OI Lennox, Jeffrey/0000-0002-2064-5565; Kelley, Colleen/0000-0001-5611-0119 FU Centers for Disease Control and Prevention [200-2002-00610/00611/00612/00613, 200-2007-3633/23634/23635/23636]; National Institutes of Health [KL2 RR025009]; Bristol Myers Squibb FX This work was supported by Centers for Disease Control and Prevention contracts 200-2002-00610/00611/00612/00613 and 200-2007-3633/23634/23635/23636. This work was supported in part by the National Institutes of Health (KL2 RR025009 to C. F. K) and a Bristol Myers Squibb Virology Fellowship award to C. F. K. NR 37 TC 23 Z9 23 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 IS 5 BP 761 EP 767 DI 10.1093/infdis/jir400 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 809QB UT WOS:000294070700013 PM 21844302 ER PT J AU Yen, C Figueroa, JR Uribe, ES del Carmen-Hernandez, L Tate, JE Parashar, UD Patel, MM Lopez-Collado, VR AF Yen, Catherine Figueroa, Jesus Reyna Uribe, Edgar Sanchez del Carmen-Hernandez, Luz Tate, Jacqueline E. Parashar, Umesh D. Patel, Manish M. Lopez-Collado, Vesta Richardson TI Monovalent Rotavirus Vaccine Provides Protection Against an Emerging Fully Heterotypic G9P[4] Rotavirus Strain in Mexico SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID DIARRHEA; CHILDREN; GASTROENTERITIS; DIVERSITY; IMPACT; BRAZIL AB After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea mortality and morbidity declined substantially among Mexican children under 5 years of age. In January 2010, surveillance identified the emergence of a novel G9P[4] rotavirus strain nationwide. We conducted a case-control study to assess the field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain and to determine whether the G9P[4] emergence was related to vaccine failure or failure to vaccinate. RV1 was 94% effective (95% confidence interval, 16%-100%) against G9P[4] rotavirus-related hospitalization, indicating that its emergence was likely unrelated to vaccine pressure. C1 [Yen, Catherine; Tate, Jacqueline E.; Parashar, Umesh D.; Patel, Manish M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Yen, Catherine] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Figueroa, Jesus Reyna; Uribe, Edgar Sanchez; del Carmen-Hernandez, Luz; Lopez-Collado, Vesta Richardson] Natl Ctr Child & Adolescent Hlth, Minist Hlth, Mexico City, DF, Mexico. RP Yen, C (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA. EM cyen@cdc.gov NR 15 TC 39 Z9 40 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2011 VL 204 IS 5 BP 783 EP 786 DI 10.1093/infdis/jir390 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 809QB UT WOS:000294070700016 PM 21810915 ER PT J AU Tak, S Groenewold, M Alterman, T Park, RM Calvert, GM AF Tak, SangWoo Groenewold, Matthew Alterman, Toni Park, Robert M. Calvert, Geoffrey M. TI Excess Risk of Head and Chest Colds Among Teachers and Other School Workers SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE communicable diseases; employee health promotion; public health ID TIME-SERIES ANALYSIS; 949 GERMAN TEACHERS; INDOOR AIR; PREVALENCE; INFECTION; PNEUMONIA; SAMPLE AB BACKGROUND: Work-related injuries and illnesses in the educational services sector have not been well studied. This analysis examined whether teachers and other school workers are at higher risk of head/chest cold compared to all other workers in the United States. METHODS: Seven years (1998-2004) of National Health Interview Survey data on currently employed workers were combined to provide a basis for estimating the incidence proportion of head/chest cold. RESULTS: The adjusted odds ratio for head/chest cold was significantly elevated for teachers and other workers employed at schools compared to all other workers. When examined by month, an excess of increased head/chest cold risk during the school year suggested that a portion of head/chest cold among teachers and other school workers is attributable to their workplace, perhaps due to close contact with students at school. CONCLUSION: Head/chest cold, a surrogate for acute respiratory infection, was more common among school workers during the school year and less common during July than for all other workers in the United States. Targeted training for school workers and students may be beneficial to reduce work-related exposure to viruses and bacteria that infect the respiratory system. C1 [Tak, SangWoo; Groenewold, Matthew; Alterman, Toni; Park, Robert M.; Calvert, Geoffrey M.] Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Tak, S (reprint author), Massachusetts Dept Publ Hlth, Occupat Hlth Surveillance Program, 250 Washington St,6th Floor, Boston, MA 02108 USA. EM Sangwoo.Tak@state.ma.us; MGroenewold@cdc.gov; TAlterman@cdc.gov; RPark@cdc.gov; GCalvert@cdc.gov OI Alterman, Toni/0000-0003-1512-4367 NR 26 TC 4 Z9 4 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD SEP PY 2011 VL 81 IS 9 BP 560 EP 565 DI 10.1111/j.1746-1561.2011.00627.x PG 6 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 806FB UT WOS:000293790600007 PM 21831069 ER PT J AU Zeh, C Oyaro, B Vandenhoudt, H Amornkul, P Kasembeli, A Bondo, P Mwaengo, D Thomas, TK Hart, C Laserson, KF Ondoa, P Nkengasong, JN AF Zeh, C. Oyaro, B. Vandenhoudt, H. Amornkul, P. Kasembeli, A. Bondo, P. Mwaengo, D. Thomas, T. K. Hart, C. Laserson, K. F. Ondoa, P. Nkengasong, J. N. TI Performance of six commercial enzyme immunoassays and two alternative HIV-testing algorithms for the diagnosis of HIV-1 infection in Kisumu, Western Kenya SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE HIV-1; Sensitivity; Specificity; Diagnosis; Immunoassay; Alternative; Algorithm ID HUMAN-IMMUNODEFICIENCY-VIRUS; FIELD-EVALUATION; UNITED-STATES; P24 ANTIGEN; ANTIBODIES; TYPE-1; ASSAYS; STRATEGIES; DIVERSITY; SURVEILLANCE AB Performances of serological parallel and serial testing algorithms were analyzed using a combination of three ELISA and three rapid tests for the confirmation of HIV infection. Each was assessed individually for their sensitivity and specificity on a blinded panel of 769 retrospective sera of known HIV status. Western blot was used as a confirmatory assay for discordant results. Subsequently, one parallel and one serial testing algorithm were assessed on a new panel of 912 HIV-positive and negative samples. Individual evaluation of the ELISAs and rapid tests indicated a sensitivity of 100% for all assays except Uni-Gold with 99.7%. The specificities ranged from 99.1% to 99.4% for rapid assays and from 97.5% to 99.1% for ELISAs. A parallel and serial testing algorithms using Enzygnost and Vironostika, and Determine followed by Uni-Gold respectively, showed 100% sensitivity and specificity. The cost for testing 912 samples was US$4.74 and US$ 1.9 per sample in parallel and serial testing respectively. Parallel or serial testing algorithm yielded a sensitivity and specificity of 100%. This alternative algorithm is reliable and reduces the occurrence of both false negatives and positives. The serial testing algorithm was more cost effective for diagnosing HIV infections in this population. Published by Elsevier B.V. C1 [Zeh, C.; Amornkul, P.; Thomas, T. K.; Laserson, K. F.] US Ctr Dis Control & Prevent CDC, Kisumu, Kenya. [Hart, C.] CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Oyaro, B.; Kasembeli, A.; Bondo, P.; Mwaengo, D.] Ctr Global Hlth Res, Kenya Med Res Inst, Kisumu, Kenya. [Nkengasong, J. N.] CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Global AIDS Program, Atlanta, GA 30333 USA. [Laserson, K. F.] Ctr Global Hlth, US Ctr Dis Control & Prevent, Atlanta, GA USA. [Vandenhoudt, H.] Inst Trop Med, B-2000 Antwerp, Belgium. [Ondoa, P.] Univ Amsterdam, Acad Med Ctr, Ctr Poverty related Communicable Dis CPCD, Dept Internal Med,Ctr Infect & Immun CINIMA,AIGHD, NL-1012 WX Amsterdam, Netherlands. RP Zeh, C (reprint author), Ctr Dis Control & Prevent, Off Kisumu Busia Rd,POB 1578-40100, Kisumu, Kenya. EM Czeh@ke.cdc.gov FU Division of HIV/AIDS Prevention, National Center for STD, HIV and TB Prevention; Global AIDS Program (GAP); Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Kenya Medical Research Institute FX The authors are grateful to the field staff for collecting samples in the rural areas of western Kenya, the regional blood center for providing samples for evaluation, the HIV research laboratory, Kenya Medical Research Institute and Kenya Ministry of Health whose participation made this study possible. The authors are also grateful to Seth Inzaule and Collins Odhiambo for critical review and helpful discussion of the manuscript. Sponsorship of the work was supported by the Division of HIV/AIDS Prevention, National Center for STD, HIV and TB Prevention, Global AIDS Program (GAP) and Centers for Disease Control and Prevention, Atlanta, Georgia, USA. This paper is published with the permission of the Director of KEMRI.; This work was supported by the Kenya Medical Research Institute through a cooperative agreement with the US Centre for Disease Control and Prevention. Kenya Medical Research Institute and CDC investigators were involved with all aspects of study design, data collection, and analysis, interpretation of findings, report writing, and decision to submit the manuscript. NR 42 TC 10 Z9 10 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD SEP PY 2011 VL 176 IS 1-2 BP 24 EP 31 DI 10.1016/j.jviromet.2011.05.021 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 809ED UT WOS:000294033700004 PM 21635920 ER PT J AU Blachere, FM Cao, G Lindsley, WG Noti, JD Beezhold, DH AF Blachere, Francoise M. Cao, Gang Lindsley, William G. Noti, John D. Beezhold, Donald H. TI Enhanced detection of infectious airborne influenza virus SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Influenza; Bioaerosols; Viral replication assay; Airborne transmission; qPCR; Air microbiology ID PLAQUE ASSAYS; TRANSMISSION AB Current screening methodologies for detecting infectious airborne influenza virus are limited and lack sensitivity. To increase the sensitivity for detecting infectious influenza virus in an aerosol sample, the viral replication assay was developed. With this assay, influenza virus is first amplified by replication in Madin-Darby canine kidney (MOCK) cells followed by detection with quantitative PCR (qPCR). Spanning a 20-h replication period, matrix gene expression levels from infectious virus were measured at several time points using qPCR and found to exponentially increase. Compared with the traditional culture-based viral plaque assay, the viral replication assay resulted in a 4.6 x 10(5) fold increase in influenza virus detection. Furthermore, viral replication assay results were obtained in half the time of the viral plaque assay. To demonstrate that the viral replication assay is capable of detecting airborne influenza virus, dilute preparations of strain A/WS/33 were loaded into a nebulizer. aerosolized within a calm-air settling chamber and subsequently collected using NIOSH Two-Stage Bioaerosol Samplers. At the most diluted concentration corresponding to a chicken embryo infectious close 50% endpoint (CEID(50)) of 2.8E+02/ml, the viral replication assay was able to detect infectious influenza virus that was otherwise undetectable by viral plaque assay. The results obtained demonstrate that the viral replication assay is highly sensitive at detecting infectious influenza virus from aerosol samples. Published by Elsevier B.V. C1 [Blachere, Francoise M.; Cao, Gang; Lindsley, William G.; Noti, John D.; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Blachere, FM (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 4020, Morgantown, WV 26505 USA. EM FBlachere@cdc.gov OI Lindsley, William/0000-0003-0720-5829 FU Environmental Protection Agency [DW7592259701] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This work was supported, in part, by an interagency agreement (DW7592259701) with the Environmental Protection Agency. NR 19 TC 14 Z9 14 U1 1 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD SEP PY 2011 VL 176 IS 1-2 BP 120 EP 124 DI 10.1016/j.jviromet.2011.05.030 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 809ED UT WOS:000294033700019 PM 21663766 ER PT J AU Smith, SK Self, J Weiss, S Carroll, D Braden, Z Regnery, RL Davidson, W Jordan, R Hruby, DE Damon, IK AF Smith, Scott K. Self, Josh Weiss, Sonja Carroll, Darin Braden, Zach Regnery, Russell L. Davidson, Whitni Jordan, Robert Hruby, Dennis E. Damon, Inger K. TI Effective Antiviral Treatment of Systemic Orthopoxvirus Disease: ST-246 Treatment of Prairie Dogs Infected with Monkeypox Virus SO JOURNAL OF VIROLOGY LA English DT Article ID ANTIPOXVIRUS COMPOUND ST-246; TIME PCR ASSAYS; POSTEXPOSURE VACCINATION; WEST-AFRICAN; SMALLPOX; EFFICACY; CONGO; MICE; VACCINIA; MODEL AB Smallpox preparedness research has led to development of antiviral therapies for treatment of serious orthopoxvirus infections. Monkeypox virus is an emerging, zoonotic orthopoxvirus which can cause severe and transmissible disease in humans, generating concerns for public health. Monkeypox virus infection results in a systemic, febrile-rash illness closely resembling smallpox. Currently, there are no small-molecule antiviral therapeutics approved to treat orthopoxvirus infections of humans. The prairie dog, using monkeypox virus as a challenge virus, has provided a valuable nonhuman animal model in which monkeypox virus infection closely resembles human systemic orthopoxvirus illness. Here, we assess the efficacy of the antiorthopoxvirus compound ST-246 in prairie dogs against a monkeypox virus challenge of 65 times the 50% lethal dose (LD(50)). Animals were infected intranasally and administered ST-246 for 14 days, beginning on days 0, 3, or after rash onset. Swab and blood samples were collected every 2 days and analyzed for presence of viral DNA by real-time PCR and for viable virus by tissue culture. Seventy-five percent of infected animals that received vehicle alone succumbed to infection. One hundred percent of animals that received ST-246 survived challenge, and animals that received treatment before symptom onset remained largely asymptomatic. Viable virus and viral DNA were undetected or at greatly reduced levels in animals that began treatment on 0 or 3 days postinfection, compared to control animals or animals treated post-rash onset. Animals treated after rash onset manifested illness, but all recovered. Our results indicate that ST-246 can be used therapeutically, following onset of rash illness, to treat systemic orthopoxvirus infections. C1 [Smith, Scott K.; Self, Josh; Weiss, Sonja; Carroll, Darin; Braden, Zach; Regnery, Russell L.; Davidson, Whitni; Damon, Inger K.] Ctr Dis Control & Prevent, Poxvirus Team, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol,Natl Ctr, Atlanta, GA 30333 USA. [Jordan, Robert; Hruby, Dennis E.] SIGA Technol Inc, Corvallis, OR USA. RP Smith, SK (reprint author), Ctr Dis Control & Prevent, Poxvirus Team, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol,Natl Ctr, Mail Stop G-06,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM sksmith@cdc.gov NR 27 TC 21 Z9 22 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD SEP PY 2011 VL 85 IS 17 BP 9176 EP 9187 DI 10.1128/JVI.02173-10 PG 12 WC Virology SC Virology GA 804AO UT WOS:000293626100066 PM 21697474 ER PT J AU Cardis, E Armstrong, BK Bowman, JD Giles, GG Hours, M Krewski, D McBride, M Parent, ME Sadetzki, S Woodward, A Brown, J Chetrit, A Figuerola, J Hoffmann, C Jarus-Hakak, A Montestruq, L Nadon, L Richardson, L Villegas, R Vrijheid, M AF Cardis, E. Armstrong, B. K. Bowman, J. D. Giles, G. G. Hours, M. Krewski, D. McBride, M. Parent, M. E. Sadetzki, S. Woodward, A. Brown, J. Chetrit, A. Figuerola, J. Hoffmann, C. Jarus-Hakak, A. Montestruq, L. Nadon, L. Richardson, L. Villegas, R. Vrijheid, M. TI Risk of brain tumours in relation to estimated RF dose from mobile phones: results from five Interphone countries SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CELLULAR-TELEPHONE USE; CORDLESS TELEPHONES; POOLED ANALYSIS; CANCER; POPULATION; MENINGIOMA; GLIOMA; COHORT; USERS AB Objectives The objective of this study was to examine the associations of brain tumours with radio frequency (RF) fields from mobile phones. Methods Patients with brain tumour from the Australian, Canadian, French, Israeli and New Zealand components of the Interphone Study, whose tumours were localised by neuroradiologists, were analysed. Controls were matched on age, sex and region and allocated the 'tumour location' of their matched case. Analyses included 553 glioma and 676 meningioma cases and 1762 and 1911 controls, respectively. RF dose was estimated as total cumulative specific energy (TCSE; J/kg) absorbed at the tumour's estimated centre taking into account multiple RF exposure determinants. Results ORs with ever having been a regular mobile phone user were 0.93 (95% CI 0.73 to 1.18) for glioma and 0.80 (95% CI 0.66 to 0.96) for meningioma. ORs for glioma were below 1 in the first four quintiles of TCSE but above 1 in the highest quintile, 1.35 (95% CI 0.96 to 1.90). The OR increased with increasing TCSE 7+ years before diagnosis (p-trend 0.01; OR 1.91, 95% CI 1.05 to 3.47 in the highest quintile). A complementary analysis in which 44 glioma and 135 meningioma cases in the most exposed area of the brain were compared with gliomas and meningiomas located elsewhere in the brain showed increased ORs for tumours in the most exposed part of the brain in those with 10+ years of mobile phone use (OR 2.80, 95% CI 1.13 to 6.94 for glioma). Patterns for meningioma were similar, but ORs were lower, many below 1.0. Conclusions There were suggestions of an increased risk of glioma in long-term mobile phone users with high RF exposure and of similar, but apparently much smaller, increases in meningioma risk. The uncertainty of these results requires that they be replicated before a causal interpretation can be made. C1 [Cardis, E.; Figuerola, J.; Villegas, R.; Vrijheid, M.] Hosp del Mar, Res Inst, Ctr Res Environm Epidemiol CREAL, CIBERESP, Barcelona 08003, Spain. [Armstrong, B. K.; Brown, J.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Bowman, J. D.] NIOSH, Engn & Phys Hazards Branch, Cincinnati, OH 45226 USA. [Giles, G. G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [Giles, G. G.] Univ Melbourne, Sch Populat Hlth, Ctr MEGA Epidemiol, Melbourne, Vic, Australia. [Hours, M.; Montestruq, L.] Univ Lyon, Inst Francais Sci & Technol Transports, Inst Natl Veille Sanitaire, Unite Mixte Rech Epidemiol & Surveillance Transpo, Lyon, France. [Krewski, D.] Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada. [McBride, M.] BC Canc Agcy, BC Canc Res Ctr, Vancouver, BC, Canada. [Parent, M. E.; Nadon, L.] Univ Quebec, INRS Inst Armand Frappier, Laval, PQ, Canada. [Sadetzki, S.; Chetrit, A.; Jarus-Hakak, A.] Chaim Sheba Med Ctr, Gertner Inst, Canc & Radiat Epidemiol Unit, IL-52621 Tel Hashomer, Israel. [Sadetzki, S.; Hoffmann, C.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel. [Woodward, A.] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand. [Hoffmann, C.] Chaim Sheba Med Ctr, Dept Diagnost Imaging, IL-52621 Tel Hashomer, Israel. [Richardson, L.] Univ Montreal, Hosp Res Ctr CRCHUM, Dept Populat Hlth, Montreal, PQ, Canada. RP Cardis, E (reprint author), Hosp del Mar, Res Inst, Ctr Res Environm Epidemiol CREAL, CIBERESP, Doctor Aiguader 88, Barcelona 08003, Spain. EM ecardis@creal.cat RI Armstrong, Bruce/K-9464-2015; Cardis, Elisabeth/C-3904-2017; Vrijheid, M/H-2702-2014; OI Armstrong, Bruce/0000-0001-8940-7525; Vrijheid, M/0000-0002-7090-1758; Woodward, Alistair/0000-0001-5425-6018; Giles, Graham/0000-0003-4946-9099 FU International Union against Cancer (UICC) [QLK4-CT-1999901563]; Mobile Manufacturers' Forum; GSM Association; National Health and Medical Research Council [219129]; University of Sydney Medical Foundation; Australian Postgraduate Award; Canadian Institutes of Health Research [MOP-42525]; Canada Research Chair programme; Guzzo-CRS Chair in Environment and Cancer; Fonds de recherche en sante du Quebec; Canadian Wireless Telecommunications Association; l'Association pour la Recherche sur le Cancer (ARC) [5142]; Health Research Council; Hawkes Bay Medical Research Foundation; Cancer Society of New Zealand FX Funding for the Interphone Study was provided by the European Fifth Framework Program, 'Quality of Life and Management of Living Resources' (contract QLK4-CT-1999901563), the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers' Forum and GSM Association. Provision of funds to the Interphone Study investigators via the UICC was governed by agreements that guaranteed Interphone's complete scientific independence. The terms of these agreements are publicly available at http://www. iarc.fr/en/research-groups/RAD/RCAd.html Specific additional funds were provided for the development and analysis of the radio frequency exposure gradient and by the Fondation Sante et Radiofrequences, France and the Bundesamt fuer Strahlenschutz, Germany. The Australian centre was supported by the National Health and Medical Research Council (EME grant 219129); BKA was supported by the University of Sydney Medical Foundation Program Grant and Julianne Brown by an Australian Postgraduate Award. The Cancer Council NSW and the Cancer Council Victoria provided most of the infrastructure for the project in Australia. The Canada-Montreal data collection was funded by a grant from the Canadian Institutes of Health Research (project MOP-42525). Additionally, Dr Siemiatycki's research team was partly funded by the Canada Research Chair programme and by the Guzzo-CRS Chair in Environment and Cancer. Dr. Parent had salary support from the Fonds de recherche en sante du Quebec. The other Canadian centres were supported by a university-industry partnership grant from the Canadian Institutes of Health Research (CIHR), the latter including partial support from the Canadian Wireless Telecommunications Association. The CIHR university-industry partnerships program also includes provisions that ensure complete scientific independence of the investigators. DK is the NSERC/SSHRC/McLaughlin Chair in Population Health Risk Assessment at the University of Ottawa. Additional funding for the study in France was provided by l'Association pour la Recherche sur le Cancer (ARC) (contract 5142) and three network operators (Orange, SFR, Bouygues Telecom). The funds provided by the operators represented 5% of the total cost of the French study and were governed by contracts guaranteeing the complete scientific independence of the investigators. In New Zealand, funding was provided by the Health Research Council, Hawkes Bay Medical Research Foundation and the Cancer Society of New Zealand. The findings and conclusions in this paper have not been formally disseminated by the National Institute for Occupational Safety and Health and should not be construed to represent any agency determination or policy. NR 29 TC 49 Z9 53 U1 5 U2 25 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD SEP PY 2011 VL 68 IS 9 BP 631 EP 640 DI 10.1136/oemed-2011-100155 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 806DZ UT WOS:000293787700002 PM 21659469 ER PT J AU Cardis, E Varsier, N Bowman, JD Deltour, I Figuerola, J Mann, S Moissonnier, M Taki, M Vecchia, P Villegas, R Vrijheid, M Wake, K Wiart, J AF Cardis, E. Varsier, N. Bowman, J. D. Deltour, I. Figuerola, J. Mann, S. Moissonnier, M. Taki, M. Vecchia, P. Villegas, R. Vrijheid, M. Wake, K. Wiart, J. TI Estimation of RF energy absorbed in the brain from mobile phones in the Interphone Study SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CELLULAR-TELEPHONE USE; CORDLESS TELEPHONES; POOLED ANALYSIS; OUTPUT POWER; TUMOR RISK; EXPOSURE; CANCER; POPULATION; VALIDATION; MENINGIOMA AB Objectives The objective of this study was to develop an estimate of a radio frequency (RF) dose as the amount of mobile phone RF energy absorbed at the location of a brain tumour, for use in the Interphone Epidemiological Study. Methods We systematically evaluated and quantified all the main parameters thought to influence the amount of specific RF energy absorbed in the brain from mobile telephone use. For this, we identified the likely important determinants of RF specific energy absorption rate during protocol and questionnaire design, we collected information from study subjects, network operators and laboratories involved in specific energy absorption rate measurements and we studied potential modifiers of phone output through the use of software-modified phones. Data collected were analysed to assess the relative importance of the different factors, leading to the development of an algorithm to evaluate the total cumulative specific RF energy (in joules per kilogram), or dose, absorbed at a particular location in the brain. This algorithm was applied to Interphone Study subjects in five countries. Results The main determinants of total cumulative specific RF energy from mobile phones were communication system and frequency band, location in the brain and amount and duration of mobile phone use. Though there was substantial agreement between categorisation of subjects by cumulative specific RF energy and cumulative call time, misclassification was non-negligible, particularly at higher frequency bands. Factors such as adaptive power control (except in Code Division Multiple Access networks), discontinuous transmission and conditions of phone use were found to have a relatively minor influence on total cumulative specific RF energy. Conclusions While amount and duration of use are important determinants of RF dose in the brain, their impact can be substantially modified by communication system, frequency band and location in the brain. It is important to take these into account in analyses of risk of brain tumours from RF exposure from mobile phones. C1 [Cardis, E.; Figuerola, J.; Villegas, R.; Vrijheid, M.] Hosp del Mar, Res Inst IMIM, Ctr Res Environm Epidemiol CREAL, CIBERESP, Barcelona 08003, Spain. [Cardis, E.; Deltour, I.; Moissonnier, M.; Vrijheid, M.] Int Agcy Res Canc, F-69372 Lyon, France. [Varsier, N.; Wiart, J.] France Telecom RD, Issy Les Moulineaux, France. [Bowman, J. D.] NIOSH, Engn & Phys Hazards Branch, Cincinnati, OH 45226 USA. [Deltour, I.] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. [Mann, S.] Hlth Protect Agcy, Ctr Radiat Chem & Environm Hazards, Didcot, Oxon, England. [Taki, M.] Tokyo Metropolitan Univ, Dept Elect & Elect Engn, Tokyo 158, Japan. [Taki, M.] Natl Inst Informat & Commun Technol, Appl Elect Res Ctr, EMC Grp, Tokyo, Japan. [Vecchia, P.; Wake, K.] NIH, Dept Technol & Hlth, Rome, Italy. RP Cardis, E (reprint author), Hosp del Mar, Res Inst IMIM, Ctr Res Environm Epidemiol CREAL, CIBERESP, Doctor Aiguader 88, Barcelona 08003, Spain. EM ecardis@creal.cat RI Cardis, Elisabeth/C-3904-2017; Vrijheid, M/H-2702-2014 OI Vrijheid, M/0000-0002-7090-1758 FU European Fifth Framework Program, 'Quality of Life and Management of Living Resources' [QLK4-CT-1999901563]; International Union against Cancer (UICC); Mobile Manufacturers' Forum; GSM Association; German Bundesamt fuer Strahlenschutz; French Fondation Sante et Radiofrequences; Committee to Promote Research on the Possible Biological Effect of Electromagnetic Fields, Ministry of Internal Affairs and Communications, Japan FX This Interphone Study was conducted with funding from the European Fifth Framework Program, 'Quality of Life and Management of Living Resources' (contract QLK4-CT-1999901563) and the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers' Forum and GSM Association. Provision of funds to the Interphone Study investigators via the UICC was governed by agreements that guaranteed Interphone's complete scientific independence. The terms of these agreements are publicly available at http://www. iarc.fr/ENG/Units/RCAd.html/. Specific additional funding for the RF dose algorithm and the analyses presented here were provided by the German Bundesamt fuer Strahlenschutz, the French Fondation Sante et Radiofrequences and the Committee to Promote Research on the Possible Biological Effect of Electromagnetic Fields, Ministry of Internal Affairs and Communications, Japan. The findings and conclusions in this paper have not been formally disseminated by the National Institute for Occupational Safety and Health and should not be construed to represent any agency determination or policy. NR 52 TC 19 Z9 19 U1 2 U2 9 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD SEP PY 2011 VL 68 IS 9 BP 686 EP 693 DI 10.1136/oemed-2011-100065 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 806DZ UT WOS:000293787700010 PM 21659468 ER PT J AU Li, Y Guo, HX Xu, WT Wu, TS Ma, HL Fontaine, RE AF Li, Yuan Guo, Hongxiong Xu, Wenti Wu, Taishun Ma, Huilai Fontaine, Robert E. TI A Community Outbreak of Rotavirus Diarrhea Associated With Exposures in a Hospital Outpatient Department in South China SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE rotavirus; outbreak; nosocomial infection; outpatient ID GROUP-A ROTAVIRUS; RISK-FACTORS; CHILDREN; DISEASE; EPIDEMIOLOGY; GASTROENTERITIS; INFECTIONS; SURVIVAL; SPREAD; VIRUS AB Introduction: Between October 1 and December 10, 2006, Bao'an, China had a 5-fold increase in acute rotavirus gastroenteritis (ARGE) cases compared with the same time in 2005. To identify the risk factors for ARGE during this outbreak, we conducted a case-control study among children <= 24 months old from the most heavily affected area. Methods: We defined an ARGE case as diarrhea, with group A rotavirus antigen detected from fecal samples by the enzyme-linked immunosorbent assay test. In the case-control study, 86 confirmed ARGE cases were identified. We enrolled 98 healthy control children matched by age. We administered questionnaires about exposures through telephone interviews. Results: Of 8 general exposure types, we identified the following as being associated with ARGE: visiting outpatient services of hospital X, odds ratio (OR) = 7.1 (95% confidence interval [CI], 2.2-26); contact with other children with diarrhea, OR = 2.1 (95% CI, 1.1-3.7); and hand-washing before eating, OR = 0.48 (95% CI, 0.27-0.82). After improvements in the outpatient department of hospital X, ARGE incidence in the community during the ARGE transmission season (October through December) decreased from 4.3/10000 in 2006 to 1.4/10000 in 2009. Conclusions: Outpatient services in hospital X may have contributed to the transmission of ARGE and improvements in infection control practices in this setting were associated a marked decrease incidence of ARGE in this community. C1 [Guo, Hongxiong] Jiangsu Ctr Dis Control & Prevent, Nanjing 210009, Peoples R China. [Li, Yuan; Wu, Taishun] Shenzhen Baoan Ctr Dis Control & Prevent, Shenzhen, Peoples R China. [Xu, Wenti] Tianjing Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Ma, Huilai] China Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Fontaine, Robert E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Guo, HX (reprint author), Jiangsu Ctr Dis Control & Prevent, Nanjing 210009, Peoples R China. EM guohongxiong@jscdc.cn NR 19 TC 2 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD SEP PY 2011 VL 30 IS 9 BP 745 EP 748 DI 10.1097/INF.0b013e31821fa542 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 809IF UT WOS:000294044400007 PM 21587095 ER PT J AU Jhung, MA Davidson, H McIntyre, A Gregg, WJ Dasgupta, S D'Mello, T White, V Fowlkes, A Brammer, L Finelli, L AF Jhung, Michael A. Davidson, Heidi McIntyre, Anne Gregg, William J. Dasgupta, Sharoda D'Mello, Tiffany White, Victoria Fowlkes, Ashley Brammer, Lynnette Finelli, Lyn TI Preliminary results of 2009 pandemic influenza surveillance in the United States using the Aggregate Hospitalization and Death Reporting Activity SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE H1N1 influenza; pandemic; surveillance ID INFECTIOUS-DISEASE HOSPITALIZATIONS; SEASONAL INFLUENZA; H1N1 INFLUENZA; VACCINE; BURDEN; VIRUS; OLDER; WAVE AB Background To augment established influenza surveillance systems in the United States, the Centers for Disease Control and Prevention and the Council of State and Territorial Epidemiologists implemented the Aggregate Hospitalization and Death Reporting Activity (AHDRA) in August 2009. The AHDRA was designed to meet increased demands for timely and detailed information describing illness severity during the 2009 H1N1 influenza A (pH1N1) pandemic response. Objectives We describe the implementation of AHDRA and provide preliminary results from this new surveillance activity. Methods All 50 US states were asked to report influenza-associated hospitalizations and deaths to AHDRA each week using either a laboratory-confirmed or syndromic surveillance definition. Aggregate counts were used to calculate age-specific weekly and cumulative rates per 100 000, and laboratory-confirmed reports were used to estimate the age distribution of pH1N1 influenza-associated hospitalizations and deaths. Results From August 30, 2009, through April 6, 2010, AHDRA identified 41 689 laboratory-confirmed influenza-associated hospitalizations and 2096 laboratory-confirmed influenza-associated deaths. Aggregate Hospitalization and Death Reporting Activity rates peaked earlier than hospitalization and death rates seen in previous influenza seasons with other surveillance systems, and the age distribution of cases revealed a tendency for hospitalizations and deaths to occur in persons <65 years for age. Conclusions Aggregate Hospitalization and Death Reporting Activity laboratory-confirmed reports provided important information during the 2009 pandemic response. Aggregate Hospitalization and Death Reporting Activity syndromic reports were marked by low representativeness and specificity and were therefore less useful. The AHDRA was implemented quickly and may be a useful surveillance system to monitor severe illness during future influenza pandemics. C1 [Jhung, Michael A.; Davidson, Heidi; McIntyre, Anne; Gregg, William J.; Dasgupta, Sharoda; D'Mello, Tiffany; White, Victoria; Fowlkes, Ashley; Brammer, Lynnette; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Jhung, MA (reprint author), 1600 Clifton Rd,MS A32, Atlanta, GA 30333 USA. EM mjhung@cdc.gov; lyf8@cdc.gov NR 21 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2011 VL 5 IS 5 BP 321 EP 327 DI 10.1111/j.1750-2659.2011.00230.x PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 805RX UT WOS:000293747800005 PM 21668693 ER PT J AU Eisenstein, AR Prohaska, TR Kruger, J Satariano, WA Hooker, S Buchner, D Kealey, M Hunter, RH AF Eisenstein, Amy R. Prohaska, Thomas R. Kruger, Judy Satariano, William A. Hooker, Steven Buchner, David Kealey, Melissa Hunter, Rebecca H. TI Environmental Correlates of Overweight and Obesity in Community Residing Older Adults SO JOURNAL OF AGING AND HEALTH LA English DT Article DE obesity; walking; environment; aging ID PHYSICAL-ACTIVITY; BUILT ENVIRONMENT; PUBLIC-HEALTH; UNITED-STATES; WALKING; ASSOCIATION AB Objective: This study examines the role of environmental correlates of overweight and obesity among older adults independent of walking activity and lower body function. Methods: In-person interviews were conducted with 789 adults aged 65 and older, residing in four areas in the U.S. Demographic information, general health, lower body function, walking behavior, and awareness of environmental infrastructure features using the modified Neighborhood Environment Walking Survey (NEWS) were obtained. Regression analyses examined the association between Body Mass Index (BMI) and environmental infrastructure features, adjusting for demographics and lower body function. Results: Older adults who perceived their neighborhood as less safe from crime and had reduced access to services were more likely to have higher BMI. Controlling for demographic and functional characteristics, access to services remained significant. This association remained significant for those with lower functional status. Discussion: This research suggests that neighborhood environment may have an influence on BMI above and beyond walking activity. C1 [Eisenstein, Amy R.] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL 60608 USA. [Kruger, Judy] Ctr Dis Control & Prevent, Druid Hills, GA USA. [Satariano, William A.; Kealey, Melissa] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Hooker, Steven] Univ S Carolina, Columbia, SC 29208 USA. [Buchner, David] Univ Illinois, Champaign, IL USA. [Hunter, Rebecca H.] Univ N Carolina, Chapel Hill, NC USA. RP Eisenstein, AR (reprint author), Univ Illinois, Inst Hlth Res & Policy, 1747 W Roosevelt Rd,MC 275, Chicago, IL 60608 USA. EM aeisen3@uic.edu OI Hooker, Steven/0000-0001-9969-6244 FU NCCDPHP CDC HHS [CDC-U 48 DP00033-01]; NIA NIH HHS [T32 AG020501-05S1]; PHS HHS [1-P50-ESO12383] NR 20 TC 10 Z9 10 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD SEP PY 2011 VL 23 IS 6 BP 994 EP 1009 DI 10.1177/0898264311404557 PG 16 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 802HF UT WOS:000293499200006 PM 21508306 ER PT J AU Louis, GMB Schisterman, EF Sweeney, AM Wilcosky, TC Gore-Langton, RE Lynch, CD Barr, DB Schrader, SM Kim, S Chen, Z Sundaram, R AF Louis, Germaine M. Buck Schisterman, Enrique F. Sweeney, Anne M. Wilcosky, Timothy C. Gore-Langton, Robert E. Lynch, Courtney D. Barr, Dana Boyd Schrader, Steven M. Kim, Sungduk Chen, Zhen Sundaram, Rajeshwari CA LIFE Study TI Designing prospective cohort studies for assessing reproductive and developmental toxicity during sensitive windows of human reproduction and development - the LIFE Study SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE cohort; environment; fecundity; fertility; LIFE Study; preconception; pregnancy; study design; enrolment ID EARLY-PREGNANCY LOSS; SPONTANEOUS-ABORTION; DYSGENESIS SYNDROME; RECRUITMENT; FERTILITY; FECUNDITY; OBESITY; STYLE; TIME; RISK AB The relationship between the environment and human fecundity and fertility remains virtually unstudied from a couple-based perspective in which longitudinal exposure data and biospecimens are captured across sensitive windows. In response, we completed the LIFE Study with methodology that intended to empirically evaluate a priori purported methodological challenges: implementation of population-based sampling frameworks suitable for recruiting couples planning pregnancy; obtaining environmental data across sensitive windows of reproduction and development; home-based biospecimen collection; and development of a data management system for hierarchical exposome data. We used two sampling frameworks (i.e. fish/wildlife licence registry and a direct marketing database) for 16 targeted counties with presumed environmental exposures to persistent organochlorine chemicals to recruit 501 couples planning pregnancies for prospective longitudinal follow-up while trying to conceive and throughout pregnancy. Enrolment rates varied from <1% of the targeted population (n = 424 423) to 42% of eligible couples who were successfully screened; 84% of the targeted population could not be reached, while 36% refused screening. Among enrolled couples, similar to 85% completed daily journals while trying; 82% of pregnant women completed daily early pregnancy journals, and 80% completed monthly pregnancy journals. All couples provided baseline blood/urine samples; 94% of men provided one or more semen samples and 98% of women provided one or more saliva samples. Women successfully used urinary fertility monitors for identifying ovulation and home pregnancy test kits. Couples can be recruited for preconception cohorts and will comply with intensive data collection across sensitive windows. However, appropriately sized sampling frameworks are critical, given the small percentage of couples contacted found eligible and reportedly planning pregnancy at any point in time. C1 [Louis, Germaine M. Buck; Schisterman, Enrique F.; Kim, Sungduk; Chen, Zhen; Sundaram, Rajeshwari] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, NIH, Rockville, MD 20852 USA. [Sweeney, Anne M.] Texas A&M Hlth Sci Ctr, Sch Rural Publ Hlth, College Stn, TX USA. [Wilcosky, Timothy C.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Gore-Langton, Robert E.] EMMES Corp, Rockville, MD USA. [Lynch, Courtney D.] Ohio State Univ, Coll Med, Dept Obstet & Gynecol, Columbus, OH 43210 USA. [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA. [Schrader, Steven M.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Louis, GMB (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, NIH, 6100 Execut Blvd, Rockville, MD 20852 USA. EM louisg@mail.nih.gov RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013; OI Sundaram, Rajeshwari/0000-0002-6918-5002; Schisterman, Enrique/0000-0003-3757-641X; Buck Louis, Germaine/0000-0002-1774-4490 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [N01-HD-3-3355, N01-HD-3-3356, N01-HD-3-3358] FX This study was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (contracts #N01-HD-3-3355, N01-HD-3-3356, N01-HD-3-3358). The authors acknowledge the support of the Texas Parks and Wildlife Department in providing the database for study purposes. The authors have no competing interests. NR 22 TC 69 Z9 69 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD SEP PY 2011 VL 25 IS 5 BP 413 EP 424 DI 10.1111/j.1365-3016.2011.01205.x PG 12 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 804MV UT WOS:000293658800002 ER PT J AU Tinker, SC Reefhuis, J Dellinger, AM Jamieson, DJ AF Tinker, Sarah C. Reefhuis, Jennita Dellinger, Ann M. Jamieson, Denise J. CA Natl Birth Defects Prevention Stud TI Maternal injuries during the periconceptional period and the risk of birth defects, National Birth Defects Prevention Study, 1997-2005 SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE maternal prenatal injuries; congenital malformations; intentional injury; accident; domestic abuse ID SUSPECTED HUMAN TERATOGENS; CONGENITAL-MALFORMATIONS; WASHINGTON-STATE; LIFE EVENTS; PREGNANCY; TRAUMA; FETAL; EPIDEMIOLOGY; EXPOSURE; OUTCOMES AB Maternal injuries during pregnancy are common (similar to 7% prevalence). However, few studies have examined the association between maternal injuries and birth defects. The National Birth Defects Prevention Study is a population-based case-control study of birth defects in 10 US states. Cases were ascertained through surveillance; controls were randomly selected from infants delivered without major birth defects in the study regions. Mothers completed a telephone interview on exposures before and during pregnancy, including injuries. We assessed associations between periconceptional (month before until the end of the third month of pregnancy) maternal injuries and birth defects. We used logistic regression to estimate adjusted odds ratios (AORs) and 95% confidence intervals (CI). Periconceptional injuries were associated with interrupted aortic arch type B [AOR = 5.2, 95% CI 1.2, 23.2]; atrioventricular septal defect [AOR = 2.2, 95% CI 1.1, 4.4]; pulmonary atresia [AOR = 3.2, 95% CI 1.6, 6.4]; tricuspid atresia [AOR = 2.8, 95% CI 1.2, 6.7]; hypoplastic left heart syndrome [AOR = 2.0, 95% CI 1.1, 3.4]; anorectal atresia/stenosis [AOR = 1.7, 95% CI 1.0, 2.7]; longitudinal limb deficiency [AOR = 2.1, 95% CI 1.1, 3.9]; and gastroschisis [AOR = 1.8, 95% CI 1.2, 2.8]. Associations with longitudinal limb deficiency, gastroschisis and hypoplastic left heart syndrome were stronger for intentional injuries. Our results suggest maternal injury during the periconceptional period, particularly those inflicted intentionally, may be associated with select birth defects. This analysis was hypothesis-generating, with many associations tested. Further research is warranted. C1 [Tinker, Sarah C.; Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, CDC, Atlanta, GA 30333 USA. [Dellinger, Ann M.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Jamieson, Denise J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Tinker, SC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, CDC, 1600 Clifton Rd NE,Mail Stop E-86, Atlanta, GA 30333 USA. EM zzu9@cdc.gov FU Centers for Disease Control and Prevention FX This study was funded by the Centers for Disease Control and Prevention. The authors thank the participating families and study investigators and staff at the National Birth Defects Prevention Study sites for their important contributions. NR 29 TC 6 Z9 6 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-5022 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD SEP PY 2011 VL 25 IS 5 BP 487 EP 496 DI 10.1111/j.1365-3016.2011.01215.x PG 10 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 804MV UT WOS:000293658800009 PM 21819430 ER PT J AU Leichliter, JS Lewis, DA Sternberg, M Habel, MA Paz-Bailey, G AF Leichliter, Jami S. Lewis, David A. Sternberg, Maya Habel, Melissa A. Paz-Bailey, Gabriela TI Health Care Seeking Among Men With Genital Ulcer Disease in South Africa: Correlates and Relationship to Human Immunodeficiency Virus-1 and Herpes Simplex Virus Type 2 Detection and Shedding SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; INFECTION; BEHAVIOR; MANAGEMENT; DETERMINANTS; METAANALYSIS; STRATEGIES; EPIDEMICS; ETIOLOGY; HIV-1 AB Background: Episodic acyclovir therapy has been added to genital ulcer disease (GUD) syndromic management guidelines in several sub-Saharan African countries with human immunodeficiency virus (HIV) epidemics. We examined the correlates of health care seeking in men with GUD and its relationship to HIV-1 and herpes simplex virus type 2 outcomes. Methods: Men with GUD (n = 615) were recruited from primary health care clinics in Gauteng province, South Africa for a randomized controlled trial of episodic acyclovir therapy. We used baseline survey and sexually transmitted infection/HIV-testing data to examine delay in health care seeking (defined as time from ulcer recognition to baseline study visit). Results: Median delay in health care seeking for GUD was 5 days, and one-quarter of men had previously sought care for the current ulcer. Previous care seekers were older, had more episodes of ulceration in the past year, and were more likely to test seropositive for HIV-1 and HSV-2. Delay in health care seeking was significantly associated with age, education level, and sex during the ulceration episode. Delays in care seeking were related to poorer HIV-1 outcomes; these findings were valid after controlling for advanced HIV. Conclusions: Interventions to help shorten the duration between ulcer recognition and health care seeking for men with GUD are needed. C1 [Leichliter, Jami S.; Sternberg, Maya; Habel, Melissa A.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Lewis, David A.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, STI Reference Ctr, Johannesburg, South Africa. [Lewis, David A.] Univ Witwatersrand, Dept Internal Med, Johannesburg, South Africa. [Paz-Bailey, Gabriela] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Paz-Bailey, Gabriela] Tephinet Inc, Atlanta, GA USA. RP Leichliter, JS (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS E-44, Atlanta, GA 30333 USA. EM jleichliter@cdc.gov FU National Health Laboratory Service, South Africa; U.S. Centers for Disease Control and Prevention [U62/CCU022901] FX Financially supported by National Health Laboratory Service, South Africa (core funding) and U.S. Centers for Disease Control and Prevention Cooperative Agreement (U62/CCU022901). NR 26 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD SEP PY 2011 VL 38 IS 9 BP 865 EP 870 DI 10.1097/OLQ.0b013e31821d4ceb PG 6 WC Infectious Diseases SC Infectious Diseases GA 805NE UT WOS:000293733400015 PM 21844743 ER PT J AU Magee, E Tryon, C Forbes, A Manangan, L AF Magee, Elvin Tryon, Cheryl Forbes, Alstead Manangan, Lilia TI The National Tuberculosis Surveillance System Training Program to Ensure Accuracy of Tuberculosis Data SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE surveillance; training; tuberculosis AB Objectives: The Centers for Disease Control and Prevention implemented a national training program for health care workers and surveillance staff to ensure accuracy of data reported to the Centers for Disease Control and Prevention's National Tuberculosis Surveillance System and increase training capacity in tuberculosis surveillance. Methods: To address the changing epidemiology of tuberculosis and related reporting requirements, a working group of tuberculosis experts revised the Report of Verified Case of Tuberculosis (RVCT), the National Tuberculosis Surveillance System data collection form. The revision prompted a need for training in accurately completing the form. A Centers for Disease Control and Prevention interdisciplinary training team collaborated with key partners in assessing health care worker training needs regarding the RVCT. The team conducted 5 field tests to ensure instructional effectiveness of the training materials. Participants worked through materials, shared experiences, asked questions, and stated concerns about the RVCT. On the basis of these inputs, the team developed an innovative and comprehensive training program. Results: The training materials included instructions for completing each item on the RVCT form, case studies to enable participants to apply the instructions to real-life situations, and visual aids to enhance learning. In both quantitative and qualitative responses, participants indicated that the RVCT training course and self-study materials helped them gain the knowledge needed to accurately complete the RVCT. The team conducted 14 facilitator-led courses and trained 343 health care workers and surveillance staff; 82 of these were training-of-trainers participants. Conclusions: Collaboration and innovation are essential in implementing an effective national surveillance-training program to ensure the accurate collection and reporting of tuberculosis surveillance data. C1 [Magee, Elvin; Tryon, Cheryl; Forbes, Alstead; Manangan, Lilia] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Magee, E (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM EMagee@cdc.gov NR 9 TC 3 Z9 3 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2011 VL 17 IS 5 BP 427 EP 430 DI 10.1097/PHH.0b013e31820f8e43 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 797LC UT WOS:000293128200009 PM 21788780 ER PT J AU Williams, W Lowery, NE Lyalin, D Lambrecht, N Riddick, S Sutliff, C Papadouka, V AF Williams, Warren Lowery, N. Elaine Lyalin, David Lambrecht, Nichole Riddick, Sherry Sutliff, Cynthia Papadouka, Vikki TI Development and Utilization of Best Practice Operational Guidelines for Immunization Information Systems SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE consensus workshops; group processes; immunization information system; immunization; registries ID CONSENSUS METHODS; PUBLIC-HEALTH AB Objective: To describe collaborative efforts to develop best practice operational guidelines for immunization information systems (IIS) and discuss awareness, acceptance, and utilization of the guidelines by the IIS community. Design: Business analysis and facilitation techniques were used to support collaboration among IIS stakeholders who analyzed existing practices, brainstormed new approaches, and developed consensus-based recommendations. The guideline development process and its impact on IIS were evaluated using a postworkshop questionnaire, the IIS Annual Report, and an online survey for one of the guidelines. Setting: Immunization information systems domain in the United States. Participants: Staff from IIS; federal agencies; state, regional, and county health departments; privately run registries; and vendors/consultants. Main Outcome Measure(s): These included (1) completion of best practice guidelines; (2) degree of satisfaction among the participating IIS stakeholders with the work process and outcomes, interest, and willingness to implement best practice guidelines in their own IIS; (3) awareness and use of, as well as satisfaction with, the guidelines for patient active/inactive immunization status among IIS; and (4) acceptance and implementation of best practice guidelines across the US IIS. Results: Since 2005, operational guidelines (that contain best practice recommendations) have been developed for 5 IIS functional areas: reminder/recall notifications, data quality assurance, vaccination level deduplication, management of patient active/inactive status, and adverse events reporting. Immunization information systems stakeholders who participated in the development of the recommendations expressed a high level of satisfaction with the process and the recommendations. Based on IIS Annual Report data, from 2007 to 2009 use of the guidelines increased from 46% to 80% of IIS. Conclusions: Best practice recommendations offer practical guidelines on the most challenging operational areas for IIS. Initial evidence indicates adoption of the recommendations and satisfaction with the development process. Additional studies are needed to assess the degree of guidelines use across the IIS community. C1 [Williams, Warren] Ctr Dis Control & Prevent, Immunizat Informat Syst Support Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Lowery, N. Elaine] Publ Hlth Informat Inst, Decatur, GA USA. [Lyalin, David] Northrop Grumman CDC Informat Technol Support Con, Atlanta, GA USA. [Lambrecht, Nichole] Kansas Immunizat Registry KSWebIZ, Topeka, KS USA. [Riddick, Sherry] CHILD Profile, Immunizat Registry, Seattle, WA USA. [Sutliff, Cynthia] AIRA, New York, NY USA. [Papadouka, Vikki] NYC Dept Hlth & Mental Hyg, New York, NY USA. RP Williams, W (reprint author), Ctr Dis Control & Prevent, Immunizat Informat Syst Support Branch, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS E-62, Atlanta, GA 30333 USA. EM wxw4@cdc.gov OI Lambrecht, Nils/0000-0002-1275-1384 NR 25 TC 6 Z9 6 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2011 VL 17 IS 5 BP 449 EP 456 DI 10.1097/PHH.0b013e31821138fe PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 797LC UT WOS:000293128200012 PM 21788783 ER PT J AU Liu, AY Vittinghoff, E Sellmeyer, DE Irvin, R Mulligan, K Mayer, K Thompson, M Grant, R Pathak, S O'Hara, B Gvetadze, R Chillag, K Grohskopf, L Buchbinder, SP AF Liu, Albert Y. Vittinghoff, Eric Sellmeyer, Deborah E. Irvin, Risha Mulligan, Kathleen Mayer, Kenneth Thompson, Melanie Grant, Robert Pathak, Sonal O'Hara, Brandon Gvetadze, Roman Chillag, Kata Grohskopf, Lisa Buchbinder, Susan P. TI Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco SO PLOS ONE LA English DT Article ID ANTIRETROVIRAL THERAPY; ABACAVIR-LAMIVUDINE; GENITAL-TRACT; INFECTION; METHAMPHETAMINE; EMTRICITABINE; FRACTURES; EFAVIRENZ; WOMEN; RISK AB Background: Pre-exposure prophylaxis (PrEP) trials are evaluating regimens containing tenofovir-disoproxil fumarate (TDF) for HIV prevention. We determined the baseline prevalence of low bone mineral density (BMD) and the effect of TDF on BMD in men who have sex with men (MSM) in a PrEP trial in San Francisco. Methods/Findings: We evaluated 1) the prevalence of low BMD using Dual Energy X-ray Absorptiometry (DEXA) in a baseline cohort of 210 HIV-uninfected MSM who screened for a randomized clinical trial of daily TDF vs. placebo, and 2) the effects of TDF on BMD in a longitudinal cohort of 184 enrolled men. Half began study drug after a 9-month delay to evaluate changes in risk behavior associated with pill-use. At baseline, 20 participants (10%) had low BMD (Z score <=-22.0 at the L2-L4 spine, total hip, or femoral neck). Low BMD was associated with amphetamine (OR = 5.86, 95% CI 1.70-20.20) and inhalant (OR = 4.57, 95% CI 1.32-15.81) use; men taking multivitamins, calcium, or vitamin D were less likely to have low BMD at baseline (OR = 0.26, 95% CI 0.10-0.71). In the longitudinal analysis, there was a 1.1% net decrease in mean BMD in the TDF vs. the pre-treatment/placebo group at the femoral neck (95% CI 0.4-1.9%), 0.8% net decline at the total hip (95% CI 0.3-1.3%), and 0.7% at the L2-L4 spine (95% CI 20.1-1.5%). At 24 months, 13% vs. 6% of participants experienced >5% BMD loss at the femoral neck in the TDF vs. placebo groups (p = 0.13). Conclusions: Ten percent of HIV-negative MSM had low BMD at baseline. TDF use resulted in a small but statistically significant decline in BMD at the total hip and femoral neck. Larger studies with longer follow-up are needed to determine the trajectory of BMD changes and any association with clinical fractures. C1 [Liu, Albert Y.; Irvin, Risha; Buchbinder, Susan P.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Liu, Albert Y.; Vittinghoff, Eric; Mulligan, Kathleen; Grant, Robert; Buchbinder, Susan P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sellmeyer, Deborah E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Mayer, Kenneth] Fenway Hlth, Boston, MA USA. [Thompson, Melanie] AIDS Res Consortium Atlanta, Atlanta, GA USA. [Grant, Robert] Gladstone Inst, San Francisco, CA USA. [Pathak, Sonal; O'Hara, Brandon; Gvetadze, Roman] Northrop Grumman, Atlanta, GA USA. [Chillag, Kata; Grohskopf, Lisa] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Liu, AY (reprint author), San Francisco Dept Publ Hlth, San Francisco, CA USA. EM albert.liu@sfdph.org FU U.S. Department of Health and Human Services, Centers for Disease Control and Prevention [200-2003-03003, 200-2003-03007, 200-2004-09853]; University of California, San Francisco Clinical and Translational Science Institute Clinical Research Center [UL1 RR024131]; Gilead Sciences, the pharmaceutical company; Gilead FX This research was supported by funds from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Contracts #200-2003-03003, #200-2003-03007, and #200-2004-09853; and University of California, San Francisco Clinical and Translational Science Institute Clinical Research Center Grant #UL1 RR024131. The US Department of Health and Human Services, Centers for Disease Control and Prevention were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript. The University of California, San Francisco Clinical and Translational Science Institute was involved in data collection only.; Dr. Kenneth Mayer has received educational and research grants from Gilead Sciences, the pharmaceutical company that manufactures tenofovir. Dr. Melanie Thompson's organization (AIDS Research Consortium of Atlanta) has received research grant funding from Gilead and other pharmaceutical companies and has had a prevention research consultancy with Gilead Sciences. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. NR 46 TC 70 Z9 74 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 29 PY 2011 VL 6 IS 8 AR e23688 DI 10.1371/journal.pone.0023688 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 817MF UT WOS:000294676900015 PM 21897852 ER PT J AU Calafat, AM AF Calafat, Antonia M. TI Human biomonitoring of environmental chemicals SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 242nd National Meeting of the American-Chemical-Society (ACS) CY AUG 28-SEP 01, 2011 CL Denver, CO SP Amer Chem Soc (ACS) C1 [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30341 USA. EM aic7@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD AUG 28 PY 2011 VL 242 MA 87-TOXI PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 880BE UT WOS:000299378307555 ER PT J AU Kalb, SR Wang, DX Parks, BA Baudys, J Barr, JR AF Kalb, Suzanne R. Wang, Dongxia Parks, Bryan A. Baudys, Jakub Barr, John R. TI Detection, differentiation, and subtyping of botulinum neurotoxins with mass spectrometry SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 242nd National Meeting of the American-Chemical-Society (ACS) CY AUG 28-SEP 01, 2011 CL Denver, CO SP Amer Chem Soc (ACS) C1 [Kalb, Suzanne R.; Wang, Dongxia; Parks, Bryan A.; Baudys, Jakub; Barr, John R.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30341 USA. EM skalb@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD AUG 28 PY 2011 VL 242 MA 163-ANYL PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 880BE UT WOS:000299378300521 ER PT J AU Stepanov, I Knezevich, A Zhang, LQ Watson, CH Hatsukami, DK Hecht, SS AF Stepanov, Irina Knezevich, Aleksandar Zhang, Liqin Watson, Clifford H. Hatsukami, Dorothy K. Hecht, Stephen S. TI Carcinogenic nitrosamines in US cigarettes: Three decades of remarkable neglect by the tobacco industry SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 242nd National Meeting of the American-Chemical-Society (ACS) CY AUG 28-SEP 01, 2011 CL Denver, CO SP Amer Chem Soc (ACS) C1 [Stepanov, Irina; Knezevich, Aleksandar; Hatsukami, Dorothy K.; Hecht, Stephen S.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA. [Stepanov, Irina; Knezevich, Aleksandar; Hatsukami, Dorothy K.; Hecht, Stephen S.] Univ Minnesota, Tobacco Use Res Programs, Minneapolis, MN USA. [Zhang, Liqin; Watson, Clifford H.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM stepa011@umn.edu NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD AUG 28 PY 2011 VL 242 MA 1-TOXI PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 880BE UT WOS:000299378307474 ER PT J AU Scinicariello, F Yesuprya, A Fowler, BA Chang, M Dowling, N AF Scinicariello, F. Yesuprya, A. Fowler, B. A. Chang, M. Dowling, N. TI The modifying effect of NOS3 variants on the association between blood lead and hypertension SO TOXICOLOGY LETTERS LA English DT Meeting Abstract CT 47th Congress of the European-Societies-of-Toxicology CY AUG 28-31, 2011 CL Paris, FRANCE SP European Soc Toxicol C1 [Scinicariello, F.; Fowler, B. A.] CDC ATSDR, Div Toxicol, Atlanta, GA USA. [Yesuprya, A.; Chang, M.; Dowling, N.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-4274 J9 TOXICOL LETT JI Toxicol. Lett. PD AUG 28 PY 2011 VL 205 SU 1 BP S196 EP S196 DI 10.1016/j.toxlet.2011.05.676 PG 1 WC Toxicology SC Toxicology GA 806NI UT WOS:000293814500624 ER PT J AU Guh, AY Hadler, JL AF Guh, Alice Y. Hadler, James L. TI Use of the state immunization information system to assess rotavirus vaccine effectiveness in Connecticut, 2006-2008 SO VACCINE LA English DT Article DE Immunization information system; Vaccine effectiveness; Rotavirus vaccine ID UNITED-STATES; CHILDREN; PROGRESS AB Immunization information systems (IIS) contain individual vaccination records and have potential use for evaluating post-licensure vaccine effectiveness (VE). A matched case-control study was performed by using the Connecticut state IIS to calculate rotavirus VE against hospitalization; results were compared with pre-licensure efficacy and with estimates previously obtained by traditional case-control methods using matched controls from medical sources and medical chart abstracted data. Case-patients (n=54) were vaccine-eligible children with IIS entry and hospitalized for rotavirus gastroenteritis during July 2006-December 2008; each was matched to five control subjects (n =270) who were randomly selected from IIS based on case-patient's birth date and town of residence. VE of at least one dose was 90.6%, comparable to the pre-licensure efficacy of 96% and to the unadjusted 83.5-90.7% estimates by using traditional case-control methods. IIS can be a convenient and potentially accurate tool for calculating VE. Published by Elsevier Ltd. C1 [Guh, Alice Y.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Guh, Alice Y.; Hadler, James L.] Connecticut State Dept Publ Hlth, Hartford, CT 06134 USA. RP Guh, AY (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd,NE,MS A-31, Atlanta, GA 30329 USA. EM ggt4@cdc.gov NR 19 TC 15 Z9 15 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 26 PY 2011 VL 29 IS 37 BP 6155 EP 6158 DI 10.1016/j.vaccine.2011.06.066 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 825AR UT WOS:000295243800003 PM 21723356 ER PT J AU Richardson, V Parashar, U Patel, M AF Richardson, Vesta Parashar, Umesh Patel, Manish TI Childhood Diarrhea Deaths after Rotavirus Vaccination in Mexico SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Richardson, Vesta] Natl Ctr Child & Adolescent Hlth, Mexico City, DF, Mexico. [Parashar, Umesh; Patel, Manish] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Richardson, V (reprint author), Natl Ctr Child & Adolescent Hlth, Mexico City, DF, Mexico. EM mpatel@cdc.gov NR 5 TC 50 Z9 50 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 25 PY 2011 VL 365 IS 8 BP 772 EP 773 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 811JM UT WOS:000294205300038 PM 21864191 ER PT J AU Collier, SA Smith, S Lowe, A Hawkins, P McFarland, P Salyers, M Rocco, P Bumby, G Maillard, JM Williams, C Fleischauer, A Radke, V Roberts, JM Hightower, AW Bishop, HS Mathison, BA da Silva, AJ Carpenter, J Hayden, AS Hlavsa, MC Xiao, LH Roberts, VA Brunkard, J Beach, MJ Hill, V Yoder, J Dunbar, EL Dearen, T Bopp, C Humphrys, MS Phillips, G Chang, L Meites, EM AF Collier, Sarah A. Smith, Steven Lowe, Anita Hawkins, Patricia McFarland, Pam Salyers, Martha Rocco, Phyllis Bumby, Ginger Maillard, Jean-Marie Williams, Carl Fleischauer, Aaron Radke, Vincent Roberts, Jacquelin M. Hightower, Allen W. Bishop, Henry S. Mathison, Blaine A. da Silva, Alexandre J. Carpenter, Joe Hayden, Althea S. Hlavsa, Michele C. Xiao, Lihua Roberts, Virginia A. Brunkard, Joan Beach, Michael J. Hill, Vincent Yoder, Jonathan Dunbar, Elizabeth L. Dearen, Theresa Bopp, Cheryl Humphrys, Michael S. Phillips, Ghasi Chang, Loretta Meites, Elisa M. TI Cryptosporidiosis Outbreak at a Summer Camp-North Carolina, 2009 (Reprinted from MMWR, vol 60, pg 918-922, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Hlavsa, Michele C.; Xiao, Lihua; Roberts, Virginia A.; Brunkard, Joan; Beach, Michael J.; Hill, Vincent; Yoder, Jonathan; Dunbar, Elizabeth L.; Dearen, Theresa; Bopp, Cheryl; Humphrys, Michael S.] Natl Ctr Zoonot Vector Borne & Enter Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30341 USA. [Phillips, Ghasi; Chang, Loretta; Meites, Elisa M.] CDC, Atlanta, GA 30333 USA. [Collier, Sarah A.] IHRC, Atlanta, GA USA. [Smith, Steven; Lowe, Anita; Hawkins, Patricia; McFarland, Pam] Transylvania Cty Hlth Dept, Brevard, NC USA. [Salyers, Martha; Rocco, Phyllis; Bumby, Ginger] N Carolina Publ Hlth Reg Surveillance Team 6, Asheville, NC USA. [Maillard, Jean-Marie; Williams, Carl] N Carolina Dept Hlth & Human Svcs, N Carolina Div Publ Hlth, Raleigh, NC USA. [Fleischauer, Aaron] Off Publ Hlth Preparedness & Emergency Response, Career Epidemiol Field Officer Program, New York, NY USA. [Roberts, Jacquelin M.; Hightower, Allen W.; Bishop, Henry S.; Mathison, Blaine A.; da Silva, Alexandre J.] Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [Radke, Vincent] Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Svcs, Atlanta, GA USA. [Carpenter, Joe; Hayden, Althea S.] Natl Ctr Preparedness Detect & Control Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA. RP Hlavsa, MC (reprint author), Natl Ctr Zoonot Vector Borne & Enter Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30341 USA. EM healthywater@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 1 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 24 PY 2011 VL 306 IS 8 BP 816 EP 818 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 810VY UT WOS:000294157300009 ER PT J AU O'Connor, M Lincoln, J Conway, GA AF O'Connor, Mary Lincoln, Jennifer Conway, George A. TI Occupational Aviation Fatalities-Alaska, 2000-2010 (Reprinted from MMWR, vol 60, pg 837-840, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [O'Connor, Mary; Lincoln, Jennifer; Conway, George A.] CDC, Alaska Pacific Reg Off, NIOSH, Atlanta, GA 30333 USA. RP O'Connor, M (reprint author), CDC, Alaska Pacific Reg Off, NIOSH, Atlanta, GA 30333 USA. EM mboconnor@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 24 PY 2011 VL 306 IS 8 BP 818 EP 820 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 810VY UT WOS:000294157300010 ER PT J AU Kennedy, ED Santibanez, TA Bryan, LN Wortley, PM Euler, GL Singleton, JA Bridges, CB Weinbaum, CW Koonin, LM AF Kennedy, Erin D. Santibanez, Tammy A. Bryan, Leah N. Wortley, Pascale M. Euler, Gary L. Singleton, James A. Bridges, Carolyn B. Weinbaum, Cindy W. Koonin, Lisa M. TI Place of Influenza Vaccination Among Adults-United States, 2010-11 Influenza Season (Reprinted from MMWR, vol 60, pg 781-785, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Kennedy, Erin D.; Santibanez, Tammy A.; Bryan, Leah N.; Wortley, Pascale M.; Euler, Gary L.; Singleton, James A.; Bridges, Carolyn B.; Weinbaum, Cindy W.] Natl Ctr Immunizat & Resp Dis, Immunizat Svcs Div, Atlanta, GA 30333 USA. [Koonin, Lisa M.] CDC, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA 30333 USA. RP Kennedy, ED (reprint author), Natl Ctr Immunizat & Resp Dis, Immunizat Svcs Div, Atlanta, GA 30333 USA. EM edkennedy@cdc.gov NR 1 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 24 PY 2011 VL 306 IS 8 BP 820 EP 822 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 810VY UT WOS:000294157300011 ER PT J AU Cook, S Conrad, C Fowlkes, AL Mohebbi, MH AF Cook, Samantha Conrad, Corrie Fowlkes, Ashley L. Mohebbi, Matthew H. TI Assessing Google Flu Trends Performance in the United States during the 2009 Influenza Virus A (H1N1) Pandemic SO PLOS ONE LA English DT Article ID EMERGENCE AB Background: Google Flu Trends (GFT) uses anonymized, aggregated internet search activity to provide near-real time estimates of influenza activity. GFT estimates have shown a strong correlation with official influenza surveillance data. The 2009 influenza virus A (H1N1) pandemic [pH1N1] provided the first opportunity to evaluate GFT during a non-seasonal influenza outbreak. In September 2009, an updated United States GFT model was developed using data from the beginning of pH1N1. Methodology/Principal Findings: We evaluated the accuracy of each U. S. GFT model by comparing weekly estimates of ILI (influenza-like illness) activity with the U. S. Outpatient Influenza-like Illness Surveillance Network (ILINet). For each GFT model we calculated the correlation and RMSE (root mean square error) between model estimates and ILINet for four time periods: pre-H1N1, Summer H1N1, Winter H1N1, and H1N1 overall (Mar 2009-Dec 2009). We also compared the number of queries, query volume, and types of queries (e. g., influenza symptoms, influenza complications) in each model. Both models' estimates were highly correlated with ILINet pre-H1N1 and over the entire surveillance period, although the original model underestimated the magnitude of ILI activity during pH1N1. The updated model was more correlated with ILINet than the original model during Summer H1N1 (r = 0.95 and 0.29, respectively). The updated model included more search query terms than the original model, with more queries directly related to influenza infection, whereas the original model contained more queries related to influenza complications. Conclusions: Internet search behavior changed during pH1N1, particularly in the categories "influenza complications'' and "term for influenza.'' The complications associated with pH1N1, the fact that pH1N1 began in the summer rather than winter, and changes in health-seeking behavior each may have played a part. Both GFT models performed well prior to and during pH1N1, although the updated model performed better during pH1N1, especially during the summer months. C1 [Cook, Samantha; Mohebbi, Matthew H.] Google Inc, New York, NY USA. [Conrad, Corrie] Google Inc, London, England. [Fowlkes, Ashley L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Cook, S (reprint author), Google Inc, New York, NY USA. EM cconrad@google.com FU Google.org; Google Inc. FX This research was funded by Google.org, the non-profit arm of Google Inc. This funder played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Three of the authors (SC, CC, MM) are employees of one of the funders of the study (Google Inc.) and were involved with the study design, data collection and analysis, decision to publish, and preparation of the manuscript.; Yes, the authors have the following competing interest. This study was supported by funding from Google Inc., and three of the authors (SC, CC, MM) are employees of Google Inc. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors. NR 13 TC 79 Z9 84 U1 3 U2 20 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 19 PY 2011 VL 6 IS 8 AR e23610 DI 10.1371/journal.pone.0023610 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 810LZ UT WOS:000294128100022 PM 21886802 ER PT J AU Hankins, CA Glasser, JW Chen, RT AF Hankins, Catherine A. Glasser, John W. Chen, Robert T. TI Modeling the impact of RV144-like vaccines on HIV transmission SO VACCINE LA English DT Editorial Material ID EFFICACY TRIAL; DOUBLE-BLIND; THAILAND; INFECTION C1 [Hankins, Catherine A.] Joint United Nations Programme HIV AIDS, Programme Branch, Off Deputy Execut Director, Geneva, Switzerland. [Glasser, John W.; Chen, Robert T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Hankins, CA (reprint author), Joint United Nations Programme HIV AIDS, Programme Branch, Off Deputy Execut Director, Geneva, Switzerland. EM hankinsc@unaids.org OI Hankins, Catherine/0000-0002-1642-8592 FU Intramural CDC HHS [CC999999] NR 20 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 18 PY 2011 VL 29 IS 36 SI SI BP 6069 EP 6071 DI 10.1016/j.vaccine.2011.07.001 PG 3 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 828JK UT WOS:000295497100001 PM 21762753 ER PT J AU Chen, RT Hu, DJ Dunne, E Shaw, M Mullins, JI Rerks-Ngarm, S AF Chen, Robert T. Hu, Dale J. Dunne, Eileen Shaw, Michael Mullins, James I. Rerks-Ngarm, Supachai TI Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines SO VACCINE LA English DT Editorial Material DE HIV vaccine; Hepatitis B vaccine; HPV vaccine; Influenza vaccine; Annual strain selection; Program implementation ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-PAPILLOMAVIRUS VACCINE; HEPATITIS-B-VIRUS; CONSENSUS ENVELOPE GLYCOPROTEIN; IMMUNIZATION PRACTICES ACIP; UNITED-STATES; ADVISORY-COMMITTEE; IMMUNE-RESPONSES; SUBTYPE-B; ET-AL AB some of the experience of CDC and its associated partners in preparing for the availability and implementation of newly licensed vaccines to further this dialogue. This paper summarizes the presentations on some lessons for future HIV vaccine implementation from the introduction of hepatitis B vaccine, human papillomavirus (HPV) vaccine, the annual influenza virus vaccine strain selection, a potential annual HIV vaccine strain selection, as well as planning for next steps in Thailand in response to the RV144 trial, and highlights from the moderated discussions with the audience on issues relevant to low/middle income countries and developed countries (Table 1). Hopefully these ideas will facilitate preparations for the introduction of a future licensed HIV vaccine. C1 [Chen, Robert T.; Hu, Dale J.; Dunne, Eileen; Shaw, Michael] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Mullins, James I.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. [Rerks-Ngarm, Supachai] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. RP Chen, RT (reprint author), CDC, HIV Vaccine & Special Studies Team, Div HIV AIDS Prevent, MS-E45, Atlanta, GA 30333 USA. EM bchen@cdc.gov FU Intramural CDC HHS [CC999999]; NIAID NIH HHS [P01 AI057005] NR 76 TC 5 Z9 5 U1 2 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD AUG 18 PY 2011 VL 29 IS 36 SI SI BP 6072 EP 6078 DI 10.1016/j.vaccine.2011.07.015 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 828JK UT WOS:000295497100002 PM 21745523 ER PT J AU Cavallaro, E Date, K Medus, C Meyer, S Miller, B Kim, C Nowicki, S Cosgrove, S Sweat, D Phan, Q Flint, J Daly, ER Adams, J Hyytia-Trees, E Gerner-Smidt, P Hoekstra, RM Schwensohn, C Langer, A Sodha, SV Rogers, MC Angulo, FJ Tauxe, RV Williams, IT Behravesh, CB AF Cavallaro, Elizabeth Date, Kashmira Medus, Carlota Meyer, Stephanie Miller, Benjamin Kim, Clara Nowicki, Scott Cosgrove, Shaun Sweat, David Phan, Quyen Flint, James Daly, Elizabeth R. Adams, Jennifer Hyytia-Trees, Eija Gerner-Smidt, Peter Hoekstra, Robert M. Schwensohn, Colin Langer, Adam Sodha, Samir V. Rogers, Michael C. Angulo, Frederick J. Tauxe, Robert V. Williams, Ian T. Behravesh, Casey Barton CA Salmonella Typhimurium Outbreak TI Salmonella Typhimurium Infections Associated with Peanut Products SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID UNITED-STATES; BUTTER; OUTBREAK AB BACKGROUND Contaminated food ingredients can affect multiple products, each distributed through various channels and consumed in multiple settings. Beginning in November 2008, we investigated a nationwide outbreak of salmonella infections. METHODS A case was defined as laboratory-confirmed infection with the outbreak strain of Salmonella Typhimurium occurring between September 1, 2008, and April 20, 2009. We conducted two case-control studies, product "trace-back," and environmental investigations. RESULTS Among 714 case patients identified in 46 states, 166 (23%) were hospitalized and 9 (1%) died. In study 1, illness was associated with eating any peanut butter (matched odds ratio, 2.5; 95% confidence interval [CI], 1.3 to 5.3), peanut butter-containing products (matched odds ratio, 2.2; 95% CI, 1.1 to 4.7), and frozen chicken products (matched odds ratio, 4.6; 95% CI, 1.7 to 14.7). Investigations of focal clusters and single cases associated with nine institutions identified a single institutional brand of peanut butter (here called brand X) distributed to all facilities. In study 2, illness was associated with eating peanut butter outside the home (matched odds ratio, 3.9; 95% CI, 1.6 to 10.0) and two brands of peanut butter crackers (brand A: matched odds ratio, 17.2; 95% CI, 6.9 to 51.5; brand B: matched odds ratio, 3.6; 95% CI, 1.3 to 9.8). Both cracker brands were made from brand X peanut paste. The outbreak strain was isolated from brand X peanut butter, brand A crackers, and 15 other products. A total of 3918 peanut butter-containing products were recalled between January 10 and April 29, 2009. CONCLUSIONS Contaminated peanut butter and peanut products caused a nationwide salmonellosis outbreak. Ingredient-driven outbreaks are challenging to detect and may lead to widespread contamination of numerous food products. C1 [Cavallaro, Elizabeth; Date, Kashmira; Adams, Jennifer; Hyytia-Trees, Eija; Gerner-Smidt, Peter; Hoekstra, Robert M.; Schwensohn, Colin; Langer, Adam; Sodha, Samir V.; Angulo, Frederick J.; Tauxe, Robert V.; Williams, Ian T.; Behravesh, Casey Barton] Ctr Dis Control & Prevent, Program Off Sci Educ & Profess Dev, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Cavallaro, Elizabeth; Date, Kashmira; Kim, Clara] Ctr Dis Control & Prevent, Program Off Sci Educ & Profess Dev, Epidem Intelligence Serv, Atlanta, GA USA. [Medus, Carlota; Meyer, Stephanie] Minnesota Dept Hlth, St Paul, MN USA. [Miller, Benjamin] Minnesota Dept Agr, St Paul, MN USA. [Kim, Clara; Nowicki, Scott] Ohio Dept Hlth, Columbus, OH USA. [Cosgrove, Shaun] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Sweat, David] N Carolina Div Publ Hlth, Raleigh, NC USA. [Phan, Quyen] Connecticut Dept Publ Hlth, Hartford, CT USA. [Flint, James] Publ Hlth Agcy Canada, Ottawa, ON, Canada. [Daly, Elizabeth R.] New Hampshire Dept Hlth & Human Serv, Concord, NH USA. [Rogers, Michael C.] US FDA, Silver Spring, MD USA. RP Cavallaro, E (reprint author), Ctr Dis Control & Prevent, Program Off Sci Educ & Profess Dev, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM ecavallaro@cdc.gov OI Miller, Benjamin/0000-0003-1647-0122 NR 28 TC 38 Z9 39 U1 4 U2 29 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 18 PY 2011 VL 365 IS 7 BP 601 EP 610 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 808ER UT WOS:000293960500007 PM 21848461 ER PT J AU Bensley, L VanEenwyk, J Ta, M AF Bensley, Lillian VanEenwyk, Juliet Ta, Myduc TI Contribution of Occupational Physical Activity Toward Meeting Recommended Physical Activity Guidelines-United States, 2007 (Reprinted from MMWR vol 60, pg 656-660, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID RELIABILITY C1 [Bensley, Lillian; VanEenwyk, Juliet] Washington State Dept Hlth, Off Epidemiol, Washington, DC USA. [Ta, Myduc] CDC, EIS, Atlanta, GA 30333 USA. RP Bensley, L (reprint author), Washington State Dept Hlth, Off Epidemiol, Washington, DC USA. EM lillian.bensley@doh.wa.gov NR 10 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 17 PY 2011 VL 306 IS 7 BP 695 EP + PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 807LP UT WOS:000293900000008 ER PT J AU Viall, AH Dooley, SW Branson, BM Duffy, N Mermin, J Cleveland, JC Cagle, C Lyon, WA AF Viall, Abigail H. Dooley, Samuel W. Branson, Bernard M. Duffy, Nadezhda Mermin, Jonathan Cleveland, Janet C. Cagle, Chris Lyon, Wendy A. TI Results of the Expanded HIV Testing Initiative-25 Jurisdictions, United States, 2007-2010 (Reprinted from MMWR vol 60, pg 805-810, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID ANTIRETROVIRAL THERAPY; PREVENTION; COHORT C1 [Viall, Abigail H.; Dooley, Samuel W.; Branson, Bernard M.; Duffy, Nadezhda; Mermin, Jonathan; Cleveland, Janet C.; Cagle, Chris; Lyon, Wendy A.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Viall, AH (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM aviall@cdc.gov RI Mermin, Jonathan/J-9847-2012 NR 10 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 17 PY 2011 VL 306 IS 7 BP 698 EP 700 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 807LP UT WOS:000293900000009 ER PT J AU Richardson, LC Tai, E Rim, SH Joseph, D Plescia, M AF Richardson, Lisa C. Tai, Eric Rim, Sun Hee Joseph, Djenaba Plescia, Marcus TI Vital Signs: Colorectal Cancer Screening, Incidence, and Mortality-United States, 2002-2010 (Reprinted from MMWR vol, 60, pg 884-889, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID ADULTS; RATES C1 [Richardson, Lisa C.; Tai, Eric; Rim, Sun Hee; Joseph, Djenaba; Plescia, Marcus] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Richardson, LC (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA. EM lrichardson@cdc.gov NR 21 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 17 PY 2011 VL 306 IS 7 BP 701 EP 703 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 807LP UT WOS:000293900000010 ER PT J AU Schleicher, RL Encisco, SE Chaudhary-Webb, M Paliakov, E McCoy, LF Pfeiffer, CM AF Schleicher, Rosemary L. Encisco, Sara E. Chaudhary-Webb, Madhulika Paliakov, Ekaterina McCoy, Leslie F. Pfeiffer, Christine M. TI Isotope dilution ultra performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 in human serum SO CLINICA CHIMICA ACTA LA English DT Article DE 25-hydroxyvitamin D; UHPLC; LC-MS/MS; Vitamin D; Mass spectrometry ID VITAMIN-D METABOLITES; D-3; SYSTEM AB Background: An ultra performance liquid chromatography-tandem mass spectrometry method with calibration traceable to NIST SRM was developed and validated to measure concentrations of 25-hydroxyvitamin D-2 (25OHD(2)), 25-hydroxyvitamin D-3 (25OHD(3)) and the C-3 epimer of 25OHD3 (epi-25OHD(3)) in human serum. Methods: Tri- and hexa-deuterated internal standards were added to serum (100 mu l) to monitor recovery. Liquid-liquid extraction was used to extract the hexane-soluble materials. Calibration solutions ([8-100 nmol/L 25OHD(2), 12-150 nmol/L 25OHD(3), and 4-50 nmol/L epi-25OHD(3)] prepared in phosphate-buffered saline containing 4% albumin were similarly processed. Using a pentafluorophenyl column (2.1 x 100 mm) and isocratic methanol/water (72/28, v/v) flowing at 0.4 ml/min, run time was 14 min per sample; 25OHD(3) and epi-25OHD(3) were baseline separated. Atmospheric pressure chemical ionization in the positive ion mode with selected reaction monitoring captured the following transitions: 25OHD(2), m/z 3953>377.3 (209.1 qualifier); (epi-)25OHD(3), m/z 383.3>365.3 (105.1 qualifier); d(3)-25OHD(2), m/z 398.3>380.3; and d(6)-25OHD(3), m/z 389.3>371.3. Results: Recovery averaged >= 98%. Total imprecision was <= 10% when concentrations were >= 20 nmol/l. Bias averaged <5%. Detection limits were <5 nmol/l. Median (nmol/l) 250HD(2), 25OHD(3) and epi-25OHD(3) were quantitated in 98 blood donors (= 3 years with available medical records at 4 Shenyang City hospitals from 20 October to 30 November 2009. A critical patient was any confirmed, hospitalized pH1N1 patient who developed >= 1 of the following: death, respiratory failure, septic shock, failure or insufficiency of >= 2 nonpulmonary organs, mechanical ventilation, or ICU admission. In a retrospective cohort study, we evaluated the risk of developing critical illness in relation to early (< 72 hours of influenza-like illness [ILI] onset) glucocorticoids treatment. Results. Of the 83 hospitalized case-patients, 46% developed critical illness, 17% died, and 37% recovered and were discharged. Critically ill and other patients did not differ by underlying conditions and severity, median temperature at first clinic visit, and other measured risk factors. Of 17 patients who received early glucocorticoid treatment, 71% subsequently developed critical disease compared with 39% of 66 patients who received late (> 72 hours) or no glucocorticoid treatment (RR(M-H) = 1.8, 95% CI = 1.2-2.8, after adjusting for 2 summary variables; ie, presence of underlying diseases and presence of underlying risk factors). Proportional hazards modeling showed that use of glucocorticoids tripled the hazard of developing critical disease (hazard ratio [HR] = 2.9, 95% CI = 1.3-6.2, after adjusting for the same summary variables). Conclusions. Early use of parenteral glucocorticoids therapy for fever reduction and pneumonia prevention increases the risk for critical disease or death from pH1N1 infection. We recommend that guidelines on glucocorticoid use be established and enforced. C1 [Han, Ke; Ma, Huilai; Su, Yang; Chen, Jing; Zhao, JinHui; Zhu, Bao-Ping; Zeng, Guang] Chinese Ctr Dis Control & Prevent, Chinese Field Epidemiol Training Program, Beijing 100050, Peoples R China. [Han, Ke] Guangdong Ctr Dis Control & Prevent, Inst Immunizat Program, Guangzhou, Guangdong, Peoples R China. [An, Xiangdong; Lian, Zhiyong] Shenyang Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Liaoning, Peoples R China. [Fontaine, Robert E.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Feng, Zijian] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing, Peoples R China. RP Zeng, G (reprint author), Chinese Ctr Dis Control & Prevent, Chinese Field Epidemiol Training Program, Beijing 100050, Peoples R China. EM guangzeng4605@sohu.com FU Ministry of Health of China; US Centers for Disease Control and Prevention (CDC) [U2GGH000018-03] FX This work was supported by the general funds for emergency public health response from the Ministry of Health of China, and by Cooperative Agreement Number U2GGH000018-03 from the US Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. NR 50 TC 38 Z9 41 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2011 VL 53 IS 4 BP 326 EP 333 DI 10.1093/cid/cir398 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 804DW UT WOS:000293635500003 PM 21810744 ER PT J AU Sheth, AN Hoekstra, M Patel, N Ewald, G Lord, C Clarke, C Villamil, E Niksich, K Bopp, C Nguyen, TA Zink, D Lynch, M AF Sheth, Anandi N. Hoekstra, Mike Patel, Nehal Ewald, Gwen Lord, Cathy Clarke, Carmen Villamil, Elizabeth Niksich, Katherine Bopp, Cheryl Thai-An Nguyen Zink, Donald Lynch, Michael TI A National Outbreak of Salmonella Serotype Tennessee Infections From Contaminated Peanut Butter: A New Food Vehicle for Salmonellosis in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID EAT SAVOURY SNACK; AGONA INFECTION; HEAT TOLERANCE; TYPHIMURIUM AB Background. Salmonella serotype Tennessee is a rare cause of the estimated 1 million cases of salmonellosis occurring annually in the United States. In January 2007, we began investigating a nationwide increase in Salmonella Tennessee infections. Methods. We defined a case as Salmonella Tennessee infection in a patient whose isolate demonstrated 1 of 3 closely related pulsed-field gel electrophoresis patterns and whose illness began during the period 1 August 2006 through 31 July 2007. We conducted a case-control study in 22 states and performed laboratory testing of foods and environmental samples. Results. We identified 715 cases in 48 states; 37% of isolates were from urine specimens. Illness was associated with consuming peanut butter more than once a week (matched odds ratio [mOR], 3.5 [95% confidence interval {95% CI}, 1.4-9.9]), consuming Brand X peanut butter (mOR, 12.1 [95% CI, 3.6-66.3]), and consuming Brand Y peanut butter (mOR, 9.1 [95% CI, 1.0-433]). Brands X and Y were produced in 1 plant, which ceased production and recalled products on 14 February 2007. Laboratories isolated outbreak strains of Salmonella Tennessee from 34 Brands X and Y peanut butter jars and 2 plant environmental samples. Conclusions. This large, widespread outbreak of salmonellosis is the first linked to peanut butter in the United States; a nationwide recall resulted in outbreak control. Environmental contamination in the peanut butter plant likely caused this outbreak. This outbreak highlights the risk of salmonellosis from heat-processed foods of nonanimal origin previously felt to be low risk for Salmonella contamination. C1 [Sheth, Anandi N.; Hoekstra, Mike; Patel, Nehal; Ewald, Gwen; Bopp, Cheryl; Thai-An Nguyen; Lynch, Michael] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. [Sheth, Anandi N.; Niksich, Katherine] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Sheth, Anandi N.; Niksich, Katherine] Ctr Dis Control & Prevent, Epidemiol Elect Program, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Lord, Cathy] Iowa State Hyg Lab, Iowa City, IA USA. [Clarke, Carmen] Oklahoma Dept Hlth, Oklahoma City, OK USA. [Villamil, Elizabeth] New York State Dept Hlth, Albany, NY USA. [Zink, Donald] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. RP Sheth, AN (reprint author), Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, 1600 Clifton Rd NE,Mailstop A-38, Atlanta, GA 30333 USA. EM asheth@cdc.gov NR 31 TC 32 Z9 33 U1 0 U2 25 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2011 VL 53 IS 4 BP 356 EP 362 DI 10.1093/cid/cir407 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 804DW UT WOS:000293635500007 PM 21810748 ER PT J AU Taha, TE Hoover, DR Chen, S Kumwenda, NI Mipando, L Nkanaunena, K Thigpen, MC Taylor, A Fowler, MG Mofenson, LM AF Taha, Taha E. Hoover, Donald R. Chen, Shu Kumwenda, Newton I. Mipando, Linda Nkanaunena, Kondwani Thigpen, Michael C. Taylor, Allan Fowler, Mary Glenn Mofenson, Lynne M. TI Effects of Cessation of Breastfeeding in HIV-1-Exposed, Uninfected Children in Malawi SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HIV-INFECTED CHILDREN; INFANTS BORN; MORTALITY; TRANSMISSION; COTRIMOXAZOLE; PROPHYLAXIS; BOTSWANA; MOTHERS; UGANDA; ZAMBIA AB Background. We assessed morbidity rates during short intervals that accompanied weaning and cumulative mortality among HIV-exposed, uninfected infants enrolled in the postexposure prophylaxis of infants in Malawi (PEPI-Malawi) trial. Methods. Women were counseled to stop breastfeeding (BF) by 6 months in the PEPI-Malawi trial. HIV-uninfected infants were included in this analysis starting at age 6 months. Breastfeeding and morbidity (illness and/or hospital admission and malnutrition [weight-for-age Z-score, < 2]) were assessed during age intervals of 6-9, 9-12, and 12-15 months. BF was defined as any BF at the start and end of the interval and no breastfeeding (NBF) was defined as NBF at any time during the interval. The association of NBF with morbidity at each mutually exclusive interval was assessed using Poisson regression models controlling for other factors. Cumulative mortality among infants aged 6-15 months with BF and NBF was assessed using an extended Kaplan-Meier method. Results. At age 6 months, 1761 HIV-uninfected infants were included in the study. The adjusted rate ratios for illnesses and/or hospital admission for NBF, compared with BF, was 1.7 (P < .0001) at 6-9 months, 1.66 (P = .0001) at 9-12 months, and 1.75 (P = .0008) at 12-15 months. The rates of morbidity were consistently higher among NBF infants during each age interval, compared with BF infants. The 15 months cumulative mortality among BF and NBF children was 3.5% and 6.4% (P = .03), respectively. Conclusions. Cessation of BF is associated with acute morbidity events and cumulative mortality. Prolonged BF should be encouraged, in addition to close monitoring of infant health and provision of support services. C1 [Taha, Taha E.; Chen, Shu; Kumwenda, Newton I.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat, Piscataway, NJ USA. [Hoover, Donald R.] Rutgers State Univ, Inst Hlth Hlth Policy & Aging Res, Piscataway, NJ USA. [Mipando, Linda] Johns Hopkins Univ Res Project, Coll Med, Blantyre, Malawi. [Nkanaunena, Kondwani; Fowler, Mary Glenn] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Thigpen, Michael C.; Taylor, Allan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Epidemiol Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediatr Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Bethesda, MD USA. RP Taha, TE (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Rm E7138,615 N Wolfe St, Baltimore, MD 21205 USA. EM ttaha@jhsph.edu OI Mofenson, Lynne/0000-0002-2818-9808 FU Centers for Disease Control and Prevention; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [U50 PS022061-05, U50/CC0222061] FX This work was supported by a Cooperative Agreement from the Centers for Disease Control and Prevention and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (U50 PS022061-05; U50/CC0222061). NR 28 TC 31 Z9 31 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2011 VL 53 IS 4 BP 388 EP 395 DI 10.1093/cid/cir413 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 804DW UT WOS:000293635500013 PM 21810754 ER PT J AU Prabhu, M Nicholson, WL Roche, AJ Kersh, GJ Fitzpatrick, KA Oliver, LD Massung, RF Morrissey, AB Bartlett, JA Onyango, JJ Maro, VP Kinabo, GD Saganda, W Crump, JA AF Prabhu, Malavika Nicholson, William L. Roche, Aubree J. Kersh, Gilbert J. Fitzpatrick, Kelly A. Oliver, Lindsay D. Massung, Robert F. Morrissey, Anne B. Bartlett, John A. Onyango, Jecinta J. Maro, Venance P. Kinabo, Grace D. Saganda, Wilbrod Crump, John A. TI Q Fever, Spotted Fever Group, and Typhus Group Rickettsioses Among Hospitalized Febrile Patients in Northern Tanzania SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID TICK BITE FEVER; COXIELLA-BURNETII INFECTION; INVASIVE BACTERIAL; SEROLOGIC EVIDENCE; FUNGAL-INFECTIONS; REFERENCE VALUES; HIV-INFECTION; DIAGNOSIS; DISEASES; HUMANS AB Background. The importance of Q fever, spotted fever group rickettsiosis (SFGR), and typhus group rickettsiosis (TGR) as causes of febrile illness in sub-Saharan Africa is unknown; the putative role of Q fever as a human immunodeficiency virus (HIV) coinfection is unclear. Methods. We identified febrile inpatients in Moshi, Tanzania, from September 2007 through August 2008 and collected acute- and convalescent-phase serum samples. A >= 4-fold increase in immunoglobulin (Ig) G immunfluorescence assay (IFA) titer to Coxiella burnetii phase II antigen defined acute Q fever. A >= 4-fold increase in IgG IFA titer to Rickettsia conorii or Rickettsia typhi antigen defined SFGR and TGR, respectively. Results. Among 870 patients, 483 (55.5%) were tested for acute Q fever, and 450 (51.7%) were tested for acute SFGR and TGR. Results suggested acute Q fever in 24 (5.0%) patients and SFGR and TGR in 36 (8.0%) and 2 (0.5%) patients, respectively. Acute Q fever was associated with hepato- or splenomegaly (odds ratio [OR], 3.1; P = .028), anemia (OR, 3.0; P = .009), leukopenia (OR, 3.9; P = .013), jaundice (OR, 7.1; P = .007), and onset during the dry season (OR, 2.7; P = .021). HIV infection was not associated with acute Q fever (OR, 1.7; P = .231). Acute SFGR was associated with leukopenia (OR, 4.1; P = .003) and with evidence of other zoonoses (OR, 2.2; P = .045). Conclusions. Despite being common causes of febrile illness in northern Tanzania, Q fever and SFGR are not diagnosed or managed with targeted antimicrobials. C. burnetii does not appear to be an HIV-associated co-infection. C1 [Prabhu, Malavika; Morrissey, Anne B.; Bartlett, John A.; Crump, John A.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Durham, NC 27710 USA. [Nicholson, William L.; Roche, Aubree J.; Kersh, Gilbert J.; Fitzpatrick, Kelly A.; Oliver, Lindsay D.; Massung, Robert F.; Crump, John A.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Bartlett, John A.; Crump, John A.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27710 USA. [Onyango, Jecinta J.; Maro, Venance P.; Kinabo, Grace D.; Crump, John A.] Kilimanjaro Christian Med Ctr, Moshi, Tanzania. [Maro, Venance P.; Kinabo, Grace D.; Crump, John A.] Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania. [Saganda, Wilbrod] Mawenzi Reg Hosp, Moshi, Tanzania. RP Crump, JA (reprint author), Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Box 102359, Durham, NC 27710 USA. EM john.crump@duke.edu FU United States National Institutes of Health (NIH) [U01 AI062563]; NIH Fogarty International Center [R24 TW007988]; AIDS International Training and Research Program [D43 PA-03-018]; Duke Clinical Trials Unit and Clinical Research Sites [U01 AI069484]; Center for AIDS Research [2P30 AI064518] FX International Studies on AIDS Associated Co-infections award, a United States National Institutes of Health (NIH) funded program (U01 AI062563); the NIH Fogarty International Center through the International Clinical Research Fellows Program at Vanderbilt University (R24 TW007988 to M. P.); AIDS International Training and Research Program (D43 PA-03-018 to J. A. B., J. J. O., V. P. M., and J. A. C.); the Duke Clinical Trials Unit and Clinical Research Sites (U01 AI069484 to J. A. B., J. J. O., V. P. M., and J. A. C.); and the Center for AIDS Research (2P30 AI064518 to J. A. B.). NR 48 TC 44 Z9 44 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2011 VL 53 IS 4 BP e8 EP e15 DI 10.1093/cid/cir411 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 804DW UT WOS:000293635500001 PM 21810740 ER PT J AU Curtis, KA Kennedy, MS Luckay, A Cong, ME Youngpairoj, AS Zheng, Q Smith, J Hanson, D Heneine, W Owen, SM Garcia-Lerma, JG AF Curtis, Kelly A. Kennedy, M. Susan Luckay, Amara Cong, Mian-er Youngpairoj, Ae S. Zheng, Qi Smith, James Hanson, Debra Heneine, Walid Owen, S. Michele Garcia-Lerma, J. Gerardo TI Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure Prophylaxis SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV antibodies; HIV infections; animal models; pre-exposure prophylaxis; anti-HIV agents ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; VIRAL LOAD STANDARDS; GROUP M SUBTYPES; TYPE-1; TRANSMISSION; PREVENTION; PERFORMANCE; RESPONSES; IMMUNOASSAY AB Background: Pre-exposure prophylaxis (PrEP) is a novel intervention strategy for the prevention HIV transmission. Because several clinical trials are at various stages of completion, it is important to understand the impact of PrEP treatment on the development of the immune response to HIV, particularly in individuals who exhibit breakthrough infections despite PrEP. Methods: A model of HIV infection, using rhesus macaques and the simian/human immunodeficiency virus (SHIV), was used to evaluate the effects of PrEP on the evolution of the humoral immune response. Time to seroconversion, neutralizing and binding antibody levels, and antibody avidity were measured in 12 rhesus macaques infected during daily or intermittent PrEP with FTC (emtricitabine) or Truvada (FTC/tenofovir combination) and compared with 11 untreated, simian HIV-infected controls. Results: Macaques that became infected while receiving PrEP exhibited significantly lower peak virus loads during acute infection as compared with untreated animals. Although the timing of seroconversion and SHIV binding and neutralizing antibody levels were not impacted by treatment, lower maturation rates of antibody avidity for anti-p27, gp120, gp160, and gp41 were observed. Conclusions: This study suggests that reduced virus loads associated with PrEP treatment have little impact on timing of seroconversion and neutralizing/binding antibody levels; however, maturation of antibody avidity was suppressed. C1 [Curtis, Kelly A.; Kennedy, M. Susan; Luckay, Amara; Cong, Mian-er; Youngpairoj, Ae S.; Zheng, Qi; Smith, James; Heneine, Walid; Owen, S. Michele; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Hanson, Debra] Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Curtis, KA (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,MS-A25, Atlanta, GA 30333 USA. EM czv2@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported with intramural funding from the Centers for Disease Control and Prevention. NR 37 TC 15 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 15 PY 2011 VL 57 IS 5 BP 355 EP 362 DI 10.1097/QAI.0b013e3182234a51 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 800RE UT WOS:000293381300009 PM 21637113 ER PT J AU Harris, JR Marston, BJ Sangrujee, N DuPlessis, D Park, B AF Harris, Julie R. Marston, Barbara J. Sangrujee, Nalinee DuPlessis, Desiree Park, Benjamin TI Cost-Effectiveness Analysis of Diagnostic Options for Pneumocystis Pneumonia (PCP) SO PLOS ONE LA English DT Article ID POLYMERASE-CHAIN-REACTION; HUMAN-IMMUNODEFICIENCY-VIRUS; BRONCHOALVEOLAR LAVAGE SPECIMENS; REAL-TIME PCR; HIV-INFECTED PATIENTS; MEDIATED ISOTHERMAL AMPLIFICATION; TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; ORAL-WASH SAMPLES; CARINII-PNEUMONIA; RESPIRATORY SPECIMENS AB Background: Diagnosis of Pneumocystis jirovecii pneumonia (PCP) is challenging, particularly in developing countries. Highly sensitive diagnostic methods are costly, while less expensive methods often lack sensitivity or specificity. Cost-effectiveness comparisons of the various diagnostic options have not been presented. Methods and Findings: We compared cost-effectiveness, as measured by cost per life-years gained and proportion of patients successfully diagnosed and treated, of 33 PCP diagnostic options, involving combinations of specimen collection methods [oral washes, induced and expectorated sputum, and bronchoalveolar lavage (BAL)] and laboratory diagnostic procedures [various staining procedures or polymerase chain reactions (PCR)], or clinical diagnosis with chest x-ray alone. Our analyses were conducted from the perspective of the government payer among ambulatory, HIV-infected patients with symptoms of pneumonia presenting to HIV clinics and hospitals in South Africa. Costing data were obtained from the National Institutes of Communicable Diseases in South Africa. At 50% disease prevalence, diagnostic procedures involving expectorated sputum with any PCR method, or induced sputum with nested or real-time PCR, were all highly cost-effective, successfully treating 77-90% of patients at $26-51 per life-year gained. Procedures using BAL specimens were significantly more expensive without added benefit, successfully treating 68-90% of patients at costs of $189-232 per life-year gained. A relatively cost-effective diagnostic procedure that did not require PCR was Toluidine Blue O staining of induced sputum ($25 per life-year gained, successfully treating 68% of patients). Diagnosis using chest x-rays alone resulted in successful treatment of 77% of patients, though cost-effectiveness was reduced ($109 per life-year gained) compared with several molecular diagnostic options. Conclusions: For diagnosis of PCP, use of PCR technologies, when combined with less-invasive patient specimens such as expectorated or induced sputum, represent more cost-effective options than any diagnostic procedure using BAL, or chest x-ray alone. C1 [Harris, Julie R.; Park, Benjamin] Ctr Dis Control & Prevent, Mycot Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Marston, Barbara J.; Sangrujee, Nalinee] Ctr Dis Control & Prevent, Global AIDS Program, Ctr Global Hlth, Atlanta, GA USA. [DuPlessis, Desiree] Natl Inst Communicable Dis, Parasitol Reference Unit, Natl Hlth Lab Serv, Johannesburg, South Africa. RP Harris, JR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. EM ggt5@cdc.gov NR 111 TC 11 Z9 12 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 15 PY 2011 VL 6 IS 8 AR e23158 DI 10.1371/journal.pone.0023158 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 808CV UT WOS:000293953700005 PM 21858013 ER PT J AU Lingappa, JR Dumitrescu, L Zimmer, SM Lynfield, R McNicholl, JM Messonnier, NE Whitney, CG Crawford, DC AF Lingappa, Jairam R. Dumitrescu, Logan Zimmer, Shanta M. Lynfield, Ruth McNicholl, Janet M. Messonnier, Nancy E. Whitney, Cynthia G. Crawford, Dana C. TI Identifying Host Genetic Risk Factors in the Context of Public Health Surveillance for Invasive Pneumococcal Disease SO PLOS ONE LA English DT Article ID STREPTOCOCCUS-PNEUMONIAE INFECTION; C-REACTIVE PROTEIN; MULTILOCUS GENOTYPE DATA; TOLL-LIKE RECEPTOR-2; MENINGOCOCCAL DISEASE; PROMOTER POLYMORPHISM; CONJUGATE VACCINE; SEVERE SEPSIS; SURFACTANT PROTEINS; SEPTIC SHOCK AB Host genetic factors that modify risk of pneumococcal disease may help target future public health interventions to individuals at highest risk of disease. We linked data from population-based surveillance for invasive pneumococcal disease (IPD) with state-based newborn dried bloodspot repositories to identify biological samples from individuals who developed invasive pneumococcal disease. Genomic DNA was extracted from 366 case and 732 anonymous control samples. TagSNPs were selected in 34 candidate genes thought to be associated with host response to invasive pneumococcal disease, and a total of 326 variants were successfully genotyped. Among 543 European Americans (EA) (182 cases and 361 controls), and 166 African Americans (AA) (53 cases and 113 controls), common variants in surfactant protein D (SFTPD) are consistently underrepresented in IPD. SFTPD variants with the strongest association for IPD are intronic rs17886286 (allelic OR 0.45, 95% confidence interval (CI) [0.25, 0.82], with p = 0.007) in EA and 59 flanking rs12219080 (allelic OR 0.32, 95% CI [0.13, 0.78], with p = 0.009) in AA. Variants in CD46 and IL1R1 are also associated with IPD in both EA and AA, but with effects in different directions; FAS, IL1B, IL4, IL10, IL12B, SFTPA1, SFTPB, and PTAFR variants are associated (p <= 0.05) with IPD in EA or AA. We conclude that variants in SFTPD may protect against IPD in EA and AA and genetic variation in other host response pathways may also contribute to risk of IPD. While our associations are not corrected for multiple comparisons and therefore must be replicated in additional cohorts, this pilot study underscores the feasibility of integrating public health surveillance with existing, prospectively collected, newborn dried blood spot repositories to identify host genetic factors associated with infectious diseases. C1 [Lingappa, Jairam R.] Univ Washington, Dept Global Hlth, Dept Med, Seattle, WA 98195 USA. [Lingappa, Jairam R.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Dumitrescu, Logan; Crawford, Dana C.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA. [Crawford, Dana C.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA. [Zimmer, Shanta M.] Emory Univ, Atlanta, GA 30322 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [McNicholl, Janet M.; Messonnier, Nancy E.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lingappa, JR (reprint author), Univ Washington, Dept Global Hlth, Dept Med, Seattle, WA 98195 USA. EM lingappa@u.washington.edu RI Crawford, Dana/C-1054-2012 FU U.S. Federal Government, National Heart, Lung, and Blood Institute [N01-HV-48195] FX Genotyping services were provided by the Johns Hopkins University under U.S. Federal Government contract number N01-HV-48195 from the National Heart, Lung, and Blood Institute. Intramural support was also provided through the Centers for Disease Control and Prevention (CDC) Genetics Working Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 77 TC 11 Z9 11 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 15 PY 2011 VL 6 IS 8 AR e23413 DI 10.1371/journal.pone.0023413 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 808CV UT WOS:000293953700021 PM 21858107 ER PT J AU Xu, P Li, Z Sun, DY Lin, Y Wu, JG Rota, PA He, BA AF Xu, Pei Li, Zhuo Sun, Dengyun Lin, Yuan Wu, Jianguo Rota, Paul A. He, Biao TI Rescue of wild-type mumps virus from a strain associated with recent outbreaks helps to define the role of the SH ORF in the pathogenesis of mumps virus SO VIROLOGY LA English DT Article DE SH; Paramyxovirus; Mumps virus; Apoptosis; TNF-alpha; Parainfluenza virus 5; Attenuation; Rat brain; Vaccine; Outbreak ID SMALL HYDROPHOBIC PROTEIN; V-PROTEIN; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; SIMIAN VIRUS-5; MESSENGER-RNA; GENE; PARAMYXOVIRUS; EXPRESSION; CELLS AB Mumps virus (MuV) causes acute infections in humans. In recent years, MuV has caused epidemics among highly vaccinated populations. The largest outbreak in the U.S. in the past 20 years occurred in 2005-2006 with over 5000 reported cases in which the majority of the cases was in vaccinated young adults. We sequenced the complete genome of a representative strain from the epidemic (MuV-IA). MuV-IA is a member of genotype G, the same genotype of MuV that was associated with the outbreak in the UK in 2004-2005. We constructed a reverse genetics system for MuV-IA (rMuV-IA), and rescued a virus lacking the open reading frame (ORF) of the SH gene (rMuV Delta SH). rMuV Delta SH infection in L929 cells induced increased NF-kappa B activation, TNF-alpha production and apoptosis compared to rMuV-IA. rMuV Delta SH was attenuated in an animal model. These results indicated that the SH ORF of MuV plays a significant role in interfering with TNF-alpha signaling and viral pathogenesis during virus infection. (C) 2011 Elsevier Inc. All rights reserved. C1 [Xu, Pei; Li, Zhuo; Sun, Dengyun; Lin, Yuan; He, Biao] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA. [Xu, Pei; Sun, Dengyun] Penn State Univ, Intercoll Grad Program Cell & Dev Biol, University Pk, PA 16802 USA. [Wu, Jianguo; He, Biao] Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China. [Wu, Jianguo] Wuhan Univ, Chinese French Liver Dis Res Inst, Zhongnan Hosp, Wuhan 430072, Peoples R China. [Rota, Paul A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP He, BA (reprint author), Univ Georgia, Coll Vet Med, Dept Infect Dis, 501 DW Brooks Dr, Athens, GA 30602 USA. EM bhe@uga.edu RI Sun, Dengyun/K-2033-2012 FU NIH [K02 065795]; National Natural Science Foundation of China [30928001] FX We appreciate comments, suggestions, and technical help from members of the He lab. We are grateful to Dr. Steven Rubin for the neurotoxicity test and ant-HN antibody. This work has been supported by grants from NIH (K02 065795 to B.H.) and National Natural Science Foundation of China Funds for Distinguished Young Scholar-B Plan (No. 30928001 to B.H. and J.W.). NR 47 TC 18 Z9 18 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD AUG 15 PY 2011 VL 417 IS 1 BP 126 EP 136 DI 10.1016/j.virol.2011.05.003 PG 11 WC Virology SC Virology GA 806PO UT WOS:000293820300015 PM 21676427 ER PT J AU Rasmussen, SA Friedman, JM AF Rasmussen, Sonja A. Friedman, Jan M. TI Emerging Issues in Teratology: An Introduction SO AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS LA English DT Editorial Material ID BIRTH-DEFECTS; THALIDOMIDE; EMBRYOPATHY; RISK C1 [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Friedman, Jan M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Friedman, Jan M.] Assoc Prof Human Genet, Kansas City, MO USA. RP Rasmussen, SA (reprint author), CDC, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM skr9@cdc.gov OI Friedman, Jan/0000-0002-7482-9570 FU Intramural CDC HHS [CC999999] NR 15 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4868 J9 AM J MED GENET C JI Am. J. Med. Genet. C PD AUG 15 PY 2011 VL 157C IS 3 SI SI BP 147 EP 149 DI 10.1002/ajmg.c.30305 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 802VM UT WOS:000293539100001 PM 21766432 ER PT J AU Gilboa, SM Broussard, CS Devine, OJ Duwe, KN Flak, AL Boulet, SL Moore, CA Werler, MM Honein, MA AF Gilboa, Suzanne M. Broussard, Cheryl S. Devine, Owen J. Duwe, Kara N. Flak, Audrey L. Boulet, Sheree L. Moore, Cynthia A. Werler, Martha M. Honein, Margaret A. TI Influencing Clinical Practice Regarding the Use of Antiepileptic Medications During Pregnancy: Modeling the Potential Impact on the Prevalences of Spina Bifida and Cleft Palate in the United States SO AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS LA English DT Article DE antiepileptic drugs; carbamazepine; cleft palate; spina bifida; valproic acid ID NEURAL-TUBE DEFECTS; MAJOR CONGENITAL-MALFORMATIONS; FOLIC-ACID ANTAGONISTS; BIRTH-DEFECTS; VALPROIC ACID; ANTICONVULSANT DRUGS; BIPOLAR DISORDER; UK-EPILEPSY; OROFACIAL CLEFTS; CHILDBEARING AGE AB Selected antiepileptic drugs (AEDs) increase the risk of birth defects. To assess the impact of influencing AED prescribing practices on spina bifida and cleft palate we searched the literature for estimates of the association between valproic acid or carbamazepine use during pregnancy and these defects and summarized the associations usingmeta-analyses. We estimated distributions of the prevalence of valproic acid and carbamazepine use among women of childbearing age based on analyses of four data sets. We estimated the attributable fractions and the number of children born with each defect that could be prevented annually in the United States if valproic acid and carbamazepine were not used during pregnancy. The summary odds ratio estimate for the association between valproic acid and spina bifida was 11.9 (95% uncertainty interval (UI): 4.0-21.2); for valproic acid and cleft palate 5.8 (95% UI: 3.3-9.5); for carbamazepine and spina bifida 3.6 (95% UI: 1.3-7.8); and for carbamazepine and cleft palate 2.4 (95% UI: 1.1-4.5) in the United States. Approximately 40 infants (95% UI: 10-100) with spina bifida and 35 infants (95% UI: 10-70) with cleft palate could be born without these defects each year if valproic acid were not used during pregnancy; 5 infants (95% UI: 0-15) with spina bifida and 5 infants (95% UI: 0-15) with cleft palate could be born without these defects each year if carbamazepine were not used during pregnancy. This modeling approach could be extended to other medications to estimate the impact of translating pharmacoepidemiologic data to evidence-based prenatal care practice. Published 2011 Wiley-Liss, Inc.(dagger) C1 [Gilboa, Suzanne M.] Ctr Dis Control & Prevent CDC, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Honein, Margaret A.] CDC, Birth Defects Branch, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Boulet, Sheree L.] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. RP Gilboa, SM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mail Stop E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM sgilboa@cdc.gov OI Werler, Martha/0000-0003-3392-6814 FU Centers for Disease Control and Prevention; U.S. Department of Energy FX The authors acknowledge librarian Rebecca Satterthwaite of Northrop Grumman, a contractor to the Centers for Disease Control and Prevention, as well as an undergraduate student from Kennesaw State University, Brandi Cooke, and two graduate students from Emory University's Rollins School of Public Health who assisted with the abstraction of manuscripts, Jessica Knight, and Stacey Peters. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the Centers for Disease Control and Prevention. NR 102 TC 10 Z9 10 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4868 J9 AM J MED GENET C JI Am. J. Med. Genet. C PD AUG 15 PY 2011 VL 157C IS 3 SI SI BP 234 EP 246 DI 10.1002/ajmg.c.30306 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 802VM UT WOS:000293539100012 PM 21766433 ER PT J AU Kourtis, AP Fowler, MG AF Kourtis, Athena P. Fowler, Mary Glenn TI Antiretroviral Use During Pregnancy and Risk of Preterm Delivery: More Questions Than Answers SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID PREMATURE DELIVERY; THERAPY C1 [Kourtis, Athena P.] CDC, DRH, NCCDPHP, Atlanta, GA 30341 USA. [Fowler, Mary Glenn] Johns Hopkins Univ, Makerere Hosp, Kampala, Uganda. RP Kourtis, AP (reprint author), CDC, DRH, NCCDPHP, MS-K34,4770 Woodcock Blvd, Atlanta, GA 30341 USA. EM apk3@cdc.gov NR 9 TC 8 Z9 8 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2011 VL 204 IS 4 BP 493 EP 494 DI 10.1093/infdis/jir318 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 799RS UT WOS:000293304400001 PM 21791648 ER PT J AU Dunne, EF Sternberg, M Markowitz, LE McQuillan, G Swan, D Patel, S Unger, ER AF Dunne, Eileen F. Sternberg, Maya Markowitz, Lauri E. McQuillan, Geraldine Swan, David Patel, Sonya Unger, Elizabeth R. TI Human Papillomavirus (HPV) 6, 11, 16, and 18 Prevalence Among Females in the United States-National Health and Nutrition Examination Survey, 2003-2006: Opportunity to Measure HPV Vaccine Impact? SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID YOUNG-WOMEN; INFECTION; RISK AB The 2003-2006 National Health and Nutrition Examination Surveys were used to assess human papillomavirus (HPV) types 6, 11, 16, and 18 DNA detection from females aged 14-59 years who self-collected cervicovaginal swab specimens. Prevalence was 8.8% (95% confidence interval [CI], 7.8%-10.0%) and was highest among women aged 20-24 years (18.5%; 95% CI, 14.9%-22.8%). Age group, education, marital status, and sexual behavior were associated with detection. These data provide baseline information before HPV vaccine introduction. Early impact of vaccine in the United States may be determined by a reduction in the prevalence of HPV 6, 11, 16, and 18 infection among young women. C1 [Dunne, Eileen F.; Sternberg, Maya; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [McQuillan, Geraldine] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. [Swan, David; Patel, Sonya; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Dunne, EF (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM dde9@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 FU National Center for HIV; Viral Hepatitis; STD; TB Prevention; National Center for Health Statistics, Centers for Disease Control and Prevention FX This study was supported by the National Center for HIV, Viral Hepatitis, STD, and TB Prevention, and the National Center for Health Statistics, Centers for Disease Control and Prevention. NR 18 TC 33 Z9 34 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2011 VL 204 IS 4 BP 562 EP 565 DI 10.1093/infdis/jir342 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 799RS UT WOS:000293304400012 PM 21791658 ER PT J AU Hariri, S Unger, ER Sternberg, M Dunne, EF Swan, D Patel, S Markowitz, LE AF Hariri, Susan Unger, Elizabeth R. Sternberg, Maya Dunne, Eileen F. Swan, David Patel, Sonya Markowitz, Lauri E. TI Prevalence of Genital Human Papillomavirus Among Females in the United States, the National Health and Nutrition Examination Survey, 2003-2006 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; POLYMERASE-CHAIN-REACTION; SQUAMOUS-CELL; HPV TYPES; CANCER; WORLDWIDE; INFECTION; DISEASE; WOMEN; DNA AB Background. Genital human papillomaviruses (HPV) include >40 sexually transmitted viruses. Most HPV infections do not progress to disease, but infection with certain types of HPV can cause cervical and other anogenital and oropharyngeal cancer, and other types of HPV are associated with anogenital warts. HPV vaccines prevent infection with HPV 16 and 18, which account for 70% of cases of cervical cancer, and HPV 6 and 11, which cause 90% of the cases of anogenital warts. Methods. Using data and self-collected cervicovaginal specimens from 4150 females, 14-59 years of age, from consecutive National Health and Nutrition Examination Surveys (2003-2006), we estimated the prevalence of type-specific HPV DNA and examined sociodemographic and sexual determinants. Results. The overall prevalence of HPV was 42.5% in females 14-59 years of age and varied significantly by age, race or ethnicity, and number of sex partners. Individual type prevalence was less than 7%, ranging from < 0.5% through 6.5%. The most common type was nononcogenic HPV 62 (found in 6.5% of subjects), followed by HPV 53 and HPV 16 (4.7%), both of which are oncogenic types. The most prevalent species was nononcogenic alpha 3. Conclusions. HPV infection is common among US females, with the highest burden of infection found in young females 20-24 years of age. Monitoring trends in HPV type distribution will contribute to our understanding of the early impact of HPV vaccines. C1 [Hariri, Susan; Sternberg, Maya; Dunne, Eileen F.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr Hepatitis HIV STD & TB Prevent, Atlanta, GA USA. [Unger, Elizabeth R.; Swan, David; Patel, Sonya] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Hariri, S (reprint author), 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM shariri@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 FU National Center for HIV/AIDS; Viral Hepatitis; STD; TB Prevention; National Center for Health Statistics, Centers for Disease Control and Prevention FX This study was supported by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, and the National Center for Health Statistics, Centers for Disease Control and Prevention. NR 38 TC 157 Z9 159 U1 1 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2011 VL 204 IS 4 BP 566 EP 573 DI 10.1093/infdis/jir341 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 799RS UT WOS:000293304400013 PM 21791659 ER PT J AU Mota, RMS Kerr, LRFS Kendall, C Pinho, A de Mello, MB Dourado, I Guimaraes, MDC Brito, A Batista, S Abreu, F Benzaken, A Oliveira, L Moraes, A Merchan-Hamann, E Freitas, G Albuquerque, EM Mcfarland, W Rutherford, G AF Salani Mota, Rosa Maria Franco Sansigolo Kerr, Ligia Regina Kendall, Carl Pinho, Adriana de Mello, Maeve Brito Dourado, Ines Crosland Guimaraes, Mark Drew Brito, Ana Batista, Sonia Abreu, Fabiano Benzaken, Adele Oliveira, Lisangela Moraes, Adao Merchan-Hamann, Edgar Freitas, Giselle Albuquerque, Elizabeth Maciel Mcfarland, Willi Rutherford, George TI Reliability of Self-Report of HIV Status Among Men Who Have Sex With Men in Brazil SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE MSM; HIV/AIDS; self-reporting; HIV testing; predictive value; kappa coefficient ID HIGH AGREEMENT; LOW KAPPA; PARADOXES AB Introduction: The aim of this study was to evaluate the reliability of self-reported HIV among men who have sex with men (MSM) in Brazil. Methods: MSM 18 years of age or older were recruited to a multicenter study using respondent-driven sampling. We compared self-report of the HIV test with a rapid HIV test using the kappa coefficient. Results: A total of 3859 MSM were recruited, and 39% reported ever having an HIV test; their results were reported and they agreed to a new test. Agreement between self-report and the test was very good (kappa = 0.88). Conclusion: Our results suggest that self-report of HIV infection is a reliable indicator among MSM. C1 [Franco Sansigolo Kerr, Ligia Regina] Univ Fed Ceara, Dept Saude Comunitaria, BR-60430971 Fortaleza, Ceara, Brazil. [Kendall, Carl] Tulane Univ, Sch Publ Hlth & Trop Med, Ctr Global Hlth Equ, New Orleans, LA USA. [Pinho, Adriana; Albuquerque, Elizabeth Maciel] Fundacao Oswaldo Cruz, CICT, Rio De Janeiro, Brazil. [de Mello, Maeve Brito] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Dourado, Ines] Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil. [Crosland Guimaraes, Mark Drew] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil. [Brito, Ana] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Reicife, Brazil. [Batista, Sonia] Univ Fed Rio de Janeiro, NESC, Rio De Janeiro, Brazil. [Abreu, Fabiano] Secretaria Saude Santos, Santos, Brazil. [Benzaken, Adele] Fundacao Alfredo Mata, Manaus, Amazonas, Brazil. [Oliveira, Lisangela] Secretaria Saude Curitiba, Curitiba, Parana, Brazil. [Moraes, Adao] Secretaria Saude Itajai, Itajai, Brazil. [Merchan-Hamann, Edgar] Univ Brasilia, Brasilia, DF, Brazil. [Freitas, Giselle] Secretaria Saude Campo Grande, Campo Grande, Brazil. [Mcfarland, Willi; Rutherford, George] Univ Calif San Francisco, Inst Global Hlth, San Francisco, Brazil. RP Kerr, LRFS (reprint author), Univ Fed Ceara, Dept Saude Comunitaria, Rua Prof Costa Mendes 1608,5 Andar, BR-60430971 Fortaleza, Ceara, Brazil. EM ligiakerr@gmail.com RI Dourado, Ines/Q-6535-2016 OI Dourado, Ines/0000-0003-1675-2146 FU Department of STD, AIDS and Viral Hepatitis (DSAVH) of the Ministry of Health [CSV 234/07] FX The authors thank the Department of STD, AIDS and Viral Hepatitis (DSAVH) of the Ministry of Health, which funded the research (CSV 234/07), Center for Global Health Equity of the Tulane University for technical support, Institute for Global Health of the University of San Francisco California where the project was conceived, and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) BEX 3495/06-0 for supporting L.R.F.S.K.'s postdoctoral. The authors also thank Dr Marcio Antonio de Sa and Dr. Gerson Pereira for coordinating the Project in the 10 cities on behalf of the DSAVH; Dr Ana Roberta Pati Pascom (from DSAVH) and Dr Aristides Barbosa (from the Centers of Diseases Control and Prevention/GAP Brazil) for their technical and implementation assistance in the respondent-driven sampling methodology in Brazil; and Prof Dr Gabriela Calazans, Dr Ligia Rivero Pupo, Prof Dr Fernando Seffner, and Prof Dr Alexandre Grangeiro for their suggestions. NR 12 TC 12 Z9 13 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 15 PY 2011 VL 57 SU 3 BP S153 EP S156 DI 10.1097/QAI.0b013e31821e9c10 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 798TU UT WOS:000293235900005 ER PT J AU Ye, XY Zhou, XL Furr, J Ahn, KC Hammock, BD Gray, EL Calafat, AM AF Ye, Xiaoyun Zhou, Xiaoliu Furr, Johnathan Ahn, Ki Chang Hammock, Bruce D. Gray, Earl L. Calafat, Antonia M. TI Biomarkers of exposure to triclocarban in urine and serum SO TOXICOLOGY LA English DT Article DE Triclocarban; 2 '-OH-triclocarban; 3 '-OH-triclocarban; Biomarkers; Exposure assessment; Oxidative metabolism ID DEUTERIUM-LABELED DEHP; DI(2-ETHYLHEXYL)PHTHALATE DEHP; MASS-SPECTROMETRY; 3,4,4'-TRICHLOROCARBANILIDE; METABOLITES; TRICLOSAN; RAT; BIOTRANSFORMATION; ABSORPTION; MONKEY AB 3,4,4'-Trichlorocarbanilide (triclocarban, TCC) is widely used as an antimicrobial agent in a variety of consumer and personal care products. TCC is considered a potential endocrine disruptor, but its potential toxic effects in humans are still largely unknown. Because of its widespread uses, the potential for human exposure to TCC is high. In order to identify adequate exposure biomarkers of TCC, we investigated the metabolic profile of TCC in adult female Sprague Dawley rats after administering TCC once (500 mg/kg body weight) by oral gavage. Urine was collected 0-24h before dosing, and 0-24h and 24-48h after dosing. Serum was collected at necropsy 48 h after dosing. We identified several metabolites of TCC in urine and serum by on-line solid phase extraction-high performance liquid chromatography-mass spectrometry. We unambiguously identified two major oxidative metabolites of TCC, 3'-hydroxy-TCC and 2'-hydroxy-TCC, by comparing their chromatographic behavior and mass spectral fragmentation patterns with those of authentic standards. By contrast, compared to these oxidative metabolites, we detected very low levels of TCC in the urine or serum. Taken together these data suggest that in rats, oxidation of TCC is a major metabolic pathway. We also measured TCC and its oxidative metabolites in 50 urine and 16 serum samples collected from adults in the United States. The results suggest differences in the metabolic profile of TCC in rats and in humans: oxidation appears to be a minor metabolic pathway in humans. Total (free plus conjugated) TCC could serve as a potential biomarker for human exposure to TCC. Published by Elsevier Ireland Ltd. C1 [Ye, Xiaoyun; Zhou, Xiaoliu; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Furr, Johnathan; Gray, Earl L.] US EPA, Reprod Toxicol Branch, Tox Assessment Div, Natl Hlth & Environm Effects Res Lab,Off Res & De, Res Triangle Pk, NC 27711 USA. [Ahn, Ki Chang; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Ahn, Ki Chang; Hammock, Bruce D.] Univ Calif Davis, Canc Res Ctr, Davis, CA 95616 USA. RP Ye, XY (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM xay5@cdc.gov FU EPA IAG [RW-75-92285501-0,]; NTP [Y1-ES-80124-01]; NIEHS [R01 ES002710, P42 ES004699]; NIOSH [PHS OH07550] FX This work was supported by EPA IAG # RW-75-92285501-0, NTP # Y1-ES-80124-01, NIEHS (R01 ES002710, P42 ES004699), and NIOSH (PHS OH07550). We thank Dr. James R. Sanborn form Department of Entomology, University of California - Davis, Davis, CA for providing assistance during this research. NR 25 TC 19 Z9 20 U1 3 U2 21 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-483X J9 TOXICOLOGY JI Toxicology PD AUG 15 PY 2011 VL 286 IS 1-3 BP 69 EP 74 DI 10.1016/j.tox.2011.05.008 PG 6 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 793HI UT WOS:000292810600007 PM 21635932 ER PT J AU Ward, JW Averhoff, FM Koh, HK AF Ward, John W. Averhoff, Francisco M. Koh, Howard K. TI World Hepatitis Day: a new era for hepatitis control SO LANCET LA English DT Editorial Material C1 [Ward, John W.; Averhoff, Francisco M.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Ward, John W.; Averhoff, Francisco M.; Koh, Howard K.] US Dept Hlth & Human Serv, Off Secretary, Washington, DC 20201 USA. RP Ward, JW (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM jward@cdc.gov NR 13 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD AUG 13 PY 2011 VL 378 IS 9791 BP 552 EP 553 DI 10.1016/S0140-6736(11)60839-8 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 812UX UT WOS:000294319500009 PM 21802132 ER PT J AU Griffin, MR Monto, AS Belongia, EA Treanor, JJ Chen, QX Chen, JF Talbot, HK Ohmit, SE Coleman, LA Lofthus, G Petrie, JG Meece, JK Hall, CB Williams, JV Gargiullo, P Berman, L Shay, DK AF Griffin, Marie R. Monto, Arnold S. Belongia, Edward A. Treanor, John J. Chen, Qingxia Chen, Jufu Talbot, H. Keipp Ohmit, Suzanne E. Coleman, Laura A. Lofthus, Gerry Petrie, Joshua G. Meece, Jennifer K. Hall, Caroline Breese Williams, John V. Gargiullo, Paul Berman, LaShondra Shay, David K. CA US Flu-VE Network TI Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 US Communities SO PLOS ONE LA English DT Article ID 2009 H1N1 VACCINE; LIVE ATTENUATED VACCINES; SEASONAL INFLUENZA; ANTIBODY-RESPONSE; UNITED-STATES; RISK GROUPS; CHILDREN; MONOVALENT; SAFETY; IMMUNOGENICITY AB We estimated the effectiveness of four monovalent pandemic influenza A (H1N1) vaccines (three unadjuvanted inactivated, one live attenuated) available in the U.S. during the pandemic. Patients with acute respiratory illness presenting to inpatient and outpatient facilities affiliated with four collaborating institutions were prospectively recruited, consented, and tested for influenza. Analyses were restricted to October 2009 through April 2010, when pandemic vaccine was available. Patients testing positive for pandemic influenza by real-time RT-PCR were cases; those testing negative were controls. Vaccine effectiveness was estimated in logistic regression models adjusted for study community, patient age, timing of illness, insurance status, enrollment site, and presence of high-risk medical conditions. Pandemic virus was detected in 1,011 (15%) of 6,757 enrolled patients. Fifteen (1%) of 1,011 influenza positive cases and 1,042 (18%) of 5,746 test-negative controls had record-verified pandemic vaccination > 14 days prior to illness onset. Adjusted effectiveness (95% confidence interval) for pandemic vaccines combined was 56% (-23%, 75%). Adjusted effectiveness for inactivated vaccines alone (79% of total) was 62% (25%, 81%) overall and 32% (-92%, 76%), 89% (15%, 99%), and -6% (-231%, 66%) in those aged 0.5 to 9, 10 to 49, and 50+ years, respectively. Effectiveness for the live attenuated vaccine in those aged 2 to 49 years was only demonstrated if vaccination >7 rather than >14 days prior to illness onset was considered (61%: 12%, 82%). Inactivated non-adjuvanted pandemic vaccines offered significant protection against confirmed pandemic influenza-associated medical care visits in young adults. C1 [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN 37235 USA. [Griffin, Marie R.; Talbot, H. Keipp] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Chen, Qingxia] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA. [Talbot, H. Keipp; Williams, John V.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Williams, John V.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN USA. [Monto, Arnold S.; Ohmit, Suzanne E.; Petrie, Joshua G.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Belongia, Edward A.; Coleman, Laura A.; Meece, Jennifer K.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Treanor, John J.; Lofthus, Gerry; Hall, Caroline Breese] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. [Hall, Caroline Breese] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Chen, Jufu; Gargiullo, Paul; Berman, LaShondra; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Griffin, MR (reprint author), Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN 37235 USA. EM marie.griffin@vanderbilt.edu RI Williams, John/F-6962-2010; OI Williams, John/0000-0001-8377-5175; Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention; Marshfield Clinic Research Foundation [U01 IP000183]; University of Michigan [U01 IP000170]; University of Rochester [U01 IP000172]; Vanderbilt University [U01 IP000184]; NIAID [1K23AI074863-01] FX This study was funded by the Centers for Disease Control and Prevention through cooperative agreements with the Marshfield Clinic Research Foundation (U01 IP000183), the University of Michigan (U01 IP000170), the University of Rochester (U01 IP000172), and Vanderbilt University (U01 IP000184). Internal CDC funds were used to support CDC investigators and to provide laboratory validation of RT-PCR methods at the enrolling site laboratories. As part of the cooperative agreement, CDC investigators participated in study design, analysis, decision to publish and preparation of the manuscript. Dr. Talbot received salary support from the NIAID (1K23AI074863-01). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 30 TC 66 Z9 66 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 12 PY 2011 VL 6 IS 8 AR e23085 DI 10.1371/journal.pone.0023085 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 808CT UT WOS:000293953500020 PM 21857999 ER PT J AU Zhao, GX Ford, ES Li, CY Tsai, J Dhingra, S Balluz, LS AF Zhao, Guixiang Ford, Earl S. Li, Chaoyang Tsai, James Dhingra, Satvinder Balluz, Lina S. TI Waist circumference, abdominal obesity, and depression among overweight and obese U.S. adults: national health and nutrition examination survey 2005-2006 SO BMC PSYCHIATRY LA English DT Article DE abdominal obesity; depressive symptoms; PHQ-9 diagnostic algorithm; waist circumference ID BODY-MASS INDEX; 1966 BIRTH COHORT; METABOLIC SYNDROME; GENERAL-POPULATION; PSYCHIATRIC-DISORDERS; PHYSICAL-ACTIVITY; MENTAL-DISORDERS; FAT DISTRIBUTION; VISCERAL FAT; FOLLOW-UP AB Background: Obesity is associated with an increased risk of mental illness; however, evidence linking body mass index (BMI)-a measure of overall obesity, to mental illness is inconsistent. The objective of this study was to examine the association of depressive symptoms with waist circumference or abdominal obesity among overweight and obese U.S. adults. Methods: A cross-sectional, nationally representative sample from the 2005-2006 National Health and Nutrition Examination Survey was used. We analyzed the data from 2,439 U.S. adults (1,325 men and 1,114 nonpregnant women) aged >= 20 years who were either overweight or obese with BMI of >= 25.0 kg/m(2). Abdominal obesity was defined as waist circumference of > 102 cm for men and > 88 cm for women. Depressive symptoms (defined as having major depressive symptoms or moderate-to-severe depressive symptoms) were assessed by the Patient Health Questionnaire-9 diagnostic algorithm. The prevalence and the odds ratios (ORs) with 95% confidence intervals (CIs) for having major depressive symptoms and moderate-to-severe depressive symptoms were estimated using logistic regression analysis. Results: After multivariate adjustment for demographics and lifestyle factors, waist circumference was significantly associated with both major depressive symptoms (OR: 1.03, 95% CI: 1.01-1.05) and moderate-to-severe depressive symptoms (OR: 1.02, 95% CI: 1.01-1.04), and adults with abdominal obesity were significantly more likely to have major depressive symptoms (OR: 2.18, 95% CI: 1.35-3.59) or have moderate-to-severe depressive symptoms (OR: 2.56, 95% CI: 1.34-4.90) than those without. These relationships persisted after further adjusting for coexistence of multiple chronic conditions and persisted in participants who were overweight (BMI: 25.0-< 30.0 kg/m(2)) when stratified analyses were conducted by BMI status. Conclusion: Among overweight and obese U.S. adults, waist circumference or abdominal obesity was significantly associated with increased likelihoods of having major depressive symptoms or moderate-to-severe depressive symptoms. Thus, mental health status should be monitored and evaluated in adults with abdominal obesity, particularly in those who are overweight. C1 [Zhao, Guixiang; Ford, Earl S.; Tsai, James] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Li, Chaoyang; Dhingra, Satvinder; Balluz, Lina S.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. RP Zhao, GX (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA. EM fwj4@cdc.gov NR 56 TC 58 Z9 61 U1 0 U2 19 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-244X J9 BMC PSYCHIATRY JI BMC Psychiatry PD AUG 11 PY 2011 VL 11 AR 130 DI 10.1186/1471-244X-11-130 PG 9 WC Psychiatry SC Psychiatry GA 814GN UT WOS:000294436400001 PM 21834955 ER PT J AU Capewell, S Ford, ES AF Capewell, Simon Ford, Earl S. TI Why have total cholesterol levels declined in most developed countries? SO BMC PUBLIC HEALTH LA English DT Article ID CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; MORTALITY-RATES; RISK; DECREASE; TRENDS; SWEDEN; ADULTS; LIPIDS AB Background: Our paper addresses three major public health issues: cholesterol, statins and policies to prevent cardiovascular disease. Discussion: Total cholesterol levels in whole populations have fallen substantially in the USA, UK and most other developed countries. This has greatly contributed to decreases in cardiovascular disease deaths. The evidence identifying diet as the major contributor to these historical falls in cholesterol is powerful and consistent. Large falls occurred before statins were introduced. Additional substantial falls occurred before statins were widely used. Now, up to 14% adults in Western populations currently receive statins for primary prevention. Furthermore, because diet is now only slowly improving, the statin contribution currently appears proportionately larger. Summary: In conclusion, diet change explains most of the historical falls in cholesterol. Until very recently, the contribution from statins has been surprisingly modest. Furthermore, many middle income countries may have neither the resources nor the infrastructure for mass statin therapy. Further substantial falls in cholesterol are therefore unlikely to be obtained simply by increased use of statins or dietary advice to individuals if unsupported by the wider environment. This further emphasises the need for more effective structural policies. Regulatory and fiscal interventions could easily eradicate industrial transfats, halve the intake of dietary saturated fat, and subsidise healthier fats. C1 [Capewell, Simon] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Ford, Earl S.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Capewell, S (reprint author), Univ Liverpool, Liverpool L69 3BX, Merseyside, England. EM capewell@liverpool.ac.uk FU HEFCE; CDC, Atlanta FX SC was funded by HEFCE, ESF by CDC, Atlanta. However, the findings and conclusions in this article are those of the authors and do not necessarily represent the official position of HEFCE, NICE or the Centers for Disease Control and Prevention. NR 22 TC 19 Z9 19 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD AUG 11 PY 2011 VL 11 AR 641 DI 10.1186/1471-2458-11-641 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 814HS UT WOS:000294439800001 PM 21834954 ER PT J AU Pushko, P Pearce, MB Ahmad, A Tretyakova, I Smith, G Belser, JA Tumpey, TM AF Pushko, Peter Pearce, Melissa B. Ahmad, Attiya Tretyakova, Irina Smith, Gale Belser, Jessica A. Tumpey, Terrence M. TI Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes SO VACCINE LA English DT Article DE Influenza; Virus-like particles; VLP; Influenza vaccine; Trivalent ID IMMUNE-RESPONSES; UNITED-STATES; H5N1 VIRUSES; A VIRUSES; IN-VITRO; VACCINES; VACCINATION; MICE; FERRETS; EXPRESSION AB Despite existing vaccines and specific therapies, epidemics of seasonal influenza annually claim 200,000-500,000 lives worldwide. Pandemic influenza represents an even greater threat, with numerous potentially pandemic viruses circulating in nature. Development of multi-specific vaccines against multiple pandemic or seasonal strains is important for human health and the global economy. Here we report a novel virus-like particle (VLP) platform that contains three hemagglutinin (HA) subtypes. This recombinant vaccine design resulted in the expression of three HA subtypes co-localized within a VLP. Experimental triple-HA VLPs containing HA proteins derived from H5N1, H7N2, and H2N3 viruses were immunogenic and protected ferrets from challenge from all three potentially pandemic viruses. Similarly, VLPs containing HA subtypes derived from seasonal H1N1, H3N2, and type B influenza viruses protected ferrets from three seasonal influenza viruses. We conclude that this technology may represent a novel strategy for rapid development of trivalent seasonal and pandemic vaccines. Published by Elsevier Ltd. C1 [Pearce, Melissa B.; Belser, Jessica A.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Pushko, Peter; Tretyakova, Irina] Medigen Inc, Frederick, MD USA. [Ahmad, Attiya; Smith, Gale] Novavax Inc, Rockville, MD USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM tft9@cdc.gov NR 39 TC 38 Z9 40 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 11 PY 2011 VL 29 IS 35 BP 5911 EP 5918 DI 10.1016/j.vaccine.2011.06.068 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 810RX UT WOS:000294145900011 PM 21723354 ER PT J AU Marsh, JW Shutt, KA Pajon, R Tulenko, MM Liu, S Hollick, RA Kiehlbauch, JA Clark, TA Stephens, DS Arnold, KE Myers, RA Mayer, LW Harrison, LH AF Marsh, Jane W. Shutt, Kathleen A. Pajon, Rolando Tulenko, Mary M. Liu, Stephen Hollick, Rosemary A. Kiehlbauch, Julia A. Clark, Thomas A. Stephens, David S. Arnold, Kathryn E. Myers, Robert A. Mayer, Leonard W. Harrison, Lee H. TI Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates SO VACCINE LA English DT Article DE Meningococcal vaccine; FHbp; Genetic lineage; Recombination ID SEROGROUP-B MENINGOCOCCUS; HERD-IMMUNITY; VACCINE; DISEASE; IMMUNOGENICITY; EVOLUTIONARY; LIPOPROTEIN; COMPONENTS; COVERAGE; STRAINS AB Several meningococcal vaccines under development for prevention of serogroup B disease target the factor H-binding protein (FHbp), an immunogenic lipoprotein expressed on the surface of Neisseria meningitidis. Based upon sequence and phylogenetic analyses, FHbp can be classified into 3 protein variants (1,2 or 3) or 2 subfamilies (A or B). The potential effect of FHbp-containing vaccines on meningococcal carriage is not known. We determined the diversity of FHbp among a population of carriage isolates obtained from Georgia and Maryland high school students in 1998 and 2006-2007. Analysis of the fHbp gene sequence from 408 carriage isolates identified 30 different FHbp protein sequences. The majority of carriage isolates harbored FHbp proteins belonging to variant 2/subfamily A. Association between FHbp proteins and genetic lineage was observed among the carriage isolates. However, split decomposition analysis, together with tests of linkage disequilibrium and pairwise homoplasy suggest recombination at fHbp contribute to allelic diversity. Of note, the FHbp proteins in serogroup B vaccines under development are either absent or not well represented in this carriage population. The FHbp genetic repertoire observed in carriage isolate populations will be useful in understanding the potential impact of FHbp-containing vaccines on meningococcal carriage. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Marsh, Jane W.; Shutt, Kathleen A.; Tulenko, Mary M.; Liu, Stephen; Harrison, Lee H.] Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15261 USA. [Marsh, Jane W.; Shutt, Kathleen A.; Tulenko, Mary M.; Liu, Stephen; Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Pajon, Rolando] Childrens Hosp Oakland, Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA 94609 USA. [Hollick, Rosemary A.; Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Kiehlbauch, Julia A.; Myers, Robert A.] Maryland Dept Hlth & Mental Hyg, Labs Adm, Baltimore, MD USA. [Clark, Thomas A.; Mayer, Leonard W.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Stephens, David S.] Emory Univ, Robert W Woodruff Hlth Sci Ctr, Atlanta, GA 30322 USA. [Stephens, David S.] VA Med Ctr, Med Res Serv, Atlanta, GA USA. [Arnold, Kathryn E.] Publ Hlth & Emerging Infect Program, Georgia Div, Atlanta, GA USA. RP Marsh, JW (reprint author), Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, 865 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM jwmarsh@pitt.edu; shuttk@pitt.edu; rpajon@chori.org; olearym@pitt.edu; rhollick@jhsph.edu; kiehlbauch@aol.com; tnc4@cdc.gov; DSTEP01@emory.edu; kearnold@dhr.state.ga.us; myersr@dhmh.state.md.us; lwm1@cdc.gov; lharriso@edc.pitt.edu RI Stephens, David/A-8788-2012; OI Shutt, Kathleen/0000-0003-3376-6152 FU Centers for Diseases Control and Prevention; Sanofi Pasteur; National Institute of Allergy and Infectious Diseases; Novartis Vaccines; Department of Veterans Affairs; Georgia Research Alliance FX This study was supported in part by the Centers for Diseases Control and Prevention. Sanofi Pasteur supported the 2006-2007 meningococcal carriage study through a grant to the CDC Foundation.; Dr. Harrison receives funding from the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases. He receives research support and lecture fees from Sanofi Pasteur; lecture fees from Novartis Vaccines; and has served as a consultant to GlaxoSmithKline, Novartis Vaccines, Sanofi Pasteur, and Pfizer. Ms. Shutt and Dr. Marsh receive research support from Sanofi Pasteur. Dr. Stephens has research funding from the National Institute of Allergy and Infectious Diseases, the Department of Veterans Affairs and the Georgia Research Alliance. Other authors: no disclosures. NR 44 TC 10 Z9 10 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 11 PY 2011 VL 29 IS 35 BP 6049 EP 6058 DI 10.1016/j.vaccine.2011.06.025 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 810RX UT WOS:000294145900029 PM 21704667 ER PT J AU Chun, C Weinmann, S Riedlinger, K Mullooly, JP Houston, H Schmid, DS Seward, JF AF Chun, Colleen Weinmann, Sheila Riedlinger, Karen Mullooly, John P. Houston, Heather Schmid, D. Scott Seward, Jane F. TI LABORATORY CHARACTERISTICS OF SUSPECTED HERPES ZOSTER IN VACCINATED CHILDREN SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE herpes zoster; varicella vaccine ID VARICELLA VACCINE; UNITED-STATES; VIRUS; DIAGNOSIS; RESPONSES AB Varicella vaccination of children has decreased varicella disease incidence, but introduced the occurrence of herpes zoster (HZ) from vaccine-type virus. We identified 14 vaccinated children with suspected HZ and confirmed varicella virus by polymerase chain reaction in 6 cases. Two cases were due to vaccine-type virus. Serum varicella IgM and IgG were not useful for diagnosis of HZ among vaccinated children. C1 [Chun, Colleen] NW Permanente, Div Pediat Infect Dis, Mailcode CDRCP, Portland, OR 97239 USA. [Weinmann, Sheila; Riedlinger, Karen; Mullooly, John P.; Houston, Heather] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. [Schmid, D. Scott] Ctr Dis Control & Prevent, Natl VZV Lab, Atlanta, GA USA. [Seward, Jane F.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Chun, C (reprint author), NW Permanente, Div Pediat Infect Dis, Mailcode CDRCP, 707 SW Gaines St, Portland, OR 97239 USA. EM Colleen.Chun@kp.org NR 12 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD AUG 11 PY 2011 VL 30 IS 8 BP 719 EP 721 DI 10.1097/INF.0b013e3182137e35 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 796PN UT WOS:000293064200025 PM 21346684 ER PT J AU del Rio, C Hall, G Hook, EW Whittington, WLH Kirkcaldy, RD Papp, JR Weinstock, H Murray, EL AF del Rio, Carlos Hall, Geraldine Hook, Edward W. Whittington, William L. H. Kirkcaldy, Robert D. Papp, John R. Weinstock, Hillard Murray, Erin L. TI Cephalosporin Susceptibility Among Neisseria gonorrhoeae Isolates-United States, 2000-2010 (Reprinted from MMWR, vol 60, pg 873-877, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Kirkcaldy, Robert D.; Papp, John R.; Weinstock, Hillard] Natl Ctr HIV Hepatitis STD & TB Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hall, Geraldine] Cleveland Clin, Dept Clin Pathol, Cleveland, OH 44106 USA. [Hook, Edward W.] Univ Alabama, Div Infect Dis, Birmingham, AL USA. [Whittington, William L. H.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Murray, Erin L.] CDC, Atlanta, GA 30333 USA. RP Kirkcaldy, RD (reprint author), Natl Ctr HIV Hepatitis STD & TB Prevent, Div STD Prevent, Atlanta, GA 30333 USA. EM rkirkcaldy@cdc.gov RI del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 10 PY 2011 VL 306 IS 6 BP 599 EP 602 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 804XD UT WOS:000293687300009 ER PT J AU Alarcon, WA Graydon, JR Calvert, GM AF Alarcon, Walter A. Graydon, Janet R. Calvert, Geoffrey M. TI Adult Blood Lead Epidemiology and Surveillance-United States, 2008-2009 (Reprinted from MMWR, vol 60, pg 841-845, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID EXPOSURE; WORKERS C1 [Alarcon, Walter A.; Graydon, Janet R.; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Washington, DC 20210 USA. RP Alarcon, WA (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, CDC, Washington, DC 20210 USA. EM walar-con@cdc.gov RI Alarcon, Walter/C-4470-2008 OI Alarcon, Walter/0000-0002-4907-4380 NR 10 TC 0 Z9 0 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 10 PY 2011 VL 306 IS 6 BP 602 EP 605 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 804XD UT WOS:000293687300010 ER PT J AU Dubowitz, N Johnson, TM Goodman, RA AF Dubowitz, Nadine Johnson, Theodore M., II Goodman, Richard A. TI Exercise Interventions and Glycemic Control in Patients With Diabetes SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID PHYSICAL-ACTIVITY C1 [Dubowitz, Nadine; Johnson, Theodore M., II] Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Atlanta, GA 30322 USA. [Goodman, Richard A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Dubowitz, N (reprint author), Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Atlanta, GA 30322 USA. EM ndubow2@emory.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 10 PY 2011 VL 306 IS 6 BP 607 EP 608 DI 10.1001/jama.2011.1104 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 804XD UT WOS:000293687300013 PM 21828318 ER PT J AU Carroll, DS Emerson, GL Li, Y Sammons, S Olson, V Frace, M Nakazawa, Y Czerny, CP Tryland, M Kolodziejek, J Nowotny, N Olsen-Rasmussen, M Khristova, M Govil, D Karem, K Damon, IK Meyer, H AF Carroll, Darin S. Emerson, Ginny L. Li, Yu Sammons, Scott Olson, Victoria Frace, Michael Nakazawa, Yoshinori Czerny, Claus Peter Tryland, Morten Kolodziejek, Jolanta Nowotny, Norbert Olsen-Rasmussen, Melissa Khristova, Marina Govil, Dhwani Karem, Kevin Damon, Inger K. Meyer, Hermann TI Chasing Jenner's Vaccine: Revisiting Cowpox Virus Classification SO PLOS ONE LA English DT Article ID CELL-SURFACE; ORTHOPOXVIRUSES; GENOME; CAT; SEQUENCES; DIVERSITY; WILDLIFE AB Cowpox virus (CPXV) is described as the source of the first vaccine used to prevent the onset and spread of an infectious disease. It is one of the earliest described members of the genus Orthopoxvirus, which includes the viruses that cause smallpox and monkeypox in humans. Both the historic and current literature describe "cowpox" as a disease with a single etiologic agent. Genotypic data presented herein indicate that CPXV is not a single species, but a composite of several (up to 5) species that can infect cows, humans, and other animals. The practice of naming agents after the host in which the resultant disease manifests obfuscates the true taxonomic relationships of "cowpox" isolates. These data support the elevation of as many as four new species within the traditional "cowpox" group and suggest that both wild and modern vaccine strains of Vaccinia virus are most closely related to CPXV of continental Europe rather than the United Kingdom, the homeland of the vaccine. C1 [Carroll, Darin S.; Emerson, Ginny L.; Li, Yu; Olson, Victoria; Nakazawa, Yoshinori; Karem, Kevin; Damon, Inger K.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Sammons, Scott; Frace, Michael; Olsen-Rasmussen, Melissa; Khristova, Marina; Govil, Dhwani] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Atlanta, GA USA. [Nakazawa, Yoshinori] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Czerny, Claus Peter] Univ Gottingen, Dept Anim Sci, Div Microbiol & Anim Hyg, Gottingen, Germany. [Tryland, Morten] Norwegian Sch Vet Sci, Sect Arctic Vet Med, Dept Food Safety & Infect Biol, Tromso, Norway. [Tryland, Morten] Genok, Ctr Biosafety, Tromso, Norway. [Kolodziejek, Jolanta; Nowotny, Norbert] Univ Vet Med Vienna, Dept Pathobiol, Zoonoses & Emerging Infect Grp, Vienna, Austria. [Nowotny, Norbert] Sultan Qaboos Univ, Fac Med & Hlth Sci, Dept Microbiol & Immunol, Muscat, Oman. [Meyer, Hermann] Bundeswehr Inst Microbiol, Munich, Germany. RP Carroll, DS (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. EM DCarroll@cdc.gov NR 25 TC 34 Z9 34 U1 3 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 8 PY 2011 VL 6 IS 8 AR e23086 DI 10.1371/journal.pone.0023086 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 806AM UT WOS:000293773300018 PM 21858000 ER PT J AU John, TJ Jain, H Ravishankar, K Amaresh, A Verma, H Deshpande, J Pallansch, MA Singh, AP Sreevatsava, M Burton, A Malankar, P Chatterjee, A Sutter, RW AF John, T. Jacob Jain, Hemant Ravishankar, Kanithi Amaresh, A. Verma, Harish Deshpande, Jagadish Pallansch, Mark A. Singh, Ajit Pal Sreevatsava, Meghana Burton, Anthony Malankar, Pradeep Chatterjee, Arani Sutter, Roland W. TI Monovalent type 1 oral poliovirus vaccine among infants in India: Report of two randomized double-blind controlled clinical trials SO VACCINE LA English DT Article DE Polio vaccine; Monovalent type 1 oral poliovirus vaccine; Immunogenicity; Controlled trial; Birth dose ID POLIOMYELITIS VACCINE; ANTIBODY-RESPONSE; IMMUNIZATION; TRIVALENT; EFFICACY; SABIN; IMMUNOGENICITY; NEWBORNS; CHILDREN; TROPICS AB Background: To provide the polio eradication initiative with more immunogenic oral poliovirus vaccines (OPVs), we evaluated newly developed monovalent type 1 OPV (mOPV1) among infants in India. Methods: Two double-blind randomized controlled clinical trials compared two mOPV1s (mOPV1 A and mOPV1 B) versus trivalent OPV (tOPV X) given at birth (trial I), or assessed two products of higher-potency mOPV1 (mOPV1 C and mOPV1 D) versus regular-potency mOPV1 (mOPV1 B) or tOPV Y given at birth and at 30 days (trial II). Results: In trial I, 597 newborns were enrolled, 66 withdrawn or excluded, leaving 531 (88.9%) subjects for analysis. Seroconversion to poliovirus type 1 was 10.4% for mOPV1 A, 15.6% for mOPV1 B and 10.2% for tOPV X. In trial II, 718 newborns were enrolled, 135 withdrawn or excluded, leaving 583 (81.2%) subjects for analysis. Seroconversion to poliovirus type 1 following a birth dose was 15.1%, 19.7%, 18.0% and 10.6%, following the 30-day dose 87.1%, 89.2%, 84.4%, or 55.9%, and cumulative for both doses 90.4%, 90.3%, 89.5% and 61.9% for mOPV1s B, C, and D and tOPV V. respectively. Conclusions: In both studies, seronconversion rates were unexpectedly low to poliovirus type 1 after mOPV1 or tOPV given at birth but high for all formulations of mOPV1 given at age 30 days. The cause for low immunogenicity of OPV at birth in India is not known. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Sreevatsava, Meghana; Burton, Anthony; Malankar, Pradeep; Sutter, Roland W.] World Hlth Org, Polio Eradicat Dept, CH-1211 Geneva 27, Switzerland. [John, T. Jacob] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Jain, Hemant] MGM Med Coll, Indore, Madhya Pradesh, India. [Ravishankar, Kanithi; Amaresh, A.] Niloufer Hosp, Hyderabad, Andhra Pradesh, India. [Verma, Harish] World Hlth Org, Natl Polio Surveillance Project, New Delhi, India. [Deshpande, Jagadish] Enterovirus Res Ctr, Bombay, Maharashtra, India. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Singh, Ajit Pal; Chatterjee, Arani] Panacea Biotec Ltd, New Delhi, India. RP Sutter, RW (reprint author), World Hlth Org, Polio Eradicat Dept, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM sutterr@who.int OI Deshpande, Jagadish/0000-0001-5194-0375 FU Bill and Melinda Gates Foundation [37460]; World Health Organization, Geneva, Switzerland FX Bill and Melinda Gates Foundation (Grant Identification #37460) and the World Health Organization, Geneva, Switzerland. NR 34 TC 12 Z9 12 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 5 PY 2011 VL 29 IS 34 BP 5793 EP 5801 DI 10.1016/j.vaccine.2011.04.133 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 810RW UT WOS:000294145800030 PM 21641951 ER PT J AU Pritt, BS Sloan, LM Johnson, DKH Munderloh, UG Paskewitz, SM McElroy, KM McFadden, JD Binnicker, MJ Neitzel, DF Liu, GP Nicholson, WL Nelson, CM Franson, JJ Martin, SA Cunningham, SA Steward, CR Bogumill, K Bjorgaard, ME Davis, JP McQuiston, JH Warshauer, DM Wilhelm, MP Patel, R Trivedi, VA Eremeeva, ME AF Pritt, Bobbi S. Sloan, Lynne M. Johnson, Diep K. Hoang Munderloh, Ulrike G. Paskewitz, Susan M. McElroy, Kristina M. McFadden, Jevon D. Binnicker, Matthew J. Neitzel, David F. Liu, Gongping Nicholson, William L. Nelson, Curtis M. Franson, Joni J. Martin, Scott A. Cunningham, Scott A. Steward, Christopher R. Bogumill, Kay Bjorgaard, Mary E. Davis, Jeffrey P. McQuiston, Jennifer H. Warshauer, David M. Wilhelm, Mark P. Patel, Robin Trivedi, Vipul A. Eremeeva, Marina E. TI Emergence of a New Pathogenic Ehrlichia Species, Wisconsin and Minnesota, 2009 SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ANAPLASMA-PHAGOCYTOPHILUM; ORDER RICKETTSIALES; UNITED-STATES; AGENT; TICKS; IDENTIFICATION; CHAFFEENSIS; RUSSIA; MICROORGANISMS; EPIDEMIOLOGY AB BACKGROUND Ehrlichiosis is a clinically important, emerging zoonosis. Only Ehrlichia chaffeensis and E. ewingii have been thought to cause ehrlichiosis in humans in the United States. Patients with suspected ehrlichiosis routinely undergo testing to ensure proper diagnosis and to ascertain the cause. Methods We used molecular methods, culturing, and serologic testing to diagnose and ascertain the cause of cases of ehrlichiosis. RESULTS On testing, four cases of ehrlichiosis in Minnesota or Wisconsin were found not to be from E. chaffeensis or E. ewingii and instead to be caused by a newly discovered ehrlichia species. All patients had fever, malaise, headache, and lymphopenia; three had thrombocytopenia; and two had elevated liver-enzyme levels. All recovered after receiving doxycycline treatment. At least 17 of 697 Ixodes scapularis ticks collected in Minnesota or Wisconsin were positive for the same ehrlichia species on polymerase-chain-reaction testing. Genetic analyses revealed that this new ehrlichia species is closely related to E. muris. CONCLUSIONS We report a new ehrlichia species in Minnesota and Wisconsin and provide supportive clinical, epidemiologic, culture, DNA-sequence, and vector data. Physicians need to be aware of this newly discovered close relative of E. muris to ensure appropriate testing, treatment, and regional surveillance. C1 [Pritt, Bobbi S.] Mayo Clin, Div Clin Microbiol, Rochester, MN 55905 USA. [Munderloh, Ulrike G.; Nelson, Curtis M.] Univ Minnesota, St Paul, MN 55108 USA. [Neitzel, David F.; Liu, Gongping] Minnesota Dept Hlth, St Paul, MN USA. [Johnson, Diep K. Hoang; McFadden, Jevon D.; Steward, Christopher R.; Davis, Jeffrey P.] Wisconsin Div Publ Hlth, Madison, WI USA. [Paskewitz, Susan M.] Univ Wisconsin, Madison, WI 53706 USA. [Franson, Joni J.; Martin, Scott A.; Trivedi, Vipul A.] Mayo Clin Hlth Syst, Eau Claire, WI USA. [Bogumill, Kay] Eau Claire City Cty Hlth Dept, Eau Claire, WI USA. [Bjorgaard, Mary E.] Dept Hlth & Human Serv, Siren, WI USA. [Warshauer, David M.] Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA. [McFadden, Jevon D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Nicholson, William L.; McQuiston, Jennifer H.; Eremeeva, Marina E.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. RP Pritt, BS (reprint author), Mayo Clin, Div Clin Microbiol, Hilton 470-B,200 1st St, Rochester, MN 55905 USA. EM pritt.bobbi@mayo.edu OI Pritt, Bobbi/0000-0003-0261-1326 FU National Institutes of Health [R01 AI042792]; Centers for Disease Control and Prevention; [5U50C1000483-03] FX Funded by the National Institutes of Health and the Centers for Disease Control and Prevention.; Supported in part by a grant from the National Institutes of Health (R01 AI042792, to Dr. Munderloh) and a cooperative agreement with the CDC (5U50C1000483-03, to Mr. Neitzel). NR 25 TC 76 Z9 80 U1 1 U2 25 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD AUG 4 PY 2011 VL 365 IS 5 BP 422 EP 429 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 801NW UT WOS:000293447800006 PM 21812671 ER PT J AU Wethington, HR Sherry, B Polhamus, B AF Wethington, Holly R. Sherry, Bettylou Polhamus, Barbara TI Physician practices related to use of BMI-for-age and counseling for childhood obesity prevention: A cross-sectional study SO BMC FAMILY PRACTICE LA English DT Article ID BODY-MASS INDEX; PRIMARY-CARE; OVERWEIGHT CHILDREN; PEDIATRIC PRACTICE; NATIONAL-SURVEY; NUTRIENT INTAKE; MANAGEMENT; ADOLESCENTS; ADULTHOOD; IDENTIFICATION AB Background: Screening for obesity and providing appropriate obesity-related counseling in the clinical setting are important strategies to prevent and control childhood obesity. The purpose of this study is to document pediatricians (PEDs) and general practitioners (GPs) with pediatric patients use of BMI-for-age to screen for obesity, confidence in explaining BMI, access to referral clinics, and characteristics associated with screening and counseling to children and their caregivers. Methods: The authors used 2008 DocStyles survey data to examine these practices at every well child visit for children aged two years and older. Counseling topics included: physical activity, TV viewing time, energy dense foods, fruits and vegetables, and sugar-sweetened beverages. Chi-square tests were used to examine differences in proportions and logistic regression to identify characteristics associated with screening and counseling. Results: The final analytic sample included 250 PEDs and 621 GPs. Prevalence of using BMI-for-age to screen for obesity at every well child visit was higher for PEDs than GPs (50% vs. 22%, chi 2 = 67.0, p <= 0.01); more PEDs reported being very/somewhat confident in explaining BMI (94% vs. GPs, 87%, p < 0.01); more PEDs reported access to a pediatric obesity specialty clinic for referral (PEDs = 65% vs. GPs = 42%, chi 2 = 37.5, p <= 0.0001). In general, PEDs reported higher counseling prevalence than GPs. There were significant differences in the following topics: TV viewing (PEDs, 79% vs. GPs, 61%, chi 2 = 19.1, p <= 0.0001); fruit and vegetable consumption (PEDs, 87% vs. GPs, 78%, chi 2 = 6.4, p <= 0.01). The only characteristics associated with use of BMI for GPs were being female (OR = 2.3, 95% CI = 1.5-3.5) and serving mostly non-white patients (OR = 1.8, 95% CI = 1.1-2.9); there were no significant associations for PEDs. Conclusions: The findings for use of BMI-for-age, counseling habits, and access to a pediatric obesity specialty clinic leave room for improvement. More research is needed to better understand why BMI-for-age is not being used to screen at every well child visit, which may increase the likelihood overweight and obese patients receive counseling and referrals for additional services. The authors also suggest more communication between PEDs and GPs through professional organizations to increase awareness of existing resources, and to enhance access and referral to pediatric obesity specialty clinics. C1 [Wethington, Holly R.; Sherry, Bettylou; Polhamus, Barbara] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Wethington, HR (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,Mail Stop K-25, Atlanta, GA 30341 USA. EM HWethington@cdc.gov FU Division of Nutrition, Physical Activity, and Obesity, Centers for Disease Control and Prevention FX The DocStyles 2008 items analyzed in this article were supported by the Division of Nutrition, Physical Activity, and Obesity, Centers for Disease Control and Prevention. NR 41 TC 9 Z9 9 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2296 J9 BMC FAM PRACT JI BMC Fam. Pract. PD AUG 3 PY 2011 VL 12 AR 80 DI 10.1186/1471-2296-12-80 PG 9 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 811IA UT WOS:000294200900001 PM 21812987 ER PT J AU Prejean, J Song, RG Hernandez, A Ziebell, R Green, T Walker, F Lin, LS An, Q Mermin, J Lansky, A Hall, HI AF Prejean, Joseph Song, Ruiguang Hernandez, Angela Ziebell, Rebecca Green, Timothy Walker, Frances Lin, Lillian S. An, Qian Mermin, Jonathan Lansky, Amy Hall, H. Irene CA HIV Incidence Surveillance Grp TI Estimated HIV Incidence in the United States, 2006-2009 SO PLOS ONE LA English DT Article ID HIV/AIDS SURVEILLANCE DATA; INFECTION; REDISTRIBUTION; TRANSMISSION; DIAGNOSES AB Background: The estimated number of new HIV infections in the United States reflects the leading edge of the epidemic. Previously, CDC estimated HIV incidence in the United States in 2006 as 56,300 (95% CI: 48,200-64,500). We updated the 2006 estimate and calculated incidence for 2007-2009 using improved methodology. Methodology: We estimated incidence using incidence surveillance data from 16 states and 2 cities and a modification of our previously described stratified extrapolation method based on a sample survey approach with multiple imputation, stratification, and extrapolation to account for missing data and heterogeneity of HIV testing behavior among population groups. Principal Findings: Estimated HIV incidence among persons aged 13 years and older was 48,600 (95% CI: 42,400-54,700) in 2006, 56,000 (95% CI: 49,100-62,900) in 2007, 47,800 (95% CI: 41,800-53,800) in 2008 and 48,100 (95% CI: 42,200-54,000) in 2009. From 2006 to 2009 incidence did not change significantly overall or among specific race/ethnicity or risk groups. However, there was a 21% (95% CI: 1.9%-39.8%; p = 0.017) increase in incidence for people aged 13-29 years, driven by a 34% (95% CI: 8.4%-60.4%) increase in young men who have sex with men (MSM). There was a 48% increase among young black/African American MSM (12.3%-83.0%; p < 0.001). Among people aged 13-29, only MSM experienced significant increases in incidence, and among 13-29 year-old MSM, incidence increased significantly among young, black/African American MSM. In 2009, MSM accounted for 61% of new infections, heterosexual contact 27%, injection drug use (IDU) 9%, and MSM/IDU 3%. Conclusions/Significance: Overall, HIV incidence in the United States was relatively stable 2006-2009; however, among young MSM, particularly black/African American MSM, incidence increased. HIV continues to be a major public health burden, disproportionately affecting several populations in the United States, especially MSM and racial and ethnic minorities. Expanded, improved, and targeted prevention is necessary to reduce HIV incidence. C1 [Prejean, Joseph; Song, Ruiguang; Hernandez, Angela; Green, Timothy; Walker, Frances; Lin, Lillian S.; An, Qian; Mermin, Jonathan; Lansky, Amy; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Ziebell, Rebecca] Ginn Grp, Peachtree City, GA USA. RP Prejean, J (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM nzp1@cdc.gov RI Mermin, Jonathan/J-9847-2012 FU Centers for Disease Control and Prevention (CDC) FX The Centers for Disease Control and Prevention (CDC) provides funding to state and local health departments to conduct surveillance of HIV disease in accordance with their own disease reporting regulations. CDC provides technical guidance for the collection of data by the state and local health departments and data are sent to CDC for national-level analyses. The analysis methods for this manuscript were developed by CDC. CDC makes all decisions regarding the publication of national surveillance data as a means to describe the HIV epidemic. The Ginn Group, Peachtree City, Georgia, United States of America, a subcontractor of the Northrop Grumman Corporation, employs Rebecca Ziebell and provided scientific analysis services as directed by CDC through a contract with CDC. NR 25 TC 511 Z9 520 U1 1 U2 56 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 3 PY 2011 VL 6 IS 8 AR e17502 DI 10.1371/journal.pone.0017502 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 803CQ UT WOS:000293558900001 PM 21826193 ER PT J AU Kegler, SR Annest, JL Kresnow, MJ Mercy, JA AF Kegler, Scott R. Annest, Joseph L. Kresnow, Marcie-jo Mercy, James A. TI Violence-Related Firearm Deaths Among Residents of Metropolitan Areas and Cities-United States, 2006-2007 (Reprinted from MMWR vol 60, pg 573-578, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Kegler, Scott R.; Annest, Joseph L.; Kresnow, Marcie-jo] CDC, Off Stat & Programming, Atlanta, GA 30333 USA. [Mercy, James A.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Kegler, SR (reprint author), CDC, Off Stat & Programming, Atlanta, GA 30333 USA. EM skegler@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 3 PY 2011 VL 306 IS 5 BP 482 EP 484 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 800SH UT WOS:000293386500008 ER PT J AU Koppaka, R AF Koppaka, Ram TI Ten Great Public Health Achievements-Worldwide, 2001-2010 (Reprinted from MMWR vol 60, pg 814-818, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 CDC, Global Publ Hlth Achievements Team, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Svcs, Atlanta, GA 30333 USA. RP Koppaka, R (reprint author), CDC, Global Publ Hlth Achievements Team, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Svcs, Atlanta, GA 30333 USA. EM rkoppaka@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 3 PY 2011 VL 306 IS 5 BP 484 EP 487 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 800SH UT WOS:000293386500009 ER PT J AU Husain, F Anderson, M Cardozo, BL Becknell, K Blanton, C Araki, D Vithana, EK AF Husain, Farah Anderson, Mark Cardozo, Barbara Lopes Becknell, Kristin Blanton, Curtis Araki, Diane Vithana, Eeshara Kottegoda TI Prevalence of War-Related Mental Health Conditions and Association With Displacement Status in Postwar Jaffna District, Sri Lanka SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID REFUGEES; METAANALYSIS; INSTRUMENT; CONFLICT; TORTURE; TRAUMA AB Context Nearly 2.7 million individuals worldwide are internally displaced (seeking refuge in secure areas of their own country) annually by armed conflict. Although the psychological impact of war has been well documented, less is known about the mental health symptoms of forced displacement among internally displaced persons. Objectives To estimate the prevalence of the most common war-related mental health conditions, symptoms of posttraumatic stress disorder (PTSD), anxiety, and depression, and to assess the association between displacement status and these conditions in postwar Jaffna District, Sri Lanka. Design, Setting, and Participants Between July and September 2009, a cross-sectional multistage cluster sample survey was conducted among 1517 Jaffna District households including 2 internally displaced persons camps. The response rate was 92% (1448 respondents, 1409 eligible respondents). Two percent of participants (n=80) were currently displaced, 29.5% (n=539) were recently resettled, and 68.5% (n=790) were long-term residents. Bivariable analyses followed by multivariable logistic regression models were performed to determine the association between displacement status and mental health. Main Outcome Measures Symptom criteria of PTSD, anxiety, and depression as measured by the Harvard Trauma Questionnaire and the Hopkins Symptom Checklist-25. Results The overall prevalences of symptoms of PTSD, anxiety, and depression were 7.0% (95% confidence interval [CI], 5.1%-9.7%), 32.6% (95% CI, 28.5%-36.9%), and 22.2% (95% CI, 18.2%-26.5%), respectively. Currently displaced participants were more likely to report symptoms of PTSD (odds ratio [OR], 2.71; 95% CI, 1.285.73), anxiety (OR, 2.91; 95% CI, 1.89-4.48), and depression (OR, 4.55; 95% CI, 2.47-8.39) compared with long-term residents. Recently resettled residents were more likely to report symptoms of PTSD (OR, 1.96; 95% CI, 1.11-3.47) compared with long-term residents. However, displacement was no longer associated with mental health symptoms after controlling for trauma exposure. Conclusion Among residents of Jaffna District in Sri Lanka, prevalence of symptoms of war-related mental health conditions was substantial and significantly associated with displacement status and underlying trauma exposure. C1 [Husain, Farah] Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Atlanta, GA 30341 USA. [Araki, Diane] United Nations Childrens Fund, Jaffna, Sri Lanka. [Vithana, Eeshara Kottegoda] Minist Healthcare & Nutr, Colombo, Sri Lanka. RP Husain, F (reprint author), Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, 4770 Buford Hwy NE,MS F-60, Atlanta, GA 30341 USA. EM fhusain@cdc.gov FU CDC; UNICEF FX This study was supported by the CDC and UNICEF. NR 30 TC 26 Z9 27 U1 0 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 3 PY 2011 VL 306 IS 5 BP 522 EP 531 DI 10.1001/jama.2011.1052 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 800SH UT WOS:000293386500019 PM 21813430 ER PT J AU Weinkopff, T Lammie, P AF Weinkopff, Tiffany Lammie, Patrick TI Lack of Evidence for the Direct Activation of Endothelial Cells by Adult Female and Microfilarial Excretory-Secretory Products SO PLOS ONE LA English DT Article ID HUMAN LYMPHATIC FILARIASIS; BRUGIA-MALAYI INFECTION; BANCROFTIAN FILARIASIS; NUDE-MICE; IMMUNE-RECONSTITUTION; PATHOLOGY; PAHANGI; HISTOPATHOLOGY; ABNORMALITIES; CHILDREN AB Lymphangiectasia (dilation of the lymphatic vessel (LV)) is pathognomonic for lymphatic filariasis. In both infected humans and animal models of infection, lymphangiectasia is not restricted to the site of the worm nest, but is found along the infected vessel. These observations argue that soluble products secreted by the worm could be mediating this effect by activating the lymphatic endothelial cells (LEC) lining the vessel. We tested the ability of filarial Excretory-Secretory products to activate LECs, but were unable to detect a direct effect of the Excretory-Secretory products on the activation of LEC as assessed by a variety of approaches including cellular proliferation, cell surface molecule expression and cytokine and growth factor production (although other mediators used as positive controls did induce these effects). Collectively, these results do not support the hypothesis that Excretory-Secretory products directly activate LECs. C1 [Weinkopff, Tiffany] Univ Georgia, Dept Cell Biol, Athens, GA 30602 USA. [Lammie, Patrick] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Weinkopff, T (reprint author), Univ Georgia, Dept Cell Biol, Athens, GA 30602 USA. EM tiffany.weinkopff@unil.ch FU Center for Tropical and Emerging Infectious Diseases [T32 AI 060546]; Centers for Disease Control and Prevention's Emerging Infectious Disease FX This work has been supported by a training grant to the Center for Tropical and Emerging Infectious Diseases (T32 AI 060546) with additional support from the Centers for Disease Control and Prevention's Emerging Infectious Disease Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 3 Z9 3 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 2 PY 2011 VL 6 IS 8 AR e22282 DI 10.1371/journal.pone.0022282 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 802LF UT WOS:000293511900004 PM 21829611 ER PT J AU Su, JR Beltrami, JF Zaidi, AA Weinstock, HS AF Su, John R. Beltrami, John F. Zaidi, Akbar A. Weinstock, Hillard S. TI Primary and Secondary Syphilis Among Black and Hispanic Men Who Have Sex With Men: Case Report Data From 27 States SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; HIV PREVENTION INTERVENTION; UNITED-STATES; REPRODUCTIVE HEALTH; SOCIAL DETERMINANTS; ADOLESCENTS; EPIDEMIOLOGY; TRANSMISSION; ORIENTATION; DISPARITIES AB Background: Until 2005, national-level data on the sex of sex partners that describe how primary and secondary syphilis affects men who have sex with men (MSM) of different races or ethnicities were not reported. Objective: To present data from 27 states comparing trends in primary and secondary syphilis among MSM of different races or ethnicities. Design: Review of case report data and regression analysis. Setting: Federal database of case reports in the National Electronic Telecommunications System for Surveillance. Participants: Men reported to be MSM. Measurements: Cases of primary and secondary syphilis per 100 000 males of matching race or ethnicity ("rates"), determined by using population data from the National Center for Health Statistics as the denominator to compare age and racial and ethnic differences. Results: For each year during 2005 to 2008, 27 states from all U. S. census regions reported data on the sex of sex partners for 70% or more of male cases of primary and secondary syphilis. Regression analysis revealed significantly different trends in rates of primary and secondary syphilis: Absolute increases in rates among black MSM and Hispanic MSM were, respectively, 8.0 times and 2.4 times the absolute increase in rate among white MSM. By region, rates among MSM increased 30% in the Midwest, 48% in the South, 73% in the Northeast, and 77% in the West. By age group, the largest absolute increase in rates occurred among MSM aged 20 to 29 years. Limitation: Results from 27 states may not be generalizable to the United States as a whole. Conclusion: Rates of primary and secondary syphilis disproportionately increased among black and Hispanic MSM (compared with white MSM) and among young MSM. Care providers should offer counseling about safer sexual practices and screening for syphilis and other sexually transmitted infections when caring for MSM. C1 [Su, John R.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Su, JR (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS-E02, Atlanta, GA 30333 USA. EM ezu2@cdc.gov FU Centers for Disease Control and Prevention FX Centers for Disease Control and Prevention. NR 48 TC 30 Z9 32 U1 2 U2 11 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 2 PY 2011 VL 155 IS 3 BP 145 EP + DI 10.7326/0003-4819-155-3-201108020-00004 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 800DJ UT WOS:000293339600002 PM 21810707 ER PT J AU Shen, J Johnston, M Hays, RD AF Shen, Joannie Johnston, Michael Hays, Ron D. TI Asthma outcome measures SO EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH LA English DT Review DE asthma control; asthma exacerbation; asthma outcomes; asthma self-management; health-related quality of life ID QUALITY-OF-LIFE; PERFORMANCE QUESTIONNAIRE HPQ; RANDOMIZED CONTROLLED-TRIAL; HEALTH-ORGANIZATION HEALTH; AIRWAY HYPERRESPONSIVENESS; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; INFLAMMATORY MARKERS; PULMONARY-FUNCTION; PRODUCTIVITY LOSS AB Asthma is a common chronic disease with underlying inflammation of the airway. Advances in science have led to increased understanding of the heterogeneous nature of asthma and its complex mechanisms. Traditionally, asthma-practice guidelines have focused on optimizing lung function and the US FDA has required increases in lung function and reduction of exacerbation as primary outcomes in clinical trials of new asthma therapeutics. Improved lung function is a critical indicator of bronchodilator therapy, but the importance of long-term asthma control while maintained on controller medication is increasingly emphasized. The NIH asthma guidelines suggest the use of patient-reported outcomes, including health-related quality-of-life measures, to assess asthma control. Clinical practices and research studies concerning asthma can benefit from harmonizing the major outcome measures so that comparisons across studies can be made. In this article, we review common asthma outcome measures with a focus on recent efforts to harmonize outcomes for therapeutic clinical trials in asthma. C1 [Shen, Joannie] Ctr Dis Control & Prevent CDC, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Johnston, Michael; Hays, Ron D.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RP Shen, J (reprint author), Ctr Dis Control & Prevent CDC, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM gmq6@cdc.gov RI Hays, Ronald/D-5629-2013 FU National Institute on Aging [P30AG021684]; National Center on Minority Health and Health Disparities [2P20MD000182] FX Ron Hays was supported in part by the National Institute on Aging Grant P30AG021684 and National Center on Minority Health and Health Disparities Grant 2P20MD000182. Joannie Shen is an advisory member to the the National Committee on Quality Assurance (NCQA) for respiratory care quality performance measures. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 66 TC 6 Z9 6 U1 0 U2 0 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7167 J9 EXPERT REV PHARM OUT JI Expert Rev. Pharmacoecon. Outcomes Res. PD AUG PY 2011 VL 11 IS 4 BP 447 EP 453 DI 10.1586/ERP.11.48 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 848BH UT WOS:000297021300017 PM 21831026 ER PT J AU Stevens, JA Haas, EN Haileyesus, T AF Stevens, Judy A. Haas, Elizabeth N. Haileyesus, Tadesse TI Nonfatal bathroom injuries among persons aged >= 15 years-United States, 2008 SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Aged; Bathroom; Injury; Falls; Elderly; Older adult ID GENDER-DIFFERENCES; FALLS; ADULTS AB Problem: Information about where nonfatal unintentional injuries occur is limited, but bathrooms commonly are believed to be a hazardous location. Methods: Data from a nationally representative sample of hospital emergency departments (ED) was used to quantify and characterize nonfatal unintentional bathroom injuries among people aged >= 15 years. Results: In 2008, an estimated 234,094 nonfatal bathroom injuries were treated in EDs. Most injuries (81.1%) were caused by falls and 37.3% of injuries occurred when bathing, showering, or getting out of the tub or shower. Both injury and hospitalization rates increased with age. Summary: These results suggest that bathrooms tend to be most hazardous for persons in the oldest age groups. Impact on Industry: Bathroom injuries among all household members might be reduced by increasing awareness about potentially hazardous activities in the bathroom combined with simple environmental changes such as adding grab bars inside and outside the tub or shower. (C) 2011 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Stevens, Judy A.; Haas, Elizabeth N.; Haileyesus, Tadesse] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Haas, Elizabeth N.] Columbus Technol & Serv Inc, Atlanta, GA USA. RP Stevens, JA (reprint author), CDC Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA. EM jas2@cdc.gov NR 17 TC 3 Z9 3 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD AUG PY 2011 VL 42 IS 4 BP 311 EP 315 DI 10.1016/j.jsr.2011.07.001 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 850WK UT WOS:000297230100013 PM 22017838 ER PT J AU Tate, JE Parashar, UD AF Tate, Jacqueline E. Parashar, Umesh D. TI Monitoring impact and effectiveness of rotavirus vaccination SO EXPERT REVIEW OF VACCINES LA English DT Article DE diarrhea; impact study; rotavirus; rotavirus vaccine; surveillance; vaccine-preventable disease ID UNITED-STATES; HOSPITALIZATIONS; GASTROENTERITIS; REDUCTION; EFFICACY; CHILDREN; SAFETY AB Rotavirus infection is the most common cause of severe gastroenteritis in children < 5 years of age globally. Since 2009, the WHO has recommended inclusion of rotavirus vaccine in the national immunization programs of all countries. Data regarding rotavirus vaccine impact and effectiveness under conditions of routine use are important for encouraging countries to implement vaccination programs. In the absence of a national rotavirus vaccination program in France, the IVANHOE study was initiated to determine the real-world impact and effectiveness of rotavirus vaccine following introduction in a limited geographic area. This study found a twofold reduction in rotavirus hospitalizations among children < 2 years of age who were age-eligible to receive rotavirus vaccine and a 98% vaccine effectiveness, highlighting the health benefits of a vaccination program. C1 [Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tate, JE (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jqt8@cdc.gov NR 14 TC 11 Z9 12 U1 0 U2 2 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD AUG PY 2011 VL 10 IS 8 BP 1123 EP 1125 DI 10.1586/ERV.11.94 PG 3 WC Immunology SC Immunology GA 842OQ UT WOS:000296609200010 PM 21854307 ER EF